<SEC-DOCUMENT>0001628280-24-022194.txt : 20240509
<SEC-HEADER>0001628280-24-022194.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509160401
ACCESSION NUMBER:		0001628280-24-022194
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		24930361

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b5443692-b648-47ae-ab89-daa7dd92e886,g:144bc5eb-acb5-4055-8fa1-fd0ab68e078a,d:745479549cf04f87b26b2a1df73a11c9-->
<html xmlns:sgmo="http://www.sangamo.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-28">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-29">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-154" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-514">5.5</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>sgmo:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-21</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-21</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:FullTimeEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:ContractedEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:FullTimeEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:ContractedEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-09</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i745479549cf04f87b26b2a1df73a11c9_1"></div><div style="min-height:36pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2024</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30171</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:30.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">501 Canal Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Richmond</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94804</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">510</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">970-6000</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"/><td style="width:38.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:2pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;&#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of May&#160;6, 2024, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">207,510,076</ix:nonFraction> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.180%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i745479549cf04f87b26b2a1df73a11c9_16">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_19">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_22">Condensed Consolidated Balance Sheets at March 31, 2024 and December 31, 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_25">Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_28">Condensed Consolidated Statements of Comprehensive (Loss) Income for the Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_34">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_88">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_88">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_109">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_109">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_109">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_112">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_112">37</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i745479549cf04f87b26b2a1df73a11c9_115">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_118">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_118">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_121">Item&#160;1A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_121">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_124">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_124">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_124">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_127">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_127">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_130">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_130">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_133">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_133">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_136">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_136">43</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i745479549cf04f87b26b2a1df73a11c9_139">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_139">44</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. and Sangamo Therapeutics UK Ltd.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some statements contained in this report are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development, manufacturing and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for substantial additional financing, and our ability to obtain additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to operate as a going concern, including our estimate that our available cash and cash equivalents as of March 31, 2024, in combination with potential future cost reductions, will not be sufficient to fund our planned operations for one year from the issuance date of the Condensed Consolidated Financial Statements included in Part I, Item 1, &#8220;Financial Statements and Supplementary Data&#8221; of this Quarterly Report on Form&#160;10-Q;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected operating and financial performance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategic pipeline prioritization, including plans for advancing our preclinical programs, and the expected charges and cost savings associated with our restructurings and any future cost reduction measures;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated research and development of product candidates and potential commercialization of any resulting approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, rate of progress, enrollment, dosing, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of our product candidates, including the durability of therapeutic effects;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of technologies used by us in our product candidates, including our gene therapy and cell therapy technologies, zinc finger, or ZF, technology platform, zinc finger nucleases, or ZFNs, and zinc finger transcriptional regulators, or ZF-transcriptional regulators, which include zinc finger repressors, or ZFRs, and zinc finger activators, or ZFAs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential of our adeno-associated virus, or AAV, capsid delivery platform, including our ability to utilize capsids we discover using our technology to resume programs that were previously paused pending the identification of a suitable capsid; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including our ability to find potential new collaboration partners for programs that were previously the subject of collaboration agreements as well as for our Fabry disease gene therapy program;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the impact of the macroeconomic environment on our business and operations and the business and operations of our collaborators, including preclinical studies, clinical trials and manufacturing, and our ability to manage such impacts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers or from our own in-house manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates and the timing and costs associated with obtaining regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain and maintain rights to the technologies required to develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet such competition;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operational and legal risks; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by use of future dates or by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is substantial doubt about our ability to continue to operate as a going concern. We need substantial additional funding to execute our operating plan and to continue to operate as a going concern. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. Future sales and issuances of equity securities would also result in substantial dilution to our stockholders.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a biotechnology company with a reprioritized preclinical focus and no approved products or product revenues. Our success depends substantially on results of preclinical studies and clinical trials demonstrating safety and efficacy of our product candidates to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are early in our research and development efforts for our core preclinical neurology programs that are the current focus of our business. We may encounter difficulties in advancing product candidates from research programs to preclinical and clinical development.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials may be materially different from final data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our product candidates are based on novel ZF technologies that have yet to yield any approved commercially viable therapeutic products.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We are currently substantially reliant on third&#8209;party manufacturers. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties, who may or may not be competitors, may allege that we are infringing, misappropriating, or otherwise practicing in an unauthorized manner their patents or other proprietary rights. Such allegations may result in infringement actions, other misappropriation actions or threats of such actions, all of which could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our recent restructurings may not result in anticipated savings or operational efficiencies, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which may be challenging given the uncertainty regarding our ability to obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sufficient additional funding and to continue to operate as a going concern as well as the competition among numerous biopharmaceutical companies and academic institutions for individuals with these skills. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable global economic conditions could have a negative impact on our operations, which could materially and adversely affect our ability to continue to operate as a going concern and otherwise have a material adverse effect on our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently do not meet, and may not regain compliance with, the listing standards of the Nasdaq Stock Market LLC, and as a result our common stock may be delisted. Delisting could adversely affect the liquidity of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have fully impaired our goodwill and indefinite-lived intangible assets, have recorded significant impairment of our right-of-use and other long-lived assets, and may be required to record significant additional charges if our long-lived assets become further impaired in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on March 13, 2024, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q, and we encourage you to refer to that additional discussion. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes discussion of certain clinical studies and trials relating to various product candidates. These studies typically are part of a larger body of clinical data relating to such product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical data are subject to differing interpretations, and even if we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_19"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_22"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">54,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">45,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-32">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-36">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-37">923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">12,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">12,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">68,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">94,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-42">22,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-43">26,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-44">20,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-45">25,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refundable research income tax credits and other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-46">17,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-47">16,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="f-48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">128,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">165,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">15,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">15,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">6,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">8,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">18,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">23,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">40,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">47,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">30,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">33,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">72,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">82,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-70">2,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-71">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-72">1,515,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-73">1,492,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-74">1,455,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-75">1,406,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-76">5,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-77">4,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-78">56,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-79">82,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-80">128,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">165,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except per share amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.821%"><tr><td style="width:1.0%"/><td style="width:73.632%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.152%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-82">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-83">157,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-84">35,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-85">63,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">11,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-87">18,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-88">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-89">20,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-91">38,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-92">52,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-93">139,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-94">51,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-95">18,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-96">2,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-97">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-98">48,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-99">21,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-100">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-101">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-102">49,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-103">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-104">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-105">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-106">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-107">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net (loss) income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-108">180,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-109">168,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-110">180,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-111">169,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.787%"><tr><td style="width:1.0%"/><td style="width:71.895%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-112">49,089</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-113">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-114">980</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-115">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension gain (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-116">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-117">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on marketable securities, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-118">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-119">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-120">50,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-121">23,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"/><td style="width:30.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.421%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-122">178,133,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-124">1,492,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-125">1,406,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-126">4,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-127">82,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-128">24,761,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-129">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-130">21,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-131">21,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-132">790,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-133">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-134">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-135">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-136">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-137">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="f-138">980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="f-139">980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="f-140">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="f-141">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-142">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-143">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">49,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">49,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-146">203,686,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">2,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">1,515,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-149">1,455,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-150">5,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">56,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"/><td style="width:30.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.405%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">166,793,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-153">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">1,450,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">1,148,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">8,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">294,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-158">3,962,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-159">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-160">9,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-161">9,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-162">1,015,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-163">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-164">1,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-165">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-166">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-167">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="f-168">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="f-169">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="f-170">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="f-171">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-172">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-173">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-176">171,771,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-177">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-178">1,467,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-179">1,127,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">5,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">335,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">49,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-184">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-185">20,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-186">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-187">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of discount on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-188">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-189">1,048</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-190">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-191">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-192">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-193">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-195">38,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="f-196">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="f-197">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-198">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-199">3,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-200">783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-201">6,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-202">4,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-203">1,905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-204">2,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-205">8,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-206">1,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-207">1,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-208">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-209">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-211">149,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-212">48,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-213">66,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-215">36,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-216">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-217">82,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-218">34,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-221">10,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-222">35,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-223">35,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-224">22,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-227">9,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-228">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-229">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">22,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-231">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-232">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-233">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-234">8,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-235">22,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-236">46,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-237">101,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-238">55,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-239">79,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering expenses in relation to issuance of common stock included in unpaid liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sgmo:StockIssuanceCostsNotYetPaid" scale="3" id="f-240">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sgmo:StockIssuanceCostsNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in unpaid liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-242">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-243">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-244" continuedAt="f-244-1" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-244-1" continuedAt="f-244-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. The Company believes its zinc finger (&#8220;ZF&#8221;) epigenetic regulators are ideally suited to potentially address devastating neurology disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system (&#8220;CNS&#8221;) in preclinical studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company announced its strategic transformation into a neurology-focused genomic medicine company focused on developing epigenetic regulation therapies designed to address serious neurological diseases and novel adeno-associated virus (&#8220;AAV&#8221;) capsid delivery technology. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-245" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#8220;2023 Annual Report&#8221;) as filed with the SEC on March 13,&#160;2024.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-246" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2023, included in the 2023 Annual Report.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity, Going Concern, and Capital Resources</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects will require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#8217;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of March&#160;31, 2024, the Company had capital resources of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-247">54.4</ix:nonFraction>&#160;million consisting of cash and cash equivalents. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements&#8212;Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effects of management&#8217;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-244-2" continuedAt="f-244-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probable of being effectively implemented, the plans must have been approved by the Company&#8217;s board of directors before the date that the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on additional financing to fund its operations after the current resources are exhausted raise substantial doubt about its ability to continue to operate as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. The Company&#8217;s current operating plan, its cash and cash equivalents as of March&#160;31, 2024 are expected to allow the Company to meet its liquidity requirements only into the third quarter of 2024, which is less than one year following the date these Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through the sale of the Company&#8217;s common stock;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through debt or royalty financing; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish collaborations with potential partners to advance the Company&#8217;s product pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to raise capital on acceptable terms, or at all, or if it is unable to procure collaboration arrangements or external direct investments to advance its programs, the Company would be required to discontinue some or all of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful. Additional capital may not be available to the Company on a timely basis, on terms that are acceptable or at all. In particular, the perception of the Company&#8217;s ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of its operations, particularly in light of currently challenging macroeconomic and market conditions. Further, the Company may be unable to attract new investments as a result of the speculative nature of its newly reprioritized core neurology preclinical programs. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which would have a material adverse effect on its business and prospects, or the Company may be required to cease operations entirely, liquidate all or a portion of its assets, and/or seek protection under the U.S. Bankruptcy Code.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-248" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary (&#8220;Kite&#8221;). This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-249">8.9</ix:nonFraction>&#160;million, a decrease in net loss of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" sign="-" name="sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-250">8.9</ix:nonFraction>&#160;million, and a decrease in the Company&#8217;s basic and diluted net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-36" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareBasic" scale="0" id="f-251">0.06</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-36" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareDiluted" scale="0" id="f-252">0.05</ix:nonFraction>, respectively for the three months ended March 31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-253" continuedAt="f-253-1" escape="true"><ix:continuation id="f-244-3" continuedAt="f-244-4"><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company&#8217;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the </span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-244-4" continuedAt="f-244-5"><ix:continuation id="f-253-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><ix:nonNumeric contextRef="c-1" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="f-254" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaboration and license agreements for the three months ended March&#160;31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.687%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-37" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-255">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-38" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-256">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-39" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-257">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license agreements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-40" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-258">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-259" continuedAt="f-259-1" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to acquired in-process research and development (&#8220;IPR&amp;D&#8221;) projects and are initially measured at their respective fair values as of the acquisition date. Goodwill and indefinite-lived intangible assets are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#8217;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value (but not in excess of the carrying value of goodwill).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing each annual impairment assessment and any interim impairment assessment for its indefinite-lived intangible assets, the Company determines if it should qualitatively assess whether it is more likely than not the fair value of its IPR&amp;D asset is less than its carrying amount (the qualitative impairment test). If the Company concludes that is the case, or elects not to use the qualitative impairment test, the Company will proceed with quantitatively determining the fair value of the IPR&amp;D asset and comparing its fair value to its carrying value to determine the amount of impairment, if any (the quantitative impairment test).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the qualitative impairment test, the Company considers the results of the most recent quantitative impairment test and identifies the most relevant drivers of the fair value for the IPR&amp;D asset. The most relevant drivers of fair value identified are consistent with the assumptions used in the quantitative estimate of the IPR&amp;D asset. Using these drivers of fair value, the Company identifies events and circumstances which may have an effect on the fair value of the IPR&amp;D asset since the last time the IPR&amp;D&#8217;s fair value was quantitatively determined. The Company then weighs these factors to determine and conclude if it is not more likely than not the IPR&amp;D asset is impaired. If it is more likely than not the IPR&amp;D asset is impaired, the Company proceeds with quantitatively determining the fair value of the IPR&amp;D asset.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing the quantitative impairment test, the Company uses the income approach to determine the fair value of its IPR&amp;D asset. This approach calculates fair value by estimating the after-tax cash flows attributable to an in-process project over its useful life and then discounting these after-tax cash flows back to a present value. This estimate includes judgmental assumptions regarding the estimates that market participants would make in evaluating the IPR&amp;D asset, including the probability of successfully completing clinical trials and obtaining regulatory approval, the timing of and the expected costs to complete IPR&amp;D projects, future net cash flows from potential drug sales, which are based on estimates of the sales price of the drug, the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-244-5" continuedAt="f-244-6"><ix:continuation id="f-259-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">size of the patient population and cure rate, its competitive position in the marketplace, and appropriate discount and tax rates. Any impairment to be recorded is calculated as the difference between the estimated fair value and the carrying value of the IPR&amp;D asset on the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If this review indicates that the carrying amount of the asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, impairment of indefinite-lived intangible assets, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-260" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash in current assets consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-261">0.9</ix:nonFraction>&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-263" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-262" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-264">54,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-265">45,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-266">78,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-267">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-268">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-273">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-274">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-275">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-276">55,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-277">46,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-278">79,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-279">101,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-280" continuedAt="f-280-1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-244-6" continuedAt="f-244-7"><ix:continuation id="f-280-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="sgmo:WarrantOrRightPolicyPolicyTextBlock" id="f-281" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants to Purchase Shares of Company Stock </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#8217;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#8217;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If financial instruments, such as the warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants are also required to meet equity classification criteria to be classified in stockholders&#8217; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#8217;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. The warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="f-282" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 712&#8221;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 420&#8221;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-283" escape="true"><ix:continuation id="f-244-7"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></div></ix:continuation></ix:nonNumeric><div id="i745479549cf04f87b26b2a1df73a11c9_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-285" continuedAt="f-285-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-284" continuedAt="f-284-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-284-1" continuedAt="f-284-2"><ix:continuation id="f-285-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-286" continuedAt="f-286-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-287">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-288">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-291">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-292">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-284-2"><ix:continuation id="f-286-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-295">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-296">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-299">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-300">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-303">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-305">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-307">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-309">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-311">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-313">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-315">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-317">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-319">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-321">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-323">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-325">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-327">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-329">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-331">38,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-332">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-333">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-335" continuedAt="f-335-1" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="f-335-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-336" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-337">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-340">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-341">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-344">8,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-345">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-348">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-349">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-352">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-353">22,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-354">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-356">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-357">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-358">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-359">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-360">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-361">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-362">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-364">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-365">2,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-366">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-368">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-369">5,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-371">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-372">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-373">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-374">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-376">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-377">35,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-378">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-379">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-380">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-381">38,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="f-382">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="f-383">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-384">38,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-385" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.687%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-386">10,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-387">24,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-388">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="0" id="f-389">no</ix:nonFraction>t material during the three months ended March&#160;31, 2024. There were <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt-sec:numwordsen" id="f-390">no</ix:nonFraction> realized gains and losses on the sales of investments during the three months ended March&#160;31, 2023. Total unrealized gains for securities with net gains in accumulated other comprehensive income (loss) were not material during the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-391">no</ix:nonFraction>t record an allowance for credit losses related to its marketable securities for the three months ended March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2023. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that were in a continuous unrealized loss position for greater than 12 months as of December&#160;31, 2023. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. No significant facts or circumstances had arisen to indicate that there had been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, the Company determined that <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-392">no</ix:nonFraction> allowance for credit losses related to its marketable securities was required at December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods the Company had investment in debt securities, the Company also considered whether it was more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. No impairment charges were recorded during the three months ended March&#160;31, 2024 and 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-393" continuedAt="f-393-1" escape="true">BASIC AND DILUTED NET (LOSS) INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-393-1" continuedAt="f-393-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share has been computed by dividing net (loss) income by the weighted-average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding. During the three months ended March 31, 2024, both basic and diluted weighted-average number of shares outstanding included <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-394"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-395">251,177</ix:nonFraction></ix:nonFraction> shares from pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-396">3,809,523</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-397">0.01</ix:nonFraction> per share.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-398" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net (loss) income per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-399">49,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-400">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-401">180,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-402">168,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-403">180,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-404">168,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-406">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-95" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-96" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-408">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-409">180,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-410">169,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="f-411">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" id="f-412">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="f-413">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="f-414">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-393-2">Warrants to purchase shares of common stock with the exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-415">1.00</ix:nonFraction> per share entitle holders to participate in dividends but are not required to absorb losses incurred and as a result were excluded from basic net loss per share calculations during the three months ended March 31, 2024. The computation of diluted net loss per share for the three months ended March 31, 2024 excluded <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-416">55.6</ix:nonFraction> million shares subject to stock options, restricted stock units outstanding, warrants to purchase common stock, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net income per share for the three months ended March 31, 2023 excluded <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-417">14.7</ix:nonFraction>&#160;million shares subject to stock options because their inclusion would have had an anti-dilutive effect on diluted net income per share.</ix:continuation> </span></div><div id="i745479549cf04f87b26b2a1df73a11c9_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-418" continuedAt="f-418-1" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="f-418-1" continuedAt="f-418-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company was responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) <ix:nonNumeric contextRef="c-97" name="sgmo:AgreementTerminationTerm" format="ixt-sec:duryear" id="f-419">15</ix:nonNumeric> years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-418-2" continuedAt="f-418-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="f-420">70.0</ix:nonFraction>&#160;million and was eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-421">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-422">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. To date, <ix:nonFraction unitRef="milestone" contextRef="c-100" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" format="ixt-sec:numwordsen" scale="0" id="f-423">two</ix:nonFraction> milestones of $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-424">55.0</ix:nonFraction>&#160;million in aggregate have been achieved and paid. The Company is eligible to earn from Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="f-425">220.0</ix:nonFraction>&#160;million in remaining milestone payments for giroctocogene fitelparvovec and up to $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="f-426">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are <ix:nonFraction unitRef="number" contextRef="c-103" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-427">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-428">20</ix:nonFraction>% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-429">134.0</ix:nonFraction>&#160;million during the periods through December 31, 2020. No revenue was recognized during the three months ended March&#160;31, 2024 and 2023. The remaining development, intellectual property and regulatory milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Pfizer&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales milestones and royalties are not recognized until triggered based on the contractual terms.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, subsequently assigned to Alexion, AstraZeneca Rare Disease (&#8220;Alexion&#8221;) in September 2023, for the development and commercialization of potential gene therapy products that use zinc finger transcriptional regulators (&#8220;ZF-transcriptional regulators&#8221;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-transcriptional regulators that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer (now Alexion) an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-transcriptional regulators that satisfy pre-agreed criteria. During a specified period, neither the Company nor Alexion will be permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins (&#8220;ZFPs&#8221;) that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) <ix:nonNumeric contextRef="c-106" name="sgmo:AgreementTerminationTerm" format="ixt-sec:duryear" id="f-430">15</ix:nonNumeric> years after the first commercial sale of a licensed product in a major market country. Alexion also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Alexion to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Alexion without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Alexion to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Alexion to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Alexion&#8217;s material breach, Alexion will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Alexion for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-431">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-432">60.0</ix:nonFraction>&#160;million in development milestone payments from Alexion contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-433">90.0</ix:nonFraction>&#160;million in commercial milestone payments if annual </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-418-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">worldwide net sales of the licensed products reach specified levels. In addition, Alexion will pay the Company royalties of <ix:nonFraction unitRef="number" contextRef="c-110" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-434">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-435">20</ix:nonFraction>% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party is responsible for the cost of its performance of the research program. Alexion is operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-436">5.0</ix:nonFraction>&#160;million has been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="c-112" decimals="INF" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="f-437">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="c-112" decimals="INF" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="f-438">no</ix:nonFraction> royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Alexion in accordance with ASC Topic 606 and concluded that Alexion was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-439">17.0</ix:nonFraction>&#160;million during the periods through December 31, 2020. No revenue was recognized during the three months ended March&#160;31, 2024 and 2023. The remaining development milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Alexion&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales related milestones and royalties are not recognized until triggered based on the contractual terms. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, Pfizer notified the Company of Pfizer&#8217;s assignment of the collaboration and license agreement to Alexion, AstraZeneca Rare Disease, pursuant to a definitive purchase and license agreement for preclinical gene therapy assets and enabling technologies that closed on September 20, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company also had a collaboration and license agreement with Kite. During the three months ended March&#160;31, 2023, in addition to the agreement with Kite, the Company had collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;), and Biogen MA, Inc. (&#8220;Biogen&#8221;). These collaboration agreements were designed for the research, development, and commercialization of various potential therapy products, including potential engineered cell therapies for cancer and gene regulation therapies to treat neurodevelopmental disorders and diseases. The collaboration agreements with Novartis and Biogen were both terminated effective June 2023. The Company&#8217;s services under the Kite collaboration agreement were completed during the year ended December 31, 2023, and the agreement expired pursuant to its terms in April 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed each of these collaboration agreements in accordance with ASC Topic 606, concluding Kite, Novartis and Biogen were customers. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-440" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under these agreements were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:74.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-442">11,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-444">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-446">12,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-448">7,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-450">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-452">9,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-454">130,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-456">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-458">132,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other license agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-459">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-460">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-461">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-462">157,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, the Company had no receivables, no deferred revenue, and no amounts included in transaction price remaining to be recognized related to any license and collaboration agreements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:AssetImpairmentChargesTextBlock" id="f-463" continuedAt="f-463-1" escape="true">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-463-1" continuedAt="f-463-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company experienced a sustained decline in stock price and related market capitalization, the collaboration agreements with Biogen and Novartis were terminated, and actions were initiated including deferral and reprioritization of certain research and development programs, announcement and execution of restructuring of operations and reductions in force. As a result, throughout the year the Company tested various long-lived and indefinite-life intangible assets for impairment and recognized a pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-464">38.1</ix:nonFraction>&#160;million, a pre-tax indefinite-lived intangible asset impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-465">51.4</ix:nonFraction>&#160;million along with the income tax benefit from the reduction of the associated deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" format="ixt:num-dot-decimal" scale="6" id="f-466">6.3</ix:nonFraction>&#160;million, and a pre-tax long-lived assets impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-467">65.5</ix:nonFraction>&#160;million during the year ended December 31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three months ended March 31, 2024</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company&#8217;s Board of Directors approved the wind-down of operations in France and corresponding reduction in workforce, including closure of the Company&#8217;s cell therapy manufacturing facility and research labs in Valbonne, France (the &#8220;France Restructuring&#8221;), and also initiated several actions aimed at reducing costs, including actions to commence the closure of its facility in Brisbane, California. As such, the Company reassessed its long-lived assets for impairment as of March 31, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the France Restructuring, the Company concluded its equipment, furniture and fixtures located in France met the held for sale criteria as of March 31, 2024. The Company wrote down the carrying value of these assets to their estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-468">1.0</ix:nonFraction>&#160;million, net of the estimated costs to sell, recognizing a loss of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-469">1.8</ix:nonFraction>&#160;million. Assets held for sale are included within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations. The sale of these assets is expected to occur within one year, either collectively or separately through vendor(s) or at auction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reassessed whether its remaining long-lived assets continued to represent a single asset group for purposes of impairment assessment. After considering changes in the manner in which the right-of-use assets and leasehold improvements related to the Company&#8217;s Brisbane and Valbonne, France, facilities are used, costs incurred to cease use of these assets, the France Restructuring, and the Company&#8217;s activities to market these facilities for sublease, the Company concluded the identifiable operations and cash flows of these assets are now largely independent of the operations and the cash flows of each other, as well as of the remainder of the Company. Accordingly, the Company assessed impairment of the resulting asset groups separately.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the changes in the use of assets related to the Brisbane and Valbonne facility leases, the Company concluded there were indicators of impairment for these asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-470">2.0</ix:nonFraction>&#160;million on the right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-471">0.5</ix:nonFraction>&#160;million on the related leasehold improvements during the three months ended March 31, 2024. No impairment was recognized on the remaining long-lived assets, as their carrying values were not in excess of their fair values.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess whether its long-lived assets are impaired in future periods. As the Company finalizes the wind-down of its France operations and corresponding reduction in force of all France employees, as well as the closure of its Brisbane facility, it is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three months ended March 31, 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and other long-lived assets. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operated as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-472">38.1</ix:nonFraction>&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March&#160;31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-463-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before completing the goodwill impairment assessment, the Company also tested its indefinite-lived intangible assets and then its long-lived assets for impairment. Based on the qualitative assessment, the Company determined it was more likely than not that its indefinite-lived intangible assets were not impaired. The Company determined all of its long-lived assets represented one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable as it exceeded the future undiscounted cash flows the assets were expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction and a cost replacement method to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level&#160;3 nonrecurring fair value measurements. Based on this analysis, the Company recognized pre-tax long-lived asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-473">11.2</ix:nonFraction>&#160;million on the right-of-use assets, $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-474">5.0</ix:nonFraction>&#160;million on the related leasehold improvements, and $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-475">4.2</ix:nonFraction>&#160;million on construction-in-progress, during the three months ended March 31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.</span></div></ix:continuation><div id="i745479549cf04f87b26b2a1df73a11c9_549755815296"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-476" continuedAt="f-476-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-476-1" continuedAt="f-476-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company entered into an amendment to the operating lease of office and research and development laboratory facilities in Brisbane, California. The amendment established early termination rights for the landlord upon <ix:nonNumeric contextRef="c-138" name="sgmo:LesseeOperatingLeaseRequiredNoticeOfTermination" format="ixt-sec:durwordsen" id="f-477">thirty days</ix:nonNumeric> notice to the Company, with the earliest date the landlord may terminate the lease being September 30, 2024. Additionally, the amendment authorizes the landlord to draw on the existing letter of credit to satisfy the majority of the Company&#8217;s February 2024 through April 2024 rent payments and obligates the Company to provide a cash security deposit or replenish the letter of credit back to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="sgmo:LesseeRequiredLetterOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-478">1.5</ix:nonFraction>&#160;million by June 1, 2024.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="f-476-2" continuedAt="f-476-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the amendment represented a lease modification to be accounted for as a single contract with the existing lease under ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-476-3">, and remeasured its lease liability using the current incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-139" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-479">9.6</ix:nonFraction>%, and recorded an adjustment to reduce both the lease liability and the corresponding right-of-use asset by $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-480"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-481">1.9</ix:nonFraction></ix:nonFraction>&#160;million.</ix:continuation> </span></div><div id="i745479549cf04f87b26b2a1df73a11c9_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-482" continuedAt="f-482-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-483" escape="true"><ix:continuation id="f-482-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:74.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-484">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-485">4,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-486">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-487">3,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-488">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-489">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i745479549cf04f87b26b2a1df73a11c9_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-490" continuedAt="f-490-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-490-1" continuedAt="f-490-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="sgmo:StockOfferingProgramMaximumValue" format="ixt:num-dot-decimal" scale="6" id="f-491">150.0</ix:nonFraction>&#160;million through Jefferies as the Company&#8217;s sales agent or principal. In December 2022, the Company entered into Amendment No. 2 to the Open Market Sale Agreement&#8480; which increased the aggregate offering price under the at-the-market offering program by an additional $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="sgmo:SaleOfStockIncreaseToAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="f-492">175.0</ix:nonFraction> million. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="sgmo:SaleOfStockOutstandingAmountAvailable" format="ixt:num-dot-decimal" scale="6" id="f-493">194.5</ix:nonFraction>&#160;million remained available under the sales agreement as of March 31, 2024. The Company is not obligated to sell any shares under the sales agreement. <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-494">No</ix:nonFraction> shares were sold under the sales agreement during the three months ended March&#160;31, 2024. During the three months ended March&#160;31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-495">3,962,430</ix:nonFraction> shares of its common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-496">9.7</ix:nonFraction> million. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance and Sale of Common Stock and Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Investors&#8221;). On March 26, 2024 the Company issued and sold in a registered direct offering (the &#8220;Registered Direct Offering&#8221;) an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-497">24,761,905</ix:nonFraction> shares of common stock of the Company, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-498">0.01</ix:nonFraction> per share, and pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-499">3,809,523</ix:nonFraction> shares of common stock, together with </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-490-2" continuedAt="f-490-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accompanying warrants (&#8220;Common Warrants&#8221;) to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-153" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-500">28,571,428</ix:nonFraction> shares of common stock. The combined offering price of a unit consisting of <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" format="ixt-sec:numwordsen" id="f-501">one</ix:nonFraction> share of common stock and the accompanying Common Warrant to purchase <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" id="f-502">one</ix:nonFraction> share of common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-503">0.84</ix:nonFraction>. The combined offering price of a unit consisting of a pre-funded warrant to purchase <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" format="ixt-sec:numwordsen" id="f-504">one</ix:nonFraction> share of common stock and the accompanying Common Warrant to purchase <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" id="f-505">one</ix:nonFraction> share of common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-506">0.83</ix:nonFraction>. The pre-funded warrants are immediately exercisable at any time, until exercised in full, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-507">0.01</ix:nonFraction> per share of common stock. The Common Warrants are exercisable <ix:nonNumeric contextRef="c-156" name="sgmo:WarrantOrRightOutstandingExercisablePeriodAfterIssuance" format="ixt-sec:durwordsen" id="f-508">six months</ix:nonNumeric> from issuance, expire five and a half years from the issuance date and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-509">1.00</ix:nonFraction> per share. Both pre-funded warrants and Common Warrants can be exercised net in limited circumstances and entitle holders to dividends if and when paid by the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barclays Capital Inc. and Cantor Fitzgerald &amp; Co. (the &#8220;Placement Agents&#8221;) acted as the placement agents for the offering, pursuant to a Placement Agency Agreement, dated March 21, 2024 (the &#8220;Placement Agreement&#8221;). Pursuant to the Placement Agreement, the Company paid the Placement Agents a cash placement fee equal to <ix:nonFraction unitRef="number" contextRef="c-157" decimals="2" name="sgmo:SaleOfStockPlacementFeePercentageOfGrossProceeds" scale="-2" id="f-510">6.0</ix:nonFraction>% of the aggregate gross proceeds raised in the Registered Direct Offering from sales arranged by the Placement Agents. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received aggregate net proceeds from the Registered Direct Offering of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-511">21.8</ix:nonFraction>&#160;million, net of the Placement Agents&#8217; fees of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="sgmo:SaleOfStockAgentPlacementFees" format="ixt:num-dot-decimal" scale="6" id="f-512">1.4</ix:nonFraction>&#160;million and other offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="sgmo:SaleOfStockOtherOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-513">0.7</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-490-3">Common Warrants and pre-funded warrants were determined to be equity-classified and proceeds received from their issuance were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The Company determined that the warrants should be equity classified because they are freestanding financial instruments, do not embody an obligation for the Company to repurchase its shares, do not contain exercise contingencies tied to observable markets or indices, permit the holders to receive a fixed number of shares of common stock upon exercise in exchange for a fixed amount of consideration, subject only to adjustments that are inputs to the fair value of a fixed price/fixed consideration-option, and meet the equity classification criteria. The Common Warrants and pre-funded warrants had not been exercised and remained outstanding as of March 31, 2024.</ix:continuation> The pre-funded warrants were exercised in full on April 8, 2024.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-515" continuedAt="f-515-1" escape="true">RESTRUCTURING CHARGES</ix:nonNumeric></span></div><ix:continuation id="f-515-1" continuedAt="f-515-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;April 2023 Restructuring&#8221;), designed to reduce costs and increase focus on certain strategic priorities. The April 2023 Restructuring resulted in the elimination of approximately <ix:nonFraction unitRef="employee" contextRef="c-158" decimals="-1" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-516">110</ix:nonFraction> roles, including <ix:nonFraction unitRef="employee" contextRef="c-159" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-517">55</ix:nonFraction> full-time employees and <ix:nonFraction unitRef="employee" contextRef="c-160" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-518">55</ix:nonFraction> contracted employees and eliminated open positions, in the United States, or approximately <ix:nonFraction unitRef="number" contextRef="c-158" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-519">23</ix:nonFraction>% of the total United States workforce as of April 26, 2023, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The Company had estimated that it will incur $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-520">5.0</ix:nonFraction> million in expenses related to employee severance and notice period payments, benefits and related restructuring charges for the April 2023 Restructuring. <ix:nonFraction unitRef="usd" contextRef="c-162" decimals="INF" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-521">No</ix:nonFraction> expenses related to the April 2023 Restructuring were incurred during the three months ended March&#160;31, 2024. The Company expects the April 2023 Restructuring and the cash payments related to the April 2023 Restructuring to be substantially complete by the third quarter of 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">November 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;November 2023 Restructuring&#8221;), designed to reduce costs and advance its strategic transformation into a neurology-focused genomic medicine company. The November 2023 Restructuring resulted in the elimination of approximately <ix:nonFraction unitRef="employee" contextRef="c-163" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-522">162</ix:nonFraction> roles, including <ix:nonFraction unitRef="employee" contextRef="c-164" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" id="f-523">108</ix:nonFraction> full-time employees and <ix:nonFraction unitRef="employee" contextRef="c-165" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-524">54</ix:nonFraction> contracted employees and eliminated open positions, in the United States, or approximately <ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-525">40</ix:nonFraction>% of the total United States workforce, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. As of March&#160;31, 2024, the Company estimates it will incur approximately $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-526">8.7</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-527">9.7</ix:nonFraction> million in expenses related to employee severance and notice period payments, benefits, Brisbane facility close-out costs, and other related restructuring charges for the November 2023 Restructuring. The Company had recorded $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-528">6.7</ix:nonFraction> million of expenses relating to the November 2023 Restructuring in the fourth quarter of 2023. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-529">0.7</ix:nonFraction> million of expenses during three months ended March&#160;31, 2024, of which $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-530">0.5</ix:nonFraction> million is included in research and development expense and $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-531">0.2</ix:nonFraction> million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur additional estimated costs of $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-532">1.3</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-533">2.3</ix:nonFraction> million through the second quarter of 2024. The Company expects the November 2023 Restructuring and the cash payments related to the November 2023 Restructuring to be substantially complete by the second quarter of 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><ix:continuation id="f-515-2" continuedAt="f-515-3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">France Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company&#8217;s Board of Directors approved the France Restructuring which will result in the elimination of all <ix:nonFraction unitRef="employee" contextRef="c-174" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-534">93</ix:nonFraction> roles in France, or approximately <ix:nonFraction unitRef="number" contextRef="c-174" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-535">24</ix:nonFraction>% of the total global workforce. The Company is expected to make severance payments as required by French law and the terms of the applicable collective bargaining agreements, and other employee-related costs. As of March&#160;31, 2024, the Company estimates it will incur approximately $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-536">7.8</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-537">9.6</ix:nonFraction> million in expenses related to employee severance and notice period payments, benefits, contract termination costs, and other related restructuring charges for the France Restructuring. The Company had recorded $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-538">4.7</ix:nonFraction> million of expenses relating to the France restructuring in the fourth quarter of 2023. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-539">0.2</ix:nonFraction> million of expenses during three months ended March&#160;31, 2024, of which $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-540">0.1</ix:nonFraction> million is included in research and development expense and $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-541">0.1</ix:nonFraction> million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur additional estimated costs of $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-542">2.9</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-543">4.7</ix:nonFraction> million through the fourth quarter of 2024. The Company expects the France Restructuring and its related cash payments to be completed no later than the fourth quarter of 2024. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-544" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-545">11,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-546">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-547">5,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-548">7,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-515-3">Sangamo may also incur other cash expenses or charges not currently contemplated or estimable due to events that may occur as a result of, or associated with, the April 2023 Restructuring, November 2023 Restructuring and France Restructuring. There were no restructuring charges incurred during the three months ended March&#160;31, 2023.</ix:continuation> </span></div><div id="i745479549cf04f87b26b2a1df73a11c9_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-549" continuedAt="f-549-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-549-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exercise of Pre-funded Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2024, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-550">3,809,523</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-551">0.01</ix:nonFraction> to an investor upon exercise of pre-funded warrants issued as part of the Registered Direct Offering. Following this issuance, <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt-sec:numwordsen" id="f-552">none</ix:nonFraction> of the pre-funded warrants sold in the Registered Direct Offering remain outstanding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Deficiency Notice</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2024, the Company received a deficiency notice (the &#8220;Notice&#8221;) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying the Company that, for the last 30 consecutive business days, the bid price of the Company&#8217;s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company&#8217;s common stock on the Nasdaq Global Select Market.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include, without limitation, statements containing the words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to, the &#8220;Risk Factors&#8221; described in Part I, Item 1A our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2023 as filed with the Securities and Exchange Commission on March 13,&#160;2024, or the 2023 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. You should also read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and accompanying notes included in this Quarterly Report and the Consolidated Financial Statements and accompanying notes thereto included in our 2023 Annual Report.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Updates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered Direct Offering</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we issued and sold in a registered direct offering with institutional investors, or the Registered Direct Offering, an aggregate of 24,761,905 shares of common stock of the Company, par value $0.01 per share, and pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of common stock, and received aggregate net proceeds of $21.8&#160;million, net of placement agents&#8217; fees of $1.4&#160;million and other offering costs of $0.7&#160;million. We anticipate using the net proceeds from this offering to fund the development of our neurology-focused genomic medicines pipeline, and novel adeno-associated virus, or AAV, capsid delivery technology and for other general corporate purposes.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">France Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our strategic transformation into a neurology-focused genomic medicine company, Sangamo has been actively seeking additional investors in, or collaboration partners for its Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy programs located in Valbonne, France since the middle of 2023. As this search has been unsuccessful in securing additional funds to sustain these programs, on March 1, 2024, the Board of Directors of Sangamo approved a wind-down of Sangamo&#8217;s French operations and a corresponding reduction in workforce, including closure of Sangamo&#8217;s cell therapy manufacturing facility and research labs in Valbonne, France, or the France Restructuring. This restructuring commenced in April 2024 and is expected to be substantially complete by the fourth quarter of 2024. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Position</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, our cash and cash equivalents as of March&#160;31, 2024 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors, including to progress our preclinical and clinical programs as described in our 2023 Annual Report and in this Quarterly Report. Although we raised capital via the Registered Direct Offering as described above, we will still need substantial additional capital in order to continue to operate as a going concern and fund our operations. We have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs. However, we have been unsuccessful in securing any such additional capital to date. If we are unable to secure additional funding in the very near term, we will likely seek protection under the U.S. Bankruptcy Code. We have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Core Preclinical Neurology Programs and Technologies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our neurology preclinical development is focused on two innovative areas aligned with our strategic transformation: (i) development of epigenetic regulation therapies treating serious neurological diseases and (ii) development of novel engineered AAV capsids to deliver our therapies to the intended neurological targets. Indications for our wholly-owned preclinical programs include chronic neuropathic pain, prion disease and tauopathies. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurology Epigenetic Regulation Programs</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investigational new drug, or IND, enabling toxicology studies are nearing completion in the Nav1.7 program to treat chronic neuropathic pain. An IND submission is expected in the fourth quarter of 2024, subject to our ability to secure adequate funding.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial authorization, or CTA, enabling activities continue to advance for our epigenetic regulation program to treat prion disease, leveraging our novel AAV capsid known as STAC-BBB. A CTA submission is expected in the fourth quarter of 2025, subject to our ability to secure adequate funding.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We intend to resume development of our previously paused tau program, developing epigenetic regulation therapies treating tauopathies including Alzheimer&#8217;s disease. This program will leverage our STAC-BBB capsid. An IND submission for this zinc finger repressor program could occur as early as the fourth quarter of 2025, subject to our ability to secure adequate funding.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We showcased 10 poster presentations at the American Society for Cell and Gene Therapy, or ASGCT, Annual Meeting demonstrating advances in epigenetic regulation for the treatment of various neurological diseases, including prion disease, tauopathies, Charcot-Marie-Tooth disease type 1A and 2A, or CMT1A and CMT2A, Dravet Syndrome, SOD1-mediated amyotrophic lateral sclerosis, or ALS, Phelan-McDermid syndrome, Parkinson&#8217;s disease, Angelman syndrome, and other neurology disorders.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novel AAV Capsid Delivery Technology</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2024, we announced preclinical data from STAC-BBB, our novel proprietary neurotropic AAV capsid variant, which demonstrated industry-leading blood-brain barrier, or BBB, penetration in non-human primates, or NHPs, following intravenous administration, with capsid-enabled delivery of zinc finger payloads targeting prion disease and tauopathies resulting in potent and widespread repression of target genes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">STAC-BBB demonstrated robust penetration of the BBB with 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published capsid variants evaluated in the study.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The data showed that STAC-BBB mediated robust expression of zinc finger cargo in neurons, with potent and widespread repression of prion and tau genes observed across key brain regions, demonstrating the potential for modification of disease progression in prion disease and various tauopathies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2024, we presented two platform and four poster presentations at the 27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASGCT Annual Meeting outlining developments in Sangamo&#8217;s AAV capsid delivery capabilities, as developed through our SIFTER capsid engineering platform. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are engaged in ongoing business development discussions with potential collaborators for STAC-BBB. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Next-Generation Genome Engineering</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2024, we presented one platform and three poster presentations at the 27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASGCT Annual Meeting showcasing our next-generation engineering capabilities, including the discovery of next-generation integrase technology. Our Modular Integrase, or MINT, platform builds on Sangamo&#8217;s deep expertise in protein-DNA interactions derived from its zinc finger platform that allows targeting of a serine recombinase engineered to enable large-scale genome editing to potentially treat &#8211; with a single medicine &#8211; patients who have unique mutations in the same gene. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our MINT platform, derived from compact Bxb1 variants, is intended to integrate entire genes into the genome, to avoid double-stranded DNA breaks and the need for assistance from ancillary genome editing or DNA-repair modulating cargo. The MINT platform could be deployed for neurology-focused indications, and also could provide potential partnering opportunities, both for human disease and in agricultural biotech settings. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2024, we published a manuscript in bioRxiv titled, &#8220;Systematic Development of Reprogrammed Modular Integrases Enables Precise Genomic Integration of Large DNA Sequences&#8221; further detailing the discovery and potential of our MINT platform.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are engaged in ongoing business development discussions with potential collaborators for Sangamo&#8217;s modular integrase capabilities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Programs</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fabry Disease</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Since our last update in March 2024, we have dosed the final patient in the Phase 1/2 STAAR study of isaralgagene civaparvovec, our investigational gene therapy for the treatment of Fabry disease, resulting in a total of 33 patients dosed in the study. Screening, enrollment and dosing are now complete for this Phase 1/2 study.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One additional treated patient has been withdrawn from enzyme replacement therapy, or ERT, resulting in a total of 14 patients withdrawn from ERT to date. The four patients dosed since February 2024 who began the study on ERT have plans in place to withdraw from ERT treatment at the appropriate time. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2024, we presented updated clinical data at the 20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual WORLD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symposium</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in San Diego, CA, showing sustained benefit and a differentiated safety profile for isaralgagene civaparvovec.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2024, we aligned with U.S. Food and Drug Administration, or FDA, on an abbreviated pathway to potential approval of isaralgagene civaparvovec. The FDA agreed in a Type D meeting that data from a single, adequate, and well-controlled study may form the primary basis of approval of a Biologics License Application, or BLA, for isaralgagene civaparvovec. The proposed study would enroll up to 25 patients, both male and female, without the need for a control arm. A head-to-head comparison with ERT is not part of the proposed study design deemed acceptable by the FDA. This approach enables a potentially more rapid, efficient and cost-effective pathway to BLA submission than originally anticipated. In addition, isaralgagene civaparvovec was also granted both priority medicine, or PRIME, eligibility from the European Medicines Agency, or EMA, and Innovative Licensing and Access Pathway, or ILAP, from the U.K. Medicines and Healthcare products Regulatory Agency, or MHRA.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently engaged in active discussions with potential collaboration partners for the Fabry disease program. We continue to defer additional investments in planning for a potential registrational trial until a collaboration partnership or financing for this program is secured.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Program</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia A</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy that we are developing with Pfizer Inc., or Pfizer, for patients with moderately severe to severe hemophilia A, continues to progress. Dosing of all patients in the trial is now complete.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pivotal readout is expected in the middle of 2024, with Pfizer anticipating submitting a biologics license application, or BLA, and a marketing authorization application, or MAA, in early 2025 if the pivotal readout is supportive.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are eligible to earn from Pfizer up to $220.0 million in potential milestone payments upon the achievement of certain regulatory and commercial milestones for giroctocogene fitelparvovec and product royalties of 14% - 20% if giroctocogene fitelparvovec is approved and commercialized, subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our zinc finger, or ZF, technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal of bringing our medicines more rapidly to patients. We believe these collaborations will potentially expand the addressable markets of our product candidates. To date, we have received approximately $817.0 million in upfront licensing fees, milestone payments and proceeds from sale of our common stock to collaborators and have the opportunity to earn up to $1.9 billion in potential future milestone payments from our ongoing collaborations, in addition to potential product royalties.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &amp; Process Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following restructuring of our operations in 2023, we expect to be substantially reliant on external partners to manufacture clinical supply for our neurology portfolio. We are retaining our in-house analytical and process development capabilities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and operations and those of our collaborators may continue to be affected by financial instability and a general decline in economic conditions in the United States and other countries caused by political instability and conflict, including the ongoing conflict between Russia and Ukraine and conflicts in the Middle East, and economic or financial challenges caused by current and potential future bank failures or by general health crises, which have led to market disruptions, including significant volatility in commodity prices, credit and capital markets instability, including disruptions in access to bank deposits and lending commitments, supply chain interruptions, rising interest rates and global inflationary pressures. These macroeconomic factors could materially and adversely affect our ability to continue to operate as a going concern and could otherwise have a material adverse effect on our business, operations, operating results and financial condition as well as the price of our common stock. In particular, our ability to raise the substantial additional capital we need in order to fund our business and to continue to operate as a going concern may be adversely impacted by these macroeconomic factors, and we cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, our cash and cash equivalents as of March&#160;31, 2024 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Our history of significant losses, negative cash flows from operations, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management&#8217;s assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q are issued. Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors, including to progress our preclinical and clinical programs as described in the 2023 Annual Report and this Quarterly Report on Form 10-Q. Although we raised capital via the Registered Direct Offering as described above, we will still need substantial additional capital in order to continue to operate as a going concern and fund our operations. We have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs. We may be unable to attract new investments as a result of the speculative nature of our newly reprioritized core neurology preclinical programs. We have been unsuccessful in securing such additional capital to date. Additional capital may not be available on acceptable terms or at all. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. If we are unable to secure additional funding in the very near term, we will likely seek protection under the U.S. Bankruptcy Code. We have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues have consisted primarily of revenues from collaboration agreements, which included upfront licensing fees, reimbursements for research services, and milestone achievements, and research grant funding. In 2022, our collaboration agreement with Sanofi S.A., or Sanofi, terminated. In 2023, our collaboration agreements with Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, and Novartis Institutes for BioMedical Research, Inc., or Novartis, were terminated, and the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary, or Kite, expired pursuant to its terms in April 2024. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements. For additional information concerning the terms of our ongoing and terminated collaboration agreements, see Note 5 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major Customers, Partnerships and Strategic Alliances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception and expect to incur losses for at least the next several years as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect research and development expenses to decrease in the near-term in connection with the restructuring of operations and reduction in workforce and significant reduction in our internal manufacturing and allogeneic research footprints in California announced in April 2023, or the April 2023 Restructuring, the further restructuring of operations and corresponding reduction in workforce announced in November 2023, or the November 2023 Restructuring, and the France Restructuring, we expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our product candidates from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research stage through clinical trials. Pursuant to the terms of our termination and transition agreement with Sanofi, certain expenses related to research and development activities may be reimbursed to us. Any reimbursement funds to be received from Sanofi will decrease our research and development expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expense, professional fees, allocated facilities and information technology expenses, patent prosecution expenses and other general corporate expenses. Although we expect general and administrative expenses to decrease in the near-term in connection with the April 2023 Restructuring, November 2023 Restructuring and France Restructuring, we expect the growth of our business to require increased general and administrative expenses as we continue to advance our product candidates into and through the clinic.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements and the related disclosures have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies and estimates relating to revenue recognition and valuation of long-lived assets including goodwill and indefinite-lived intangible assets are the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements. See Note 1 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization, Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2024, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II, Item 7 of the 2023 Annual Report.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended March&#160;31, 2024 and 2023</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.656%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,476)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.7%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues during the three months ended March&#160;31, 2024 primarily consisted of royalties from our license agreements with Sigma-Aldrich Corporation, or Sigma, and Open Monoclonal Technology, Inc. (now Ligand Pharmaceuticals Inc.), or Ligand. We anticipate revenues in the future will be derived primarily from our license agreements. The terminations of our collaboration agreements with Biogen and Novartis became effective in June 2023, following which we are not entitled to any further milestone payments or royalties from either Biogen or Novartis, nor does either Biogen or Novartis have any further obligations to develop or to reimburse us the costs of any of the programs previously subject to the Biogen and Novartis collaborations. Further, our collaboration agreement with Kite expired pursuant to its terms in April 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $157.5&#160;million in revenues for the three months ended March&#160;31, 2024, compared to the same period in 2023, was primarily attributed to decreases of $132.3&#160;million and $9.8&#160;million in revenues relating to our collaboration agreements with Biogen and Novartis, respectively, due to the termination of collaboration agreements in June 2023, a decrease of $12.3&#160;million in revenue relating to our collaboration agreement with Kite, and a decrease of $3.1 million in revenue relating to our license agreements with Sigma and Ligand. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.656%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,136&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,916)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63%)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted primarily of compensation related expenses, including restructuring charges and stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply, contracted research, and allocated facilities and information technology expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $27.3 million in research and development expenses for the three months ended March&#160;31, 2024, compared to the same period in 2023, was primarily attributable to lower compensation and other personnel costs of $13.2&#160;million which was mainly due to lower headcount as a result of restructuring of operations and a corresponding reduction in workforce announced during 2023 and a reduction in the bonus expense, lower preclinical and clinical expenses of $10.0 million primarily related to the termination of collaboration agreements with Biogen and Novartis, and deferral and reprioritization of certain programs, and lower facilities, infrastructure related expenses, and allocated overheads of $4.7 million. Stock-based compensation expense included in research and development expenses was $1.4 million and $4.9 million for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future. While we anticipate that our research and development expenses will decrease in the near-term in connection with the April 2023 Restructuring, November 2023 Restructuring and France Restructuring and the related reprioritization of certain programs and deferral of certain new investments, we ultimately expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our preclinical product candidates into clinical trials and/or if we are successful in securing new collaborations or other capital necessary to advance our clinical programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required to complete our development programs and our development costs for those programs may be impacted by the results of preclinical testing, scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, whether we pursue development of our product candidates with a partner or collaborator or independently and our ability to secure the necessary funding to progress the development of our programs. For example, our current focus is on our core neurology preclinical program, and we do not yet know whether and to what extent we will progress any resulting product candidates from our preclinical program into the clinic and in what therapeutic areas. In this regard, in connection with the April 2023 Restructuring and November 2023 Restructuring, we have paused further development of certain preclinical programs following conclusion of collaborations with Biogen and Novartis and are deferring new investments in registrational trial planning activities for our Fabry disease gene therapy program until we secure a collaboration partner or external investment in this program. We are actively seeking collaboration partners or a direct external investment, as applicable, to progress our Fabry disease, STAC-BBB and modular integrase programs. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with our development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation related expenses including restructuring charges and stock-based compensation for executive, legal, finance and administrative personnel, professional fees, allocated facilities and information technology expenses, and other general corporate expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $6.4&#160;million in general and administrative expenses for the three months ended March&#160;31, 2024, compared to the same period in 2023, was primarily attributable to lower compensation and other personnel costs of $4.6 million which was mainly due to lower headcount as a result of restructuring of operations and a corresponding reduction in workforce announced during 2023 and a reduction in the bonus expense, lower Biogen contract cost asset amortization of $2.7 million primarily driven by a notification of termination of the collaboration agreement in March 2023, and lower facilities and infrastructure related costs of $1.8 million. These decreases were partially offset by higher allocated overheads of $2.9 million. Stock-based compensation expense included in general and administrative expenses was $1.3 million and $3.4 million for the three months ended March&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we anticipate that our general and administrative expenses will decrease modestly in the near-term in connection with the April 2023 Restructuring, November 2023 Restructuring and France Restructuring, we expect higher general and administrative expenses in the next several years if we are successful in advancing our clinical programs and if we are able to progress our preclinical product candidates into clinical trials and/or if we are successful in securing new collaborations or other capital. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charges</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we executed a series of restructurings of operations and corresponding reductions in workforce announced in April 2023 and November 2023. In 2024, we are executing a wind-down of our French operations and a corresponding workforce reduction announced in March 2024. These restructurings were designed to reduce overall costs and advance our strategic transformation into a neurology focused genomic medicine company focused on epigenetic regulation programs addressing serious neurological diseases and novel AAV capsid delivery technology. In connection with the April 2023 Restructuring, November 2023 Restructuring and France Restructuring, during the period ended March 31, 2024, we incurred approximately $0.9 million in expenses related to employee severance and notice period payments, benefits, and related restructuring charges, of which $0.7 million is included in research and development expense and $0.2 million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations included in this Quarterly Report on Form 10-Q. We did not incur any restructuring charges during the three months ended March 31, 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information see&#160;Note&#160;10&#160;&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form&#160;10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Goodwill and Long-lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, our Board of Directors approved the France Restructuring, and we initiated several actions aimed at reducing costs, including actions to commence closing of our facility in Brisbane, California. As a result of these factors, we concluded our long-lived assets, primarily comprising right-of-use assets, related leasehold improvements, and certain manufacturing and laboratory equipment, were impaired. Based on our analyses, we recognized a pre-tax long-lived assets impairment charge of $4.3 million during the three months ended March&#160;31, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we concluded our goodwill and certain long-lived assets were impaired due to a sustained decline in our stock price and related market capitalization, and termination of the collaboration agreements with Biogen and Novartis. Based on this analysis, we recognized a non-cash, pre-tax goodwill impairment charge of $38.1 million and long-lived asset impairment charge of $20.4 million during the three months ended March 31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information see&#160;Note&#160;6&#160;&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Goodwill and Long-lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $2.5 million and $3.3 million for the three months ended March&#160;31, 2024 and 2023, respectively. The decrease of $0.8&#160;million was primarily driven by a decrease of $1.9&#160;million in interest income due to decrease in marketable securities, partially offset by $0.5 million related to fluctuations in foreign currency exchange rates, and $0.3 million in research tax credits.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses, and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, we had cash and cash equivalents totaling $54.4&#160;million, compared to cash, cash equivalents, and marketable securities of $81.0&#160;million as of December&#160;31, 2023. Our most significant use of capital during the year was for employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including U.S. government-sponsored entity debt securities, commercial paper securities, money market funds, corporate debt securities, asset-backed securities and certificates of deposit. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an Open Market Sale Agreement&#8480;, or the sales agreement, with Jefferies LLC, providing for the sale of up to $150.0&#160;million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under an existing shelf registration statement. In December 2022, we entered into Amendment No. 2 to the Open Market Sale Agreement&#8480;, which increased the aggregate offering price under the sales agreement by an additional $175.0 million. Approximately $194.5&#160;million remained available under the sales agreement as of March&#160;31, 2024. No shares were sold during the three months ended March&#160;31, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification Topic 205-40, Presentation of Financial Statements&#8212;Going Concern, or ASC Topic 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the company&#8217;s ability to continue as a going concern. The mitigating effects of management&#8217;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved by the company&#8217;s board of directors before the date that the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, our cash and cash equivalents as of March 31, 2024 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Our history of significant losses, negative cash flows from operations, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management&#8217;s assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q are issued. Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors, including to progress our preclinical and clinical programs as described in this Quarterly Report on Form 10-Q. Although we raised capital via the Registered Direct Offering for net proceeds of approximately $21.8&#160;million after deducting placement agents&#8217; fees and estimated offering expenses payable by us, we will still need substantial additional capital in order to continue to operate as a going concern and fund our operations. We have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs. We may be unable to attract new investments as a result of the speculative nature of our newly reprioritized core neurology preclinical programs. We have been unsuccessful in securing such additional capital to date. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. If we are unable to secure additional funding in the very near term, we will likely seek protection under the U.S. Bankruptcy Code. We have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders. Additional capital may not be available on acceptable terms or at all.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the April 2023 Restructuring, November 2023 Restructuring and France Restructuring to be complete by the third quarter of 2024, the second quarter of 2024, and fourth quarter of 2024, respectively, we may also incur other charges </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, each of the restructurings. In addition, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, or we may use our available capital more quickly than we expect, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend, or entirely cease, our operations. Moreover, we rely in part on our collaboration partners to provide funding for and otherwise advance our preclinical and clinical programs. However, in June 2022, our collaboration agreement with Sanofi terminated, in June 2023 our collaboration agreements with Biogen and Novartis terminated, and in April 2024, our collaboration agreement with Kite expired. While we may identify new collaboration partners who can progress some of the programs that were the subject of these collaborations as well as our Fabry disease, STAC-BBB and modular integrase programs, we have not yet been, and may never be, successful in doing so in a timely manner, on acceptable terms or at all, and we may otherwise fail to raise sufficient additional capital in order to progress these programs ourselves, in which case, we will not receive any return on our investments in these programs. In any event, we need substantial additional funding in order to progress the programs that were the subject of these collaborations as well as our Fabry disease, STAC-BBB and modular integrase programs, and to otherwise execute on our current operating plan. If we raise additional capital through public or private equity offerings, including sales pursuant to our at-the-market offering program with Jefferies LLC, the ownership interest of our existing stockholders will be diluted, and such dilution may be substantial given our current stock price decline, and the terms of any new equity securities may have a preference over, and include rights superior to, our common stock. If we raise additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, we may need to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If we raise additional capital through debt financing, we may be subject to specified financial covenants or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict our ability to commercialize our product candidates or operate as a business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek regulatory approvals of our product candidates from the FDA or other comparable foreign regulatory authorities, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. In particular, our ability to raise the substantial additional capital we need in order to fund our business may be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as has been experienced recently due in part to, among other things, the ongoing conflict between Russia and Ukraine and conflicts in the Middle East and disruptions in access to bank deposits and lending commitments due to bank failure. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $48.7&#160;million for the three months ended March&#160;31, 2024, primarily due to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net loss of $49.1&#160;million, adjusted for non-cash long-lived asset impairment charges of $4.3&#160;million, other non-cash expenses related to stock-based compensation of $2.7&#160;million, depreciation and amortization of $1.4&#160;million, and amortization of operating lease right-of-use assets of $1.1&#160;million, offset by accretion of discounts and impairment of marketable securities of $0.3&#160;million; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in accounts payable and other accrued liabilities by $4.9&#160;million, a decrease in accrued compensation and employee benefits by $2.6&#160;million, a decrease in lease liabilities by $1.2&#160;million, and an increase in prepaid expenses and other assets by $0.8&#160;million. These were partially offset by a decrease in interest receivable by $0.4&#160;million, and a decrease in accounts receivable by $0.2&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $66.3 million for the three months ended March 31, 2023, primarily reflecting our net income of $21.1 million, adjusted for non-cash goodwill and long-lived asset impairment charges of $38.1 million and $20.4 million, respectively, a decrease in prepaid expenses and other assets by $6.2 million, and $12.8 million of non-cash expenses related to stock-based compensation, depreciation and amortization, amortization of premium on marketable securities, and amortization of operating lease right-of-use assets. These increases were offset by a decrease in deferred revenues of $149.8 million mainly attributed to the impact of termination related contract modification for our collaboration agreement with Biogen and the change in estimate for our collaboration agreement with Kite, a decrease in accrued compensation and employee benefits by $8.6 million mainly attributed to bonus pay-outs, an increase in accounts receivable by $3.3 million, a decrease in accounts payable and other accrued liabilities by $1.9 million, and a decrease in lease liabilities by $1.2 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $35.8&#160;million for the three months ended March&#160;31, 2024, related to sales of marketable securities of $34.7&#160;million, and maturities of marketable securities of $1.1&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $35.7 million for the three months ended March 31, 2023, related to maturities of marketable securities of $82.2 million, partially offset by purchases of marketable securities of $36.2 million, and purchases of property and equipment of $10.2 million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $22.1&#160;million for the three months ended March&#160;31, 2024, related to $22.5&#160;million of proceeds from issuance of common stock, net of offering expenses of $1.4&#160;million, partially offset by taxes paid related to net share settlement of equity awards of $0.4&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $8.0 million for the three months ended March 31, 2023, mostly related to $9.4 million of proceeds from the at-the-market offering, net of offering expenses of $0.3 million, partially offset by taxes paid related to net share settlement of equity awards of $1.1 million.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital and Capital Expenditure Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continuing to incur operating losses for at least the next several years and need to raise substantial additional capital. The effects of the current macroeconomic environment, including the effects of war in Ukraine and conflicts in the Middle East, financial and liquidity challenges associated with current and potential future bank failures, inflation, climate change, rising interest rates and other economic uncertainty and volatility, has resulted and may continue to result in significant disruption of global financial markets, which could impair our ability to access capital on terms that are acceptable or at all, and in turn could negatively affect our liquidity and our ability to continue to operate as a going concern. Future capital requirements beyond the third quarter of 2024, the period into which we expect our existing cash and cash equivalents, in combination with potential future cost reductions, will be sufficient to fund our planned operations, will be substantial, and we need to raise substantial additional capital to continue to operate as a going concern and to fund the development, manufacturing and potential commercialization of our product candidates. In this regard, we have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations and other direct investments in our programs. We have been unsuccessful in securing such additional capital to date. Additional capital may not be available on acceptable terms or at all. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. If we are unable to secure additional funding in the very near term, we will likely seek protection under the U.S. Bankruptcy Code.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. Our future capital requirements will depend on many forward-looking factors, including the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of preclinical testing of our early-stage core neurology program product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of potential disputes and litigation.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future minimum contractual obligations as of December&#160;31, 2023 were reported in the 2023 Annual Report. During the three months ended March&#160;31, 2024, there have been no material changes outside the ordinary course of our business from the contractual obligations previously disclosed in our 2023 Annual Report.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_109"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk relates to our cash, cash equivalents, and marketable securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We have in the past selected investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks have decreased materially from those discussed in Item&#160;7A of our 2023 Annual Report due to decrease in our cash and cash equivalents balance as of March&#160;31, 2024.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in the United States as well as in Europe. The functional currency of each foreign subsidiary is the local currency. We are exposed to foreign currency risk, primarily through operations of our subsidiaries in Europe which conduct business primarily in Euros. We record gains and losses within our stockholders&#8217; equity due to the translation of our subsidiaries&#8217; financial statements into U.S. dollars. Our foreign currency exchange risk at March&#160;31, 2024 has not changed materially from that discussed in Item&#160;7A of our 2023 Annual Report.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_112"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of March&#160;31, 2024. Based on that evaluation, as of March&#160;31, 2024, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_118"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_121"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below we are providing, in supplemental form, changes to our risk factors from those previously disclosed in Part I, Item 1A of the 2023 Annual Report. Our risk factors disclosed in Part I, Item 1A of the 2023 Annual Report provide additional discussion about these supplemental risks and we encourage you to read and carefully consider the risk factors disclosed in Part I, Item 1A of the 2023 Annual Report for a more complete understanding of the risks and uncertainties material to our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a history of recurring net losses, including $49.1&#160;million for the three months ended March 31, 2024 and $257.8 million and $192.3 million for the years ended December 31, 2023 and 2022, respectively, and we have otherwise generated operating losses since we began operations in 1995. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZF technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. We expect to continue to incur additional operating losses for the next several years as we continue to develop our preclinical core neurology therapeutic programs and capsid engineering platform. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to further curtail or suspend, or entirely cease, our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is substantial doubt about our ability to continue to operate as a going concern. We need substantial additional funding to execute our operating plan and to continue to operate as a going concern. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. Future sales and issuances of equity securities would also result in substantial dilution to our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. Based on our current operating plan, we estimate that our available cash, cash equivalents and marketable securities as of March 31, 2024, in combination with potential future cost reductions, will be sufficient to fund our planned operations only into the third quarter of 2024. Our financial position raises substantial doubt about our ability to continue to operate as a going concern. Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors, including to progress our preclinical and clinical programs as described in our 2023 Annual Report and in this Quarterly Report. In this regard, we have been seeking, and continue to actively seek substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs. Although we raised capital via a registered direct offering of common stock and accompanying warrants in March 2024, or the 2024 Registered Direct Offering, for net proceeds of approximately $21.8 million after deducting placement agents&#8217; fees and estimated offering expenses payable by us, we will still need substantial additional capital in order to continue to operate as a going concern and fund our operations. We have been unsuccessful in securing such additional capital to date. Additional capital may not be available on acceptable terms or at all. In particular, the perception of our ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of our operations, particularly in light of currently challenging macroeconomic and market conditions. Further, we may be unable to attract new investments as a result of the speculative nature of our newly reprioritized core neurology preclinical programs. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. If we are unable to secure additional funding in the very near term, we will likely seek protection under the U.S. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bankruptcy Code. We have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we announced a restructuring of operations and a reduction in force and a significant reduction in our internal manufacturing and allogeneic research footprints in California, or the April 2023 Restructuring, and in November 2023, we announced a further restructuring of operations and reduction in force, or the November 2023 Restructuring, including a strategic transformation to focus resources on our proprietary neurology-focused epigenetic regulation programs and AAV capsid delivery technology and move all U.S. operations, including our headquarters, to our Richmond, California facility. On March 1, 2024, our board of directors approved the wind-down of our operations in France and closure of our facility in Valbonne France by the end of 2024, or the France Restructuring. While we expect the April 2023 Restructuring, November 2023 Restructuring and France Restructuring to be complete by the third quarter of 2024, the second quarter of 2024 and the fourth quarter of 2024, respectively, we may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, each of the restructurings. In addition, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, or we may use our available capital more quickly than we expect, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend, or entirely cease, our operations. Moreover, we have historically relied in part on collaboration partners to provide funding for and otherwise advance our preclinical and clinical programs. However, in June 2022, our collaboration agreement with Sanofi terminated, in June 2023 our collaboration agreements with Biogen and Novartis terminated, and our collaboration agreement with Kite expired pursuant to its terms in April 2024. While we may identify new collaboration partners who can progress some of the programs that were the subject of these collaborations as well as our Fabry disease, STAC-BBB and modular integrase programs, we have not yet been, and may never be, successful in doing so in a timely manner, on acceptable terms or at all, and we may otherwise fail to raise sufficient additional capital in order to progress these and our other programs ourselves, in which case, we will not receive any return on our investments in these programs. In any event, we need substantial additional funding in order to progress the programs that were the subject of these collaborations as well as our Fabry disease, STAC-BBB and modular integrase programs, and to advance our core neurology programs and otherwise execute on our current operating plan.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through public or private equity offerings, including sales pursuant to our at-the-market offering program with Jefferies LLC, the ownership interest of our existing stockholders will be diluted, and such dilution may be substantial given our current stock price decline. For example, in the 2024 Registered Direct Offering, we issued 24,761,905 shares of common stock, pre-funded warrants to purchase 3,809,523 shares of common stock and accompanying warrants to purchase an aggregate of 28,571,428 shares of common stock at a price per share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant of $0.84 per share. In addition, the terms of any new equity securities we may issue may have a preference over, and include rights superior to, our common stock. If we raise additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, we may need to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If we raise additional capital through debt financing, we may be subject to specified financial covenants or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict our ability to commercialize our product candidates or operate as a business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek regulatory approvals of our product candidates from the FDA or other comparable foreign regulatory authorities, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. In particular, our ability to raise the substantial additional capital we need in order to fund our business may be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as has been experienced recently. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our ability to continue to operate as a going concern and our ability to develop our technology and products candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek to reorganize under the U.S. Bankruptcy Code, our future operations are uncertain, and such reorganization could be unsuccessful and/or result in no recovery for holders of our common stock. If we are unable to successfully reorganize, we may be forced to pursue a liquidation of some or all of our assets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, our cash, cash equivalents and marketable securities as of March 31, 2024 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Although we completed the 2024 Registered Direct Offering, we have continued to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs, and we have been unsuccessful in securing any such additional capital to date. As a result, we have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders. In the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">event we file for relief under the U.S. Bankruptcy Code, our operations, our ability to develop our product candidates and execute on our operating plan, and our ability to continue as a going concern will be subject to the risks and uncertainties associated with bankruptcy proceedings, including, among others: our ability to execute, confirm and consummate a plan of reorganization; the additional, significant costs of bankruptcy proceedings and related fees; our ability to obtain sufficient financing to allow us to emerge from bankruptcy and execute our business plan thereafter, and our ability to comply with terms and conditions of any such financing; our ability to continue our operations in the ordinary course; our ability to maintain our relationships with our collaborators, counterparties, employees and other third parties; our ability to obtain, maintain or renew contracts that are critical to our operations on reasonably acceptable terms and conditions or at all; our ability to attract, motivate and retain key employees; the ability of third parties to use certain provisions of the U.S. Bankruptcy Code to terminate contracts without first seeking Bankruptcy Court approval; the ability of third parties to seek and obtain court approval to terminate or shorten the exclusivity period for us to propose and confirm a plan of reorganization, to appoint a trustee, or to convert a proceeding under Chapter 11 of the U.S. Bankruptcy Code to a proceeding under Chapter 7 of the U.S. Bankruptcy Code; and the actions and decisions of our stakeholders and other third parties who have interests in our bankruptcy proceedings that may be inconsistent with our operational and strategic plans. Any delays in our bankruptcy proceedings would increase the risks that we may not be able to reorganize our business and emerge from bankruptcy proceedings and may increase our costs associated with the bankruptcy process or result in prolonged operational disruption. In addition, we would need the prior approval of the Bankruptcy Court for transactions outside the ordinary course of business during the course of any bankruptcy proceedings, which may limit our ability to respond timely to certain events or take advantage of certain opportunities. Because of the risks and uncertainties associated with any bankruptcy proceedings, we cannot accurately predict or quantify the ultimate impact of events that could occur during any such proceedings. There can be no guarantees that if we seek protection under the U.S. Bankruptcy Code, we will emerge from any such proceedings as a going concern or that holders of our common stock will receive any recovery from any bankruptcy proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we are unable to pursue protection under Chapter 11 of the U.S. Bankruptcy Code, or, if pursued, successfully emerge from such proceedings, it may be necessary for us to pursue protection under Chapter 7 of the U.S. Bankruptcy Code for all or a part of our businesses. In such event, a Chapter 7 trustee would be appointed or elected to liquidate our assets for distribution in accordance with the priorities established by the U.S. Bankruptcy Code. We believe that liquidation under Chapter 7 would result in significantly smaller distributions being made to our stakeholders than those we might obtain under Chapter 11, or no distribution at all, primarily because of the likelihood that the assets would have to be sold or otherwise disposed of in a distressed fashion over a short period of time rather than in a controlled manner and as a going concern. In such event, you may lose part or all of your investment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have fully impaired our goodwill and indefinite-lived intangible assets, have recorded significant impairment of our long-lived assets, and may be required to record significant additional charges if our long-lived assets become further impaired in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test goodwill, indefinite-lived intangible assets and long-lived assets for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest impairment exists. Any significant change in market conditions, including fluctuations in our stock price, that indicates a reduction in carrying value may give rise to impairment in the period that the change becomes known. For example, during the year ended December 31, 2023 and the three months ended March 31, 2024, we recognized impairment charges of $155.0 million and $4.3&#160;million, respectively. We have fully impaired our goodwill and indefinite-lived intangible assets and have significantly impaired our long-lived assets. The Company will continue to assess whether its long-lived assets are impaired in future periods. As the Company finalizes the wind-down of its France operations and corresponding reduction in force of all France employees, as well as the closure of its Brisbane facility, it is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated. For additional information regarding these impairment charges, see Note 6 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Goodwill and Long-lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that changes in circumstances, many of which are outside of our control, or in the numerous variables associated with the assumptions and estimates used in assessing the appropriate valuation of our long-lived assets, could in the future result in significant additional impairment charges to our long-lived assets, which could adversely affect our results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently do not meet, and may not regain compliance with, the listing standards of the Nasdaq Stock Market LLC, or Nasdaq, and as a result our common stock may be delisted. Delisting could adversely affect the liquidity of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on the Nasdaq Global Select Market, which has minimum requirements that a company must meet in order to remain listed. These requirements include maintaining a minimum closing bid price of $1.00 per </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share, which closing bid price cannot fall below $1.00 per share for a period of more than 30 consecutive trading days, or the Bid Price Requirement. On April 24, 2024, we received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff of Nasdaq notifying us that, for the last 30 consecutive business days, the bid price of our common stock had closed below $1.00 per share, thereby failing to satisfy the Bid Price Requirement set forth in the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of our common stock on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until October 21, 2024, to regain compliance with the Bid Price Requirement by having shares of our common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. In the event we do not regain compliance with the Bid Price Requirement prior to the expiration of the compliance period, unless Nasdaq exercises its discretion to extend this period, our common stock may be subject to a delisting action by Nasdaq.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reverse stock split may allow us to meet the Bid Price Requirement, but we cannot assure you that a reverse stock split will be approved by our stockholders or that any reverse stock split, if implemented, will be sufficient to enable us to maintain our Nasdaq listing. Additionally, if a reverse stock split is implemented, there can be no assurance that the market price per new share of our common stock following the reverse stock split will remain unchanged or will increase in proportion to the reduction in the number of old shares of our common stock outstanding before the reverse stock split. The liquidity of the shares of our common stock may be affected adversely by any reverse stock split given the reduced number of shares of our common stock that will be outstanding following such reverse stock split. Furthermore, following any reverse stock split, the resulting market price of our common stock may not attract new investors and may not satisfy the investing requirements of those investors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that our common stock is delisted from Nasdaq as a result of our failure to regain compliance with the Bid Price Requirement, as a result of Nasdaq not granting us an extension or the panel not granting us a favorable decision or due to our failure to continue to comply with any other requirement for continued listing on Nasdaq, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board, but there can be no assurance that our common stock will be eligible for trading on such alternative exchange or market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if our common stock is delisted from Nasdaq, the liquidity of our common stock would be adversely affected, the market price of our common stock could decrease, our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired and transactions in our common stock could lose federal preemption of state securities laws. Furthermore, there could also be a further reduction in our coverage by securities analysts and the news media and broker-dealers may be deterred from making a market in or otherwise seeking or generating interest in our common stock, which could cause the price of our common stock to decline further. Moreover, delisting may also negatively affect our collaborators&#8217;, vendors&#8217;, suppliers&#8217; and employees&#8217; confidence in us and employee morale.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_124"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_127"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_130"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i745479549cf04f87b26b2a1df73a11c9_133"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.801%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/sgmo-20230602xex33.htm">Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K filed June 2, 2023).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828022032209/sgmo-20221219xxex31fifth.htm">Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 19, 2022).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex41.htm">Form of Pre-Funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on March 25, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex42.htm">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Current Report on Form 8-K filed on March 25, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="secondamendmenttoleaseag.htm">Second Amendment to Lease Agreement between the Company and PPF OFF 7000 Marina Boulevard LP dated February 5, 2024.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312524076613/d816036dex101.htm">Form of Securities Purchase Agreement, dated March 21, 2024 by and among Sangamo Therapeutics, Inc. and the purchasers party thereto (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on March 25, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240331xex311.htm">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240331xex312.htm">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240331xex321.htm">Certifications Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2024 is formatted in Inline XBRL and it is contained in Exhibit 101</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">#&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Indicates management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">+&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i745479549cf04f87b26b2a1df73a11c9_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i745479549cf04f87b26b2a1df73a11c9_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;9, 2024 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ALEXANDER D. MACRAE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Alexander D. Macrae</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PRATHYUSHA DURAIBABU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prathyusha Duraibabu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>secondamendmenttoleaseag.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>secondamendmenttoleaseag</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- secondamendmenttoleaseag001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="secondamendmenttoleaseag001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    SECOND AMENDMENT TO LEASE AGREEMENT    THIS SECOND AMENDMENT TO LEASE (this &#8220;Second Amendment&#8221;) is entered  into as of February 5, 2024, (the &#8220;Second Amendment Effective Date&#8221;), by and between PPF  OFF 7000 MARINA BOULEVARD LP, a Delaware limited partnership (&#8220;Landlord&#8221;), and  SANGAMO THERAPEUTICS, INC., a Delaware corporation (&#8220;Tenant&#8221;), with reference to  the following facts:  A. Landlord (as successor to Marina Boulevard Property, LLC) and Tenant are  parties to that certain Lease Agreement dated November 3, 2017 (the &#8220;Original Lease&#8221;), as  amended by that certain First Amendment to Lease Agreement dated as of January 1, 2019 (the  Original Lease, as so amended, being referred to herein as the &#8220;Lease&#8221;), pursuant to which  Landlord leases to Tenant the entire rentable square feet of the building located at 7000 Marina  Boulevard, Brisbane, California (the &#8220;Building&#8221;), which contains approximately 87,695 rentable  square feet in the aggregate (the &#8220;Premises&#8221;).  The Building is part of a multi-building complex  known as Marina Landing.  B. Landlord and Tenant desire to amend certain provisions of the Lease to modify  the circumstances upon which Landlord may draw upon the existing Letter of Credit delivered to  Landlord by Tenant, and to provide for Landlord to deliver written notice terminating the Lease.  NOW, THEREFORE, in consideration of the above recitals which by this reference are  incorporated herein, the mutual covenants and conditions contained herein and other valuable  consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and  Tenant agree as follows:  1. Letter of Credit; Application to Rent and Reduction.    (a) Landlord currently holds that certain Irrevocable Standby Letter of Credit  No SVBFS014272, issued by Silicon Valley Bank, as originally dated August 5, 2019, and  amended September 17, 2019.  The current value of the Letter of Credit is One Million Five  Hundred Thousand Dollars ($1,500,000).  Supplementing and amending Section 6 of the Lease,  Tenant hereby authorizes and directs Landlord to draw upon the Letter of Credit so as to satisfy  in whole or, for April, 2024, in part Tenant&#8217;s scheduled monthly Rent obligations for the months  of February, 2024, March, 2024, and April, 2024, as follows:  Period: Monthly  Base Rent  Monthly Cost  Recovery  Elevator  Deposit  Amort.  Total Rent  02/01/2024 &#8211; 02/29/2024 $409,515.09 $171,950.54 $2,347.34 $583,812.97  03/01/2025 &#8211; 03/31/2024 $409,515.09 $171,950.54 $2,347.34 $583,812.97  04/01/2026 &#8211; 04/30/2024 $409,515.09 $171,950.54 $2,347.34 $583,812.97*    *Tenant acknowledges that applying Letter of Credit amount will not be sufficient to pay  for the full amount of April, 2024 Rent, and accordingly Landlord shall only request the amount  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- secondamendmenttoleaseag002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="secondamendmenttoleaseag002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  2  then available under the Letter of Credit and the balance of April, 2024 Rent shall be timely paid  by Tenant on or before April 1, 2024.    (b) Landlord shall deliver a draw request in said amounts (each a &#8220;Requested  Amount&#8221;) to the Issuing Bank (which Landlord acknowledges is First Citizens Bank, as  successor to Silicon Valley Bank, and not Wells Fargo Bank, N.A. as set forth in the Lease) on  or about February 1, 2024, March 1, 2024, and April 1, 2024, respectively, and without further  notice to Tenant.  This use of the Letter of Credit shall be conditioned, at Landlord&#8217;s sole  election, on there being no Event of Default as of the date in question and, except upon an Event  of Default, Tenant shall not be required to reinstate the full amount of the Letter of Credit as  reduced by such draws.  So long as Issuing Bank disburses the Requested Amount to Landlord  within ten (10) business days after Landlord&#8217;s request in accordance with the terms of the Letter  of Credit (the &#8220;Payment Period&#8221;), Tenant shall not be deemed to be in breach of its obligation to  pay the Requested Amount.  If Issuing Bank does not disburse the Requested Amount to  Landlord within the Payment Period for any reason, including the inability or refusal on the part  of Issuing Bank, at Landlord&#8217;s option, Tenant&#8217;s right to pay Rent by way of a draw on the Letter  of Credit shall be void, and Tenant shall pay the full unpaid amount to Landlord within five (5)  business days after receipt of written notice from Landlord.  Except for permitting the payment  of Rent by utilizing the draws upon the Letter of Credit on the aforesaid terms and conditions,  Landlord is not modifying or waiving any of Tenant&#8217;s obligations to pay Rent under the Lease or  waiving any of Landlord&#8217;s rights or remedies under the Lease in any respect, including  Landlord&#8217;s remedies for an Event of Default.  Landlord acknowledges that, assuming all  payments are actually made as contemplated in this Second Amendment, as of the Second  Amendment Effective Date no Event of Default exists with regard to the payment of Rent, nor  (without any duty of investigation) does Landlord have any actual, current knowledge of the  existence of any other Event of Default.  The application of the Letter of Credit to Tenant&#8217;s Rent  obligations is intended to be a temporary accommodation and does not otherwise modify  Tenant&#8217;s obligation under the Lease to provide Letter of Credit security to Landlord.  On or  before June 1, 2024, Tenant shall accordingly deposit a cash security deposit with Landlord in  the amount of One Million Five Hundred Thousand Dollars ($1,500,000) or replace the Letter of  Credit with a new Letter of Credit in such amount with terms and from a bank reasonably  satisfactory to Landlord (and Landlord hereby agrees that First Citizens Bank, as successor to  Silicon Valley Bank, is acceptable to Landlord).   2. Landlord&#8217;s Early Termination Rights.    (a) Tenant acknowledges that Landlord intends to commence to market the  Premises for leasing to one or more third parties. Notwithstanding anything in the Lease to the  contrary, Landlord shall have the unconditional and continuing right to advance the Expiration  Date of the Lease to a date or dates selected by Landlord.  Landlord may terminate this Lease as  to all or only a portion of the Premises, provided that the remaining portion of the Premises  under the Lease following a partial termination shall constitute a commercially reasonable  demising of the Premises leaving the remaining Premises as a functional architectural unit  suitable for marketing for leasing or subleasing to a third party.  In that event Tenant shall pay  for the cost of any demising walls or other improvements as if such were necessitated by a  proposed subletting or assignment pursuant to Article 10 of the Lease; provided, however, that  Tenant&#8217;s payment obligations under this sentence shall not exceed Two Hundred Fifty Thousand  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- secondamendmenttoleaseag003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="secondamendmenttoleaseag003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  3  Dollars ($250,000) in the aggregate.  To exercise its early termination rights under this  paragraph, Landlord must give Tenant written notice (the &#8220;Expiration Notice&#8221;) at least thirty  (30) days (&#8220;Expiration Period&#8221;) prior to the effective early Expiration Date, and such early  Expiration Date may not be earlier than September 30, 2024. The reference date of September  30, 2024 relates solely and exclusively to the timing of the Expiration Period in circumstances  absent any breach or default by Tenant giving Landlord the independent right to terminate the  Lease prior to September 30, 2024.  For example, without limiting Landlord&#8217;s other rights, if  Tenant does not reinstate the full amount of the Letter of Credit referenced above on or before  June 1, 2024, or should otherwise default or breach under the Lease, in each case beyond any  applicable notice and cure periods, Landlord shall have the right to enforce Landlord&#8217;s rights  under the Lease (including lease termination) prior to September 30, 2024.  Rent shall be  adjusted on a pro rata basis as of the Expiration Date, and if the Expiration Date is not the last  day of a calendar month, Tenant shall only be required to pay such prorated amount for the final  calendar month of the Term. Landlord agrees that it shall not seek to collect from Tenant any fee  or payment in connection with an Expiration Notice, and that in no event shall Tenant be liable  to Landlord for any such fee or payment.  Upon reasonable advance notice to Tenant and during  reasonable hours, Tenant shall reasonably cooperate with Landlord to make the property  available for showings and inspections to facilitate such leasing plans.  Landlord agrees that the  early termination rights in this paragraph 2 shall not apply in the event the Premises are subject  to any sublease approved by the Landlord pursuant to Section 10 of the Lease.    (b) By written notice to Landlord, Tenant may extend the Expiration Period  for a period of up to an additional sixty (60) days if Tenant&#8217;s legally mandated and unavoidable  facility decommissioning obligations would reasonably require more than thirty (30) days to  complete.  In all circumstances, the extension of the Expiration Period shall be expressly  conditioned upon Tenant&#8217;s diligent efforts to commence and conclude any such  decommissioning work within the Expiration Period.  Tenant&#8217;s &#8220;diligent efforts&#8221; shall require, at  a minimum, that Tenant at all times be compliance with the following:  (i) Tenant submits the  detailed plans for such decommissioning (&#8220;Decommissioning Plans&#8221;) to Landlord within ten  (10) business days after the date of the Expiration Notice, (ii) Tenant promptly submits the  Decommissioning Plans to the proper governmental authorities along with all other required  documents, plans and specifications related thereto in compliance with all governmental  requirements, simultaneously providing copies of all such submissions to Landlord; (iii) Tenant  pays in a timely manner any fees required by the governmental authorities in order for the  Decommissioning Plans to be approved; (iv) Tenant cooperates with the governmental  authorities by (a) submitting any additional information or documents, as may be required from  time to time, within ten (10) business days following request therefor, and (b) responding to any  questions or comments from governmental authorities within ten (10) business days following  oral or written notice to Tenant of said questions or comments, as the case may be, with copies of  each to Landlord; (vi) Tenant keeps Landlord advised of Tenant&#8217;s progress in obtaining the  approval of the Decommissioning Plans, including (a) providing Landlord with copies of reports,  comments, revised submissions, and any revisions to the Decommissioning Plans, and (b)  meeting with Landlord on a regular basis to discuss in detail the status of the Decommissioning  Plans.  Landlord shall cooperate with Tenant, at no out-of-pocket expense to Landlord, in  securing the approval of the Decommissioning Plans.      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- secondamendmenttoleaseag004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="secondamendmenttoleaseag004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  4  3. Miscellaneous.  (a) This Second Amendment sets forth the entire agreement between the  parties with respect to the matters set forth herein.  There have been no additional oral or written  representations or agreements.  Except as herein modified or amended, the provisions, conditions  and terms of the Lease shall remain unchanged and in full force and effect.  (b) In the case of any inconsistency between the provisions of the Lease and  this Second Amendment, the provisions of this Second Amendment shall govern and control.  (c) Submission of this Second Amendment by Landlord is not an offer to  enter into this Second Amendment.  Landlord and Tenant shall not be bound by this Second  Amendment until Landlord and Tenant have mutually executed and delivered the same to  Tenant.  (d) Capitalized terms used in this Second Amendment shall have the same  definitions as set forth in the Lease to the extent that such capitalized terms are defined therein  and not redefined in this Second Amendment.  (e) Tenant hereby represents to Landlord that Tenant has dealt with no broker  in connection with this Second Amendment.  Tenant agrees to defend, indemnify and hold  Landlord harmless from all claims of any brokers claiming to have represented Tenant in  connection with this Second Amendment.  Landlord hereby represents to Tenant that Landlord  has dealt with no broker in connection with this Second Amendment.  Landlord agrees to  indemnify and hold Tenant harmless from all claims of any brokers claiming to have represented  Landlord in connection with this Second Amendment.   (f) Each signatory of this Second Amendment represents hereby that such  signatory has the authority to execute and deliver the same on behalf of the party hereto for  which such signatory is acting.  (g) This notice is given pursuant to California Civil Code Section 1938.  The  Premises have not been issued a disability access inspection certificate.  A Certified Access  Specialist (CASp) can inspect the Premises and determine whether the Premises complies with  all of the applicable construction-related accessibility standards under state law. Although state  law does not require a CASp inspection, Landlord may not prohibit Tenant from obtaining a  CASp inspection.  If Tenant desires to perform a CASp inspection, Tenant will provide written  notice to Landlord, and Landlord may elect, in its sole discretion, to retain a CASp to perform  the inspection.  If Landlord does not so elect, the time and manner of any CASp inspection  performed by Tenant, as well as the CASp selected to perform such inspection, will be subject to  the prior written approval of Landlord, not to be unreasonably withheld, conditioned or delayed.   In either event, the payment of the fee for the CASp inspection shall be borne by Tenant.  The  cost of making any repairs necessary to correct violations of construction-related accessibility  standards within the Premises shall be borne by Tenant.  (h) Tenant represents and warrants to Landlord that Tenant is currently in  compliance with and shall at all times (including any extension thereof) remain in compliance  with the regulations of the Office of Foreign Asset Control (&#8220;OFAC&#8221;) of the Department of the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- secondamendmenttoleaseag005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="secondamendmenttoleaseag005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  5  Treasury and any statute, executive order (including the September 24, 2001, Executive Order  Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to  Commit, or Support Terrorism), or other governmental action relating thereto.  (i) This Second Amendment may be executed in multiple counterparts each  of which is deemed an original but together constitute one and the same instrument.  This Second  Amendment may be executed in so-called &#8220;pdf&#8221; format and each party has the right to rely upon  a pdf counterpart of this Second Amendment signed by the other party to the same extent as if  such party had received an original counterpart.  Electronic signatures on this Second  Amendment shall be valid and effective to bind the party so signing electronically.  [SIGNATURES ARE ON FOLLOWING PAGE]  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- secondamendmenttoleaseag006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="secondamendmenttoleaseag006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  6  IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Second  Amendment as of the Second Amendment Effective Date.  LANDLORD:    PPF OFF 7000 MARINA BOULEVARD LP,  a Delaware limited liability company      By: /s/ Derek Simmons     Name: Derek Simmons   Title: Vice President       TENANT:    SANGAMO THERAPEUTICS, INC.,  a Delaware corporation      By:  /s/ Scott B. Willoughby    Scott B. Willoughby  General Counsel      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sgmo-20240331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ifac7d413e49349dd8d2299a195e10f98_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alexander D. Macrae, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2024</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sgmo-20240331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6055df441079458e996e123eedbc85ed_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Prathyusha Duraibabu, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2024</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sgmo-20240331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i880a3bd73bd54d7b8d9a8c36652ca1d4_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his or her capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2024, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sgmo-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b5443692-b648-47ae-ab89-daa7dd92e886,g:144bc5eb-acb5-4055-8fa1-fd0ab68e078a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000007 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000008 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>0000009 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSINCOMEPERSHARE" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARE">
        <link:definition>0000010 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
        <link:definition>0000011 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS" roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS">
        <link:definition>0000012 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000014 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000015 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGES" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGES">
        <link:definition>0000016 - Disclosure - RESTRUCTURING CHARGES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000017 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>9954474 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSINCOMEPERSHARETables" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables">
        <link:definition>9954475 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
        <link:definition>9954476 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGESTables" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables">
        <link:definition>9954478 - Disclosure - RESTRUCTURING CHARGES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954479 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails">
        <link:definition>9954480 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails">
        <link:definition>9954481 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails">
        <link:definition>9954483 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>9954484 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails">
        <link:definition>9954485 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails">
        <link:definition>9954486 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails">
        <link:definition>9954487 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails">
        <link:definition>9954488 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails">
        <link:definition>9954489 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails">
        <link:definition>9954490 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9954491 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails">
        <link:definition>9954492 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>9954493 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGESNarrativeDetails" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails">
        <link:definition>9954494 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails">
        <link:definition>9954495 - Disclosure - RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9954496 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" abstract="false" name="IncreaseDecreaseInNetIncomeLossAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CommonWarrantMember" abstract="true" name="CommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" abstract="true" name="AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_November2023RestructuringPlanMember" abstract="true" name="November2023RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_ChangeInAgreementEstimateMarch2023Member" abstract="true" name="ChangeInAgreementEstimateMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareDiluted" abstract="false" name="IncreaseDecreaseInEarningsPerShareDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" abstract="false" name="IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_WarrantOrRightPolicyPolicyTextBlock" abstract="false" name="WarrantOrRightPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" abstract="false" name="WarrantOrRightOutstandingExercisablePeriodAfterIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" abstract="false" name="LesseeRequiredLetterOfCreditOutstandingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_April2023RestructuringPlanMember" abstract="true" name="April2023RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_DirectOfferingMember" abstract="true" name="DirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sgmo_FullTimeEmployeesMember" abstract="true" name="FullTimeEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" abstract="false" name="SaleOfStockIncreaseToAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockAgentPlacementFees" abstract="false" name="SaleOfStockAgentPlacementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockOtherOfferingCosts" abstract="false" name="SaleOfStockOtherOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContractedEmployeesMember" abstract="true" name="ContractedEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockPlacementFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" abstract="true" name="WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveMember" abstract="true" name="SBFiveTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PreFundedCommonStockWarrantMember" abstract="true" name="PreFundedCommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_StockIssuanceCostsNotYetPaid" abstract="false" name="StockIssuanceCostsNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_FranceRestructuringPlanMember" abstract="true" name="FranceRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockOutstandingAmountAvailable" abstract="false" name="SaleOfStockOutstandingAmountAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" abstract="false" name="ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sgmo_EquipmentFurnitureAndFixturesMember" abstract="true" name="EquipmentFurnitureAndFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" abstract="true" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" abstract="false" name="LesseeOperatingLeaseRequiredNoticeOfTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" abstract="false" name="SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_OtherLicensingAgreementsMember" abstract="true" name="OtherLicensingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareBasic" abstract="false" name="IncreaseDecreaseInEarningsPerShareBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>sgmo-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b5443692-b648-47ae-ab89-daa7dd92e886,g:144bc5eb-acb5-4055-8fa1-fd0ab68e078a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c6361553-8e03-487d-8138-37bea385b917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1fbf4e5f-89fa-43a6-81c7-d8386173eb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6361553-8e03-487d-8138-37bea385b917" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1fbf4e5f-89fa-43a6-81c7-d8386173eb1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_4468e21b-c91d-40a7-9e83-cedbd6e08a1f" xlink:href="sgmo-20240331.xsd#sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6361553-8e03-487d-8138-37bea385b917" xlink:to="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_4468e21b-c91d-40a7-9e83-cedbd6e08a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_328b7738-6cba-47de-b684-f5abc88d7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6361553-8e03-487d-8138-37bea385b917" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_328b7738-6cba-47de-b684-f5abc88d7bf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_79424e24-a0f8-454f-bf65-ccb5861a0447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6361553-8e03-487d-8138-37bea385b917" xlink:to="loc_us-gaap_AssetsCurrent_79424e24-a0f8-454f-bf65-ccb5861a0447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8bc09872-9d36-4764-b086-e5a96c055d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6361553-8e03-487d-8138-37bea385b917" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8bc09872-9d36-4764-b086-e5a96c055d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_54984c61-5cc6-49f1-8c76-74f6a7de1e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bfa90c6f-7e6c-4d90-8b25-7b705bbd4941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_54984c61-5cc6-49f1-8c76-74f6a7de1e22" xlink:to="loc_us-gaap_PreferredStockValue_bfa90c6f-7e6c-4d90-8b25-7b705bbd4941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3404f76-97a3-446c-9120-36e2a86e8aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_54984c61-5cc6-49f1-8c76-74f6a7de1e22" xlink:to="loc_us-gaap_CommonStockValue_b3404f76-97a3-446c-9120-36e2a86e8aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8579591b-8382-4703-9d78-18aabbf4ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_54984c61-5cc6-49f1-8c76-74f6a7de1e22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8579591b-8382-4703-9d78-18aabbf4ba74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bb6fc92-1941-40c2-b8df-1d8334cd1601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_54984c61-5cc6-49f1-8c76-74f6a7de1e22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bb6fc92-1941-40c2-b8df-1d8334cd1601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5debcedd-2fc9-4e21-bb4f-46f48470aac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_54984c61-5cc6-49f1-8c76-74f6a7de1e22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5debcedd-2fc9-4e21-bb4f-46f48470aac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_adee35a8-0218-4827-830a-597b33884ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_af1a9e9b-c1d6-4dff-9f7c-b1592b4f2bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_adee35a8-0218-4827-830a-597b33884ae3" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_af1a9e9b-c1d6-4dff-9f7c-b1592b4f2bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_79b1838e-0512-4014-9c42-a8170df31690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_adee35a8-0218-4827-830a-597b33884ae3" xlink:to="loc_us-gaap_AccountsPayableCurrent_79b1838e-0512-4014-9c42-a8170df31690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ee8b4bd3-f5ca-4c5c-b7b1-2e83d4c29c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_adee35a8-0218-4827-830a-597b33884ae3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ee8b4bd3-f5ca-4c5c-b7b1-2e83d4c29c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_21819898-b45e-443c-847b-1c69c41f91b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f88565fc-d3f4-4329-9a8d-a56008934242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_21819898-b45e-443c-847b-1c69c41f91b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f88565fc-d3f4-4329-9a8d-a56008934242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9bf51e8c-dc41-4da5-967d-b37149d6691f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_21819898-b45e-443c-847b-1c69c41f91b2" xlink:to="loc_us-gaap_LiabilitiesCurrent_9bf51e8c-dc41-4da5-967d-b37149d6691f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d0b9ac9d-8aef-4669-acdd-d1b7ee2f1503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_21819898-b45e-443c-847b-1c69c41f91b2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d0b9ac9d-8aef-4669-acdd-d1b7ee2f1503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_665de2d6-2649-47cc-91f8-a8451ae002be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd346eab-d7f0-4884-9f3c-5bfd9c43f50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_665de2d6-2649-47cc-91f8-a8451ae002be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd346eab-d7f0-4884-9f3c-5bfd9c43f50d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_1e24384a-6de6-43dc-8b68-36523207d627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_665de2d6-2649-47cc-91f8-a8451ae002be" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_1e24384a-6de6-43dc-8b68-36523207d627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cb05ee37-5530-4337-9f0f-7c74d30e4b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_665de2d6-2649-47cc-91f8-a8451ae002be" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cb05ee37-5530-4337-9f0f-7c74d30e4b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_82df74b8-8f92-4709-88be-a800382cb9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_665de2d6-2649-47cc-91f8-a8451ae002be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_82df74b8-8f92-4709-88be-a800382cb9b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_3f8cf7fe-1308-4458-a55f-06d8d22375a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_665de2d6-2649-47cc-91f8-a8451ae002be" xlink:to="loc_us-gaap_RestrictedCashCurrent_3f8cf7fe-1308-4458-a55f-06d8d22375a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_43c11a5a-d0ce-47cc-bb85-9b74675c205a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_604b90db-6043-4e08-a551-fdc951d6ce8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_43c11a5a-d0ce-47cc-bb85-9b74675c205a" xlink:to="loc_us-gaap_Liabilities_604b90db-6043-4e08-a551-fdc951d6ce8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1a4b617b-92fc-459c-8ecd-12ba037d667f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_43c11a5a-d0ce-47cc-bb85-9b74675c205a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1a4b617b-92fc-459c-8ecd-12ba037d667f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c357dd3-3695-409d-b464-9f888af55639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_43c11a5a-d0ce-47cc-bb85-9b74675c205a" xlink:to="loc_us-gaap_StockholdersEquity_6c357dd3-3695-409d-b464-9f888af55639" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d7c1e1e7-b0ae-4108-bdcd-dc0c67a38268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4466aa6-c6d3-4844-aa9f-5bbf64d6916e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d7c1e1e7-b0ae-4108-bdcd-dc0c67a38268" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4466aa6-c6d3-4844-aa9f-5bbf64d6916e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6e9836fc-d973-4704-b45c-afd9e6b39aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d7c1e1e7-b0ae-4108-bdcd-dc0c67a38268" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6e9836fc-d973-4704-b45c-afd9e6b39aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_18f1a850-f322-45aa-af17-44377160fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8700bffc-ae6e-4b52-8400-fa08b1ab6dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_18f1a850-f322-45aa-af17-44377160fb97" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8700bffc-ae6e-4b52-8400-fa08b1ab6dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_24fa6b80-d0cd-43e1-9a5b-8a65a7a4568b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_18f1a850-f322-45aa-af17-44377160fb97" xlink:to="loc_us-gaap_OperatingExpenses_24fa6b80-d0cd-43e1-9a5b-8a65a7a4568b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c6ba8c5c-0428-4c52-9ce3-a4e085a5a510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_29a05447-84b7-4d91-b0fd-ea0e2a4b4f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c6ba8c5c-0428-4c52-9ce3-a4e085a5a510" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_29a05447-84b7-4d91-b0fd-ea0e2a4b4f51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a6e125bb-98c7-42a9-b7a7-1eac3fa07318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c6ba8c5c-0428-4c52-9ce3-a4e085a5a510" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a6e125bb-98c7-42a9-b7a7-1eac3fa07318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_0efe47cc-98a4-4fb2-8fd8-12a8a3e11051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c6ba8c5c-0428-4c52-9ce3-a4e085a5a510" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_0efe47cc-98a4-4fb2-8fd8-12a8a3e11051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0d591b6d-e6fc-4518-8a15-cc654ede31e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c6ba8c5c-0428-4c52-9ce3-a4e085a5a510" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0d591b6d-e6fc-4518-8a15-cc654ede31e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8104dc1-b552-4c53-b1b7-d166a97379ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d716a66c-c89d-46fe-8ce1-4b2dda21bc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8104dc1-b552-4c53-b1b7-d166a97379ed" xlink:to="loc_us-gaap_OperatingIncomeLoss_d716a66c-c89d-46fe-8ce1-4b2dda21bc1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_b0aa88af-b3cb-4b97-b04d-a6f9d7e4863a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8104dc1-b552-4c53-b1b7-d166a97379ed" xlink:to="loc_us-gaap_InterestAndOtherIncome_b0aa88af-b3cb-4b97-b04d-a6f9d7e4863a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0b9c7eee-392b-4f84-9e04-7115e9661e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a712fb1c-bacb-4ce3-b43f-8e855679362a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0b9c7eee-392b-4f84-9e04-7115e9661e61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a712fb1c-bacb-4ce3-b43f-8e855679362a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9448ac25-1db4-48c8-af29-a9c0be5d5b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0b9c7eee-392b-4f84-9e04-7115e9661e61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9448ac25-1db4-48c8-af29-a9c0be5d5b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_4db70ccf-1391-47ca-8b25-318bc3c4e1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0b9c7eee-392b-4f84-9e04-7115e9661e61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_4db70ccf-1391-47ca-8b25-318bc3c4e1c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93e09774-0906-44b7-bc66-a213057a3404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0b9c7eee-392b-4f84-9e04-7115e9661e61" xlink:to="loc_us-gaap_NetIncomeLoss_93e09774-0906-44b7-bc66-a213057a3404" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6e3b0466-60a2-47f3-9fe6-19b5206c8283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6e3b0466-60a2-47f3-9fe6-19b5206c8283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_19612b19-10cd-46cb-b8b6-fc56847a9e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_ShareBasedCompensation_19612b19-10cd-46cb-b8b6-fc56847a9e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8c50a13b-7e9f-4f98-85e5-2b8d3e8dc30e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8c50a13b-7e9f-4f98-85e5-2b8d3e8dc30e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1754ac4c-8a7f-42af-b06c-36a24d255ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1754ac4c-8a7f-42af-b06c-36a24d255ca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24df8834-d7e2-4677-a6c6-7b6a45619493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_24df8834-d7e2-4677-a6c6-7b6a45619493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e9796963-69f7-423f-9ca4-e2e1cdeae950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e9796963-69f7-423f-9ca4-e2e1cdeae950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ead774ef-1ad5-4ff0-aa1b-828079f7607c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ead774ef-1ad5-4ff0-aa1b-828079f7607c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f09d3f8-0ac6-442c-a7f6-06a68d921c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f09d3f8-0ac6-442c-a7f6-06a68d921c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_04358fa0-c9ba-437b-8f05-04ab20f98eef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_04358fa0-c9ba-437b-8f05-04ab20f98eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c69ca233-8907-462f-8091-9f48a8aabb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_NetIncomeLoss_c69ca233-8907-462f-8091-9f48a8aabb7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_94be861b-fc62-4f0c-aa99-01c8a586e8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_94be861b-fc62-4f0c-aa99-01c8a586e8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_116f3d47-9ce1-43b0-b9c2-aa1b89059b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_116f3d47-9ce1-43b0-b9c2-aa1b89059b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9ee1d36d-8ea6-4985-ab7a-90c95873c3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9ee1d36d-8ea6-4985-ab7a-90c95873c3b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_71d9b1ed-3d56-45ae-8463-df81cb83299c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_71d9b1ed-3d56-45ae-8463-df81cb83299c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8b34d0af-e4a8-451d-939e-b2e2b185940a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e38f4ab-7036-4435-a49d-6cd1aa1aa1c3" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8b34d0af-e4a8-451d-939e-b2e2b185940a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9ac0ae0-99d0-4cb5-a3a2-eff5b376e456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_13783010-b4d5-4e25-a3e7-76fa20b002e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9ac0ae0-99d0-4cb5-a3a2-eff5b376e456" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_13783010-b4d5-4e25-a3e7-76fa20b002e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3562331b-5643-4297-aae8-363960cad1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9ac0ae0-99d0-4cb5-a3a2-eff5b376e456" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3562331b-5643-4297-aae8-363960cad1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28c16d64-0fc6-4e63-bfe8-dab53d74fae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c63b0cb-fe90-4ee1-8fc5-885b92efc1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28c16d64-0fc6-4e63-bfe8-dab53d74fae9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c63b0cb-fe90-4ee1-8fc5-885b92efc1f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_3c00b81d-e1ba-40b7-a526-258394219654" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28c16d64-0fc6-4e63-bfe8-dab53d74fae9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_3c00b81d-e1ba-40b7-a526-258394219654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_581d1d9d-5885-4d4b-8187-e29b90c546f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28c16d64-0fc6-4e63-bfe8-dab53d74fae9" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_581d1d9d-5885-4d4b-8187-e29b90c546f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_8ccc4d74-3ab9-4ddf-be24-c5180e417ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28c16d64-0fc6-4e63-bfe8-dab53d74fae9" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_8ccc4d74-3ab9-4ddf-be24-c5180e417ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6c49832-ada0-4a01-a9db-e07df4ddb28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_847fb5d1-1e1c-436b-87df-1fe8ddceb47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6c49832-ada0-4a01-a9db-e07df4ddb28a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_847fb5d1-1e1c-436b-87df-1fe8ddceb47d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b50e3981-d503-457d-9179-7e3a730e3818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6c49832-ada0-4a01-a9db-e07df4ddb28a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b50e3981-d503-457d-9179-7e3a730e3818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a75a371d-2034-474e-ad9d-7050244f7002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6c49832-ada0-4a01-a9db-e07df4ddb28a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a75a371d-2034-474e-ad9d-7050244f7002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_933f63bc-6c56-43d6-8642-52a8b5b5b974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c6c49832-ada0-4a01-a9db-e07df4ddb28a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_933f63bc-6c56-43d6-8642-52a8b5b5b974" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2242e3c1-951b-4400-87d3-06bb77fbeec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2c8d422-1ade-4281-ab69-f54dac5f4034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2242e3c1-951b-4400-87d3-06bb77fbeec9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2c8d422-1ade-4281-ab69-f54dac5f4034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e092e288-e852-4e74-87bc-ccb655ddfac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2242e3c1-951b-4400-87d3-06bb77fbeec9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e092e288-e852-4e74-87bc-ccb655ddfac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_12b6e665-be43-4241-81eb-f06247e86688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2242e3c1-951b-4400-87d3-06bb77fbeec9" xlink:to="loc_us-gaap_RestrictedCashCurrent_12b6e665-be43-4241-81eb-f06247e86688" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_24e0ca97-34a8-4bb5-9a6c-cc94c1cfd197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c8787ca4-791b-4da6-9b35-be8403344abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_24e0ca97-34a8-4bb5-9a6c-cc94c1cfd197" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c8787ca4-791b-4da6-9b35-be8403344abf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_77c449b6-f3b7-4ba2-a178-155e7eea622e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_24e0ca97-34a8-4bb5-9a6c-cc94c1cfd197" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_77c449b6-f3b7-4ba2-a178-155e7eea622e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f310dbb4-aa28-4cda-9e7c-26a40e7dfe92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_40cf0192-719a-4fcf-a1ac-aec79627886e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f310dbb4-aa28-4cda-9e7c-26a40e7dfe92" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_40cf0192-719a-4fcf-a1ac-aec79627886e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b07b90c4-e1b4-43fe-98ac-4efa036578ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f310dbb4-aa28-4cda-9e7c-26a40e7dfe92" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b07b90c4-e1b4-43fe-98ac-4efa036578ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_511cecf2-503c-43ad-86a1-3e36e65dd90a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f310dbb4-aa28-4cda-9e7c-26a40e7dfe92" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_511cecf2-503c-43ad-86a1-3e36e65dd90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9b86430-673f-4f54-a655-18605f460b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_9cf67f74-2586-459d-8638-ef3bb5b8d368" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9b86430-673f-4f54-a655-18605f460b40" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_9cf67f74-2586-459d-8638-ef3bb5b8d368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_26815227-65ff-4055-a555-fdb53cad905b" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9b86430-673f-4f54-a655-18605f460b40" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_26815227-65ff-4055-a555-fdb53cad905b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_98d15cbf-faa9-44d8-a5d2-5ed5f1e29fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9b86430-673f-4f54-a655-18605f460b40" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_98d15cbf-faa9-44d8-a5d2-5ed5f1e29fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_9921a8a7-1c87-41db-b86b-0ead77a5fad7" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_7756976b-face-47ef-a4d2-e3fd1a4e074f" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_9921a8a7-1c87-41db-b86b-0ead77a5fad7" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_7756976b-face-47ef-a4d2-e3fd1a4e074f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_7256808b-777b-4629-8bd2-e5d5f865a364" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_9921a8a7-1c87-41db-b86b-0ead77a5fad7" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_7256808b-777b-4629-8bd2-e5d5f865a364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_5d0ba624-27d9-4c2b-9676-7089d094a2fa" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_9921a8a7-1c87-41db-b86b-0ead77a5fad7" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_5d0ba624-27d9-4c2b-9676-7089d094a2fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4c107d0b-69a9-4ca6-bca3-055c82c60534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c652fed0-e271-49c8-978f-295250c8a3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4c107d0b-69a9-4ca6-bca3-055c82c60534" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c652fed0-e271-49c8-978f-295250c8a3cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5e5404a6-c065-4b93-aba7-77580a1f3407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_4c107d0b-69a9-4ca6-bca3-055c82c60534" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5e5404a6-c065-4b93-aba7-77580a1f3407" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ff10808-7ab3-4d46-aef9-aba11d80932d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9f6529f4-89fd-4731-9626-b19d2ad583f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ff10808-7ab3-4d46-aef9-aba11d80932d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9f6529f4-89fd-4731-9626-b19d2ad583f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8932c213-c3e0-4a79-8606-8532eb7880e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ff10808-7ab3-4d46-aef9-aba11d80932d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8932c213-c3e0-4a79-8606-8532eb7880e8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>sgmo-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b5443692-b648-47ae-ab89-daa7dd92e886,g:144bc5eb-acb5-4055-8fa1-fd0ab68e078a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d9972dce-3990-4057-abb1-8a7efb027ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d9972dce-3990-4057-abb1-8a7efb027ee9" xlink:to="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e" xlink:to="loc_us-gaap_EquityComponentDomain_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e" xlink:to="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6258e285-7bab-40d7-bdfd-726a7d8d439b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_CommonStockMember_6258e285-7bab-40d7-bdfd-726a7d8d439b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2487cc92-e52c-4b18-9406-ed5a6449425f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2487cc92-e52c-4b18-9406-ed5a6449425f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0fe6545e-31d7-4fc6-a593-0fc0031ef4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_RetainedEarningsMember_0fe6545e-31d7-4fc6-a593-0fc0031ef4c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24b23a96-be6d-48f4-bf17-07360f1a0f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24b23a96-be6d-48f4-bf17-07360f1a0f31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dda25bd-6a17-4eef-8b56-a10e09d86485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dda25bd-6a17-4eef-8b56-a10e09d86485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_6e83b622-52ed-428c-b4f5-f3d2e4d84321" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dda25bd-6a17-4eef-8b56-a10e09d86485" xlink:to="loc_sgmo_AtTheMarketOfferingMember_6e83b622-52ed-428c-b4f5-f3d2e4d84321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9972dce-3990-4057-abb1-8a7efb027ee9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aabcaa64-63af-4c7d-897a-612d0f427bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aabcaa64-63af-4c7d-897a-612d0f427bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52d0c953-6e7e-46f4-a705-040a345ff3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockholdersEquity_52d0c953-6e7e-46f4-a705-040a345ff3b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3fa3450-d11d-48fb-b880-4c5f827ce2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3fa3450-d11d-48fb-b880-4c5f827ce2d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_efdb0eab-6ed8-45d6-9fbd-0eea312a8368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_efdb0eab-6ed8-45d6-9fbd-0eea312a8368" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_eeb6e4d6-7328-4861-b9c5-8db83a9dcb96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_eeb6e4d6-7328-4861-b9c5-8db83a9dcb96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ea833cdb-6f7d-454e-9548-513fb903627a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ea833cdb-6f7d-454e-9548-513fb903627a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b8a3481-592b-4e52-84b6-4802e6ad5ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b8a3481-592b-4e52-84b6-4802e6ad5ec8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e4293205-5dae-41cc-8fa5-7486006e1774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e4293205-5dae-41cc-8fa5-7486006e1774" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_0a287ddf-af3d-41a2-9602-496aefc2c6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_0a287ddf-af3d-41a2-9602-496aefc2c6a6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2a11d3cc-55b9-4423-98ab-4ed9c8b936e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2a11d3cc-55b9-4423-98ab-4ed9c8b936e7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ca361c4-c6b8-4610-96c0-10583acc8465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_NetIncomeLoss_7ca361c4-c6b8-4610-96c0-10583acc8465" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_59c22421-066f-4404-9386-6615baa1d5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6319c52-1a16-4e0b-8d86-64c95dc3d921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d05a287-5742-4193-adba-fbdeaa7e9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_StatementTable_8d05a287-5742-4193-adba-fbdeaa7e9f8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a861538f-19e4-4962-8055-968eb47cf0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d05a287-5742-4193-adba-fbdeaa7e9f8f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a861538f-19e4-4962-8055-968eb47cf0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a861538f-19e4-4962-8055-968eb47cf0a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a861538f-19e4-4962-8055-968eb47cf0a3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a861538f-19e4-4962-8055-968eb47cf0a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a861538f-19e4-4962-8055-968eb47cf0a3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_4aad065d-b8d6-4733-bf97-1e2c88710653" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:to="loc_sgmo_DirectOfferingMember_4aad065d-b8d6-4733-bf97-1e2c88710653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_47ba4498-6e3f-4afe-904f-c7671663a92a" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:to="loc_sgmo_AtTheMarketOfferingMember_47ba4498-6e3f-4afe-904f-c7671663a92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc14eeca-85d8-44ba-8ae0-02adfa85fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_NetIncomeLoss_cc14eeca-85d8-44ba-8ae0-02adfa85fa8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79476bcb-231e-4a04-8337-0fb1f986e310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79476bcb-231e-4a04-8337-0fb1f986e310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3882f182-16c8-40f5-bb06-3b1e730100a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3882f182-16c8-40f5-bb06-3b1e730100a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32251619-2fd7-4f9d-83de-4ef0f928c201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32251619-2fd7-4f9d-83de-4ef0f928c201" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_93712a07-a69c-478d-a5e6-6a2099b925c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_93712a07-a69c-478d-a5e6-6a2099b925c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bd4a376b-9ded-4250-8e38-98ed181cb7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_ShareBasedCompensation_bd4a376b-9ded-4250-8e38-98ed181cb7fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5bb3faaf-a795-4fc2-bf5a-3f91422e77bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5bb3faaf-a795-4fc2-bf5a-3f91422e77bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_05c8b5e6-fcef-4581-8638-2093b18cddae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_05c8b5e6-fcef-4581-8638-2093b18cddae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58e9ba0f-155e-4062-a416-65143ad5482e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58e9ba0f-155e-4062-a416-65143ad5482e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0ee1aa52-0044-42e7-a606-ebe938875873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0ee1aa52-0044-42e7-a606-ebe938875873" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0f43752f-335e-4d6f-8116-6b4d0ce46332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0f43752f-335e-4d6f-8116-6b4d0ce46332" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_99f69d18-b818-4cff-8ecb-78d7820a5da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_99f69d18-b818-4cff-8ecb-78d7820a5da1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fd75c410-9e5b-4f6d-bf0a-92602e408b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fd75c410-9e5b-4f6d-bf0a-92602e408b4a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_446eb46a-26ae-463d-b61d-de860ad92a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_446eb46a-26ae-463d-b61d-de860ad92a77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3821d99b-da01-410e-9098-948bbde55e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3821d99b-da01-410e-9098-948bbde55e44" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ce928ff-634b-4eae-9e67-7db9016f2e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ce928ff-634b-4eae-9e67-7db9016f2e0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_45932b5c-145a-4997-89ec-c8cff7805efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_45932b5c-145a-4997-89ec-c8cff7805efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_abb4d5aa-d354-44b3-9671-0b4bd9dec104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_abb4d5aa-d354-44b3-9671-0b4bd9dec104" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1cca4e13-9d93-4c50-9d3d-c029b51d94be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1cca4e13-9d93-4c50-9d3d-c029b51d94be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9157450-62b5-4ca6-bc8d-df5099c773e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9157450-62b5-4ca6-bc8d-df5099c773e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbbe0933-db78-4182-bf5c-752d965273e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbbe0933-db78-4182-bf5c-752d965273e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b03ef832-b086-4558-b84a-45ca087824b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b03ef832-b086-4558-b84a-45ca087824b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6a8fad0-4e24-4aa5-9976-eb83ae9e7519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6a8fad0-4e24-4aa5-9976-eb83ae9e7519" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a97c265e-177b-453c-8fc0-13a3561b28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a97c265e-177b-453c-8fc0-13a3561b28ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d682c78-84e5-46b2-a467-413be0cabda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d682c78-84e5-46b2-a467-413be0cabda1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c34dfe3c-86ed-4c69-afe1-7a1fc326e271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c34dfe3c-86ed-4c69-afe1-7a1fc326e271" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_483699c4-6d34-4187-ad54-74a57a2d7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_483699c4-6d34-4187-ad54-74a57a2d7eb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5770a2b6-b8fb-46da-8974-cb92b0fd2f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuanceCostsNotYetPaid_2e06c79b-a54e-4a70-853f-3f89bc17eef4" xlink:href="sgmo-20240331.xsd#sgmo_StockIssuanceCostsNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:to="loc_sgmo_StockIssuanceCostsNotYetPaid_2e06c79b-a54e-4a70-853f-3f89bc17eef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_492a16a4-75c4-4e6c-8356-382516648b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_492a16a4-75c4-4e6c-8356-382516648b8d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5fabcacf-624a-4625-bc03-334aa613a2c4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:to="loc_srt_CounterpartyNameAxis_5fabcacf-624a-4625-bc03-334aa613a2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5fabcacf-624a-4625-bc03-334aa613a2c4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5fabcacf-624a-4625-bc03-334aa613a2c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5fabcacf-624a-4625-bc03-334aa613a2c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51569722-7412-466d-867c-67ef75a82d4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5fabcacf-624a-4625-bc03-334aa613a2c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51569722-7412-466d-867c-67ef75a82d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1a494df3-f88d-4d2b-a4e3-c091690dd4b7" xlink:href="sgmo-20240331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51569722-7412-466d-867c-67ef75a82d4d" xlink:to="loc_sgmo_KitePharmaIncMember_1a494df3-f88d-4d2b-a4e3-c091690dd4b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_11749cb9-c50f-42ef-9b19-87a051abc8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_11749cb9-c50f-42ef-9b19-87a051abc8f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_11749cb9-c50f-42ef-9b19-87a051abc8f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_11749cb9-c50f-42ef-9b19-87a051abc8f5" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_11749cb9-c50f-42ef-9b19-87a051abc8f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_afded666-8739-4171-b47a-0bfdae8b8186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_11749cb9-c50f-42ef-9b19-87a051abc8f5" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_afded666-8739-4171-b47a-0bfdae8b8186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_c0c5c0e7-6690-4571-a9c3-053ddfd517e7" xlink:href="sgmo-20240331.xsd#sgmo_ChangeInAgreementEstimateMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_afded666-8739-4171-b47a-0bfdae8b8186" xlink:to="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_c0c5c0e7-6690-4571-a9c3-053ddfd517e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_0bf1b574-1f80-4533-9497-33f0519066c9" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_0bf1b574-1f80-4533-9497-33f0519066c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_4645b12d-4a4f-4302-be4d-7a04f1c69c0c" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_4645b12d-4a4f-4302-be4d-7a04f1c69c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_a5629dee-33ee-4378-af89-e1911924ef1c" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_a5629dee-33ee-4378-af89-e1911924ef1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_b47ab0e9-b1d0-4565-a3a3-6602ea49ccce" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_b47ab0e9-b1d0-4565-a3a3-6602ea49ccce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_da06f0ad-ebfc-43d5-807f-1f4f60dac177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_da06f0ad-ebfc-43d5-807f-1f4f60dac177" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26fa5cc9-39f7-4595-9724-0aaa23fb10c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26fa5cc9-39f7-4595-9724-0aaa23fb10c7" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_59aae405-ae8f-4d08-8bec-0c11d39bf259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_59aae405-ae8f-4d08-8bec-0c11d39bf259" xlink:to="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5f756f7c-41be-457a-b049-ba535653c1c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:to="loc_srt_CounterpartyNameAxis_5f756f7c-41be-457a-b049-ba535653c1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f756f7c-41be-457a-b049-ba535653c1c6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5f756f7c-41be-457a-b049-ba535653c1c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f756f7c-41be-457a-b049-ba535653c1c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5f756f7c-41be-457a-b049-ba535653c1c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_b32df2df-f08f-4188-bd1f-3eed5ee5f890" xlink:href="sgmo-20240331.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_b32df2df-f08f-4188-bd1f-3eed5ee5f890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_af22cc2b-656f-4a6c-802d-ee3d2207d578" xlink:href="sgmo-20240331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_BiogenMAIncMember_af22cc2b-656f-4a6c-802d-ee3d2207d578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_916d6033-d211-4bf0-b61b-f219c87d057a" xlink:href="sgmo-20240331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_KitePharmaIncMember_916d6033-d211-4bf0-b61b-f219c87d057a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_fe1b96c2-4c9c-4e3e-857e-c46e7ca86b2f" xlink:href="sgmo-20240331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_fe1b96c2-4c9c-4e3e-857e-c46e7ca86b2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8da69ee4-e444-4d01-99d1-beee6a06a504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8da69ee4-e444-4d01-99d1-beee6a06a504" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8da69ee4-e444-4d01-99d1-beee6a06a504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8da69ee4-e444-4d01-99d1-beee6a06a504" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8da69ee4-e444-4d01-99d1-beee6a06a504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25d2a11c-a446-407b-8c58-616c56ea0397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8da69ee4-e444-4d01-99d1-beee6a06a504" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25d2a11c-a446-407b-8c58-616c56ea0397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_c5dc39c0-5875-4736-91f1-381803459b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25d2a11c-a446-407b-8c58-616c56ea0397" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_c5dc39c0-5875-4736-91f1-381803459b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fcc56728-5666-49e6-83ce-6fd18782e14f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fcc56728-5666-49e6-83ce-6fd18782e14f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fcc56728-5666-49e6-83ce-6fd18782e14f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fcc56728-5666-49e6-83ce-6fd18782e14f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fcc56728-5666-49e6-83ce-6fd18782e14f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6ea41163-dcf3-4f1d-bf74-a43feee8f157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fcc56728-5666-49e6-83ce-6fd18782e14f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6ea41163-dcf3-4f1d-bf74-a43feee8f157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4d10f2b1-8759-494a-a85c-9508e0b8830b" xlink:href="sgmo-20240331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6ea41163-dcf3-4f1d-bf74-a43feee8f157" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4d10f2b1-8759-494a-a85c-9508e0b8830b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3948a568-e968-4a2d-a157-d09cf6e3beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_59aae405-ae8f-4d08-8bec-0c11d39bf259" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3948a568-e968-4a2d-a157-d09cf6e3beaf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_91144cb7-6897-408e-b8b4-7b2f2be5e999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_91144cb7-6897-408e-b8b4-7b2f2be5e999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_91144cb7-6897-408e-b8b4-7b2f2be5e999_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_91144cb7-6897-408e-b8b4-7b2f2be5e999" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_91144cb7-6897-408e-b8b4-7b2f2be5e999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a69ca247-f467-4f12-bde3-49a2dc691722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_91144cb7-6897-408e-b8b4-7b2f2be5e999" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a69ca247-f467-4f12-bde3-49a2dc691722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c0f84ae3-8118-4aa1-81cd-ae25aac8f4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a69ca247-f467-4f12-bde3-49a2dc691722" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c0f84ae3-8118-4aa1-81cd-ae25aac8f4a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eafeb3f8-b98e-43ea-a786-5bd74cabd560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eafeb3f8-b98e-43ea-a786-5bd74cabd560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c2a86cf-b633-41f5-b2cf-34785faa089c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c2a86cf-b633-41f5-b2cf-34785faa089c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d7fb245b-1efe-4eb7-b9eb-691524e1f747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d7fb245b-1efe-4eb7-b9eb-691524e1f747" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a153aeca-8c14-420c-85d4-741846e0e795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a153aeca-8c14-420c-85d4-741846e0e795" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a153aeca-8c14-420c-85d4-741846e0e795_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a153aeca-8c14-420c-85d4-741846e0e795" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a153aeca-8c14-420c-85d4-741846e0e795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a153aeca-8c14-420c-85d4-741846e0e795" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_80845109-4084-4198-86e0-c030f540fa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_MoneyMarketFundsMember_80845109-4084-4198-86e0-c030f540fa3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_26731e71-6032-43de-be5b-0c9c32e551ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_26731e71-6032-43de-be5b-0c9c32e551ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_241a48a3-7c49-4ee3-93cb-b617b6027592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_CommercialPaperMember_241a48a3-7c49-4ee3-93cb-b617b6027592" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1f68b693-a194-488f-a085-f5bb0fb7040f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1f68b693-a194-488f-a085-f5bb0fb7040f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5142998c-145f-4b69-979d-b7685a1b451d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5142998c-145f-4b69-979d-b7685a1b451d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_826d4ca3-6f4e-495e-8dbd-0f602f211711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_826d4ca3-6f4e-495e-8dbd-0f602f211711" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d2f5b778-0608-4655-9b27-97f4f1bbf308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d2f5b778-0608-4655-9b27-97f4f1bbf308" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_655e2856-f405-45cf-9839-d7d767423f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_655e2856-f405-45cf-9839-d7d767423f55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f4082e7a-abaa-40c0-873b-8acecada637f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f4082e7a-abaa-40c0-873b-8acecada637f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_797cb927-4ff8-470b-95df-82a0ec6b42fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_797cb927-4ff8-470b-95df-82a0ec6b42fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_10bedf1a-b4fe-43c9-a1c7-b9ecaeb899e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_10bedf1a-b4fe-43c9-a1c7-b9ecaeb899e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_10bedf1a-b4fe-43c9-a1c7-b9ecaeb899e4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2984ebda-076f-4065-8a25-a83bdd645501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2984ebda-076f-4065-8a25-a83bdd645501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_7dad40c2-5496-43f7-bd95-5d117f179b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CashEquivalentsMember_7dad40c2-5496-43f7-bd95-5d117f179b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0ab8708c-2ff6-4080-a9d0-517fac4e99ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0ab8708c-2ff6-4080-a9d0-517fac4e99ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_32aad618-a3e9-4a86-a31e-77905d375b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CommercialPaperMember_32aad618-a3e9-4a86-a31e-77905d375b2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8fc47a78-06d7-4460-bbed-b5bec75e391a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8fc47a78-06d7-4460-bbed-b5bec75e391a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7d2ce8c0-df69-44e7-b3c5-ca62dd5b8686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7d2ce8c0-df69-44e7-b3c5-ca62dd5b8686" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_9fc34cdb-a48f-4827-9863-84592b4fcb04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_9fc34cdb-a48f-4827-9863-84592b4fcb04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_383a63ea-4ba5-400f-b683-6b1b30b80007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_383a63ea-4ba5-400f-b683-6b1b30b80007" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76abd21f-8bbd-469c-87c3-c6c4c8c13419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76abd21f-8bbd-469c-87c3-c6c4c8c13419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_3856c968-81f5-4b79-8631-a5b0944e561a" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_3856c968-81f5-4b79-8631-a5b0944e561a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_f4fcdf62-2b51-41ee-95a4-58eab06c0267" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_f4fcdf62-2b51-41ee-95a4-58eab06c0267" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54761e3b-a16a-4f03-b366-c4d5bef6214a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54761e3b-a16a-4f03-b366-c4d5bef6214a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba010427-90f6-43e0-8545-25c4d1e2da26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba010427-90f6-43e0-8545-25c4d1e2da26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dbab19e4-1630-4c82-97d6-878242ba915f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dbab19e4-1630-4c82-97d6-878242ba915f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3f6d72d5-cab8-4b76-a8f3-0f829904842a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3f6d72d5-cab8-4b76-a8f3-0f829904842a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_574d17d6-fe56-408f-8705-a3c3cd58521e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_574d17d6-fe56-408f-8705-a3c3cd58521e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_acd3af5e-8a58-43b6-912f-b528747de34a" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_acd3af5e-8a58-43b6-912f-b528747de34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_abe4db24-1e6e-4e88-af63-f191c6aa25ab" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_abe4db24-1e6e-4e88-af63-f191c6aa25ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2b9e9489-f4ca-46a7-bbc8-e41127ec3ddb" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2b9e9489-f4ca-46a7-bbc8-e41127ec3ddb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_4db36e91-03af-4ac6-a4f1-450f6107b1e5" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_4db36e91-03af-4ac6-a4f1-450f6107b1e5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d3923c00-3c39-4e01-9c29-21b60d41c8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d3923c00-3c39-4e01-9c29-21b60d41c8a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5bdc9d6d-918a-4e7d-999c-9f712606e5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d3923c00-3c39-4e01-9c29-21b60d41c8a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5bdc9d6d-918a-4e7d-999c-9f712606e5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5bdc9d6d-918a-4e7d-999c-9f712606e5e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5bdc9d6d-918a-4e7d-999c-9f712606e5e0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5bdc9d6d-918a-4e7d-999c-9f712606e5e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f28546e6-8fa4-4bd1-a429-fea76578051e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5bdc9d6d-918a-4e7d-999c-9f712606e5e0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f28546e6-8fa4-4bd1-a429-fea76578051e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_33c5a882-6d97-436b-bfdf-1c792d7bb9c0" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f28546e6-8fa4-4bd1-a429-fea76578051e" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_33c5a882-6d97-436b-bfdf-1c792d7bb9c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9485d94-faa0-41be-82aa-25deab946272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9485d94-faa0-41be-82aa-25deab946272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d40e153-4a92-4ed5-81f7-24362103289b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d40e153-4a92-4ed5-81f7-24362103289b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e825f8fe-29ad-4a3b-ba8b-af990dd7c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e825f8fe-29ad-4a3b-ba8b-af990dd7c8ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_fe88548d-a23e-41c0-95a2-9021be7b6f09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_SharePrice_fe88548d-a23e-41c0-95a2-9021be7b6f09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b05ed4d-f67c-479f-bc0e-206e13613855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b05ed4d-f67c-479f-bc0e-206e13613855" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a336f59d-e763-40f8-ab58-bf156d271780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a336f59d-e763-40f8-ab58-bf156d271780" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_5b4915f8-f5e8-4ee5-bb99-b8d6213283c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_5b4915f8-f5e8-4ee5-bb99-b8d6213283c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c85cade-920e-4dcd-926f-d4e2986f6310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_5b4915f8-f5e8-4ee5-bb99-b8d6213283c4" xlink:to="loc_us-gaap_AwardTypeAxis_5c85cade-920e-4dcd-926f-d4e2986f6310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c85cade-920e-4dcd-926f-d4e2986f6310_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5c85cade-920e-4dcd-926f-d4e2986f6310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c85cade-920e-4dcd-926f-d4e2986f6310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5c85cade-920e-4dcd-926f-d4e2986f6310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d0037abb-6ca8-4903-ad1a-58dd8e8b1b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d0037abb-6ca8-4903-ad1a-58dd8e8b1b5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7f395285-d60a-409e-a540-3a72a5bd1093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:to="loc_us-gaap_StockCompensationPlanMember_7f395285-d60a-409e-a540-3a72a5bd1093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_3541d650-f2c5-4461-b1e2-0dba958a01c3" xlink:href="sgmo-20240331.xsd#sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:to="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_3541d650-f2c5-4461-b1e2-0dba958a01c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_78f1672b-7cf6-4c0a-aaea-d9fb3efb076d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_3541d650-f2c5-4461-b1e2-0dba958a01c3" xlink:to="loc_us-gaap_NetIncomeLoss_78f1672b-7cf6-4c0a-aaea-d9fb3efb076d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5610957d-532d-45b1-bdab-d5a96e34832c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5610957d-532d-45b1-bdab-d5a96e34832c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dda11b3-a1a2-417b-8c9b-06487763fe13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5610957d-532d-45b1-bdab-d5a96e34832c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dda11b3-a1a2-417b-8c9b-06487763fe13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_00a40ee6-be16-430b-b0e7-0b676806c20a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_40b1d2b0-94f7-4959-ad38-eee798989c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_40b1d2b0-94f7-4959-ad38-eee798989c28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c812aa5c-1bc0-440d-8883-9b159ff15171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c812aa5c-1bc0-440d-8883-9b159ff15171" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:href="sgmo-20240331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ac766395-69ce-4409-a67e-891decbe9852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:to="loc_us-gaap_EarningsPerShareBasic_ac766395-69ce-4409-a67e-891decbe9852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6b33702f-496d-4db4-a654-50b1a5954160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6b33702f-496d-4db4-a654-50b1a5954160" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_720c3aca-1895-462c-b7e4-97e6d77f486f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_srt_CounterpartyNameAxis_720c3aca-1895-462c-b7e4-97e6d77f486f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_720c3aca-1895-462c-b7e4-97e6d77f486f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_720c3aca-1895-462c-b7e4-97e6d77f486f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_720c3aca-1895-462c-b7e4-97e6d77f486f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_720c3aca-1895-462c-b7e4-97e6d77f486f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_61638c9e-fc02-4840-a564-a7b3849e8f2f" xlink:href="sgmo-20240331.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:to="loc_sgmo_PfizerMember_61638c9e-fc02-4840-a564-a7b3849e8f2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_8d3ccc79-ffaa-42a2-b8e9-f6cbb4d16bc5" xlink:href="sgmo-20240331.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:to="loc_sgmo_PfizerSB525Member_8d3ccc79-ffaa-42a2-b8e9-f6cbb4d16bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_5adb653b-4e8a-40d3-b3a7-c76093c5b9de" xlink:href="sgmo-20240331.xsd#sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:to="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_5adb653b-4e8a-40d3-b3a7-c76093c5b9de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c75e57e-ec97-4e00-9f15-c1c1b4c87619" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_srt_ProductOrServiceAxis_8c75e57e-ec97-4e00-9f15-c1c1b4c87619" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c75e57e-ec97-4e00-9f15-c1c1b4c87619_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c75e57e-ec97-4e00-9f15-c1c1b4c87619" xlink:to="loc_srt_ProductsAndServicesDomain_8c75e57e-ec97-4e00-9f15-c1c1b4c87619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c75e57e-ec97-4e00-9f15-c1c1b4c87619" xlink:to="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:href="sgmo-20240331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_9f91e1e0-7a08-4d42-b762-4bbe3834c1d6" xlink:href="sgmo-20240331.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:to="loc_sgmo_SBFiveTwoFiveMember_9f91e1e0-7a08-4d42-b762-4bbe3834c1d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_d60d1766-d88b-4953-911d-d12e859b627c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_d60d1766-d88b-4953-911d-d12e859b627c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1a49100c-6363-4965-b3fb-d7f6a796ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:to="loc_us-gaap_LicenseMember_1a49100c-6363-4965-b3fb-d7f6a796ede9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_1d33599a-23c4-4686-95ed-ccc159a0577a" xlink:href="sgmo-20240331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:to="loc_sgmo_CNineORFSevenTwoMember_1d33599a-23c4-4686-95ed-ccc159a0577a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a812c581-a3ce-4eeb-9afa-b32699d6c86f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a812c581-a3ce-4eeb-9afa-b32699d6c86f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a812c581-a3ce-4eeb-9afa-b32699d6c86f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a812c581-a3ce-4eeb-9afa-b32699d6c86f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a812c581-a3ce-4eeb-9afa-b32699d6c86f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a812c581-a3ce-4eeb-9afa-b32699d6c86f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_e2fb8609-8d7e-4ede-9cfd-8a39a636be54" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_e2fb8609-8d7e-4ede-9cfd-8a39a636be54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8e741801-91ff-428e-92a9-912edaf472a1" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8e741801-91ff-428e-92a9-912edaf472a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_81f42375-8702-4c3b-acb3-ae4575455ee2" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_81f42375-8702-4c3b-acb3-ae4575455ee2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b432ee2-b730-4a45-94d7-8c832c41e553" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_srt_RangeAxis_5b432ee2-b730-4a45-94d7-8c832c41e553" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b432ee2-b730-4a45-94d7-8c832c41e553_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5b432ee2-b730-4a45-94d7-8c832c41e553" xlink:to="loc_srt_RangeMember_5b432ee2-b730-4a45-94d7-8c832c41e553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5b432ee2-b730-4a45-94d7-8c832c41e553" xlink:to="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdc437fe-7e5c-4290-bb0a-84e3347eeb45" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:to="loc_srt_MinimumMember_cdc437fe-7e5c-4290-bb0a-84e3347eeb45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5489b82d-aa13-46c9-91b3-76f3ce1be013" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:to="loc_srt_MaximumMember_5489b82d-aa13-46c9-91b3-76f3ce1be013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_256cc2eb-ce43-4b81-a9e7-71869bfbb9a4" xlink:href="sgmo-20240331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_AgreementTerminationTerm_256cc2eb-ce43-4b81-a9e7-71869bfbb9a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_511a7984-87fb-42f8-9e5f-22ff3bd3cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_511a7984-87fb-42f8-9e5f-22ff3bd3cdd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_e4f6ebd5-6aaa-4fd0-bd43-a849720f0be8" xlink:href="sgmo-20240331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_e4f6ebd5-6aaa-4fd0-bd43-a849720f0be8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_4693e4cd-a91b-4b9e-83ac-c11f3596fdbc" xlink:href="sgmo-20240331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_4693e4cd-a91b-4b9e-83ac-c11f3596fdbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_b646b0db-2b3a-46d1-a0fe-59a023e1e784" xlink:href="sgmo-20240331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_b646b0db-2b3a-46d1-a0fe-59a023e1e784" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_db46a98c-602b-4648-984c-c37ed9171a48" xlink:href="sgmo-20240331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_MilestonePaymentsReceived_db46a98c-602b-4648-984c-c37ed9171a48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_6823fa3b-e38c-449d-82e8-6844e44c45f9" xlink:href="sgmo-20240331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_MilestoneRevenueReceivable_6823fa3b-e38c-449d-82e8-6844e44c45f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_c1193335-d943-4bb5-a793-90f2e31ae690" xlink:href="sgmo-20240331.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_c1193335-d943-4bb5-a793-90f2e31ae690" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_3a5f634b-b7ee-490b-9b19-e7cc089acce9" xlink:href="sgmo-20240331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_3a5f634b-b7ee-490b-9b19-e7cc089acce9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0cfebefe-2374-4491-84ae-2fcc6ba8f7f5" xlink:href="sgmo-20240331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0cfebefe-2374-4491-84ae-2fcc6ba8f7f5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_4ef71cf7-0bba-447a-8d23-2b9be896dc40" xlink:href="sgmo-20240331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_4ef71cf7-0bba-447a-8d23-2b9be896dc40" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_197dc152-5807-4f8a-be3d-b615dae9bde4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_197dc152-5807-4f8a-be3d-b615dae9bde4" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9788256c-8106-40b0-9ca6-c854bcfaa8ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:to="loc_srt_CounterpartyNameAxis_9788256c-8106-40b0-9ca6-c854bcfaa8ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9788256c-8106-40b0-9ca6-c854bcfaa8ab_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9788256c-8106-40b0-9ca6-c854bcfaa8ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9788256c-8106-40b0-9ca6-c854bcfaa8ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9788256c-8106-40b0-9ca6-c854bcfaa8ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_c7b284bd-ef14-4b45-ac72-fb652c79b561" xlink:href="sgmo-20240331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_KitePharmaIncMember_c7b284bd-ef14-4b45-ac72-fb652c79b561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_86d3c8e8-d9d1-4434-bfdf-485e9b214733" xlink:href="sgmo-20240331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_86d3c8e8-d9d1-4434-bfdf-485e9b214733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_11906361-a0e8-486e-a3c8-c5539734b27f" xlink:href="sgmo-20240331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_BiogenMAIncMember_11906361-a0e8-486e-a3c8-c5539734b27f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_b6c607d0-efc9-45e1-8baf-f067649f975d" xlink:href="sgmo-20240331.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_b6c607d0-efc9-45e1-8baf-f067649f975d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_33b0e1f7-61b7-4ce9-8295-555225713fa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:to="loc_srt_ProductOrServiceAxis_33b0e1f7-61b7-4ce9-8295-555225713fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_33b0e1f7-61b7-4ce9-8295-555225713fa0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_33b0e1f7-61b7-4ce9-8295-555225713fa0" xlink:to="loc_srt_ProductsAndServicesDomain_33b0e1f7-61b7-4ce9-8295-555225713fa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_33b0e1f7-61b7-4ce9-8295-555225713fa0" xlink:to="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a78715ad-e3d1-4bec-b381-b0996d2fc0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:to="loc_us-gaap_LicenseMember_a78715ad-e3d1-4bec-b381-b0996d2fc0f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9866b836-7514-4808-a6c1-eb51b781e394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:to="loc_us-gaap_ServiceMember_9866b836-7514-4808-a6c1-eb51b781e394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_07d11ffc-40d4-4299-a283-c3987327eb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_197dc152-5807-4f8a-be3d-b615dae9bde4" xlink:to="loc_us-gaap_RevenuesAbstract_07d11ffc-40d4-4299-a283-c3987327eb9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a0e4dd6-c8ac-4dd1-a99a-041c57e1ae44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_07d11ffc-40d4-4299-a283-c3987327eb9e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a0e4dd6-c8ac-4dd1-a99a-041c57e1ae44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_1326b0f6-d98c-4bf3-b16a-da6792ffaa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_1326b0f6-d98c-4bf3-b16a-da6792ffaa1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_1326b0f6-d98c-4bf3-b16a-da6792ffaa1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EquipmentFurnitureAndFixturesMember_c733072b-3d9f-4199-9c15-7baaf1e97401" xlink:href="sgmo-20240331.xsd#sgmo_EquipmentFurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:to="loc_sgmo_EquipmentFurnitureAndFixturesMember_c733072b-3d9f-4199-9c15-7baaf1e97401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_64c9cc70-a2ab-4969-80d9-d855331d70cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_64c9cc70-a2ab-4969-80d9-d855331d70cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ffaae0c6-41a5-4a67-9a9e-b3d741e8bac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:to="loc_us-gaap_ConstructionInProgressMember_ffaae0c6-41a5-4a67-9a9e-b3d741e8bac4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a0df5e7e-a4d0-4ecd-8a9f-47fd2ffb9eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a0df5e7e-a4d0-4ecd-8a9f-47fd2ffb9eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4e0b0a20-46f8-49de-8295-56d4f6e87cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4e0b0a20-46f8-49de-8295-56d4f6e87cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_575a5811-a8cf-46a4-b7e0-ca6cb2ca2fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_575a5811-a8cf-46a4-b7e0-ca6cb2ca2fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_c3ec1f9e-92ab-414c-8f41-8768995960ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_c3ec1f9e-92ab-414c-8f41-8768995960ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_880b45d3-1b71-4a93-9629-6c13ac3f9021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_880b45d3-1b71-4a93-9629-6c13ac3f9021" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_63cc6959-1597-43ac-b54c-e71b1e73033c" xlink:href="sgmo-20240331.xsd#sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_63cc6959-1597-43ac-b54c-e71b1e73033c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_78049a9b-049c-4bea-b4bd-967ad204f436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_us-gaap_OtherCommitmentsTable_78049a9b-049c-4bea-b4bd-967ad204f436" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1fcdcb50-1576-4aad-9ed0-a74c44c63379" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_78049a9b-049c-4bea-b4bd-967ad204f436" xlink:to="loc_srt_StatementGeographicalAxis_1fcdcb50-1576-4aad-9ed0-a74c44c63379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1fcdcb50-1576-4aad-9ed0-a74c44c63379_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1fcdcb50-1576-4aad-9ed0-a74c44c63379" xlink:to="loc_srt_SegmentGeographicalDomain_1fcdcb50-1576-4aad-9ed0-a74c44c63379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b3888b53-2eca-4cff-b53a-64cf94cf3b80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1fcdcb50-1576-4aad-9ed0-a74c44c63379" xlink:to="loc_srt_SegmentGeographicalDomain_b3888b53-2eca-4cff-b53a-64cf94cf3b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_9c3795d2-7fb5-4b6d-a31f-15183a274074" xlink:href="sgmo-20240331.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b3888b53-2eca-4cff-b53a-64cf94cf3b80" xlink:to="loc_sgmo_RichmondCaliforniaMember_9c3795d2-7fb5-4b6d-a31f-15183a274074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_bed92dbf-4216-4381-842c-95558030771d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_bed92dbf-4216-4381-842c-95558030771d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bcccf272-9e51-465e-ad14-5f64173ce98e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bcccf272-9e51-465e-ad14-5f64173ce98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_70a08db2-e932-44be-8e1f-f535bd7368dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_70a08db2-e932-44be-8e1f-f535bd7368dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_3b25a343-639f-4db1-8e70-1a3706c5fcaa" xlink:href="sgmo-20240331.xsd#sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_3b25a343-639f-4db1-8e70-1a3706c5fcaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_5a532118-004b-4892-b417-49a211316f2d" xlink:href="sgmo-20240331.xsd#sgmo_LesseeRequiredLetterOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_5a532118-004b-4892-b417-49a211316f2d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3caf56a3-df41-4619-9ba5-a9e5664c1d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3caf56a3-df41-4619-9ba5-a9e5664c1d42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_186fd3ae-97a4-49bb-b907-3d1a3950fd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_186fd3ae-97a4-49bb-b907-3d1a3950fd3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d423c0ab-26bf-4c73-a945-247a4571128e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d423c0ab-26bf-4c73-a945-247a4571128e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d423c0ab-26bf-4c73-a945-247a4571128e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d423c0ab-26bf-4c73-a945-247a4571128e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d423c0ab-26bf-4c73-a945-247a4571128e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fc5f3d53-c029-4ef7-83c2-cc9a9f155dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d423c0ab-26bf-4c73-a945-247a4571128e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fc5f3d53-c029-4ef7-83c2-cc9a9f155dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_26437c40-50d6-453a-b14e-db59ecd6e334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fc5f3d53-c029-4ef7-83c2-cc9a9f155dde" xlink:to="loc_us-gaap_SubsequentEventMember_26437c40-50d6-453a-b14e-db59ecd6e334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8840d4f3-d354-40f4-93e9-de4b3580aa74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8840d4f3-d354-40f4-93e9-de4b3580aa74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8840d4f3-d354-40f4-93e9-de4b3580aa74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8840d4f3-d354-40f4-93e9-de4b3580aa74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8840d4f3-d354-40f4-93e9-de4b3580aa74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7fe38186-3078-443b-9635-bb200c969656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8840d4f3-d354-40f4-93e9-de4b3580aa74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7fe38186-3078-443b-9635-bb200c969656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_c4891461-e843-42ad-875e-e9934818103c" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7fe38186-3078-443b-9635-bb200c969656" xlink:to="loc_sgmo_DirectOfferingMember_c4891461-e843-42ad-875e-e9934818103c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7e36823d-bcba-4968-b36c-faec18d08510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7e36823d-bcba-4968-b36c-faec18d08510" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e36823d-bcba-4968-b36c-faec18d08510_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7e36823d-bcba-4968-b36c-faec18d08510" xlink:to="loc_us-gaap_ClassOfStockDomain_7e36823d-bcba-4968-b36c-faec18d08510_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_adb827aa-3707-4b20-b0df-6b92d7f1bf17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7e36823d-bcba-4968-b36c-faec18d08510" xlink:to="loc_us-gaap_ClassOfStockDomain_adb827aa-3707-4b20-b0df-6b92d7f1bf17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_bed827e3-e348-4998-8d42-22187cd659d1" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_adb827aa-3707-4b20-b0df-6b92d7f1bf17" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_bed827e3-e348-4998-8d42-22187cd659d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81e21123-95f8-4a16-ab5e-3726eb4917fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_81e21123-95f8-4a16-ab5e-3726eb4917fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685e9ab7-0c40-4403-89fc-b90085a6fa93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685e9ab7-0c40-4403-89fc-b90085a6fa93" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3dbcd87-811e-4426-b914-4db0f5e2fb1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_srt_CounterpartyNameAxis_d3dbcd87-811e-4426-b914-4db0f5e2fb1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3dbcd87-811e-4426-b914-4db0f5e2fb1e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d3dbcd87-811e-4426-b914-4db0f5e2fb1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3dbcd87-811e-4426-b914-4db0f5e2fb1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_293e1074-7620-4b83-a7b4-0d7f39047a19" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d3dbcd87-811e-4426-b914-4db0f5e2fb1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_293e1074-7620-4b83-a7b4-0d7f39047a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_50b5ffc7-c555-4ab9-a531-e4e541f544fe" xlink:href="sgmo-20240331.xsd#sgmo_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_293e1074-7620-4b83-a7b4-0d7f39047a19" xlink:to="loc_sgmo_JefferiesLLCMember_50b5ffc7-c555-4ab9-a531-e4e541f544fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e9dce241-eb28-41d5-ad80-4da114ff7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e9dce241-eb28-41d5-ad80-4da114ff7b59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e9dce241-eb28-41d5-ad80-4da114ff7b59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e9dce241-eb28-41d5-ad80-4da114ff7b59" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e9dce241-eb28-41d5-ad80-4da114ff7b59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e9dce241-eb28-41d5-ad80-4da114ff7b59" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_62f196fc-afc2-4733-9dc9-ea59ed41ffac" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_62f196fc-afc2-4733-9dc9-ea59ed41ffac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_890d6e26-33a8-4443-92da-f8a03ac97ce8" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:to="loc_sgmo_DirectOfferingMember_890d6e26-33a8-4443-92da-f8a03ac97ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_754b4825-bf79-415c-8da1-6c2581ac9925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_754b4825-bf79-415c-8da1-6c2581ac9925" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_754b4825-bf79-415c-8da1-6c2581ac9925_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_754b4825-bf79-415c-8da1-6c2581ac9925" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_754b4825-bf79-415c-8da1-6c2581ac9925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_754b4825-bf79-415c-8da1-6c2581ac9925" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonWarrantMember_db004b52-72d3-4005-8cd8-e90b3969f8ef" xlink:href="sgmo-20240331.xsd#sgmo_CommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:to="loc_sgmo_CommonWarrantMember_db004b52-72d3-4005-8cd8-e90b3969f8ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_f14e6771-2e42-4ecf-a6bf-db63b3040405" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_f14e6771-2e42-4ecf-a6bf-db63b3040405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f51d013f-d92a-4cb7-9dae-27377a4059aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f51d013f-d92a-4cb7-9dae-27377a4059aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f51d013f-d92a-4cb7-9dae-27377a4059aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f51d013f-d92a-4cb7-9dae-27377a4059aa" xlink:to="loc_us-gaap_ClassOfStockDomain_f51d013f-d92a-4cb7-9dae-27377a4059aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_34037de2-b03a-4bf4-befb-b3324251d2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f51d013f-d92a-4cb7-9dae-27377a4059aa" xlink:to="loc_us-gaap_ClassOfStockDomain_34037de2-b03a-4bf4-befb-b3324251d2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_4d59851b-112b-4cef-95d8-4d019ff82166" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_34037de2-b03a-4bf4-befb-b3324251d2b2" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_4d59851b-112b-4cef-95d8-4d019ff82166" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ec324844-9451-43cb-8845-ff63d4974817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ec324844-9451-43cb-8845-ff63d4974817" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ec324844-9451-43cb-8845-ff63d4974817_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ec324844-9451-43cb-8845-ff63d4974817" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ec324844-9451-43cb-8845-ff63d4974817_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bf1fbbe7-6c72-460e-8847-96547fb61102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ec324844-9451-43cb-8845-ff63d4974817" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bf1fbbe7-6c72-460e-8847-96547fb61102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3c0862bb-ae23-417d-a1ea-a0228fa8c0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bf1fbbe7-6c72-460e-8847-96547fb61102" xlink:to="loc_us-gaap_SubsequentEventMember_3c0862bb-ae23-417d-a1ea-a0228fa8c0c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_d3572096-e029-4997-9540-16e558f28818" xlink:href="sgmo-20240331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_d3572096-e029-4997-9540-16e558f28818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_156bc7f8-6a83-44f5-9097-f3506c829066" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_156bc7f8-6a83-44f5-9097-f3506c829066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOutstandingAmountAvailable_bf1a70ca-f096-4192-8f94-ea5ecbf73137" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockOutstandingAmountAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockOutstandingAmountAvailable_bf1a70ca-f096-4192-8f94-ea5ecbf73137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b50c8cb0-e9fa-4b6e-96c0-a622c4670b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b50c8cb0-e9fa-4b6e-96c0-a622c4670b79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d157e40-72cc-4fa7-a6c3-54e3d253e916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d157e40-72cc-4fa7-a6c3-54e3d253e916" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_19b563f4-88b4-4b64-bce0-9f1f908b2766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_19b563f4-88b4-4b64-bce0-9f1f908b2766" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a655d278-2650-47d3-9e5f-805325db79b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a655d278-2650-47d3-9e5f-805325db79b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_747444ab-1799-4b1c-ae6d-fb726f24ff8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_747444ab-1799-4b1c-ae6d-fb726f24ff8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8606754d-1541-4e75-8d86-f80473ea2eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8606754d-1541-4e75-8d86-f80473ea2eeb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_3384a74d-768b-41e6-a40a-3500b2e6237d" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_3384a74d-768b-41e6-a40a-3500b2e6237d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aaed046f-b1b1-403c-b931-aae74b66b047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aaed046f-b1b1-403c-b931-aae74b66b047" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6d9f084f-68ad-430a-8b16-ec3d2533040d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SharePrice_6d9f084f-68ad-430a-8b16-ec3d2533040d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_a4703219-f809-4787-9dc1-150f8e416396" xlink:href="sgmo-20240331.xsd#sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_a4703219-f809-4787-9dc1-150f8e416396" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_561b22c6-8d43-43e1-b7fb-df42f191fa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_561b22c6-8d43-43e1-b7fb-df42f191fa8d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a38323da-f837-45b0-997b-a1aef7a03544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a38323da-f837-45b0-997b-a1aef7a03544" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_df40977c-0407-4f2f-ad2d-ac7b38db82aa" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_df40977c-0407-4f2f-ad2d-ac7b38db82aa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockAgentPlacementFees_339f08d1-96f2-47c7-978a-c0b52e077687" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockAgentPlacementFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockAgentPlacementFees_339f08d1-96f2-47c7-978a-c0b52e077687" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOtherOfferingCosts_702b1dcd-535a-44c9-a895-8c2da667a3d2" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockOtherOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockOtherOfferingCosts_702b1dcd-535a-44c9-a895-8c2da667a3d2" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#RESTRUCTURINGCHARGESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_5a16f996-f077-49ac-8c0c-e525ebad4096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_us-gaap_RestructuringPlanAxis_5a16f996-f077-49ac-8c0c-e525ebad4096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5a16f996-f077-49ac-8c0c-e525ebad4096_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_5a16f996-f077-49ac-8c0c-e525ebad4096" xlink:to="loc_us-gaap_RestructuringPlanDomain_5a16f996-f077-49ac-8c0c-e525ebad4096_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_5a16f996-f077-49ac-8c0c-e525ebad4096" xlink:to="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_April2023RestructuringPlanMember_a510e611-4ae1-4a7b-909e-0cfec066b76c" xlink:href="sgmo-20240331.xsd#sgmo_April2023RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:to="loc_sgmo_April2023RestructuringPlanMember_a510e611-4ae1-4a7b-909e-0cfec066b76c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_November2023RestructuringPlanMember_9dee1840-f6d7-46de-a425-e7429d9f190c" xlink:href="sgmo-20240331.xsd#sgmo_November2023RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:to="loc_sgmo_November2023RestructuringPlanMember_9dee1840-f6d7-46de-a425-e7429d9f190c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FranceRestructuringPlanMember_d15086ed-9a99-4e1f-9cbb-9e0eb7cc6cd1" xlink:href="sgmo-20240331.xsd#sgmo_FranceRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:to="loc_sgmo_FranceRestructuringPlanMember_d15086ed-9a99-4e1f-9cbb-9e0eb7cc6cd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2c9535a0-88af-4f75-a314-ac9c127e468e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_srt_TitleOfIndividualAxis_2c9535a0-88af-4f75-a314-ac9c127e468e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c9535a0-88af-4f75-a314-ac9c127e468e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2c9535a0-88af-4f75-a314-ac9c127e468e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c9535a0-88af-4f75-a314-ac9c127e468e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2c9535a0-88af-4f75-a314-ac9c127e468e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FullTimeEmployeesMember_32591807-f312-4c98-8797-71279e7169c8" xlink:href="sgmo-20240331.xsd#sgmo_FullTimeEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:to="loc_sgmo_FullTimeEmployeesMember_32591807-f312-4c98-8797-71279e7169c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractedEmployeesMember_1abca964-69c5-44c6-93c9-3a5099216d92" xlink:href="sgmo-20240331.xsd#sgmo_ContractedEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:to="loc_sgmo_ContractedEmployeesMember_1abca964-69c5-44c6-93c9-3a5099216d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bdc01d00-30de-4faf-9900-51a4c5ce4ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bdc01d00-30de-4faf-9900-51a4c5ce4ad8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bdc01d00-30de-4faf-9900-51a4c5ce4ad8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bdc01d00-30de-4faf-9900-51a4c5ce4ad8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bdc01d00-30de-4faf-9900-51a4c5ce4ad8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bdc01d00-30de-4faf-9900-51a4c5ce4ad8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff27348b-2437-4dfe-bb1b-ab848f098dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff27348b-2437-4dfe-bb1b-ab848f098dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6cf0a850-17e1-42ec-aa3e-d0f0dd99ea59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6cf0a850-17e1-42ec-aa3e-d0f0dd99ea59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_srt_RangeAxis_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12" xlink:to="loc_srt_RangeMember_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12" xlink:to="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_93f83d23-f8a3-478a-beea-00f46feb5efe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:to="loc_srt_MinimumMember_93f83d23-f8a3-478a-beea-00f46feb5efe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aba64e81-2b13-41e3-8336-8cb7dfe31b07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:to="loc_srt_MaximumMember_aba64e81-2b13-41e3-8336-8cb7dfe31b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_617045e6-a29e-47f1-9587-98fcf422463d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_srt_StatementScenarioAxis_617045e6-a29e-47f1-9587-98fcf422463d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_617045e6-a29e-47f1-9587-98fcf422463d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_617045e6-a29e-47f1-9587-98fcf422463d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_617045e6-a29e-47f1-9587-98fcf422463d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bd5fcf45-9845-428e-9a20-fdbdd4c4ae97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_617045e6-a29e-47f1-9587-98fcf422463d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bd5fcf45-9845-428e-9a20-fdbdd4c4ae97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4f4bc687-b270-4913-a67b-f1fcc7c23c5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bd5fcf45-9845-428e-9a20-fdbdd4c4ae97" xlink:to="loc_srt_ScenarioForecastMember_4f4bc687-b270-4913-a67b-f1fcc7c23c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8aae3ecb-4214-444d-8096-922bf923b417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8aae3ecb-4214-444d-8096-922bf923b417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f159f438-b763-45cb-b86e-108645459112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f159f438-b763-45cb-b86e-108645459112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0bc1714f-d54e-4caa-bf02-45c48cd71773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0bc1714f-d54e-4caa-bf02-45c48cd71773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_67a88c72-4fab-4138-a0ab-e24111b64095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringCharges_67a88c72-4fab-4138-a0ab-e24111b64095" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_ba437af4-2908-4e8f-8459-0cd3de1c5658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_ba437af4-2908-4e8f-8459-0cd3de1c5658" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:to="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5204b678-badc-486c-b585-1f9ad58524b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5204b678-badc-486c-b585-1f9ad58524b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5204b678-badc-486c-b585-1f9ad58524b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5204b678-badc-486c-b585-1f9ad58524b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5204b678-badc-486c-b585-1f9ad58524b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1e15cde7-db45-41b2-a1bc-28db48bf28a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5204b678-badc-486c-b585-1f9ad58524b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1e15cde7-db45-41b2-a1bc-28db48bf28a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b56242c0-e9d6-46ed-a34e-abfe2bca1568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1e15cde7-db45-41b2-a1bc-28db48bf28a3" xlink:to="loc_us-gaap_SubsequentEventMember_b56242c0-e9d6-46ed-a34e-abfe2bca1568" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c359247-89b1-4688-bcce-097560902b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c359247-89b1-4688-bcce-097560902b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c359247-89b1-4688-bcce-097560902b3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c359247-89b1-4688-bcce-097560902b3c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c359247-89b1-4688-bcce-097560902b3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4033fb36-1a6d-4016-a627-4caebfe4a057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c359247-89b1-4688-bcce-097560902b3c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4033fb36-1a6d-4016-a627-4caebfe4a057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_afa25e16-392e-4c30-9a3d-40fce42f26bf" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4033fb36-1a6d-4016-a627-4caebfe4a057" xlink:to="loc_sgmo_DirectOfferingMember_afa25e16-392e-4c30-9a3d-40fce42f26bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8" xlink:to="loc_us-gaap_ClassOfStockDomain_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0afecb94-2eb6-4b41-b6e0-715683a84f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8" xlink:to="loc_us-gaap_ClassOfStockDomain_0afecb94-2eb6-4b41-b6e0-715683a84f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_1a709c2f-34fa-45f3-8970-5a342eeebd19" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0afecb94-2eb6-4b41-b6e0-715683a84f6a" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_1a709c2f-34fa-45f3-8970-5a342eeebd19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c95eadfd-af9d-40f1-b4dd-becd9dc2ef5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c95eadfd-af9d-40f1-b4dd-becd9dc2ef5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e13f9d58-a427-4b11-9d36-4cc01562e481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e13f9d58-a427-4b11-9d36-4cc01562e481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ebea6eb3-e57c-42d1-8c74-9425656d7e36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ebea6eb3-e57c-42d1-8c74-9425656d7e36" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>sgmo-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b5443692-b648-47ae-ab89-daa7dd92e886,g:144bc5eb-acb5-4055-8fa1-fd0ab68e078a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sgmo_EquipmentFurnitureAndFixturesMember_4834a248-a4ad-4b8c-9987-c207eff09276_terseLabel_en-US" xlink:label="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Fixtures</link:label>
    <link:label id="lab_sgmo_EquipmentFurnitureAndFixturesMember_label_en-US" xlink:label="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Fixtures [Member]</link:label>
    <link:label id="lab_sgmo_EquipmentFurnitureAndFixturesMember_documentation_en-US" xlink:label="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Fixtures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EquipmentFurnitureAndFixturesMember" xlink:href="sgmo-20240331.xsd#sgmo_EquipmentFurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EquipmentFurnitureAndFixturesMember" xlink:to="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7eada0f6-9a95-4c65-b67e-712eefca1448_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization in operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_e03f382f-877a-4ae3-9269-e317f3dd388e_terseLabel_en-US" xlink:label="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable, period after issuance</link:label>
    <link:label id="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_label_en-US" xlink:label="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Or Right Outstanding, Exercisable, Period After Issuance</link:label>
    <link:label id="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_documentation_en-US" xlink:label="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Or Right Outstanding, Exercisable, Period After Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:href="sgmo-20240331.xsd#sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:to="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4c572f42-fe5d-456b-90d0-8733acb0427f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cc8c6d2e-16f4-44c1-9a5e-22fd2fbd96c3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ee20ac65-5f1e-4c11-88d9-a632238293a5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DirectOfferingMember_1cbb9e50-b68a-44d6-a845-64f8c11f2f74_terseLabel_en-US" xlink:label="lab_sgmo_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct offering</link:label>
    <link:label id="lab_sgmo_DirectOfferingMember_label_en-US" xlink:label="lab_sgmo_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Offering [Member]</link:label>
    <link:label id="lab_sgmo_DirectOfferingMember_documentation_en-US" xlink:label="lab_sgmo_DirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DirectOfferingMember" xlink:to="lab_sgmo_DirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_516daf3f-2a31-43e4-aa1a-c9d724e1e65e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bf6afdd6-82ac-4650-a0ae-26405ce53edc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc14af33-bf62-49f9-935f-ad316c9dcb37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3fecff75-b950-4288-b251-1757e65637eb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_76b2e1d9-5850-4ae2-aa95-17d91909ca82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e9d5d85d-01bc-4ac4-9f31-c5bcec2856db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cfa5db81-0077-4083-86d7-675d2369fb99_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_09cf6ad5-cb13-4fa1-a561-24464f8dcee7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_JefferiesLLCMember_8b8b3c2b-dce0-4ebd-acaf-01cf11835c58_terseLabel_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_label_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_documentation_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember" xlink:href="sgmo-20240331.xsd#sgmo_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_JefferiesLLCMember" xlink:to="lab_sgmo_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1f7b948-0664-4ff9-8ad0-8d84c7bd0343_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_5a8e72bb-500d-43cc-9f36-85243d7e7088_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees eliminated in restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_dd2aadf7-fdc5-4c3d-9846-60b9d8021f76_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e9cfe6ef-2931-4a7b-840d-61cdb56a482a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockOtherOfferingCosts_d8316325-6378-4490-9e2d-aafeebae0724_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from other offering expenses</link:label>
    <link:label id="lab_sgmo_SaleOfStockOtherOfferingCosts_label_en-US" xlink:label="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Other Offering Costs</link:label>
    <link:label id="lab_sgmo_SaleOfStockOtherOfferingCosts_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Other Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOtherOfferingCosts" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockOtherOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockOtherOfferingCosts" xlink:to="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_15831bf1-54dc-48b4-bbb8-96ddde06a732_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_a4ec2b5b-5fff-4f8b-9a9c-66faea29ccf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9f9a337d-77d8-4dbe-9e15-7d9bbe9767b7_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_9f62cb2e-07ee-4ec6-b921-db15d245230a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_49038352-6b40-4267-bfb8-44830443acef_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_d5eb05c8-909f-4531-979b-8e1a20a31240_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:to="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_894463d7-499c-45c3-a1ad-cff89e5fd0be_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a238cffb-26fc-49ae-b586-326f008f1dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_7758d115-75a2-42a2-a5d7-07484eae3eea_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_be0e3ea9-0da3-4c11-a3d6-26e436cb190b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_fc468769-71c4-4787-a21b-ee822b7b33a4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_5116ca26-971c-4b90-9dd7-61b75150c844_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20240331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bdc6d4e5-4bf3-4005-a197-90cffb2b6bd0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_15286d2e-f71f-4a85-9460-4e6b829f5be8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_01342422-f5c6-463e-b83f-54b362951f99_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_6847bb5d-b1ee-4230-8edb-f0607e1c0965_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f5a1cdaf-b770-44e1-bec3-d1c0813ca73d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9ad9f03e-eafe-4a87-b098-097a79230783_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fcb437d6-cd4d-4e1c-9df4-ea0cbdf4e061_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9d1f2b5a-57d9-4127-82d2-448eb2ec1864_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreFundedCommonStockWarrantMember_dadffd12-9970-47bb-b439-f42fc51f196d_terseLabel_en-US" xlink:label="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants</link:label>
    <link:label id="lab_sgmo_PreFundedCommonStockWarrantMember_label_en-US" xlink:label="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre Funded Common Stock Warrant [Member]</link:label>
    <link:label id="lab_sgmo_PreFundedCommonStockWarrantMember_documentation_en-US" xlink:label="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre Funded Common Stock Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreFundedCommonStockWarrantMember" xlink:to="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_b2c2cd26-b615-4f5b-a7b6-703ac004357a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_268981fc-ddde-47dd-909a-b46f3b8826c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c37b5fff-34c2-48d9-b9b3-5825fe95a1c3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_faee4eac-78aa-46b7-9c35-2432e3db0506_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S B Five Two Five And Other Products [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:href="sgmo-20240331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:to="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockIssuanceCostsNotYetPaid_7bacd0c9-6ab1-4bc8-a1a1-ee6642d65d81_terseLabel_en-US" xlink:label="lab_sgmo_StockIssuanceCostsNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering expenses in relation to issuance of common stock included in unpaid liabilities</link:label>
    <link:label id="lab_sgmo_StockIssuanceCostsNotYetPaid_label_en-US" xlink:label="lab_sgmo_StockIssuanceCostsNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Not Yet Paid</link:label>
    <link:label id="lab_sgmo_StockIssuanceCostsNotYetPaid_documentation_en-US" xlink:label="lab_sgmo_StockIssuanceCostsNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuanceCostsNotYetPaid" xlink:href="sgmo-20240331.xsd#sgmo_StockIssuanceCostsNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockIssuanceCostsNotYetPaid" xlink:to="lab_sgmo_StockIssuanceCostsNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d9a132e8-fa0f-4ec8-ab58-4a06dc7e73c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_94aba0b3-430b-4cb9-9df3-78ad3986dd50_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7ce6ef2c-0bbf-4f3a-9b23-b556592bc8f6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ef845a58-86e8-4698-acb2-0ad026dc5389_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_50e4a44b-0539-4ed3-91bd-7b4019f9d469_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0f053f72-8dfb-4d89-a170-7644cf17cc0c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_69275fd4-3117-4abf-b9aa-d8f5bb24f07a_terseLabel_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_label_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember" xlink:href="sgmo-20240331.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondCaliforniaMember" xlink:to="lab_sgmo_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2474f48f-99ee-43b0-be11-35669e66063d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_7fcceb6c-a840-456e-93fc-7ab20f956823_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_98812b45-d1ac-4f78-ad8c-8f55956da657_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_817a4621-191d-4628-b7fc-c14627082c16_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0fc05300-d083-4d21-89d6-da0cf0496a7f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5f859d5a-4274-4f07-8e18-29d814385e3b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d7d78eb2-ef66-40d0-9cb0-0731a74aba8f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e0bc278-4b94-41dd-ba14-d3ef4b0b06f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ec86bfcc-7796-4fbb-a75d-ae7d654042fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_a03e338b-3863-49bb-8a44-6915e6d15a94_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20240331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e4cf45e6-6480-4a5c-b64c-b83fa932e53a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_d16f96f1-6799-4445-a9e6-d2c190aa3391_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kite Pharma, Inc.</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20240331.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e84a2c2e-1679-4514-80da-73a808490174_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_457ec452-baae-4593-b647-7d43a7a44233_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6664b21e-aac8-4804-b082-3c6dd3dc3a84_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_025e6699-d87d-4e0b-9aab-e68dd90cd435_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20240331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_6a93521e-ca69-4966-b7d0-e407566a3ec4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2068552f-2866-423d-a610-fe4775dfd823_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_089cd629-0cce-4a42-a0b1-e603e854ab0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_32773236-1635-4baf-9aab-4e836c60fa69_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_79b49e70-f895-4935-b398-18d6d4df9058_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_dbe246d9-f428-42b3-a94d-32b62e65f462_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_594fb954-c9ef-4ba1-b3af-115b41dc3d34_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction, per unit (in shares)</link:label>
    <link:label id="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_label_en-US" xlink:label="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction, Per Unit</link:label>
    <link:label id="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction, Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:to="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_c2372641-03f6-4512-943b-09c21fdcd55f_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Required Notice Of Termination</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Required Notice Of Termination</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Required Notice Of Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:href="sgmo-20240331.xsd#sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:to="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_56dfa700-4016-4273-8cb7-5ceff21fdf8f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_038c6c62-c1b1-4c45-8182-e8f4e46bcadf_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_032ddb33-3cda-4fb0-bfe9-3cead95356e4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bc135437-1df6-4758-a5d0-40a0416c2cd8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESTRUCTURING CHARGES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FranceRestructuringPlanMember_19969677-7214-4bdd-9216-2a21f1b401ac_terseLabel_en-US" xlink:label="lab_sgmo_FranceRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France Restructuring Plan</link:label>
    <link:label id="lab_sgmo_FranceRestructuringPlanMember_label_en-US" xlink:label="lab_sgmo_FranceRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">France Restructuring Plan [Member]</link:label>
    <link:label id="lab_sgmo_FranceRestructuringPlanMember_documentation_en-US" xlink:label="lab_sgmo_FranceRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">France Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FranceRestructuringPlanMember" xlink:href="sgmo-20240331.xsd#sgmo_FranceRestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FranceRestructuringPlanMember" xlink:to="lab_sgmo_FranceRestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_d81e026c-cfb7-44ba-8ec7-8e6557286d30_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock offering program, increase to aggregate offering price</link:label>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_label_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Increase To Aggregate Offering Price</link:label>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Increase To Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:to="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e15a84f-5d52-4458-b912-f344c25b338f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8d5017e5-82c3-443b-858f-767b759c5d1c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_db651653-d067-487a-9095-05e08faf7e30_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in revenue</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7356020e-0651-42f8-b15f-d1e4512d3c1e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4be60fe-f384-4902-8250-921bf0531f35_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_November2023RestructuringPlanMember_98d0edda-163d-4b20-91e6-b3428901b44e_terseLabel_en-US" xlink:label="lab_sgmo_November2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">November 2023 Restructuring Plan</link:label>
    <link:label id="lab_sgmo_November2023RestructuringPlanMember_label_en-US" xlink:label="lab_sgmo_November2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">November 2023 Restructuring Plan [Member]</link:label>
    <link:label id="lab_sgmo_November2023RestructuringPlanMember_documentation_en-US" xlink:label="lab_sgmo_November2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">November 2023 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_November2023RestructuringPlanMember" xlink:href="sgmo-20240331.xsd#sgmo_November2023RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_November2023RestructuringPlanMember" xlink:to="lab_sgmo_November2023RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_22368b71-9b5e-4e4a-8e7a-38ceb034fff5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5c550bc7-2e85-4451-b34e-355174e186c6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_16d07921-9ef0-40e3-b6b8-21b15ff9596d_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, gross unrealized losses</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_96f97c24-ec23-42ce-937b-5179812c394b_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_97dee787-b29c-4c62-9af8-2fd95ef91133_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4c462891-2c1d-4265-81fe-0c90be094b51_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b655f13a-dd82-4d0d-94d2-840bd2575c5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_321a68d8-2079-4504-864a-ae4e607c8dbb_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20240331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_April2023RestructuringPlanMember_9350b1b1-3b34-44d5-962d-a846b2770337_terseLabel_en-US" xlink:label="lab_sgmo_April2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2023 Restructuring Plan</link:label>
    <link:label id="lab_sgmo_April2023RestructuringPlanMember_label_en-US" xlink:label="lab_sgmo_April2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2023 Restructuring Plan [Member]</link:label>
    <link:label id="lab_sgmo_April2023RestructuringPlanMember_documentation_en-US" xlink:label="lab_sgmo_April2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2023 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_April2023RestructuringPlanMember" xlink:href="sgmo-20240331.xsd#sgmo_April2023RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_April2023RestructuringPlanMember" xlink:to="lab_sgmo_April2023RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5860ea6f-10cd-4d1b-ba65-2b075b7c6aad_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_fb90e2d8-69e2-4384-8b85-1efa121fcb33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cfd3a14-19e7-43e1-be6a-8add677fb569_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_196581c2-9237-4c96-b1e7-033827d9e7c6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef73c65b-9b2a-4c85-98e9-ee0c0518f52c_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d157c698-41d9-4501-b2ce-a8c140583602_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_16e5c425-440f-490b-8cc9-2a4952c0eaff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b6392fe0-5ed3-4b18-991e-941ba39ac740_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_da6792fd-0795-4861-b511-ff11ab171ae4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_4cc8bf02-2768-4e98-9680-6c6d646bddeb_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5f042f5e-f7d0-4a13-aaf0-b6e317902c94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_7eafe266-207b-455d-af9d-d6685eb06947_negatedLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, gross unrealized losses</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_0c903640-0d62-44b4-98a4-076f5ea6e0a7_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, amortized cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_7c2632b6-3669-41a2-b75e-bea1786812d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_90d695ef-6c37-4636-b67f-c5e12ec5f405_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4ea7bfec-bff2-4507-b2c5-0022e3ac3be7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_89e49f96-cc2b-48d8-bb75-03f20ceb8b73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net pension gain (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_6afb4bfc-8a4d-4090-8f1d-b1e10076554f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net pension gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bcb95c41-0139-4adc-a932-ed8aa3836b4c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_26cfec20-ea0f-44f5-90c4-30a4aa6077b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_12e8b6f2-5668-432b-8f39-f85e998808d2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_88a9d650-3939-488c-9586-6e436e30f17b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIC AND DILUTED NET (LOSS) INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_77e78940-5a95-488d-9689-d3be02962b8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ae026e64-e1b1-4214-af8f-0b40aa289558_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a6699250-7bc4-4d3f-a011-1a6ca8d91aea_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price of each common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1853acc2-10c3-42c8-ac02-519b9c2cf466_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_404f3696-42e6-41f1-8f40-da41439a2300_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e9129d42-d365-41d9-b179-b42a6091b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_6518205a-dcc3-452d-8a68-d157ec9a9e1f_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refundable research income tax credits and other non-current assets</link:label>
    <link:label id="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_label_en-US" xlink:label="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Refundable Research Credits And Other Non-current Assets</link:label>
    <link:label id="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax, Refundable Research Credits And Other Non-current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:href="sgmo-20240331.xsd#sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:to="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_6056608c-0e05-4d24-98c6-e2bc8916b36d_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, estimated fair value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4c30d819-279c-4b10-9382-904a332ad0c4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_71c9c9fb-140a-48c5-a0c2-4629f913062e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_53d8e4a4-08d7-496f-a048-39ff4ad61fdf_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_08423ce5-090c-4569-990a-808ec023f6ce_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_391ffb2d-d967-4e36-8527-eda40f44da3e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6b800d55-ca20-40f3-9f3c-31008a2dc926_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cdda5ca4-470b-425d-8213-33b72b24e819_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c422cde2-2644-47ad-b35b-66a9b27649f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a6ab464e-915f-4fe8-a194-c7fcda596d39_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_9210eaeb-bfc0-4fbd-8567-7acd8b6587bf_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6d367a17-4b39-42b0-a8a1-629ab3a82e16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a95e52b0-4bd9-4f21-85ab-97abd5641a21_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (loss) gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_324f6130-5a73-462d-9561-c97a1b02f5ea_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other products</link:label>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_label_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturedProductOtherMember" xlink:to="lab_us-gaap_ManufacturedProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_135e593b-0193-4d17-ba54-996bab1fd84c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateMarch2023Member_14dd3e9e-9889-4204-96b2-dad9aced4958_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, March 2023</link:label>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateMarch2023Member_label_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, March 2023 [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateMarch2023Member_documentation_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, March 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:href="sgmo-20240331.xsd#sgmo_ChangeInAgreementEstimateMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:to="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_59c7640d-73e6-41bf-ac90-f67f1128734c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_aadfbe3a-a34a-45a4-81b3-2cea63c42ef1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_20529036-6082-4e40-8d79-fb135d8cec78_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_315aadb5-abfb-477c-acd8-7ceec94da180_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c747efa6-67c4-4c6d-bddd-33408f5e51c9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Marketable Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f9294165-8bf4-4bc1-a1e4-8fcc23bfcff7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c52db0c2-c743-4115-ba2a-54e18a1a0f75_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_613a8a69-318e-4f33-95e1-a09f04c02224_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_96df4d9e-5615-4ee3-8a3d-cf6ecfa4e949_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c1b41d79-72f5-4112-b8b2-cf3d9c0812ec_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_cd7cb9da-fa1b-4466-a225-8baf4874ed05_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, number of milestones achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:href="sgmo-20240331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_16f2c7ed-7060-4c52-9af5-284bbacebb32_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20240331.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_660b7e04-8752-4ed4-bb5f-095139e6cd57_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7222be48-bc4d-4f50-816b-bf307c56ea5e_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_85f0dda7-b6f0-4633-9acb-1f38a07fa629_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1f6b861e-89b7-47fc-a3a7-bb47d5c9bf22_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b7c1ea1a-ced4-4c77-8e28-b99cfa03f23c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_679c663a-e8d1-425b-82a3-eb7a4acdc83d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_466ed227-8974-4e24-80f7-6fb246deac40_terseLabel_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_e16a8e17-7aec-46fb-b710-baf4d316171e_verboseLabel_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share:</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS [Abstract]</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="sgmo-20240331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_825d48c0-edb3-44b4-ae42-acf12ecebd19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fc90ce49-b952-4bee-8509-e38b00eb099b_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_207ca5b8-05dc-4730-9dd5-6290cf021f7a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19b5e256-2197-4204-a073-b521ff6ad905_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5852ebed-79e7-42c2-bb5b-9a18cb397827_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a7c4dfe9-a9c9-4f2c-b818-50987f97e7a1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_51d1282b-a7c5-4134-b443-fae17d14293e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0e13b484-9ed7-4c2a-a249-7923e1640657_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of positions eliminated in restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_6a297ad2-6db6-4cde-8330-e25908bda570_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement Of Commercial Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1595fdb6-d1ad-46d6-9219-7bfb20b55877_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_598fe20e-25e1-420a-a09f-fec80fbe7eaa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9ac3a182-dfca-4aa2-a334-168bfb1cc7f8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_8bcd2db4-f7e2-4b17-a7ce-adf733f4d99f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_3d14431b-f99e-475c-aa88-f82ddb892f67_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain and losses on the sales of investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f0a3ead9-326d-4ef3-86b8-fb172953c0d2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of new stock issued during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_a370c44e-d35e-4f0a-afeb-d992c01a8b84_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_903a7c63-3d21-4550-b1b4-f082a7f7ff86_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_12052f36-01b5-4b81-90a8-bf9227f80545_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_563023d5-36ea-48d8-9786-02b0f24b03a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractedEmployeesMember_7a687763-b327-4001-84ba-29628454feea_terseLabel_en-US" xlink:label="lab_sgmo_ContractedEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contracted Employees</link:label>
    <link:label id="lab_sgmo_ContractedEmployeesMember_label_en-US" xlink:label="lab_sgmo_ContractedEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracted Employees [Member]</link:label>
    <link:label id="lab_sgmo_ContractedEmployeesMember_documentation_en-US" xlink:label="lab_sgmo_ContractedEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contracted Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractedEmployeesMember" xlink:href="sgmo-20240331.xsd#sgmo_ContractedEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractedEmployeesMember" xlink:to="lab_sgmo_ContractedEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3ebda2bd-5e9d-4198-82e2-b9d41fae18d5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d47fd328-10f5-4762-8e0a-db9daefe375d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_f30fde47-2a77-4336-b084-3a514eb8bd90_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2023</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_4b505ebb-4da7-459d-bf9d-1d7bea36535d_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at March 31, 2024</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_539d06df-a277-4279-8dcf-8140ff9afa9f_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20240331.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherLicensingAgreementsMember_c22fbe7e-2805-40df-a520-01f15bd9d4ff_terseLabel_en-US" xlink:label="lab_sgmo_OtherLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other license agreements</link:label>
    <link:label id="lab_sgmo_OtherLicensingAgreementsMember_label_en-US" xlink:label="lab_sgmo_OtherLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Licensing Agreements [Member]</link:label>
    <link:label id="lab_sgmo_OtherLicensingAgreementsMember_documentation_en-US" xlink:label="lab_sgmo_OtherLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Licensing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember" xlink:href="sgmo-20240331.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherLicensingAgreementsMember" xlink:to="lab_sgmo_OtherLicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f096f50a-7f7e-4483-8e65-f379a36e5d74_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_424cd9f1-240c-4e43-8004-26164685f263_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a7213f6c-9b40-4d13-8b10-6ed44337f05a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0032309f-cfce-4a91-b45e-1d421b52317a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_6a40c3bb-30e3-46ed-89a9-00907b519b05_negatedLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in net loss</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Net Income (Loss) Attributable To Parent</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Net Income (Loss) Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:to="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_64eed192-03dc-4bcd-8a6d-5c9e1760b0aa_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_7739d37b-a43f-4b91-894c-de04c521d596_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_e3fc9a79-e0d7-428f-8d7f-1220debe529c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_950bc362-aaff-47f0-9566-220217998646_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingMember" xlink:to="lab_sgmo_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_143942b9-a611-4003-96a5-922b944bdc40_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ec782a9-fbb5-4409-a7de-a2d713cc7ec3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_55789772-f765-498b-ad7e-8dd53f83de65_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a7056fa4-515a-4cd0-825c-24800ffc3b11_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_4c534e60-4288-471c-b4c2-92b6c533fd35_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_9718dc6b-6c6c-42fa-9af1-806f7747fb66_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:to="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_9efa7ffc-b949-4d21-8ea0-6152ebf72a83_terseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20240331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6d240a19-3849-48c1-a18f-a7b510d5ccc3_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_57d1c7a7-b2d0-4b20-a526-47ada48aa85a_terseLabel_en-US" xlink:label="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net (loss) income per share</link:label>
    <link:label id="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_label_en-US" xlink:label="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract]</link:label>
    <link:label id="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_documentation_en-US" xlink:label="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic And Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:href="sgmo-20240331.xsd#sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:to="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_36544b0d-2441-4a1b-b507-d7759021f69e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_232d6b03-6faa-4794-aea2-2dfeef8ce0b4_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5697a5ea-f47d-4d6c-8081-e9f28d853b6e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3e5c01-d611-4ebc-bb6f-37b0a05ec74a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommonWarrantMember_3c9d9948-8446-4933-8586-6c4d323ccd3f_terseLabel_en-US" xlink:label="lab_sgmo_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common warrants</link:label>
    <link:label id="lab_sgmo_CommonWarrantMember_label_en-US" xlink:label="lab_sgmo_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Warrant [Member]</link:label>
    <link:label id="lab_sgmo_CommonWarrantMember_documentation_en-US" xlink:label="lab_sgmo_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonWarrantMember" xlink:href="sgmo-20240331.xsd#sgmo_CommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommonWarrantMember" xlink:to="lab_sgmo_CommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_7cc52545-43a7-4271-a623-a37dc8b8d5f3_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20240331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c60af56e-2cc6-4560-be37-bc10e5d2b1ef_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b4e41c6d-89f0-4ea9-81a0-da446646cdaa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2c45a6e8-17b7-4766-bf20-4703192b39cd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_39350bc1-39e1-4513-ae79-fc7a21134382_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_a8c14a7e-e2bc-4abd-bb80-af051266ab5d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b29d53a8-5b77-4255-9669-f1c4ccf801c5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb1fe60d-907c-4ee9-aa63-8c68618ef590_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_12501c77-fdb4-44d4-b7c8-2304885bf404_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52d05427-3e20-4f15-a97e-a086e96d1284_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb45dd17-3470-4737-af4c-018ff62f6895_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90821a64-09e2-49df-9d31-41d45d42ded8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_9cd7ae21-02a5-4df2-a04c-8a6784b0a3f6_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d8f5ecd6-fea5-4200-8a41-b374f90e8e90_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_4f0eaee7-efe8-4a04-8b0e-cbe8e832b31d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_76386ad4-fd2c-4611-9bfb-0708eebd1e43_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_c39d82ca-acd0-492b-9cd9-626270ac2fa9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss related to marketable securities, not previously recorded</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_62156e22-a5e7-4719-99fb-d9115a4962a3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2f5231ef-4cbf-4eaf-9c60-9b8248ddb717_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_49392f97-4cb2-476d-a109-c8b3bbe76bf5_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dc0fdf3c-ea8e-4955-ab16-0b5e2037d18e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_506e5380-286d-402c-bf76-7c81aed6320f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_dcf8a1f6-50c1-4fbc-a461-e79534546cb4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_550fd383-873b-4c12-9157-8858863ebcfd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_966342b0-b97c-434a-8375-a46c3afd6db5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e2c18263-f758-4296-b4a4-eef2e13c1b8f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b5c2359a-61b2-402e-a7bd-9cd162a206b0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_582f2923-0483-4bea-8bb2-b2866101017a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d6a902bc-1453-4909-b812-f16ca788a98f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_62b2d6fd-4e9b-4b28-a8af-b43d61476f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f7574645-b5e1-471c-9867-85585b1ecb81_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_401ec7f5-d55b-49b6-ae75-0b32a264b32c_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc.</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc. [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20240331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b34540d3-a299-401f-ab66-94edd35a1fb4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1c92ef2e-aa1e-438c-a849-f79c8db2e321_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fda74f7c-077e-4151-b72a-980ebe2d277e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e6cfdacb-0c1f-4bc9-9239-fd6de322b19d_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_5deab0a2-04ba-4586-a466-296430eb14e1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock price (USD) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4faab37d-8949-4c0b-8672-6a8f2de88ad7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_b28ea7dd-6b47-40cc-9999-c95f0740a5b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d1f5a937-69a3-44c2-a0e5-9b9f87a93724_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_22cf6ba4-82b1-433a-9056-b448edbf6efa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c5d3a868-7257-404a-be39-bd4c8e2ff01c_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of share-based payment arrangements (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_d9d3d941-0557-4f43-a688-1a80ce3a4f8f_terseLabel_en-US" xlink:label="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Required Letter Of Credit Outstanding, Amount</link:label>
    <link:label id="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_label_en-US" xlink:label="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Required Letter Of Credit Outstanding, Amount</link:label>
    <link:label id="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_documentation_en-US" xlink:label="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Required Letter Of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:href="sgmo-20240331.xsd#sgmo_LesseeRequiredLetterOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:to="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_6fc85734-5844-4411-8d44-a57fa78d93a5_terseLabel_en-US" xlink:label="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</link:label>
    <link:label id="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_label_en-US" xlink:label="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease [Member]</link:label>
    <link:label id="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_documentation_en-US" xlink:label="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:href="sgmo-20240331.xsd#sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:to="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7c4651fa-e467-4214-8680-7f9dcc8d41c1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_19e6e308-066c-404e-bc10-a54d6b647513_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_7a86f7b9-ba8f-45fb-8b20-8b317f2fdfae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e17ae73f-0d24-40b4-90e3-28d18dc15341_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_145a2b36-2420-4cdf-981c-6554b6a69b55_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_97cbff54-12d1-43a6-85e5-c2d057b6dca8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8b3d3813-270f-4e12-9a13-939a2571113a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_dc77ae9d-164d-48a1-b23f-f0e86d95ed43_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_91c5caca-b224-4eb3-8067-09f09ca970d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_daca58d6-d1fe-4df8-8c46-9fd814938340_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3bf757ad-9f76-4f11-98af-e42eebeb7aa6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock_731de854-aae9-4a70-8fbc-7cbbcecbb8e1_terseLabel_en-US" xlink:label="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to Purchase Shares of Company Stock</link:label>
    <link:label id="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Or Right, Policy [Policy Text Block]</link:label>
    <link:label id="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Or Right, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:href="sgmo-20240331.xsd#sgmo_WarrantOrRightPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:to="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FullTimeEmployeesMember_39cd635b-413a-49c8-8be9-167d2c459929_terseLabel_en-US" xlink:label="lab_sgmo_FullTimeEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Full-Time Employees</link:label>
    <link:label id="lab_sgmo_FullTimeEmployeesMember_label_en-US" xlink:label="lab_sgmo_FullTimeEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Full-Time Employees [Member]</link:label>
    <link:label id="lab_sgmo_FullTimeEmployeesMember_documentation_en-US" xlink:label="lab_sgmo_FullTimeEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Full-Time Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FullTimeEmployeesMember" xlink:href="sgmo-20240331.xsd#sgmo_FullTimeEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FullTimeEmployeesMember" xlink:to="lab_sgmo_FullTimeEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_65a06772-7e88-4899-8735-ffe5b25604ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_39d858af-87df-40dc-b335-f22da527ec1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_de512d45-687c-48dd-8502-f94301800d34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5532f64e-581b-453e-874d-d998847398e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_5e6fb04d-67a0-4ce4-8664-7637768c5021_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20240331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c8d1147d-7f65-4cc4-81fc-3c31f74f72a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_edb9c848-c963-4745-a333-edd95041f4b0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_878b771f-a562-47ec-8418-f41d88da0538_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20240331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e59a5cdc-df99-4ee8-9001-0285a9ea660d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_0bc2f394-e3f2-4f5c-8359-41d47464c818_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a4e1c8ab-8a98-4a75-bebc-3f26d0fd08fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_d8a2a9cd-533a-4c48-8a5c-2f18c72d8af1_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a00d27f1-ce75-4309-bfc0-a1eb403c3bfd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19ec3282-4771-4396-b4fe-00d507573afb_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a3354918-4aed-4138-b137-811da64eb14f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock for each Common warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_55c10968-9c20-478a-b0f5-b4b2210922c0_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_79dc27f6-5c59-489a-ab22-f799838d5cfe_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_73768e27-3055-4042-9c40-461bd10d4e3d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_a413d2a1-5815-4f7b-8305-c46c8942d148_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c0843338-30c9-4d5f-abcc-5e8a505cce0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_778cba33-d1eb-4518-af23-726601ece21b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_921466cd-b059-459e-89af-16ce9e5e96b9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_bd982984-7e77-4b1c-9eb6-daa7e869f899_terseLabel_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liabilities</link:label>
    <link:label id="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_label_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount</link:label>
    <link:label id="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_documentation_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:href="sgmo-20240331.xsd#sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:to="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_a183316c-8eaa-4993-9bf9-99bf248a4417_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering Agreement</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:to="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a139d7df-c1fb-4787-b1c4-5ff706b48a00_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1361f536-e52d-4588-88dd-2c661fabd494_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_cf8a61df-5a39-400e-ad8e-252c20b3a128_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockAgentPlacementFees_8283ca42-33ac-4ccc-96a4-b146b4eef54a_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net of placement fees</link:label>
    <link:label id="lab_sgmo_SaleOfStockAgentPlacementFees_label_en-US" xlink:label="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Placement Fees</link:label>
    <link:label id="lab_sgmo_SaleOfStockAgentPlacementFees_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Placement Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockAgentPlacementFees" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockAgentPlacementFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockAgentPlacementFees" xlink:to="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_96f9ac57-8792-421b-94e5-bfe9ce2b6fe0_terseLabel_en-US" xlink:label="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_label_en-US" xlink:label="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available To Common Stockholders, Basic And Diluted [Abstract]</link:label>
    <link:label id="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_documentation_en-US" xlink:label="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available To Common Stockholders, Basic And Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:href="sgmo-20240331.xsd#sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_eb33f838-6d80-4cf0-b596-9be6bacdaf73_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6be37e6b-fda3-4ee2-9cfe-c6bbe08cc15c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6a084525-8d2e-4ed3-8154-4e17f89f5d84_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_62917683-1292-450e-ab86-2a1cb5d6cc8d_negatedLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decreased net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Basic</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:to="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_97375200-9a1e-4f80-b7a3-1058df573bb6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a5860e7c-d85b-461d-a0ba-3fee58e52d02_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e765a94f-279e-4ae9-acc1-6c45066d38e0_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, at carrying value, total</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_e0afaca7-af2b-4d90-86cd-397b753c3b6e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_a8b2e53f-92f9-41a3-a883-c629d970c249_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of equipment, furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3a346c38-1851-41b5-9060-7bb44a40591d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockOutstandingAmountAvailable_cdc4098c-11c8-481d-ab19-f778f83ee94b_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock agreement</link:label>
    <link:label id="lab_sgmo_SaleOfStockOutstandingAmountAvailable_label_en-US" xlink:label="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Outstanding Amount Available</link:label>
    <link:label id="lab_sgmo_SaleOfStockOutstandingAmountAvailable_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Outstanding Amount Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockOutstandingAmountAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:to="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_54d6114b-f89a-4827-8dd8-ef6c2a8b50d1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e4b541e7-9376-4db1-a360-9575309f67d9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_89489ff6-4712-4dcf-a7ff-a18bd91848a6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_d4b49f86-a6de-4682-90c1-87e69cf48e9f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_523c2231-07d5-41a7-ab38-6d505519d679_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cost remaining</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5a3c2594-469a-47b7-ab41-bd527e6a395f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_12b39f41-7c12-4e13-a6c3-15ae9dee2692_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dc74ebb2-f75e-4f7c-b33f-34406508ae11_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b9641c7-063e-4d20-8acf-2e3e6c6e8751_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_7ac75f32-c4e9-4449-93b8-e41d8df227c8_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e940e7af-bcd5-4d90-a91d-c779c3cc98e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e4bb21-7d27-4b3d-9a1e-d026fe5e949d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_0cc63339-d45e-40eb-ad23-a9b274e5ebf0_terseLabel_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock offering program, maximum value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_label_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_documentation_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue" xlink:href="sgmo-20240331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockOfferingProgramMaximumValue" xlink:to="lab_sgmo_StockOfferingProgramMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_c34807cc-5aba-449b-82cf-8c747a70d6b8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5d9d542b-c8eb-48a5-b435-5edb113d5af0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ab991df-8c30-403c-a176-2148a9e20cc9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_6c74ca1f-8294-42b8-b01c-9e43d7cf238d_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20240331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5f8ec77d-b896-4c41-a834-dd3e3ee8a53e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_fc8ed2f1-2610-416d-91a9-339f988cd0b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_00bdf3f5-d10a-4405-87f6-a8e0c111e735_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_df74b551-5e07-4c55-8b18-3987aeb6aa61_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_de2730a7-3d9f-4a04-92f5-0690a4f8c350_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20240331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4b55a0bf-db0e-4775-956f-c7e0a60752b3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_83bb5064-bb82-4dc6-80af-efdc8a5a7eb0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aac57898-a0f2-4330-9a62-4cea0209165c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_8afdb29d-f846-4a6b-9752-2b584f5bf372_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_8741b61e-efaa-4e54-8812-688ff3b0e226_terseLabel_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_label_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_documentation_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:href="sgmo-20240331.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:to="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f7a6e7b6-c609-4e11-a4f9-34d4dfa5d1c8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3848d5c9-1b51-443c-83df-82ac359b96de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b05487ff-aa69-44f1-8c8a-f756afc2fd26_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2db3d454-3732-4a04-a3e8-1d47afc7703c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_addd837f-e224-4668-a00d-4180437b7420_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_aa42b842-cb3d-4b5e-8891-2053e7c9b707_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5ccdfd9a-be3b-4dcd-9d02-3bc77688df4a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9095ec53-2cc5-46d0-8898-4de18a729881_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0f56aa80-240d-46e8-a088-c8af159c5116_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b6f2e8c5-4eca-4b54-9697-a6b231402d59_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f7ff5e42-f3cb-4d9d-9588-0c7c5e5c4a37_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_380977a1-82b0-46b7-9e0a-3688c2110e94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment on right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1e7d69f3-0d2a-479e-8958-a34c6d8616bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_9ead8d98-691c-42a4-a960-4de0d05ad6a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_3e27966f-67a4-4bfa-b829-b67d04fce797_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_2cf759e4-b1c2-4361-b920-64670e9580a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_4ce4f80c-179f-4ee7-8299-ac5a9da1df01_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_70967d63-6158-4bee-953c-b8debda15d4e_negatedTerseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreased net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Diluted</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:to="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_29c2d4d3-010d-441f-896a-bd8be1e881f7_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">S B Five Two Five</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S B Five Two Five [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S B Five Two Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember" xlink:href="sgmo-20240331.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveMember" xlink:to="lab_sgmo_SBFiveTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_866240d4-a3bf-4f48-84a4-b3068cc15527_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d3949437-8378-41ab-892f-f57d08c29b55_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_46789b55-eefd-4040-a187-7ed205e747f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_516275d6-75e1-4e7e-bc1d-c7576e5f7efa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8673f942-4812-47b5-9d23-97f72de82222_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_30bee3ed-aee3-4f8f-baaa-6cfeede4290e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_23071093-2201-45eb-a9d3-e594e6e0057d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_912485d9-fe7c-44df-98b9-78c73abd040a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_650717bd-03ca-40b1-95f3-5d9c5743f5f2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_6667be95-1e96-4fb5-8d31-bd5857d6b87f_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen MA, Inc. [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20240331.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_b10fcc7b-3f54-40a8-be9c-3be8264aaff8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7646e826-a6f4-4882-806a-9f1df37cfcd8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31df7941-12e6-4162-8fe9-54cf41f76629_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_11b8d54b-fee1-4846-82e3-b1d401730186_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ad0b352b-2cb5-4ad6-a44f-a905dd3849a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_dad3e0b8-38aa-416c-935b-577c5531d156_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_824f004a-d18f-4c77-b776-50b469833463_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20240331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f5db0bff-c860-4381-bd2f-9b4ecb7ee0bd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2e8b875f-98b7-47ed-8c5a-6904b714069d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_fe6952cb-020d-49ea-8086-33aba78c3472_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bfaa84b8-90d2-462c-a642-b61a9bd5dfb0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_eb98e5f5-f59b-474c-ac0b-8efce79e45d5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_956e57ff-fc2e-475a-9a5b-b1401dbcf618_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue related to Sanofi agreement:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68b55f40-8a3d-4eec-911e-da6d9e27bde9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c87766bf-9da5-481d-b993-1a50b9e3aee8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_14fab713-c67c-43e8-af1e-096e13e47323_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_266d7db9-45a2-4ae6-bdfc-c3e6f6407e73_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_0fcc254f-787b-4f18-af54-848b366306ca_terseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized gain before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b1dccc3e-a96a-44da-be9f-01325cc0bfd3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_8b7a9021-84b7-48f4-9a52-48d892061c46_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_dbff008d-e0e3-4186-a49f-fff7f2f1c69b_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_104dcaea-3617-4cb0-96ea-dfcd857df253_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a74fed9b-3519-4ddc-b697-7fdb9a441407_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_140135c6-881d-4b90-b2e4-0c9ce9765b99_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a937d71c-3cc2-474d-8950-2b9a223d8691_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_301cc0ea-0dee-4912-afa5-b61f2e74fb1b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_125dc6c2-47c2-443c-8d07-751061644093_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_baac0a04-1c80-4039-9d34-a429b69525ba_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash placement fees</link:label>
    <link:label id="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:to="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_da097105-249a-403f-91b0-f226a5c88a6d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss related to marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a6937a87-60ed-4018-991b-b1fa09a5e42f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6dd1a7cb-8ccc-4fe3-bb66-0d68b87df908_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>sgmo-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b5443692-b648-47ae-ab89-daa7dd92e886,g:144bc5eb-acb5-4055-8fa1-fd0ab68e078a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c776eddd-ae63-41b9-a78d-d124ca40ebb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_DocumentType_c776eddd-ae63-41b9-a78d-d124ca40ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9f343224-32f0-4953-b2af-6f24480030b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_DocumentQuarterlyReport_9f343224-32f0-4953-b2af-6f24480030b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b88ee44e-5257-4ad2-990e-7937b8a7ffbd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_DocumentPeriodEndDate_b88ee44e-5257-4ad2-990e-7937b8a7ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_70158032-b0e4-4043-9cbe-cfc1dc3e33f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_DocumentTransitionReport_70158032-b0e4-4043-9cbe-cfc1dc3e33f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e19914c5-4145-4a70-9717-6fda8c4baf0d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityFileNumber_e19914c5-4145-4a70-9717-6fda8c4baf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_88776122-409c-49b7-86e9-6b1ae6a97798" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityRegistrantName_88776122-409c-49b7-86e9-6b1ae6a97798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9b57123b-0948-458e-84bc-03019cdf43e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9b57123b-0948-458e-84bc-03019cdf43e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1b70ebfa-2279-4450-bb82-e91d866514c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityTaxIdentificationNumber_1b70ebfa-2279-4450-bb82-e91d866514c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_74430bb8-5dd3-4dc1-a169-d41041984363" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityAddressAddressLine1_74430bb8-5dd3-4dc1-a169-d41041984363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_50ecadc3-809a-4fa6-8e47-b3c968de7d7a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityAddressCityOrTown_50ecadc3-809a-4fa6-8e47-b3c968de7d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fc36dfaf-eeb8-4fb1-94eb-9cede8a236b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityAddressStateOrProvince_fc36dfaf-eeb8-4fb1-94eb-9cede8a236b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_002f2739-b703-40aa-814b-7b62e4ca381f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityAddressPostalZipCode_002f2739-b703-40aa-814b-7b62e4ca381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1238c540-4815-41b1-9e5a-38eb4568ed7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_CityAreaCode_1238c540-4815-41b1-9e5a-38eb4568ed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2415713b-cdce-45ac-9877-3de82ebccf87" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_LocalPhoneNumber_2415713b-cdce-45ac-9877-3de82ebccf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b6e96480-fe2d-4ab7-8222-1c3e17747969" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_Security12bTitle_b6e96480-fe2d-4ab7-8222-1c3e17747969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e3be3ebc-991e-4cd2-b3b3-134e5741294a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_TradingSymbol_e3be3ebc-991e-4cd2-b3b3-134e5741294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_308106ea-f160-4277-96c2-74784486e7dd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_SecurityExchangeName_308106ea-f160-4277-96c2-74784486e7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d972ef29-5b77-434c-8a5b-26ffe0a092a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityCurrentReportingStatus_d972ef29-5b77-434c-8a5b-26ffe0a092a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_20a02799-f9ab-4207-92da-262cb9b28f13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityInteractiveDataCurrent_20a02799-f9ab-4207-92da-262cb9b28f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c7a3d26f-9ccb-47f7-a5f9-957be81f3e58" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityFilerCategory_c7a3d26f-9ccb-47f7-a5f9-957be81f3e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9738199b-0671-4a2b-a447-161fb113c863" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntitySmallBusiness_9738199b-0671-4a2b-a447-161fb113c863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e28f5508-6e7a-46d3-ab1d-ce83bb5e3740" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityEmergingGrowthCompany_e28f5508-6e7a-46d3-ab1d-ce83bb5e3740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_17e8ab7a-2fb1-4b1d-9cf0-cbe28c5a10ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityShellCompany_17e8ab7a-2fb1-4b1d-9cf0-cbe28c5a10ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_29d2bd3d-7231-4250-bde6-2ed9e1deb8a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_29d2bd3d-7231-4250-bde6-2ed9e1deb8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ad4daebb-4079-4d16-a0e3-73e954b6b74a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_AmendmentFlag_ad4daebb-4079-4d16-a0e3-73e954b6b74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5863b5f1-b064-48e9-a59c-be962dc30772" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_DocumentFiscalYearFocus_5863b5f1-b064-48e9-a59c-be962dc30772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8660246c-d28a-4635-9e78-53456a81e37f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8660246c-d28a-4635-9e78-53456a81e37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4c2178cb-f58e-4ada-8dfa-4df9cca8c351" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_EntityCentralIndexKey_4c2178cb-f58e-4ada-8dfa-4df9cca8c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_720447ee-e88c-4aa1-80d4-46e2396317c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c6d1dfe1-6287-45e7-bf16-d9ca15c14ca8" xlink:to="loc_dei_CurrentFiscalYearEndDate_720447ee-e88c-4aa1-80d4-46e2396317c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6494ff03-4db9-4dfc-9db2-cf48019406d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6494ff03-4db9-4dfc-9db2-cf48019406d0" xlink:to="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6882909-5c64-4be9-a684-0459666311ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6882909-5c64-4be9-a684-0459666311ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e95cf833-53a2-4c8f-a5ad-ff8ee73e7c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:to="loc_us-gaap_RestrictedCashCurrent_e95cf833-53a2-4c8f-a5ad-ff8ee73e7c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_68eaf436-37fa-40a4-b001-c37b999bf735" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_68eaf436-37fa-40a4-b001-c37b999bf735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b04419a2-3b42-46c5-9c29-32f0a079b455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b04419a2-3b42-46c5-9c29-32f0a079b455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0de3e6e4-e528-4c38-a4b9-dadf5d3b52f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0de3e6e4-e528-4c38-a4b9-dadf5d3b52f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d54409f0-c50e-4877-aa1e-405ee289e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d486eaf0-58e6-4a69-a499-a01e526df828" xlink:to="loc_us-gaap_AssetsCurrent_d54409f0-c50e-4877-aa1e-405ee289e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cae4cef9-2598-448c-8585-7f63ecf16909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cae4cef9-2598-448c-8585-7f63ecf16909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d82e8bc5-6641-42c9-bbf9-daf849cde018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d82e8bc5-6641-42c9-bbf9-daf849cde018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_27db2a12-7f5c-478b-8d79-8ad74a383056" xlink:href="sgmo-20240331.xsd#sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:to="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_27db2a12-7f5c-478b-8d79-8ad74a383056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4b74c28a-ee1e-4b38-8f21-64af8a6a459a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4b74c28a-ee1e-4b38-8f21-64af8a6a459a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bbdf9bf7-e645-4876-8058-d8b9d1469369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bceba9b-3ce1-4220-a5cf-cf7073605911" xlink:to="loc_us-gaap_Assets_bbdf9bf7-e645-4876-8058-d8b9d1469369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6494ff03-4db9-4dfc-9db2-cf48019406d0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6ec08b0d-72d8-4241-92e8-579d08d5b9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6ec08b0d-72d8-4241-92e8-579d08d5b9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_26ca4215-e46a-460a-8ffc-9af5cfb8ecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ec08b0d-72d8-4241-92e8-579d08d5b9b2" xlink:to="loc_us-gaap_AccountsPayableCurrent_26ca4215-e46a-460a-8ffc-9af5cfb8ecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8df26702-e386-4495-ab76-3ae75d906703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ec08b0d-72d8-4241-92e8-579d08d5b9b2" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8df26702-e386-4495-ab76-3ae75d906703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6eefb52f-5b6f-437d-974b-fada2fc9360d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ec08b0d-72d8-4241-92e8-579d08d5b9b2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6eefb52f-5b6f-437d-974b-fada2fc9360d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c589588a-8bb6-49e7-bf43-65ea883ef525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6ec08b0d-72d8-4241-92e8-579d08d5b9b2" xlink:to="loc_us-gaap_LiabilitiesCurrent_c589588a-8bb6-49e7-bf43-65ea883ef525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be21fd22-bde0-468d-a7eb-4f53811648c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_be21fd22-bde0-468d-a7eb-4f53811648c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_65c614e1-60fd-4966-afcd-26a3ce0fb38a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_65c614e1-60fd-4966-afcd-26a3ce0fb38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7f0b27f3-5e61-4d07-ace7-993775022b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:to="loc_us-gaap_Liabilities_7f0b27f3-5e61-4d07-ace7-993775022b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2981b766-512d-44b0-8f27-2214c77d220a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2981b766-512d-44b0-8f27-2214c77d220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ac0311c4-e845-487a-aeff-d939286889cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:to="loc_us-gaap_PreferredStockValue_ac0311c4-e845-487a-aeff-d939286889cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_de447f4c-9c19-4a80-bd77-e9d1bb4cecc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:to="loc_us-gaap_CommonStockValue_de447f4c-9c19-4a80-bd77-e9d1bb4cecc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_51bea676-82fb-4c6f-9c46-793ff3bc6690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_51bea676-82fb-4c6f-9c46-793ff3bc6690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_930315c5-d296-4945-aac6-48067ef68f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_930315c5-d296-4945-aac6-48067ef68f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4be16b7a-fc7d-47bc-a166-5b78a3d4901b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4be16b7a-fc7d-47bc-a166-5b78a3d4901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_532aa944-dcc5-4070-bc24-9207ad2def7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6821c2a8-8026-43c6-b6fd-9a57695a22e1" xlink:to="loc_us-gaap_StockholdersEquity_532aa944-dcc5-4070-bc24-9207ad2def7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_73850724-dbe1-4ade-94e0-b8de0af9687a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d63960d1-b71d-40dc-a30f-37ac452549f2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_73850724-dbe1-4ade-94e0-b8de0af9687a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3083553e-681a-47e2-845d-fcd744b3fdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_us-gaap_RevenuesAbstract_3083553e-681a-47e2-845d-fcd744b3fdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e391e7db-b947-4f4d-bf82-afaa0b5dbf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3083553e-681a-47e2-845d-fcd744b3fdfe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e391e7db-b947-4f4d-bf82-afaa0b5dbf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_acf5319e-98d5-4f90-a66b-ad0dc64f84fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_us-gaap_OperatingExpensesAbstract_acf5319e-98d5-4f90-a66b-ad0dc64f84fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8725ee18-ab96-404d-be96-5caea1525630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_acf5319e-98d5-4f90-a66b-ad0dc64f84fa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8725ee18-ab96-404d-be96-5caea1525630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ea0fbe7f-1f93-492f-929a-031afc884dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_acf5319e-98d5-4f90-a66b-ad0dc64f84fa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ea0fbe7f-1f93-492f-929a-031afc884dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9b11ab93-7aca-4e31-9673-171f88328a41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_acf5319e-98d5-4f90-a66b-ad0dc64f84fa" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9b11ab93-7aca-4e31-9673-171f88328a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a93ae8e8-0d50-4dcb-8444-2650f4829345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_acf5319e-98d5-4f90-a66b-ad0dc64f84fa" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a93ae8e8-0d50-4dcb-8444-2650f4829345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d3382e40-7875-4757-ba60-3a7ab9d2b9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_acf5319e-98d5-4f90-a66b-ad0dc64f84fa" xlink:to="loc_us-gaap_OperatingExpenses_d3382e40-7875-4757-ba60-3a7ab9d2b9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ba589999-192c-469e-81e0-ec00a69f0987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_us-gaap_OperatingIncomeLoss_ba589999-192c-469e-81e0-ec00a69f0987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_3a248967-934b-4434-9c6a-76a3b2e6c910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_us-gaap_InterestAndOtherIncome_3a248967-934b-4434-9c6a-76a3b2e6c910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_642fb498-f952-4b69-8fec-43617434e269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_642fb498-f952-4b69-8fec-43617434e269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c3cafc5-3f7b-486e-9afc-23871a165b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6c3cafc5-3f7b-486e-9afc-23871a165b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e68c184e-dfe6-4243-a74e-3587c63314c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_us-gaap_NetIncomeLoss_e68c184e-dfe6-4243-a74e-3587c63314c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_33f56259-74d1-412d-9ca7-d9d4d6cce282" xlink:href="sgmo-20240331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_33f56259-74d1-412d-9ca7-d9d4d6cce282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_715f71fc-6b12-46f3-996a-7569b1ed61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_33f56259-74d1-412d-9ca7-d9d4d6cce282" xlink:to="loc_us-gaap_EarningsPerShareBasic_715f71fc-6b12-46f3-996a-7569b1ed61b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8c801a43-d47e-4f9a-baa0-49902823ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_33f56259-74d1-412d-9ca7-d9d4d6cce282" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8c801a43-d47e-4f9a-baa0-49902823ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_5c6b86d3-8c86-4ed9-8705-2e180d548767" xlink:href="sgmo-20240331.xsd#sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9a6b4b74-b10f-404b-b533-6145eea29155" xlink:to="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_5c6b86d3-8c86-4ed9-8705-2e180d548767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e133146-2646-4a06-8e4a-3840fd1eec8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_5c6b86d3-8c86-4ed9-8705-2e180d548767" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7e133146-2646-4a06-8e4a-3840fd1eec8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64f29f7b-556f-46c0-b742-fa3396dc9cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_5c6b86d3-8c86-4ed9-8705-2e180d548767" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_64f29f7b-556f-46c0-b742-fa3396dc9cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6e9a6116-109b-4c60-862e-9607da76cac9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c49ddce6-5a69-4cc5-8250-612751bb1951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6e9a6116-109b-4c60-862e-9607da76cac9" xlink:to="loc_us-gaap_NetIncomeLoss_c49ddce6-5a69-4cc5-8250-612751bb1951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6fa3db92-1b6e-44bf-895c-cd1c5b086a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6e9a6116-109b-4c60-862e-9607da76cac9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6fa3db92-1b6e-44bf-895c-cd1c5b086a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_8754d071-4ee7-42b6-bcd0-a6fb0ada6d58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6e9a6116-109b-4c60-862e-9607da76cac9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_8754d071-4ee7-42b6-bcd0-a6fb0ada6d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c4dd0ce3-9f55-4396-aed0-0be903d97688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6e9a6116-109b-4c60-862e-9607da76cac9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c4dd0ce3-9f55-4396-aed0-0be903d97688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5208ad05-96ba-4313-b0e3-ff5d404a7286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6e9a6116-109b-4c60-862e-9607da76cac9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5208ad05-96ba-4313-b0e3-ff5d404a7286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d8a7683c-95b9-4e19-9d9d-386fd45e358d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d8a7683c-95b9-4e19-9d9d-386fd45e358d" xlink:to="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6af034bc-3d8f-4b88-bd4e-baf4c171aa9e" xlink:to="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6258e285-7bab-40d7-bdfd-726a7d8d439b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_CommonStockMember_6258e285-7bab-40d7-bdfd-726a7d8d439b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2487cc92-e52c-4b18-9406-ed5a6449425f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2487cc92-e52c-4b18-9406-ed5a6449425f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0fe6545e-31d7-4fc6-a593-0fc0031ef4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_RetainedEarningsMember_0fe6545e-31d7-4fc6-a593-0fc0031ef4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24b23a96-be6d-48f4-bf17-07360f1a0f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6680d18-588a-4388-bf01-a2bbf5900279" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_24b23a96-be6d-48f4-bf17-07360f1a0f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dda25bd-6a17-4eef-8b56-a10e09d86485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_df5b1914-c8c0-4f0d-92e7-7d4024f0fc74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dda25bd-6a17-4eef-8b56-a10e09d86485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_6e83b622-52ed-428c-b4f5-f3d2e4d84321" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0dda25bd-6a17-4eef-8b56-a10e09d86485" xlink:to="loc_sgmo_AtTheMarketOfferingMember_6e83b622-52ed-428c-b4f5-f3d2e4d84321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d9972dce-3990-4057-abb1-8a7efb027ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_457c166c-5749-416d-bf72-b161e1b686f4" xlink:to="loc_us-gaap_StatementLineItems_d9972dce-3990-4057-abb1-8a7efb027ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9972dce-3990-4057-abb1-8a7efb027ee9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aabcaa64-63af-4c7d-897a-612d0f427bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aabcaa64-63af-4c7d-897a-612d0f427bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52d0c953-6e7e-46f4-a705-040a345ff3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockholdersEquity_52d0c953-6e7e-46f4-a705-040a345ff3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3fa3450-d11d-48fb-b880-4c5f827ce2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3fa3450-d11d-48fb-b880-4c5f827ce2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_efdb0eab-6ed8-45d6-9fbd-0eea312a8368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_efdb0eab-6ed8-45d6-9fbd-0eea312a8368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_eeb6e4d6-7328-4861-b9c5-8db83a9dcb96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_eeb6e4d6-7328-4861-b9c5-8db83a9dcb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ea833cdb-6f7d-454e-9548-513fb903627a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ea833cdb-6f7d-454e-9548-513fb903627a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b8a3481-592b-4e52-84b6-4802e6ad5ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b8a3481-592b-4e52-84b6-4802e6ad5ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e4293205-5dae-41cc-8fa5-7486006e1774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e4293205-5dae-41cc-8fa5-7486006e1774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_0a287ddf-af3d-41a2-9602-496aefc2c6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_0a287ddf-af3d-41a2-9602-496aefc2c6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2a11d3cc-55b9-4423-98ab-4ed9c8b936e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2a11d3cc-55b9-4423-98ab-4ed9c8b936e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ca361c4-c6b8-4610-96c0-10583acc8465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_NetIncomeLoss_7ca361c4-c6b8-4610-96c0-10583acc8465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_59c22421-066f-4404-9386-6615baa1d5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_59c22421-066f-4404-9386-6615baa1d5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6319c52-1a16-4e0b-8d86-64c95dc3d921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a6552695-33dd-4711-8d33-e2d179abd03a" xlink:to="loc_us-gaap_StockholdersEquity_d6319c52-1a16-4e0b-8d86-64c95dc3d921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_91aec626-3ffd-4064-a02b-a202e8b832eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d05a287-5742-4193-adba-fbdeaa7e9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_91aec626-3ffd-4064-a02b-a202e8b832eb" xlink:to="loc_us-gaap_StatementTable_8d05a287-5742-4193-adba-fbdeaa7e9f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a861538f-19e4-4962-8055-968eb47cf0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d05a287-5742-4193-adba-fbdeaa7e9f8f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a861538f-19e4-4962-8055-968eb47cf0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a861538f-19e4-4962-8055-968eb47cf0a3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_4aad065d-b8d6-4733-bf97-1e2c88710653" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:to="loc_sgmo_DirectOfferingMember_4aad065d-b8d6-4733-bf97-1e2c88710653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_47ba4498-6e3f-4afe-904f-c7671663a92a" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38f05759-b5ad-4b5a-a1ef-18fe83dcd317" xlink:to="loc_sgmo_AtTheMarketOfferingMember_47ba4498-6e3f-4afe-904f-c7671663a92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d05a287-5742-4193-adba-fbdeaa7e9f8f" xlink:to="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc14eeca-85d8-44ba-8ae0-02adfa85fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_NetIncomeLoss_cc14eeca-85d8-44ba-8ae0-02adfa85fa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79476bcb-231e-4a04-8337-0fb1f986e310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79476bcb-231e-4a04-8337-0fb1f986e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3882f182-16c8-40f5-bb06-3b1e730100a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3882f182-16c8-40f5-bb06-3b1e730100a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32251619-2fd7-4f9d-83de-4ef0f928c201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32251619-2fd7-4f9d-83de-4ef0f928c201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_93712a07-a69c-478d-a5e6-6a2099b925c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_93712a07-a69c-478d-a5e6-6a2099b925c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bd4a376b-9ded-4250-8e38-98ed181cb7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_ShareBasedCompensation_bd4a376b-9ded-4250-8e38-98ed181cb7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5bb3faaf-a795-4fc2-bf5a-3f91422e77bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebe333a0-e395-4d2b-aa70-408171f04260" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5bb3faaf-a795-4fc2-bf5a-3f91422e77bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_05c8b5e6-fcef-4581-8638-2093b18cddae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_05c8b5e6-fcef-4581-8638-2093b18cddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58e9ba0f-155e-4062-a416-65143ad5482e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58e9ba0f-155e-4062-a416-65143ad5482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0ee1aa52-0044-42e7-a606-ebe938875873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0ee1aa52-0044-42e7-a606-ebe938875873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0f43752f-335e-4d6f-8116-6b4d0ce46332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0f43752f-335e-4d6f-8116-6b4d0ce46332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_99f69d18-b818-4cff-8ecb-78d7820a5da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_99f69d18-b818-4cff-8ecb-78d7820a5da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fd75c410-9e5b-4f6d-bf0a-92602e408b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fd75c410-9e5b-4f6d-bf0a-92602e408b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_446eb46a-26ae-463d-b61d-de860ad92a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_446eb46a-26ae-463d-b61d-de860ad92a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3821d99b-da01-410e-9098-948bbde55e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c93572b9-721b-4a3c-a3e8-f252644c9ccd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3821d99b-da01-410e-9098-948bbde55e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ce928ff-634b-4eae-9e67-7db9016f2e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1a326418-1078-47ce-ae3f-012f16c57f0f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ce928ff-634b-4eae-9e67-7db9016f2e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_45932b5c-145a-4997-89ec-c8cff7805efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_45932b5c-145a-4997-89ec-c8cff7805efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_abb4d5aa-d354-44b3-9671-0b4bd9dec104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_abb4d5aa-d354-44b3-9671-0b4bd9dec104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1cca4e13-9d93-4c50-9d3d-c029b51d94be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_1cca4e13-9d93-4c50-9d3d-c029b51d94be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9157450-62b5-4ca6-bc8d-df5099c773e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9157450-62b5-4ca6-bc8d-df5099c773e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbbe0933-db78-4182-bf5c-752d965273e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_06a3808b-56d3-441d-8e31-dde1b90eef4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbbe0933-db78-4182-bf5c-752d965273e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b03ef832-b086-4558-b84a-45ca087824b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b03ef832-b086-4558-b84a-45ca087824b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6a8fad0-4e24-4aa5-9976-eb83ae9e7519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6a8fad0-4e24-4aa5-9976-eb83ae9e7519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a97c265e-177b-453c-8fc0-13a3561b28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a63ab8ce-c291-4e87-bea3-a565af032ba1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a97c265e-177b-453c-8fc0-13a3561b28ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d682c78-84e5-46b2-a467-413be0cabda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d682c78-84e5-46b2-a467-413be0cabda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c34dfe3c-86ed-4c69-afe1-7a1fc326e271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c34dfe3c-86ed-4c69-afe1-7a1fc326e271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_483699c4-6d34-4187-ad54-74a57a2d7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_483699c4-6d34-4187-ad54-74a57a2d7eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5770a2b6-b8fb-46da-8974-cb92b0fd2f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5770a2b6-b8fb-46da-8974-cb92b0fd2f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18326ea6-edaa-402e-80c1-b99288612ef0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuanceCostsNotYetPaid_2e06c79b-a54e-4a70-853f-3f89bc17eef4" xlink:href="sgmo-20240331.xsd#sgmo_StockIssuanceCostsNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:to="loc_sgmo_StockIssuanceCostsNotYetPaid_2e06c79b-a54e-4a70-853f-3f89bc17eef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_492a16a4-75c4-4e6c-8356-382516648b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cce61d3c-b6b0-40a7-91b4-ad9f80b1ff3d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_492a16a4-75c4-4e6c-8356-382516648b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f05d746-1fe9-4502-809c-75d9f09e57aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_17ad8f76-5c78-42b7-824d-303aa2f8df0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f05d746-1fe9-4502-809c-75d9f09e57aa" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_17ad8f76-5c78-42b7-824d-303aa2f8df0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5e7ef60-4173-4d98-b403-c7dc3f0b2615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bfabee18-c3de-4142-abb7-391130d1665c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5e7ef60-4173-4d98-b403-c7dc3f0b2615" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bfabee18-c3de-4142-abb7-391130d1665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4e078ec5-6cf4-4458-bc38-0898337f3d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_48623744-8ab5-437c-9ffe-45ba82d75090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4e078ec5-6cf4-4458-bc38-0898337f3d62" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_48623744-8ab5-437c-9ffe-45ba82d75090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARE" xlink:type="simple" xlink:href="sgmo-20240331.xsd#BASICANDDILUTEDNETLOSSINCOMEPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2effb6b8-ab5a-467e-a126-3dd4df411e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e8335471-a141-4845-b2de-67a1a499b59f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2effb6b8-ab5a-467e-a126-3dd4df411e6c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e8335471-a141-4845-b2de-67a1a499b59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20240331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63ba9c08-f44f-4d4b-8f68-124cdd9e7f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6475aa7c-47ff-4125-af3c-5fa1a5318dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63ba9c08-f44f-4d4b-8f68-124cdd9e7f98" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6475aa7c-47ff-4125-af3c-5fa1a5318dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_134c525c-6ffd-4ab3-88ee-c9d9631ae98c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock_b8eafed8-4bdf-4590-b89c-c050b8dde7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_134c525c-6ffd-4ab3-88ee-c9d9631ae98c" xlink:to="loc_us-gaap_AssetImpairmentChargesTextBlock_b8eafed8-4bdf-4590-b89c-c050b8dde7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sgmo-20240331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c642ac48-3b71-4494-b469-56eef3bd9be2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_68a97ca4-d4f7-46f2-8256-7ad002dcf109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c642ac48-3b71-4494-b469-56eef3bd9be2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_68a97ca4-d4f7-46f2-8256-7ad002dcf109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20240331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c83e4a8e-531a-4f1e-81b2-db320e853c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_403a889b-4cfc-4a8f-9ed6-a96e44090873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c83e4a8e-531a-4f1e-81b2-db320e853c63" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_403a889b-4cfc-4a8f-9ed6-a96e44090873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20240331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_49372ac5-f6fb-490f-8d1a-e978e5cd5482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2a0b660e-2fe5-4e47-8664-e4e7b33df659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_49372ac5-f6fb-490f-8d1a-e978e5cd5482" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2a0b660e-2fe5-4e47-8664-e4e7b33df659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGES" xlink:type="simple" xlink:href="sgmo-20240331.xsd#RESTRUCTURINGCHARGES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dd649757-ef03-46d8-b16f-8b2edf07f664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_cb61d902-ef72-4dfe-b223-87c371a322da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dd649757-ef03-46d8-b16f-8b2edf07f664" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_cb61d902-ef72-4dfe-b223-87c371a322da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sgmo-20240331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_62831cc7-52d1-4a3b-9086-5fd759df2b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ea166eb9-7f25-414d-8e30-f5db0eb35f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_62831cc7-52d1-4a3b-9086-5fd759df2b94" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ea166eb9-7f25-414d-8e30-f5db0eb35f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e35ca231-5bf3-485a-a498-68e5ef663c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e35ca231-5bf3-485a-a498-68e5ef663c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f4887a64-aafb-4d0f-8e09-f53302095493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f4887a64-aafb-4d0f-8e09-f53302095493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fe1af5f7-e34d-4a82-bc16-230bfdcaac98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_UseOfEstimates_fe1af5f7-e34d-4a82-bc16-230bfdcaac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_dde782bc-7e83-4959-a10d-7bbe973d6395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_dde782bc-7e83-4959-a10d-7bbe973d6395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_bdb1d44f-8459-4e8c-a08b-10f04c4c1632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_bdb1d44f-8459-4e8c-a08b-10f04c4c1632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6531213b-9c03-4743-ba21-23d1d716c798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6531213b-9c03-4743-ba21-23d1d716c798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_67a85d82-7af9-43a3-bff5-6f0a629b28d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_67a85d82-7af9-43a3-bff5-6f0a629b28d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock_9b74900d-3adb-4c3a-94c3-f55e8694e25f" xlink:href="sgmo-20240331.xsd#sgmo_WarrantOrRightPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock_9b74900d-3adb-4c3a-94c3-f55e8694e25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_90c32fae-e816-4f5a-9f88-14aa931d4495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_90c32fae-e816-4f5a-9f88-14aa931d4495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_be08031c-2b47-47a5-9517-e1c88d608b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_be08031c-2b47-47a5-9517-e1c88d608b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9c17a5ad-773d-466c-baba-2bfd18a84939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eed9a316-fc53-41e8-a4f3-e81fa891e437" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9c17a5ad-773d-466c-baba-2bfd18a84939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a632e779-eb00-4b52-bda5-c6e4dd1a0f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_1bb6b1f4-69fa-4fc0-8147-9d7f2a704629" xlink:href="sgmo-20240331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a632e779-eb00-4b52-bda5-c6e4dd1a0f50" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_1bb6b1f4-69fa-4fc0-8147-9d7f2a704629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_230d1b53-5aa1-415b-be98-41cdd23af019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a632e779-eb00-4b52-bda5-c6e4dd1a0f50" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_230d1b53-5aa1-415b-be98-41cdd23af019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2c5f863a-1df4-471e-9c1d-148bec39194c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a632e779-eb00-4b52-bda5-c6e4dd1a0f50" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2c5f863a-1df4-471e-9c1d-148bec39194c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20240331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_87a9f001-a260-4e35-b991-9496dba3cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e20e695f-066d-499c-83e1-db0c60466bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87a9f001-a260-4e35-b991-9496dba3cef8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e20e695f-066d-499c-83e1-db0c60466bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8c758950-b68c-48be-9706-1c763e9e28bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_e74e82e4-7f2d-4836-8f80-4351f241e767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8c758950-b68c-48be-9706-1c763e9e28bd" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_e74e82e4-7f2d-4836-8f80-4351f241e767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_b62833aa-be65-40b4-8f5b-cf823942c22d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8c758950-b68c-48be-9706-1c763e9e28bd" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_b62833aa-be65-40b4-8f5b-cf823942c22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables" xlink:type="simple" xlink:href="sgmo-20240331.xsd#BASICANDDILUTEDNETLOSSINCOMEPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5330ae40-b62f-41a3-9231-d98955c5b785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75d0c281-3437-4ff0-9ab0-7294a618937b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5330ae40-b62f-41a3-9231-d98955c5b785" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_75d0c281-3437-4ff0-9ab0-7294a618937b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20240331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a826585-d5de-4868-8376-dee08e66c251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d9b57b54-d389-49f7-bad0-30eedca57c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a826585-d5de-4868-8376-dee08e66c251" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_d9b57b54-d389-49f7-bad0-30eedca57c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20240331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_003ad3ab-3d92-4bec-afb2-82f032cde95c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d54c5d3-b263-4679-921c-00a43e4e207d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_003ad3ab-3d92-4bec-afb2-82f032cde95c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8d54c5d3-b263-4679-921c-00a43e4e207d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables" xlink:type="simple" xlink:href="sgmo-20240331.xsd#RESTRUCTURINGCHARGESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6965bf89-d775-419d-bf2e-f55317b0ff65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_edb349f5-3e99-4402-b0a7-862f894425df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6965bf89-d775-419d-bf2e-f55317b0ff65" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_edb349f5-3e99-4402-b0a7-862f894425df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b8fadf98-4ef6-4534-8b1f-3324c42a8959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b8fadf98-4ef6-4534-8b1f-3324c42a8959" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5fabcacf-624a-4625-bc03-334aa613a2c4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:to="loc_srt_CounterpartyNameAxis_5fabcacf-624a-4625-bc03-334aa613a2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51569722-7412-466d-867c-67ef75a82d4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5fabcacf-624a-4625-bc03-334aa613a2c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51569722-7412-466d-867c-67ef75a82d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1a494df3-f88d-4d2b-a4e3-c091690dd4b7" xlink:href="sgmo-20240331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51569722-7412-466d-867c-67ef75a82d4d" xlink:to="loc_sgmo_KitePharmaIncMember_1a494df3-f88d-4d2b-a4e3-c091690dd4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_11749cb9-c50f-42ef-9b19-87a051abc8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_11749cb9-c50f-42ef-9b19-87a051abc8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_afded666-8739-4171-b47a-0bfdae8b8186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_11749cb9-c50f-42ef-9b19-87a051abc8f5" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_afded666-8739-4171-b47a-0bfdae8b8186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_c0c5c0e7-6690-4571-a9c3-053ddfd517e7" xlink:href="sgmo-20240331.xsd#sgmo_ChangeInAgreementEstimateMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_afded666-8739-4171-b47a-0bfdae8b8186" xlink:to="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_c0c5c0e7-6690-4571-a9c3-053ddfd517e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9e6146d5-50e3-4c60-b2a9-222c71b3a92d" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_0bf1b574-1f80-4533-9497-33f0519066c9" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_0bf1b574-1f80-4533-9497-33f0519066c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_4645b12d-4a4f-4302-be4d-7a04f1c69c0c" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_4645b12d-4a4f-4302-be4d-7a04f1c69c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_a5629dee-33ee-4378-af89-e1911924ef1c" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_a5629dee-33ee-4378-af89-e1911924ef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_b47ab0e9-b1d0-4565-a3a3-6602ea49ccce" xlink:href="sgmo-20240331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_b47ab0e9-b1d0-4565-a3a3-6602ea49ccce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_da06f0ad-ebfc-43d5-807f-1f4f60dac177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_da06f0ad-ebfc-43d5-807f-1f4f60dac177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26fa5cc9-39f7-4595-9724-0aaa23fb10c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_5d67a4ed-778b-4ba0-8695-8cc277c1c9e1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26fa5cc9-39f7-4595-9724-0aaa23fb10c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_70f2e9b4-70b9-4609-b522-af39a0d18acc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_70f2e9b4-70b9-4609-b522-af39a0d18acc" xlink:to="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5f756f7c-41be-457a-b049-ba535653c1c6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:to="loc_srt_CounterpartyNameAxis_5f756f7c-41be-457a-b049-ba535653c1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5f756f7c-41be-457a-b049-ba535653c1c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_b32df2df-f08f-4188-bd1f-3eed5ee5f890" xlink:href="sgmo-20240331.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_b32df2df-f08f-4188-bd1f-3eed5ee5f890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_af22cc2b-656f-4a6c-802d-ee3d2207d578" xlink:href="sgmo-20240331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_BiogenMAIncMember_af22cc2b-656f-4a6c-802d-ee3d2207d578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_916d6033-d211-4bf0-b61b-f219c87d057a" xlink:href="sgmo-20240331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_KitePharmaIncMember_916d6033-d211-4bf0-b61b-f219c87d057a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_fe1b96c2-4c9c-4e3e-857e-c46e7ca86b2f" xlink:href="sgmo-20240331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17ddf2e7-95bd-4020-9b56-a16bf45f2cbf" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_fe1b96c2-4c9c-4e3e-857e-c46e7ca86b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8da69ee4-e444-4d01-99d1-beee6a06a504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8da69ee4-e444-4d01-99d1-beee6a06a504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25d2a11c-a446-407b-8c58-616c56ea0397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8da69ee4-e444-4d01-99d1-beee6a06a504" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25d2a11c-a446-407b-8c58-616c56ea0397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_c5dc39c0-5875-4736-91f1-381803459b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25d2a11c-a446-407b-8c58-616c56ea0397" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_c5dc39c0-5875-4736-91f1-381803459b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fcc56728-5666-49e6-83ce-6fd18782e14f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fcc56728-5666-49e6-83ce-6fd18782e14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6ea41163-dcf3-4f1d-bf74-a43feee8f157" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fcc56728-5666-49e6-83ce-6fd18782e14f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6ea41163-dcf3-4f1d-bf74-a43feee8f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4d10f2b1-8759-494a-a85c-9508e0b8830b" xlink:href="sgmo-20240331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6ea41163-dcf3-4f1d-bf74-a43feee8f157" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_4d10f2b1-8759-494a-a85c-9508e0b8830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_59aae405-ae8f-4d08-8bec-0c11d39bf259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_51ab34a6-1636-48da-a365-4f4a9b94cc49" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_59aae405-ae8f-4d08-8bec-0c11d39bf259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3948a568-e968-4a2d-a157-d09cf6e3beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_59aae405-ae8f-4d08-8bec-0c11d39bf259" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3948a568-e968-4a2d-a157-d09cf6e3beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dac3686-50d0-4ae0-a040-99e876f6ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef1970ae-8c25-4ba6-be9e-66ac3fc2f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dac3686-50d0-4ae0-a040-99e876f6ff20" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef1970ae-8c25-4ba6-be9e-66ac3fc2f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7daeb323-f690-4a70-8762-def51d349ded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dac3686-50d0-4ae0-a040-99e876f6ff20" xlink:to="loc_us-gaap_RestrictedCashCurrent_7daeb323-f690-4a70-8762-def51d349ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_71ddbcfe-6742-49ad-9685-5db20d8b3851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dac3686-50d0-4ae0-a040-99e876f6ff20" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_71ddbcfe-6742-49ad-9685-5db20d8b3851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65088f12-2ad7-4723-b7c0-9ff4519c5d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0dac3686-50d0-4ae0-a040-99e876f6ff20" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65088f12-2ad7-4723-b7c0-9ff4519c5d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aa0eaa87-a30f-4085-bc8b-c63366576ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aa0eaa87-a30f-4085-bc8b-c63366576ba5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_91144cb7-6897-408e-b8b4-7b2f2be5e999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_91144cb7-6897-408e-b8b4-7b2f2be5e999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a69ca247-f467-4f12-bde3-49a2dc691722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_91144cb7-6897-408e-b8b4-7b2f2be5e999" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a69ca247-f467-4f12-bde3-49a2dc691722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c0f84ae3-8118-4aa1-81cd-ae25aac8f4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a69ca247-f467-4f12-bde3-49a2dc691722" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c0f84ae3-8118-4aa1-81cd-ae25aac8f4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50c9fe5c-de35-4d4a-8d8d-a77cc75c490c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eafeb3f8-b98e-43ea-a786-5bd74cabd560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eafeb3f8-b98e-43ea-a786-5bd74cabd560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c2a86cf-b633-41f5-b2cf-34785faa089c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c2a86cf-b633-41f5-b2cf-34785faa089c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d7fb245b-1efe-4eb7-b9eb-691524e1f747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0ec28e3-2c91-4ee9-9d2e-825a807eee14" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d7fb245b-1efe-4eb7-b9eb-691524e1f747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a153aeca-8c14-420c-85d4-741846e0e795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a153aeca-8c14-420c-85d4-741846e0e795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a153aeca-8c14-420c-85d4-741846e0e795" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_80845109-4084-4198-86e0-c030f540fa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_MoneyMarketFundsMember_80845109-4084-4198-86e0-c030f540fa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_26731e71-6032-43de-be5b-0c9c32e551ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_26731e71-6032-43de-be5b-0c9c32e551ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_241a48a3-7c49-4ee3-93cb-b617b6027592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_CommercialPaperMember_241a48a3-7c49-4ee3-93cb-b617b6027592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1f68b693-a194-488f-a085-f5bb0fb7040f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1f68b693-a194-488f-a085-f5bb0fb7040f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5142998c-145f-4b69-979d-b7685a1b451d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5142998c-145f-4b69-979d-b7685a1b451d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_826d4ca3-6f4e-495e-8dbd-0f602f211711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_826d4ca3-6f4e-495e-8dbd-0f602f211711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d2f5b778-0608-4655-9b27-97f4f1bbf308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec4d5c2f-c85b-4c53-a162-bf9beecc8b45" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d2f5b778-0608-4655-9b27-97f4f1bbf308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5dd86c66-04f5-4625-afdf-864db001b81b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_655e2856-f405-45cf-9839-d7d767423f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_655e2856-f405-45cf-9839-d7d767423f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f4082e7a-abaa-40c0-873b-8acecada637f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_f4082e7a-abaa-40c0-873b-8acecada637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_797cb927-4ff8-470b-95df-82a0ec6b42fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d0dad66d-ec21-4c0b-85e2-542d7ff5434e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_797cb927-4ff8-470b-95df-82a0ec6b42fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b7cc1880-83aa-42cf-801a-477125ec2519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_10bedf1a-b4fe-43c9-a1c7-b9ecaeb899e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b7cc1880-83aa-42cf-801a-477125ec2519" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_10bedf1a-b4fe-43c9-a1c7-b9ecaeb899e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_10bedf1a-b4fe-43c9-a1c7-b9ecaeb899e4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8ea1f0a-63dd-4b93-b8fd-12440d15c00a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2984ebda-076f-4065-8a25-a83bdd645501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2984ebda-076f-4065-8a25-a83bdd645501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_7dad40c2-5496-43f7-bd95-5d117f179b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CashEquivalentsMember_7dad40c2-5496-43f7-bd95-5d117f179b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0ab8708c-2ff6-4080-a9d0-517fac4e99ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_0ab8708c-2ff6-4080-a9d0-517fac4e99ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_32aad618-a3e9-4a86-a31e-77905d375b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CommercialPaperMember_32aad618-a3e9-4a86-a31e-77905d375b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8fc47a78-06d7-4460-bbed-b5bec75e391a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8fc47a78-06d7-4460-bbed-b5bec75e391a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7d2ce8c0-df69-44e7-b3c5-ca62dd5b8686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7d2ce8c0-df69-44e7-b3c5-ca62dd5b8686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_9fc34cdb-a48f-4827-9863-84592b4fcb04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_9fc34cdb-a48f-4827-9863-84592b4fcb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_383a63ea-4ba5-400f-b683-6b1b30b80007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_82a69399-de2f-4bbd-b9b0-a23cf979b6d5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_383a63ea-4ba5-400f-b683-6b1b30b80007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_10bedf1a-b4fe-43c9-a1c7-b9ecaeb899e4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76abd21f-8bbd-469c-87c3-c6c4c8c13419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76abd21f-8bbd-469c-87c3-c6c4c8c13419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_3856c968-81f5-4b79-8631-a5b0944e561a" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_3856c968-81f5-4b79-8631-a5b0944e561a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_f4fcdf62-2b51-41ee-95a4-58eab06c0267" xlink:href="sgmo-20240331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_f4fcdf62-2b51-41ee-95a4-58eab06c0267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54761e3b-a16a-4f03-b366-c4d5bef6214a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54761e3b-a16a-4f03-b366-c4d5bef6214a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba010427-90f6-43e0-8545-25c4d1e2da26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba010427-90f6-43e0-8545-25c4d1e2da26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dbab19e4-1630-4c82-97d6-878242ba915f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dbab19e4-1630-4c82-97d6-878242ba915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3f6d72d5-cab8-4b76-a8f3-0f829904842a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3f6d72d5-cab8-4b76-a8f3-0f829904842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_574d17d6-fe56-408f-8705-a3c3cd58521e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_075edd86-96bb-4072-a535-1f6318d704c2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_574d17d6-fe56-408f-8705-a3c3cd58521e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_acd3af5e-8a58-43b6-912f-b528747de34a" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_acd3af5e-8a58-43b6-912f-b528747de34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_abe4db24-1e6e-4e88-af63-f191c6aa25ab" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_abe4db24-1e6e-4e88-af63-f191c6aa25ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2b9e9489-f4ca-46a7-bbc8-e41127ec3ddb" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2b9e9489-f4ca-46a7-bbc8-e41127ec3ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_4db36e91-03af-4ac6-a4f1-450f6107b1e5" xlink:href="sgmo-20240331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f4f6c356-242d-413f-b82c-e9248865879e" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_4db36e91-03af-4ac6-a4f1-450f6107b1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4964367d-7f03-4a30-92ce-ad3c607ace93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cf4fe63b-c035-4bf3-9bc9-82bbc113d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4964367d-7f03-4a30-92ce-ad3c607ace93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cf4fe63b-c035-4bf3-9bc9-82bbc113d36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb10ac5f-e085-446a-bfe1-6c473bd5ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4964367d-7f03-4a30-92ce-ad3c607ace93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb10ac5f-e085-446a-bfe1-6c473bd5ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_76509a59-96e5-4977-a221-e693a8d1c9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4964367d-7f03-4a30-92ce-ad3c607ace93" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_76509a59-96e5-4977-a221-e693a8d1c9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05b00cae-d38e-4ba7-9d87-ad8e009f2555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_3b525c1b-d7ec-4aed-8ff9-bdde2de2b28d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05b00cae-d38e-4ba7-9d87-ad8e009f2555" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_3b525c1b-d7ec-4aed-8ff9-bdde2de2b28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_c2e8ab0b-4174-49c7-931e-415e70ecebd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05b00cae-d38e-4ba7-9d87-ad8e009f2555" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_c2e8ab0b-4174-49c7-931e-415e70ecebd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_c0654411-c53d-474b-a9ee-aa995b2e286a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05b00cae-d38e-4ba7-9d87-ad8e009f2555" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_c0654411-c53d-474b-a9ee-aa995b2e286a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ea7f7511-9f2c-4aac-b849-c65061f55adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d3923c00-3c39-4e01-9c29-21b60d41c8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea7f7511-9f2c-4aac-b849-c65061f55adf" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d3923c00-3c39-4e01-9c29-21b60d41c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5bdc9d6d-918a-4e7d-999c-9f712606e5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d3923c00-3c39-4e01-9c29-21b60d41c8a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5bdc9d6d-918a-4e7d-999c-9f712606e5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f28546e6-8fa4-4bd1-a429-fea76578051e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5bdc9d6d-918a-4e7d-999c-9f712606e5e0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f28546e6-8fa4-4bd1-a429-fea76578051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_33c5a882-6d97-436b-bfdf-1c792d7bb9c0" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f28546e6-8fa4-4bd1-a429-fea76578051e" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_33c5a882-6d97-436b-bfdf-1c792d7bb9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_d3923c00-3c39-4e01-9c29-21b60d41c8a7" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9485d94-faa0-41be-82aa-25deab946272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9485d94-faa0-41be-82aa-25deab946272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d40e153-4a92-4ed5-81f7-24362103289b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d40e153-4a92-4ed5-81f7-24362103289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e825f8fe-29ad-4a3b-ba8b-af990dd7c8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e825f8fe-29ad-4a3b-ba8b-af990dd7c8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_fe88548d-a23e-41c0-95a2-9021be7b6f09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_SharePrice_fe88548d-a23e-41c0-95a2-9021be7b6f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b05ed4d-f67c-479f-bc0e-206e13613855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0b05ed4d-f67c-479f-bc0e-206e13613855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a336f59d-e763-40f8-ab58-bf156d271780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_9455fd59-ecf1-4b65-bda9-cb08250d2f23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a336f59d-e763-40f8-ab58-bf156d271780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d5a5561a-24b6-4f18-8604-1d1334604e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_5b4915f8-f5e8-4ee5-bb99-b8d6213283c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d5a5561a-24b6-4f18-8604-1d1334604e49" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_5b4915f8-f5e8-4ee5-bb99-b8d6213283c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c85cade-920e-4dcd-926f-d4e2986f6310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_5b4915f8-f5e8-4ee5-bb99-b8d6213283c4" xlink:to="loc_us-gaap_AwardTypeAxis_5c85cade-920e-4dcd-926f-d4e2986f6310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5c85cade-920e-4dcd-926f-d4e2986f6310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d0037abb-6ca8-4903-ad1a-58dd8e8b1b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d0037abb-6ca8-4903-ad1a-58dd8e8b1b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7f395285-d60a-409e-a540-3a72a5bd1093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_053dd2fc-3837-491e-878b-0b823a860669" xlink:to="loc_us-gaap_StockCompensationPlanMember_7f395285-d60a-409e-a540-3a72a5bd1093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_5b4915f8-f5e8-4ee5-bb99-b8d6213283c4" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_3541d650-f2c5-4461-b1e2-0dba958a01c3" xlink:href="sgmo-20240331.xsd#sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:to="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_3541d650-f2c5-4461-b1e2-0dba958a01c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_78f1672b-7cf6-4c0a-aaea-d9fb3efb076d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_3541d650-f2c5-4461-b1e2-0dba958a01c3" xlink:to="loc_us-gaap_NetIncomeLoss_78f1672b-7cf6-4c0a-aaea-d9fb3efb076d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_ddc3e915-ec59-4de8-a156-a32b9ba65c47" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5610957d-532d-45b1-bdab-d5a96e34832c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5610957d-532d-45b1-bdab-d5a96e34832c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dda11b3-a1a2-417b-8c9b-06487763fe13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5610957d-532d-45b1-bdab-d5a96e34832c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dda11b3-a1a2-417b-8c9b-06487763fe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_00a40ee6-be16-430b-b0e7-0b676806c20a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_00a40ee6-be16-430b-b0e7-0b676806c20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_40b1d2b0-94f7-4959-ad38-eee798989c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_40b1d2b0-94f7-4959-ad38-eee798989c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c812aa5c-1bc0-440d-8883-9b159ff15171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d0c9feab-b22c-4a9f-bb1d-cf395de13c43" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c812aa5c-1bc0-440d-8883-9b159ff15171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:href="sgmo-20240331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_70a51ca6-cd11-4d34-a49e-61d9ad391090" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ac766395-69ce-4409-a67e-891decbe9852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:to="loc_us-gaap_EarningsPerShareBasic_ac766395-69ce-4409-a67e-891decbe9852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6b33702f-496d-4db4-a654-50b1a5954160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_bfbca9c9-4605-4f64-8a0b-c19aca14a373" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6b33702f-496d-4db4-a654-50b1a5954160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_201b805e-2fde-49e9-8676-91b87b23644d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_201b805e-2fde-49e9-8676-91b87b23644d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_720c3aca-1895-462c-b7e4-97e6d77f486f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_srt_CounterpartyNameAxis_720c3aca-1895-462c-b7e4-97e6d77f486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_720c3aca-1895-462c-b7e4-97e6d77f486f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_61638c9e-fc02-4840-a564-a7b3849e8f2f" xlink:href="sgmo-20240331.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:to="loc_sgmo_PfizerMember_61638c9e-fc02-4840-a564-a7b3849e8f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_8d3ccc79-ffaa-42a2-b8e9-f6cbb4d16bc5" xlink:href="sgmo-20240331.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:to="loc_sgmo_PfizerSB525Member_8d3ccc79-ffaa-42a2-b8e9-f6cbb4d16bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_5adb653b-4e8a-40d3-b3a7-c76093c5b9de" xlink:href="sgmo-20240331.xsd#sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b55b43a5-7ce9-415e-95f8-64806eb74fe5" xlink:to="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_5adb653b-4e8a-40d3-b3a7-c76093c5b9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c75e57e-ec97-4e00-9f15-c1c1b4c87619" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_srt_ProductOrServiceAxis_8c75e57e-ec97-4e00-9f15-c1c1b4c87619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c75e57e-ec97-4e00-9f15-c1c1b4c87619" xlink:to="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:href="sgmo-20240331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_9f91e1e0-7a08-4d42-b762-4bbe3834c1d6" xlink:href="sgmo-20240331.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:to="loc_sgmo_SBFiveTwoFiveMember_9f91e1e0-7a08-4d42-b762-4bbe3834c1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_d60d1766-d88b-4953-911d-d12e859b627c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_3ff03483-7512-4b38-b829-2d4d47fbdcd3" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_d60d1766-d88b-4953-911d-d12e859b627c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1a49100c-6363-4965-b3fb-d7f6a796ede9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:to="loc_us-gaap_LicenseMember_1a49100c-6363-4965-b3fb-d7f6a796ede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_1d33599a-23c4-4686-95ed-ccc159a0577a" xlink:href="sgmo-20240331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cc8d029-bd28-4bbc-9e50-7e096d26bb4f" xlink:to="loc_sgmo_CNineORFSevenTwoMember_1d33599a-23c4-4686-95ed-ccc159a0577a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a812c581-a3ce-4eeb-9afa-b32699d6c86f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a812c581-a3ce-4eeb-9afa-b32699d6c86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a812c581-a3ce-4eeb-9afa-b32699d6c86f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_e2fb8609-8d7e-4ede-9cfd-8a39a636be54" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_e2fb8609-8d7e-4ede-9cfd-8a39a636be54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8e741801-91ff-428e-92a9-912edaf472a1" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8e741801-91ff-428e-92a9-912edaf472a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_81f42375-8702-4c3b-acb3-ae4575455ee2" xlink:href="sgmo-20240331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3c04a106-bfa9-40ca-889e-5927610fde37" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_81f42375-8702-4c3b-acb3-ae4575455ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b432ee2-b730-4a45-94d7-8c832c41e553" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_srt_RangeAxis_5b432ee2-b730-4a45-94d7-8c832c41e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5b432ee2-b730-4a45-94d7-8c832c41e553" xlink:to="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cdc437fe-7e5c-4290-bb0a-84e3347eeb45" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:to="loc_srt_MinimumMember_cdc437fe-7e5c-4290-bb0a-84e3347eeb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5489b82d-aa13-46c9-91b3-76f3ce1be013" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0172f1d-5b12-425d-ba3a-746ded069201" xlink:to="loc_srt_MaximumMember_5489b82d-aa13-46c9-91b3-76f3ce1be013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_89db8d21-eee6-43f5-a476-502c044a0fc0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_256cc2eb-ce43-4b81-a9e7-71869bfbb9a4" xlink:href="sgmo-20240331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_AgreementTerminationTerm_256cc2eb-ce43-4b81-a9e7-71869bfbb9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_511a7984-87fb-42f8-9e5f-22ff3bd3cdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_511a7984-87fb-42f8-9e5f-22ff3bd3cdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_e4f6ebd5-6aaa-4fd0-bd43-a849720f0be8" xlink:href="sgmo-20240331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_e4f6ebd5-6aaa-4fd0-bd43-a849720f0be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_4693e4cd-a91b-4b9e-83ac-c11f3596fdbc" xlink:href="sgmo-20240331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_4693e4cd-a91b-4b9e-83ac-c11f3596fdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_b646b0db-2b3a-46d1-a0fe-59a023e1e784" xlink:href="sgmo-20240331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_b646b0db-2b3a-46d1-a0fe-59a023e1e784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_db46a98c-602b-4648-984c-c37ed9171a48" xlink:href="sgmo-20240331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_MilestonePaymentsReceived_db46a98c-602b-4648-984c-c37ed9171a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_6823fa3b-e38c-449d-82e8-6844e44c45f9" xlink:href="sgmo-20240331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_MilestoneRevenueReceivable_6823fa3b-e38c-449d-82e8-6844e44c45f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_c1193335-d943-4bb5-a793-90f2e31ae690" xlink:href="sgmo-20240331.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_c1193335-d943-4bb5-a793-90f2e31ae690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_3a5f634b-b7ee-490b-9b19-e7cc089acce9" xlink:href="sgmo-20240331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_3a5f634b-b7ee-490b-9b19-e7cc089acce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0cfebefe-2374-4491-84ae-2fcc6ba8f7f5" xlink:href="sgmo-20240331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0cfebefe-2374-4491-84ae-2fcc6ba8f7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_4ef71cf7-0bba-447a-8d23-2b9be896dc40" xlink:href="sgmo-20240331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cce76882-c5f7-42a6-9fb1-80f743f06cbb" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_4ef71cf7-0bba-447a-8d23-2b9be896dc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b50bf2b6-5b67-4bc2-88ba-85586204bcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b50bf2b6-5b67-4bc2-88ba-85586204bcd0" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9788256c-8106-40b0-9ca6-c854bcfaa8ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:to="loc_srt_CounterpartyNameAxis_9788256c-8106-40b0-9ca6-c854bcfaa8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9788256c-8106-40b0-9ca6-c854bcfaa8ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_c7b284bd-ef14-4b45-ac72-fb652c79b561" xlink:href="sgmo-20240331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_KitePharmaIncMember_c7b284bd-ef14-4b45-ac72-fb652c79b561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_86d3c8e8-d9d1-4434-bfdf-485e9b214733" xlink:href="sgmo-20240331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_86d3c8e8-d9d1-4434-bfdf-485e9b214733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_11906361-a0e8-486e-a3c8-c5539734b27f" xlink:href="sgmo-20240331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_BiogenMAIncMember_11906361-a0e8-486e-a3c8-c5539734b27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_b6c607d0-efc9-45e1-8baf-f067649f975d" xlink:href="sgmo-20240331.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6dcc1b1-fd1a-413e-b414-3c0899c86b78" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_b6c607d0-efc9-45e1-8baf-f067649f975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_33b0e1f7-61b7-4ce9-8295-555225713fa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:to="loc_srt_ProductOrServiceAxis_33b0e1f7-61b7-4ce9-8295-555225713fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_33b0e1f7-61b7-4ce9-8295-555225713fa0" xlink:to="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a78715ad-e3d1-4bec-b381-b0996d2fc0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:to="loc_us-gaap_LicenseMember_a78715ad-e3d1-4bec-b381-b0996d2fc0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9866b836-7514-4808-a6c1-eb51b781e394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4ab3ed70-d8cd-49d3-91d5-b8a5af9688ba" xlink:to="loc_us-gaap_ServiceMember_9866b836-7514-4808-a6c1-eb51b781e394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_197dc152-5807-4f8a-be3d-b615dae9bde4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_530f85a1-9763-43a1-a32d-06ba800e5d43" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_197dc152-5807-4f8a-be3d-b615dae9bde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_07d11ffc-40d4-4299-a283-c3987327eb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_197dc152-5807-4f8a-be3d-b615dae9bde4" xlink:to="loc_us-gaap_RevenuesAbstract_07d11ffc-40d4-4299-a283-c3987327eb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a0e4dd6-c8ac-4dd1-a99a-041c57e1ae44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_07d11ffc-40d4-4299-a283-c3987327eb9e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a0e4dd6-c8ac-4dd1-a99a-041c57e1ae44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c188be17-0e86-4482-8b43-39038f05bc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_1326b0f6-d98c-4bf3-b16a-da6792ffaa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c188be17-0e86-4482-8b43-39038f05bc05" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_1326b0f6-d98c-4bf3-b16a-da6792ffaa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_1326b0f6-d98c-4bf3-b16a-da6792ffaa1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e82ee8a-fb9c-499a-ad4d-03f549ad8a37" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EquipmentFurnitureAndFixturesMember_c733072b-3d9f-4199-9c15-7baaf1e97401" xlink:href="sgmo-20240331.xsd#sgmo_EquipmentFurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:to="loc_sgmo_EquipmentFurnitureAndFixturesMember_c733072b-3d9f-4199-9c15-7baaf1e97401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_64c9cc70-a2ab-4969-80d9-d855331d70cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_64c9cc70-a2ab-4969-80d9-d855331d70cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ffaae0c6-41a5-4a67-9a9e-b3d741e8bac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_daacda96-61d3-443c-b895-ed76db4ce532" xlink:to="loc_us-gaap_ConstructionInProgressMember_ffaae0c6-41a5-4a67-9a9e-b3d741e8bac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_1326b0f6-d98c-4bf3-b16a-da6792ffaa1d" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a0df5e7e-a4d0-4ecd-8a9f-47fd2ffb9eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a0df5e7e-a4d0-4ecd-8a9f-47fd2ffb9eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4e0b0a20-46f8-49de-8295-56d4f6e87cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_4e0b0a20-46f8-49de-8295-56d4f6e87cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_575a5811-a8cf-46a4-b7e0-ca6cb2ca2fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_575a5811-a8cf-46a4-b7e0-ca6cb2ca2fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_c3ec1f9e-92ab-414c-8f41-8768995960ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_c3ec1f9e-92ab-414c-8f41-8768995960ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_880b45d3-1b71-4a93-9629-6c13ac3f9021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_880b45d3-1b71-4a93-9629-6c13ac3f9021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_63cc6959-1597-43ac-b54c-e71b1e73033c" xlink:href="sgmo-20240331.xsd#sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_25cb5818-051d-4086-82a9-002ff596d4af" xlink:to="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_63cc6959-1597-43ac-b54c-e71b1e73033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1f36b1c9-f189-40ba-89e3-d1db60ec8c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_78049a9b-049c-4bea-b4bd-967ad204f436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1f36b1c9-f189-40ba-89e3-d1db60ec8c9c" xlink:to="loc_us-gaap_OtherCommitmentsTable_78049a9b-049c-4bea-b4bd-967ad204f436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1fcdcb50-1576-4aad-9ed0-a74c44c63379" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78049a9b-049c-4bea-b4bd-967ad204f436" xlink:to="loc_srt_StatementGeographicalAxis_1fcdcb50-1576-4aad-9ed0-a74c44c63379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b3888b53-2eca-4cff-b53a-64cf94cf3b80" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1fcdcb50-1576-4aad-9ed0-a74c44c63379" xlink:to="loc_srt_SegmentGeographicalDomain_b3888b53-2eca-4cff-b53a-64cf94cf3b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_9c3795d2-7fb5-4b6d-a31f-15183a274074" xlink:href="sgmo-20240331.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b3888b53-2eca-4cff-b53a-64cf94cf3b80" xlink:to="loc_sgmo_RichmondCaliforniaMember_9c3795d2-7fb5-4b6d-a31f-15183a274074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_78049a9b-049c-4bea-b4bd-967ad204f436" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_bed92dbf-4216-4381-842c-95558030771d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_bed92dbf-4216-4381-842c-95558030771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bcccf272-9e51-465e-ad14-5f64173ce98e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bcccf272-9e51-465e-ad14-5f64173ce98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_70a08db2-e932-44be-8e1f-f535bd7368dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_70a08db2-e932-44be-8e1f-f535bd7368dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_3b25a343-639f-4db1-8e70-1a3706c5fcaa" xlink:href="sgmo-20240331.xsd#sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_3b25a343-639f-4db1-8e70-1a3706c5fcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_5a532118-004b-4892-b417-49a211316f2d" xlink:href="sgmo-20240331.xsd#sgmo_LesseeRequiredLetterOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_6145d2e0-f27c-4244-a031-6a564ddc8a9a" xlink:to="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_5a532118-004b-4892-b417-49a211316f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4349f377-823f-4009-996f-0cb736dfeba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4349f377-823f-4009-996f-0cb736dfeba5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30cc88ac-bb44-410d-bda6-b7b8a7fd24bf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3caf56a3-df41-4619-9ba5-a9e5664c1d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3caf56a3-df41-4619-9ba5-a9e5664c1d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_186fd3ae-97a4-49bb-b907-3d1a3950fd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_756032a1-7d42-4fc5-918a-37e264038abb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_186fd3ae-97a4-49bb-b907-3d1a3950fd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d423c0ab-26bf-4c73-a945-247a4571128e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d423c0ab-26bf-4c73-a945-247a4571128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fc5f3d53-c029-4ef7-83c2-cc9a9f155dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d423c0ab-26bf-4c73-a945-247a4571128e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fc5f3d53-c029-4ef7-83c2-cc9a9f155dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_26437c40-50d6-453a-b14e-db59ecd6e334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fc5f3d53-c029-4ef7-83c2-cc9a9f155dde" xlink:to="loc_us-gaap_SubsequentEventMember_26437c40-50d6-453a-b14e-db59ecd6e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8840d4f3-d354-40f4-93e9-de4b3580aa74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8840d4f3-d354-40f4-93e9-de4b3580aa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7fe38186-3078-443b-9635-bb200c969656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8840d4f3-d354-40f4-93e9-de4b3580aa74" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7fe38186-3078-443b-9635-bb200c969656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_c4891461-e843-42ad-875e-e9934818103c" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7fe38186-3078-443b-9635-bb200c969656" xlink:to="loc_sgmo_DirectOfferingMember_c4891461-e843-42ad-875e-e9934818103c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7e36823d-bcba-4968-b36c-faec18d08510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7e36823d-bcba-4968-b36c-faec18d08510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_adb827aa-3707-4b20-b0df-6b92d7f1bf17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7e36823d-bcba-4968-b36c-faec18d08510" xlink:to="loc_us-gaap_ClassOfStockDomain_adb827aa-3707-4b20-b0df-6b92d7f1bf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_bed827e3-e348-4998-8d42-22187cd659d1" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_adb827aa-3707-4b20-b0df-6b92d7f1bf17" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_bed827e3-e348-4998-8d42-22187cd659d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a567e79d-323b-4b8a-95ae-d26d2c744f98" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_81e21123-95f8-4a16-ab5e-3726eb4917fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_81e21123-95f8-4a16-ab5e-3726eb4917fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685e9ab7-0c40-4403-89fc-b90085a6fa93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7cdb2f3e-3a0f-4e7b-a3d8-c5584cd05356" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685e9ab7-0c40-4403-89fc-b90085a6fa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d138946f-64d7-41f9-92e5-f904e746521b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d138946f-64d7-41f9-92e5-f904e746521b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3dbcd87-811e-4426-b914-4db0f5e2fb1e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_srt_CounterpartyNameAxis_d3dbcd87-811e-4426-b914-4db0f5e2fb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_293e1074-7620-4b83-a7b4-0d7f39047a19" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d3dbcd87-811e-4426-b914-4db0f5e2fb1e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_293e1074-7620-4b83-a7b4-0d7f39047a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_50b5ffc7-c555-4ab9-a531-e4e541f544fe" xlink:href="sgmo-20240331.xsd#sgmo_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_293e1074-7620-4b83-a7b4-0d7f39047a19" xlink:to="loc_sgmo_JefferiesLLCMember_50b5ffc7-c555-4ab9-a531-e4e541f544fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e9dce241-eb28-41d5-ad80-4da114ff7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e9dce241-eb28-41d5-ad80-4da114ff7b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e9dce241-eb28-41d5-ad80-4da114ff7b59" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_62f196fc-afc2-4733-9dc9-ea59ed41ffac" xlink:href="sgmo-20240331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_62f196fc-afc2-4733-9dc9-ea59ed41ffac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_890d6e26-33a8-4443-92da-f8a03ac97ce8" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02f2cc17-58bc-42bc-a1af-109cfdfb9812" xlink:to="loc_sgmo_DirectOfferingMember_890d6e26-33a8-4443-92da-f8a03ac97ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_754b4825-bf79-415c-8da1-6c2581ac9925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_754b4825-bf79-415c-8da1-6c2581ac9925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_754b4825-bf79-415c-8da1-6c2581ac9925" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonWarrantMember_db004b52-72d3-4005-8cd8-e90b3969f8ef" xlink:href="sgmo-20240331.xsd#sgmo_CommonWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:to="loc_sgmo_CommonWarrantMember_db004b52-72d3-4005-8cd8-e90b3969f8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_f14e6771-2e42-4ecf-a6bf-db63b3040405" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0d1bfdaf-01dc-46ee-8e56-a38fb80c375e" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_f14e6771-2e42-4ecf-a6bf-db63b3040405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f51d013f-d92a-4cb7-9dae-27377a4059aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f51d013f-d92a-4cb7-9dae-27377a4059aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_34037de2-b03a-4bf4-befb-b3324251d2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f51d013f-d92a-4cb7-9dae-27377a4059aa" xlink:to="loc_us-gaap_ClassOfStockDomain_34037de2-b03a-4bf4-befb-b3324251d2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_4d59851b-112b-4cef-95d8-4d019ff82166" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_34037de2-b03a-4bf4-befb-b3324251d2b2" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_4d59851b-112b-4cef-95d8-4d019ff82166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ec324844-9451-43cb-8845-ff63d4974817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ec324844-9451-43cb-8845-ff63d4974817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bf1fbbe7-6c72-460e-8847-96547fb61102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ec324844-9451-43cb-8845-ff63d4974817" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bf1fbbe7-6c72-460e-8847-96547fb61102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3c0862bb-ae23-417d-a1ea-a0228fa8c0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bf1fbbe7-6c72-460e-8847-96547fb61102" xlink:to="loc_us-gaap_SubsequentEventMember_3c0862bb-ae23-417d-a1ea-a0228fa8c0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4405da4-1412-4e1d-bc2f-c4b9d355d91c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_d3572096-e029-4997-9540-16e558f28818" xlink:href="sgmo-20240331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_d3572096-e029-4997-9540-16e558f28818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_156bc7f8-6a83-44f5-9097-f3506c829066" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_156bc7f8-6a83-44f5-9097-f3506c829066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOutstandingAmountAvailable_bf1a70ca-f096-4192-8f94-ea5ecbf73137" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockOutstandingAmountAvailable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockOutstandingAmountAvailable_bf1a70ca-f096-4192-8f94-ea5ecbf73137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b50c8cb0-e9fa-4b6e-96c0-a622c4670b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b50c8cb0-e9fa-4b6e-96c0-a622c4670b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d157e40-72cc-4fa7-a6c3-54e3d253e916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2d157e40-72cc-4fa7-a6c3-54e3d253e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_19b563f4-88b4-4b64-bce0-9f1f908b2766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_19b563f4-88b4-4b64-bce0-9f1f908b2766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a655d278-2650-47d3-9e5f-805325db79b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a655d278-2650-47d3-9e5f-805325db79b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_747444ab-1799-4b1c-ae6d-fb726f24ff8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_747444ab-1799-4b1c-ae6d-fb726f24ff8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8606754d-1541-4e75-8d86-f80473ea2eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8606754d-1541-4e75-8d86-f80473ea2eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_3384a74d-768b-41e6-a40a-3500b2e6237d" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_3384a74d-768b-41e6-a40a-3500b2e6237d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aaed046f-b1b1-403c-b931-aae74b66b047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aaed046f-b1b1-403c-b931-aae74b66b047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6d9f084f-68ad-430a-8b16-ec3d2533040d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_SharePrice_6d9f084f-68ad-430a-8b16-ec3d2533040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_a4703219-f809-4787-9dc1-150f8e416396" xlink:href="sgmo-20240331.xsd#sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_a4703219-f809-4787-9dc1-150f8e416396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_561b22c6-8d43-43e1-b7fb-df42f191fa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_561b22c6-8d43-43e1-b7fb-df42f191fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a38323da-f837-45b0-997b-a1aef7a03544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a38323da-f837-45b0-997b-a1aef7a03544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_df40977c-0407-4f2f-ad2d-ac7b38db82aa" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_df40977c-0407-4f2f-ad2d-ac7b38db82aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockAgentPlacementFees_339f08d1-96f2-47c7-978a-c0b52e077687" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockAgentPlacementFees"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockAgentPlacementFees_339f08d1-96f2-47c7-978a-c0b52e077687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOtherOfferingCosts_702b1dcd-535a-44c9-a895-8c2da667a3d2" xlink:href="sgmo-20240331.xsd#sgmo_SaleOfStockOtherOfferingCosts"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_828a1f15-6b88-4dae-9ecb-5a8921ddb190" xlink:to="loc_sgmo_SaleOfStockOtherOfferingCosts_702b1dcd-535a-44c9-a895-8c2da667a3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#RESTRUCTURINGCHARGESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_852e133a-bcc3-4624-8cfe-d2d83db20a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_852e133a-bcc3-4624-8cfe-d2d83db20a70" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_5a16f996-f077-49ac-8c0c-e525ebad4096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_us-gaap_RestructuringPlanAxis_5a16f996-f077-49ac-8c0c-e525ebad4096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_5a16f996-f077-49ac-8c0c-e525ebad4096" xlink:to="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_April2023RestructuringPlanMember_a510e611-4ae1-4a7b-909e-0cfec066b76c" xlink:href="sgmo-20240331.xsd#sgmo_April2023RestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:to="loc_sgmo_April2023RestructuringPlanMember_a510e611-4ae1-4a7b-909e-0cfec066b76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_November2023RestructuringPlanMember_9dee1840-f6d7-46de-a425-e7429d9f190c" xlink:href="sgmo-20240331.xsd#sgmo_November2023RestructuringPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:to="loc_sgmo_November2023RestructuringPlanMember_9dee1840-f6d7-46de-a425-e7429d9f190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FranceRestructuringPlanMember_d15086ed-9a99-4e1f-9cbb-9e0eb7cc6cd1" xlink:href="sgmo-20240331.xsd#sgmo_FranceRestructuringPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6d1cae15-f3d0-498c-a33a-9745b721d8ac" xlink:to="loc_sgmo_FranceRestructuringPlanMember_d15086ed-9a99-4e1f-9cbb-9e0eb7cc6cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2c9535a0-88af-4f75-a314-ac9c127e468e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_srt_TitleOfIndividualAxis_2c9535a0-88af-4f75-a314-ac9c127e468e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2c9535a0-88af-4f75-a314-ac9c127e468e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FullTimeEmployeesMember_32591807-f312-4c98-8797-71279e7169c8" xlink:href="sgmo-20240331.xsd#sgmo_FullTimeEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:to="loc_sgmo_FullTimeEmployeesMember_32591807-f312-4c98-8797-71279e7169c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractedEmployeesMember_1abca964-69c5-44c6-93c9-3a5099216d92" xlink:href="sgmo-20240331.xsd#sgmo_ContractedEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_91014188-a7de-4f6b-99b8-52abd18699b4" xlink:to="loc_sgmo_ContractedEmployeesMember_1abca964-69c5-44c6-93c9-3a5099216d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bdc01d00-30de-4faf-9900-51a4c5ce4ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bdc01d00-30de-4faf-9900-51a4c5ce4ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bdc01d00-30de-4faf-9900-51a4c5ce4ad8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff27348b-2437-4dfe-bb1b-ab848f098dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ff27348b-2437-4dfe-bb1b-ab848f098dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6cf0a850-17e1-42ec-aa3e-d0f0dd99ea59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d7c97735-c15e-4bf3-a85f-1315903be3ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6cf0a850-17e1-42ec-aa3e-d0f0dd99ea59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_srt_RangeAxis_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bf0b42cb-ba1f-4a3d-9908-b0a3f7c07b12" xlink:to="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_93f83d23-f8a3-478a-beea-00f46feb5efe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:to="loc_srt_MinimumMember_93f83d23-f8a3-478a-beea-00f46feb5efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aba64e81-2b13-41e3-8336-8cb7dfe31b07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c1ddc5ef-c0c7-49d7-b34c-eaca912b7fce" xlink:to="loc_srt_MaximumMember_aba64e81-2b13-41e3-8336-8cb7dfe31b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_617045e6-a29e-47f1-9587-98fcf422463d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_srt_StatementScenarioAxis_617045e6-a29e-47f1-9587-98fcf422463d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bd5fcf45-9845-428e-9a20-fdbdd4c4ae97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_617045e6-a29e-47f1-9587-98fcf422463d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bd5fcf45-9845-428e-9a20-fdbdd4c4ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4f4bc687-b270-4913-a67b-f1fcc7c23c5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bd5fcf45-9845-428e-9a20-fdbdd4c4ae97" xlink:to="loc_srt_ScenarioForecastMember_4f4bc687-b270-4913-a67b-f1fcc7c23c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2762ea24-e120-474b-9285-da4e392bbb8b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8aae3ecb-4214-444d-8096-922bf923b417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8aae3ecb-4214-444d-8096-922bf923b417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f159f438-b763-45cb-b86e-108645459112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f159f438-b763-45cb-b86e-108645459112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0bc1714f-d54e-4caa-bf02-45c48cd71773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_0bc1714f-d54e-4caa-bf02-45c48cd71773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_67a88c72-4fab-4138-a0ab-e24111b64095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringCharges_67a88c72-4fab-4138-a0ab-e24111b64095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_ba437af4-2908-4e8f-8459-0cd3de1c5658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c1295e41-a741-4b77-a808-c85e26410c45" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_ba437af4-2908-4e8f-8459-0cd3de1c5658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9bf98201-a98d-4723-a93c-4d558295801f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_c80a8911-60fb-4cbc-b4f8-34c08f596f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9bf98201-a98d-4723-a93c-4d558295801f" xlink:to="loc_us-gaap_RestructuringReserveRollForward_c80a8911-60fb-4cbc-b4f8-34c08f596f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_bee11de1-a29f-44dc-9759-6e1458331b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c80a8911-60fb-4cbc-b4f8-34c08f596f1d" xlink:to="loc_us-gaap_RestructuringReserve_bee11de1-a29f-44dc-9759-6e1458331b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8d528f27-45a2-49c0-b3df-3708d1fe038e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c80a8911-60fb-4cbc-b4f8-34c08f596f1d" xlink:to="loc_us-gaap_RestructuringCharges_8d528f27-45a2-49c0-b3df-3708d1fe038e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_065c8eef-99eb-4457-a9e2-1ca2997abbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c80a8911-60fb-4cbc-b4f8-34c08f596f1d" xlink:to="loc_us-gaap_PaymentsForRestructuring_065c8eef-99eb-4457-a9e2-1ca2997abbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_62c8296d-277d-4e4c-a6f8-6bbbbff901ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_c80a8911-60fb-4cbc-b4f8-34c08f596f1d" xlink:to="loc_us-gaap_RestructuringReserve_62c8296d-277d-4e4c-a6f8-6bbbbff901ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sgmo-20240331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9725dc91-f2ec-44bf-88cc-b3e721434aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9725dc91-f2ec-44bf-88cc-b3e721434aae" xlink:to="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5204b678-badc-486c-b585-1f9ad58524b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5204b678-badc-486c-b585-1f9ad58524b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1e15cde7-db45-41b2-a1bc-28db48bf28a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5204b678-badc-486c-b585-1f9ad58524b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1e15cde7-db45-41b2-a1bc-28db48bf28a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b56242c0-e9d6-46ed-a34e-abfe2bca1568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1e15cde7-db45-41b2-a1bc-28db48bf28a3" xlink:to="loc_us-gaap_SubsequentEventMember_b56242c0-e9d6-46ed-a34e-abfe2bca1568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3c359247-89b1-4688-bcce-097560902b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3c359247-89b1-4688-bcce-097560902b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4033fb36-1a6d-4016-a627-4caebfe4a057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3c359247-89b1-4688-bcce-097560902b3c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4033fb36-1a6d-4016-a627-4caebfe4a057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DirectOfferingMember_afa25e16-392e-4c30-9a3d-40fce42f26bf" xlink:href="sgmo-20240331.xsd#sgmo_DirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4033fb36-1a6d-4016-a627-4caebfe4a057" xlink:to="loc_sgmo_DirectOfferingMember_afa25e16-392e-4c30-9a3d-40fce42f26bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0afecb94-2eb6-4b41-b6e0-715683a84f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b8ccdd10-5b0b-42ec-9450-98f4d9974ed8" xlink:to="loc_us-gaap_ClassOfStockDomain_0afecb94-2eb6-4b41-b6e0-715683a84f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_1a709c2f-34fa-45f3-8970-5a342eeebd19" xlink:href="sgmo-20240331.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0afecb94-2eb6-4b41-b6e0-715683a84f6a" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_1a709c2f-34fa-45f3-8970-5a342eeebd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_18904763-85cd-4e67-991c-33b7eec2c8cc" xlink:to="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c95eadfd-af9d-40f1-b4dd-becd9dc2ef5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c95eadfd-af9d-40f1-b4dd-becd9dc2ef5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e13f9d58-a427-4b11-9d36-4cc01562e481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e13f9d58-a427-4b11-9d36-4cc01562e481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ebea6eb3-e57c-42d1-8c74-9425656d7e36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_510a45b0-89d6-4fa4-9d3b-e0f641f22f60" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ebea6eb3-e57c-42d1-8c74-9425656d7e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>secondamendmenttoleaseag001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 secondamendmenttoleaseag001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4#")5'"C/R@EB!DY ';TVM/.N'4KBWN+V&XTYK9)+2]BA <L2=P?JIXVD$
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M)8 $/T*X.>GXXH WZ*\G\'>+?%OBKQ'XKTE=1L(&T:<PP.UF6$GSNHW@.#_
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MF)FV1&:0*7;T /6N(\!>.[K6M3\8)J][9'3]&NA'!=( BF+=(-[-G'10<]*
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MP.!704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-PFR>))4SG:ZAAG\: /$_B5X5UC4?A]_;4HL5O;*9M4,T,K&3Y\;E!QC"J$
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MA$(.0#T.X Y]17>?8K3[9]L^RP_:MNWSO+&_'INZXHCL[6&4RQ6T*2'.76,
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MU.>,=<\5S'B[5["P\8^'H+IK:RN)(KDPZG=-A81A0R("0I=N/O9QCH<XKCM
M-C?^#OL7]OOIFH0^);@VEV57]U/NE9!(IP,,H8;>.2.* /7K'4;/4HGELKF.
M=$<QN8VSM8=5/H1D<4MY?VFGQ++=W$<*,VU=YQN;T [GCH*YOP+J6HWUOJT6
MJV]HM]:WQAFNK//DW1")\ZYZ'& 1V(_"J'B*Z;3?BEX;O;]@FDR6MQ;12N<)
M%<L5(W'H"RKM&>O(H Z>3Q%I2Z+-J\=];RV<0;=(D@QN'\.>QSQCUKG/!NHZ
MEXEMM*UY-?1XIH"]_IHB1E1G&4", &0J>.2<CWK/L42#7OB%JD,T::--#$!(
M& C:=82)64].Z@GUXZBMSX9S13?#7P]Y4B/ML8E;:V<$+@@^] %?QOJ^JZ5J
M_AJ#3KXP1ZGJ LY@8D?"E2=RY'!X]Q6S96^J0:T1+K"WEDL#"6*2%%>.0E2A
MRH'&-_!'I7(_%%[&36?!5K>2Q!'UE"Z-)M.W:PSUR!DCGWK5\1^&Q8>"/$T?
MAV*1;J^M'8(CEBS!-ORY).2HQ0!OV^O:5J-R]C9:I;O=F,NJHX+;>FY1_$ >
MXR*Y;P3XWM)M"LXO$.O6G]K7-U<1QK,Z1O(%F=%PHQZ #UJIX?U+PEXJU+0;
MZRU"[O-4LU9H;;?AK,,F)!(H PO&WG@G&*YRTM]*N_@SK6E/%;RZM+>7<<=L
MH7SS<F9_*^7[V[[I_P!WVH ]4O\ Q5X?TN6:*^UFQMY(%#2I).H* D 9&>,D
MU+'XAT:6VNKF/5+-H;0XN)%F4B'C/S'/''/-</906C_%Y++46M;FZ7PQ%%*)
M-K;W$K;N#U)'Z&J<FI6.F:O\2[&[N8H+JY17MX&.'E4V@&47JPR#G'3'- 'H
MTVN:7;VMM<R7\'DW2[[=E?=YRXW93'WACG([4QO$6BI9VEVVK60M[Q@EM(9U
MVS,3@!.?F.?2O-]%U_2H;?P);M<6MG.=! 35)GR$PL2O!&"=ID) /S XVXP<
MU@V]YIS_  JT2UGN(F\GQ.JS)-@%1]K<D,#C'RG)'8'WH ]?M/&'AN^GA@M-
M=T^::9V2*..X4M(PZA1GG'M6C'J%G+?RV,=S$UW"H>2$."Z*>A(Z@&N6\=:,
MQT*+6M%MXQJ>CS_VC;B)0/.X_>H<==Z9'N<5I^$V:_L)=>DC>.35G%PB.,,D
M( $2GT^4;B.Q=J #QEXC@\+>&I]1FGC@8LL,4DBEE5W. Q Y(7EB!V4U6\%S
MZE?64E_=^)['7;28 6[V=J(E0C.[.&.3TXXQBMC5=;TK15M_[5OH+1+F3R8V
MG;:K-@G&3P. >M<MX>M-,T;Q!XFUO3I(H/#LL$4TC1?ZDS(',KICC&W9DC@G
M/<&@#N:YW7;+Q1J$[IHVKV^DPQ(-KO:B=IW]\G"H.!TR3GI@9UM*U6QUO3(-
M2TVY2YLYUW1RIG##.._(Y!&*YOQ7XVT72;L:)-KEKI][,FZ2:20 V\9_B _O
MG^$?B>!@@&5;>/=2E\ Z/?2VT$6MZI?C2XP 3$)?,9#)C.2H",V/PS6Q'K=]
MI?B^3P[<R-J#3Z>U[92R!(W=T;:\3;0%[J0<#J<YQ7.:^=)OO#GAG5?#C+-H
MWA_6(&D>($J(5&UV!/W@NX$GV;T-:5PT.H?%:#6$N(O[-T729/M%UO'EK)(V
M0I;ID(I8^@(]: &W]]XP\,ZWHEQ?ZI9ZG8:G?)8SVD5H(C;M("0T;9)8#!SN
M[#\M7Q_XCN] \-7[Z4J/J:6LMPA<96%$&3(P_( =R1V!QBV_CWPCK6MVU_-K
M=JY@<QZ;9(VZ1Y&^3S"H_B(.U1V#'/+86CXYTSQ9:^&?%UVUUHDEE<V\S.6A
ME\\0!2%0'=M&%SVQDD]S0!Z3IDTESI-G/*<R2P(['&,DJ":M5RFC:]%HVA^'
M[3Q'J%C#?Z@JPVJPJZK*<#:HSGG!4')QD\=:Z2]CEEL+F.$XE>)E0^C$'% '
M/6'BJWN=(O\ Q+<W(@T.!I$@(&?,2-BK2'N<LI"@=L'DGC&U7QE+>:9X/U?2
M=02"VU'4K:"\A&Q\+(A=D9B.", <8[U!X.4R? *.&.-O,72[F(H!SO'F*1CU
MR#6)=:GI5]X#^&<0N[69(]1T^.92X*AEA(93VR"0".V>: /4]+UW2=;29]+U
M&UO%@?9*8)0^P^^*;9Z_I%_>FSM-1MIKD)Y@B20$LG3</4>XXKS77O.NO$OQ
M'L](D5KZ?1;;;'$PWNP60$ #DMM./Q%:OA_4O"7BK5="U"QU"[O=4LU=H;<O
MAK,,F)!(H P. O/!.,4 =EXEU&YTCP]=W]I:S74T*J1%#'O?:6 8JO\ $0I+
M8[XQ63#XIG?7M,LVTW5EM;S3A=1S-:<;\,628_P, J\#J7Q75U%=2F"TFF4
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M+9X]3U.*&ZN((\EDA!3Y!WP$!8CW:@#T?3-?TK6)'CT^^BG=$60JIP=C?=<
M]5/9AP?6J?C2^O-*\&ZMJ5A.8;FSM9+B,[%8$JI."".AQ7&^ ?[ U_5-(\1V
M6NW=YJD.E+9RVJB,)!'U*R!4!&&Z9/.,C(!KJ/B/-'#\-_$1ED1 VGS*NXXR
M2A  ]Z .)TGQ=XRN_A.GC:*]M+FXA$LMQ92VH"/&CLK;64@@A1GG/2NX\-^.
M-*\0>#[3Q$TJ6<$Y\MTE<927.TH/[QSTQR<CBO+/"OB'3[+]G1]-6XCGU.Z@
MNK6&QB;?,[R.ZC"#GHV>G2J\^EP^ /A%X=@\0V#R:C+JRW40:5TCM)3G#2%#
MDX4<J.2<\\9H ]IM_%>A75C?7L.IP-!8$BZ.2&A([,IY!]L<UE>#_'^D^+M,
MNKZ&>.!(9)#LD;:RPJ<"1\],]?:O.? D_G_$#XB0_:6N+BZM@\9,1C:;Y6^8
M)C@?,,>Q')SSAZ2\]Y^S/J6FZ:YDO;>9GNH(LETC\X$[@.G'.#U /H: /<9-
M=M=;TJ_BT'5X$ODM]Z2F,OY889638>64]B,@]LUE6S>,&D\-//>0XD1EU* 6
MFTN,'$N[_EF?N_+ZG'TQ? ?]@:_K&F^);#7;N]U)-*6TFM@(PD$><[9 J#!#
M=,GG'&0,UZ;0!A:/K,DNLZCH-ZP:^L0DJ2 8\^!\[7QV((96QQD9&,X&[7 7
M$R6WQKNM0DD$=G9>&<W<I^ZG[]F&?P5C79:3JUAKFEP:EIERES9S@F.5,X;!
MP>O(Y!&#Z4 <K?>)GT7XE3VNJ:O%;Z(NC?:]L^Q%20S!,[L9/';/>NA?Q1H,
M>GVM^^LV*V=TVV"<SJ$E;T4YY/M7+WSV4'QLMY=0:WC1M 987G( +B?)"D]]
MI/3G%9NA^$8]:\)^++& "WT_4-4EN=)=1@1D!=LJ>B^8I(QU'3@T >COJ-E%
M>06<EU$MS<*6AB+@-(!U('?%27-S!9VTES=31P01*6>21@JJ/4D]*Y'P-?7W
MB1/[>U2U>VN8(?[/$3C&)%/^D,/9G4+_ -LZL_$6_L].\%W<]_9)=VWFPJR2
M,RHI,BX=RO.U3ACCKC'>@#8@\0:1<QW,D>HVVVU -QND"^2",@MG&T$=">M0
MP>*_#]U>6MG!K5C)<W2;X(DG4M(O7(&>>.:X+3]5L6^)&O/)K%O>+<:%$RS*
M%6.3:TF[9C@J/7+8Z$UD6DUA!\+OALZR6\;#6;)F(900=S!R??'6@#U'Q'KE
MGIFG7<9U2&SO%MVD0M@E.N&(/ &1C)XJ/P/J-UJW@;1-0OI?-NKFSCDED( W
M,1DG X%<9IFM65C?^/\ 3=>N88-1GNI985N&"F>U:(+$$S]X  C SR?>NE^&
M,\4_PT\/F&17"64:-M.<,!@@^] %.;Q5_8WQ#U6UUK68;?1XM.AN(A/LC5'>
M1U(#8R3A?4UUJZOISZ8FI)?6[6+@,EPL@*,"<#!Z')X^M<6\FGV_QGOY-1:V
MB#Z'$(6N"H#8EDW[2WL1G%<A$C^&M)TW59A<VWAA?$EW<(85_P"/>VD5DADV
MX.$W$GIT8>HH ]-U3QMH6F^&K[7!?17%O:;E98FRQD XCQU#'T/3KTJY;>)M
M%NI;6!-4LS<W2[H81,I9\==HZG'->=>(X=!O/ OCC5/#]S/J$EY9I]JNQ)OC
MD9!P!@8W*O7'J,UM>+;FWF\-Z-XQTF5+K^PYTN#) =PDMV&R=5(Z_*<_5/:@
M#K[?Q!H]U#=36^J6DL5H2+ETE!$)'4,?X<>]%UX@TBRM8KJYU&WC@E3S(W+C
M#)W8?[/(YZ<UYY;VFJVGBVYTR:"06GB^(7DJ[<"U*,!-&<=S"44GNU6=5UBQ
MT/XEZG%XAU*;3+._L8/L-P6"Q.J;P\98@@'+9Q[_ $H ] FU;3H+**]DO8!;
M3 &*4."),C(VX^]D<\56'B70S96][_:]E]FN9/*@D\]<2/G&U>>3GC'6O-II
M=)\(ZAX5E6>_L/"IM;JVM[IF)\J1Y%=68L"0KJIVY['L,TSQ+#X;A\'>=I4Q
MFLK[Q%;3R3SR;DN)#(OF,F>"N."1QP?2@#U#3=?TC69KF'3=2M;N2V(698)0
MY0GIG'T/Y5'XEN+FS\,ZG>6<YAN+:UEGC8*&&Y4) ((/'%<Q#/:K\<)(XI80
M6\.H-JL.2)SCCZ?I70^,IHH/!6N/+(D:_8)QEC@9\MJ /)8OB7XMM?A?9>-9
M+RSN6:^-M-926P567)&592"#Q[_I6]XV\<:YINL>"%TJZ^S6WB)T66*:%':$
M,8A\I(ZXD/7/(K,^#'AG0-?^'ME+J=NM]-;7<K"":=WCC;/!\K=L!QWVTSXU
MRVK>.OA_#).J*E\3-MEV-&IDAYR""O .#QTH Z30O&>LM\4=5\#:G+%<K#!Y
MT%_!$$D4%5;#KRO1L9QU'3GC*\">+_$/B:Y\5+J>NK:0:+,$22.UCY7,@);(
M_P!@=/6O1-(\-Z%H,MS?Z?:1QS77S3W<DC222#K\TCDDC\:\.^&6@:;XKU#Q
MW9SW!$K7J2VI2X902'E(8J#AQD#J#UH ]WT!-6BTUHM:N([B\2:11-'&(Q(F
MX[#M'3Y<9]ZU*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *:\:2##HK#T89IU<QX^\8P>!O"D^L
M2Q>=+N$5O#G DD;. 3Z8!)]A0!T?D0Y!\I,CH=HH$$05E$2!6&&&T8(]ZXBR
M3Q;>> TUMM=9-8FM/MD=LMM%]G4E=RQ$%=^,8!.[.>?:L:V^)%UXE^#VI^)M
M.D_L_5=/1A,B*KJ)% /1@?E((/J.F>* /4);>&>+RIH8Y(_[CJ"/R-/ "J%4
M  < #M7F'AC4O$OB3X>:9JP\4RP:UJ*S""(VL!B9T+X&-F<83DY[_A5?Q5XG
M\2:;\4_#?ARVU:2"SU2%&G @A9D8LP.TE#_='7- 'JSQI(5+HK;3N7<,X/J*
M:UO"Z,C0QLC$EE*@@D]<US^D1ZL-?D<ZX^IZ2(I8F66&)7BN$=1]Y%7(QO&,
M<%:U-<?4(]#O3I*!]1,++;!L8$A&%)SV!()]A0!>CCCAC6.)%1%& JC 'X4D
ML4<T;1RQK(C=5<9!_"O(ED^*NE^)_#]AJ_B+29HM1NMCQ6L +^6B[Y#S&, *
M,9SU84NI?$'6;P>.=0TR[%O;^&9(HK>#RD9;A@["0R$C.#M(&TKB@#UP0Q"(
M1"-!&!@)M& /I2I&D8PB*H/]T8KS6Y^(<VL:UX*TC2I#:'7K<WES*H5GAC"$
M[%W C)96!)!Z5F1?%F[LO ?B>[NUBGU?1+YK&-BNU9B7*QNP&!GAB0,9V\8S
M0!ZX\,4AR\:,?4J#3P !@# KS;2O%^IZ?\0M&\-:G>&]BU?2$O$EDC1&CGPY
M91L &PA#P<D'O7I!&00"1[CM0 R."&)W>.*-&D.795 +'W]:!;P"<SB&/SB,
M&3:-V/3/6O()?'?B/PY\4K'3M8OUN/#NH7,MM"[PHK(X<H,LH&<'9GV:KWQC
M\;Z[X6L(9- N(X#%*B7+O$LF3('**-P(&!&Q/^\OK0!ZEY4>_?Y:;_[VT9I'
MMX9)/,>&-G*E-Q4$[3U&?3VJII<DBZ):SW=TTKF!9))I J]5R3\H  KCOAY\
M0_\ A,-9\0Z?<1F&6RNBUM&R[6-N?E!(ZYR,G_?% '>F*-MFZ-#L.4ROW?IZ
M4A@A(P8HR,D_='4]:\R^)/BC7O#_ (S\)Z?IFIO!:ZQ<^1.GDQ-L&^-<J64D
M'#GKFI+OQ=K?ASXMZ5X5N+M=5T_5( ZL\*I/ ?G'5  1\F>G3/IR ==KNE:U
MJES%:VFHVUKH\L317D?D$S,#U\ML@+D9&<<9SSVWD18T5$4*JC  & !7EFM^
M*/$%I\;](\*P:M(FEWUOY\B^1$64XD.%8IT^0=<GDU4\?^,O%W@?Q:E]!(=0
M\,Q>4;N!H4#1^86&-P4$#Y>">^ >O(!ZY+#%<1[)HDD3.=KJ"/UHDCW0/&NT
M94J,KD#CT[CVKF;?5SKFJ:%?:1K$ATF]MY9FC2.,A]NS R5++RQ!&<\=JJ?$
M_P 8S^"_",E_91^;?,ZK$I7<%&X;F;V XSZLOK0!U.FZ?!I=BEI;@[%9G).,
MLS,68G''+$GC YXJ=H(G;<T2,3W*@U5T;5;;7-%LM5LVW6]W"LJ>H!&<'W'0
M_2KCJ61E#E"1@,N,CW&>* %5%1=JJ OH!Q3$@BBB\J.)$C_N*H _*O&_#OBO
MQ3K5]X[@G\2FV7P_(ZVTC6L&TA6E'[SY.>(QT(ZFM#0_BS=#X0S^+=<L5^UP
MS-;1)&"BW3\;2,]!R<_[K8]* /5!;PJ01#&".A"BGD!@00"#U!KA=%7Q9K/@
M>'6WUTP:K>6WVJ"VCMHOLZ!AN1""I<@C&3NSS[5B:;\2KOQ1\(]7U^S?^S]9
MTN)S,D:JZ;U7((# _*P_$8(SQD@'I&H:9#J1MEGP8H)5F";1DLI#+SV (!XZ
MX';(-ZN)^&FJZKXH^'=EJVIZE*U[>>;F1(HU$>V1E&T;<=%'7-8/BSQ)XAT/
MX.V?B.VUB1M39()'=X(MK>9C(V[. ,\?UH ]"T[25TJ[NS:L%M+J1IV@(_U<
MK?>*GT8\D>I)[U>^SP[0ODQX'0;1Q61X0NKN_P#"&D7]]=/<7-W:17$CLJKA
MG0,0 H QDUPWCSQ1X@T?XE>&=#T_59(+'5G5)E\B)F3+[3M+(>Q[YH ]1$4:
MOO6- WJ%&:2."&)W>.*-&D.795 +'U/K7-Z7%K$FMM(FOS7^CM#/ WF00K)#
M<)(J@AE4 CB08(ZCO7)>"?%NOGXG:YX1\3:B9I;9=]CB&.,2H.<G"Y)*LIX/
M9J /5:" 001D'J#6#IK:A=>)=3F_M*5]*@*P1VYCCP9L9<A@NXJ,JHYZAL]*
MYOQY\1E\(>*/#NGE?]%N9_\ 3Y2O$<; JO/8YRWKA/>@#O&M+9ITG:WB,R#"
MR%!N4>Q[4Z:"&XC\N>))4SG:ZAA^1K)\775U8^$-7O[&Y:WN;2SEN(W55;YD
M0L 0P((R*\QL/%_BN?X,OXV.NC[? S%H);6+R9%$NS'"A@2/]KK0![,\:21F
M-T5D(P5(R"/3%$<<<48CC1411@*HP /I7F'B3QQK#?!2#QGITAT^_:.)S%Y:
MNA+2!#PP)QR2/J.M5=1\5^*] ^&^C^-EOX]2BDA@EO[.Y@1!B3 S&R %<,0.
M=W7VY /5H;:"W0I##'&K')5% !/X4OV>#&/)CQ_NBJ>A:Q;>(-"LM7LR?L]W
M"LJ!NHR.A]P>/PKB?C+XFUKPAX5MM6T6^-O,UVD#(T2.K*5<Y^92<_*.] 'H
M,EO!+$(I(8WC!SL901^5/2-(\[$5=QR<#&3ZU3T9IGT:SDN+A[B:2%'>1U4$
MDJ">% 'Z5YUXD\2>(+7XSZ-X5M-8E@TW4;8S/B"%GC/[WA24/'R#KGO0!ZB\
M:2 !T5L?WAFD:*-E"M&A Z CI7G?P[\:ZOK?BCQ)X<U8PW+Z/.4COH8]GF*'
M*X8#@-QGCW]*]'H C^SPXQY,>/3:*/L\.<^5'G_=%5K_ %:QTPQ+=SA))B1%
M&JEW? R=JJ"3@=<#BI+#4+35+&*]L+F.XMI1E)8VRK<X_F"* )EBC0$)&J@]
M<#&:;';00Q&**"-(R<E%0 $_2N9^(^J:AH?@34]6TN[:VN[1 Z'8CAOF48(8
M'L3TQ4&I1^*=/\._VKI>L_VA=0P"=[2]MXPDP R55HU4J>N,YYQ0!UWV>#&/
M)CQ_NBAX(9#&9(D<QG*%E!VGU'I6'HGB_3-9\*:?KXD\F"]7Y(V^9]_(9 !R
MQ!5N@[9K&\=>)2?AGJFM^&]7V26^ LT 5L-O"LC!@<'D\<$4 =L(8A&(Q$@C
M'1=HP/PI/L\''[F/CI\HJEJ&N:;I3A+VZ6.0QF78%+L$'5R%!(4=R>*:WB+1
MTEL(SJ,!?4 &LPK9\\8SE".O'/':@#06&-&W+&@;U"@&D2WABD>2.&-'DY=E
M4 M]3WJE;:]I=Y->0VUXDLME_P ?**"3$?1AC@^U12^)]&BMX)S?HT<\1GB\
MM6<M&.KX )VC(^;IR.: -+[/!C'DQX_W12F&(Q^68T*#G;M&/RK,G\3Z%:PV
M<T^KV:1WH#6S&9<2C&<KZC'?I38O%6AW&F0ZC!J,4UK/N\IX@7+[3AL* 2<=
M^.* -BHC;0$Y,,?_ 'R*987]IJEC%>V-S%<VLPW1RQ,&5A[$5S/Q"U'4-*T:
MQNM/O9+9SJ5M#($52)$>158'()'![8H ZH01*"!$@!Z@*.:/L\(! BCP>HVC
MFL=[ZT_X2\0_V^JRQ63M)I8*8 W+^^;N,9QR<<U&?''A<+ W]NV12>4Q1N)0
M59L[>O3&>,]* -WR8O+:/RTV-U7:,'\*(HHX(Q'#&D<:]%10 /P%9MGXET6_
MU2?3+34[::]@4O)"CY(4'!/N >#CH:PY?%FF:%X<U[77UQM8MK>ZDP(PK")]
MH(@4J.0..3TSR>* .MAMX;<,(88XPQW$(H&3Z\4ODQ88>4F&.XC:.3ZUGKK^
MG?V=!>O<J(YN$ 5BS-C)"J!DD<]!VIT.OZ3<:1_:T6H6[6'><.-H.<8^N>,=
M<\4 7Q&@0H$4(>J@<4X  8 P*XC2?$$U_P#%2_TV'499]/CTI)_LSQ!##*92
MI!&T-]T*?F_O>AKLY[B&U@>>XECAAC&YY)&"JH]23TH (;>&W#""&.(,=Q"*
M%R?7BG.B2##HK#T89K"A\;^%[B^M+*'7;%[F[ ,$8E&9,],>Y[#OVJU?>)=&
MTV>2&\U"*)HMOFDYVQ;ON[V PF>VXC- &DD4<9RD:KG^Z,4K(KC#J& .<$9Y
MK)U+Q7H&CW$D&H:O:6\T4)G>-Y!N5,@;B.HY(QZYXK/L/'FB:AKU[IL%TFRU
MMXIC<-D1MO#G@GC 50<].?:@#I@B!RX4!FX+8Y-"HB9V*J[CDX&,GUK#A\:^
M&KB:SBAUNS=[UMML%DSYAR1@'W(('KCC-7-3\0:5HY/]H7L<&U0[D@D1J3@,
MV!\JY!Y.!Q0!>AMX;=2L$,<2DY(10H)]>*><[3M )[9-8]_XL\/Z8^R]UBRA
M?R?M&UI1GR^/FX['(QZYXIS^*=$2%)CJ$1A>-)!*H+(%<90E@,+NR,9QG/%
M#['1ULS?7#.LE]?-NGF9.#A=JJ%S]U1T&>Y/4FK.FZ=!I=BMI;@[ S.2<99F
M8LQXP.22>./2N/;Q/_8_Q"URWUC6/+TJ"PMYH4F"@1L[/D+M&6X7OD\5M:QJ
M^G7&F:9<1>)(K"*[N86MYXF1OM0+#]VN<Y#9QQR* -V:WAN$"3PQRJ#D!U#
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MC>&\M8PK,SHK;00=T8W$*W!..:[+P-?7NJ>"M)U+4+IKBZO+9)Y&**H!89P
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M_IUU'/9G3&3SX_N%BLP STZD#Z\=>*]KIJHJ !5"@#' QQ3J .%\>Q/<^)/
M]O!GS_[8\[C_ )YI&Q?\,8KIM(\1Z3KTU_%IEXL\EA.;>Y4*RF.0=1R!GH>1
MQP:>FE(VM'5;EA+<)&8;<8P(4)!;'^TQ"Y/^R!ZYFM-/BM;FYN0Q>>X(WNP
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M@].X/XT :KZP^A?\)/JNIZI<7.GZ>%:.$I$ J^4KX!50226P,GN/K6+X"O\
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M )P39@IU S_$> .2<4 =,;#7YUAN?^$CNX;2/3U8^7!;EYISN)9B8R  -O
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M4<L?FW;=V,>]<GX/\2ZS\3=3U/4+;49M)\.V4WD6\=LB>=<-C.YW=6VC!!P
M/O=>.:'PX\):OX=USQ'X5U6>6;35LPMA-CAHI&;.WT.>H['/KDU?A1<CX</K
M'A3Q4Z::YNOM%K=7!V07"E0I*N?E_A4XSGGU!H ],TVTURS\031W>HM?:4;8
M&!I(D619-WS!BH ;C&#@=_K6]7/WGB^PM]%U+5K>&YO+*PA\TS6Z96;KE8S_
M !8[D<#/7@XK6/C[1;JS\/S3F>SEUT'['#/$V21@8)&0.2,9/.1B@#J:Q_\
MA*=%^VQVOVY?,DN#:H^QO+:8=8Q)C87X(VYSD$5L5X=>ZU:WNC:3.%>Q-IXG
MB>XTN"V(6S N&RTAVY+MG=U .[ '% 'N-<!;W6M7WQ0UG1/^$AOH+"ULH;B)
M(H;?(9R01EHB2.*[U&#HK@$!AD9!!_(]*\VLM8TVS^-'B&>YO[:&%M.MXUDD
MD"J7!)*@G@D9Z4 :=OXAU;0?'MIX9URX2^M-4B>33K[RQ')O09:.0+\IXY!
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M1SV4K0-+'=PF)4,0V@Y(QC;WS[T =]=:YIUI;PS/<>8DZ>9$+=&F:1, EE5
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M*    8 Q1@<<=*** *6H:;%J1MUN6<P0RK,81C;(ZD,A;O@, <>H&<U=HHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN^;IUXQGH<5'/J^I^)-(\5-9WD-M!I9FL%'D[O/ECC!D+9.0N6V@ @\9R>E
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M8,HYZG8"3_A0!W5%%<AXHUC5;"]NTANX;2WBL#/:A(_/FGF&[(:/!(C4!<D
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MNB:G%97<MN+:[AN+<S13H#E3@,I##US_ /7ZJF2R+#$TC!RJC)"(6/X 9)H
MP/"/ANX\,VE_!/J O/M=]-> B'R]AD8L1U.?TKH)(TEB>.10R."K ]P:R]!\
M2Z5XFM6NM)GEG@5BAD:WDC7<." 749Q[5K4 >?Z5X7:;X?7_ ( N[J2VEA26
M"*X49,D!<M'(!W&"%8>H([BKUOX/U?\ X2*PUJ[U^*2XM[%[*5(;(1JZDJP*
M_,2IRHSU]MM=C@9!P,CO2T <I:^$;F36M%U75KVVN;S28W1+B&V,4D^Y-G[P
MECQ@DX'<YXZ5U=%% ',Z]X:O=<AU2REO;233=0B">1<6ID-NVW:70[ASW QP
M1G/6J\W@Z[MM?T[5='U5+9K?3ETR9;BW\XR0JP92#N7#@YY.1STKKJIZCJEE
MI,,,M]<) DT\=O&6_BD=MJC\2: .*7X9S+X8BTT:ZZ7UIJ+ZC8WR6X#02,S-
MAESAP=Q!Z9K3N_!MSKWAJ_TWQ'J[7EQ>(JB:WA$*P;3N4HN3SNP22>< < 5U
MU% '+:;X:U62RFM?$^N#5XGMWM@D=L(%*L-K,^"=SD<9X R>.:K>&_".N:(+
M>QN_$[WVCV9'V:W-JJ2[5^XKR _,%XZ 9P,\<5V5% '(GP?=7MWHTVK7]O=/
MI-QY\-S';%)WP" C,6/'(S_>VCI0W@^ZO;K1I=6O[>Z?2;G[1#<);%)VP" C
M,6/'(S_>VCI7744 <7;^!KFPTS5=#L-42+1-1>5O):W+2VZR_P"L2-]V,')Q
ME3MSWJY'X2>V\6Z=J]G>0PV=CIYT^.S^SDGRR5/W]_!&T8XKJ** "L#Q5X=E
M\0V^G?9KU;.ZT^^COH9'A\U2R!AM9=RY!#'H16_1TH Y9?"M[8>);G7-*U**
M.>_@CBOX[FW+I,\8PLHVLNU@,@CH1Z=:U?#^AP>'M*%E"[2LTCSS3,,&65V+
M.Q';)/3L,"M,$, 000>01WI: &2B0Q,(619,?*SKN /N 1G\ZY"\\ Q:OX+L
MO#NK7@E-I+%)%<P1&)AL;/ W'!*[ESGOFMZU\06%YK]YHD)F^VV<22S!XF50
MK$@8) W=#R,BM2@#EM9\)W.I>)M U:VO[>UBT4R^3;FU+APZ!""0XP !Q@5D
M:G\.KZ_L_$VGQZ^L5AK<YN2C6@>2.0A1C>6Y3Y!Q@'W]>_# D@$'!P<=J6@#
MEX/#&H)XQM?$$VJPRM%IYL9(OLA7>"X<L#OXY P,'CU/-/C\-WL/C#4M?CU&
M#_3+1+58&M2?+V%BK%M_/+'(P*T=7\06&B3:?#>F8/?W*6L&R)F4R,> 6 P.
M_4]C6I0!P<7P]O(?!FA^'DUF#&E7<5RLYLS^\\M]ZJ5\SCGJ<_E3=2^'E_?P
M>)K--?6*QUUO.=#:;I(Y-JKPY;E/E'RXSZ$=^H3Q-I#^(?[!-TT>I^695@EA
M>,N@ZE"R@-_P$GH?2I[[6;+3KRTM+EIA-=L4@"6\CAV +$952!PI/)Z"@">P
M@FMK""&XG$\R(%>4)L#'V7G ]LGZFL_Q3HTWB'PW?:/#=I:_;(6A>5XC)M5A
M@X&X<_C6Q10!QEWX.UC4?"L?ANZU^WCT_P A+:9K6P*321J ,!FD8+D#D[35
MB?P6EKJFD:IH-PEC=:;:?8 DL9DCFMN,1M@@@@@$$'KU!KJZ* ./O_ <6IZ!
MX@LKF\_T_6W66XNTBP%9 HC"KD_*H1>"<GGGFE@\*ZS)XHTS7]0UR":YL[:2
MW>*&SV1N'*GC+D@_+R<G/8"NOJO?WL.FV$][<[Q! A=S'&SL .N%4$G\!0!Q
MP^'9G\/:WI-[JF_^T=1?4HKBW@,3VTS,&!&6.<$#T[UL^']'URR?S=>UX:I*
MB>7$(K40( <99@"=S' YX YP.:U-*U.WUG2;34[0L;:[B6:(L,':PR,CM5R@
M#G]+\*6NE>*M6UR*5B=0VGR/X8GP!(P]WV1D_P"[7/:C\.;^]TWQ#I<?B%8[
M'5KPWRJUF&DCD+*VTMN^9,H,# /3G P?0:* .9M_#5]'XV3Q'-JD,I_LX6#P
M_92I8!]^X-OX.3TQT_.J!\$ZC9:CKC:/K,5MIVM,\MS:SVID,<SKAGC8.,;N
MX(/2MC7O&&B^&FQJ=Q,F%#R&*VDE$2DX#.44A!UZXS@ULV]Q#=VT5Q;R++#*
M@>.1#D,I&00?0B@#-\,:-+X>\-:?I$MV+HV<*PB41^7N51@<9/\ .K>IVTU[
MIES:V\R0R31M&)'C+A<C&< C/YU;K U_QGH?AF18]3NI%D*>8RPV\DQ1,XWM
ML4[5X/)QT/I0 [P?H$WA?PQ9:++>)=K:)Y:2K"8R1DGD;FYYJ.P\.W5EXTU3
M7VOXI(M0ABB-L+<@H(]VT[]YS]XYXK0.OZ4-#76OMT3::Z!UN%.X,#P,8Y))
M(  YSQC-.T_6+/4Y)X8'=9[?;YL,T;1R)N&5)5@#@\X/3@^AH YR#P5=Z=;Z
MQINF:I'!I.J222M$]N6DMC(,2"-MP&#R1D':?7I61>67]F_%/PUIND2V]NMK
MHDT4<<JEP4#( O!!S@9S[5V]GK^EZAJ]YI5I=K->62JUPB@X0-G'.,'H>E8>
ML>-O!FC:W+:ZE<QKJ,&TR;;&25D) (RR(><$=Z (;[X>P:EHVHPW%_(FJWMZ
MNH'4(4VF&=,",HN3\J@ 8)R>><FK$7AK7KG1;^UUCQ%'>7=S:O:1RI9B..)7
M&&8H&^9CQSD 8X YSOZ3JUEKFEP:EITQFM)P6BD*,FX D=& /4>E6IIHK:"2
M>>1(XHU+N[G"JHY))["@#EKSP9)??#9?",^HKNCM8K=+N.#&/**E&*%C_<&>
M?RJAXPN;"[T";PAJ>HQ77B"]@#6\4,9C9I"W[N15&=JJPSG)P%))KM;>Y2X@
MCF4,BR?<$B[6(^AY' S@\UG:9K>F:QJNHV]JKF[TUUAG:6 H5+#< -P!(QSZ
M4 4]5TZ]TWP6-/T+47LKNWC1(KC[,+AV((S\A^\S<\GN<UN61N38VYO @NO*
M7S@GW=^/FQ[9S4]% &/XIT:;Q%X;OM'ANTM?MD30O*\1DVJPP<#<.?QK+@T#
MQ/;Z%;Z3%XBL(HX8$MQ/'IC"7:H"Y!,Q ; ZXZ]JZ6ZNX;.(23N0&8(H )+,
M>@ ')-"7<,EW+;(Q:6( R  X7/(!/3..<=<$'N* .7U#PCJ4WC*S\0V&K6EL
M;2S:SBMY;%I5V$Y.2)5.>GY5I0:+J%S<W+Z[J%K?6TMNUNMK!:&&,*WWRV7<
ML2 !VP,^II/^$RT1[N[MK:>>\DLSBY^QVLLZQ'T+(I&[_9SGVK0TC6=-U[3T
MOM*O(KNV8D"2,YP1U!'4'V/- &!HGAK6_#5HNF:9K5M+I41(MH[ZU:26!/[F
M]77<H[9 (]:MZ^D]IX6O+&VD>ZU2^C>&#>>7E<;=V!T5<Y/8 5T58^@>)]&\
M41W4VD70N%M)VMY6V,NUQU'(&1[CB@"?0-(BT#P]I^DPMNCL[=(0V/O;1@G\
M3S^-5?%WA]O%'ANXTI+QK221HW28)O"LCAQE<C<,KR*VZQ]!\4:/XF%X=)N_
MM LYS;S_ ",NUQ]0,CW'% &1!X2U=/$\NO3:[#)<SZ<+*6-;+;'D,S K\^0O
MS="22>X'%4X_A_>1>$= T%=9@QH]Y%=+,;,_O?+;<JE?,XY/)S^5=W10!QH\
M&ZC8:YJUYH^L0VUGK'[R\M9K4R;9=NTR1D.-I/<$,/KTK8\):%+X:\+V&C2W
M@NS:1B-91%Y>0.G&3_.G:MXJT;0M3T[3M2NV@NM1D$5HIAD82N2%QN"D Y8=
M2.M;% !7,1^%[Q/B#+XI.I0%9+(6/V7[,1B,/O!W[_O9]L>U3:KXW\/Z)K5M
MI&H7DL-_=$""$6DS&4DX&TJA!Y]ZZ!6#H&&<$9&00?R/2@#E/$?A*^U#7K3Q
M!H6L?V7JL$)MI&> 313PD[MC+D=#R"#3=2\(7^HP:,)-:5[FPU%-1EFEM<^?
M(H*A0H8!%PV,#/0<DY)ZZB@#BM4\!SZM?>))I=66.+6[)+0I%;D-"$W;3NW_
M #?>.1@9'I3K7P?K">(-*UJYU^"2YLK-[1TCL0B.A*D8&\E3E1GDY[;:[.B@
M#@6^'EZW@*Y\+G6H-L]V;DW'V(Y&9O.QM\S^\,9STK:?PU=_\)K%XBBU-(RU
MDEG=0?9\^8%<N"K%ODY8@Y#<>AYJ]K7B72O#SV*ZI<^1]NG%O =C,"YZ D#@
M>YJO%XQT2>\U2UCNF,NE.$O1Y3#R0<_,<CE>#DC('4\<T ;U<EJ'A"]N/$NI
M:I::R+>#4[)+2YA>V$CJ%W8,;%@%^\<@@C^G6*P90RD%2,@@\$4M '"V?@/4
M;2W\*1G7(9#X?SL+61_>@Q^7CB3CY3[\\].*N:YX1U&X\2IXA\/ZV-+OV@%M
M=+);B>*XC!)7*Y&&&3SGVKKJ* *FFV<EC8QP374EU-RTD\@ ,C$Y)P. /0#H
M,"K=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<IX_UG5="T.VN]*D@65[ZW@<31EMRO(%P#GY>
MO7!KJZX/XMRHGA&V4W"0.^IVFQV(XQ*IS@]<=: "'5_$NB^/;;1-5O+74K;5
M;6::SD2W\@PRQ %D."<I@CDY/]:VG>*=73Q%X7L[B_CO/[5$\=ZL<(^SQ2I&
M7 AD &X @J>6^H-=!-X7.JWSW^JWR7$ILI+.W-K$8EA24#>XRS$L<+SG  Z=
M3639_#Z_M_\ A&S+XE>1M!+);[+)$#1&/R]I&3\VW^+D<=.] $>@7GBSQ!J&
ML*=;M+:#3=8EM"([$%I(Q&I &6.T@MD'GG.>.*P-'U?7=)^!-SX@M]4\V]03
MS!KF%7P?M$FX\8R23G)R!Z5WWAKPY/H%SJ\LE^ERNI7KWK*MN8_+=@H(!W'(
MPHK%7X>3IX%O_":ZXQLK@NL3-:@M#&SER.&&YLGJ>,=J +>H:[?W/B%="L1=
M(\>GI>336JPF3+L54 2D+CY&)X)Y'3ODW/BGQ'HOA_2[CQ1:3Z>AN9(M0O;.
M))C'& ?+D*C>%#<9X.,=LBM76?!=]>ZEI^LZ9KS:9K5K;_99+A+821W$6<[6
MC9O7D<\9^F-!="U. 6;P:V7N(_,^U/=6X=;HOMZJK*%QM&,=!QSSD M^&[QK
M_0H+IM1@U$2-(4NH,!9$WMLZ< [=H/N#7._%1[N/P@CVE[+;9OK:.3RP/WBM
M,BX.1TYSQUZ'C(K?\->'K?PUI;V=NP;S;B6Y?8FQ [L6(1<G:HS@#)X'6F^*
M_#P\3Z!+IGVIK5VDCECG5 ^QT<.IVGJ,KTH S/[5O;SQ>_A>#4)(C:6"W5S=
MK&GFNSL510"I4  $G@]1TYJ7P9K][JQUC3M3$9O](O6M9)8EVK,N R/CL2#R
M/6B?PG=?V]::_9ZJL6K1VQM;F26VWQ7,9;=@H&4@@]"#TX.:T]"T.+18KMA(
M9KJ]N&NKJ8KMWR-@<#LH   R>!U)R: ,GXE274/PYUV:SNY+66.T=O,C W$8
MY&3TSZCGTKGM;@O8]9^'<<=X)+DS3[)IHQA<VS?PKC.!^?K7=>(-'B\0>'M0
MTB:1HH[R!H3(HR5R,9_"L-_"&H37?AVZGUM)9M&9F!-G@2ED\L\!QM&WZ\\Y
MQQ0!G66O>(DM/&&GM>6-SJ.C3(+>\NE$$91XU?,F.!M!//&<"I=*UW4+SQ?J
M.@)J5Q-:G2TO+>\FM5CE1B[(=HVA67@$$K^8I=1^'LFIIXE6;6/+_MN2";,5
MM@P/#MV=6.X?(,@]?:K]CX3OH/%J>(;O77N9S8BSGB6U6-' <L".25&3TY/O
MCB@"G\)VNY_AWI=W=WLMR]Q&TA\P#*DNQ)R!DY)SS6SXMUU_#VA_:H41KF:X
MAM8/,^X'D<(&;'89R?7&*9X/\-2^%-#CTDZD]Y;P96WW0A#&FXG!QG<>>OL.
M!SFSXG\/6GBKP_<Z1>-)'', 5EB.'C=2&5E/J"!0!EW]YKGAG^U=4O;N/4-$
MM=->Y'F*J3B=,DJ-JA=A7N<D'UJG:7OC%]3TB>.VEGL+I3]O$ZVZI!E<J\6Q
M]Y /56W$CN#5_3_"U\]C<6OB77'UI9;=[4#[.L"B-AAB0I.7(XW9X[ 9.:_A
MWP?JVB""UNO%-QJ&EVG_ !Z6LELB,N/N"20'+A>PXZ#TQ0!E:!>^+?$%KJ5U
M)KMM;0V-_>6CI#9*6D5,JK L3M(.#C#=\D]!!X4O=7MOA;X>O!JL8%T\7VF>
MYV[HHV+;O+X.^0G  .<D]#75^&?#,N@6FI6TU\MVE]=S79VP>64:4Y8?>.1G
MI_6L*#X=7=MH&C:=#XBD$NC72SV4K6BE0H##:Z;OF.'(W9'08 YR ,L/%&L3
M:-XS"7 :XT5G-K/=6NUV3R1( Z#;SU&<#MQ3)?$GB&2#P";:[M4;6X5^U&2W
MW9<V_F%A@CC/.T8^N*TH? ]U"?$I_MUY/[=CVR>9:K^[8QB-FX(SP.!QCONI
MR^"KI4\*J-6B_P"*>4+'_HA_??N_+Y^?CY?3OS[4 2>$=5U2?6_$>BZK=)>2
M:7<1"*Y6(1ETDC#@%1QD<C-=96!H_AV?2_$FMZO)?),-5:)FA$!3RS&FP8.X
MYXZ\=?2MR42&)A"Z))CY6=2P!]P",_G0!PGP=_Y$!/\ K^NO_1S5K:WK=Y_P
MDUOX?L$N1(UF]Y-+;"(R*H<(H7S3MZDY.#T QSD4O#G@[7/"^CG3+#Q%:M#Y
MLDH:;32S NQ8])0.I/:C4? =U<?V5?V'B">RUZP5T;4/(5Q<"0[G#QD@8+<@
M9X_*@"*'5/%L&@P?VT+;3IEU(P2W3M&7EM>2CQHI9?-8X7;SSG Z54M/%VMM
MX=\3RQPSWUSI.HBWB9;;;.T!\MF8QX +JCL0,#.!Q6K?>"[V\BTJX'B"7^U[
M"[-V;N6W5TE8IL(,0( &W@8/'7DDFDL_!>H:?)K$UKXCE$NHW<5X&>U0['79
MNR 1N#!,8&W 8]3S0!GQ^.(QX;O=7TS5X]8A>>WMK4/&J2PRR.$*RJ G0L&Y
MVY Q[UK:3/XIC\4F"[MKB;1);;=]HNOLZRPS _= B;YD(]1D'O4%W\/++5(M
M>.HS*9]92%99+2+R1&8B2CJ"6._<<Y)YP!];_A[0-8TYUDUOQ'+K#1+L@!ME
M@"CNS;2=S8XR3W/'- '1UYI\0(+3Q7-J.C327"BPM<V[102.!>L R$E%."BA
M?PF->DN',;"-E5\':6&0#VR,C/YUE^'])N-'L)(+J\2\FDGDG>=8?++,[%CD
M;CTS@>P [4 9/A7Q7)KGP[BUT0-+?16SBXM@,,9XP0R8[$L.![BL&'Q-X@N+
M3P9=V>I6\SZ_Q<PM:AU@_=EV*!2K80@J=S'\ZT(]"NO!5KXIUB/4);FVO3+>
MM96MIAXY2O)C.X\GC.0>F>*YGP[+-9):MH/C;0=8N]BJ;*+3(Q/..,AW1]Z^
MI=AQU- '16&I>*-3\5^(+,:O9V]GH][!D"RW&6)HP[)RWR\'[V2<^G>&S\0>
M+=8TW2->TBQGFANY4DELY/LZP_9F/56W[]X&#D\$Y^4=*Z/1O#<^E>(-;U26
M_CN%U:1)'A%OL\LH@08.XY& ,\=?2LG1? 5]H4IL;7Q-<_\ "."4R)IAMU+(
M"=QC$V=VS/;&<<9ZT 5KO7_$VL6^KW/AR"<S6-[):VT.V PS&)MKB0NP<9(;
M&W;@8ZU,VJ^)+WQV="6[@T^&314OBHMQ(\$ADV%<[B&(P>>GL>M3'P/J%GK]
M_>Z'XFN-,L=2F,]Y9"V27,A^\\;-]PGOP>?PQH1>%YK?Q@->@OHU1=.&G);-
M 6P@;<"6WY)S[=/SH XJ3Q9XKC^'EUXE?4;3SM(NI()H5M1MO!'-Y9+$GY,C
MLO0CKS@=1J.MZIJ/B#5='TG[5$=/@B)EMD@<F60,PW"5A\@ '09.3R,<UG^'
ML\O@C5/#+ZS'Y>H7+W#SBT.Y-\GF, -_KT/IZU9U3P7J,VOIKVC^(6TK4I(%
MM[TK:"6&Y5?NG8S?*PR<')X_'(!F/KWC);WP;97J6>FWNJ?:8[Z QB4*\<;,
M&#*Y&#@-M!]B:S=9UK79/!7C[3[G5"UWHQ*QWL,*QM)&T0<*1T!^8C(P?H>:
MZVX\(SRZKX?ODU4EM(::0^=!O:X>52KLQ# #J2 !@?3BJ\G@5KF/Q7%=:F'C
M\0KB01V^TPD($!!+'/ '![T =!H44L.AV:S7+7#^2AWLJJ<;1Q@ "LWQ-KD]
MAJ6B:-9,L=YJ]PT2S,NX11HA=V Z%L  9XR<G.,'4T>RN=.TJ"UN[W[9-&H4
MS>4(P<# PHSCIZGO6;XJ\+#Q&EA/;WSZ?J6G3_:+.[1 ^QL8(93C<I'!&10!
MS%BFI6/Q+\6%+F.\NTT:![9KD+&"<R%1(5 &-V>0!Q^=6-)\2:E)XMTK2GU(
MWL&H:;+,\WV<*B3)MR86"@/'\Q_O=!S5BX\ 76I7FLW6IZ\TCZKIHL)EM[41
M*H&[#+EF/\70GUYQP)K/P5J$6M:)JMUXB>>?3+=[8JEFD:RQMMX R=I^49/.
M>VV@#F_#>N:CHO@N_P!0EO9;^ZN-;ELH5F5/]8]SY8<XV]N<9 XQQVW)==\1
M^'KG4[[4[2YN/#]OISW0FN?LZ3),G/E@1-RK#H2.#WIX^',,FA:QHESJD\EA
M?74EU L<81[61I/,W!^2Q##CIQD'-6['PC?S:=<V7B?7Y=;CFMWM@OV=;<*C
M##$A2=SX_B)XYP.30!S/B4:K<V7@74K[4!)]JUNREEMEB41QLP9@$(&[ Y'S
M$YZ\5ZE7 CX?ZL^F:/IMQXH,MKH]Y#<VC?85$A6/(57;<0V 0,@#IR#V[T#
M SGWH \_\9^%?^$H\3*+:Y:SU6RL%N-/NU/,,HD.,^JGH14>B^+&\1W^@VFH
M0"SU[3M1DAU"S/\  _V6?#KZHW4'^?6NO&E78\3'5OML7DFV^S_9_LYSC=NS
MOW=?PJM>^$=/N_&.F^)U'E:C9H\;,H_UR,A4!O<$Y!^H^@!BV^MZSXCTW7]2
MTB]6U.G7<UM:0&)728PCDRDC=AFR!M*X&.M4QXSU"YMO!WB))?L^B:M(MO?0
MF-2897!"88C.TN-I)[$=,ULQ>#KG3KK6/[(U5;2RU>1IYX'MO,:*5QAWB;<-
MI/7#!AGGVJYJ/A#3KWP._A6(&"S%L((6')B*XV/[D, WN10!FZKXCOM-M+Z_
MB<SQSZC%IVGQ,BX#LZQNQ/&</O !(^YUYR(TN_&%KJ&I(T4C:9]@::"\OD@+
MPW"_P%8G&Y2.0< @^M:VK^$;'5_"'_".RR31PK&@BG1OWB.A!60'^]D9/KSZ
MU6T[PUK<5C<1ZMXF;4[EH&@@D:S6)(@PP6**?G;@<D_3J<@'+1>)O%2^'/!V
MO-J-I)_:]Q;VDUJUJ G[X$;]P.<@\X&!CCW.G_:>KPZSXF\/:G?1WT<>D"]@
MF$ B*;MZLA /(RN0>OUJU_P@=R/#7AW1EU>,+HEU#<QRFT),IB^Z"-_'7G'Z
M5??PI+-XIO\ 69]04QWNGBP>!(-I5 6((8L><L>U '#:7JOB7PQ\/_">NK?6
ML^CB&S@N-/\ LV&6)]J!Q)G)<$CC '/MST%YKWB36(]:E\.0S^=I]W):VT06
M PS/'C<)2[!ADY V[<#!YK0L/!,T6D:7HNH:FEWI6F/&T,2VWEO)Y?,8E;>0
MP! / 7) SW!BD\$:A:^(K[4="\2W&EVFHR>=>V8MDE#28P7C9ON,0.>#S^ H
M I76J^+;_P 9)H5M>VFEF?0Q?$/;"9K>;S I4G=A\'(SP,$\'@UWT0D6%%E<
M/(% 9@N 3W..U<]#X6EM_&4&O17ZB*'3QIRVK0ECY88-G>7SNR.N.GYUTE '
M/>,H]4;PMJ46B:=!>75Q"Z/&\OEE@5VDCY2&;'0'';Z4[P1?6&H^"='N=,@D
MM[+[*D<4,ART80;-I/<@J1GO4MSI^O2:I/+;Z[!%82J%6W>Q#O"<8)23>.3U
M^96 K.U;1M0TS0M*T[PO?26)M)D C^SB83H.JNQ^Z#G<6Z]<<D4 =76?J$]I
MI-G=7KP[VDQE$&7G?&U4 [D\ "M"N5UOPUKVI:ZFHV7B@6$<*;8;?^STF$9(
M^9LL?O'IG P..YR <;>Z'/X:T;X=>'YF&S^VEEN A^029>4(/4!F./\ =%=#
M=2/%\<[!8LXGT&03@=U68%2?H2?S-:LOA.>_T".SU76)KW4(;I;R&_,*H8I4
M.4*H.  !@COEO6KFG: ;?7+G7+ZX2ZU*:!;8/'%Y:10J2VU5+,>6))))SQTQ
M0!B:/_R5[Q/_ -@ZR_G)6QXGNFT?PS?26"*EY<'R;; QNN)6"(??YF!/L*98
M^'+BT\8ZCK[7\<BWL,<#6XMRNU8]VW#;SS\QSQ^57M2TG^TK_2YY)ML-C.;@
MP[<^8^QE7)SP!N)^H'I0!/I>G0Z1I-GIUL,0VL*0I]%  _E7*^/[MVO_  MH
MH.(=2U5/M [/'&#)L/L2%_ 5VM<SXST:;4;?3-0LXS)>:1?1WL<:]95&1(@]
MRI./<"@#*\6"_?XD>#K>#4YK>";[8QC1%*ADBX;D<G#$<].U8X.L1^)?B/<Z
M3J$5E);/!-N: 2EV6U4A>3@#CGJ>>V.>NU;0QXCU#0]<T_5&M9M/:5HW$(<.
MDB['4AL;6X[]".14$?@^ZCNO$TXU6(MKJJ&!M3^YQ'Y8Q\_/R_3G\J *%OXN
MO]93P_:6L,\=QJ&D+JEPUH(BZ [ %3S3MQN8Y)SP ,<Y&[X3G\03:;.GB.U$
M-U#<O'#("F9X1]R0JC$*Q!P1GM6%-\/+E=.T#^SM?DL=7T2W%I!?1VP998<
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M#M!D=4 #'GJ>Y&:]/\#>$&\$^&1HL=^+M$D=XY6@V$%N>1N.>?I7#ZOX1O/
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MH).Q0SX _AKB_!4UGX9^(6I>&K**X@TG5(A?:>D]O)#ME4!9D =03D -QV%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHV*@!N>0<9QUS785D:=H:VFJW&K74YNM2N(D@:;8$5(U)(1%YP,L2<DDD^P
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MJX8C<0O')(&#TH ](HK@-*U74I/&>KZ*EWJ$=G_94=Y;M=HAEC<NZEER"<'
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M2HP+/#P4+X &_!P<#MGO0!O45POB*769_B%INBV6N7%C9WNG7$CB**,E&0H
MRDKU^;OGOC!Y%;[7X@UB77-+L+ZZ^TZ3Y=I#<))%&7F\E7\V12IR"S=.F >,
MT >ATR66."%Y975(T4L[L<!0.22:\^EN_$\GBSPWI5YJYM'O=-G:]CM$C95E
MCV M&67@G<>N0/2N=U^]U.]^%7BNWO-5NII-*UDV23Y57FB$L0 DP #Q(0<8
MS@9H ]FK'UGQ';Z)?:5:W%M<.=2NA:Q21A=BN03\Q)!Z*>@/2LC53>0:W9Z;
M_;%W+"UG(PMK;;]KEEWC$C-@*L:@D9)4$D YKC9=5U+Q'X*^'-_=7074+C64
M5[@1@_,%G7=MZ9XSZ9[=J /7+F;[-;2S>5)+Y:EMD8!9L=AD@9JCX=URW\2^
M'[/6;2.6.WNTWQK* & R1S@D=O6N6T>YUG2/'M_X9O\ 59M5LIM,_M&VGN40
M2Q$/L9"4 !!SD<5A>$=9NK/P#X#TBSW+)J:2JSHRJVR-6<JI;@$G'/IG'."
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M:KXDGM-7E:2QT];BS@L%'^C$(S,\Y8;2&(&%R25!PO>@#T%Y8XWC1W56D.U
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M:POGLI$GV[BZ!23\I(Q\WK6U0!CV.@+!JHU6]NY;[4%@^SQRR(J"-"06"JH
MRQ )/L.@XK8HHH Y[3/"D>F>*=3U]=1NY;C4EC6XBD">7B-=J8PH(P#ZU6US
MP1#JNO1ZY9:MJ&D:D(O(EFLF7]]'G(5U8$''8_\ UJZJB@#FYO!UM)J&B7B7
M]Y&^D&1H1E6\UI 0[2%E)).3W')JE>_#NRU"/74N-2OR=8FBN)&4HIBDCV[&
M3"]MHX.:W=8U^RT5K6*?S)KN[<QVMI NZ69@,G:.!@#DDD =R*K/XE^S7=E;
M7^DZA9O>3"&%G$;H6()P61F"\ ]<9[9H IP>"A%KK:TVN:G+?260LY7<QX<
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MD:6OEPABF\ @OSQU'3)Z^E &KH>B-H\,GGZC=ZE=RX\RZNV!8@9PH"@  9/
M'<]:?J.E37E_:7MOJ,]I-;)(FU%5DD5]N0X(YQL&,$&M.B@#C;KX<Z;)8V*6
M=[>6-_8W,MW!?VY42"24DR9&-I5L_=QC  K(\.:=;7/C7QUI5Y=37D-[;6D#
MS3,-TX\IUDP0 .-V"%&!GH*]"O;G[%8W%T89IO)B:3RH4W.^!G:H[DXP!ZUS
M</CVRFM]$G_LO5TBU69K?<]J0+257\O;/S\A+_*.O- %>V^'R1-HC3^(-4N'
MT9\VA;RAM79L"$!,'Y>"2"Q]144OPSLY-.NM.76M5CLI;W[=# C1XMY?,\PE
M24R1G/#$@9Z9YKJ]/U.'4#/&H:.YMG\N>!_O1G&1]00001P?SJ[0!@V7A=++
MQ1<:\-1NY9KBW2V>*384*)G;_#NSDDYSSFLQOA[;1ZW>7UCK.J6-I?RF:]T^
MWE AF<_>/(W+N[[2"?45V-% "*JHH50%4#  ' %8%AX4ALM<UC4WOKBY.K[!
M=03*GED(FQ0 %! VG'7FIM'\1Q:QJ^L::MI<6\NERI%+YVWYRZ[@1M)XP1^=
M7;Z^FM+BRBBL)[I;B;RY)(BN(!@G>V3TXQQZT <YH/P_@T">..'6M5GTN!_,
MMM-FE#0Q'.1SC<0#R 3@'!Y/--B^'=I:ZM=W%GK&J6NG7LQGNM+BE402.?O=
MMRANX!&>G3BNRK%3Q'$WC)_#1M+A)UL3>B=MOENF\)@8).<D]0.E #4\,01>
M+)_$$-[=Q27$,<5Q;(5\J79G83\NX8W'H0#WJYK>BV/B'1KK2=1B\VTN4VNH
M.".X(/8@@$>XK0HH P;/PSY=Y876H:C<ZE-IZLMJTZH-A8;2YV@;GV\9/J>.
M:72/#*Z1K>JZHFH74\FIR))/'*$V@JNU=N%!' '<]*W:* ,SQ#H=KXET"\T>
M\:1;>Z38S1'#+R"",]P0*SF\(^;K&C:I/K%_/=:4LJQM((\2^8 '+ (.H Z8
MQBNDID<T4KRI'(K-$VR0 _=; ;!]\,#^- '*O\/M-N;'7;*^NKJZ@UF?[3.'
M**8Y!C#(548(VKC.>GUJ[X>\,2:(WF7>MZEJTRIY44EZZGRDXR % R3@98Y/
M%=!5+2[Z;4+1IKBPGL7$KIY4Y7<0K$!N">"!D4 0>(M!M?$NBRZ9=R31QR,C
MB2$@.C(P92,@C@@=0:CL] $6J1ZI?WDM_?10F&&21%41*Q!;:J@ %L#)]@!@
M<5L44 <,_P ,K5](ETC^V]473/M0NK>V0Q@6[>9YA"G9EANSC=D#/3/-;B^&
M5'BQ?$1U&Z:Z%E]A\LA-ACW;LGY<[MW.<_A6[10!Q_\ PKK3)?#^IZ-=7EY<
M07]X]\9&*+)#.S;BZ%5&,-R,Y_*IK;P7(FN:=K%YX@U*\O;&&2!&=8E5U?&0
MP5!_=Z]?>NJHH XV7X=VDWAW6=$DU6_-MJ]V]W</B/>'=@S!3LP 2!V-:5SX
M:$VOZ=KLE_=R7.G0211Q*L860.!NS\O4[1T(Q7044 >.Z.\DD3?9O%'B;3=4
MEEDFDTIM-\XPR.Y8IEXOF&3]XMCOD#IZU8?:O[.MOMVS[9Y2>?Y?W?,P-V/;
M.:L4A. 2 3[#O0!S<7@NQ^UZ_+=W$]Y%KH47=O,%"8";!MV@$?+[^_6EL?"$
M=NFF0WFI7>H6VEN'LXK@)\K!2JLQ !<J"0"?J<G!K8TF]FU'2X+NXL9["60$
MM;3XWQ\D8."1[_C5R@#CQ\/K6'6KV\LM7U.SLM0E,U[IT$BB&9S]X]-R[N^T
MC-.O_ %I>WVMS+J>H6]OK4 BO+6%D".0GEA@2I9?E[ X..<CBNNILLB0Q/+*
MZI&BEF9C@ #J30!R[>![<C0'75=12XT:-X8KA63?+&ZA65OEQT4<@ C'!SS4
M$GP^MUUV\U&PUG5=/@OY/-O;*UE"Q3OW;D$J6[E2"?45V"L'4,IRI&0?6L;Q
M1XCB\+:1_:4]I<7$(ECB;R=OREV"@G)'&6'3- %*Y\%P_P#"1_VYI>I7>E74
MD*V]RML(RDZ+]W*NI (' ([5=\+>&X?"NC#3+:[N;B$2/(IN"I*EV+$# '&2
M>N:VJ* .=OO"4-YXF_MV+4KZTFDM1:7$<#+MGC#%@#E25.2>5(/N*SX?AU9V
M_AS2='AU;4E_LJZ6ZM+G,9DC8;@%P4VE<,1R*WKS7(K;58]+AMI[N^:$W!BA
MVC9'G;N8LP R> .IP?0U1F\96$6@_P!JQVM]<G[0UK]CMX/,N/.5BK)L!ZKM
M8GG& 3DB@#H(T\J)(]S-M4#<QR3CN3ZU2;2HY-?BU9Y&:2&V:WBC/W4#,&9O
MJ=J#\*QM$\;P:UK8TG^Q-;L+@P-< W]H(E**0"?O$]6':NCNKJWLK66ZNIDA
MMX5+R22-M55'4DT 9NHZ#'>:K;ZK;W$EIJ,$30">-5.^)B"48$$$9 (]"/<@
MUSX.TH^&VT0K+Y+2&<S[AYQGW[_.W8^_O^;.,=L8XJW9:[#>6$FH-;W%KIZQ
MF47-R!&&0#.[:3N QS\P'%4K?Q?9R7&FI/:7EI#J?%E<7"J$F;&X+PQ*L5Y
M8#/UXH M6&@Q6NJS:K<W$EYJ$L*V_G2*J[(@2=BA0  2<GN3[  4+?P3801V
MMI]HG?2[.Y^U6U@VWRXWR649QN*JQ)52>..H  FU_P 6P:#=16HTK5]3G=/,
M9--M#.8ES@%^1C)#8]=I]*V[6<W-I#.8983*BOY4HPZ9&<,.<$=Z )""5(!P
M?7TK _X1.VET75M)O;NXO+74VE:42A 4,G7;M48P>1G.,5T%% ',:SX(LM6T
MG2=+2[N;*STN6&:W2W"?>B&$R64\"DN_!,%UK=YJ8U74(#?VJVU]#"R!+@*"
M%)RI*G#'[I%=13))HHGB6215:5MD8)^\V"<#WP"?PH Y*U^'\%K%X>1-8U%O
M["S]F+>6=V4V8;Y.FWC QZ]>:U;WPW'>^*-/UXWUS'/8Q2110J$\LJ^-V<KG
ML._:MNL6/Q'$_C&3PV;2X2=++[:)FV['3>$XP2<YSU Z4 91\ 6S:!K>C-JM
M\;?6+F2YN6Q'N#2$%POR8 .!V-2/X&A.KG44U?48GFLTLKM(S&!<HN=I/RY4
M\GE<?A6CXJ\1Q>%-!FU>XM+BYAB9598=N5W,%!.XCC)'3/TK:H R?#.@1>&=
M M=(@NKBYBMEV(]P5+!>P^4 8'TK6HHH **** "BBB@ HHHH **** "BBB@
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M2KL7=MNDC8AQNP#E.@W-QQUYS6@?!VGRZOJ]_<SW-R-6MUMKJWE*>4T:@@
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M"1N0LJ8CX(Z=S^==I<?";198M9M8=0U2UT_5Y/-N;*"5!%YF<[ERI(^F<>W
MQ9O?AEI-]8Z!:27^I+%H3*UEMDCR"I&"Q*'.-H% '(ZC?ZS>?&#Q)H,>O:C:
MZ=#H[72102XVOMC/RD@E>6SQ].E94'C'Q=<_ >PU2VNKB2[%\8+V^5=TL=N&
M;+Y]1\H+>G/O7IC_  _T]_%>H>(_M^H+?WUJUI+AH]@C*@8 V<$;0<^HKE?$
MO@AO#/P^L] \.7>JB+^U(IOM&T3&W&=Q9U1<L@(!Q@\XSQ0!8\-W&H7WQ6U2
MULM4O[OPQ:V:,D@NC+%Y[*H*>8<EN"S?>X(_"O0DTNS2.VC6$;+9B\:[B0&_
MO'GDY).3DY)/6O//"8\<6WBVSAN_$@U[1Y(Y#=.VG_9Q 0OR8;:,DM@8!/&<
MCO7I] '#W5Q)9?&K3XXB?+U#1I$F4="8I-R,?<;F'XUW%<O!H[ZAXKO?$4XE
MA5;+[!9*!MD"%BSR8/0D[0/9<]ZN>$]+O-'T%+.]O;R[=9'*27LHEF"$_*'8
M<$X_+..<9H P]6OY]$^($<>H:E<IHNJ:?,8OWF!;SQ?,^".F8\D9SRIQ67X2
MU?4]5T6'0K^\O8]>@U)H[R1W"RB%?WFX@< ,A1..[YZUV^N>'M/\0QV2:A&7
M6SNDNXL'^-<X!]002".]+;^']/MO$E[K\49%]>01P2MVVH3@CW.0#_NK0!Y\
M]G=W'B'XDS6NJW=@]L8)4-J54EUM%(W$@Y''08SWJ])KVK7-E\.=0^WRQ_VK
M)"+V%%4)*6@+DGC(Y'0''M72)X.MDN->G74;_?K8 NN8OEPFP;/DX^7CG/Y\
MU"/ UF+/0+4:CJ CT)E:T^:+)*KM&[Y.<*2.WYT 9MK+J?C&'Q(]GJ\VG7=A
MJ,MC9>4?DA,6WYG7^/<2<[LC!&!W-6ZLY]0^+D$']HRP,_AG]Y<6F%9_](&=
MI.=H)Y[G'?O6S=> +"7Q!=:M:ZEJNGF]P;VVL[CRXKD@8RPQD''!*D&KX\+6
MR>)UUZ*[NHKA++["D*>7Y2Q;MV -F>H!Z_I0!0^'6I7NI>%,ZA<O=7%M>7%J
M9Y,;I%CE95+8[X IC7LVO>-M8T$WD]I;Z=9P.HMY"CR22[SOW#G"A5 '3).<
M\8U_#GAVW\-6,UI:W5S/'+.]P3<%"0[DLV-JC@DDU1USP39ZSK<&M0ZAJ.EZ
ME%%Y#7%A*$:6+.=CAE((SR.* ,@:AJT.N>&O"6H:KY\\]M/-?7MNOE-/Y> J
M#'W3SEB,'Y>,9K)U;6];TN'QUH\>IW/_ !*[!=0L+L[6E161B8V)!R RG!^]
MCO797O@[3KN'3/*EN;6[TQVDM+R*0-*K-]_<6!#;\G=N!S27/@ZRO-,U:TGN
M[MI=74)>W8*"61 NT*/EVJ ,@ #N3U)- '.07.K:?XI\&%]:O+J/6K>9+N"7
M;Y8*P"160 ?*01U))/<UG^'4GT_P[XZNX-<>RFBUB[B2ZO7,D<6-@#D'JW8=
M>PQVKLW\(6\EYH5TVHWYDT566VYCPVY-AW_)S\O'&/SJG=?#O2;NUURTDN]0
M%KK$QN)H%F 6*4E6,B?+D'**>21QP.30!0T34;X?$2XT99M1CT^;1ENT6]8/
M()/-*;UW$E00?NMW'W17/2:[KW_"IY=376KD7\6L-;F<JF9$^U^7AN.!M/\
M#MKN+3P7;VNO0ZVVK:K<:A':&T:2:92)$W;@6 4#(/88'J#S54_#O3SX9DT
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M]$L-32,QK>6T=P$)R5#J&QGVS698>*#J.H^(+"'3+@7.C[ 8V=,SLZ%U"X)
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MK&[,,=UC@;P.<XXR"#7644 8EQX5T^?7[+64>XM[FTM_LJK;R;$>+<&",!U
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M[B:-EL=(=YUWC'G7!7:N!Z*"QSW)&.AK2T[24TVYOYEN[R<WL_GLMQ,76(X
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MR&5MI )&5P:9J/@S2K[2-.TV'S["/395FLY;-]LD+@$9!(.<@G.0<YYKH:*
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M:4'02 #!^HP1V/2JT?P]T6+P]:Z'%)?)96UP+I%^T$GS V\')SC#<X&!GJ*
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MK=VD1NG=I%C# *IW_,,# P:ZC5=:M-'6V^TEVENIA!;PQC+RR$$[1VZ G)(
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MBNNL[G[7:I-Y,L6[^"5=K#\* )Z*S=0UFVLKN*PV37%[.C2);6XR^Q< L22
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MF )'YY&10!NT5C67B:SOYK-8(;KR;T,;6Y,?[N8 $Y!SQD#(R!GM6R2 "2<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=4;6[4-$!%9R/'< S;A(D@&T@@],YSGBO:+:7SK:*38Z;E!VR+M8?4=JEHH
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M6-K+=3175M/Y,*[G94F1FVCN< G% &3J6IM9?%72[IHM1Q/HT[?8E+2,7$B
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MEC2.)"[,S(0  /<T 9*?$/1RVEF2WU&*WU2,/:W#VI\N1BF\1C&27QT !!/
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M*V>22#QV[XJI?0ZB--\':XWAB\O[;2[9K.^TZ6W!GVO'&/,2-NNUDQZGZ<T
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M>&Y]=TB]L8[9_LUL+B6UEC9R#L/.TASR.] '36WC/1[[1[#4;.26X6_D,-M
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M:7R8V52V!GJQ '^>O2@"_17*:+XO,_A+1-1U*TG2]U**$0P($+7,CQAR4 ;
M7&X_,5P!SBM/2O$=KJ>IWFEF&>TU&S"M+:W(4-L;[KJ5)5E/J#P>#B@#8HK"
MUWQ98>']0T^RNX+R2:_9U@\B N"RJ6Q]3C  SU';FLVV^(NE3:=K-S+9ZE:S
MZ,N^]LI[<"=$P6#8!(*D G.?Z4 =?17+6WCO3Y[1[I[#4[>W*P?9Y)K?:MVT
MW")%S\S9X[=<].:N6_BFWEU:?2);&\MM3C@^TQVLWE[IX\XRC!RIP>""01].
M: -VBN<T_P 96.I^%_[?MK2]-OYIA$+*@F+A_+QMW<'=Q@D&F6U_I$OQ!N;<
M6MW'K*:8K22R$B/R/,. !NP3NSR!VZT =-17E_Q!\00ZOX5LKJRM;\VCZG;+
M!?*P6&3]\H)P'W%2 0"5P>W49[/5?%$&F"^*6-Y?"P0279M0A\D8W<[F7)V_
M-A<G&/49 -VBJNG:A:ZMIMMJ%E*);6YC66)Q_$I&17GJ;/%WC#Q5IFN:;>):
M6@MHX)3+$IL?W1D+A@Y*LQ.<KG@ -@#% 'IE%<NGC;38;;3KB6WOHM,O76&V
MU&55\IRW"$_-O4-V9E YYQD4VX\>64.M7VDPZ7J]W=V30B9;>UW860G#CD?*
M,<GWXSS@ ZJBL'QLN? ^N2!W22&PGEC>-RC(ZQL001R"#4/@%,> M"F9Y))I
M["&:6261G9W9 2222>IH Z2BN>U7Q?9Z7=:A;+9WEY)IUJ+N\^S*G[F,[L$[
MF7)PK' R>/IF.[\<:7:W.C0+#>W!UB%IK-H("P=0F_VY((_/G R0 =%-'YL,
MD>]TWJ5WH<,N1U!]:RO#_AV+0+=U^W7VH7,FT27=_-YDKJN=JYP.!DX&.Y/4
MU4L/&VEW>D:GJ%PESIZZ7*T-Y#=H!)$P (&%+ Y##&"<YKG-2OY;KXL>#M]A
MJ%D7@O&*W#KMD'E#& KL 1DYZ'D4 >C45Y[X.U"TT2+QQ>7URZ6=IK<Q9Y79
MRJ^7'QSDGK@#\*Z2/Q5;+K%KI=]97NGW-Y&TEJ+E4(GVC+*I1FPP'.TX- &]
M17*:;X]L-5OFMK73=5*1W<MI/<-; 16[QC)\QL_*.W\\9&>;\;Z]'J]AX9N[
M2TU!;2;7+/[/>9"Q3*91R5#;L,!D%E_F,@'I]%4M7OWTO1[R_2UDNFMXFE\F
M-E4O@9ZL0!_GKTK T/Q@;CPAHVJ:G:3QW>HI$L,*;"US(Z;OW8#<#&3\VW !
M)Q0!UE!Y!P<'UK'TOQ':ZEJMWI30W%GJ5HJR26MR%#&-NCJ5)5E/3(/!X.*G
MU36;?2FM8I$DFNKN3RK>VA +RL 6.,D   $DD@#\J *OA_PW'X>EU-XKVXN/
M[0NWO)1,$PLC  [=JCC"C@YK;KSCPOJL-IXV\?WMZMU9V]LMF\D=TV]H_P!V
MY.,%A@]0%)Z\>E=/%XIM9M=AT*\LKVPN[N!I;87&P"=5^]M9'.& .<'!H Z"
MBO*-%O-+L/A3K\FN17EUIB:E>1S)"S-(4$Q ^;<#V')(KNI/$MI9Z_IFA-:7
M:RW\3/;2X7RV"+EADMG(&.,9^M &[16/+XCM8#?>;!<(MI.EMNPI\Z5PI5(P
M&R2=ZCG'7V.*)\<6$-SJ=I>65_:WNG6OVR2V>-7>2'^^FQF!&1@\\&@#IJ*P
M/#WBNW\2%'M=.U*&WDM8[F.YN(-D4@?^%6R<L.X_+(YJ5_$ENGBAO#YL[O[9
M]D-W&V$$<J A3M);KD@8('KTYH VJ*YNQ\9V>H>'Y=8@L;[RH[G[*8&5!*9?
M,$>W;OP#N(')%03>/;*/6;W2HM)UBYN[)H5G2"UW;1+G#=?NC')]^,X. #JZ
M*X7_ (273-+T_P 9:OI&E7LMW82F2]CE;;YDBQ [@&;A0H&< 'T!IMSXVU2V
MLO"@_L6Z:75I8TE<M",_N]YVC?C+8XSC ST.* .\HK U/Q7!IL-[*-/OKM;"
M,27OV<1G[."N[!RXR0IW$+GC'J,U9/'NE?;["SM8+Z]DO[,WEJ;>#*RIQP"2
M.?F'7@=R* .IKGM4\*"^UK^U[+6-2TN^:%8)'M71EE122H9)%9>"S8( ZFK?
MAWQ#:>)=.DN[6*X@,,[VT\%PH62&5#AE8 D9^A/6J5]XRM+/Q#-H2:?J5UJ$
M=J+I8X( 1(F[;\I8@=<\G XZYP" :NFZ8FG(Y-Q/=7$F/-N;A@7?'0<   9/
M  ')XY-7JYVT\::5>^';/68A<>7>3?9H+9D F:;<5\O;G 8%6SS@ $YQS2Q^
M+8)+K4+ V%Y'JME;_:38R^6KRQG@,C!BA&>,[N#UH Z&BO.7\66.L?"V#6/$
M^E7WV*Z,3NMN1\Q:0;-I1P0H;:/FVD^AKL+_ %^&SO7L8+2YOKR.#[1)!;!-
MR1Y(!)=E')! &<G!XXH UJ*P+3Q?IVI:7IM[IT=Q=G44:2VMT4+(RKPY.X@*
M%) ))ZD 9R*L>'_$5EXCMKF2U6:*6UN'MKFWG4"2&5>JM@D>G()!]: ->BN5
M3Q1>R?$2?P\-+G%M!9).9@T?S;W(#_>R%&TC'7.>.E23^.-.MC8S36UVNG7U
MP+:#4=J>2SDD+_%O"D@X8K@]<X(- '345RB^/K&75KK3;?2M8N)K2ZCMK@PV
MFX1%QD.W.0F#UQGVJJ_Q-TI-(DU8Z=JQT^"Y:VN;C[.H6W*OL)?+9QG^Z"1W
M H [6BN?MO%UI<>(H]%DLK^UFGA>:UEN(0L=RJ8W;.2P(R#A@#BL>R\5>'M&
MT/Q+K5M9:DD%IJ4HOU*%G:<*NYE4MPO(_NCCI0!W%%<[9^,K*[U^VTAK*_MI
M+N%I[2:XA"QW"KC<%YSD @\@<5##X[TR9[%UMKP65_>M86UZ53RGF!88QNW@
M$HP!*XX^E '445R>E>*[R_\ &.OZ5)I-S';:8(5#@QL<LC/N(#9^8;0  >G.
M,\4-*\7^&]#\#V&I6-GJ,>E7-X\$2,AD=7:9D);+' +Y/7..W:@#NZ*P-,\6
M6FI:W=Z0]G>V-W;PK<A;R,)YL))'F+@GC(QS@CTJE)\0=,CL]/OOL>H/8ZC/
MY%G<I$K+,Y)V@ -N&[!QD#./I0!UE%4M4OWT[1[J_2UDN6@A:40(55FP,XRQ
M %>::WKEQK/@WP1KM[;W-M-)J]A(^ULK(K'<=J(QR/0$9XZ4 >L45SVG>,+"
M^O-4M+BWN]-GTV-9YUO45/W1!(D!#$;?E/N,<BDC\86?]KZ=I]U97MFVI*S6
M4UPB!)R!N*\,2K8YPP'Y\4 =%17*_$G<GP\URXCDEBF@M'EBDBD*,C 9!!!!
MK2\*Q+%X4TH@NS/:1.[.Y=F8H,DDDDF@#8HK#U7Q/!IGVWR[&\OOL$8DN_LH
M0^2"-W.YER=OS87)QCU&81XSTZX>RCTR&YU*6\LC?Q1VP4'R 0-Q+LH&20,9
MSGM0!T5%<_;>,=-O],TB]L4GN?[6#&UA4*KMM!+9W$ ;<'//TS4R>)+=[&WF
M-I=K<7,\EO%9LJB9G0L&'WMN!L8YW8QCGD4 ;5%8VA>)+379K^VBBGMKW3Y1
M#=6MP%#Q$C*GY2001R"":V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4^)-K=:A\/]7T^
MQM9KF[NH/+BBB0L6)(_ ?C75T4 <E;>(+RVT&TM[?P_JSWRP1Q*DEOM17P!E
MFS@*#U(["N6\76GB#6;;Q?IESHU_=.T.-+,&U;=H]@RQ^8;I-V>""1QC R:]
M6HH X"WBOI/'GAW49-+O8;>'1Y;>9GBSY<C,A53MSV4].G0\USLNA:Z^C7]U
M::9<M<V7BYM:BM9%V&Z@SP%)XR02<'GCITKV&B@#@()[[4OB;IVM)H>J0:>-
M(EMWDN(1&4<R*V"I;/\ ">@SZ CFL"/P[K<_@MC;Z?<+J&G>)6UB*TF7RS<Q
MB5F"@GC)5L_4=J]>HH XJXM9/$'C;0=>CM+RVL]'M[EI&N+=HWD>5541A"-Q
MP Q) QG&":P],\-:KJ7P2U#PV;::SU.3[3MCG79DM.TBC/3!! ]L\UZC10!Y
ME?WNL:]-X.F_X1C589[#4%DO4>)56/$3J=K%@&7)X/3'OQ75^/-,N]9\":UI
MUA%YMW<6K)%'N W-Z9/%=%10!PUS9S^*;OPLL=C=VL.E7*WMS)=0F(JR1LJQ
MJ#]XDMDD97"]>E0:OH%T/B-&EDR#3==@$FJ19YS;LI# >CAEC;VKT"L30/#-
MMH'G.E[J%]/+P9]0N3-(J9)" GHH)/'YYH VZX7QA;7EQXZ\'7=O8W4]MI]Q
M/)=2Q0EEC5X]JGWY],]*[JB@#B?B#IM_-)HFLV.EKJZZ9<N]QI[!29HG0JQ4
M-P67@@5C^([2;6OASKZ:5X2FTV2^A2&"V-JD=Q,P;)+JA(50.FXYZ^HSZ=10
M!Q&IQ7=S\0?"VH06-TUM;6ETDTK0L%C:14V!N,]5.?3O7*M;^(M0M?#5[J'A
M[59-7LM:2:_)V!%4>8,0KNP$Y7D #CDD\U[#10!YW;6MZFI_$*9].O%34$3[
M(?(8^=BW$9 X_O<<X]>E4K73M5LK3X;7?]D7LQTFW>VO(8T DC=K<1CAB!C<
M.N<5ZC10!BZ;X@>^\0:CI$VF7=H]HJNDTH&RX4_Q(1V!X_R<97B:;5E\4:5"
MNGWUUHCPRB?[ 0',V5V*[;@1'C/0@$XSQ74Q6L,,TLR)B67&]R22<=!D]ADX
M'09/K4U 'CEOI&L0> K'2WT*]BGM?$2W)C6,,/*%R9"RX/0*1Z9[9K>UW1K[
M6_&VM+!!<0V]]X:;3HKMXF5!,7<X)QD<,#GIVZUZ+10!Y+</KE_X0\+Z6_AC
M5$U#2=1LOM2B-?+*PG!9'+88$#/' [D=_2M:MY;[P]J%M"G[Z>UDC120/F9"
M ,].IK0HH \JM]-UM-#\!:JFCWJS>'%6WN[)PHDD1H1%(Z+GG;C('!/./?IM
M/TV74?B-/XH$$T%HFE+I\7GQF-YF,ID9MC , .!R!DD]N3U]% '!^.KC[+XR
M\#S>5+*%OKC*Q+N;'D,"0!R<=<#GCC-4-;T6\U*3QIK4%C<@7^C?V990F(B2
M=]KY<J>5&651NQT)Z8SV.K^&H=8UC2]3EO;R&73)&D@2$Q[2S*5);<A)X)'6
MMJ@#SS7-'U6^\#^%KBPM)6OM%N+2\DL7&QY?*7:Z#/&[DX[''%:)L9?$'C[1
MM>BMKFVL]+M)U9KF%HFEDEV@(%8 X4 DG&,D8SSCLJ* .&TSPWJ%AX\U*)8Q
M_P ([/,NK)[71!1DQZ9 D]B%]:9?Z7>7_P 2-4=(+B*UNO#_ -@2\\L[!,9'
M;&?8,#GIVSFN\HH \=FCUZ7X8Z?X9D\-:E_:FF3VD4GEQJ8I$BE7YT?(# JO
MX<YP.:U+BVNM$\9ZO/?^#9]<T_5WCN+>:""*:2"3RU1HY-QP!\H(.<?7G'IU
M% %33(6M],MXGMH+5E09@@ "1_[(QZ=,]^O%<1::3=ZCX@^($$EO=6D&M110
MVES)"P5L6WELWM@^N,]J]"HH \NFTO5->^&-CX+NM,NK74X_LUK<2M&?)CCA
M="95D^ZV53@ YRW0<FM_0[>ZB^)GBB[EL[E+6\AM$@G:(A',:N'&?JPZ]>U=
ME10!B>,4EF\&:S;6\$L]Q<64T$442%F9V1@!QTY/4\5@^'-:O-%\#:592>'-
M9DOK.PBA:!;<#<ZH%QN)QC(ZUW-% 'FVOQ>(=0U#7--OM)O+N"72U33S:$+;
MM*8V\PRDL,D.1M!R,#@9J'3K/4Q=?#5YM(OH5TNTDBO-T6?*)MQ&N<9ZL#[@
M<G%>GT4 >1ZOX=UK5;7QLEC8SK<3ZE;7UDLR%%NEB$>5R>F2AQG':MFXN]1U
MWQOX/U6+P[JT%O:K=BZ^T1*GDEXU49RW(R.O?MGG'H=% 'DUUX9UC6/#?C>Q
MMK6:WN[O6?[0L1.A19U3RB!D],F,C!QV)KH-0@N/%VK^&+E=/O;)-,N3>W9N
M83&8V"$")<_?)8]5R,*>>@/<T4 >>>'M&O[SPQXUTJ6WN+&;4[^_>VDFC*@I
M,,(X_P .H]*QIVUV]\$^&]'?PQJB:CI%_8BY41KY;+"PRR.6PP(7/'3OBO7*
M* *.JP2WNAWUO$F)9[:1%5B/O,I ![=37FUMI>N)X<\"ZDFCWBW'APK%=64@
M422H8O*D=!GG;U X)YQ[^KT4 <A8Z;+J7Q&?Q.L$\%G#I0L(_/C:)YG:3>QV
M, P50 .0,DG'3-5_&-KJ=IXM\-^);*QGU"UL//@N[:W&Z54E4 2(O\6"O('.
M*[>B@#R>_P!#UGQ'=^/5M]+NK1=4@LFLI;M517>%<[2,Y&3@=.,G..E=!X7N
M?M]U;S/X%;1+FV5C<SSVL:X;:1MA*_,V2>N ,9'4BNXHH \E;2=4?X1>)]*&
MEWHO[N\NF@@,)W.LDI92.V,?E^5=1XPTN]U+PK8ZEI5N[:QI,D5[:1,I5G9>
M'C(//S*6&/I7944 <)XK\-ZG-X)LULK>&^U.RO8]2FMG(V7;ABTJ<\8.YL9]
M *CB<:GH&KSV7@R?1V?3Y;?$UHD=Q-(PP$0(2=F>I.!R/0UW]% &#X*BFMO!
M&B6MS!+!<6UC#!+%*A5E=4"D>_(ZUG>-])U.:XT76M"B5]5T^ZV!7^ZT,P\M
M\^PRK_\  377T4 >?Z%X1O=$\:7-M%N;P\XBU$,YR3=A3&P/KG D)_O 5>T&
MWNH?B7XJNY;.YCM;R*T6WG:(A)#&KAP#[%AUZ]J[*B@#S5-(U*\LOB3;)87"
M2:KYALC+&4$V;<1C!/3YAWQ1>P:K/HO@>]70]0SI=W%]IMMJ^<%$#(6V[NFX
MXZ^_2O2J* /+Y+6ZT/Q?K#ZAX,FUNQU>5+JVGMX(IGAD,:HT4F\@* 5&#G']
M-0V-Y#\0?#MR=+:&UMM,G@F-K"?)A=RA5 0.1\I&0,?2N\HH X[P#:W5H?$@
MNK2XM_M.MW%U#YL97?$^W:PSZX/'4>E-,%RGQ=EU)K.Y^PC1!:_:!"Q4RB8N
M5&!S\IZ].W6NSHH \?L= UR#P[HM_%IMT;K1]=N+V6R==KRP2.^2F>"P5L@9
M]1UKJ_[+FUSQV/$$4$]O:6^E/9H;B)HGED=LGY6 8*H'4@9+<9Q7:T4 >12:
M;K,GP,A\/G0[]-2M_L\/DE 2Y2968C!/R[5SDXSVK<O)M6\-_$"\UN'1;_5-
M)UFT@1OL<8::WEBW  HQ&%(8\]C7H-% 'G'BBTU==6T+Q--X<&J0Q0SVU[ID
M:I++%'(RLC*#PSC: V#ZXXYKK/#2JUE+<1Z&NC13/N2V:)(Y2,?>D"$@$^F2
M0 ,]<#;HH XFXLK^'XIW%V+"YDLK[2([4746W;$ZRN6W$GCA@1ZU@>$;*[TV
MRM/#6I>!4?4;(B%=4-M$UJ\:GY92Y.[=M_A R3Z9./5:* .,\*PW-MXO\87-
MQ974,%W<Q36\CPL!*JQ*C8_$=.I[5RL^D:K+\(_$^DKI5[]OO+^X>" PD,ZR
M3;U/IC;ZGC\J]=HH XG58KF[^(?A+4(;*[:TM;>[6>4P,!$9%0(#QZJ?IWKG
M+G2]3E\$?$&R32[TW.IZE/+9QF%@9D=4"L/3[IZXQ7K-% '"7\%W<>-?!-Y%
M8W9M[.WNEN9# P$1DC15#<>JD>W?BN9GM_$>I6.A76H^'M4EUBQUZ*XO"-OE
M+&KOQ"N[&W!7D 9QDDU[#10!Q6D0W^F_$;Q/<W&F77V344M9HKE%#(!'$58'
M!SNSP  2<^E<I#I.K)\*=*TMM)OA?0ZR+B2#R3E8Q=M+N]/ND=_:O8** .)>
M"9_BM)J+V5Q_9K:%]E,[Q%4\SS2Y4D]/E[GCMG-<;HMY#;:%HEOK&@^)H]+T
MJ<7T 6R66*+!8H6E5BSQH&R"%!. 3GI7L-[9P:C87%C=)YEO<1-%*F2-RL,$
M9'(X-8%CX+ALXUMY-;UF\L57:+.YN5:/:.BDA0S+VP6((X.: -K4X7O-&O((
M<,\UNZ)SP25('\Z\S%GJTG@+P38/HFH1W&EZA8M<HT62$A_UC\$_+Z=SV%>L
M44 >;ZUH-]KOBSQ3#%;W$,&I:"ME!=21,L9E!<D$XZ?,.?K4_A.2:[>QMKOP
M&-+U*TQ]JO9;:(0@J,$Q.IRQ8],# R>3CGT&B@#F?B%;W%[X"UFQL[::YNKJ
MU>&&*)"Q9B,#Z#W-5-.U^\L/"]A;1^'=7DOX;2*(1- %7S H'+$X"YZGTKL:
M* /,;FSN]!\:ZO-J'A*7Q!8:LT4\%S:V\<KQ2"-49'#D;5.T$'.!GZXT;I=8
MA\0Z=93Z%.=%;3SM@TS:L:7)<YCD;*_(%QZ*222#P!WM% 'DFB>'_.^'WA[1
M/$7A_5(#:M-_I-L#Y]I*&)61/+);!#$=#T'&.:6ZT?Q1%I.A:K?V,GB!M)O;
ME6M9XU\^YLW^5)"IX\P  X////.:]:HH Y#3]0:QT34-9L?!MS:*0GEV,=O'
M'=W!!P2RJ< #=P"<\-ZBNN4ED#%2I(S@]12T4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7*>,/B!I/@=[4ZS;WPAN25CGAC5TR.H/S9'7T^E=77+>*]#L
M/$E]9:3J<(EM;BVN58=U/[O# ]B#R#0!I7WB&VM-+M-2@@GO[6Z>)(I+38P/
MF,JH?F8<$L!GMGG%5]:\7Z9H=[8Z?.)I]4OC_H]A;J'F?U.,@*!@\D@<'GBO
M'= O=9\ >(XOASK(>YL;G4+6;2KH#C N$8CV! .1V;V.:T])\YOVI=4^WYW+
M:'[+NZ;?+3&W\-WZT >F)XRT^/Q!;Z'J,%SIFH72[K9+L)MG]0CHS*3[$@^U
M58_B!I;^.#X0:TOH]4 +#>B",KMW;@V[D8YXY]N*\_\ VA_,%OX6:TW?V@+U
M_LVS[^<+T_X%M_2IOC397.A:GX<\?V29N=.G6&Z"_P 2$Y /M]]3_OB@#N;+
MXA:9>^,YO"8L[^'5806=)D15"@ Y!W\C!!XS6[!JRW&M76EBUN%>VC21YF"^
M60^=H!#9S\IXQQCW&?#?'MW<:=XC\._%6S#FRENA#LV[2;<#"D_[Z^:<GL5%
M>T^' 9--DU24%9-1D-V=PP50@",$=B(U3(]<T ;-<1JWQ/TO1-*;5;[2]7CT
M\7+6JW'DQX=P6'RC?N(^5N<8XKMZ\C_:%1(OAI;)&JH@U&+"J, ?))0!W%OX
MPCGN1;G1M5BD>S:]B\Q(L2QJ5!VL'(W?.O!(-0>%O'VG>,=*N]1T>QU"2WMG
M,;%TC0LX )507ZX(/.!6I81H?"UI(44NM@H#8Y *#(S^ _*O(/@*-:/@74O[
M-?3Q#]O?=]I5RV[RX^FT@8QB@#T?PU\1-,\6:3>ZGI-CJ,MM9DK(72-26 R0
M 7Y.#FHM#^)-CXETF;5-&T76;RTAD,3O'%%D, &("F3<>&'0=ZX/X ?\DX\0
M?]?4G_HE:SO@A_;?_"+6GV+R/[+_ +?;[9][S<>0F,=MN[;GO0!ZCK7Q'T?0
M?#&G^(KRUO\ ^SKX)Y;I$I92P+!64L"#@'VJ2?XA:3I]_IUIJUM?:8=1P+66
MZC4QR$XP-R,P!Y'7'6N*_: ^SCX9VR6VP1IJB)A.@(23(_/-8/B2YF\6^.O"
M_A#Q-%'HUC B3V\T3F7[:2J[5#$+LS@KT.#QSQ0!ZIXE\?:;X6UC3]+O[._>
MXU%Q':&%$996R!C)<8Y8#G'6KMOXG636XM)N-'U.TN9HGEB:=(_+<+C(#*[#
M/(XKS'XU>9_PL#X>^3M\W[;\F_[N?-AQG':O2/#7V];>XD\1"W&HC4)5C,>=
MF" $"9YQLQ^M %&Q^(UAJ?B#4-#L=)U6?4-/)^T1*L(VX..ID //I6A%XUTH
M:/J6J:@MSI<&G3&"Y%]&$96VJPP 3NR'7&.N>*\AT ZX/B[\0SX>6T.H>5+L
M^TEL9WC&,=_3/%3_ !Y6Y7P7X98JPMI9E:[;'WI/*4*6]3@/U]* /39?'UG:
MZ'%KEWI6K6VD2;6^V20H0J-]UV17+A3D<[>]3^(_'.D^&= @UVY6>YTR8J$N
M+0*Z_,,J>6'!]12^.!;?\*WU\'9]G_LN?;Z8\L[<?IBO!I3=G]EZ+[3N\O\
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M>:NUR'B._O[3Q[X0MH+Z5+.]EN4N+8!=K[86923C=U]\=.*YV:77;UO'J_\
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M('XUYE9ZYJD&J^$7&J7-\NHW<MO>W(&+6Y^1V'E*>0%*C#* ".[5<\(6,_\
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M)OKVXT>WE$L5A,4* AMX5F"AF4-R 3VYR*N3^%8?[?N-:T^_NM.O+N)8KKR
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M8+R !B-JJ1P!WXKI:* .5T#P/%H!0+K>KWL<"E+.*[G5UM@1C*C:,D D MG
MX]:LZ1X.T_2O#5QX?>:XOM.G\W>ET5)Q(27&55>I8GVKH:* .5\/^!H?#Y0+
MK>KWD-NI6SANYU=+8$$94;1D@$@;LX'%0'X=V)\(R>&CJFI?87N/M!;,7F;O
M,\W&?+QC?ST_2NQHH Y34_ EM?:ZNM6VKZIINH/"L%S+92JGVE%Z;P5(R/4
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M8]I1B"V1LZD@'/M6>_P\T:?1=2TJZEN[BWU"[:^=G=0\<[')=&51M.?P_,T
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M;N6)9FP\C#Y8V]2NQ\YYR5KI-*TBVT>"9+?>[SRM//-(<O+(W5F(P,\ 8
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MHY9UN#%!'*5CBB20H(RGW6RJY)()RW!&!CJ+B[OH/'OA"SCOIQ97=A<F6V!
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M><JNP;ODY^7C_P"OS5:X^'FFRSZN;>_U*RMM7#_;;2VF412.ZX9P"I*L>^"
M>X(XH U_"G_(G:'_ -@^#_T6M9&IZI->_$6R\+F:6"T_LV2_E,,AC:9O,"*F
MX8( ^9C@@GCMG/1:5IL.D:5:Z=;O*\-M&L2&5]S;0,#)^E4M8\-VFKW]CJ)F
MGM-1L2WD7=L5#JK##*0P*LI]"#[8H \Q\6WM^_A/XA^'KR\N9XM&\B2UN#(0
M[1S*&$;D??V\CGJ",YKHO$5@P\<> [2&\N8]RW_[XOOD ,*YPS9^GM733^#]
M+N]$U33+KSIEU4EKRX9@)96P #D  8"J  ,#'2H_^$/MCJ.CW\FI:E+<Z4)!
M \DJ-NWC:Y;*\Y  XP!VQ0!QL?B35-#TCQ'9?VA-<M::[#86UU>29>**8QY+
M.0<[=[8)![<'&*W?[,\36&I7TW]IK;Z5-8.!";Y[F:.X7)#QF2/@$=5R1W K
M1/@329K;7+:\>YNX-:?S+N.9EQO  #+M4%2-JX^@HTGP5;Z5:30_VQK%X\D)
M@CFO;D2O!&>JIE<#.!R03P/2@#/^'%MJ%YX=TGQ!J&N:A>37>GHLEO*X\D$G
M.\#&=V."<\Y/MCI/$-A=ZEH-Y;:?>2V=ZT3?9YXGVE),?+GU&>HHT#1(/#NB
M6VDVLT\MM;+LB,Y!95[#( SBM.@#AO"^LR>*-.\/;)KF*>WB:74E\UMPD3,9
MC?GO(&;GM&?6L.[UG4;:31+ZVU6[O6N/$26D]XC%;22)Y&0Q)&3@[1@;PO53
M\QYKT'2?#^GZ+=:G<646R34;DW,Y]7( ./;()^K'UKGD^&.CQV$-BE_JRVMM
M>+>VD2W6%MG#%\)QTR3UR1G@B@"&&/S?BSXB0LZYT6V^9&*L/GDZ$<BL.VUW
M5I?AKX'U5]1N?MMUJ=I#<2A\>:CRE65AT.0*[VV\-6UKXEN-=2ZNVN;B!;=X
MW92AC7.T?=SP2><YYYK$C^&6DQZ?;Z?_ &CJQLK2Z6ZM(#<C;;LK%@J87.,G
MODCL1SD P_&VJZA9V/BN_L=5O)KG3_+>W^R,8X;'"J2D@)VR,Q))&&(!&<<5
M;U.SEU?XL64*W]S9>;X<=GDM&"R8\]. Q!V\XY'-:][\.=(OCK*/>:G';:O\
MUU;1W.(S)@#S ,9W<#J2#CD5=D\'VOVZQO[?4-0MK^TMC:BY217:2(G<5<.K
M*>1G@#';CB@#SG7;W4V^%?CS1]3O9+]M)NA;0WDH&^2,F-U#D=6&[!-=GJ%[
M?ZSXSU+0;=BD-E90RA4OGM79Y"^7#(K$A0JC' R3D'C&E?\ @K2[_P ,76@.
M]S':WDAENI$<>;.Y8,69B#R2!TQT &!Q46M^!;'6[^SU)M1U.RU2UB\D7UE.
M(I9(\YVOA=I&>>E %[PK#K5MX>M[;Q!=VUWJ<.Y)9[=B5?!^4G('S;<9XZUM
M55TZP@TRQBM+?>8XP?FD<N[DG)9F/)))))/<U:H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKEO
M&VL3::FB6D4S6ZZIJD5E+.IPR(P9B%/8MM"YZC=D<XH ZFBO/_%D^H>!/#WB
M36;/5Y[A'@C-I9W+-,;9]PC:0,[%F7+JVT\ CWI^OM=^%]6\+7>G:A>W,-_?
MQZ==PSW#3+,LBDB0!B0K*5S\N!@XZ4 =[17CT_\ :DWA3Q[?MXAU<3Z/J5T;
M,I<E=GEQHP!QC<O;:?EZ\9.:V_$6M:E9O8ZK?6FHW.A2Z8C7#Z5.R2VDS9+2
MLBD%D(QSSC:>.>0#N;J[O(=3L;>'3WGMIS)Y]R)546^%RN5/+;CQQT[U%X@U
M?^P= OM6-K)<K9PM,T4;!254$GDGT%<A+J,Q\5_#[[%K-S=6%];W'F$.0ER%
MM\J[#J3DYY[_ $K*O+F3Q;\-_&.LW-Y=QR1_;88(8KAD2&.)2 C(#M8L 2VX
M'[W; P >F:9>#4=*L[X)Y8N8$FV9SMW*#C/?K5JO-["_N]0U#1_#D1_<Q^'K
M>\V+?26K2,QV$[XU+':%'&0/GYSQBIJL/B72=+\,6-[XCE:[;7X[.26UER6@
M=78+(2H+. %Y(P>"0<T >IU%<7,-JBO/(L:LZQJ6/5F8*H_$D"N)FTYK#6;/
M1%US6-2Q:32BR-TRSY:08FDG#*0B\H <GT!(KDC-<>(/ 7PZO]3NKF:[DUN&
M&25;AT+C=*N3M(^;"+\W7K@\F@#UMKN\&MI9C3W-D;<R&]\U=HDW "/9][..
M<]*NUP\EU=:?\54LUO+R6P7P_).+5I2R[UE10>>2V.,G)Y//-8#:IJ5Y\(?^
M$X@U2YCUA(VON)V\C"R',)BSL*[1MZ9R,YS0!ZO17G2?;=<^(TUC-JNIVUC<
M:##>-;0W!C\MVD8$ C!7H.1@\=<9!V/AK?WFH^!;.6_N9+FXCEG@,TIR[B.9
MT4L>YPHYH ZVHI;F&"6"*615>=RD2D\NP4L0/P4G\*EK@/%^GPW7Q-\%>8]R
MOF"]5O*NI(^%AR,;6&#SR1@D<'(H Z/1?$8U?7-;TLV4EM)I4L4;-(ZGS-Z;
MP0!T&"._?M6Y7E4NGR7OB7XE.FHWUFT MY(S9SF([Q: @EAR<8Z9P>X/&+>G
M>(=2UP^$]-E<,]]H0U"<_:WM3/+B,8#HI;C<S8&,Y'88(!Z517/^$;'6--L+
MNSUC4([UTNG-N1*TKQPG!5)'8 LPYY/48JQXL>:/PAK$UO<RV\T5E-)'+$0&
M5E0D8/U% &Q17EBSZAHW@[P]JYUK4+FZUQ=/M)OM5UB*+>H+,ORG8Q'REN3S
MGKS5K6YO$7@NP\0ZTEW$UD-/+V]C+>2W;QW 8+YBM(H.S# E<XSCUH ])HKE
M5TR73KJRUFUUZ[FMEM9!/;32M*M\Q3<K+N;"-P3\HP0<< 5SVCKXBU_0O#_B
M6SU.&WED:.YNY)-0E:&6,_ZR+R=FQ<= 1R"O4G)H [ZVN[R;4[ZWFT]X+:#R
M_(N3*K"XW#+84<KM/'/7M5VO-WO-275OB3 -5O0ME:P2VI\P9@)@=SL&,#GV
MK)D.M:5X9\&>*X=?U.YNKEK&&[M9YMT,\<RJ" G]_D?-U)R30!ZRES#)<2VZ
M2*TL(4R*#RN>F?RJ6N \$:?#%XW\:R*]R6CU",*'NI&'S0(3D%L'KQG..@P*
M[^@ HKRC4]4OK=;#4K'5;Z\+^(X[>2]$K1VSQ-,4,"Q;B&"CY2VT<@D$G-::
M6=[K'C_Q9I<VN:K%9Q6MI)%';W)C\MG$F=I7!'([=>,YH ]$K#TKQ&-3\3:W
MHILI('TH0$R.ZGS1*&(( Z#"]SWZ"N&T#Q1J.LZ9\/\ 3+R\F5]7@GFN[A'*
M22B%>%##D%C@DC!X]ZU_!]FMC\3/'$*33RILT]E,\K2, 8Y.-S$DCZF@#OJ*
M*\ST/5[F+Q)I^D^)3JECJLDTQBN!<N]EJ2E7P$(;:A *L%P"-H]: /3*RM6U
MI--NK"QCC$U_J$CI;1,^Q3L0NQ9L'  'H>2.*\VN]5U-/A#XHO5U.^%Y8:G<
MQV]Q]H?S$5)PJC=G) 7C!S6YXLTV"Z^)G@HR278\X7H?R[N6/&V$8V[6&WWV
MXSWS0!K0^,+ZX86,>@2QZV();A[">X" (C[,K( 0=Q^[P <'..^KX?U:_P!8
MM)+B^T2YTG# 11W,BL[J5!W$*?EY)&#Z5RBZ7;GXWR?O+SC0DFXO)?O?:#Q]
M[[O^S]WVK*E\2ZGH>@>.;HZC/-)::REK!-<,'^SH_DKD#H N\D#&,T >KU2T
MJ[O+VQ$U]I[V$^]U\AY5D. Q ;*\<@ ^V:RX-"FL=<2Z@UV\%G-:F!K.>9IM
M\O42HSL=I SP!@_A7$:1XCU2/P+H$<M[+/<:EKDUA)<W%P58H))B%W@$J3L5
M00. >,<$ 'K%%>;:S8^(M#T+Q9<G6&@M#ITES90)>R3S02QH2Q6210VPG''8
M],9IML^H:;XB\"7']L:A<?VO#)'>13SEHWQ;^8I"=%((ZCD]R: /2Z*\[T8W
MOC+PM)KB:]<Z9J OI6#K(QBMHXI2OEM%N"L"B\EN<MGT%37^I-X0^(#W&I7]
MV^B:I9N\ EG9DMYX@7=%!. '3D>ZD"@#OJ*R?#=I=6FAP"^DF>[ES-,)I6D,
M;.=VP$D\+D*/IGJ:S/B%KMSX>\(S7EH_E3R30VZS8!\D2.%+\\< G&>^* .I
MKFM2\53PW6HP:5I,FJ/IAB%Y'%*$D!<;L1J1AV"D$@E>HP2>*R]6>[\,^-/#
M*6-W>366J2R6EU;7%P\PR$+K(I<DJ1@YQP1VJOX)TRW@\<^,W22[)@OH53?=
MRN"#;K]X%B'//!;..W2@#T '(!P1GL:6BO*KZ34[63Q;X774]1.J2/%=:)+]
MK?S"DHVJH)/W4=6W?[/)SB@#U*5VCB=TC:1@,A%(!8^@R0*R/"?B%/%7AJTU
ME+9[9;@R 1.P8KM=DY(_W<_C6%X1U8>*H]&OH9KJ..UL=UU'Y[\W#'9L?GYB
MICDSNYY4UP^BB\TOX6>&]<M-4OHIHM46(0),5A:-[MD960<-D$G)R1V(H ]B
M%W>'6VLSI[BR%N)1>^:NTR;L>7L^]G'.>E7:X2[U2]TWXFZJOVJYGM(?#OVU
M;1G^02"5AP!W(4#/6E\/VMWK7A_PUXD7Q%<PW,PBN;W,C/#.''S0B,ML3#$*
M"!D;>Y)H WO#OB,:_/J\7V*2U;3;TVC"1U8N0JMNXX'WO4UN5X]+:3MI?Q*U
M"WU._LYK&_GN(/LLQB'F);HP+8Y8< 8/'M7J>BW4E]H.G7<Q!EGM8Y7P,<LH
M)_G0!>HKG/&$YBM=.B&HS6AFOHT,-NI\Z[&"3"A!!4G );(P <D"N(FU/5XO
M"WQ$A%_?6SZ7(9+0FY,DL(,*OL\PY)&3Z\= : /6J*\WO&OM#M-#9=7O[J7Q
M!=6UO.;N[*QQ8B=B(B%)C+D!>,GTP>:Z'P[IFM:7KFHB]OHWTVY59+6T>[DN
M9(&'#D.X#%3D''.#TZT =*[%8V94+D D*N,GV&>*QO"OB)?%&B_VDMH]K^_E
MA,3N&(,;E#DCCM6W7B%L+S3/A=<>(+/5+Z"YLM9E,444Q6(@WFUE=!PX(8_>
MS[8H ]OHK@KNXU'Q'XI\1Z-!*T0TZ.".'R]0EM61I(]_F_NU.[DXY./DZ<G.
M==PZ^=>\$Z1J'B*X\ZZ@O8;^33Y=B2M&@PPX&&Y.3V.<8(% 'IU8=]XC%CXM
MTG06LI&_M&.9TN=ZA5\M02,=2>1Z=:Y:&/4-1UK6/#,-]=3+I%M;PQ32ZG)!
M.6>,MYS-&OSG.!SQ\O3DU1O=/U2?Q-X!L-6U;?J"V^HQ7-[8-M+E50'!(X.!
M@G (.<8ZT >IT5Y?9Z?KEQ+XR\(P:]J3M8K!/IE_)<-YT32(S>6[CEE!7OG@
M_3&KX;UL^+5T#R9;J!K.!IM2B$[AEE!,0BDYRV761N?^>8[&@#NZ**\S\:7M
MVD7BZXLM4OIKBPM%DA6UF:"/3F6,M\Y#8D9C\V,' P#@&@#TRL/Q!XC&@7>C
MPM923KJ5\ED)5=0L;,"03W/"GH/QK!MM6FUWQ?9Z)=W,T4 T./4&2"5H6GD=
MMI.Y"&PH'0'JW/05C^+X;[0M!\*0SWT^NW=GXBB(8 ++)\DK)&<GEL%1DGGK
M0!ZE17!6-W_:_@'5?$=KJ]X;JZM9IL1S,%LW53^Z5&)"E2,$XR3D\ @#&LIM
M2LK+X<ZN=:U*>?5/L]O=QS7!:*1'MRW*=-P(!W=3W)H ]6HKSO39[OQ?I'B>
M^.HWMG>6E_<VMGY%PT:VWD@!<H#M8D_,=P.<XZ8JC;Z_J-Q8>!O%UY<7,5K?
M%;34K=)F6+=(I6.7;G &\?DX]* /4JPV\1A?&T7ALV4@:2Q>\6Y+KM(5E7:
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MLC"@8ZY .J\-ZTOB/PW8:PD!@6\A$HB9MQ4'MFM6N3^&'_),O#O_ %Y)764
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M(9G5<<$D=\CTP:TKKPK:7>JZ7J+7=\MQI:NMJ1*&V[UVL3N!+$C^]GVK=HH
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MNW[/[_;=Z5I5G+HEHFNIJZF9;A+7[(J"4B()NW?<Z9SW]*T: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(+:[B$L8D7:P!]10!?HKF_'>K7FD>$;Z33(VEU.6)X[2-/O%]C,2/]U59O\
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MLG11*C+G/1BI'RMR">AKCIO&\_B+X+W.KZJ^JZ0)G.[4+&-3Y:FX8*$^<,P
M"H>AY^IH ]@HKE(_%VG:78>'+ 27NI7^IVR&TB 4SSJ(PQD?<P5>.22>N<9I
M&^(FACPG>>(U^TO:6,I@NXEC'FP.&"E64GL2.A/6@#K**XW3OB9H>I:WI6EI
M!J$$FJV_VBSFN+?9'*,9P#G.>#VQZ$Y&=WQ+K:^&_#E]K#VTMRMI$TIBBQDX
M'J>@]3_.@#5HKS_P[\1H3\.8_$_B..:T7;N9_+&V9F=MJQ $DXP!SCU/<UT6
ME>++'4];N-%>&YLM5@B6=K2Z"AS&W1@59E(YP><@]: -ZBN ^,MU=Z=\-K_4
M;"]N[.[MWB\N6VN'B(W2*ISM(SP3UKA?$^N7^A_#GPCK.C>(-1;Q%=K;[[=K
MV2X^T[H\MF)V8?>QT ZX]* />:*PKWQ/!I2:3;7L,C:KJ6%AL;< NSA=SXW$
M !>Y) K*O?B;H%CX6'B&1;MK);DVDRI&#)!*,@HZ[NN1VSV[&@#LJ*Y32_B!
MI&J^)FT!+>_M[W[,+J+[3;[!/'ZISG\P.AK*\$^/[KQ9XIUZT;3+J&TLYUMH
MB57$14/N,ASD,Q& !D# ]S0!Z!161KOB33O#JV8O78S7LZVUK"F-TLAZ 9(
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MR/''@X^(OAWJ$_AKP_?VES->17DL5V7^TW94,&)5F)R-^>3DX/'3/5_\*O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTH7(&T<?* ,#\ZU: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK!%&I3E-A!R,XV\8&*Z$=.:Q_$GB2P\+:-)JFH+<-;I@'R(3(>2 .G Y(Y)
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M$7CL:#=0@>1!;B_NT'19_FC2,_1A*WU1#WJCXB^U_P#"Z/#OV(P";^R[G_7
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M7FGS,RQ74#P.5Z@,I4X]^:P[GP=]OL(],U'6K^\TM2N^VF$>90I!"NX4,RY
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M))M>NII[^_M[6YMV1!%)'*Y5L@+G=T.<_0"N^7PM&GB'4M:34;Q;F_MUMY%
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M1!%)'*Y5L@+G=T.<]N *Z.&^NO%<OBS;?W%G#I<[V%M' 0,.D89I&R/FR6P
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M6RR+'DG 8LRX)QG'I]:S=2_Y+'H'_8)N_P#T..NEUO4X]$T._P!3=-WV>%I
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MP1@'T^E:^GM</IEJUV\+W)A0S- <QL^!N*G^[G./:N*\3_\ )8/ ?_7+4/\
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M1;I5X'F J>0.-R[2.QK1\1:Q_8'AZ^U;[+)=+9PM,T4;!2549/)]A5K3KO\
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MU(9KH.Z@[R -RD*,'Y5]N.E:&J:^MCJ=II5M:O>:C=(\J0JX0+&F SLQZ#+
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M]^.*=10!D:WX<L]<ELKF62>WO;&0RVMW;L%DB)&& R"""."""#1!X>M[>#4
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MD.H=X\8VEL>G?K[U6O/!NGWVC:=ILMS>J--D22SN(Y0LT)5=HPP'/RDCD'-
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ML$&$XQQ@''OWS4-OX2LH#9I)<WES;V4_VBVMYY R12<X8'&XXW' )(&>!P,
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MGB[P&EOS,=3=QM_YYB)M_P"&*ZBU\/:=;:?>630^?'?,[7C3G<UPS##%_7C
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M#ED)Z#&..,$CL2:Y77+$R^,;Z;4(?%MH3%#!;WFBM(R7,:@G,GE@A6#.XP5
MQSWKLO"MG?66E/'>7-].AF+6YU!U>X6+ X<KP3NW$=P" >10!B^+?"D^LZY%
MJ_AW66TOQ+8VZIN(W1S0LS%4E7NI96P><<\'C&"?'^KV_A7Q&FIZ?#IOB+2I
MK:"[DB;,1$S*BS*2#CY<GG.,#Z5W=[X<M[O6#J\5W>VE^8%M_-MY0 8U9F *
M,"AY8\D'VQ3(O"6DKI^I6=S$]Z-3YOI;EMSS\;1DC&,   +@#MB@#G;R#7O#
M5S>:]'=1_P!G1:=,TFGRZA+=&:9$9T9"ZC:<*00#@CG'%6=%T^XU#3/#?B"/
MQ%=(\L237H>5GBN_-0?($+;8_F(QM&1TK1T#P3IGAX$17&H7BB,PQ+?W33K#
M&>J(IX4' [9XJ+0_ .C^'KM9;*74#;QN7M[*6[=[>W8YR4C/ /)ZYQGB@#EO
M"M@+;0/'LUK=WT,T.J7Z1R"ZD8KM52#AB06X^\1N]ZETO7;V\M_AUHUQ=W 3
M5M.:YNYQ*RR3F.%6"[P=W);<2#DXZ\FNLC\':;!)K#02WD0U9G>X19SL#. '
M95.0"P R>OIBFMX*TIM&TS3=URHTIE:PN%DQ-;[1@;6QR,<$$$$=<T <CJM]
MJFE7?C;0X-1O?LMKH_\ :=E.9BTMLVUP4WMEB"RY&3D<BGVKW^G:GX O1K&H
MSMJT?DWD4\Y:*0?9BX(3H"".HY/<FNQD\*6,VGZG;337,DFJ)Y=Y<LP\V5-I
M7;D#"C!(PH&,D]234;>#[%_[%S=7G_$F_P"//YU^7Y=O/R_-\O'/\^: +'BZ
M[N=/\&:W>661=06$TD17J&"$@_A7GUG_ &GX,\!^#]2TO4Y;FSD:UCNK%XHR
MDBSXW,A"A@^Y\Y+'.>:]995="CJ&5A@@C((K"L_".FV26D*-</9V4OG6EI(X
M,4#<X*\9.,G 8D#MC P :6K7K:;HU]?K&96MK>28(/XBJDX_'%>:ZCJ6I6?P
MIT[QQ:ZG=RZLL=O=SH9V,,XD90\1CSM ^8@8 (VCG.:]5(#*58 @C!![USEG
MX(TJR@2SB>Z.F13BXBTYY 8(W#;A@8W8#<A22H/:@#!O--@F^-=DS27:E]$E
ME(6[E7#":,8&&X7_ &1P?2NP\00K<>'-2B<R!6MI,F.1D;[IZ%2"*@E\-VLO
MB>/Q ;FZ6^C@-LNUUV"(G<5VX[D YZ^]:TL231/%(H9'4JRGN#U% 'CALUB^
M$_@'R9IU>?4M,8NTK2;"3U4,2%'L!CVK9N=4OO"7B#Q?#;WEY>P6VAKJ<,5Y
M,TVR8&0'!/(4[02!QZ8KHD^'VD1Z18:6ESJ MK&X2YMPUP6*.AS& 2#\J]AT
M]<UH#PO8G7KG6)9)YKBYMA:3)(5,;Q#)VE<>I/YT <_IVGZY)>:#K5MJD:6;
MHIO!+J,LZ7B2*-I5&0*C;CD;<#G'2NTO?^/&X_ZY-_*N=T#P!H_AR[66RFU%
MX8B6M[2>[>2"V)SDQH> <$C)R>3ZUT5Y;?;+26W,LD0D4J7C(# 'KC(- ''_
M  @_Y)1H'_7%_P#T8U&I:E<:OXYDT"W<-;0Z:MT$2_DM3(S2.C,&C4L0NP#&
M0,L>O&+NG^ [+2=)CTNPU76;>RC4JD4=V1M!))P<9')/>G:MX!T;58]-^:\L
MKG38A#:W=E<-%,D>,;=PZCCO[^IH Q$BU;3[/0])UK7Y+R\6[F4VUB[>?>H$
M+(K290KL#*S,< @#/7FCI5]XDNO!^LQ6;37=W8:_+;I;O>$2R6Z.K-"LQYW;
M<@,3G KK;GP/I%Q'I>U[V";37=X+F&Y83$O_ *S<YR6W=R>:9;^ ])LDN5LY
M]0@,][]NW+=,2DO<KNR.>^<Y[Y'% ')CQC$N@S'39]0M[BYUJWLKFUU.1UET
M_P P*&7<VXJIVDAAG&\D=*ZG1-*UK3?%%S+/?1C2KFV!2QDO9;F1)E89=6D
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M /0Z*S/#UA<:;H=M!=S2S797?.\DS2?O&Y8 L2=H)P!Z 5IT %%%% !1110
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MFUS1K ZNNQ94BCF6+?&>K;FXP!S6O:7 N[*"Y"/&)HUD".,,N1G!'K0!G_\
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MS74DGF+D\OD_,>3R>G:M^B@#EA\/M!'AQM "WG]FLZMY1NY#@*VY5!)R%!Y
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MTF;3-1C>6SF&V2-963</0E2#^M '(^,8GN_'7@RVBU"]@M[U[M)EMKED611
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MD@#!-=*O@_1ECU9!%<;=6R;T?:Y?WN1M/\7'''&.*B/@;0/.T^86TZR6%O\
M98&2[E4F'_GFQ#9=/9LB@#SNVN]0OOAOX"N9M3OENI==BM99DN6W/'YTBX;L
MW"+RP/2MH6,=GXD\9Z$DUU)IKZ1%=>3-<R2;9#Y@8AF8GG:,\\UTT7P_\.06
M%I8Q6<R6UI=?;($6[E'ER@D@C#= 2<#H,GCDUHIX:TN/6;G5A%*UY=0B"9GG
M=E>,9PI4G;CD]N] &+\.M.M#\--"1XO,2>Q@DD65BZD[0>AR!TZ#BH?&K:K;
MZI9WUKIK:SIL$#B[TZ";9.A8C;,BY^<@*P Z\G'>NCT/0-.\.:>MCID4D=NO
MW5DF>0J.R@L20H[ <"EO=#M+[4([]I+F&ZCB,(D@N'3Y"<D$ X//J,CMB@"O
MX2O;+4/">F7.G7$]Q:- HCEN,^8V.#OSSNR"#[@UQ5_?7&C^)7;Q!:W#Z?<Z
MJC66MV4Y98OWBA;>9 ?E7(*'J"3G&<FO1M/L+72["&QLH5AMH5VQHO8?4\D^
MYY-9O_")Z499"R7#PR77VQ[=[AVB,V[?NV$X^]SCIGG&: .6TV >-K;Q0+K4
M;FTO[359K2"6&4JUDD9&PJ,@#."Q/?)&< 8;<:?;ZS\6Q!/<3R6[^&8RS12M
M$9A]H;J4P<'K@$?EQ70WW@+P[J&N/K$]DXNI0!.(YW2.XQT\Q%(5_P 1SWS5
M\^'--.OMKFR<:@UO]F,JW$@'E9SM"YV@9YZ=: /-M'UV_3PKX7TV:]<Q76LW
M5A)<7$K9=(VE\N-G!W<E4'7D#'0FKGB$ZMX&T/7KF+5T6"\DMA!;H6;^SP[B
M.212Q. <D@= 1QWKKV\!>''\/3:%)8-)ITLIG,4D\CE9"22RL6)4Y)/![GUJ
M6S\&:%9Z)=:1]C,]I=KMN/M,K2O*.V68D\=N>.V* .9U;1K+3OBCX*^S"0++
M#?(X:5G#8B7YCDGYCGENIXSTK O+N[3X.^+YQ>W8GL]5NTMYOM#[X@LX50&S
MG '&,UWUGX"T*SNM.NE6]EGTX,+1YKZ:0Q!@ 5&6Z8&,=,4R[^'GAN].I">U
MG:'49#+<0"ZD$32$@LX0-M#''+ 9Z^M %'5>?BWX7_[!M[_.*N?TN#5/%_A.
M+Q!#K$&GZA'=23279DD+0;)#NB9,A=FT8V],<\DY/?GPQI9U:QU0QSF\L8C%
M;N;J0[4/4$;L'.!G.<XJ@/A]X:37Y-92Q9+F6432HD[B&20'(=HP=I.>>1UY
MZT 8=C(GBR]\9_VC)+NT^Y>RMH4E9/(18P1(N#PS,6.[K@ =!6M\,/\ DF/A
MW_KR2KM[X+T6]UF;5GAN(;NXC$5PUO<R1"X4# $BJ0&P/7Z=*T-%T6Q\/:3!
MIFFQ/%:0#$:-(SX'U8DT <-;Z4FL>-_'6GWEYJ+VD45FT42WLJB-FB<D@AL@
M9YQG&>W QA6CW7_"">!O$SZC?R:M-?V<$LSW3D/$[[&0IG:01U.,D\DYKTZ+
MPQI<.I:EJ$27"76I*JW4@NI/G"C"\;L+@$@8QUJI_P (-H']BV.D"WN!86,R
MS6T0NY1Y;J<J<[L\'D GB@#%TC;XOUWQ=;:G).K6-X+.VCCF:,V\?E@B1<$8
M9B6.[KP!T%<OI^HZKKFE_#Z?4-0O4N+B_N+2XDAG:,7"(LH#$ XR0H^;&><@
MBO2[GPKIESJ<FI!;B"[FB$,\MM</$9D'0/M(R1V/4>M%QX4T:Y;2RUJT8TLY
MLDAF>-83C'"J0#QQSVH \[O[1(-*^*6AB6YDT^RM4GMHIKAY#&SVQ=L,Q)(W
M '!.*M:GI\2:;\-[>)YHEEO(F9EE8L";9LX))(_#IVQ7=+X4T=;K5K@V\CR:
MM&(KX23R,LRA2H!4M@84D<8JNG@?0HX--B$-T5TV3S+4F]F)1@-H.=V3A>!G
M.!P.* .:TA&T_5OB#HT,]P]A:P0RP1S3/*8S) Q?#,2<$C.,UF"UNH?A%X3\
M0V+W)ET>UMKF:WBF95N+<*/,0J#@_+EAG^[[UZ /"FDB\U2[$=P)]418[QQ=
M2_O% P!][Y< D<8ZUGW:7'AC3K'0?#WA^XO;:2)X8W:<-%;8 "B0NQ;9SVSP
M, 'I0!+X>N(==U6]\0VT[R6+HEM:%9&\N0+R\@7.,EFV9QG]W[UB_%X,?"NG
M!&"O_;%IM)&0#YGIWKL-$TFWT+1++2K4 0VD*Q+QC.!R?J3S^-0:]X:TOQ+!
M#!JL4LL4,BRHB7$D8#KT;Y",D4 <7IL<DWQ;=/%DH?5+2!WT-HE\NWDA88D*
MJ<GS1T8%CQR!QFI)TN_%WB'Q7I)N8XI+%XX+<&61'MU:)6650I')8L<_[('2
MNOU;PUI6MQV:ZA!)(]E();>99W26-\8R'4AOUYJAJW@+P]K6I0ZC>6TWVR*,
M1&>&YDB>1!_"Y5@6'UYH Y>2RNY?&?A/3K[6[N[$NEW27<EO</$EPT>P;L!O
ME)R<E<$^M<]K,/F?"KQE8S2SS0Z7KQ@L_-F9S'&)8<+DG) WMC.:]7?PQI+:
MK8ZD+=TN;&(P6QCF=$BC( *A =N.!V["JW_"$Z"=-U33VM97M=5E,UY')<2-
MYDAP2V2WRG@=,=!0!N6UM%:6ZP0AA&N<;G+'KGJ237F^FL_BOPIXGU2ZNKB#
M4[>\NXH)(YF1K+RO]6J@' X )_O9.:]%LK*'3[..UM_,\N,8!DD:1CZDLQ))
M]R:RI_!^CSWE[<^3-']OQ]LBAG=([CC&70'!)'!]1P<T <!:--XM\0^")]6:
M>*2]T">2X$$C0L^3%GYEP5!Z\$>G2H+Y;K3O!OQ+T!KNXN].TU +.2XD,CH)
M(0[1[CR0I(Z^M>FZAX;TW4;FSNGCDANK)2EO-;2M$T:G&5^4@%3@<'(XID_A
M;2+G0KC1I;9S97)9KA1,X:8MRQ=P=S$]R30!S&JO+%XJ^'ACN+A$F,J2Q+,P
MC<"V8C*9VD@]\9K-U@:G>'QK:RIJ$NK)(O\ 8TMF'(B!C4QJK+Q&V[)?)'!!
M/RXKN)O"NE3W&ESRQW#2Z7G[&WVJ7,>1@_Q?-QQSGBN$ET 7&NZG+JOAGQ$E
M_<W;NL^D7Y2"5.%0\2J VU5SN YSVP  ;$UGMU71=&N+BZU"^CTUY)=.>X<Q
M%BR@SR2L2V VY5&&// &*Y!0^L?#GP!<ZE+-<7(\010&5YF+%1-(O7.2<*!G
MKQ7H-GX*LIH]-NM6-S/J=I$\(G^UR!VB9RPBD92/- & =W7!/<U,G@'PY'H8
MT>.RD2R6X%U&J7$@:*0,6!1@VY,$G ! Y/J: ,J7S+'XN6-O!-=-;_V#,_V=
MIW9"RR1@$*20#CC/>N<CNKC5?@S-XR6^GBUZ..:]%RDK#RW21OW6W.-F%V[2
M,'KUYKT9/#&E)K5OJZQ3"]MX/LT3_:),"/J5V[L') )R,DU77P9HB2W!2WD6
MWN)OM$UH)G$#R9!W&/.WD@$C&">HH Y2*WDUSXE);7\]_%;77AN*ZGLTNY$0
M2-+@@8;*] ,*1G'.>:HZ/)KUW\/-,-B?[4EL=3N4DLKFY*/>V\;RH(]YZE?E
M//!V#/H?0V\.Z<VOOKFR<:B]O]F,HN) /+SG;MSM'//3K5.W\$Z+9VD%M:QW
M4"07#743)>2[DE8$,P);ON;(/!STH @\":G8ZIHMS)9)>P&.[DCGM+[/FVLO
M!:,Y)X&1CM@@=JQO%&F6MS\5?"/FK*?.@OM^V9U^ZD>,8/'X8SWKM=-TNTTJ
M&6.U0CSI6FE=F+-)(>K,3R3P!]  .!56]\-Z;J&M6FKW"3F^LU9;>1;F11&&
M&&PH8#D 9XH Y/14_P"$RD\7#4+BXBN+/4Y;&U\N9D-K&B+L=,$88DEMW?IT
M&*Y[3K[4?$\7PVN-2O;V&744NX[L07#Q"=4B<!B%( ) SN&#\W!'&/2+KPGI
M5UJ5S?[)X+B[01W1M[AXA<*!@;PI&2!QGKCC-.N?"VD75YIET]NZ2:6"+(0S
M/&L((VD!5('3CD=.* +FFZ9#IFDPZ;#)/)##'Y:M-*SR$>['G->0Q6%M:_!K
MQP\*,I%W?Q >8Q 42G P3C\>M>UUS<G@3P]+;ZG;M:3>1J<C2742W4H5F8Y;
M #87<0"=N,X&>@H YY;8Z+\0?"/V6[O&&J65TMXLMP[K*8XXV0[2=JD$G[H
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M21J)3*H. #\N#V&.0,U:T^&.'5OB/IX9_LEM%;^5&\A(C_T7<2,G@[N<^O-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7>L0P;;^\C2.>7>QW*F=HQG QGL*OT44 %%%% !1110 4444 %%%% !1110
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M/T?9/$W_ $&=+_\ !7)_\?H VZ*Q/LGB;_H,Z7_X*Y/_ (_1]D\3?]!G2_\
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M6)]D\3?]!G2__!7)_P#'Z/LGB;_H,Z7_ ."N3_X_0!MT5B?9/$W_ $&=+_\
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M ."N3_X_0!MT5R^C2>)]5T/3]1.JZ5&;NVCG*#39#MW*&QGS^<9J[]D\3?\
M09TO_P %<G_Q^@#;HK$^R>)O^@SI?_@KD_\ C]'V3Q-_T&=+_P#!7)_\?H V
MZ*Q/LGB;_H,Z7_X*Y/\ X_1]D\3?]!G2_P#P5R?_ !^@#;HK$^R>)O\ H,Z7
M_P""N3_X_1]D\3?]!G2__!7)_P#'Z -NBL3[)XF_Z#.E_P#@KD_^/T?9/$W_
M $&=+_\ !7)_\?H VZ*Q/LGB;_H,Z7_X*Y/_ (_1]D\3?]!G2_\ P5R?_'Z
M-NBL3[)XF_Z#.E_^"N3_ ./T?9/$W_09TO\ \%<G_P ?H VZ*Y>27Q.FNVVF
M_P!JZ41-;2S^9_9LG&QHUQCS^_F?I5W[)XF_Z#.E_P#@KD_^/T ;=%8GV3Q-
M_P!!G2__  5R?_'Z/LGB;_H,Z7_X*Y/_ (_0!MT5B?9/$W_09TO_ ,%<G_Q^
MC[)XF_Z#.E_^"N3_ ./T ;=%8GV3Q-_T&=+_ /!7)_\ 'Z/LGB;_ *#.E_\
M@KD_^/T ;=%8GV3Q-_T&=+_\%<G_ ,?H^R>)O^@SI?\ X*Y/_C] &W16)]D\
M3?\ 09TO_P %<G_Q^C[)XF_Z#.E_^"N3_P"/T ;=%8GV3Q-_T&=+_P#!7)_\
M?H^R>)O^@SI?_@KD_P#C] &W16)]D\3?]!G2_P#P5R?_ !^C[)XF_P"@SI?_
M (*Y/_C] &W16)]D\3?]!G2__!7)_P#'ZL^'[Z?4_#VGWUSY?GSVZ22>6I"[
MB.< DX'XF@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9KSB/1M1U3XC?$B"WM[B$:GIK6]I<21,D<C[%7 <C'4$?G64FBZGJ_A#X?\
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MDYX'>NZKRGX2VUWH^O\ B_3[^PO()IM4>>-G@81M'EL,'QM.>,8.>?3->K4
M%8OA#_D3M'_Z](_Y5M5B^$/^1.T?_KTC_E0!M4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8OAO\ U6I_]A*X_P#0JVJQ?#?^JU/_ +"5Q_Z%6U0 4444 %%%% !1110
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M))$CLWW3R"0W /7:/45ZW)X(1_B)'XQ_M%Q<I!]F%OY0V>7SWSG/)Y_2NLH
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M]"K:K%\-_P"JU/\ ["5Q_P"A5M4 %%%% !1110 4444 %%%% !1110 4444
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MV80$E-Q.-W'3H,@$@UQ-IX:U<:/\3M7:PO%776D2PM?(;S91E\,8\;AG>,9
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MC_H):/\ ^"^7_P"/5BZ?JNJ-X@\1>%8KO-Q:)#/8W4XWLD4HPV[^\4(;&>O
M)ZFJMM'KOAOX@Z3IAUV\UC3=5@N'F2]"%[=H@IWJ45<*2P7&,<T =)]G\4?]
M!+1__!?+_P#'J/L_BC_H):/_ ."^7_X]7._$+Q%J5G:I%HT_DK;WMJE[< <_
MO)4 B7W*G<WH-H_BX[V@#$^S^*/^@EH__@OE_P#CU'V?Q1_T$M'_ /!?+_\
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M>2!CG:*VZQ?"'_(G:/\ ]>D?\J -JBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\-_ZK
M4_\ L)7'_H5;5<EI$FN+)J@L;33I(/[1GPT]RZ-G=SP(R/UK2\[Q1_SX:/\
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M>0C&^9]R*?QS.2.V5K4\[Q1_SX:/_P"!LO\ \:H\[Q1_SX:/_P"!LO\ \:H
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M+##$; ?]WW-=&[>))&C9],T5FC;<A-Y(2IP1D?NN#@D?B:=YWBC_ )\-'_\
M V7_ .-4 >86'A'Q!JGPR\3V,EVT]PVI336UN]L(BTL<^\L#GD28X'09ZUUF
MIX\8^*?"<EBLAMM.E>_O&9"ODMLVI&V>CEF.5Z@*<]JZ/SO%'_/AH_\ X&R_
M_&J/.\4?\^&C_P#@;+_\:H XSQ%X3L=46\T/PR;J(:K/OU&2&X<6MLI(,C;0
M=ID8#&P>N2!C-=DFN:5IFN67A55FCN#:AX!Y3>644$!0_3=A"<>@I?.\4?\
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M3:ZUXP\3Z[J$<;:)<646G1--PDZ %I&Y_AR0 >^#BNC\[Q1_SX:/_P"!LO\
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MFW-[#IDL[^'&M;>2%922B7+ F58B>J?=)[9.!T-=:9?$[ @Z?HY!X(-[+_\
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M^Z?GHK%< G^\OK0!J6&N:K+JGB'PXKQSZGI_DO:W,R@!XI1PSJN 2AW9 QN
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M?(P!XW'@#((YS@XQ6'J?CJX\,1>*[6^/VRXT>WBNK65P%,\<ORJ'"@#*OP2
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MA+#IT5W+%9RW*LSBW,A$(88)Y7!YZ#'3% %[5O$+1>.H= N-2.E6TEA]I@F
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M#).K&#3;) S2!G.TN1C[[=!_=4G.,M@ [#Q1K:^&_"^I:RT7F_8X&E$><;F
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MPVJ!@9Y.3[<VH/%4>J^!(?$.FKA[R!?LT;\XF<[%0_1R : +/VW7?^@!;_\
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M $"G?;]>QC^P8,?]?X_^(I?%6OP>&M GU"::WB?*Q0FX?;'YCG:NX]E!.3[
MU6\*7/B&]MY+K6;S0KJVD53:R:3YA5ASDEF)![8Q[T 3"\UP1^6/#]N$QC;]
MN&,>F-E(;O6FB\H^'K8QXQL-Z,8^FRH_$>ORZ=J.CZ/8B,ZCJT[1Q-*"5CC1
M=\CD C.!@ 9')%9%WX\_L&#Q-%J\:2W6B11SJ81L%S'(/DX).T[OE/4=^^
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M!_[!UO\ ^BUK9H YZX?5KLQ&X\-VLAB</&6O0=K#N/DJ8WVNGKH$!_[?A_\
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MRC;CG#-@@CU/'2F:WXHU2?Q4WA_PWJ'AZ.]MXU:>+4Y'WNS#(6-4()PN"?\
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M_P#$4G@[)\&:,6&#]DCR,]/E%;=8OA#_ )$[1_\ KTC_ )4 ;5%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &+X;_U6I_]A*X_]"K:KF+"YU+2I=0A;P]J-PLE[+,DL$EO
MM96.0?FE!_,5<_MR_P#^A6UC_OY:_P#Q^@#;K@_#"C1?'7CB.]<1+-)#J$<C
MG :$QD%A[*RD'TKH?[<O_P#H5M8_[^6O_P ?JK>77]H-&U[X)O[DQG*&86;[
M?IF;CH* .'\':/XKA\(Z%-96&GS6[23W[6U]</"0\DA:(D*C9 4[@#W8'J!4
MO@G4M>LK'QG-<6MC&[:S<)&8IV<_;'\M%0 J,IEE^;K[5WO]N7__ $*VL?\
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MIMK,+>YL98E>,$1OY(;<H[$GDGO53288;;PM\488(TBB2]OL(@  _P!&7L*
M/0?#M]-J?AC2=0N-OGW5G#-)M&!N9 QP/J:NWDTEO9S310-/(B%DB0X+MCA0
M>V3QFL#PIJ-C:^#_  M;7%Y;PSW6G6ZP122!6E(B4D*#RV/:NCDD2&)Y975(
MT!9G8X"@=23V% '#_P#"1>*]%\3Z39>(;72I;#5I6@BDT_S ]O*%+!6W_>!
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M\8XH[C0].M-NAQQ/%!>EUB@$YPR_NQDYXV\<=^U>B:\<>'=3)Z?9)?\ T T
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M6AM=2LK>\MR0QBN(A(N1T.",5:HH S6\.Z(WG[M'T\B=%CFS;)^\51A5;CD
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M1[![!&W+;-;IY:GU"XP#6I10!F1^'-#BBGBCT;3TCN%"3(ML@$B@  ,,<@
M8]J>^A:3+IJZ:^F6;6*$%;8P+Y:D="%Q@$5H44 43HNE'3VT\Z;:&R8Y:W,*
MF-CZE<8)IQTK3CIATPV%K]@*[#:^2OE;?3;C&*N44 9=CX;T/2Y8Y;#1["VD
MB78CPVZJRKU(! XJW?:?9:G (+^T@NH@P<)-&' 8=#@]_>K-% &;)X?T:6R-
ME+I-E):E_,,,D"LI;^\01R?>GC1-*%['>#3+,742[(Y_(7>B^@;&0/:K]% &
M3#X7\/VZJL.AZ;&JS"X4):H )1T<<?>Y//6IET+2$FN9ETNR66Z&+AQ;J&E'
MHQQ\WXUH44 5K'3[+3+86UA:06D .1%!&$4'Z#BHK_1M,U1XGO\ 3[6Z>+/E
MM-$K%<]0">F>]7J* *-SHNE7L5O%=:;9SQVY!@26!6$6.FT$<?A2?V'I'VJ6
MZ_LNR^TRKLDF^SKO=?0G&2/:K]% '/7]CJ>D6MK:^$-,T>"%I&\]908DC!'#
M*J#DYZCC/ZC5TK3X])TJVL8F++"@4NW5V[L?<G)/N:N44 5-0TK3M5C2/4;"
MUO$1MRK<0K(%/J 0<&DO](TW5+'[#?V%M=6G&(9HE=!CIP1CBKE% %$Z+I9T
MG^R?[.M/[.V[/LGDKY6WKC;C'6N;L?#,VF?$2/4;#3;:UT:/2?L")"53:_F^
M9D(/X?USVKLJ* ,A?"OAY&F9=#TX&:432_Z*GSN,D,>.2"2<^]2W_AW1=5N8
M+G4-)L;J>#_523VZNR?0D<5I44 9]YH>DZA<_:+S3;2XGV>7YDL*LQ3KMR1G
M;R>.G-2W&E:=>36LUS86LTMHVZW>2%6,)]4)'R]!T]*MT4 (RAU*L 5(P01P
M166/#&@+;PP#0]-$,#F2*,6J;8V/5E&.#[BM6B@"E#I&FV]_)?0Z?:1WDHQ)
M<)"HD<>[ 9-1:=X?T;2+F:YTW2;*SGG_ -;);P*C/WY('-:5% $%[96NHVDE
MI?6T-S;2C#PS('1A[@\&J:>'=$CQLT?3UQ!]G&VV0?NLYV=/NYYQTK3HH RS
MX;T)K6&U.BZ<;>!M\41M4V1MZJ,8!]Q4\>CZ9%J!U"/3K1+TKM-PL*B3'INQ
MG%7:* ,^VT'2+.\:[M=,LX;EF+&6.%5;)ZG('4]_6DN= T>\U!=0NM+LYKU4
M,:W$D"M(%.> Q&<<G\S6C10!F#PYH:BV T;3Q]E_X]_]&3]S_N\?+^%21:)I
M,$MS+%IEE')=*5N'2!09@>H<X^8?6K]% %>RL;/3;1+2PM8+6VC^Y#!&$1?H
M!P*L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>secondamendmenttoleaseag002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 secondamendmenttoleaseag002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K \7^)XO"FBB^DMYIFDE2&-8XF<!G8*"Q
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M1+*XC@O&0O=W/FA[IE!&<2_-@ @;N_/I0!DZQK_]A?%*W%]J=RFF/HTLOV8
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M&M$O8;J95$P#([&)B  Q^3(.._N*Z?Q3XEM_#.FK<2Q32RRMY<4<4+R<^K!
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M=P:C-9Q_VS:1S['"*\3/\P8^F!ZX]:BL)%/QEU5@3L?2((E?'RLZR.2H/0D
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M("K)C;S@X.<'L34%[X\\/V&HW5A-<SFZM&C6:-+25BGF$A3PO*\?>''(YY%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#IFO.M5UR\\1_!G2=4O]GVN74K99"B[02EV$SCMG;G\:Z6\_Y+3I7_8#N/\
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MEQ/(L<,2EW=NB@<DUYVOBG6K34O#PN+^.YDO]2>RO8((@UK%D.5$<NT$LNT
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M_L'Q?^@BNHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2?67OSI\5PT8P.-V\J!@D*".G7&<\UZ,O@1D\=7?BU=487MS:&T:+R!Y:K@
M$<YSE0>M9EC\(M)MO 5WX1N;V>YLYI_M,<Q4+)#)@<@]#T].Y]: &6WB/5-(
M^+$'@VZU":^M;_31<1SRH@DAE ?)!50""$)P0<$CMQ7"Q_$3Q<WPAU?7CK3?
MVE9ZS]ECF^S0\Q;4^4KLQU8G.,UZQIO@Q+?Q6WB?4[TW^JBU6TB<1>4D<8ZD
M+D_,<G)SW. *Y>7X+6LFC:GHJ>(+Z+2KV]^VK;+$G[M^.K8RPP  ./Q- $?B
M[Q-XBLO%7@6PT[5C;1:RNVZ4V\;@GY/F&5R#\Q[XZ53T#Q+X@OM+^)6EW>LW
M$DVA-*+2]6.-)0 )>#A=O_+,<XSR<8XQUNJ?#]=5UCPWJ<NJ.DN@@>2JPC;(
M?ER6Y[[1T]Z-%^'EMI-[XGGDOY;E/$18W<9C";2V_.P@\#$C#G/:@#$^#FF/
M?_":P^VZA=SVUV)@]L^P(H\^3< P4.=W?+'KQBO1A8PB_%Z06F6,Q(2>$0D$
MA1VR0,_0>E8G@KPD/!FA)I$6I7%Y;1%O)$J*OEJ6+$<#DY8\GVQBN@GGCMH'
MFE;:B#).,_D!U/M0!QG@6Z>/Q%XQT7.8++4Q-".R"9!(5'MNW'_@5=O7-^$=
M&FT\:KJ=W&8[W5[UKIXSUB3 6-#[A0,^Y-=)0!Y;8:K<^'KSXAZW<:A>7B:;
M<!E@D\O;)^X4J"0@( )QP0,=036GJNM:WX=TWP_KDVHM?07EQ!!?6S1(J 3<
M;XBJAAM8C );(Z\\UL#P5;'5==GFO)I;#6@/M5@RKL+>7Y9.[&[[HZ9Z\TRR
M\&M%9Z7I]_JCWVGZ7*DMK$\(5R4_U?F.#\^WC& N2!G- '55PWQ,6Y-OX;$%
M_<VRR:[9Q.L.W# OD$[E.<%00.F>H/%=S6+XG\.KXDT^W@^UR6DUK=Q7D$\:
MABDD9R,@\$>U '*75G?3_%][6UU22VE_X1M ]WY2/*?](;D C8"3_LXZX'I%
MI'C35KOPWX?@G9IM4U"_N;*2X@2-6*P&0EU5B$#$(HYXY)P>!73P^&)X?%9\
M0?VH99_L L-DL((*AB^XX(^;<>V!CC ZUDGX:P-X8CTAM5N4FMKUK^SOH4"2
MP3,Q8D<X(RQX]#^- &KX:/B1-1U2#6%D?3PR/83W!B$Y!'SHXB^7@]#Z'FND
MK'T+1KO3(Y)-2U>?5;Z0!6N)8TC 49PJH@  Y)/4GN>!C8H X&W_ .2]WO\
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M92!R<DYSVZ8K0/A*]NM U&PU/Q!<7]U?VS6CW<D")Y<3 @A$7 !.<DG))QZ
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M+I96.7)5OND^GE_N_P#=K6\3^'3XCM[&'[8;46EY%>*5C#%GC.5!R>F>O]*
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MZ\^U;M<#=?\ )>K#_L7I?_1XKH_%^NGPWX4U'545'EMX2T:OT+$A03[ L,T
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M6^&:X)7=E<D#&T$DD@ =Z *A\+EO$]AKK:G<//9VK6H1T0B16(+%L <D@'C
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MX5F7;]I/]TCGI7H-G;M:VD<+W$URZCYIIB-[GN3@ ?@  .PK&_X12+_A-/\
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ML,MNTVW=F+ 4'  (P,'CD$T <7;VLT?Q7\*WUY&4OM1M;ZZG1NL>50)&?]U
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M<SK'933"=A]Q,HA&U<!CGJ=HZ;A4\G@&9[Z[NT\8>(X9+I]\@BFA4>@ _=\
M#@#M75V=JME906J/(ZPQK&'D;<S8&,L>Y/<T <+\&M4M;[P!;6T#2&6VEG\T
M/"Z ;YY&7!( ;CTSCH<&O0:Y*X\(C3? 9\/:/?ZI 4=GAGMIE2?<TAD(WX
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M*+<A>+?@G;RN3R.IX^;CGHKWP?#J,-W:7>HW4VG7=P+B6T<(5!#!MJMMR%)
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MUWB,@C:H4 +U)Z9)ZYP*KR^!H9](TC3YM9U.1=*N8KJ&5C%N9XQA ?DQ@#L
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M& !["@#$\3:EK%E\/YM=M-6NHI)[Z*2$;4(%O).J*O*Y&48-ZY/6K#VLK_'
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M(&"QQD^_%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHKCOB7>:AIWA9+O3;^6SG6]MHR8P"&5Y
M54@Y&<8/8B@#L:*\]DU*_P##'CG4[:34;W4;+^P)-4,5RRDB6.3'R8 V@@]
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MH^H>=>L\=Q'(HY2/R]J,"1MVD#L<USMS>:\W@WQGJO\ PDFI"YT75+I;3:4
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M_P#B7WJN6LKJ'?\ +"<?*KE>#D Y[X.*])H **X\7=T/BU-I7VJ<V$FA_:3
M9#M$GG;-R]P=O'%<]I^L>(IO L=["M[JI@UFXCNXH)=MS):H\BXC/!+ A#@$
M$@$9YH ]1HKS2+Q='<Z5ID>BZE<7":IK!LV-X[1S6H$9<PL2"5;*A0<$X;.<
M\UTGAVPU_3M:U%-0NXI-*F"R64#W33S0L.'!9E!*DD$9)(H Z>BJVH78L--N
MKPH7%O"\I4=6V@G'Z5YK>ZSJT'PJM?'<&I3-J2QQWDT)<_9Y$9P&A\OH  V
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MD<8&,"N]ED$43R$$A%+$#J<4 /K+U76H].NK*QCB,]_?%Q;P!@N[8NYB6/0
M8]>2*X#^V=6O_A0WCJVU*>+5%22]6(.3;^6KG,)C^Z1M&-WWL\YJSJ\(U7XB
M^";LS7D'VRQNY2B3%3'^[B.!Z=>?6@#NM%U*35M+CNYM/NM/E+,KVUTH#H5)
M!Z<$'&01U&#46L>(+/1I+6WE$L][>,4M;2W4-+,0,G )   Y+$@#N:U:\XB9
MC^T+<+>'@: /L0;ICS1OQ[YS^% '5-XD-O>V-I?Z3?VCWLWDPNVQTW;2V"R,
M=O"GKU[9K=J*>.*5 )0N RE2V.&SP1[YKS719]7>W\2ZU=Z_J4Z:%JMZ([4%
M D\<<8(1\+R.F,8Q]30!Z?67XCUM/#GA^\U>6UFN8K2,R/'"5W;1U/S$#^OM
M7):7%XHOXO#FNVNH0"*?RI=0$UZSQ7$4B@G9'LVHP)&W!'H2>M8NK7D_BWX2
M>)O$$U]=1,RW:P01R%4BBC9D",G1BP4DD@GYN,8% 'I":K-+<:6L6G3R6]]$
MTDEPK+LM\*& ;)R<YP,#M5^.>*625(Y%9XFV2 'E6P&P?P(/XUPKWM_;>+?
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MH8K4SC[/+<8"PR$;MVTL5XX) !Z>AJ*WO;B;5;RT?3YXH(%C,=TQ79.6!R%
M.?EQ@Y'>O/\ 4K=[_P 9_#R26\O UQ97+2%)V7YA AR/<[CD]ZGN/$FHZ)KG
MQ!N);F:\@TJQMKFUMY<;8RT<C$#:!QD#)ZX'6@#T:BO-]7U#4]!\-^'?$MOJ
M5S=33S6JWT4C[H[E)L [4Z(06!7;CWS4,O\ ;&H:KX]MF\1ZE%%I?EO:>2R(
M4)M_,P2%^Z">@QGN30!Z=17G&G^)-3U[_A%].9AYE]H8U&Y*W#6[3/\ NQ@.
MJD@ LS$#';G (+9-0\2Z'!I>@:IJ43W&IZP;>&[BDWRQ6FTN%9BH_>8&W=CH
M<]: .OA\1QS>,+CPX;.>.>&S6\\YRNQT+[!MP2>H/7'2MJN TRQ%A\:KZ-;B
MXF1M B=!/*9"@\]AM#-DD9!/)/7TQ7?T %%8GBZYEM?#-W+#JB:9)E%%TR%R
MH+@$*HY+$$A0 3DBN4LKR]F\1^)]%>;4H+$:7%<P1W%P6FB9MX8J^XL =H."
M<CVH ]"AGBN8A+#(LD;9PRG(.#BH[^[^PV,UUY$LXB0N8XMNX@#)QN('ZURW
MPMM_)^&^AR>;-(9;.-B)'+!>.@]!73:I_P @B]_ZX/\ ^@F@"EX9\10>*=$@
MU:TM;J"UN!NB-P$#.,D9PK''3OBMBN,^$W_)+/#_ /U['_T)J/$%S+<:^]M!
MJ5S*@TYGCL=/<QR))O(\YY 0 HQ@*3R0W!QP =G17E,6NZ[J7ASX=WG]L7$$
M^J3K#=F-$Q)^[<[B"O7Y?]WV-.NO$^I>#X?'Z&]N-132([6:R-XP=D:=2,$@
M#*AL''IF@#NM6\1QZ1K>CZ9)9SR'5)FACG4KL1E4L0><YP/3'O1HWB./6-8U
MG35LY[>72Y4BD\TK\Y==P(VD\8(_/M7(>(-+>R\6^ Y6U&[NG:]D64S2EED?
MR'.\#HO?A<#GIP*IW6O3>&+SXHZS;QB2>UDM6C5AD;C;HH)]@2"?I0!ZK17
M:Y<ZAX7E\,:C:ZE=7D=]?P6%]%/)O682@XD4=$((SA<#!Z55T9M4N]4\37=Y
MXBU-K?1-59HX(_+ EC6)6,;X7E>>@QW/)Z '7^*/$<?A;2/[1FLY[F+S8XCY
M14;"[!03DCC+#IFEO/$45EXGL-$EL+XF^1C%>+#FW#@,WEE\\-M1CC%>;>(F
MN=<^#]IXCN[^X:ZO+BUN)(DD/DA6N$Q&$Z +D<_>)7D\FO7'M()+J.Y=-TL0
M(C))(7/4@=,]L]<<4 345YL=?N+/Q9_9WB"74M-N)M3_ .)?>*Y:RNX=_P D
M/'RJ^W@Y .>_.*])H **\\\::U=Z/K%T^I_VG;Z'+:JEMJ>GLQ6RF^;<TR+R
M1RF"01QC')J[:ZJWB3QKJ&C?;9DL+#3[>9#:S&,W#RY/F;U(.T # !QECG/&
M #<\5>(X_"NAR:K-9SW,4;HC"$J-NY@H)R1QDCIGZ5M5XYKFKZAJ/PH\4V6I
MRFXN-)UA+ 7)4 SHMQ"59L<;L, <>E==?WM_K?C#5="MW>.&PM(' BO&MG+R
M[_GRJDL %4 =,DY!R, ':T5C^%H]9@\.VL'B"YMKK5(@4GFMB2KX)P>@YQC/
M'7-;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS[7=*C'=@@9RG0 D8&.OKS5M_!6F7%]KES=RW-TFM1)#>02E/+*H"J[<*""
M3SGWKI** ./@^'MK&VD^?KFLW2Z3+YEF)IT^0;2NTE4!88.,DD^]7X?!VG)=
MZY-/+<7::V +R"<H8V 78,84$?+QU_7FNAHH YW3_"%K9KIT<U_?7T&FMNLH
M;ID*PD*54Y506*J2 6)QGUYJ?1O#-OHMYJES%=W5P=2F,]PDY0KO( R %&.
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M'EY)4\+@8 P/7-7+GPM:RZV^L6UW=V-_+"(+B6V9!YZ#[N]64@D=B ".F<4
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MGV7%OVPK@=,>H/;TJ>Y\#:==Z$FDS7FHO&)UN9)WGWS32J059W8$G&U< 8'
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MK:I#>:B4-TZO'A]@VKP4P,#CBM;2M(BTE;@K<7-S+<2^;+-<OO=C@ #@
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M,09V(Y<&-5.&/(7 QQGGH5\'V8\/7FCO>ZC,EZACNKJ>?S)YE(VD%V!P,<8
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MD2RW<]IJTTEQ<B209\QSEF4@#'(!QTXZ5O:?9+I]E';+-//L',MQ(7=SZDT
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MKK>D0:]HUUI=U)*EM=(8Y?*(#%3U&2#C-9Y\)6AU#1KYKV],VD1-%:DLF-K
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MW]L>SD=3$9-_F?W=P7> =H;''N<@'.^%=,C_ .%A>.=ES>(R7%N%;[2[8WP
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M;R%6-V_<F+.TKM7;DC.><YJ]%/J&O?$&"TDU34;2QO/#D=\]K#+L\MVE (!
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M=K<73:G\1;1KZ\,-H(FM@;E\PDV^\[#G*_-SP: /0Z9++'!"\LKJD:*69F.
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MI=8=[ZSO]@BDFL+M[=ID'17*D9'Z^]6KWPEI-[<:7.T<L+Z8K1VWV>9H\1L
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M/B'PSINL&#R/ML"S>5NW;,C.,X&?RK5H **** "BBB@ HHHH **** "BBB@
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MK$$G!(X_ 4 >3:=!)I_PGT?7[:]O8[VWU;;&$N76,(UZR,AC!VL""<Y!/OC
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M/D0,4R Y)*+U&1TW9&#6_-H&NV%QK+6&M6]DM]ISI;6C3R.([D$ 3*S\J/F
M( ZD'K6U%X$\.1Z9J>G?8-]GJ<IENH7E=E9SCD#.%/ Y&#P*;I_@30].TNZT
M^-+N6*ZC\F1Y[N2201]D5B<J!Z+B@#CX;Z#4-/\ $>DZEIVHZ1JT>CN\VGRW
M+R0R*N?WL3AL$$D!NF> <\TFF7+Z?X8^'FDV\C1PZO;(TYEN9%#LML&6/=DE
M03CY5P#MQT)!] @\.6$4TT\WG7<TMO\ 96DN9"[>3U*#V)ZGJ>,DX%9TGP^\
M.3>&TT":TEEL8V5XO,N)&DB*\+L<G<NT<  XQ]30!RFMOK'@O2=1C_M@"#4=
M0M(H(UD9VTZ.5MLC!WYP=K;>RG.*OW>E6VF_%[PP;8S!9-/O 4>9W&1Y?/S$
M\G/)[X&:Z.+P5H2>'[G1)K5[JTN_^/@W4SRR2GL2['=D8&,'C'&*CL_ VCV>
MH6%_OU">[L$9+>6XOI7*JV,CEN1@8P>* .DKRCQ)IVI>*O#^K:G9:5<O>2SQ
MW>DWB21X1("3$5!;=ALR-T_Y:UZ=?V46HV,UG.TJQ3*4?RI"C8/7##D?A3;/
M3X;#3(M/MVE6"*,11YD)95 P/F// H \_P#%WB+^W_@9<>(M/N9[662T24-;
MS-&T;[@KKD'D [ABIM5TQK3XDZ#:0ZEJBP:O:W8OE^VR?O?+",I'/[L_,1\F
MW X&*VXOAWX=A\/W6@I#=#3+I_,FMS=R$,V<GG=D9(!..M:4OAG3Y]6T_5)6
MN7O+!&2WD-P_RA@ V1G!R ,Y]* /-I-<OO#OASQ-96U[<B"W\0QV$,\LK2/:
MP2>66P[$GC<V"3P2*Z75HI?#_CSPU!ILMR;+5O/M;RU>=W5@L>]9!N)*L,')
M'4'FMV/P9HBP:M!);//#JSE[V.>9G65L ;L$\'@=,8P/2K&G^'+'3KB&X#W-
MS/!$889+J9I6B0XR%STS@9/4X&2: /,KB^OE^">KW@U&^%W:ZG*D4_VJ3S%4
M780#=G)&WC![5TEY8G4?BY<Z9/?:@+"30EG>WBO)(U+F<KD;2"O 'W2,XY[Y
MU+GX<^'+N+4()H+EK:_F\^6V%W((A(6#,RIG"DD<D<\G&,UIQ^&-.BUO^V$-
MT+[[-]D\TW+M^Z!R%P2<\\YZY[T >62J^I_#OPQ]ON+FYDMO$\=HDKSOO*"Z
M9!D@\D* ,]1V->T0PI;P)#'NV( HW.6./<G)/XUSP\":"-!;1A#<?8S<?:E'
MVF3>DN[?O5\[E.[G@UT-O!':V\<$08(@VC<Q8_B3R3[GDT >5P./#VH?$W6+
M&.5[JP9985:9V7<;8,2RDX;DYY_"K6KO<:/X4\,>)-+O;J:^DGLUN"\[.+U)
ML!@RDXR2V1@?+CC KMD\+Z3'KEYJZP/]JO5"W"F5C%)A=@)CSM)V\9QT^IJ#
M3_!VD::+:.!)VMK20RVMM+.SQ0-SRJD]LG&<XSQB@#?K@?AS_P AWQS_ -AV
M3_T!:[UAN4C)&1C(ZUS5MX$T>RN;RXM9=3@EO)3-<-%J,R^8YZL0&QF@"/Q9
M=V\D^E60O[@2O?!38VOW[PB,L8RV1M4 AR2<8&.<UP=]>:E'\./B!&;R[MY-
M-U&1;7R;R0F!=L;; _!*_,W!XYKT*?P+H<]E:VSQW8:UN6NH;A;R43K(WWF\
MW=N.0<<GICT%1O\ #WPZ]KJ=J;:<0:FP>[074F)" /\ :XSM!)')QSF@#%DB
MDT/XD>'A;WM]*NIV-V;R.:Y>196C5&5@I.U3R1\H ]JY76G'B;X"W_B:\N)W
MU"ZW3,5G8+&!/M$07.-H4 8QR>>O->IOX8TZ75=.U.0W+W>G(T=LYN'^56 #
M C.#D 9SGI67/\-O#=Q%?VYANTL[]_-GLXKN1("^02P0' )QVH JZB<?&'0C
MC/\ Q)[K_P!#CKG;>\NM<^$%YXQ^WW5OKD:7-XLJ3,!"T3OB+9G;MVJ%*D<Y
MR>3FO0/^$8TW^VK35L7)O+2$P0N;EV C.,@@GYLX&2<GBJ__  A>BB2[VQ3)
M;7DWGW-FLS""63()8IG'.!D#@]P: ./\BX\3^/+.UO;[4[2WO_#"W<]M;W;Q
MA)3*@.WGY2..G7'.02#9T\KXFA\9+>W%UG3+B33[6-;AU,*1Q#$G!Y9F+$L>
MN,=*[)O#NGMXD77\3C4%@^SAQ,P7RLYV[<[<9YZ53O/!.C7FL7.J;+J"YNXQ
M'=?9KEXEN !@>8JD!L"@"O\ #7_DFGAS_KPB_E7550T71K+P_I,&F:<DB6D"
M[8U>5I"!]6)/X=*OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 445ROQ$TRZO_"%W/I[RK?V(%W (
MW9?,*'<R'!Y#*",>XH ZJJ6HS:C"+7^S[2*X+W")/YDNSRX3]YQP<D<<=Z\S
M;Q5:6OC.P\5Q>:WA[4;(VI;S"56Z\OS@57IDKF/CJP([<Z'B33Y]'TCP<OVB
MXCNGU^T^TA+A]CF1BSJ1G!4'  /0 8H [YK^)KR>Q@>.2^AA68PLVW 8L%R<
M' )5NQZ5F>#?$,GBGPK::S+:K:O.TH,*OO"[)&3K@9^[Z5SNAZ;:#XQ>*IA$
M1(MK9R@[V^\PDR>O/05QFFV@L?A1H&O6]Q=)?P:LJQLMPX54:\9638#M(()S
MD9/Y4 >S";4?[;,)M(O[,^SAQ<^;\_F[L;-F.FWG.:NUPX5S\9KJU-Q<FWE\
M/B0Q?:'VJQG*DJ,_*< ?=Q7#VT$L/PGTSQ$+^_?5+750L4SW<APIO2A4C.&!
M!.<@D^N * /<*KV=];7\<DEK*LJ1RO"S+TWJ=K#\""/PJ:1%EC:-\E6!4X..
M#[BO&=&N$\._"X7-H_V07&N-9SW&]@(8#=LK'@_*-O&1@C.<YH ]HHK@)_#E
MUIEUJMTNKI;VEWI<@_L^T:2/]ZG/GHV_*G! .,9R,USMC ]CX?\ AMK<5Y>M
MJ%Y=6MM<227+L)(I(FW(5)VXX';.1GKS0![#6;I>K+J\<UU:Q[K)7:.*7=S.
MRDABH_NY! .><$],$P>+[F>S\%Z[<VI(N(=/GDB*]0PC8@C\:K^ XXXOA]X<
M2(#9_9MN>/4QJ3^IH D\,^)#XB.K@V,EFVG7[V3)(ZLS%55MWR\#[W3)Z5G3
M^.4CL]1U6&Q\W1-.N#;W%T)?G.T@2.B;?F12>3N!.UL X&8/A_\ \?\ XS_[
M&&;_ -%15R>A_P"A?L[:Y;77%S;PZA!<!NHE\R08/ODB@#TV368K?5;2TG"K
M#?#%G<*V5D<+N*'T) )'7(!Z8YOW+RQVTCP1K)*JDJCOM#'T)P<?D:\U\8QW
M6F?"3PZSAEU&PETTKG[PE4HI'ZD5Z;)_JG_W30!C>$->?Q/X4T_6GMQ;M=QE
M_*#;@GS$8S@9Z5MUX1::2VG_  2TCQ5IU[?1:U9)&]N5N7V.#-M\KR\[2ISC
M&,D]2:[O209/B!XVLY7D-L+6S<0F0[4+)(6*C/&2.U '>52U*;484MSIUI%<
MLUPBS"67R]D1/S..#D@=N]>8:/)KMW\.?!]_:P+K9B@DEO-.GN-LETO3>I;A
MBA/0_P!X=\5+?ZC:7OA'PG>:3/J4,8\26\+PW$KK(F;@[XI!GYMIXYST% 'J
M]%>=#2(=8^*'B/3[VYOI+(Z?:R?9Q>2*H9C(#C#9 XZ# ]NE8F@Z[?WGAGP!
MIUW>ADU+[4DTMRS$3-%D1QN003D=L\E1G/2@#V"BO.9_#VNZ7I>JV.G:O:W4
MLMW!=6VF2,\:*F27@#EB0KA&P.@P1T)JK:WD^L>']8L]%LY=+UJ&_@>YT>_E
M*ID!284<'&R14.,8!R>,&@#U"BN.\":I:7S:O FGW>EW\$Z?:]-N3N%NQ0 >
M61P48+D8P.IQS3-8O?M_Q.TSPW=DC3O[-EOC%G"W,H<(%;^\%7<VWIT)Z"@#
M4\.>(;C6]0URTN+..V;3+P6PV2F0.-BMNS@8^]TKH*\AM$L]*LO'MJ;^[L86
MUJ&*-[<EYB66+$2$G^+.P<C /48K8T2UDF\=^(]#N(39V$^FV\OV2"X8B-F9
MU+*1C8Q &=O< Y/6@#T:BO+O#D\UW9P>!;V25M4TV_(O9=[!Y+:,B1)<YS^\
M#1H>?XFHU>[GT3Q#-<Z[92W&CS:G$]KK5E*2;3:Z 02IG*IN4J<<'<<C)H ]
M1HJKJ<\=KI5Y<37/V6**!W>XQGR@%)+8]NOX5YII+36?BSP*;;SX[;4+2Y66
M>:8F6_"PJZR2IR 2?F')/S8..E '7:AXDU%]1U6PT#38;^[TI(7GBFG\HR&0
M%@B'! .T9R>.0/<;NG:A!JEBEW;,&C8LN0<C<K%6&1P<$$9'!KA/#6B:?)\1
MO'$;PL41K15'FOT:W^;OSG)KF_#MR-%^$OA0VT@M5U/4EM+J=G8*L9DE(R01
MM!*JI(QPQH ]IHKS;6/#]YHFE>*[A=8\FWN-)FGAL+1I(_)EC0_O4._*@Y&0
M, \5O^!]%M[/1+'5!/=RW=]I]MY[37#NI(0$$*3A>N.!VH D\2>*;G0=8T6P
MCTV.Y_M6X-O'(;GR]C 9)8;#QC/2NE7<5&X -CD Y /UK@O'W_(W^ _^PJ__
M *+-=O=74%I&&GF6(,2 3Z@%C^0!/T!H GHKR.QFEM]0\#7ME-<R0WMY)')J
M$\I6;4$:-VW/&,C;D KDY&!P*9-I:7MA\2'GO=1<Z?/+):?Z;+^Y=;=7!'S9
M.#T!R!V R: /7ZXA_'5\F@^*]1.DP>;H%Q)$81='$JI&KEMVSK\W3'XUFZ=J
MTNO>)_#6C:I(7M9/#B:FZ$X6ZG8JN&'\04;FV],G/85CQVL=EX'^*UM"7\N.
MZN@H=BQ ^SIQD\X'04 >L:?<F]TVUNF4*9X4D*@]-P!Q^M6:\[@O6O?%WAKP
M[>9_LUM!^V"/)"W$P**%;^\%7<<=.<]A7.>(9KZQ\/\ Q(T>.\O!9:5]GFL)
M%N'#Q>:@9HMP.2H[*<C#?2@#V>N?M?$5Q-XYOO#LEG''';V27:3K*6,@9RN"
MN!M^Z>YKE];MHM!U+0-/ANKU8?$.H(M_-+=.Q?9&2$4D_)O; (7&1QTXJSHV
MGVVF_&75HK1/+B?18'\L$[5/FN,*.PXS@<9)/>@#H_#&MWNMV=VVHZ0^EW=K
M<M;R6[3+*/NJP8,O!R''T.1VK<K \4V-VWA2ZM-$>WM;IF0Q*Y\M'/F*60D<
MC?RN1S\U97@;5+>\U#5K5M+NM'U. 0_:M-F;=''D-M>)AP5;GICD=.>0#M**
MX/QQ;M<>,?!L'VJ\ABN;J>*9(;AT#H('." <9_VAR,\$52AL$E\67G@]9E:R
MT_387M;>]EDD:0.TF^0$,"2#L4$YV]L9- 'I-%>9V7VVTUCPOX.U76FU* PW
M<DUQDH;IXB L3'))VACD9YVC/>LW48S9P?%.UMYITAL;6&2T43-_H[?9V?Y.
M?E&XDX'K0!Z]17GEU/*OB?X<.L\H-S%,LV)#B4"UW#<,_-@\\UEV-K?^,O#-
MSJZ:S!IVI07TS->8<R6?ERG]V1O"[=@ *D8(.3DG- 'J]5UOK9]1DL%E4W44
M2RO&.JJQ(4GZE6_*O-O$]Y<Z/J^I7VM64MYH4TL135+&4^;IA"H"CIG(0L"Q
MQU#'.<XK1T/3;/\ X7#XHG6,[Q:6<H8.WWF\S)Z\]!0!VNIRWT.F7$FFVT=S
M>JA,,,LFQ7;T+8.*LQES$AD4*Y W*#D ]QGO7*?$XNGPWUV6*>>&6*V:1'AE
M:-@1[J1D>W2L;5K4W?C[PC;/=WJV]UIMR9XH[IT5]JQXX!X^\>1@GUH ]&HK
MBOAP7AA\2:=YLLEM8:Y/;VRRR%S'%MC8*"23@%CUJ;Q (+[QA8Z?NDO9Q92R
M_P!F,VR *65?/D;KD'*J &.22 ,$T =?17D'A_7;N7POX"T_4;R8VVHWUS;W
M4S2G=((S((HB_7#$*/<+CN:V/%(7P7H^I/8ZK<16U[?6@EBW_+I\,CA)&C/5
M0P#?0\C% 'H]%</K]HGA*UUK7M'NIEF&DRM'IP;=$SQ_-Y^#SN&0">X(SS6-
MJX?2_!WA?Q+H]Q,^I//9B63S68WRS;0ZR<_-G=D?W<<8H ]1K \:>()_"WA2
M^UJWLX[MK50QB>4QY!(&<X.>O3CZURNDZ+#JOQ!\71W=WJ3Q:?>64]M$M[(
MC>2'/\7())X/ R< 5S>JM%XG^ NI^);UGDU2X\R5Y!(08L3[1$!GA H V]#U
M/)S0![8AW(K>HS2UYWXE$5_J>M0PR37MQ:Z0I:!Y/+AL20["0,,GS6QQ@<!>
MHR*RUDNM5'PMEN-0O@]_;,+HQW+IYO\ HA8D@'&[.?FZ\\$4 >L45X]>:K<^
M$]-\>6MA=7$5G9:A9I"[2M(UK'.L?FE2Q)&-S$>AYKK]4T^#PVM]X@TB\F21
M=*F\NP#[XKAT4NLA!R2W&-W?(R: .RHKSC1M(N;ZW\->);778(01&UQ*@=C?
M+( #')E\%MQXX^4] .E=KK^E?VWH-[IPFD@>>)ECFC<JT;X^5@1SP<&@#2JG
MJLM_!I=Q+IEK%=7JKF&&63RU<^A;!Q7D0\0R-8^%-?9)%.B,MMKZ>:P5"6,&
M67HQ5U9^>0,>M;GC&-C\+/$NN0SW,$U[FZA:*=TVQ@A8\8/1D^8CIES0!Z&]
M_!#=6MI-(J75RK-'$#DG: 6/T&1S[BLGPSXBN-=N=;@N+..V?3;]K/"2F0/A
M%;=G Z[NF*YO5=-M+GXN>&Y)8RSR:5<%CO89VF/;T/;)_.L"YTR*ZT;XG7SS
M723V5[<3VQAN'C$<B6Z,'PI&3D#KGVQDY /8ZR[_ %J."TU1K)8[JZTZ+?+
M9-@!V[@I;!P<<].XJ30KB6\\/:;<S-NEFM8I';U8H"3^M>?Z%IMI!J7Q'DBB
M*O'<.%.]C]ZV4GOSDDG)H [SPUJS:]X8TS5WA$+7MM'.8P<A=R@XSWZUJ5XY
MIEH-+\._#+5K6XNEN[F>UM)B;ARCPO"V4V9VX&T8X[9Z\UIQ6=]XXB\2!=3A
ML[ZTU.:VBG_>>;9"-L(5PX ! R?[V3G- 'J%5[6^MKUK@6TJR?9Y3#(5Z!P
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MK77((8V5#</'YC&_60 %')?!;)X.,J>F*YJ/1K!?A?\ $-A 08;_ %%4&]L
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M0+DDG&XG'))JAXP\0W7AO3;6[MK2&X66\AMI/,D*[!(X7( !SU]170.6",4
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M01QJ@+$*  68D_B3R:=110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$^X_4U-XZ=SXN\"V[9^ROJCR/Z;UB8I^I-=./#VE#7FUL6:C4F01M/N/S 9
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M0IJ_Q"\*ZCJEG%]NNO#1N+C<F#YH:(Y]L9/':N@^+7_)+==_ZY)_Z,6NAO\
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MEZ=;V-HFR"WC$:+[#U]3ZF@!FJ:G::-IEQJ%]*(K:!=SL?T ]23P!ZFLB_\
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M'RPM]GW'8/X<,6/'0DUT-Z8QXW^'#J5\V6WN0Y!Y=1; C/J,YH ]%HKR+3;
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MZ\FD6T\3?"OQEJ^IPQS:M&]\KLXR]L8\B.-3U4!0O ZY.<Y->I>'^?#>E_\
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MGG)/K7I-_86VJ:?/8WD2RVTZ&.1&&00:QX/ GA6W,?E:#8@12^=&IB!"/SR
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M+>&7&O6:9D0-\K/\PY['C([U6N-'TO4/C!]AN+.":Q3PVH%L5'E$"X8 %.A
M]", CVKN=3TJPUFQ:RU*TBNK9B&,<JY&0<@_4&J\?AS2(KX7T5A%'="'[.LL
M>598AT08Z+[=* /)]+U)K#P=X7LKBXB@TAM=N[29[E3)$JJTWDHXR,KN"]3C
MY1V&*]!\+Z%;:+KVL-;:E%+]L$4\EE;0B.&!L$;E4$[2^,GGG&:TU\*Z"NDS
MZ4-*M3I\[%I+8IE&8G.<'OGG/K5C1M"TKP]8_8M(L(+.WW%BD*XRQ[GU/N:
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M'@JV\5W5M87=DUO%<W%O#OBDC1POW2Q8,1NZ';G'6M?XA<?#GQ)_V#;C_P!
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M<FETZ_AU33;:^MR?*N(EE4'J P! /OS7EMSIUE9M\5].M;2"*RBT^*>.VCC
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M8[#3A\./B/BTM1/'?ZF$_=KN55P0!W &1].* /7;;4+>YTZ*^$BI!)&LFYV
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M2+$?8_\ CVQ H\G_ './E_"M0D $DX [U7M;^SO@YL[N"X"'#&&0/M/O@\4
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M(0 L0]?N ,1V+-6%X\CMO^$I\$R7"1;#J;HS2 8QY+X!)]Z[I55$"*H55&
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MN"?H!BN.M9(F^!&EK&Z8764& >G^GDCZ<5Z_=:)I5[<VMS=:99SSVG_'O)+
MK-%_NDCC\*C/AS0VLULVT;3VM5?S!"ULA0-_>QC&?>@#G+LC_A=6EC/_ # K
MC_T='6MX[C\WX?>(TV;B=,N,#&>?+;%:?]CZ7]MCO?[-L_M<:A$G\A?,51T
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M] T:*WN;>/2;!(+K/VB-;9 LW^^,8;\:NV]O!:6\=O;0QPP1J%2.-0JJ!T
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M]%.D::=1_M$Z=:?;L8^T^2OFX]-V,U#>>'M%U&^2]O=)L;F[C7:D\UNK.H]
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MB^(&&ZC"YKIKB]TZ7QSXMT?Q%K1TQ;F*'R%F,*1SVIB (5I$/1_,R >I)]:
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M,21 1)@IC<#][ SUK+$FC)XG\6>'-<U9='AD2*.V@;R(XI++R54*AD0\*=_
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MU:66.0S0,[Q^6@;((<#GD<BNO&0HR<GN<5Y_XXFBA^(WP_:61$'VJ[Y9@/\
MEB!_,BNIU37],M(WADG$TC0RR&*!PTGEHA9FP#D#@#/JP]: +D&K:;=7;VMO
MJ%K-<IDM#',K.N#@Y .1S39=:TJ#/G:G91XE\CYYU'[S .SD_>P1QUYKR;3]
M1T\:O\-9X+JQM[$+.(;9)=[V\36[8620GEB< \ 9!'.,T-I6F-X+^*4ALK8M
M#?7HC/EC]WB%&&WT^;GCO0!Z_>7UK80>=>74%M'G:'GD"+GTR2*\XD\9ZZ?
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M!//MUI_A_7;+Q'HMKJ=C+&\<\22,BN&,190VQL=&&>10!I*JHH55"JHP !@
M54N])TV_N(;B\T^UN9H#F*2:%7:,_P"R2,C\*YW7=?O-)\>Z%9RWT$&D7=M=
M2W D4+M,2J02Y/ ^;VZ5N#Q#HC::FI#6-/-B[;%N?M*>66] V<9]J 'MHFDO
M9QVCZ79-;1-OCA-NA1&]0N, ^]5-6M-3M;5I/#%KI*7TTZM<&[5D61<8))09
M+=,9K0?4K&/[-OO;9?M1Q;[I5'FGT3GYOPJ:>>&U@>>XECAA09:21@JJ/4D]
M* *FCZ:=-TU;>6033.S2SR[<"21V+.<=ADG [# [4ZST?3-/E,MEIUI;2$8+
M0P*A(],@4?VQI@2U<ZC:;;L@6Q\]<3$] G/S?A6=9>,-%O\ Q#J&BP7UN;FR
M">9^]'S,0Q95'?:%R<=,^QH VY8HYXGBFC62-P59'&0P/4$'J*JPZ/IEMY/D
M:=:1>0K)%L@5?+5NH7 X![@=:X[Q+K>KZ-\,KG5K#Q!::A=PS ?;8K="CJTX
M3: "5!4'&>>5KJ;J9QXCL(DUFW@3RI#)IS*IDN.!A@2=P"X/0<YH LVNE:=8
MN[VFGVMNSC#M%"J%OK@<T#2--&GMIXT^T%DV=UMY*^6<G)RN,=:JOXI\/1%A
M)KVEH5)5@UY&,'I@\TD5UGQ%=$ZY:O;):HW]G@)OA.3F4MG.",#!&.* +']B
M:3]@2Q_LRR^QQG*6_P!G7RU/LN,"KD44<$2Q0QI'&@PJ(H  ] !6?'XBT2:X
MMH(]8T]YKH$V\:W*%I@"0=HS\W((X]#4]YJVFZ<P6^O[6V8KN FF5.,XSR>F
M>] "R:7I\UZMY+8VSW28VSM"I=<=,-C-)>Z1IFI2PRWVG6EU)"<Q-/"KE#ZJ
M2./PJ>"Y@NH_,MYHYDSC=&P89^HK'U#Q=H^F>(K/0[F]@CO+E&DVO(%"*.F<
M]R2 !WY]* -*_P!+T_585AU&QMKR)6W*EQ$L@!]0"#S3[BQL[NS-G<VL$UJ0
M%,,D89"!T&T\8KD/#WBWR[WQ#%XCUBQA6UU8V=JTI2!2OEHP49/)RQ[DUUM]
MJ5CID GO[RWM8B<!YY @/?J: &?V/IG]GII_]G6GV)/NV_D+Y:_1<8%<UJ/A
M2:\\<Z7J']GZ;)HUG9R6QAD/.796!5-A7C;ZUUMO<P7EO'<6TT<\$@W))$P9
M6'J"."*9>7UII\(FO+J&WB+!0\SA 2>@R>]  +"S%C]A%I +3;L\@1CR]OIM
MZ8]JEAABMX4A@C2*) %1$4*JCT '2N,\)^+#>?\ "2W.K:O9/8V.HF&"Z!2.
M(1>6C#YLX/+'DDUTW]O:/LN'_M6QVVT@BG/VA,1.>BMSP?8\T 27NDZ;J3QO
M?Z?:731YV-/"KE?ID<4Z[TVPOXTCO+*VN43[BS1*X7Z CBH#K^C"P%^=6L19
ME_+%P;A!'N_N[LXS[5(-7TPWJ60U&T^UR*'2#SUWLI&00N<D8H M111PQK'$
MBQQJ,*JC 'T%#Q1R-&SQHS1MN0L,E3@C(]#@D?0FJIUG2UBEE.I6@CAD\J1O
M/7"/_=//!]NM36E[::A!Y]E<PW,.2OF0R!UR.HR* )%AB1Y'6-%>0@NP4 M@
M8&?7BJUOI.G69E-MI]K 91B3RH57>/? YJ274+*"\ALY;NWCNILF*%Y 'DQU
MVKG)_"HO[9TLQW,G]I6>RU.+AO/7$)_VSGY?QH (]'TR&UEM8M.LTMYO];$L
M"A'_ -X8P?QI[:;8N+8-96S?93FWS$I\D]/DX^7\*BM]<TB[OVL+;5+*:\5!
M(;>.X5I I&0=H.<<CGWI;C6M*M+M;2YU*SAN6("PR3JKDGH,$YY[4 ++I&F3
MZA'J$NG6DE[&,)<O"ID7Z-C(H.D:8UQ+<'3K0S2@B20P+N<'J"<9-+=:OIMC
M*8KO4+2"18S*4EF52$'5L$]!Z]*DLKZTU*TCN[&ZANK:3E)H) Z-VX(X- "V
MEC:6$/DV=K!;19SLAC"+GUP*CDTO3YKP7<MC:O<@8$S0J7 _WL9K/\0>*M*\
M-M8QZA=112WMPD$2.X7J>6.>BJ,DGZ#O6+%XK:U\>:K;:EJUE'HD.FP7<,CE
M8T4N[#)<GG( [XYZ4 =3!I.G6L4T5OI]K%'-Q*D<*J)/]X <_C3K'3+#2XVC
MT^QMK1&.2MO$L8/U %*VHV*V"W[7EN+-E#BX,J^65/0ALXP<T6.HV6IV_P!H
ML+R"Z@W%?,@D#KD=1D=Z (FT;2WAEA;3;,Q32>;*A@7#O_>(QR?<T7.C:7>V
M<=G=:;9SVL9!2&6!612.F%(P*P/B3KNI>&/!5YK6ER0K<6IC^2:/>KAI%3GD
M$8W9KJ+9)H[=%GF\Z4#YG"!<GZ=J &3V-I<V1L[BU@EM2H4P21AD('0;3QBE
MM+.UT^V2VLK:&VMT^[%"@15^@' J"\UK2M/N([>]U*SMII" D<TZHS9X& 3W
MK/F\8:+!XI'A^2^MTO/LYF</*JA/F4*G/\1W$XZX'N* -6\TZQU%56^LK>Y5
M#E1/$K@'VR*C_L?2_M$=Q_9MGY\6/+D\A=R8Z8.,BL_0/%VC^)!>MIU[!(MK
M,\9Q(,LJX!?'4+DD ]#C/>KUKKFDWWG_ &35+*X\@9F\J=6\L>K8/ ^M #[W
M2=-U-HVO]/M;IH\[#/"K[<]<9'%+<Z7I]X8C=6-K.8O]6985;9],CBH[36])
MO[@6]GJ=G<3M%YPCAG5V,><;L YVYXSTJY--%;PO--(D<2#<[NP55'J2>E %
M7^Q],\^6?^S;/SI01))Y"[G!ZY..:FM+&TL(?)L[6"VBSG9#&$&?7 J&UUC3
M+V&>:UU&TGC@_P!<\<RL(^,_,0>..>:X_2?$5]XMOKR31M>L[=K'4W@%D1'*
ML]M&55G./GRQ)(8$#H,'K0!U]WHVEW\OFWFFV=S)C&^:!7./J12VFC:7I\K2
MV6FV=M(R[2\,"H2/3('3@50\6^);?PEX=N-5N(FF9"L<,"'#32,<*@^I_(9J
M.&T\4-8"XEU2S74"F[[,+;-NK8^[G.\^F[/OM[4 :,.B:3;K&L.EV4:QR^<@
M2W0!9/[PP.&]^M(-"T@1RQC2K$)*<R*+=,.?<8YJK9Z];VVCV+Z[>V=CJ#V:
M3W,4TJQE#M!<X)X .>:LW.OZ-9P03W.K6,,,ZAXI)+A%613C!4D\CD<^] #K
MC0])N[.*TN=+LIK:$YCADMT9$/J%(P*4Z-I;020'3;,PR/YDD9@7:[?WB,8)
M]ZEN]0LK&!9[N\@MXG("O+(%5B>@!)YKB="\1W^L:!XJEF\16-K]DU*6VL]3
M\M/)BC"1E6P3AA\QZD]: .SGTC3;JS2SN-/M);6,@I#)"K(I'3"D8%$FE:=-
M9QV<NGVKVL?W(6A4HOT7&!67>>+](TS6M.T6[U&W^VW<9DW-(J *!]X^FXX
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MU/\ 9&F&X^T'3K3SPNSS/(7=MQC&<9QCBB+2-,@MI;:+3K2.WF_UL20*%?\
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M*15!LP%Y1B"2S,<D \\X%1_V];ZUHVD7^GZ]9Z>+FX@+AS'+YF[!-OR1ASN
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M3M4_=/IQCL*]:N+6WNT"7$$4R@Y"R(& /XTU;.U2V-LMM"L!ZQ! %/X=* .
MU[7+73_B792ZCK+:=I=YI.RRO5,7DF7S"74NZLHROEG/&=H]JQM5TGP]::3X
M1M]+<W>G2^*8RDLY5EE5ED+[,  QENP&">G&*]4ETO3IK06DMA:R6P.X0O"I
M0'UVXQ3I=/LIUC6:TMY!&,('C!VCT&1Q0!YU+'%%XP^(EO;JB[]%MV,<8 RW
MERC.!WQC]*Z?X=WEM=_#[0!;7$<QATZWCD\M@VQQ$N5..A'I6^EC:13M/':P
M),V<R+& QSUYZU)!;PVL0BMX8XHP20D:A0,^PH X;Q9%:3?%#P6E\D+PF*^
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M2=7U_4='M+J)KBR94;YQEW()8*.X48R1ZGTKSF%[&W\ _"QXVMXW_M.SRRD
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MVUO;6Z-]EAAB21M[>4H4,2.IQU. .:FH **** "BBB@ HHHH **** "BBB@
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MO8:E9ZG'*]G.LHBD,4F,@HX )5@>0<$<'UH M,JNI5E#*PP01D$4%5+!BHW
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M-Z^]=%!XDT:YO19PZE;M<,AD1-V-ZCJRD\,!W(SB@"_!:V]JA2W@BA0G)6-
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MLK=I[F9(HEP"[G R3@#ZD\8JE;^(M'NK.ZNXM1M_(M"1<NS[?((Y(<'!7\:
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MY[RF%!GAI!U0-T+#!RH.>*KW?C'PW8FZ%SK=C&;1E2<><"8V.< X[\$X[8H
MUWMX) H>&-@HPH90<#VI5MX4D\Q88U?^\% /YU0D\0Z/#<65N^I6PFOE#VB;
MP3.IYRG]X8YXJTFH6CZC)IZW"&[CC$KPY^94/ 8^QP?R/I0!/'&D2;(T5%ZX
M48%->WADF29X8VECSL=E!9<]<'M4E8NH>+_#FES3Q7VMV,$EOM\Y'F&8]QP
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M)UZ?7!QZ]JMW^NZ7IDCI>7L43)'YL@//EIG&]\?=7(/)P.#0!?50JA5 "@8
M':EJM8ZA9:G;_:+"\M[N#)7S;>59%R.HR#BK- !1110 4444 %%%% !1110
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M9E /_?0P/<5ZH0#U&:3:O]T?E0!XIJD[RVGQ!.F@78@UFUNI[: AFEA01&3
M'4?*<_0UZ#H_B#PKXBU==8TEX+NYCLRDU\JD>1%D-Y;L>A)YV]>"?KU04#H
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MWMR)87D D4ACQL^]G\*=J/B"VN?%RPS1-I<UWHRR17 @+W%TK,Q$"<$#;U8
M%LMQC&2 =E<>*=!M8[*2?5K1$OEW6S&48E7&=P]L<YZ5)I/B'2=<AN)=.OHI
MTMGV38RIC.,\@X(XYS7DFD7UE+X1^%\<DB9M]042"08V[8Y 3SV#%1GIGCK5
MKQ$EUJ%_\4K31W\R]GL['RXXCEI0J,)57'4[<J0/4"@#IM;\5";Q?X2M]*U6
M;[/>73K-"(ML=Q&(V(=6*Y89 Y4D<CVJ]X8U&^D\7^,;.]OY+BVL9[<0>:%
MB5H0Y'  QD]?:N:U3Q3H>N:OX"NM,N$D2.^;S(XT):WS PV. /E.<#!]/2JN
MI0W.KR?%6QT>427UPMOY*1M\T@6!0ZKZ]&7ZG% 'I5IXETB]O(K2"]4S3H9(
M RLHG4=6C) #CW4FJP\;>&FO8[--:M'N)+G[(B(^[,V =F1QGD?GCK7(ZO>V
M?BZR\&#0Y4:^@U.VN7CC/SVD2*?-$@ZH /EP<9) JQX/>&ZUGQZME) ;R342
M\+9!/$*A6]P&SSZYH E^(OBQ++PU,VD:O+!>Q7<,&Z&/*.QE57CWE2NX*6.
M0PP?0UW]>%7.NZ>WP.30YG,6M6$MO%=V,BGSDD6Y0LQ7K@]=W0[L9R<5[G'(
MLL:R(<JP!!QCB@"&^O[73+-[N]G2"!,;G<X&2< >Y)( '<FJ]AK>G:FUREK<
M9DM2!<12(T;Q9&1N5@",CD$CFL/XB:C#I?AJ*XN+.*XB^VVZM).A>.U_>#]\
MP')"XSC(YQ7 W?GZIJ7Q#LM*N[F]O-0TBV:VD,6TW "R;MNU0,$':#T.1R:
M/4[?Q'I.H7:V%MJ %S-$9(?D*^:@ZO&6&UP/5<BN>\$^)&7PC]LU[47FE;4K
MBU6:1,LY$K*BX48S@= */#_BOPSXHDTJXM+99-1LHFW^9 5;304PX9B,+T"X
MSS] 2.%\(ZN?#TMKK5]-'=:'-J%W:L."VGRO,[+* .JNIP3U Z'!(H ]7N_&
M'A^QN)K>YU6".>",220G)=0>F5 SGVZ^U6H]>TJ71X=7COH7L)@#%.K9#Y.
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M(&>!TIO_  D^CFRL+M+SS8M0&ZT$,3R/, ,DJB@L0!R>.* -<  8 P*0  8
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M26\U -V01GMT]<@#DU4/Q"\+#3Y+XZH/(BD:.4>1+OB9<;MZ;=R@9&20!R*
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MK3>(Y+JPCOY1+/<$L('XS"F%!*KD8 SU/-:=EXIT74=7DTJTOTDO4C,OE[&
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M1[$,4,A4J0P.W:5(#!L\;<9R1QS4*^+]":*_=[\0_P!GJ'NDN(GA>)2,@E'
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M,2H'R_, 2>.M;N@Z?-IUE)')J=W?Q22F6!KL?O(HV Q&2?F..>6YYP>E &H
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M<<'TH W:*YKX>WMUJ7P^T.]O9WGN9K57DE<Y9F/<UTM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<+\66C3P? \R[HEU.S+C;NR/.7/'?Z5W5<_XO\.W'B?3(+*"_CLQ%=17)=[<
MR[C&P8#&]<<CF@#F]8$6J^/[#6]'A34(]-TJ[%VT!#+/N \J#<,@L3O..WXC
M/.:=JD%UJ_P\U!#<>7$\\<MO!9ND%DS6Y40J O4'CDD\9X!KV9 P10Y!;')
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M]* *FD:K::YI5OJ5A(9+:X7<C,I4]<$$'D$$$$>U87Q"OQIOA4W#6$=W&+F
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MU'(]^E=?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !116)XKU=M(T21H687=P1!;D(6V.Y"[R!_
M"N=Q]A0!S=GXNO\ _A9HLKK"Z%J44EOIK_WI[=CYA_X%E@/4(N*ZK5O$>DZ'
M<6D&HW8@DNWV0 HQ#-@G&0,#@'K7"^-_"<NG^![>ZTW5[Z>XT1HKK38I$B8%
MTQA?DC#,2N1UY)YS5CQ%K,&M2^!=1ACF1?[32>:-XF#6X\IP=XQ\N&8#)H Z
M!?B!X=:*[9;FY,EHVV>W^Q3>>G&<F+9OVXYW8Q[UJ+XATN32[348;KSK:\ -
ML849VFR,X50-Q. 2>.,'.,&N7T>XA@^*'C"XF)2%[6S"R,I"N463> >A(R,X
MKB-'-SI/@WP'JMU9:C)I^G)=6VI16WF)-;F0C:Y52&P-O/LWO0!Z@_CKP[%I
M$^IRWYCMK>?[-/OA</%+D#8R;=RG)'4=Q5G3O%6CZKJTVEVER[7D4?G%'A=-
M\><;T+ !USQE<BO/O%2:3=_#O6[O0],NU34+BU/FRQRF6\994+-L?YR HZGK
M@]@"=C66:[^*%DUE(5,FA7,$=PH.Q9'9"@+= >,@4 ,^(GBJ%?#!?2=1O89E
MOH8%GMHW6.1O.573S-N#@;NAZ@CJ,5T]WXQT.RU&ZTZ2ZE>]MHQ+);PVTDC[
M2>,!5);H>F<8YKRZXU,-\&;?P[)87T>M:=+:PW%G]DD9@4N$)8$*000,@@\Y
MKL[&YB_X6]JET=Z0-HT""22-E&Y9'9ER1U ()'44 :J?$'PQ)!8SQZD7M[UE
M2*=8)#&K,<!7?;B-B>,,0:TM4\1:=I!E%U),3#'YTH@MWF,4?/S,$!VC@]?0
M^AKRA@W_  H2>R$,WVO^T2PMQ$WF8^W>9G;C/W/F^E;5_?V>B^/-:?7K?5'T
MO6$@EL;JR\]XVVQ!&B98CU)&1QWH [.?QKX>MY;&-]21FOX3-:^6C.)D SE2
MH.3R..I) QS6?JOQ"TJT\%:CXCL!/=I9L\+1"WD5DF'\,BD H 2,DXX/N*Q'
MM[6Q\9^ H;33GL+2VAOOW!4D6XD5=@<\[2W/!/7(YK%U*WGOO"7Q/M[2":66
MXO6FA18SF5 D>67CYAE6Z>E 'KEE=I?6B7$:RJK=I87B;_OEP"/RKB?$5W>1
M_$_0-+35KNUL+ZTN))XXY  60#:02#CKVKLM+OH=2TZ&[MQ*(9%!4RQM&2/7
M:P!'XBN!\6M8R?%GPW)>P">RM[.Z6=FMS+'&S ;0W! )Q0!U>GA+2^O9X]9N
M[^V@C"30-^^,<G# KL7))5N1SVQ7&Z7KLFMZ+<>)I+_6K>ZL;VXE\F""<P2P
MH[*L+)M*$$ 9(&X'))%=7H]_H=OJ=S;:-:"**1#=7<J0&*%" JCJH!8@=NRG
M/;/,^#[A(OA9K$4HDCE$E^WE/&RN0\CE,*1DY!&/7- %OPK>K=Z1HOBF\UG5
M8YI;5!=VTB2F&ZED4$>7&P[$G'E#D>HKJ;3Q3HUY!?RK>"(:<<7B7"-"\'&0
M65P" 1R#T/:O.I#<V_P\\":G':7MS!HWE?VC:VV])XU,#1,P"D-E2W3T/IFI
MM<M;37?"NK:MX1TF\GG+VLTDUP)EDOA#(',8$OS-A5Z]">!GG !W:^+M)>XN
M;8/<B[M[;[4;9K2597BSC<B%06&>..AZXKGV\8Z5K_P\75M0OM1T6WN"A\^W
MCDCD3,GRA7VD-G !(R.2.,UHZ1XATSQ7,;K3--G,RVS1RW5S:-"T6?\ EB&8
M L<\D*2!CD],\#)*TG[/$6E_9;M;VW6W@>!K9U?S%N%+* 1DX"DG'% 'JI\0
MZ8OB%=!,T@U)HC.L)@DP8QP6#;=N,\=>O%*=?TT1W;M,ZBUF%O)NA<$R'&%4
M$?.3D<+GJ*YSQW!<1)HWBS2+=[N[TJX!,4/WKBVEPDB#WY5AZ;:I>,=-O],\
M,Z'>);7-\=.U%;W4HK-F$D@=9!*Z;2#PTA( /0>U '8:7X@T[6+B[MK25_M-
MHP6XMYHFBDCW#*DJP!P1T/0UB_$R]O-+^'^K:EI]W-:WEK&)(I(ST.X#D'@\
M$]:3PG+H6J:A<ZOHMA>?O(EBEO[L3*TF#P@\WE@.YZ#( SSB'XL9D^&FM6T:
M/)//$$BBC4LSG>O  Y- "W^F:_!X:74=%\07C:C%;B80WBQRQ7!"Y*,-H(ST
MRI&*L>'_ ![IFM>%]&U:3=%-J:LL=K&C2.9$SY@4*"2!M//ICUJ"\\5"/PND
M&C6=YJ.JR6PB@@BMW #E< NQ 5%!ZDD5S5CIDG@/3?!F@7,3A%2X-QJEO:&>
M2&5OF,49"L5WEB,XR0O8\@ ZK6_'VFZ?X3_MVR$UY&\XMD"0/\DA?81(,97!
MZ@X)Z#DBMFX\06%M%$[BZ9Y4:18$M)6FV@X),87<!]0.H]:\F,-P?AAXDMDL
M=0\RW\0FX9)()"YC^U(^1D9<[02<9]ZW];U6#3/'4>N:G;ZL=!U+3HX(KJV6
M=3!(DCG#HF& 8/D9'X=: /0M+U6QUO38=1TVY2XM)AF.1.AYP>#R""""#R*H
MZCXLT72M473+N[9;UH3,L"0N[.HP/E"@[CR.!D^U'A:UL;71%&FZ;)I]G+(T
ML<,H8.03]]E;E2W7!YY&<'(&#JDBK\8-$D8-Y<>F7$;R;3M5F9"H+= 2 >*
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MWPL$,3[-K!B-ISS@ YX-2?$>WOC9:)J5I!+<0Z7JT%Y=P0J6=H5R&(4<L5W
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M+Q=IL[3VD$:7$B*24N+9B-Q /1@IW ]>,'@FNFBECGA2:)@\<BAE8="#R#0
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ML=7:/4-,B-K)/;2LTQ\AU/49R6( 7@\]  <>N44 >72"7[%\,@+2[W6CQ&Y
MMI,P 6Y0[_E^7YCCFKOB32+^V\;Q_P!F#_1/$\/V/40&P8S&,^:/<Q;T^NVO
M1*PM'\.S:?J,]]?:O=ZG.Q=8#<!%%O&S!BBA0,YPN2?[HZ4 ;:(L:*B*%11A
M5 P *XWQ-J$UOXRTFVFL[M-/EMI<WUG:M+*9-RXAWJI,:D#)(QD@<C!KM**
M/$M+BU;2_"7A_44T?4I!H6MW4M[:&%O,,<C2KO0'_6%0X.1GKUX..M\1W/\
MPE7@#Q-+H^D7(^T6)5))+5HI;IP#P$(#$ 8 )')) Z5Z!10!YMK%]_I_@3Q
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M Y))JU7&_$>ROY])TR_L+!]1.F:A'=S62#+3Q!71@H[L ^0/:@#1C\8Z<_\
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M2-Y"A4%MN >">>F*J^!]6O[70],\*W_AN_35--V6[R26Q^RA4.!,LI^4_+R
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MK=C+"Q&5RJYX(Z-G;[UY[8:?JECX+\,ZB^@W]VNDZC>->Z<ULZS-%,\F'1&
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MV,%T(981,@<1R@!U!Y&0"<'VJOK6L6>@:3/J=^[);P@;MJY))(50!ZDD#\:
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M'8</D$@*!W)('('4@4_0?$5EXA@N7M5EBFM)VMKFWG4+)#(O56 )'X@D'UH
MUJ*0G:I)S@#/ S7&R_$O2(M-O-0%CJKVEC=/;7<JVO$!4@,S9(. 3VR1CD4
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MG*G>!WWJPB/LPKT&L30O#,&A23S?VAJ.H7$N1Y^H7!E=$R3L7@87)_'C.<#
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M$7FNV%W8!)5\CW&.M>P44 <5-;/KOCK1?$$5K>066DVEQYC3VSQO(\H4! C
M,< ,2<8S@#/;DX=+U1/@WI6E-I5^-0AU))9+?[.VY5%V92>F,;.?TZU[#10
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M(OU!-8DFB6^H>%?"5AJFGZQ:7-GIP5-0L8I!/8SHD:E?E!.&Y[$';]#7IM%
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M4?S(_E C0D$JV=Q+$\ @#'.:=I$,7@7PQ';W4UU.LEWY=M#)-YL@,CX2/>Q
M)YR<D 9/.!4'A.TU#3/$_BB"YTZ=(+S43>0W>5\ID:-% '.=V5/&/Q]=3Q?9
MV^H:']CO=)DU2SGE5+B&('>J<_.N"#E2 >.?3F@"_INIG4&NHWLKFTEMI1$Z
M3[?F)56!4JQ!&&'XYJ35-3M-&TRXU&^E$5M;IOD?&>/0 <DDX '<FN<\#:?J
MFEC5+6XN[ZZTA)D_LQ]0!\\)M^<-D!MH;@;@#P>V*G^(6@WOB/P7>Z?IS*+W
M='- KG"NT;JX4_7;CZXH L)XHMSK%KH^H6-YI]Q?1LUJ;C9MFVC+*&1CA@.<
M''M7">%O%UMX3T/66N=-U:YLH-;O!-=00^8ENGFX!<ELD =<9P.M='?6UUXO
MUCPQ<_V==V*:9<F]NC<Q["C!"HB7^_ECR5RN%Z\@5EV-AJMIX9\5>'6TBY:^
MU&]O6MF* P-'.3M<R#@ !LD'YN, $T 7]3>&;XK^$KNWE+Q7.GWCA@Y*LH6,
MJ0.G1CT]:O:/KGAZV_X2K48H+BQ6RNBVIR7&?F=8U)91D\;<< #/I6<-$NM,
M\8>"X8;:XGLM)TV:SFNEC^4,4C5,_78>G3O5(64L6F?$5M1TF=[:^E>:".4^
M4+E/)5  W\)+# SSR.* .F'C2V75-,TZ?3-1AGU2,RVFY$8.HP6SM8X*@@D'
ML?K3#X\TX20O]EO#93:C_9BW@5/+\_<4QC=NV[@5SMZ^W-<QHE^J:OH,NNZ/
MXF2?3XOL5I<W=E&L,;R[4+.T;L2S85<G YZ<YK/U*S\2ZKIUO)J'A_4;C5K+
M78KB1U9/)$"39 @7=C[F,G )P=QH [2P\57UWX[UK16TJX%KI\$#"16C.2_F
M$N1NS@A5  !/'(&:B\/^(?#UEX4EU&PMKJULVOY81!+EI9+AI2I506/+.>!G
M\A4>GV^HV'Q+UN^ETNY-GJ5G:E+A-K)&8@^]6YSGYA@ '-<O#X;UV7P3 8-/
MG34=+\1MJ\=I+A#<1^:[!03QDJWKU% '?P>*;=]9DT>ZLKNSU 6YN8H)@C&>
M,'!*%&()!X(R#^'-9%M\3-,N=.T_4ETS54TZ\N?LOVMX5"0R&0Q@/\V<$CJH
M(&><'BEFM)=>\;:)X@6SN[:TTBUN"QGA*2222A5V!#R=H#$GIDC&><<K'HVK
MK\';#1CI-[_:46HK*]OY?(079ESGI]WW]J /7JQU\16[>)KC0/LMT+V&S%Z"
M0FR2,L5&T[NN01@XK71@Z*P! (SR,'\CTKB=2BU#3/BE%K,>E7E[9W6D"Q#6
MH4^7*LQ?Y\D;00W7VH L-\1=*70;+6&M-0%O=WWV%5$(9DD\PQ_, QXR#TR3
MV%7],\76E_JM_IMQ9WFG75E"MPRWJHH>$Y D!5B,<'.<$=Q7G]OH^N1^!-+L
M)M$O%NH/$8O'10&_<BY:0N,'.,'H0">PK;US1+_6_&>O+#;W$-M?^&SIT5V\
M9""8LYP>X&&'./4=: *OC36TUB'PA=V]C?QVL^NV;6]TY"QRH7R"5#;@&&"-
MR]NW&>NU?Q?;:3!J%R+&]N[73C_ILUL$*P_*&/#,"V%()V@X!]>*XBY;7]0\
M*^%M,?POJ27^D:E9&Z&$\LK"<%D8MA@0,^@[GIFS'9WN@>*-9@O?!<FN6NIW
M9O+.[ABA<QEP-T<I<C: 1UR>M '17OQ!TZWU".RM=/U/49IM/_M&W%G '$\6
M5 V9(R?FSVZ>I /4P2^?;Q3>6\?F(&V2##+D9P1V-<5!8WT'Q/TZ[?3G6TBT
M(V4DMO$1"DQD1]J]]N%/.,#BNYH Y*/Q)>7?C^_\.-I=P+."SC<RK)&,[V8;
MS\P(7"X&/FZ\#BN6\#>++;P[X*M%N[+4)+0ZE<027JH&CA9[EU7>68,>2.0&
MQGGFNC%OJ&G_ !3O=1.FW,UC>:9#$MQ%@K&T;N6##.<X88 !S7*-HVL'X.SZ
M-_9-[_:3:D9A;^7R4^U^;G/3[GOUXH ]#U3Q)%I[WB06%W?O91"6Z6UV?NE(
M) ^=ERV 3M&3C'J,W])U6SUO2;74["7S;2ZC$D3XQD'U'8^U>?WUK=Z-XYU3
M4;CPE+K^EZPL,L4D$$;RVTBQA"C+(1A2%!SD8KT#2HG@TR!)+6"T?;DV\ &R
M+)SM&.#C."1U.30!Q?Q50BS\.O')+$\NNVEO(T4K(6C8L&4E2,@UWT<:0QK'
M&H5%& !VKA_B9:7U_9Z%'I^G75[):ZQ;7DJP)G$49)8Y) S[9K<_MZ\N;RUM
M;70]1C\V4>;/<1*D<2#EB?FR20,# ZD4 5M1\<Z?IEL+Z>UNSI(N?LSZB@0Q
M(^_9DC=NVAOEW!<9]N:35?'6GZ4=5=K2\GM]):-;Z>%4VPEP#T+ M@,"< \'
MN>*Y'P]IM_HB2^&K[P2E_<1SR?9-6,,36\D;.65Y6)W C/( ).*3Q?8^(M;L
MO%^FW&BWUU(RXTIHF46PBVKSC<,R9#=03T P* .^O/$<-O?2V5M:7-]<0VRW
M<L=MLRL;%@I&YER25;@9Z>XRDOB2/")9V%W?7+6JW36\&P-'&V=NXNRC)PP
MSSM-<?XBT?\ MIX;E]+UG2]8MM/0V.HV()D#Y;,,FPD8R%.&X^8\CFJT]CKF
MC>(;;6=9\-?\)#'J&F6T%\+6*.22VN8P<E58@;&W'H1T^F0#T'0-=L?$NB6V
MK:;(SVMP"5WKM92"05([$$$5D^,O$MYX>;18[33Y;DZAJ,5JSHR#:"<E0&89
M9@I Z >HXSKZ)$\6E1;]/AT\L2XM8@H$0)X!V\;L=<<9SUZU@^/[&^N;?0+J
MQLIKS^S]9M[N:*'!?RU#@D D9QN'% &I/XD1+R6RMM.O+R]@@2>XMX#'N@#9
MVJQ9PNXX; !/3T()M:'K=CXBTB'4].E+V\N1\R[65@<,K ]""""*Y6P@U'P_
MX\UO4[G3[N;3]<BMYE>!/-:WFC388W"Y/(P0PX]ZU/ NA7&A:)="[3RI[Z_N
M+YH,@^3YCY"9'&0,9QQG- %WQ)XFLO"]K;7-]%<O%<7"6ZF"/?M9S@$\].?K
MZ U0T[QU97VL7>D2Z;JEEJ$$'VF.WNH K7$6<;H\,<\]C@_D<9_Q4D:+P]I<
MBQM*R:U9,(TQEB)1P,\9-336<NJ^.[/Q"MI<Q6>EV$T0:2%DDGDD(^54(W84
M*><8RPQGG  [3/B/I>I:<-4^PZG;:5]E>Z-_/ !"H1MI3()._P! !ST'((K1
M3Q9;IJUEIU]87MA-?JQM&N FV9E&2F58[6QSAL5QEEX4U;4_@,OADP266K1Q
M<13C:"Z3>8HSTP< 9]ZV=0M[SQC=^%V?3;NP;3KY;^\-Q'L\MD1@(U/\>68<
MKD8!YZ"@#9TWQ?::E;:S,+.\MSI$KQ74=P(U;<J[CC#D8Q@@D@&JEQJNDW/B
M[PTEYI=_%JL\$\ED\@VK"-@,BOAL%L;>,'&>U4M4\-7Y^(*W5D@_LG5[=5U;
MGHT# H??>I\LCTS5C7[6[F^(_A2\AL[B2TLTNUN)T3*QF1%5,_4@].G>@#.^
M(&OP7_@7Q-'9V=[<PVL,L$EW RJB3*O(^\&8*2-V 0.>N#C?L=:6TTG3+*WM
M+B^O?[/CG,%N4!5-H )+LH&3D#G)P?0XX5+#7M*\!^*/!\NAW]U<2"[-E=P*
MK17"2EF!+$C# L<KU],U9NM/U/2=;TO6[GPI-J]C/I,-C=6BQQ2W%K+&6(8*
M3@@[B.#]?2@#T#P]K]CXFT:+4]/9_)D+*4D7:\;J<,K#L017+?&1G@^&6J7D
M$LL-S 8C%-$Y1TS*@."/4$BNJT&-DTQ6;3(M,\QBZVD:J#&#TW;>-W<XX&<9
M.,GG/BQ87VK_  \U'2]-LY[N]NC&(XXES]V1&.3T' /6@#L+6VBM+9(($V1H
M, 9)_4]:PM7\8VFDV]]=FRO;JST]]EY<6ZH5A. 6X+!FV@@G:#CZ@BEF\1WL
MD<<5GX?U47$S+&&FB54BR0"[G=T49.!G.,5R-O8WN@>)-:L[WP6VN6^H7TEY
M97T,43 >9R8Y2Y&P*<\\\=J .@7QA<W'CR#1K339KBP?2_MRSQ/%^]#NJJXW
M,,*!N]SGI@9IGASQM+J.G:QJ&JV$]E;V=]+;J24<#8P01C:Q9G+>V,G )XJ+
M[!J6G_$S3]0&F--:2:(+!I+4*(H9!*&.02"J8Z=>F*P'\-Z[=>$_%.B1:8\=
MW_;,NHVDDY3R+D>>LJ*.>=P!!R  >M ':+XQMDUB72;S3[ZTOUM3=Q0R*C&>
M,'!V%&89!Z@D'OTIOAKQI;>*3;R6.EZI':7%L;B.\F@"PG#;2FX,?F[XZ<'G
MBLW0;MKU'N1X(DT1X86$S2V\8=W(QLBV'+#U8@#CISQ<^&MG=Z;\/M(T^_M9
MK6[M8?*EBE7!!!/X$8(Z4 =)>WEOIUC/>W<RPVUO&TDLC=%4#)-8B>,+5+[3
M;>]L;VQ34SMLY[A4V2/C(0[6)5B.0& STZ\4_P ;:%-XE\%ZMH]M((Y[J K&
MS' W @@'V)&#]:YZ^M=0\7V'AFSGTRZL;FQO[>]OC.FU8C""2$;H^YL %<\$
MDXZ4 5YB/%7Q!UW0]8T>ZGL(+*WCB5GBQ;ES(3,,/D$X7!7+#:.!7H=K;K:6
MD-LCR.L4:QAI&+,0!C))Y)]ZY'2(+N+XG^(;V6QNDL[NUM8H+AHSL=H]^X>H
M^\.3@&NSH \\\$2CQ_;7WB35BUQ:27<D.GV;,?)BA0X#%.C.QR23G';%:UZ;
M?P)#K.ORR7UQIGD1$6J.93 4+[M@8X53N7C.!@^U9/A.SO\ X>M?:%/IEY=Z
M,UT]QI]Y9Q^;L1SDQR(/F!![@$'/:M#QJNI:YX"URVMM-GWW5L8;6 K^]D8]
MR,X4?7GKG'2@#0M_&-O<*Y;2]3AW21Q6OG0A?MC.I8>5EN<!23G& ,FFP>-]
M+_XG*7ZSZ=/HZJ]Y#<A2RHPRK*4+!@>V#G/&,UC^+M,U*_T#P]J>GZ7]NGTJ
M=)YM,N%"F9#&T;KAN-PW9'TXSQ5#7-'OO%?@G4UT?PR-$G/DR00W44<4MR\<
M@<JP0D!?EP,GDGL!R 2ZK?27?Q4\$M)IU_9,ZWC?Z0R[7'D' PKL PSSG!Y_
M*RWB?3M)T/QEK&B:1=M=V-R[7D<S!=\RQJ2_S,<*!MX&#QP*AN;K5==\8^#M
M43PWJEO%9FZ^UB=47RB\07NW(![]QTSR*K#1=4O-#^(UFFGW"3:I+-)9"5=H
MF!A5!@GIDKT.* .\T&]N-1T2TNKFWE@FDB1F$NS+$J#N&PD8/^11J>LPZ;<6
M=J8I)[J]=D@AC*@MM4LQRQ P /6HO#4L\OAVQ^TV4]G(D*1F*?:'&% )(!..
M<UE^--+LM92QL]2TR[N;4N[B[LMWG6<@ V.NWYN<D< ]N,9H T$\20-96\QL
MKM+FYGDMXK)@@E9T+!OXMN $8YW8QCGD"J=MXYTJ6WU-KA+BTN=,G2WN;290
M91(^/+"A20V_(VX//M7&76B>*8M(T/5+RS?Q ^D7UROV2Z5?/N;-_E1V!X,@
M !P>?7G-7]9TK4M<\+M?:'X:72;JUO+:]M;*>..&6Y:%BQ#["0 <X4$YR#G&
M: .E;QE;PW6HV=SIFH07EC:?;6@81DR0\@LK!RI(((()!^M//C*P%KX>NOLU
MWY&O-&MJ^U?D9T+J'&[(X!Z9Z57@U'5/%6CW\)T.\TJ*2SDAQ?[5=Y67 VA6
M/RCGDXSD8'!KCX(-=N/#_@*R'AK4DET2]MUN_,V+_JX70LN6P5[Y.!R,9[ '
M7IX\M9]8NM,MM'UBXFM+N.UN#%; K%O&0[?-PF#UZ^U8ESXKL=%\$^+-;\.Z
M3=">UU"=;E+A@/\ 2<+ND(9C\H)7@>G '6M3PI;W=OXP\77%Q97,,%[=12VT
MLD>%D58E0X].1T.,US<F@ZO?> O'^G1Z=<)=:AJ5S<VD<B[?.C;85(SW.T\'
M!H [)_%R6NJ:/IE[I6HV]QJFY87?R3&&4;B&*R'!P,@=^W/%:MKJJ7>K7VGI
M;S@V>P23-M\LLPW!1ALYP03D#J/6N:\66DNN_#Z2]\F73+^P4:A:&YVAX98A
MN!;!(&<$'GHWX5N>&;2YMM%CEOT"ZA>,;J[ _AD?G;]%&$'LHH ?XEU>70?#
M6HZM#:-=O9V[S>4K!<A5))))' QDXY] :S=-\5$Z!HLU]:7/]HZC&BPVR^7O
MG;RP[.N&VA<9.6(QZ<@'0\56,^I^$-;L+5-]Q=6$\,2YQEVC8 9^I%<2+#65
M7P1X@32+P?V+"UI>6+[?.*/$J-(J@G.UEZ=2.U ':Z/XCM=7OK[3_)GM=0L6
M47%K<!0ZAAE6!4D,I[$'ZXK5EBCGB:*50R,,$'O7*Z1I4UUX^U+Q0T,MO;26
M,5C DJE'EVLSLY4\J.0HS@\'C&,]5+((8FD978*,X12Q/T ZT <'\'U,O@D7
M4TLLUP]W<(TLTC.Q59&4#+$\  5U.IZ_#IVIV>F);7%U?W<<DL<,.T?(F-S$
ML0 ,LHZYY^M<9\.[C4?#7A :?J/AW5UN4N9Y-L<*L"'D+#!W>AJ[?WGB*ZU?
M1GO-%OVTFXMY6GMK-E$D<Q8&-)CN'RA.N#@MUR!0!?D^(>D)X>TW6OL]^UK?
MW0M%58<O%(7*$. >S ],YQQFKNF>+K2_U74--N+.\TZZLH5N'6]5%#PMD"0%
M6(Q\ISG!'<5Y[::+K5OX#TC2GT*\CN+/Q$MRZ(JL/)6Y:0LN#T"D8Z$]A6YK
MNAW^N>,M>6&WN(;;4/#9TZ*[>,A!,7D;![@88<X]1UH K>,];36$\'7=O87\
M=K/K]DUO=.0L<J%\C*AL@,,$;E'3MWU=*,=I\6O%#O(5B&FVLKF20D+S)D\G
M@<?2L&Y;7]1\+^%-.?POJ4=_I&IV37:X3RRL)Y9&+88$#([#H3TSK7>B7NK>
M+_%L36US;6NJZ,EC#=,GR^8%D#=/3>/8XXH V_\ A.+!(M.NI[2]@TW49%CM
M;^15$3%ON9 ;<H;L64>^*CE\=VJZW?Z1!H^KW5U8R0).(+<,%67.'^]]T8R>
M_/ .#CG)M+U7Q!\.M-\(7>EW-IJ$+6T%U*R_NHTA=295?HVY4X YRW( R:W/
M#]M=P_$?Q9=S65Q':7J6@MYWCPDAC1E?Z<D=>O:@#)^(^OP:C\/?$8L[.]GM
M[=7@:\@95C653@_Q!F56X) (SZX.._TW_D%VG_7%/_017DRZ=K^F_#/7O!,N
MA7]S=H+A;2ZA56BN(Y'+AMQ(PWS'*]:]'T_4;Q)]-TZ71KR)'LO,DN&*%(77
M \ML$_,>O&?YX -NBBB@#S[PM<GQWK/B#4-1+2Z987[Z=9V18B/]V!ND=>C,
MQ(QGH.E*=1E\)?$RPT&)YI=(UFTEEAMV8N;>>(%F"9Y"LH^[T!Z8J;0=+NO!
M&OZXAM)[G1-4NS?PS6T9D:"5A\Z.BY;!P"" 1ZXJ6/2+G7/'UMXIO+66UL=*
MM9(;&*5?WLKO]^0J.5&WY0I^8]<"@!(_B;IDFF0ZH-+U9=.:Z-K-=-"H2W?S
M/+!?YLXW?W0<9YP>*[:O(9-&U=O@Y?Z,-(O?[2EU%I4M_+Y*&[$N<]/N#UZ\
M5ZY&XDC5P& 89PP((^H/2@#+O=>BM=3&F6]K/>W_ )/VAH("@*1YP&8NR@9.
M0!G)P>P)K(G^(FC0>'DUKRKUX/M8LIHUA_>6\VX*5D&>""1Z^V:K36=_H7Q+
MNM<^RW%UI6IV,<$CVZ&1[>6,G;E!R5()Y .#U]:YS5?#.J1^&M6FBTZXDN]6
M\01ZDMI& 6BA61#\W. Q5"2,]\=J /2-'U9M7@GE;3;^P,4S1;+V((SXP=ZX
M)RISP?8UHTU'$D:N P# $!@0?Q!Z4Z@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D) &2<"EKA/BL
MD0\-6%RZ,6AU:S92H)(_?+G '7CM0!W=%<OIWC>WNM?FT74--OM)NU@-S"+T
M(%FB'5E96(R.X/(_.F?\)[8)=Z2LUK/%9ZM*(;.[9D*L[#*!E#;EW#ID?7%
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M:5J-Y=6MS8S:==?9+FUFVF02G;M52I*MNWJ <XYJ;3_%MM>>)'T"XM9;2_\
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M(KJ*8DT4C.L<B.R'#A6!*GW]*?0 4444 %%%% !1110 4444 %%%% !1110
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MEOLSQ[)0"I()'5>>O-7+K1M0B^)^B:A9Z1+_ &18Z=)9F5)(@$+$;0%+;L
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MCZW<&RN=/:0M''(<;)(P2=G)Y XP.E7KBSUB#XMMX@CT.[N-.&C_ & 212P
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MRD$=O4T =#117()XY(DTF6XTJ6WL=5O6L;>223$P<%@"\1485MAP<DX(R.:
M.OHHKF+_ ,6SVWBQO#MKHEQ=79L3>1OYJ(C@.$QDG@9)R3Z< YH Z>BN2L_'
MUC<>&[?5)H#:SS7;6/V6:51MG4L&4OTVC:S;O0=,\52_X6/']GUX)IRW%[HL
M2W$T-K=+*DT)&=\;X&<8.00#0!W5%<NWC$+K'AZQ^QH8M<A:6WN1<?(-J!RN
M-N2<'CU]JV-,U&34)+W-L(X;>X:".02;O-V\,0,#&#E?J#Z9(!H452U>WANM
M'O(;B))8FA?*.H8'@]C7(_!VV@@^%VBR10QI)-$S2.J@%SO;DGO0!W=%8&L^
M*(-,U$:;$;5[[R/M!2ZNA;HJ9('S$'DD'  [')'&>7N?B'=:K8>&+S0[-1%J
M6I?9+A9I0KHZAB8^ 1@[?O>G;G@ ]'HKC+#Q)J\_Q!U;2[JTMXK"RLX)21<9
MV[]Y+GY>?NXQV SGFH_^%E:>MQI+M%";#59U@MYH[I7E1G^X9(L956]<DC(R
M!0!V]%<AIOC2\U;5[JRM/#=XR6>H?8KJ9IXP(1M#;\9^;KT!)Q]<5U] !37=
M8T9W8*BC)9C@ 5S-UXOD^SZK>:;IC7UEI4KQ73K,$=F0 R")<'?MS@Y*Y((&
M:PO&.O3:C:^#Y])C2YTW4M4MW#&79YPVNX1A@X&54_48Q0!Z!;W,%W"LUM-'
M-$W1XV#*?Q%2UG:1I%EI4=P]I8QV<EY+]IN8XF)4RD ,?3L.@&>M<CXOOIM4
M\?\ A[P<)7BL+F.6]OPC%3-&@.V/(_A+#YAW'% '>+-&^[9(C;3@X8'!]*?7
M/ZAX.T>[@MUMK*WLIK::*:&6VB$94QNKA3MQE3MP0>/Q JA'XUO+KQ#J&D67
MAN\GDT^Y@AN7,\:A$D&[S.O. 0< YQG..X!U]!( ))P!WKAKOXFZ;:);7NV"
M72Y[D6WG1W:F9<L5$ABQG9D=<YP<XJQXAUO^U=*\16-CI::C;V,+PW;22!09
M-FXH@((9E!!.2HR0,YS@ ZL7=L4A<7$168@1-O&)#C.%]> >E35YGH6I6-EX
M-^',%]I'VQKD6\=M<-MVV\OE$AN><X!Z#\:W="U_5]1\>>(M,N+2%+/3S;QH
M5FR5#(S[L;>2V1D=L#KW .OIB312M(L<B.T;;7"L"5.,X/H<$4^N&@\56&G6
M?C#5+;P]+#+I=P3>HC1A[AEC#%R<X^[CN3[4 =S17)6?C62?6M&LKK1I[2#6
M(6>SN&E5MS*F\JRCE?ER03UQT%=;0 45S=QXI<ZCJEII]BEX^ELBW,?VC9+\
MRJ^53:<J PY)'0@9Q4MKXCDNO$.LZ*EB!<Z;%%,&,WR2B3=MYQE3\O/!H WZ
M9+-'!$TLTB1QKRSNP 'U)KE]-\<6^K:)HE[:V;_:]9W_ &6T=P,!,EV9L<*
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M*C8.2IP1NX^F,$V=!U_5]1\=>(],N;2%+/3V@C0K-DJ&C+AL;>2V1GTQWZD
MZ^BD;.T[0"<< G%<3-\0G@\+ZSK3Z.X.CW;VMW:_:!O7:1EAQ@CY@?<<^U '
M;TR*:*>/S(9$D3)&Y&!&0<$9'O67_;$K:A:6L-HMP)K1KIWBF!" 8  R!G<3
MP<C.&Z8KB)_%K6?PUAU3PUHL6GQS:D;9H6<*8BUQY;, H(+$Y^F<\XP0#TLS
M1K,L)D02L"RH6&2!U('XBGUYOJ4D]K\7-+NXM*634)M$G#PPNHW$2IC=(0.
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ML[?3I;6>Y5HU&]V1LA"V<?*?S[UV%% ' _9?%7AGQ9J\NE:-%K&DZO,MT/\
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MLK+PYJ&D6RP6(6$:NMTI26%, 8B^]O*@#G '7V/<-<P)<I;-/&)W4LD1<;F
MZD#J14M ')>#M-U+3M5\327U@]O%?ZDUW;NTB-N0HBX(5B0?ES^-=;3?,3S!
M'O7>1N"YYQZXIU ' Z3H^N>&4\1:5!IK7]K?W4UW8W*31JJ&4<I*&8, K=U#
M9!]>*@N_".HZ7HG@C2-.M'O4T6]AN+F99$0$*CAL!F!))?('IWKT6D) !)(
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MT73(K%-7T"STM;95DG6-([D-S+(ASN!&,8#%><#O69IOACQ):^$/!FF3Z/\
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MC5!@;N<%><=O6NVHH \D;PYXMNK'2)+[1(KC6+#6X[NZO7O$S<QJ[$>7_=0
MCY3C&. <UTUE9:WHGB_Q+?II#7L.JF"6W>">,*C)$$*R;R"!D9R W'OQ7:T4
M >;2>#=2TK0?!NEV=N;UM+U1;^\EC=$7GS"^T,P)^:3@>@K0\=:%/?ZUH-UI
MUS]FOIY)-.G(ZR6DB,T@X[KMW*>Q^M=S6/I_A?1]+UF]U>UM2M]>,6EE>1GZ
MX)V@DA02!G&.@]!0!K1QI#$D4:A(T4*JJ,  = *=110 4444 %%%% !1110
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M;VJMJOB"ZAD$'FJ%ACB*!0S=,X4DXSRV.0,UZ3"[20H[Q-$Q&2C$$J?3@D4
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M7&T!6^8'@L/>K/C/PU!XM\)ZAH\RIOGB/DNP_P!7(.5;\P/PS0!L_:;?[/\
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MB$DJ)(7#KD'!&1Z$$5/7!:5XWL;?P5IVJ+IEII4=[J,EFD)E"0POYD@+.X7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7F'Q3TO5XH-!N?#UE:WUOI/F22Z+(@9)X@JJ"(_X@@.,#D;@172?#?5;#6?
MMC>Z;#-!;NTI\F9MS1-YC%EW=P"2 ?3&>: ,R^^(=];?$F'P7#H=O+<SQ&:*
MX>_9$V[6;D"(D'Y3ZUT.C:SJ=[J][8:CI4-H((HY8I[>[\^.<,6!P2BD$%><
MCO7E/B*WN;K]IK3H;2]:RG?3F"7"1JY0^5+SAN#7I.G/_8O@^UTC4M2^S:C#
MI3O+<]3&(U >4_0L#0!U5%?.5I=O;>(?AK>:?.[K=7D]O)J;*(IM13S44M*@
MR<?,0-S$GDD"NAET6+Q!\?\ Q)HMS<7,6GRZ4KRQ6\ICWDB+T]SD^N.<@D$
M[V_\;M8?$O3/![Z:&&H6[3I=BX^Z KG!3;ZH?XN_X5U]>,:AIEOI7Q\\#Z7!
MO>WMM'>!/-;<Q54G')[\54LK>3PI\2/$?@QHWEM?$,"OICL"_E!B00,_PH"Y
M_P"V0]: /;+N?[+9SW&S?Y4;/M!QG SBO//$'Q,U?PS_ &"NI>%[=)=9?9%$
MNIDM"<H,/^YP/OCIGH:]#M;6&RM(K6WC$<,2!$4=@.E>.?'3_D8_ 7_7^_\
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MCKD#T K>L],\:3:3I-OXD^'L^N7VELS6]]+XACC<'?N4X4_> "C=U.VO;**
M/*;#_A)=,UF\U>T^$YCO[W(N93XCC;S<^H.1^G%5;73=9LM/N;"U^#R0VMS(
MLLD:>(HQ\RL'!7NGS*IPN.@KV"B@#SWPYI-WJ8U?3=>\"OI=GJ,6;JYEUD7D
MERPPH1F!WC"YP<X&/>N^@@CMK>*WA7;%$@1%SG"@8 J2B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBC/ZT %%%% !1110 4449YQWH ***
M.E !1110 4444 %%%!..M !1110 4444 %%%% !1110 449HS0 4444 %%!.
M.M% !11D9QWHH **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !111GG% !1110 4444 %%&<T4 %%%%
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M1":Y!<;\!3@ +G&3R?3'*^"M$O-#U?4(+.74!X:,,9M;?4&)>";+;UCW?,$
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MC7:03U5 K?+P.PKMX_%(BU^+1=1T^:TO;F!Y[0;U=+@+]Y%;(PXX)!XP>IH
MZ&D)"@DD #DDUROA[QLWB2>#[+H.HQVCRSPR74OEA(7C)&U@&).<=1D9.,]<
M)\38(I_AIXA$J*X2RD=<CHP7(- '5@@@$'(/0BJ\UC!->0W94K<0@JLBG!VG
MJI]5.!P>X!Z@&L-/$$.FV&E6"(LU[+9+,L32K&JHH499FZ9)  Y)Y[ D5K#Q
M_8ZII=G<V5G<R7-S?-I_V8XS%.@)8.PR H SD9R","@#KJK0V=O:2W%R!^]F
MYEE<\D#.!GLHR<#IR3U)-<_%XYL3I&H7MQ;RV\MA?C3IH79?]<655PV<;3O4
M[CC SGI2ZUK4:>'->.LZ%<26MI;L;F!'1Q/$4)8J25R, @]#P>.F0#J 00"#
MD'O17(MXOM-*_P"$;TZVT:]=-5MMUFD&PJ@2+>$Y8<XP,G [YX-/M?'=B=$U
MK4=2M;C3FT61H[V"0J[*0H8;2I(;<&&/>@#JZ*YG_A+FB\0Z?HMUH]W'=7\)
MG@:.2-D" C?N)88*Y!( ;KQFMZ^GEM;">>& SRQH66(,%WD#ID]* +%%<1X<
M\;2W'@C2M8U:UD%SJ+I';Q1%2;B21CA5&>  /XL8 )K:L/$L=QXAFT"]M9++
M4D@%RB,P=)HLXW(PZX/!! (]QS0!NT52U?5;30])N=3OY#';6Z;W(&2>P '<
MDD #U-97_"5"VUFQTS5-.GLI=05C9NSJZR,HR8V(/ROCG'0]B: .BHKA)?B9
M%'I5_JG]@:F;+3KQ[6]D)C!AV,%9L;OFY/1<\#K6[J?B>&RO'LK6%;N[C@%P
M\9G2(!&)"C+'[S;6P/;DCC(!O45E>&_$%CXIT"UUG3B_V:X!(60892"05(]0
M013+W7A%K']D65LUYJ"P?:9(PX18X\X!9CW8@X&#T.<"@#8HKC;CXCZ=!X<_
MMD6-\ZQWHL+J *OF6LV\*5<;O4C[N[.170Z/J5SJ<$\EUI5UIKQS-&L=R4)=
M0 0XVDC!SZ]C0!HT5SFH^+!8^)X] CTF]N;N6T:ZB:,QA) K!2 2W')Y+8Z<
M9R*R&^)2C0;O5AX>U(Q:?-)#J2[HP;5D;#=6^?'7Y<\>E '=45BW/B*(:E#I
MNGP&]O9;;[7L#A%2+. S,>F3P  2<'H!FL>Y^(VGVWAFYUDV%ZWV.[%E>6P"
M>9;2[PF&&[D988*YR"* .RHKF1XO,>(KS2;FQNYKAX;6"ZDC7SE50QDW!B H
M!&>^>,$U8\->*K3Q+]OBBB>"[T^?R+F%F5MK8R"&4X92.A_2@#>I-R[MNX;L
M9QGG%<KXQ\1:CHE[H%M8V7G+J&H);R/O4$##-M /<[3R> /<\<_#=3:7\5/$
M4UCHT]W=3:7:2-;P,BG=NDR69B%]!UR>W>@#TIG5 "S!02 ,G')I:X;4_%6A
M:OX5\/ZO<Z3<7ECJ-];B!6"C[/,7VJ7^;/#9Z9Z>]7-1\;O9Z]>Z+:^']3OK
MVU@2X*PF,"2-F*[E);M@\'!/IU- %W4O"%E?ZN^K17FHZ?>R(L<TME<F,2JN
M=H=>5.,G!QGFM33=/MM/MMMLTDGF'>\TLAD>0XZEB23P![ <#BN0\9:Y'JGA
M+Q3;6FF27UM96\T%Q-N4!91&20@/WBF03TQVR1BN@\'?\B/H'_8-M_\ T6M
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MRQ5U#,DD*QR;23M+*5SC//K5NZ\-WNM:UXAULVSVK7>BG2K2&8@,Y.]B[8)
M&64#OP>E=RDL<N[RW5]K%6VG.".H^M.H X-/#^HZU\)(]"O+"33]1M[&** /
M(C,L\*J4<%20!O48YSCKBJ4_@W6+G4]%U9O+2]U!'M_$ !X,#@/L'^[L$8(_
MO9]:])HH Y#Q1I^HW7C#PG>6FGRSVMA<327,B.@"*\3(.&8$\GL.E4(-,UFP
MU?QL@TB6>WU0^=;3QRQA7_<!-F"P(;<.X QDYZ ]]10!YC_8>N+X2\ V/]C7
M!N-(O;:6\021?(L<;(Q!WX/+#&*DU/PU?77B#^V-*TR[TC7EU!5>[AE46UY;
M"3[TJACG]WV(W;L=NGH\<L<H8QR(X5BI*G.".H^M/H X#^SO$NG^(O&TNF6
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M"7S(VROE*AX5B0>,T <W\1]:'B'X;7&H6VEK+IC74(M[QI!O&)T7S F.$."
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MSP0VNIS17-O&T88S>8%9VP<<L>VZMRV\5S2^*#H5SH\UG--:O=6<DTJD3*I
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M&8LWQ! ]...*]5N-?FDUJZTC2;..\O+.%)KGS9_*2/?G8N0K$L=I.,8 [\T
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M2F&)+9)R,=.<9H ] AFBN(4FAD26)QN1T8,K#U!'6D2X@DGE@2:-IHL>9&K
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MC)PQ.,]0.>M>DQR)+&LD;J\;@,K*<@@]"#23316\+S32)%$@RSNP55'J2>E
M#+5I'M(FEA:&0J-T;$$J?3()%<<^E:[H7Q"U+6].L%U+3]9AA6X03K');RQ
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M[3NY)W9'3\*T8-+UNU\3>,]3ATU'74;>!;(2RH5D>*-E*N,G )8?AUQ7<44
M<-X6\*/HOBNXO]-L)M'TFXM2)].>96C:X+ AXU5F"@*"#TSD<5:^)NC:EXB\
M"W^C:5:^==71C"EI%14VR*QR2?13TS77U7^WV6_9]K@W9QCS!G/YT 8DNI>(
MYXHX+?0&MI)&5'GENXBL*D@,P )+$#) QR<5AVEEXO\ #'B#5H-,TNTU32=3
MO'O89Y+L0M:R28WAQ@EESR-O/Y\=_10!Y_J^A^);S7-02>UM]4LY]-6"SFEF
M$:6LVUA(QCP?F8D$$#@ #(&:KP^&+N\\(:#H7B+PQ'>VUK8+"_D7*>=!*BJJ
MLK$KC(!S@\<=>:](HH \R3PUXPT.W\.:O9M'J^JZ?;S6EY:W%P%:>!W#*!(>
M-Z;5!)ZX_/O-&DU6>T:XU:WBM)Y&RMK')YGDKCH7P-S$Y)QP,@<XR;=U=VUA
M;/<WEQ%;P)C=+,X15R<#)/'4@5-0!Q&N:3K]YXMN7^PV^H:5+8B*T\ZX"):3
M?-N<I@[B01A@"1C'&3698^%[V;P5H'A_Q%X8AO[6WM6BG2*X0RPR+L$;HQ*X
MR/,SM;CCKTKTJB@#!\&Z9J.C^%[2PU2YDN+B(N TK[W6,N2BLW\1"E03[5O4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5R7Q%UG5-#\,"YTI8?,DNH('>20J55Y%7Y< \\XSVZ
M\]*ZVN:\>:+>Z_X5EL].$37:SP3QI*^U7\N57*YP<9"F@"63Q!=G6(]$MK.V
MDU46OVNX4W+"&%"VU1OV9)8@\;1P"?3,GAGQ)'XBMKO=;M:WMC<O:7=LS;O+
MD7T;C<I!!!P,UCOHVM67C6+Q3;VD4_VNQ%I?V,<XW(58LCHS8#8SM(./45I^
M%M!ETF75[^[V"\U6\:ZDC1MPB7 5$SW( R3ZDT :&N:G-I.EM=6]A-?3[TC2
M"$')+,%!) .%&<DX. #63IGB%=;U77= O;.W$VG)&9#%-YT4BR!B.JC!!4@@
MCTJ7QKI^L:EX?$&BLAG%Q%)+"TIB%Q"K O%O'W=PXS^'>L?1=$UO3?%NL:HV
MEV,-E>V,$<<%O<<Q-&' 0#:!_$#G@#MF@#CHHHW^ OA.1HU+QWEGL8CE<W(!
MQZ5[77F">$=>C^%>B^'/L<1O[*YADD_?C85CE\S(/N..G6O3D)9%8J5)&2IZ
MCVXH P[K7Y6U^30]+MHKF]@MA<SF:8QQQJQ(09"L2QP>,< 9] <"X^)(B\-G
M5(]'E>XM]2&F7MH9@&MYMX0X./G'S C&,Y[5=N-%U+2O'\_B/3H!>VM_:);W
MEL) DB.A^21=V%(P2""1Z\]*Q-2\$ZL?#UXEM!#+J6I:VFJSIYVU(E616"!B
M.3M0#..I/:@#N='N]3N[>9M5TQ-/E29DC1;@3!XQC#Y &,Y/'M4&LZZNEWFF
MZ?#")]0U*5H[:%GV+A5+.S-@X4 =@3D@=ZUD8LBLRE"1DJ<9'MQ7+>+- O[W
M6-!U_2A')?:/-(?L\C[!/%*NV10W9L $9XH C?QM+:RZ[8WFF!=5TFU^VB".
MXRES!@G>CE01R""".#ZU!9>.KV:;PU)=Z&+;3]>11#.+H.\<K1^8 R;?NG!
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M//;3"XPQ:6)8]I4C@ C).?H#0 WPQXHO=.T[P7IEWI*QV&I6,4%O=BY!<2+
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M] ?-=%895"<$<<]A76MXRN[2-'U32H; 7DL<>G--?*%FW(SL9#C]WM"G/7/
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M"@!VF^-+C5_#6DZG9:-,]S?W+6KP;R4MF5G#L[A3A04.#CG(Z9K(UCQY?S>
M_%-_IMO;1:AH\LEL["X,D?"@^8C!?F.&& 0.1R>.:=EX5\46/AC2;$6=O,EM
MJD]Q>V+7(5+J&1W91NP<[2P)4C!QWJ5O!FOW.B>.--E@L(!K+F:U:.8E0QC1
M0A&T8 VXS^E 'H&E27<NF0/>QQ1SE 2(I3(.G7)53G\*YOQEK6LZ;K?AFSTV
M.V:&^OC'*9)F1FPC,%X4X7C)/)XQCO71:.;XZ5;_ -HV\5O<A &BCE\P+@8^
M]@9_*L3QAH^IZA>>'[_2X89Y=,O_ #WAEE\L.A1D.&P>1N!Z4 <[;3ZAI_Q+
M\7OI.DP75TUE92/&9Q#'G$F<MM))/;Y>>Y%;EOX_L;O0M"OXEAAFUB)I(8[N
MX$21A1\^Y\'H2!P,DD=!DANG:7J]IXV\0:Q-8JT%]:6\47ES+DO$&SD'H"6X
M^G-<Y8>#O%&C>&?"EQI\=J=:T!9H9+66;]U=0RD;@''0\*1D=0?Q .R\*^*!
MXC74(I+58+FPG\F3RI?-BD&,J\;X&Y2/;C%2^,?$4GA3PM>ZTEE]L^RJ&:+S
M?+R,@9S@^OI5G1'UB>W>YUFW@M)I"-EI!+YHB4>KX&YC[# P/<G-^(&D7WB#
MP1J>D:=$CW5V@C3>X55^8')/X4 0S>+[NP94U72X+![JX$5@9[Y0LJ["[-(<
M?N]H!!'/) &<YK,G^)+VVB^(KLZ2D]QHFQG%O=;H)XV&0Z2[><=",9!J_P"*
M]&UO4K?1=7T988=:TJ8S);7#_NY59"DD98=,@\'^7:KKVG^*?$_@76+.[L+6
MTO;Z$006<=R)%BYY=Y-HSGT .,#KDX +,_C'5+7Q!I^F3>'UQJD,CV+K> DL
M@#,L@VX08.<@MTZ$\46?C6[ETC7))]"E.J:1<BVDL;24S>:S;2C*VT':0X)^
M7( /%)?Z3JUWXJ\):DEB!!I<<XN09EW R1A!M'?!&3TXK'O/#7BAH?%[Z>B6
M\VJ7D-Q;_P"D;3)&@17C9EY0LJGD9Z]10!TFF^*9[OQ%JF@S64 OK*WCN%^S
MW/F)(&)&TDJ"K CH0>"#6%8^.8K+P%H6L6'AM(;:_OA:"SMY500%IF3(^4 D
MD$XXY/7O5G1]$UJQ\;RZR=(L;6PFTN.V%O;W&6B9'=@H&T D[ASP![]\BV\(
M>((/AWH&AM91&]T_5([N;%PNPHLYE^4^I!QTZ@T =5IGB>_N?$FH:%?Z0EK>
MV]JEY ([KS5FB9BO)VC:P*X(Y'O6'9^.8K'P!IFMV/AM(+>ZOS:FS@E5!$6G
M:/<,* 23DXP.3U[UK)IFIK\2;C7C9?Z"^DK9K^]7>9%D9^F<8.<=>OMS7-P^
M$/$$?PXTS0390F]M=46[?%PNPH+@S<'KG!QTZT =5IWBJZD\3WVAZMIB6,T-
MF+^)X[CS@\)8J=WRC:P(Z#(]_7,?XA7']D:)J\6C+)8ZS=+:VO\ I6V16<GR
MRX*X ;:<X)QQU[6+BSO+7X@S^)[J".#28]%-K)+)*N499#(6('\..,_I7):/
M#K>CZ'I]Y?>#XKG3K F_B,&KCRX2P+%XX648P&.U2QQGCF@#UY22H)&#CD>E
M<?=^,-7/B/5="TOPY]KN[&&*96DO%B217W=3M.T_+P.<YYQBNP!RH//([UY_
M:W-W;?%_Q(;:Q:[4Z=9A@DBJRG,F/O$#'7/.1QP: +NE_$.VUC2M(DM+)UU/
M4IY;9;&:3;Y,D0)EWM@\*!U R<KQSQ*_C:6VEUVQO-,":II5K]M$$=QE+F#!
M.]'*@CD$$$<'UK$C\ ZGI:Z)K%DT$VLV-_=7MS;[RL<PN?\ 6HC$<$#:%)'.
M.<9K2O\ PYJ&IW^NZZ]H(KR[T@Z5:6IE7*J2S%I&'RC+,. 3@+W)P #)\0>.
M/$S?#VYUVST2&QMYK*WFANI+S<X\TA6P@7.1N!!)QC!Z_+71ZGK#6OB;PQ8Z
MCH=K)<WTTRQ7*S"06K+&S'82@))4 =NIZUG:CX7U74?@XGAD1Q1:G%900 -)
ME&>(H?O#L=GZU:U;3=<U/Q!X3U-M/A0:=---=1I<!MH>,H%4D#<1G)X ],T
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M=-LEU'S+:<S*\!W9SE5.X%#VYJ*V\<7#ZSI-M+8126NIY4/:RM(]JV,J)1M
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M98YYF0RN4#^6F%/.TKR>Y QUQOZ+JBZUHEGJ2036XN8A)Y,R[7C)ZJ1Z@\4
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M;4WL9K&63<LEO,#N1E)!YP,CC(/<$5LT %%%% !1110 4444 %%%% !1110
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MF.#T '3T)/<1,[1*TB!'(^90V<'Z]Z@M]1LKN[NK2WNHI;BT95N(D8%HBPR
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M#;62)67 .SECNSV Z9/6O2!TJG=:KI]E=VUK=7L$-S=-L@A>0!Y#_LCJ:N4
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M)=6]MXH&CV4&FV^KZ>;9-.\_]T)V#!I> 0@PRC"CG!X%7I/#>M/)X(806O\
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ME;S8BL31E0NW!SNSG(QZ4GA:R\;6$%IH^K'3#8V05!J$$C&6XC7[J^61A20
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M8D&SH0.V>OXU#IW@V?3]9U?5+"QLM-%]8^0UA!.WDR3Y)\TX0!<#CA><DG%
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MBM(P9V\S<A9LM\F.=WJ<>]<]_P (/X@_X5:/"W_$M^V"[\_S?M#^7M^T^?\
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MY(V1!*Q5<D8Y(!/Z5E^%T\,+!=IX8@L(X89S!<?8H0B^8H!() &2 P]>M;U
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M^9NC+%DVD$###!YZ\_2NLK$\7Z1=:_X4U'2+1X8Y+V%H?,E)P@(P3@#D^W%
M&+#JES82^&])'V&75]1MV\NY^S%5@MT16;(WDL2=HP& .<]N8+OQIJNG+XHT
M^YMK.35=%LC?PR*&2&Y@VEL[<DJP*E2,_C5S4/"NH7,GA[5;::VAUG108U#%
MC#<1L@5T8XRN<9!P<'UIM_X1O-1A\1W<SVJ:IK-A_9Z@,QCMHMK#[V 7.7+'
M@=AQC) -'PM?>(-3M8[_ %6+3H[.ZM89K=+8OYBLRY8/GC'(QCIR.>I9X_O+
M_3O >M7NFW*V]U!:22+(T>\@ '..1@^AYQZ&M/0;.XT[0+"PNC$TUK;I"S1$
ME6VJ%R,CC.,XIGB72#K_ (9U/2!*(3>VTD D(SM+*0#CO0!PNM?VBE]\.B7M
MKB[-Q)Y9V-$F#;-C/+'COZ^U:4'CB^TZU\3)K<%K+>:+<0Q*UFKHD_G!?*&"
M6(.7 /7V%3R>&-=N+CPM<7-QIS2:-(TD@3>HDS&8\+D'L2<GOQ@=:AO/ 5SJ
MTWBY+ZYBB@UXP/$T#,7MWA4!&Y SRH;MTQ[T 7]-U[6W\4Q:==6+7&G3P,XO
M8M/GMA!(O\#B0G((Z$8YXQ76$X&3TKFO#UCXLCDC/B35-/G2W7;&+&%T,QQC
M?*6..F?E48R<]A72D9&#TH XVR\1>(-9TFQUW1K*SN-/NKH*+1LK-]GWE3+Y
MA<+GC=MVG@XSFIH]?U;6Y=<_L 62II5PUH!=1LYN)U4,ZY#+L'S!<X;G)QV.
M?X>\(^)/#JMHEKK%F?#:RL\),3_:XHV8L8@V=N.2-W)&> .,7K/PWJN@ZWK5
MSHLUF]GJTOVIXKIF4V]P1AG7:#O!P"5.WIUH S$^)EK=Z=X<OA+!I5KK$4I-
MU>QM)%%,A"^22&4 D[_F) PG3GA-<U#Q&==\$P?;;*W:\N)O/2.!I(W987(;
M.\$ICD#(YP2>,5I6WA";2=$T_0K.*QU#2(;5X;FUO\KYSLP;S,A6 YW<8_B]
MJHP^ ;[3=+\+0Z;J%O\ :=#N)91]I1FC9) X*C!SA0^%YZ 4 =Z,[1N()QR0
M,5SCZY>ZEXGU'0M(>UADTV"*2YGN8FE&^7<40*K+V7).>X&*Z-00@#-N8#DX
MQDURTWAR_L/&=UXCT9[9_M]ND-]:7+L@=D^Y(KJK8(!(P1@CN* .1\6^);WQ
M'\'?$4X6*RO+&62PU&#:7&]'56"-D8!!!R0>#CWKTRRMI(U6:[-M+>;=AFA@
M,>4SD+@LQQ^-<AJ?@.YN/ >KZ#:W-N+W6+F2ZN[J0$()'<.VU1DX  4#/09K
MMK?SOLZ?:%C67'S"-BRY]B0* ,OQ!J-_IZ69LH[=8I)MMU=W+ 1VL84G>1N4
MMD@*.>]<?<?$'58_ GB/68;>QFN]&OGM=Q5TBF4%,.%R2,AQQN[=:Z3Q3H.I
MZKJ&B7^F75LDFF7+3-;W:LT4NY"N3MYW+DE3ZFN=NO &N7'A[Q5I)U*P<:W>
M&Z63RG3RRVS=D9/]S 'ODGM0!L)K^NV_C6TT74(M/6#4;.:>U:!7+0O&5RKD
MD!QAAR O]:K:=XOU6;0-=-[%9IKNFW9LUMD1MCR,0(>K9*R;EP>.OM5^\T/4
M;CQAHNO2/9Q0:=;312Q^8Q+>8%R0=H QM[]?:LRVL=)\0_$B+7M(U".ZMH+-
M3=FVD5X99@2(<D<%E4R'V^3VH [F$2B%!.R-+M&]D4JI/? ).!^-86H:[<-X
MJ@\.::8$NC:->SS3H76.+=L4!05RS-GN,!3UKH*Y+6_#6J'QC:>*-"N;5+Q+
M4V5U;W8;RYH=VX8*Y*L&]CG^8!S'AC7)_#]AXJGNTCEOI_%+VJ+"C%&D=8E#
M!1EL8RV!D\8]ZW5\3^(8;K5X)-.6X@M[!KRUOFLYK6)G7[T3J^3N[@@X(JB?
MAWJ=UI.NV]UJUO#=7NJC5K.>VA;-O.-NTG<>1\G3W/-;-MI?BR[TB]BUR_TR
M2ZDM7MH8[-)$BRPP9'+9);T   Y]> #%7QIXE32_">KRVFER6NN/!;M;J9%=
M)98RRMO)("Y!R-I('<UL:1K^N2^(=;T'4(]/DN[*WBN;:6W#QQNLFX;7!+'(
M*]1U]!5)_!VK'PWX2TM9K+?H-S;SNY=\3"%"H &WY<@YSSC'>M.#0=3@\:ZK
MKRFT:*\LX[:.(R,"I0L02=O?<>.WO0!AVWQ"E7P/X<UR_6UL$U28QSW)B=X+
M4?/MR P/)55R2 ,Y]JO:YXGUC2/",.JA-+NV>^CA\V,L8GB>4(CH QYP0?O<
M'UHT+POK6A>$M(T0/IMY'9B2*ZBFW".YC8DC^$[2"?0CCWXI2_#RZB\&S:%I
M\MK )M4&H",LQBMU$BN(H^,D?+UXZDX[4 :5[K_B!_'=QX;T^'340::M['<3
M[VVDR%/F4$9Z'@$=<YXP:5KX^O)?!>DZE-:0)J-_J:Z4P&3#'+YK1E^N2ORD
M@9ZD#/>M==#U(>/I/$9-IY+:8+'R/,;=D.9-V=O3)QC'O[5R&I:1=>'_  =8
M^&;N_P!)2ZU#57EB:Z5C;R#>T[(Y."O. "#DG &,Y !U>DZ]J]QXXU/P_=QV
M3PV,,4_VB)71G60' VDL 05/?D<UU,@<QL(V59"#M++D ]LC(S^8KB?"\NL6
M&O-97T6@3"Z0RRSZ9+*TP*@!6E\S)(Q\H.[Z<=.XH \TNOB!K-GX(OM8GBT]
M-0TS4FL[ZV$3D!5< E/GR3L/F>A&>F,UUDVKZ@]Y=_V=%;WT%MIXN!&@*M/,
MP8HBN6V@$+GD<;E]:J'P5;2>+]3U>:3S+*_ME22S(^4S;6C:3ZF,A?Q;VJOI
MW@FXT_X=77AI-5D^V3P/#]N&=P^78GI]U%1?HM $>D^+K^7Q;8:)>O83_:[%
MYW-HC#[/,A7=&3O8-][M@@CIS6!:C_B@_BG_ -A#4_\ T0M;=AX2U^+7?#VI
MW%YI2#3+22TD@MX'"E&V?<R>IV>P'H:6#PAJL?AWQ=IK366_7;BYGC<,V(?.
M0(0?EYP!G/&?:@"%?%::#I?A/3Y[JUTZ&]TU"M]>1,\7F*D>(\AE"DAB<D_P
MX[\=II<MW-I=M)?K"MVT8,HA.4W?[)R>/2N>_L#5/[(L-,N+?2M0L8[%;6YM
M+EF"2.H 5U.PXX!XQW'/'.GX4T+_ (1GPO8Z/]H,_P!E0KO.>[$X&><#.![
M4 1^(=?;2[S2=,M5C:_U6X,,'FY*(JJ7=R!@G '3(R2.160_BK5+'7-5T&\A
MLY;^#3CJ5E/&&CBFC!VLK*2Q5@WH3D'M6CXK\-3:W)I=_8W"6^J:5<_:+9Y%
M)1@1AXVQSM8<9'(JO+X;O;W4M0UJ[^RIJ4^G'3K>&.1FCA0DLQ+E06))'\(P
M% [DT '@O6/$6OZ=8ZOJ4.F0Z?>6,<R) 7\U93C.<\;2.1W'O6SX@UJW\.^'
M[[6+L,T-G"TK*O5L= /<G _&J_A+2;K0?"NG:1=O#)+90+!YD1.'"C .".#[
M58U_1;;Q%H%]H]V6$%W"T3,O5<]"/<'!_"@#GK_Q-K&@OH5UJT=E)8:I<1VL
MHMT97M99!E#N+$.N?E)POK[5D6%UK%XWQ!6_OX)X;9Y(%1;<J0OV<%0IWG Y
MY&#DY.1G%;,?A?5M1LM$T_79[.6WTF>*X\Z MONVB!$>Y2,)SAC@MDCL*:OA
M35K:^\4M;7=FUIK69$21&#I(8A&<D<;1C/3)Z<=: ,/PQK^M:+X?\ Q30V+:
M3J4%O9!5WF=&,&Y7W9VX.WE<<>IK2U#QIJ\MMJ-WH-E]K%C=/;K:&QGD:Z\M
MMK[95^1#D-CAON\]<!Q\':M_8G@_3Q-9;M GAE=R[XF$<9C 'R_+D'/?'O2V
M_A7Q1HFMZB-!UBPCT;4KE[J2.[@9Y;61^7,6" <GD!N!Z'G( EWXF\4W7BN?
M0](LM,B?^RXM0B:_,GR[G*E7"\YX/ Z>O&#W2[MHW8W8YQTS7,6WAZ_M_'SZ
M]YL#6C::FGA&=C+\KEPY.,$G<1C\<UU% ',?V]J'_"Q9?#_V>T^SC23>Q29;
M>6\T(%8] .O0&N7/C[Q,O@8>*VL]*^SV]XT-S; 2%Y$%QY64;.%(XZ@YYZ=*
MZE]"U ?$(^(T:U-N-,-@(6=@Y/F>9NSMP.>,?C[5@-X#U=OAK=>%3<V(FGNF
MF^T9?: 9_.QMQUS\O7W]J -:+7]=MO&T6AZC#ISQWME+<VIM]X,;(R@H['.X
M88?, /I7-CQ]XN/@E?%PTS26L+:647ENK2>:\:2LA:,YP, =\YP3QP*ZRYT+
M4KKQQI6ODVJ0V=I+;R1"1BS&0J20=N.-OX^U<?X+T?4?$/PN;1B]K%IUY=72
M23AV\U8OM#[U"XP2<$!MW&[H<<@&Y=>)_$M[XKN=%T*WTG;_ &;%?V\UX9,%
M7<KAMO.2!VZ>IZ&RGB36-7L];O=#2Q,>EW$ELL4Z.S74D0!?#!AL!.5'#=,]
M\5:M/#MY:^/9=<0VJV+:='8+"&;>H1RP;IC^+&/UJK9>%]6T*[UR+1[BS;3]
M6G>Z N"P>TF<8<J ")%) (7*XZ9H JCQW<W*^$M5MH[=-"UR002O*C&6WE*G
M:N0P!RP*YQP?7-:6I^*;C2X-2O'2*6VCNXK&S5(VW23.54Y()R S8.!GY6[X
MI+WP/:2?#K_A$K20QI#;*EM.WWDE3YED..^\ G'O4FL>#UU7P4-!%[)#<ILE
MCO57+"X5@_FD=R7R3]30!2A\1^(5U6^LWT];FV6R:YM[XV4]K&LBGF)P^23C
MD$'V]ZR8?'/B7^P/"VNR6>EO:ZQ/!:O;*9%D#RY"L'R0!G&1@G'?L.@T[3O%
MTME.-=U#3)IQ T,,=G&\:.Q&/,D)R2?8 #D^V,H>"=67P?X8T19[(RZ+>6]R
MTI9\2B$Y  V\9_'&.] %F/Q?J&DZSKMAXA2S>/3M-&J1RV2,N8LN&0AB<L"G
M!&,^@HMO$^OOJNDK_9INK*_!$_E6$\1LF*Y4M(_RNN>"0%]<=JEOO"%QJOBK
M5+^]:W_L_4=(_LN2)';S%7+'<#MQ_&1C\?:D\-:'XOTR.WT_5=9L+K3;(!89
M(872XG"\(LC$X '&< DXY/7(!A3^//$\7A;6-?\ L>DB#1]0FMIX?WA:9(Y
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MF1ZI8?9]7O/MD<TL+F93N1A&QSC:NP 'GCL*UO$/A?5/$6GW^FZBFDWMK=1
M1/*K*UI+MP708;//(&X'CKSP =BN2HW#!QS7-Z_KU[I?BGPWI\4%L]KJ=Q)%
M+(^3(A6-F^4=!TZ\_2MVQMOL6GVUH97F\B)8_,<Y9]H R?<XK#\0Z#?:KXA\
M/ZA;/;K%I=P\[K(S!I-R%,# ., YS0!A64>I2_&/6$DN[1X5TNW#(UJQS$9)
M#L'[S@]<M@@_W17?Q11PQ)%$BQQHH5448"@= !V%<W::%J4'CZ_U]WM3:W5I
M':B(.V]0C,0W3!SN/'ZUTU '%:3XPN=:UF>QMKG3X[FUOI(+G39HV6YCA5B!
M("7 ;("MPN,-C/',(\8ZK_PC'C#4#'9?:= NKB*/]VVR98XU?D;L@G=CK4MY
MX/OM7U+2[K4Q8"YTZ_%S%J,!87#1!B1$1MZ$$*3N(X/'-5+WP3KK0>+=.LK^
MP33M>:6<-*CF6.22,(R\<;<J#GDXSQW !L0^)+S4]2LM)L/LT-W)IB:C<331
MM(D:N=JJJAE))(;G/ 7OGCG/%=UK=SI'@R;5=.AMM5'B2%6@2;,;$+,%8,,X
M5A@XY(SWJ_<>#O$%GJ&D:UHFIV"ZM:V"Z==I<PN+>YB!R#@$LK _G[=*NZSX
M9UG5(-",E[:S7-AJ<>I7$CAD5RH8>6BC.U<-P23TR<DDT 3^'->U6Z\3:WH6
ML)9F>P6":*:T5E5XY0W!#$G(*GG/.>@KI9Q,;>06[1K-M.QI%+*#VR 02/QK
MG]-T&^M/'.KZ[*]L;>_@AA6-68NGE[L$\8.=Q^GO724 >9S_ !#U2V\%6.N7
M"Z?#<+J9L-3@:)S]GPY5ROS\E5&[GJ.>*Z75_$\NC_VS?2+#-IVFV\?RHA$C
MW#\A-V2,8:,]/XQZ<U_^$"M)=;\07-Q*9+#5X2OV0#B.1T"2N/=@J<]OF]:6
MW\#I)\.&\*ZA>/-+-;[)[Q?O-)P0XSUP0N,]E% #;7Q!X@/B.VL'L!=V5U [
M?:DL)[9;651D*YDSN5N@(P<]JR-)\<^()O"7_"5ZE::8FE117'FPPM)YSR)(
M4C"9R "1@YY[]\#=T#3_ !C;B-=>U73KI+52(?LL;QO<M@@-,QR!USA1UP>V
M#3TGP-*GPXN?"&K3Q.DPF43V^>-[LX.".JEOQQ0!/9>(-=_X2>QL9[$W6GW<
M3F2YAT^>W%I(HR YDX96Y (QR.E=>>G%<KX<TSQ?;O!'XAU>PN;>U&(VM(72
M6Y., RDG'0YPHY.#GCGJJ /-9_&OBK^P_$^IPVFD*N@WLT3H_F-YT<:JQ P1
MAL$G=TZ#;WK<NO%DUSJ(T_3,13"QBO))9+*:Z"^9NV)MC(Q]UB23Z8!R<4?^
M$,U8^'?%VF--9;]>N9YT<.^(1*H4@C;\V O7C.>U%SX2\16>IZ?K6@:AI\&H
MQV,=A>V]TKO;W")]U@5PP89/YX^H!-IWC#5;^#0["XTO^S=;U'SS+'<QMLA2
M'[SA<AF#97 R/O'GCF:X\2ZSH^G.-:L(4O)=2%C8R0*S)<*W(E\M2S#"AB4R
M22O49R(=;\(ZW>_V/J]EJ\"^(],DD<2S1-]GF60 /&5!RJ8 QR3QZG-2:QX3
MU?Q!X="7^KQ0ZW%<QWEK/:Q$0VTL?W0JL22.6R3R=WH * *[^+]=L%UXW6D2
MW<%E9_:[2[BLIK=)2/O1LCY.X=>#R,^E2Q>,;A_#NJ:[97.GZU8V]H)H'L8V
M1C)\VY'0NQ&!M/8\GBKEK8>,)=.GDU'5--34@@2V6SB<0*0P)9]QRQ.,8& !
MGUJE!X/OK;6=3US3Q8:5J%W;1P^5;EGADD63>99/E7)(^7 '3/// !;TKQ'=
MZKIE_J.GW^DZI9I;+);36ZM&/,^;<DB[F(P I['DUS5_XCUO5?#/@+4;>XM;
M/^UM0MTN(E@9ER59P!\X.T%!QU/'(Z'>L_!\UMK6KZS#;V%C<W]D+9K:V=C%
M))DDRN=H^;G'"^O)SQ3'@?58_!WAC2XKRS%]H-W#<)(P8Q3!%9<$<$9#GUZ4
M 3^)_%&MZ#!JTY&G0QV%HLUOYZ%FU!PI:0(JOE N .0W7/056OM6UB^\=>$E
MM+R"WLKZPFN_(D@+X8(GWB'&[AR!TQSUSP[4?!>O7=WXFV:I8M!KEDL#22P,
M9(2(BA50&P$));VR>#UJP/"6M1W?A:^CU"Q^UZ3:R6D^86V.CJ@R@SG(V#KU
MSVZ4 5[_ ,:ZO-97M_H-A]L2TNWMTL_L,[O<B-]CE9E^1#D-@8;ISUP-:+Q!
M?ZSKNH:9I'V>V.G0Q-<27D+.?-E7<L8567&%P2<GKC'%9EIX5\4:'JVH1:'K
M%@FAW]R]TR7,#//:NYR_E8(4@G)&[@>AYS9'A;6-(\8WNLZ%>6AMM3BB2]M[
MT.2KQKM61&7J=O4'&?7T (OA#O/PRTSS %?S;K< <@'[3+2_%G(^'MT57<PN
MK0@9QD_:(ZTO WA^]\+^%X=)OKJ"X>*25U>%"H >1GP<GGECZ5/XQ\/R>)_#
M-QI<-REO*[Q2)(Z%E#1R*X! (X.W'XT 8R^(O$FG^,;/0]9M],$6K13-I]Q:
M"1A%)&NXI(&(W<<Y&W..@[,TSQ?JMWX7U*2YBLX_$%G?&P-JJ-Y?FEPL?5LE
M6#*V[C )]*U1I%U=ZY9:]KK6D!TN&40102%D5G #R,[!?X1@#'&3R>V1IVGZ
M5K?Q(E\0Z3?1W-I':1FX-O('AEN?F6-LC@LL;.".P9* .YC#B-1(RM( -Q5<
M GO@9./S-<WXAUG5=/OVBM_L5I9K:&5+N[4R>=/DXA5%=6S@9)YZ\"NFKD]1
M\-ZQ+XSDUFRO[06T]A]C>.YB9V@^8DM'@@?-D9!QT'7&* -3PIK;>)/"FF:R
M\(A>\MUE:,'(4GJ ?3-;%<_X)T.]\-^$K#1[ZX@GEM$\M7@0JNT=.IY/OQ70
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 445S'CG7]1\.:-;7NFQ6TKO>06[I/GD2.%XP>#SU- '
M3T5P\'B'Q+8>-H?#VLIIDBZE:RSZ?<6R.H1X\%HW!8[@ 0<C&?QXRM-\>>(%
M\"#QKJT>F?V8MM*6M8%<2O,)=D>&)("D\'J1UYS@ 'IM%<=J6OZSX;U30UU4
MV=S9ZK<K9.8(FC:WG8$IC+'<A(([$=?:L7_A*?&U[I7B*]T^+1<Z)?W$!C>.
M0FX2(*2!\WRG!//.20,#&2 >ET5Q>F>,Y?$]_IUCI'E6S7&E)J<\DR&3RPY"
MK& ",G.[)ST XYXH/\0;RTT;5OM]M''?:1J*6=]/#$SQ)"Q!%P$!W8VG[N3@
M]S0!Z'17&-XOEMM"6^%Y8ZDE[J$=IIUQ:(S(ZNJ\NJLQ+*?,RHQG:!QGBO+X
MRU30CK=SK-D\^DV5E]J@O4M7MM[YP82KD_,21AAQ@^U '5WVN:;IM_8V-W<B
M.YOI/+MX]I)=L$XX''0]:T*\U\2#66U[P)-J4UFRRZF&>*&)E,3F%S@,6.X8
MR,X'(SWP/2NU !17#>%O%]WXFFA6&]L([E3(M_ILD#)<6; ';P7RP#8!..<\
M8Z51D\=:TGPRNO$H2P^VVMZUNR>2_ENHN/)R!OR#@YZF@#MX-<TVYUJXT>&Y
M#W]O&)980I^52< YQCK[T:OKFFZ#;)<:G<BWBDD6)25+99C@# ![D5Q-\NL/
M\7M3319+*&Y;0X,RW:,ZJ/.D_A4C)/U&/?I67K_B*[\1?"^[;4K:*WU*PUJ"
MQNTA),?FQW$>2F><$$&@#UJBN2U3Q)>RZUJ6DZ4PBFL(8V:1K&6Y#R."RKA"
M-H  R<Y.[C&.>?N=8\3:EKW@(S!-(GO#=-<6,T!<)+'"XR<."5()(&1C()S0
M!Z;5+2=6LM<TV/4-.F,UK*6".49<E6*GA@#U!KD/#MQKEQ\0/&$,NHVTL=HU
MM'&C6S !6B+J!A^ "YSUS[=J$?CO7I?A[H6OI!IYN[[4EM)XRKA IN&B&WDD
M' ')SZX[4 >E$!@00"#P0:KV.GV6F6PMK"SM[2 $D101"-03U. ,5S&G^(-8
MMO&&IZ'K'V2Y$6G+J,$EG"R$*79#&0S-N.5X/&?3TR!XUUZ;0_"^L6PT]DUZ
M[6V^SM$Y\C>&*G<&^;:%(;CWXQB@#T>B@9P,]:X0^+-9U'PIJ7BC2%LVL[.2
M<PVDL;%KB*%B')<-\K-M8K\IQQG.> #NZ*\_F\7ZYJNN:39^'QIZ6VK:.VH0
M27<;EHV^3 8*W(^;&!]>V#W5K]H%G +LQ&Y\M?.,0(0OCYMN><9SC- $U%>?
M:UXRUG19C-<+8IC58[46 4R2&V=PBRLZMA&;.X!@/3D\U9U3QA<1>*;_ $&*
M\LK"^B6-K"&^B;;?!E!)5]RC.25 ]1GGH #N*I'5K(:V-'\X_;S;_:A%L;_5
M[MN[=C'7C&<URFJ^,+B'Q1?Z#%>65A?1I&UA%?1-MOMR@G:^Y1G.5QUR,\]!
MI+KNH#XEGP^ZV_V$Z4;U&53YF[S0F"<XQU/3O0!TU5[VPL]2MFMKZT@NH&^]
M%/&'4_@>*\^E\=ZU+X3M?$EG'9B.XU/[%]BEB8NBF8Q DAAE\@,1C&#CWK3D
MUKQ/<>-+WPY;2:5#Y6G17:7#PR/M9F93E=PW<KQR,9[]* .KT_2]/TF P:;8
M6MG"3DQVT*QJ3ZX4"K=>;Q^/-;N/!_A?5X;:P%QJ6J)I]U&^_:#YCH2ASP"4
M/7.,]\5?@UCQ9+XLU/PTUQI'GQVL=Y!>BUDVHC,RE3'YGS'*]=P]<'I0!W-%
M<!I?CV[O_#>@RRP1QZIJ=Q/;-Y4+RHAA+[W"+\Q!V# SQNY.!5?5?&'BG2?#
M/B:]DL(-^E[)+.\GM9(H[J-NH\LMN#*>#S@T >CT5QJ:[KUIXTTW2=0.GM;:
MM:3RP>1$X:W>,*<,Q;YP0W4!?PJ+X:W.JWFFZI<:E?171_M.ZCR("C923;G.
MXC;@  8X]30!V]%<OXWU_4_#UEIL^FPVLS7.HP6CI/N'$C8X(Z'W.?H:RX?$
M?B6P\73>'M8_LUGNK%[S3[NVA<*"A^:-U+9.,YR"/UX .\HKSV+QOJ\O@[PA
MKGEV0DU>_MK6ZB\ML!97VDH=W!&.^:LKKGBO4/&.NZ+IYTB.+3&M'62>.0EH
MY Q93AOO8'!Z<=.<@ [FBN&T/QA<ZYK+6,=Y8P7D%W+%>:7/"R3Q1+O".I+#
M?G"$D C#=L56D\::TG@GQ7JVVP-YHE_<V\?[E_+E2+&,C?D$YZY_"@#T*BN2
MU?7=7@DA,3V5G:R:?YZ3RH96FN/^>2QA@V .20#U[8K)_P"$XUJ[T?P7?V=M
M8J==D6*>.7?\C%&;*D'@97N"?YT >AT5YU<^(_$0TOQSIT]U9IJ.B6HGAO+>
MW959'B:0#8SG##:1G)'0X-=1X,%U_P (=I#7<\<SM9PLK)&4PIC7 .6;)]^,
M^@H W:*X;Q!<:N/B?X;LK6_ABM);:ZE\E[<N-R!1DX<9.'('3'/7-2+XEUG6
M-*UO5M$^QB'3;B:"&">)F-R8OODL&&W)R%X., G.<  [6CI69X>UJ#Q%X>L-
M8MT9(KR%90C=5R.0?H<BL_QGJ,%II,=C+=QVK:G*+3SGD">6A!,C9/0A V#_
M 'BOK0!M6US9ZMIT=Q;R175G<)N5A\RNI_F*;I^EZ?I,)ATZPM;.(G<4MX5C
M4GUPH%<%\+M0M;&\USP?!=Q7$&F7!GT]XY X:UE.X $==K$@_45>L];\6ZKX
MHUO2[-M'AATJ\@1GEBD8O$Z!R  WW@#UZ<?C0!V5]>V^FV%Q?7<GEVUO&TLK
M[2VU5&2<#D\#M3[6YBO+2&Z@;?#-&LD;8(RI&0<'D<&O-?#^M>(;3P%XHUN2
M]M+RYL[J^=1-;L-QB8]2'Z84   8]370VWB:\U&YT/2K4P17]]I8U*YF>,LL
M:?(,*N1DEG[G@ ]: -[6-<TW0+,7>IW(MX6=8PQ4MEB< 8 )ZD5H5YKXYEUJ
M7X77XUZVMX;N/4;>-6MV^2:,74>V0#)VY'\))Q6]J?B.\EUS4-(TMQ#-8P1N
M\K6,MR&DD#%5PA&T *"23D[N,8H ZRJ.J:QINB6GVK4[Z"T@S@/,X7)]!ZGV
M%5_#.H:AJOAVSO-6TY].OY%/GVS?P,"1Q['&1[&N?^+BJWPRU8E02#!C(Z?O
MXZ .QN;F"SMI;FYFCA@B4O))(P55 ZDD]*KV&K6.I^:+2?>\6/,C92CID9!*
ML 0".AQSVKD?B;+(8O"UCD_9[WQ!:17 [.@)?:?8E1^5+J<SVOQIT$0D@7NE
M7$5P!W5&#(3]"3^9H [JBLCQ1K\'A?PQJ&MW"&2.TB+[ <%VSA5SVR2!GWK%
MU+Q!K/AO4-".K&SN++5+E+&3[/$R-;SN"4P2QW(2"#G![^U &WJ_B32M"5VU
M"Y9!''YLGEPO+Y:9QO?8#M7(/)P.#Z&M.&:.X@CGAD62*10Z.IR&4C((/I7
M:!%J4OQ6\7)/=VDD2V]BLJ&U;YHRLI"K^\^7J<D@YST%=9XDENK3PMJ<VG3)
M;7$%K(\4ACWA"JD_=R/3C^1Z4 3:EKFFZ1/907UT(9;V=;>W7:29)&Z#@<?C
M6A7D5ZVHMX ^&TTTT-S<2:GIKQ95H^L+8#G+$G/5@!]*Z%?&>HZ+=>*K?7_L
MMS_8UI'>Q26D31>8CAOD*LS8(9<9SWH [RF2RK#$TC[MJC)VJ6/Y#FN2M-<\
M1#Q%IMO)9_:].NT<7,J6,MO]C<#*G<Y^=3R.@(Z^U=A0!FZ1K^EZ]"TVE7B7
M<*DJ9(@2N1U&<8S[5I5P/P<_Y)_'_P!?MU_Z.:MO6_$,EKKMIHEH2EQ-;273
MR_9GN-B*RJ $3G)+=3P-I]10!T=%<1;>(O$[:%YEYIUO9SQ:B;::\N!Y,/V4
M<_:0CL#SP-I.03^%58/'>H+H/B>Y>!+J;1KM85DAMW7?$P0^88R<_*K$D C(
M7C&: /0:*XE?&OD^'KW6XK^PU:QS!%9R6JE299'V;)%RQ!!9#T!P>F:MZ9K&
MO/XH%C<VIN=+EMS(+U;*2V\F4'[C!R=P(Y!'3H<T =715#11JRZ5$-<>S?4,
MMYALPPBQN.W&[G[N,^^:PO%>OZQI.N^']/TR*RD75)Y(6-QNRI6-F!R#TXY]
M>G&<T =917F[^,O$NF+XJTW4XM-DU71[ ZE;3Q1NL-Q#M8X*EL@@KCK_ "YM
M?\)5XAL=)TV^U :8QUI[.VTZ*)'!CEE&6,A)Y4#YL#'3'O0!WU%<BVO:KIWC
M&V\.7\EK)_:5K)-87:0,NV2/ET=-YR,$$$$>GO531?%>L:CX:N?M'V&/Q#!J
M3:<\*POY2R!P =N_<5V'?G(XSZ4 =8-6LCK;:.)C]O6W%R8MC?ZLMMSNQCJ.
MF<TS5]<TW0;>.XU.Y$$<DBQ(2I;<S' & #W(K#/B6]M/'EYH]\;4:?;Z.-1\
MU$8/_K"ISDD8PI/'K7)^+]2U;7OAQI^MNUK%97M[9S+:^42Z1-.A0[]V"WW<
M\8Y('3) /6*#P,FN+U/Q/J5Q>ZU::(JB;2R(U#V,LXGF,8DVED("##*/7))Z
M#F2T\4:EJVJ:=HT=JNFZC)IPU"^6X0R&W!;8(U (R2V[D] O3G@ Z#2=<T[7
M$NGTVY$ZVMPUM,0I&V10"5Y SC<.E:%<)\,A< >+1=M$UP/$-P':)2JL=D?(
M!)(SZ9/UKNZ ,^RUS3=0U2^TVTNA+=V&S[3&%(\O?G;R1@YVGI6A7FJ?VP/B
M/XW.C2V<,ZVEBYDNHVD'$<F%VJ5Z^N>/0]M#3?'-QK-CX4AMHH8-1UVW>X=G
M4ND"1KER%R"26( &>Y)SC! .ZHKA6\3>(%N_$6@QQV4NMZ;;+>6<GDMY5W$P
M.%*;LJV1MZXY!QVJO_PGMVTW@JX2>Q.G:\H6X/V=]\4A48 ._ !<[.<X/K0!
MZ%17(7WBF\L()9W\B2.ZU0:=IVR!R>,AV<!B7P4DP% SM'3.1%;ZOXMFN=8L
MH;2*3RK83Z??3V4D,<C]X71F!SG&&!QCMQ0!VE%<?H?BB^U_P]X<NK5[47NH
M$F[1H&VQ! ?- 7?D;6 3))Y8<5GW7C'7+S3;C5- L_M:PW;PQV/V*5C<(DAC
M<B8$*I.UF'! P <GH >@45PLVO>*[[QAJFAZ4-*A%M:V]U$]W'(3AV;*L%;K
MA>HZ8[YX[J@!'571D=0RL,$$9!%9%E?:#INJIX9L!;VMTL#7"V=O#L58\@%N
M!M'+#WK#^)UUJ-IX8MWT^\6W\R_MH9<Q[BZM*HQG(P.>?4<<5GZDFJ_\+:TR
M.VGM/MQT&<-/)"WEK^^3YA&&R?IN'U[4 >B45PNE^*]<O_"LER8; 7]IJDFG
MWMPS;((HXY"KS[68$@+CY=W4UGW?BW5[SPWXYBM[N".ZT6(O;WL=NR^8C0^8
M/D8\-U ;IT(% 'I5%8WA-;H>%=+^US12N;6(JT<93"[%P#EFR??CZ5LT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5PWQ7WGPC;"-U20ZI9A&89 /G+@D9&:[FL?Q!/H4$-M_;L-O
M*DDOEP+-;^<2^"<*H!.<*3^% %4:'>W?B&#7;]K;[396TD%G!$6*(TA&]V8@
M$DA5&,<#/)SQEZ;X"V_#.3P9JUS'/"R.@G@4J>7+AL'/*L1^5:"^//"\<4^W
M4-L5I\LV+:4"' Z-\OR\>M=*I#*&!R",@T <K'X:U/43HJ:_=VMPFD3+<(T"
M,&N9E4JCN#]W&XG SDXY &#SGA6SU348/'%C9W%K%!=:[>0M*X8R0Y50Q '#
M<'@$C!'?I7II (((!!Z@U6M-,L-/:1K*QMK8R'+F&)4W'WP.: .8'@EM(UG2
M]5\/310R65@--EM[C)2>!<%?F'*N",YP<YJ>V\,ZAIZ75W97EO\ VI?7XO+Q
MI(SY4B[-@B !R%"XP>>1G':NJHH \_G^&<<^FZLD%S'I=W>7T6H6WV)<Q6<T
M8 5E!QN)();@9STXS5]O"NL:_P"'[_3?%FJV]Q]JMS;J+" Q(F2#YAW$[GRJ
MGL!@\<FNNDE2*)Y)&"HBEF)[ <U1T37=,\1Z9'J6D7:75HY*K(@(Y!P000"#
M]: .3;PCXHO!X>&H:UIKMHUTLRRI:N6G549,L-X 8@]N._M7>'D&EHH XVV\
M(7EQK6AZKJTMDU_I2L&O;9&66[RA3#YZ#G)&6R>F.:R+OX>:W-X8U;PW#K%E
M'IMS>&ZMW-LQE7=,)2KG=@@'/0 GCD5Z310!RTWA_58/%Q\0V5U922S6"64\
M,T;(ORLS!U()QRQ^4Y^M4-2\!33^$I='M+V(75UJ U&[NI8SB27S1(<*#P"5
M"@9X '6NXHH XO4_"VO1^*'\0^'-5M+.YNX$AO[:[A:6&79]UQ@@A@"1[U/J
M?A34;F\\.W]MJT9O])EF=Y;F NLWFH5?Y0PQC/RC.!P.U=;10!S%CX<U'3?&
M&LZQ;WUN]KJ:PN\$D1WB2./RQ\P. IX)XS6'#X U2'P1I/AX:A9E[#4%O?/\
MML.%F,H7;GCEL9ST%>AT9QUH Y"_TZYTKQ1?^,[JXB6TAT@VTD,4;/(JHS2;
MQZG)(QC\:XO0VU;2=,LM1LM2\':FZH9(T6-Q<3._+*A5R!(Q)'"\GMBO8ZI6
MVCZ79W+7-KIMG!._WI8H%5C]2!F@"[7$6O@O4=,TO5]!T^_MUT;49)70R(3+
M:"7[ZKV8<DJ3C&>=U=+%KVG3Z_-H<<S'4(8!<21&-@!&3M!W$8//H>QHUO7M
M.\.V'VW4YFAM]ZIN$;/\S' 'R@XR2!SZT 8L7A*:R\5Z/J-C+;QZ?IFGG3TM
MF5BY0[>=W3(V#MS7652FU6T@U>VTMVD%U<QO+&!&Q4JF,Y;&!U'4U=H \XN/
MA[KDNCWVEIK=GY$FJ#4H))+5FE9O-$FV1MW(&,<#)P.0!BM3Q%X1U#Q+8ZAI
MFHS6%S:711H)I(B);-@BJS(.022I8<C&[G(KLZ,T <;XC\(7GB*RU'2KN6RN
M-/N2GV:6=&,UD0BJ67LQRI8<KRQSD<5:?0;FT\;+XE:ZC-G!I9L6B*LTA4/Y
MA?(ZGC&,5MQZK:2ZQ/I2-)]K@B29U,;!0K$@8;&#T/ -7: /&M&FOS9+KECK
M/@ZZ6>9[U!>0N+@.Y) ;8Y EP0O"Y'3FNZL-%U0^+I?$\AMXOM6FQ6ILVW;H
MF4E^6Z'EB#Q6]'HVEPWIO8M-LTNR<F=8%#G_ (%C-7: //+;P!JMOX9T/1QJ
M%FQTO51J7F^6P\W$C2;,9XY<C.3TZ5O1:!J$7CF[\1>=;&.>P2S6## C:S,&
M+>Y;&,5TM% 'G47PYU*#POI]G;ZQ%;ZOI=]+>V5['$2N9&9F1T)Y4AR.OI]*
MT-6\+>(-?\':GI>J:M9M?ZA&L)>&!E@@0'/RJ6)+'N21V].>UHH Y>Z\/:C=
M^*M UEKBU5=,AFB>(*Q,GF!02#VQM&.M2>%/#M[X<;4H9+Z&>RN+R:Z@182K
MKYC[B&;)!QT& /\ #2OM>T[3M5L-,N9F2[OV9+9/+8AR 6/S 8' /4UI4 <+
M\4_,.B:*(71)3KMD$9QE0WF<$C(R/QK9AT">[\2#7-5:'SHK1K2W@@)*QJY!
M=BQ )8X4=!@#OFM>\TVPU$(+ZRMKH(<IY\2OM/MD<595510J@!0,  < 4 >;
MP?#[7X_#VC:(VM6(MM&U"&YM7%JQ9UC<LOF?-R>0,#'UKI=(\/W^G^,=;UN:
MYMI(=32!/*1&#1^4K ')/.=QX[>]:6HZ]IVE7=A:WD[)-?S"&V C9@[GG&0,
M#@'J1TK0DD6*)Y'SM0%C@$G ]A0!QTO@^\U+4-'N=5ELGN-*NOM$=_"C">1!
MG$1ST'(R<G..@SQ0OO 6LS:?XHTFUU6SCTW6YY;H%X&,T<D@&Y<YQMR,],]N
M.H[?3-2MM7TRWU"S9VM[A \9="A(/J" 15N@#B_^$1UJ+Q!'J4.L6A633$T^
MX$EJQ*A23NB&_P"7.>0<C(!YZ52L/ >KV>D>%+%]2LY?[!N?.#"%E\T!64+U
M..&)SZ]J]!HH X]_!]W<:IXMGGNX1;^(+1+;:B'=!MC:,'GAL[L]NE;7AK3K
M[2?#]GI^H74%Q-;1)"'@B*+M50HX)))XR3[]*UJ"<#)H YO7/#M[J'B?1=;L
M+Z&WDL$FAD2:$R!TE"Y(P1AAMXSQS5&U\(ZEH[:W::1?6RZ;JTTEP%G1B]I)
M(,.4QPX/4 XP?6NRHH I:/I5MH>C6>E6:D6UI"L,>>I &,GW/6J::9?MXL;5
M)YK=[1+8V]O$%8/'E@SMGH2VU![;1[ULT4 <GK/AC4;OQSI7B73;NUMWLX'M
MYXY$9C<QL<[20>,')'7DU8T+0+W2_$VOZI/<6\D6JRQRB.-6#1%$" 9/7(&>
MU=)10!P\'@K4[;PYXDT1-2M6M=4DNF@)@8-$)R2VX[OFVY., >_LV\\%:LJ^
M']1TG4[:UUO2+3[&SR1,\%S#@ JRY!'*AA@\'\Z[2[NX;&TENKABL,2EW8*6
M( ]@"34.E:G::UI=MJ5C(9+2Y021.5*[E/0X/(H YO7O"NK:[X0ETJ?5(&OK
MFXBGFN#"1&I1U8*B9R%^0#D]R>IIFJ^%M=3Q/_PD7AW5;2SN[F!(+^VNH6EA
MFVYVN,$$,,D>X_7LZS7U[3H]?BT-IF&H2PM.D7EM@HN,G=C'<<9H L:=;36E
MC'#<7+74XR9)F&-[$DG [#)X'88%9'C;0+KQ1X7NM&MKB&W-P4W2R*6VA75^
M ,9SMQUJ_I&NZ=KGVS^SYFE^QW!MI]T;)MD !(PP']X5I4 8GB#0/^$BT6.V
MGE6"\@FCNK>=!N$,\;;E8 XR,\$>A/UJ.RT&9O$S>(=3DA:\6U%I!%"#LB3=
MN8Y/)9CCL,  <\D[]% &9XBT.U\2^'K[1KW<+>[B,;,O53U##W! /X5C1^&=
M3U!-%AU^\M;B+2)TN%>!&#7,J*51W!X7&=Q SDXY X/69HH YK2] U"P\::U
MKDEQ;/!J:01^2JL&C$08 YZ'.XYX%;FI6:ZCI=W8LY1;F%X2P&2 RD9_6K-%
M '!#P5K3>'O#.F3:G8NVAW=O.KK RB1(5*JOWCR0<EOR%6[OP5)JFN^(;F_G
MA:QUFP2R>*,$/&%W88,>"?FSTXP.M=E10!R7AO0_%.GFWMM:U^VO;*S&(3#;
MF.:? POFL6(X'8#D@9/KU4OF>4WDA#)CY=Y(&??%/I&(52QZ 9- '$>%?"_B
M;PIH7]EV^HZ3.HEDE622VD!!=BQ! ?U-+JG@[6IGTC5].UN*'Q#8I(DLTL):
M"Y60[G1DSD*&^[@\8_$=-HVN:?K]M-<:=,TL4,[V[EHV0B1?O## '@U7U#Q7
MHNEW4]M>7A26WC$DP6%W$:D$@L54@# /6@#%U/PKKNHVFEW#ZS;/JMG?K>N'
M@;[*^%*[ F[( !R#DG.3WX;8^%-?TZ\UZ[M]:M/.U*YAND)M6 5DV!U/S?=*
MH5QUPW)-;5AXNT/4[FUM[2],DEVI:WS#(HE 7<2I*@'CFMN@#@[CX;VVI1^(
M3.8M/DUB.$%+ ';%)$Q99N0,N6()X' ]R:UM"TWQ1;C?XAUNSNC!&5A^S6YB
M#G&/,ERW)QV&!R3SQCIJ* ,+PE+K,NB9UV>&XNEE=5N(8C&LR9X;:>G<#U !
M[U@>//M'_"6^!Q:M$L_]H3%?-!VG]PV0<<\CC/;/0]*[:[NH;&UDN9RPBC7<
MY5&8@>N ":QX;SPYXAL$UN.W@O[>,9BN39ES@'JF5R><]* ,R_\ "%WJ4'B*
MYGN+==2UFR_L]2 QCMH=K# Z%CEV8GCL,#'+]1\&S:KX-TO29KU(-1TMH)K2
M\B0E4FA&%;:3T(SD9[]:W=&UW3?$%B+W2KG[3:DD+,J,%;!(."0,X((XK1H
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MIZGK7=6K3M:0M<HJ7!C4RJIR V.0/;-4M9U[3/#]LMQJES]G@9@@D,;,NX]
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MX@\')JWA:TTFSO9+*YT]XI[*[ W-'+']UB/XLY.?7)JWH%CK\):?Q#J5K=7
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M-K+:B5HY6^^\3$\%NO((![&@!K:YXEO?&S:%;26-C')I$=^K36[220,S[2I
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M9JL-C<F#/ER,EQ$0ZYY (85VL_A>ZMO%4&N:/<VT.S3ETUK6>%F01JY=2I#
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MH:NW]H)-8WU[+>QP^1M>-Y""P+[CD#'& .ISFH?%/A6\U?4=.UG1M4_LS6+
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M=1VWVR(PM*\1DVJ>N ".?QI]KI5Y;^%(]):Z@:XCM1;+.(B%.%V[BN[/X9H
M\\\+ZSKFA>$/ 4WG6;Z9?O;Z>]J(6\Q=ZMMD\S=URO3;CGJ>M=3;ZWK'B(^(
M)-$GMK<:5=R64"30[_/FC4%]YR,+EMHQSQG)Z56'@._7PUX8T==5MO\ B17<
M-R)3:M^^\H$!<;^,Y.3DU>MO"NH:/JVL7.BZC;PVVK2?:)H9X"_DSD8:1"&&
M=W!*GN.O:@#+TGQY=ZU>>"I[:.*.RUZ.Y^T0NA+Q/"A)VMGIN!'(Z>E.D\7Z
MQ;6GC!C EW)HUW%%"(("6\ME1F8KN^8J&8X&,[>U6KCP&UG:>&5\/WD5K/H!
M<0&ZB,J2K(A63> 5.3G.0>M+9>$-9T^?7;FWU^+[3J=U!=*[6G$;1[-P(#C*
ML$*XX(!ZF@!MIXDOM1\.ZIJ>@:EINLHD:&S=R(=C<[Q-R,;1AOX>./>FZ5XF
MU"[\4ZGHD-Y!=QQZ;'>VMV]LR#)9E(P" Z< @J?49-0:E\.3J<&O2K=P6%[J
MPM]WV6']T&A?>&92?G+'@].,>Y-Z#PKK2>*G\03:U:O<2Z<+*6)+(JF0S,"O
MSD@?-R"23ZCH #G]/\9^)Y/#?A3Q%=2Z>;;5+V&TN+2.W8-B5RN\.6X(./EQ
M^)K>?6=1\0R^)(=+N(+:WTIFM 9(MYFG"!GW<C"#<%XYSDY[53B^']_#X-T#
MP^NKVW_$HO(KI9S:M^]\M]ZKMW\<GDYJVG@_5-.U[5KS1]6MX+/6#YEW;7%L
M9-DVW:7C(88SW!S_ $H F^%__),?#O\ UYI76UB>$-"G\,^%;#1I[M+MK2,1
MB5(O+R/ID_G6W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5GT
MZRDNA=26=NUPI!$K1*7&.G.,U9HH *;)%'-$T4J*\;C#*PR"/0BG44 -1%C1
M410J*,!5& !3J** "BBB@ HHHH **** "BBB@ JO]@L_M?VO[)!]I_Y[>6-_
M_?6,U8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M-8(5G>=8HQ,X :0*-S = 3WJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K$UW7Y]*=+>QT>\U:\9#(8;8HH1.FYF<@#)R .IP>.#6W53
M4+Z'3K9KB169CA$C09>5OX44=R?\2<#)H H^&/$UEXKTC[?9QS0E)6@GM[A-
MLD,J_>1AZCC\ZV:P_"VB-HFG7'GE/MM]=2WUWL.5$LAR0/8 !<]]N>];E !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5SVO>$+7Q!?V]Y<:CJUM
M);H4C%E>- %SU/R]STKH:* ,G0O#UMX?AG2"YOKIYG#O->W+3R' P!N;G YX
M]SZUK444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>secondamendmenttoleaseag003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 secondamendmenttoleaseag003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'98PH.1\I.UL9QGMUH [ ^,=$^R"[6YEDM_*CF:6.VE=45P&7<0ORD@@X."
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MYQ"[1++_ '"X7;G/'7KQUXK@M+OH[GQMX+OXS?W$;V-S"[BR>.*)RL>(T4*
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MS+ (SYA'VW>"%QG[GS?2NQFN83\9;*Y$@-O_ &#+'YP^X&,R,%W=,E03CTH
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M\LC1Y&<D*I. .21P,C)YKCKUQXI\ >'=$LHI(=:@N+,26[(5DLFA(\QV'\(
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M ] HKG-3\<Z)I5]>VDTLTLEA$L]\8(6D%JAZ%R.GK@9..<8K&\:?$>V\/1Z
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M1[-W*\L #D D8H UJ*IZ9J=KJ]D+NS,C0EF0,\3(25.#PP!QD'FKE !1110
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MSXETFX?PS\0-2M;2X,.LWEM]BMT@8O+Y?EAY @&<,0QSCD#/0BNLOY1-\6=
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MTS0=0 )ATS7;.[N/:,/M)_#>#0!N:AHPDTE+:?6KVUMXP7N;B.?RI9#ZF3^
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MBMGD:VMS(2-P4';A<$CMG'6@#LG\2:'J^JZ 7DU>UNI+J9+6%X)H%D=58,)
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MB0I$X8*0,,06 XS[5S%C:W^D>'O ^K7FA:A>6=A92V.H6B6[^? 7*$.(S@D
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M!C@,!C&,MFK,VD:K>:1\0M"M[&Z2^O-0DO+5WA9894*Q%0)#\IW%"N <^N*
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M5RH;.TAL+*"SMD"001K%&H_A51@#\A4U !1110 4444 %%%% !1110 4444
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MC6\32M;R+)O4E5!;:V2,@'!ZXK,ET>\CT'XA:DMG= ZZLBV=HL+&1L0>6K%
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M>K;7,-H()?LLA64QQLKA>.<$@>_:NZHH \@AL-0B^%/@VP;2]0^V6>I6DEQ
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M_-&O[NVMUR\C=A[#U/:@#C+'1I_#7Q+T^RTC4+^?3KRRGFO[:ZN7G6(J5"2
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MFKQ1122RRV<L<<<:%F9F0@  >Y% &;I_CO3M0M1=+8ZG#:O!#+#/-;%4G,I
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M:5,2%";EU4N68'!.!G\ZV?#-W%J-U'=+X(ET26WC8W$US9HC XQLB*_,^?7
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M:.#4I)T:,#80ZER.L@(R.J^U2KX[T]KG4K0V.H+>Z?+%#):LB>8[2'";!O\
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M;:@+'4=UO87DY5A*8U.-WS%P6"D@D<]\5;7QG9MI^O7?V&^']B2,EW$1'O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM'LKRYFFCVI&D2 _*W1BQP!MS@$DXQBN^UC3HM7TFYTV>>6&*[C:%VB*ABK
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MW9#1DXP5R23DEOK0!F137]S\6]%O+MY8HKG3+IH+1N!#&&CVEA_?/4^F0O\
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ML5G>:A'K:.]G);*F'*H6VG<P(;H.0 .<D8-=%I=[)J.F6]W-93V4DJ;FM[@
M/&?0X)%>=:;X1U3PZWP^LH[.6\CT<W#WL\3+M1I48<;B"0&8]!T%>H4 86J^
M)H["ZN+2VM7O;JVA$TT:2HFU3G:,L1ECM.![<D9&<QOB+I?]F:'JL5K=R:7J
M\JPQW@"!('8E=LN6RO((SR,CK69JUEJ^A^.[[5H/#G]O:9JL,(=8C'YMM+&"
MHX<@%6&._4?GJZGI=UKNDVWAV_TL06-ZC/?/!L*0KNW+$O?>3C+A<<$C!(P
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MK>65B<#_ %DF2?P'Z5SF@Z?=^*_@KH?AR*PGC^T+ );E]HCCB24.7!SR2%P
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M>6  +'ECM;CVZBJMQX\L8O\ A'V@L+^YCUV,R6CQ(O\ SS+[2"V0V,>PSR0
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M9&)7/ /!P>.AJ*R\=BYOM"CGT:[M;76H\VMU(Z$%_+\S:5!W 8S@D<XZ8YH
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MX^8,2,KAEYQGGI4TWC66VUZVTJ;0+]7OH7DL&#QG[04P64C=\G!!^;''H>*
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M_M(RS_V%?6^G6T]S#>7DSQA+8P@DE@&)/0\KD=.3V .RIKNL:,[L%11DLQP
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MMY:WUNACCNK.X:&0(3DJ2#@C(!P0:GT?3K&P$PMKF6ZGR$FFGN#-)QT4DDX
MR>!@<GCFN)\1^.WU7X7^(M0TB&6"[L_-L[D>:NZV<<%E8'##!!!'K[5IP/I&
M@7]G=)I-O9ZY>VAA6/[2L:-#'M.YR/EX+* <%N<=,X .WHKA3\4+ :')J(TZ
M[D:#41IMU#$R/Y,I8*#D'YU.1@J#GVK2_P"$P>+RX+W2I-/U">658+:[N8U#
MQIMS*7!("_,HXR<GH1S0!U%%<*?B?8#0YM0&G73O;:BNG74,3(_DR%@H.0?F
M4Y&"H.?05JV/B]9=?O=(U+3I],FM[3[<K3R(RO!N*EB5)"D$<B@#I:*YFW\7
M/-/I#G2+L:?JQQ:W*_,5RNY6D0#Y%8<@Y/N!5#5/B1INEVSZ@T2RZ7%<_9IK
MA)T\Q3OV%Q'U*!N,]>X!') .UIJ.DB!D964]"IR*YW4M<COI=4TNRTW^TULX
M1]M4NJK\R[A&N<[GV\XX'(YYJC\)_P#DEGA__KV_]F- '94UG1"H9E7<<+DX
MR?05C:GK\MIJITRSTZ2[N5M&O'+/Y<80-MVA\'+DYP/;DBN)\1ZU9:U+\/O$
MUE932FXOBT2!%\X@PR?)UQ]X>N.^<<T >HT5R%AX_M&?6(-:L;C1KO28?M-Q
M#<,KYA.<.C*2&'&.._%66\7?9+[2H=4TV6Q@U5Q':3-(K 2$96.0#[C$9QC<
M,C&: .FHKG-+\6+J%WKMK-9&SFT9@)UFE&&!7<K@C^ CG)]^.*;+XN6..RA:
MT2+4;JV^U?9;FY6(1)G WL>Y/& #R#V&: .EHK%\+>)K/Q9HHU&S1X]LKPRQ
M28+1R*<,I()!]<CJ"*DU'7%M=5MM(M8/M.I7$3SK%OV*D:D N[8.!D@# ))/
M3@D &M17%WGQ&M+'PWK&J2:;=FYT>7R;ZR#)OB8XPV2<%#D$$9X[=:T+7Q89
M?%,6AW>DW5DUS;O<6DTK(1,J$!@5!)4_,#@]NN#Q0!TE%0W=W!864]Y=2K%;
MP1M++(W1549)_(5S;>-4METFZO\ 39K73M5D2*VN6<,4=QE!*H^YN[8)P>#B
M@#IIX8KFWD@F0/%*I1T;HRD8(-<Y8^!=,T]%@CO-5>P0;4L9;^1H%7^[M)R5
M[;22,<8J"/QM/<Z_?Z19^'-0GEL+J&"Y</$!&L@W"3[W(P0<#G'7%;VO017/
MA_489XTDB:VDW(XR#\IH O1NCQJT;*R$<%3D$4ZO+/"'C4Z#X*\)Q7^BWL>E
M3V\%L-3RGEK(P &4SN"YXW$#\L$]+K?CVSTA-1FC@6ZATQMMWMN$1P0 S"-#
M]\J",]/0$D$  ZQY$BC9Y'5$49+,< "HHHK9Y3=Q!'>50/-!SE>P!]/I7!>(
M];GU'Q5X*CL[07FEWWGW2(9%"W.(-R9!Z;=V>>^.XK3T^]L]#@U/3O#.B//!
MILC/=1138"RN/,:.(-G+ $';\JC( .<@ '8T5QTWQ#L6AT"?3K"[U"'7-PM9
M(=@&Y5)*$%LALK@YX'.3Q4Q\9MY4<#Z9]GU3[.+B:RNKN.(PJ695!?)!9MK$
M =AR1QD ZNBLCPSXBLO%?A^UUFPWB"<'Y)!AD8$AE/N"#6O0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !2$X!(!..P[TM% '$^"M,U73O$/BJXO\ 3);:#4;_ .TV\C2QME=H7D*Q
M(/'ZU3^R^)/#7BW6'L?#Z:UI6K3K=1NMQ'$]M+L5&#[^JG:#D9Q[UZ$"#T-%
M '%2:9K/_"PM$U.6P,EO;:;-;W$\+QA!([(V%4L&VC:1T]*PX])\6V6C:NMG
MI=PC77B1[Z6!+F))+BR=@65'#_*QP,\CC.#7J-% 'E\7A[6X+GQQ]G\."WMM
M9T^..TCBN(AAQ"Z%2,@!LL"3TZX)[W)-&UHV?@",:1.6TAHS>CS8OW>V QG'
MS_-R<\=ORKT2D)"@DD #N: .1\+Z;JND^)O$J7%@197U_P#;(;L2J593&B[=
MN=VX%>X ]ZD^(&A:CKGA^W.D[&U"PO8;^"*1MJRM&V=A/;(S^.*ZNB@#SZ6T
MUO7O&VD:I/X?NK&R73KFTN?.N(M\;2%>0%8Y'!QW]AWI6WAS7_\ A6LO@.XT
M]O."FTCU$.GD- 7R),;MP(7C;MZ@=CD>F-(BNJ,ZAF^ZI/)^E*S*BEF("@9)
M)P!0!YY)IFO^%/%U[=Z5H0US2=2B@!1;B..6VEBC$8SOP"I51_GK:\0^'VUY
M+6WUO0)+C9 98KW39426SG+$[48LI(QMYQ@E<D<\=R"&4,I!!Y!'>D21) 3&
MZN <':<X- &5X6MM5L_"^G6^MW'VC4HX0L\F<DM[GN<8!/<UC_8-23XJ3ZS_
M &;,VG'1ULUF$D?S2"5GQMW9Q@XSCK^==<S*@RS!1D#)..32T >36/A+Q#;^
M'M%NDTYDU/1M8GO1:/-'_I$,KN656#%0VUAC) R#74#1+O6?&+^()[62RBBT
MM[&"*<KO=W;<S$*2 H  '.22>.!GL:* .5^'EEJFE^#-/TO5=/-G/91" YE1
M_,QGYAM)PIXQGGKP.\?B?3]2NO&/A2^L].EN+73YYY+F1)(UVAXB@P&8$\G/
M Z5UU% '!:O9^(-#\<W.MZ7HJZWI^IV\45S;K,D<L$D>X*PWD J0V"/\F3Q'
MINN:C%X6D&EAYK35X[ZZCMY8PL,8#C:"Q7<0&'('."?2NYID4T4ZEH94D4$J
M2C @$<$<=Z .+LM.U:W\7^,M0?2IS;:C!;):,)8OWACC96&-^1RPQG'X5CV7
MA6:?P1X<T#Q!X8FN([6U=)I(9XQ-:3*5V,C!P<$;NA/09&*]/HH \T/A_P 4
M6^D>$)KB*;5;S2=0DEF1YXQ,8&614W,Q"LRJRYYYYQGK5?Q/H?BG7+?Q7976
MBB]>YBQI<YNH_)A38,HJDY$F[=\VT9SR0 *]3ID4T5Q&)(9$DC.0&1@0<'!Y
M'O0!P[Z=KJ>+?#>M+I!=(]-EL[F,7" V[,4(+$GD?*<[=WXU3T*S\5^&I;KP
M_'X?@OK(W,LECJIN$5(XY'+XE0_,2I8]!ST]Z]$\Z+S_ "/,3S0N[R]PW8Z9
MQZ4^@!%&% )R0.M>>)HVNVD'CNP72'FCU66>>TG2>,"3S(50+@L""".<X&.A
M->B4C,J*69@J@9))P * /.FT76SI_P /XAI$Y?1WB-Z/.B_=A8#&<?/\W)SQ
MV_*C2+3Q5X9OM0T:'P]!J5A/>2W%EJ)N$185E<N5E4_,=I8_=!S7HD<B31)+
M$ZO&X#*RG(8'H0>XIU #8U*QJK-N8  MC&3]*Y'3+#4X?B9K>IRZ9,FGW=I;
MP17!DC(+1ELDJ&W ?-QQVKL** /(;CP[XH7X>:AX4AT%Y)H]1\^*Y-S$(YXS
M="4%?FR#@\A@,8ZD\5USV&J/\4;363IDHL%TA[1Y?-C^61I%?&-V2 %(SCK7
M85'%/%/O\F5)-C%&V,#M8=0<="/2@#EO NG:CIO_  D U&PDM?M>L7%Y 6D1
MMT;D;?NL<'CH:D\8PZW+-HYTVTEO=.6Y)U*T@F6*26/:0N&9E!4-@E<C/3IF
MNIHH \CN/"OB'_A#_'&CP: D;:I>&:S2&XB"%66,8&2, ;#G..V >M=1J5AJ
MEWXV\):E'I4_V6PBN5NG,D68S(BJHQOR<%3G&?QKM*8\T4;QI)(BO(=J*S %
MCC.!Z\ T >77_@[7-7M/%\:6C6=Q=:G#J.G/-(A20QA,*VUB1DH>OJ*Z*XTZ
M_P#$^O\ AV_N]+GTV+2GDN95GDC9FE*;0B[&.0"223CH,=3CLJAN;JWLH3-=
M7$4$0."\KA5'XF@#RC4?#GB<^!_%'A:WT-Y9+F_EN+>Z-Q&L<L;S!Q@;MP;U
M!  P>>@/5I9:LWQ/36WTF9;'^Q?LA<2Q'$OF[\8W9QCC..OYUV*LKHKHP96&
M00<@BEH \I7PQXA_X0-K3^R9!?6^O_VDEL9XLRQ?:/,PK!BH.T]R*]1MI)9;
M>.2:'R9&&6C+!BOL2.,_3CZTZ6:* *99$C#,$4NP&6)P /<FGT <1I.GZOX5
M\1^(C'IDVHZ?JMS]OMY()(PT<K* \;AV&!E1@C(Q6/<>#=5TKP!X<T.RLFOK
MJTU.&^N3#(BJN)C*X!=ESUP/7':O3Z* &HQ=%8HR$C)5L9'Y<5R%I8:MIGQ&
MUW45TQ[FPU*VMMD\<R#8T2N"I4D')W#';U(KL:* /)X/#/B&+X5Z#H;:-,=0
ML]1BGFC$\. B3F0D-OP>#^=:PMO$OAOQ9J\MEX>76=+U>9;M&%Q'$]K-L5&5
M]W53M!R,X]Z[^*:*XC$D,B21DD!D8$'!P>1[T^@""S2=+.%;DQF<(/,\H80-
MW"^WI7$ZG9ZU%\5K;7[?0KN[T^'2WLV>*:!6+F3=D*\@XP.^.M=[10!QFO66
MM>,M$U?2&TZ;2()+3;!)=2Q.TDVX,O$;-M5=O//.[IQ4WAJ^\37TL$>L>&H=
M): ?Z1<>?'()VP1B,+D@$\Y/0#'.<CK:9+-%"%,LJ1AF"+O8#+'@ >YH \M'
MA;Q$_P )-5\+G2PMY'/(]NQN$VW(-SYPVX/R_+Q\V.:U-8M_$MMXHL?%=AH
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MFB8JA!#;V P2V>@R  .>37.> O#TT/A^^AOKLW41\S3;.8<'['&[JGX\MSW
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M?PDKN /8GMUKFM*T;6++QXNMQ>'(K2PDT<6K0QW2&19!*7^;LS'/7)'<MVH
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MIGQ!\1ZXFC":SU..V2(?:D5U\I"I)'(YSZU-K]MXOUC1YF@M(K9EO(#]@%V
M;BV4YD4R ?*7SC'HON:[>B@#SB'PWKT&I>+)H](LH+;5]-B@MX8+@?NG2.1
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M]V$,>>%5/+' ZXR,GOTQ;\1_#?P_K%GJLZ:7"=5NX9"LS2N 92I 8X..N.U
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M<2K)(S!6\O;C9GC[V?;UV],\)3V'B=]<T_2H])\VSDCO;."X!BNYB5VLH'
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M>Q.+2[C=F9[@#*PE,<,W;GGI3M=\4:QH%AH4EQH]O-=:E>Q6<L,5U_JG<$@
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M2O8+6)F"*TSA=S'H!ZGV% '*:MX4UC6'UO54NH].U>[TT:=9>5(6$";BY+.
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MAT8%3MX4XZY)YP.NEX-\*_\ "-7>L201)96%[*DD&G1R%TMR%P[#L-Q/0<#
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M.1#D.IZ$5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDC(SSTK3USP[KFH>'-"MK9[$76GW$,MQ;32/]GN512-I8+G&<,,J>0.*I?\
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M!_"MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.GVUM-=OYEQ)%$%:5O5B.O4_F:X-_B%KR>!KK7_[+T_S;>_%BT8F<AB)A$Q
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MQ2FK&TF@L)+26T:1+Z)"%@F!QL9"^7!!SD;>G:@#H:K7M_;:?");J78K-M4
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MTRG<F%&&7)X.01GH>E>BT4 <+:>$_$-CK.C7T6H:=,+32ETZ5)HGQ$003+$
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M-8&,QHR M\O?=GCIC'/6NMHH \[T_P $^(-,MO"8@O-.D?1(9+>2*;>T3[@
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M;D ]!!W*".AYKC3X@\0:OIVHZEX<MK*=+2\>VAM)P0]UY;A9#YFX!.=V,@]
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M9DZ]_J^6_<_NA%SQ\W SVYX]Z )+?Q=/J]SH-AIJ0PW>IZ:-4F:92ZP0D+@
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M(6+*2!@'(Q]>:MW&KWT'B#2O#J36C:C=V\EQ+=BW*B.!,  (6.6+-W.!@G%
M'645YSJ/C;6M-T_Q?9NMDVK:!"MS',8F\JXA=2RG;NR&&"#SC-=7X=?79XGN
MM7FL6@GCBDMH[:-E:/*Y8.22&YQ@C'?B@#;HKE?$FL:K8:A)%!-:VEH+)I89
M73SI)YP3^[$8.[:% )('\748K&_X377+O3?!-Y9PV$9UXA)TE5SL;RF?*D'I
MD=,9[9'6@#T.BN%L=;\4W$GBO1TDTZXUC2#$]K-]F9(IQ)'O5&3?D'((SN]*
MLZ3XIN]=T7PU/8RVWVK426NU:%L1+&#YV%W94A]J<D\L* .QHK-\0W]SI7AW
M4+^RM6NKFW@>2.!0278#I@<GZ#K7+6WBZXO_  WK.LZ/K.FZC;VE@9XC]G*O
M',H=F25-X(! 7'0]>M '=T5Q+^*]46+P/.%M=FN^6MTGEME2T!DRAW<<C&"#
M3EUWQ%KFF:AJ?AU+-Q:WKVUO:3J?])$;['+/N&W.&V\<8&<YP #HX-=TZZUN
MYT:&XW7]M$)98MC#:I. <D8/(/0UHUYW/'JDWQ=U6/2Y[6UN&T.WS-<1&4)^
M]DZ("N?S&/0UT?@?7KCQ-X.T_5KN...YF#K*L6=N]'9"1GL2N?QH U;_ %.U
MTQ8S<N^^5BL4<<;222$ DA54$G@$\#M3='UBPU[3(]1TVX$]K(2%;:5((.""
M" 0001@BN-\3)J3?%;PHMO>6\:M;WIB#VY?9A(]V[#C=GMTQ[TM[XHUJYM]6
MF\.6HD?3[N2WBM?L3NMRZ-B3,@("DMNQZ8R<YP #OZ*XJY\4:E?WUYI^G1/9
MW-G:PR2![-K@B:12PC;:0  ,9[G/&,<]#X;O]1U/P]9W>K:>VGZA(G[^V)SL
M8$@X]CC(]C0!J45R,&MZMXAN=>30YK2W72KDV<?GPF3SYU0,V[##:N6"\<\$
MY[5B1>/M7UFU\'W6DPV<":Y)-!/'<HSF&2-7S@AAD!E/& 3CJ,\ 'I-%4M*3
M4DTJ!-5EMI=0"D2R6Z%8V.3@@$Y'&*\__P"$G\;WNC>(=1L?[&!T2_N83$T$
MA-RD6"0/G^0XR<\Y)QQCD ]-HKB)/%6HZA9:=?V;VUAI][I8NX9)%\Z62=N1
M$L8(8A1R2 <^V*HR>.-9/@WPSXJ"64.GW;PKJ@:)F,"N=OF(=PPH;'!!P#[4
M >BT5RFLZYJUN/$5QISV9MM)LMZB:%F+7 0R,I(<<!-G;^/VK$_X2CQ3##X1
MOG?2Y8->6.%K?R74Q2/"7#[]QR,@Y7:..,_Q4 =_=V5KJ%NUO>VT-S W6.:,
M.I_ \4ZVMH+.W2WM8(X(4&$CB0*JCV X%<*OC34M$?Q;!KAMKQ]$AAN(9;:(
MPB42JVU"I9L888SD\&KUMJWB<>(K.U-K]IT^ZAD$UP;)X!9R@94_,WSHW3'4
M>M '8T5Y9#XV\4_\(5:^*IVTOR([_P"S7-JD#[I4-R8<JQ?Y".,##9QG/.*V
MK6?5I?C!J-LVH1FSATR&1(6@/RJTC @'=]X[1ECGMQQ0!W-'0444 95AXCTK
M5-1N;"SNC+=VI N(A$X,1/0-D?+G!QGK4W]LV/\ :_\ 97FO]M*>9Y7E/]S.
M-V<8QGC.<9KD/!G_ "4KX@_]?%G_ .B*WI1(?'#>24$O]E':7&0#YO&0,4 =
M!17DR^.?&0\ 6OC5HM)>RA=C=V21.))(Q,4+(Q;"D # (/0DGG%=;!KU]X@U
MS5]/T:XM[6/3$B4S30F0R2R)O QN&% VY[DD],<@'645YH/B!K-YHF@7EI:V
M4-U=:Q_9-]!*&(20%MQ1@>!\G<'@^U=!X<UG5Y?%6N:!J\MI</8QP3PW%M"T
M09)0WRE2S<@KUSSF@#JZ*Y7QMKNJZ%'HS:6MHYO=4@LI%N%;I(3R"#QT]#UJ
MHVN:[::E#H%[<6\FHM!+=R7-G9.ZB+?MC CW'!/.220-N.<Y !VM%<1;>(/%
M#:#!+J-C:Z?.FH-;W5W/B.,6X!(G1&;.6^50I)()Z'I5.W\=:D/#/B*]>W%Q
M+I&HBU\V.V<$PDQDRM$3NRJN20,9V]J /0Z*X27QP+3PO>ZY;ZA8ZQ:M)##8
M/ -FZ20A=LHR<$$@G@<=LU<O==U;0/$^C:=J,MM=VFKEX(YHX3&T$ZKN (W'
M<C<CU&.IH Z^BO+)_&OBN+PCK/B'?I031]1FMY(!;OFX2.4(<'?\AQD_Q9/I
M72>)M=U;3KB[\B6TM+:*P,]JSIYTES,-Q*^6IW!% 7) _BZC% &]=:[IUGK-
MCI$]QMOK[>;>+8QW[5+-SC P!W-6-0U"UTK3Y[Z]E\JV@0O(^TMM4=3@ FO-
M]2U2^UW5OAGJMHEO#>WT%S,!+N:.-GM@3P.2!D\9&<8R.M6VU[6)].\:>'-?
M%K)>Z?IKS175JA1)X9(WP2I)VL""#S_B0#OK"]M]2T^VO[5]]M<Q+-$^"-R,
M 0<'D<$58KS[1O$$MGX;\&Z-:!A<76BQW#RK TQCC2.,<*,<DN.3P,'VKH?"
M>HZU?VMXFN6)@FM[EHX9A&8UN8OX9-A)*GU&>U '045R_B+5M5L=2,,,UK9V
M?V-I(IG3SI9[@'_5K&#N*A1DD ]>HQ69IWC>[UC3/"44$<$&I:]"T[L5+) D
M:YD(&<DDD!03WR<XP0#JK'7=.U+5+_3;2X\R[T_8+E-C#9O!*\D8.0#TS6C7
MFFC)KD7C7X@BVGM)=42&R-N\D)$<A$3E0RAA@GH2#[X[5M:%XHOM?\/^'+FU
MDMEO;\DWBM V(A&")@%W9&'P@R3RPXH [&BO/=:\8:SHTWG3FS4C5H[3[ B&
M1OLSN$61G4_([9W -CTP>M7)=8\37OC76?#]C<:9;QVMI#<0SRV[R,N\L,%=
MXW'Y>N1CT- ';45P6B^.;W6]%\*JD5O!J>N+,78J6CB6'/F,%SDDD  9XW9.
M<8-R[U_7=!L)QJT%M)/+J,=GIT\*DB99,89XP2<J-W (W8XQG- '8T5R^A:I
MK\OB2[L+^T>73/LXFM[\VQ@(?.&B923D]P1CC(I/&NNZKH2Z(VF+:/\ ;=4@
MLI5N%;I(3R&!XZ8Z'K0!U-%<&OC#4="U+Q-:^('M;J/2K!-1BEM(3"61MP,9
M4LW.5P#GOS3M0\3ZUH6G:'K6H&TGL+^:&&[@BB*M;>;]UD;<=P4D Y'/48Z4
M =UG%4M)U6SUO3(=1L)&DM9L[&:-D)P2#PP!'(/:N0\-3:W<^-_&4<FI02+;
M3PQ1+);'"@PAE P_ !8YZD\\C-1Z'XXU#5/"WA>61+9=7UZXEB!"'RHEC,C,
MVW.3A4P!GDD<T >@45Q]]KVN^';'4Y=6AMKA%N8+?3)X@09S*P7YT!)&UF[?
M> XQ4ND:KX@;Q2UC=VCW&DR6WFI>FT:W,4H.#&59CN!'((Z=#GK0!U=%<5\3
MKC4+;P]9&PO!;"34K6*7]WN+JTJC&<C ]?7ID5<&LZA>^*)_#EI<V\<]E9I<
M7=T8"<NY(150MP,*222>H'O0!U-8^H>*=%TJ[EM;R^6.:*,2R($9MB'.&. <
M#@_E5/P=XCN->M=1@OX8XM1TN]DLKGRL^6[+@AU!R0&!!P3Q5GQ/!%'X4U^1
M$ >6QF+MW;$1 _04 %AXOT'4[FUM[/44EDNP3;C8P$H"ECM)&#P":VZX[P2]
MM;_"SP]?72 I9Z;'<!L9*XB.2/?:6'XU3M/$_B2[.A:A:V#7-GJ#Q_:K86CI
M]FBD&1(LI.&VY&>/FZ@"@#O:*\SG\5^+6T7Q;J$,NDQ_\(_>3(%-L[>?''&K
M[?O_ "G!/.3UZ#&3OW^O:G(]C)!);6%C=6'VA)G7SI9)S@K$L8(8@*220#^%
M '6T5YNGCK7+SPSX,U6U@L$DUNZ2VN(Y%?"L0Y)4YX'R="">>M32^(/$2P^-
M=*N+VT%]I%FEU;7MO;% 5>-VP4+M@@H0#D]0<4 >A45SW@3[4? NAO=W"3,]
MA;LK+&5(4Q+@'+')]^,^E9?BSQ%K.CG6)8I+.VAL['[39(\9GDO'569]RJVY
M$7"C./XLYXQ0!VM%<+=>*=<GUCPC;:>MA%#KUE+.WG1NQA98E?J&&X?/TXSC
MJ,U6@\=:CI^A:V-32VN=4T_55TNW:)#%'</)L\MB"25^_P \GA>* .RFUW3H
M-=MM%DN,:A<QM)%%L;YE498YQCCCOWK1KSR^AU*'XN>%!?W<%RILKTH8X3&0
MVV/</O'CICOUR374^*_$"^&?#MQJ1B$TJE(H8B<!Y'8*H)[#)&?;- %FXUW3
MK76[/1YKC;?WBNT$6QCO"#+<XP,#U-:->=:O#JL7Q1\%"^O+:?=%?;3' 4V/
MY(W<;CE>F!UX/)[-N/&^MQ?#KQ!KJBP-]I5_/;*# WER)'($&1OR"1SUH ]'
MJE%JUG-K%QI22,;RWB2:1/+8 *Q(!W8P>AX!KE=6UOQ-)XW_ .$>TF73(EET
MEKV*6XA=BCB15PV&Y'/;&,YYQ@SV6N:Y-XOUG0YWL,VFGP7$+I"^-[E@=V6Y
M&5[8H ["BO,-/\:^)I?#?A7Q'='3?LFJ7D-I<6L<#[@)7*AU<MQ@X^7!^M;=
M]XFU.;5?%-I8/;VQT&UCF3SXR_VAFC:3+<C"<;>.<Y.>,4 =I16-X4U*]UGP
MOIVJ7Z1)->0)/LB0J$#*"!@DG(SU[ULT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A>,/#\GB;P[
M+IL-TMM,98IHI63>H:-U<9&1D';CKWK=HH Y.;POJ,?B6U\26=_;?VG]E^R7
ML;PE8;A-VX$ $E"IZ'YN.#ZUJ>']!715OIGE$UYJ%TUU=2JNT%B  %&3A0H
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MB4AB5=JJJYR<9)R2,D]!P*ZG3+>:TTNUMKB1))88EC9XU*JV!C(!)Q^=6J*
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M[$ <\'M/:>#-;T?5M131M?BMM$U&X:ZEMY+;?- [_?\ *?< ,GU!QZ&NXHH
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M##Y"QD,@CW8.[/.=Q[5T5% '.^+/#UWXA32EM;N&V^P:A#?$RQ%]YC)(7@C
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M+13Q;55E=,YP=H/7@_IU.C6>H6EJS:K?+>7LK;I'CC\N->,!47)P![DDDGV
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M,=N @]<G/3H*UU\.IM1L/$-M=ZFB-JE\NH6\T$1#6LRA0IY/S#Y1Z=37?44
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M63PUKUWH6H6FL>(H[N[NK5[1)4LQ''$KC#-L#?,QXY) &. .<QOX+O6M?"L
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M?18]:B^TZ3J(O[>Y-F=I8.[;63?R/WC#AAVKNH5=(4223S'50&<@#<>YP.E
M&7XHU*\TCPU?7]A:O<W,"!EB1"[8R Q"C[V!DX[XQ7&:IKL6O_#?Q==66M0:
MII_]ER")@@2:)]C[UD48P?NXX']3WNK6MW>Z<\-C>BSN=Z.DYCWA=KAB"N1D
M$ @C(X-<M>^ GOE\13&[M;6\UNS6SF:"V/EA0&RY7=EG.[J3P !SSD J:7J^
MN:7J_@^QN;FTFT_5[1HQ D!5H&CA#J=^?FR 0>!]*CU'Q;K.F7ED\\]LTLVM
MI836,,?F1Q0.^U2T@^[+C:V">_W:V9/"-[+?^%[HZI #H2NNT6A_?[H_+/\
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M^761<C.X\^Q)JSJO@[5-8T.WM+G7D>]6]BO)KE[3*LT9!5$0.-J\#N3R3U-
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M4 %%%% !1110 5@>*O#DGB*VL!;Z@UC=6%['>02^4)5WJ",,A(R,,>XK?HH
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MWF9M^5RS9P1Q[9%:T/AZ[GU6RU35K^"[O+"&2.T,5J8D1G #2,N]B6(&."
M3Z\=#10!PA^'EP? K^%_[:C\I[K[3]H^Q_-GSO.QC?C[WZ?G6CK7A2]UVTU2
MPO-3MY-/U%5#PO9[FA(15)C8OP?EW#(."<\]^JHH C@A2WMXX8\[(U"+DY.
M,5R/_"OK>:T\1Z=>7\D^E:U<27+6PB56BD?:2P?G."H(X&.^:[*LF\\0V5CX
MATW1)EG^UZB)# 1$=GR+N;+=.G89/(H S[?PO=SRZ2VMZHFH+I3^;;[+;RB\
MH4HLDAW-N8 GH%&3GT Z20.8V$;*KX^4LNX ^XR,_G3JS=:UVQT&T2>]:4^8
MVR**"%I9)6QG"HH)/ )]J .63X=SKX*/ATZWREW]L@NDM<%)/-\WYE+$,NX]
M.*M+X%>XUG4;_5-7>\BU/3Q97EN+=8U<#<,J025&'/')S_$>E;7A[Q-I7BBS
MDN=+N&D$,ABFCD1HY(G'565@"#6O0!R7AOPEJNBK;6U]XEGU+3[(8M+=[98R
MH POF."2^T=.G(![#$<'@FYBT3Q/IIU:-AKT\\SR?9"/),J!& &_G@#&>_K6
MWK_B&R\-V<-S?+.8Y9D@7RHB_P SL%&3T R1U-:U '(W/@VZN+/PS!_:L2G0
MI8Y5;[(3YQ1"@R-_'RD_C^5+=^"3<ZQXANAJLT5IKMLL%S;I$-P98C$&5^PP
M<XQU YQQ76U@0>,-,N(-:F1;O9H\ACN@;=MV0H8[5^\1@^E &/9^!-0AO?#E
MW<^(VFDT2.2&,)9(BR1,BKC&3AL*,GGV I__  KV&;3_ !#I=WJ4LNF:Q<R7
M0@6(*T$KL&+!^<X901P,=\UU&DZG!K.CV>J6H<6]W"D\>\8;:P!&1ZX-7* .
M;\/>']9TYT;6O$LNL>0NVW!MEA"\8W/@DNV.,D]SQDYK5U:RN[VVB6QOOL<\
M<RRB0Q>8"!U4KD9!'!YJ_10!QEW\/K;4--\207-RL=QKWE^=);0^6D;1CY&"
M$G)SR23S[5+#X0U&3Q'I>N:EKWVJYL[>6W=([18TE5]N>,G'W>>N>V.E=:KJ
MZ[D8,,D9!S2T <3H7@.]T%OL%OXCN&\.I*98M--NNY 6W>7YN<E,]L9(XSUS
M93P?=)-XGD_M6(G7@ P^R']SB/R^/GY^7]?RKK:* ,WP_I;Z'X>T_2GN!<?8
MX$@641[-RJ H)&3S@>M9S>%WE\9W.O37D<D-Q8#3WM# >8PQ;.[=URQ[=/SK
MHZRM.\0V6J:UJFDVXG%SIGE?:/,B*#]X&*[<]>%//3IUH Y_P]X'U+06BL?^
M$HN;G0;9P]O8/;J'0 Y5&EZLH..,#ICIQ5.7X;7;Z3<:7'XDD2S.H_VA;*;1
M6:-_-\PAVSEQG./N]><]*]!HH Y/6?!]UKMEJ6FWVJQSZ;?E"R36@:6'"*I*
M.& !)7<#MX+&K*^&;B/QF_B&+4(QG3Q8);M;E@%#%PQ;?DG)].GYUK:9J2:I
M;RS);75N(YGA*W,1C9BIQN /53V/>KM '"+\/+A? L/A<:U'Y45T+D7'V/YB
M?.\[&-^/O?I^=87B*ZM[WQK?I=>+-.T::TBB@6#5[".1)>"S20^8PPI+8."2
M2O/ %>L$@ DG %8VH:_IMGK6DZ7<)))<ZDSBU=8MR?*I8DOT' [<T ,\*W.I
M7.DLVI3PW3+*5ANH8#"MQ'@8?82<<EAUP0 1P17,7LDTGQQCCLK^VAG7P_AE
MF3S W^D?=P&4@]#UKT.F>3%YGF>4F_KNVC/YT <AJ/@%;[PCJ.B)J/E3:G=?
M:[R\,&XO)O5_E7< H^15 R< =SS4UUX/O)_$5UJT6MM;B^LDM+R)+8-N"[L-
M&6)V?>/!#=:ZRB@#A[+P!=V=IX8@_MQ91H#EHR]F/WGR%,<.,#:3ZG/.>U7!
MX1OX]5U_4;?6UAGU9[>0%;7_ %!AP%_C^8$#!!ZY_"NLHH YB/PI<)J.K:NF
MH0V^L7]FMJMQ;6NU(RNXB0HS-O;+=ST4#Z]!9Q3P6-O#<W!N9XXU62<H%\Q@
M,%L#@9/.!ZU/2,ZHN78*,@9)QR>!0 '.T[2 <<$C-<=I7A#6=%U/6+VSU^US
MJES]IE273BP1L8PN)1QC'7-=E5/4M3MM*TZZOK@NT5K&9)1$A=@ ,_='/2@#
MF;SP7J-X^G7S>(2-7LKU[L7)M 8F#)Y>SRMW "< YSU/4U5N/AS<3Z3XDTX^
M()&BUV;SI#):J3&2%#'@C).P8Z #/!ZUV.EZC#J^DV>I6P<07<"3QAQAMK*&
M&1ZX-6Z .:N?#%W=^(]#UB74H=VE12Q>4MJ<2B0*&.=_'W1CK^-<_+\,;L>&
M-1\+6OB$PZ#<L6A@>T#R6X+[R@?<,KG/!&>>M>BG@5R[?$#04GU"%VOPVG$"
M\(T^9E@R,_,54@#'.>F.: )9/#-U+XMT[7GU-6:SM7M3$UMS('(+-N##!RHQ
MQQ[UG6_@)[/1[_P_:ZKY?A^\=R;4P9EA20Y>-)-V IR<94D9//<=;97MKJ5E
M#>64\=Q;3*'CEC;*L#W!J>@#FX_"TD'C.#7H+R*."'3_ .SDLQ;G BW!OO;N
MN0.V,=N]4F\%7=IK6KW>CZU]CL]8R]Y:26HEQ*5VF2-MPVDCKD,/Z=C10!C^
M%M#;PWX:L=':\:[%I$(EE:,)D#IP/\36)J7@2XO=1\1RPZY);VFO6XAN8/LZ
MNRL(S&"KD\#'5<>N"*Z;4M233$MV>VNI_/N$MP+:$R%"QQN;'11W/:KM 'E/
MB2%--N_#WA^_\50Z=]AL2ZW>HV,;VMPW"* K$*'4*3][(#=]QJ]#HVI>+O"F
MJ>'I->T^ZTR5(E@U*RL/+7[Q+(JA]K8VI\P./F(ZCCT9XTD7:Z*R^C#(IP&!
M@=* .:\2^%)/$>G6'_$S>RU>PE$]KJ%O%]R3&#\A)RI!Y4FJUUX)EUGPY>:=
MK^M3WUY<["+R*)8/(9#N0QHO PV3G))SUQ@#KJ* .4L?#.N+IUU%JGBJ:^NW
MMWM[:X2T2$0;A]_:#\S\#DGMQC)S:L?#+Q^)U\0W]Q;S7ZV9LPUO;&$,I8,2
M^68L?E&.<#GUXZ&B@#%\5^'U\4>'+G23<M:F5HW294#%&1U=3@]1E1Q5(^&+
MZ3Q1INNS:O'++96TEN4-ICS/,(+'(?CE1@8.!USUKIZ* .#D^'5R]A=1+KHC
MN)-;_MN&9;3B.;/W2I<[D]L@^]7(/ \HU'Q!=7>M2W"ZY:);W,8@1,%49-RD
M=!AC@?F3785E7OB&RL/$&F:+,L_VO4?,\@B([/D4LV6Z=!TY/(H 3PUI%SH6
M@VFFW.H&^-M&L*2^2(\(JA5& 3V')R>?RJI?>&IKCQC:^(K74FMI8[1K.:+R
M0XEC+AQ@D_*<CKSQZ=:VKRY%E8W%TT4LJP1M(8X4WNV!G"KW)QP*+.Y%[8V]
MTL4L2S1K((YDV.N1G#+V([B@#C7^']Q)X5U[0GUB/9K%W+=23"T(,9D8,R@;
M^>0,?UJ;4_!6HS:S;:WI'B!M+U5;9;6Z=;42Q7**<C,;-P1DX.379T4 5--L
MC86,=N]Q)<R#+23RXW2,3DL<<#D]!P!P.E6Z165T5T8,K#(8'((I: "BBB@
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M#6B/[.D<J\EMN$R-N)5U##/+9R".@_'4\/>'X/#]O>)$P:2]NWO)RB;$\Q\
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MW3?<W-U!:0\ X:1PN>2!P"3@D D#D5F6:>+WUJ\M7ENH]*FL]T%Y=K;&:WN
M>@6/Y60CGD9]ZV_$GAZS\4:#<:3>F1(IL%9(FVO&ZD%64]B" :J^'_#^I:8X
MEU?Q#<ZS,B>7"TL*1+&IQDX7[S' ^8D^V,G(!A>'?$.J:WX:TZVEO7BU[[>]
MI?E8X_W1B8F7Y=N,%0 #CJZU'=:WXEUR'6I?#JW23V%[):6T:K;&"1HB PE+
MG?R<_=VX&.O.>ET_PO9:;XHU37H2WGZ@J!XS]U"!AF7W;:F?]P5D2^!;J#Q#
M>ZCHOB2]TJVU&3S;ZSBB219'Q@NA8'RV(ZD _P J *K:CXFOO'JZ'_:,>G12
MZ&MZZ1VZ2/!*9 A"L<AB/4Y'7CH1SE]J^L:WX'\/3W>J31W2>)(K&XDMT1!/
MLN2H<J5.#\H.!QGJ#TKOH_"[6_BU==M[U4\O3AIT=L8=RK&&W YW9)S^GYUE
M+\/-OAH:1_:\@DBU(:G;W*P#,<OF&3E22&&2>.* .TA1HH4C>5Y64 &1P S>
MYP ,_0"O,-+BNVLOB2]QJEY<B*XN8@DOEX(%LF#P@(P.  0,#IWKTZWC>&WC
MCDF:9U7#2. "Q]3CC\JY<^"WCG\1&VU>6.WUO<TD#0JPC=HQ&S \$\#@= ?6
M@#F="U'6]%TOX>/_ &DLNGZE#!9R67D*%0&WW*P?[VX;>><'/05=DUWQ5KNF
M7FI>'([CSH;V2&VMV%M]FE2*4H1(6;S 6"L<C&,C@]3K'P3*;#PS:#5 %T!X
MWA;[/S+L0H-WS?W2<X[U"G@*XLM9OI]*\27UAI>H3&>[T^.-&#.WWRCD9CW=
M\<^A'& #LHF=XD:1-CE063.=I],UYEH<FI+XU^(L>FV$-W-)<6ZKYTP1 Q@P
M-W!./I7IRHL<:I& JJ,* . *YW0O"\NB^(-9U9M1%PVK2))-%Y&T(47:NT[C
MQCKG/2@#CK32]=\ :/X*\,6.K0YN;J6"Z<P;P2RO(2N>P/08&<<]<5M)J&O?
MVM)X:;4+R[N[&R2>XO[.WMHY)7D=POR2G: JIS@')/;ONZ]X<DUK5-'O4OA;
MG2[@W$:>3OWL5*X)R.,$]/SJEX@\&S:GKUOKVD:U<:/JL4/V=YHHEE2:+.=K
MHW!P<X/_ -:@#"N-:\:6=KX2AU&2ULM0O=1-G=J(ED$B[797X8@9"C(!'.>1
M4]A/XGO/$GB3PZ?$946"6\\%[]CB,P$JL=A&-A *]=N<'KWK8O?!TEV=%;^U
M9#+IEW]L,LT0=KB7!!+8( &&/  QP!P,58M?#=Q:>)=8UN/4$,NI111-&UOE
M8Q&&"$?-D_>.?7VH Y-/&.N7?@3P9K27$4,^HZC:VMZ!"#YBM(4;&?NYV]AW
MXQ5S7_%=SIWB>]TN_P!2GT02>6-*N9($:UN25!97D*G:V[<,9&!@_6U%\/6A
M\+:)H*:N?*TB\2[BE-N-SE&+JK?-C&2<XZ\=.]_6?"4^N0:K8W>IJ^F:DR&6
MW>V#-%A%4^6^[Y<[,\@X)R* ,^_UG6]7U/7[#13>0R:84@A>W6W97F,8DS)Y
MISM^8#"@=#SR,4]5\6:MHPTEO$WVG1;:>S_TF\LH4GBBN]V-KDJ^U,<CZ\GB
MM/4/ UP?$<FM:#X@NM&GN8TBO(XX4F2<(,*</D!@.,\_SSHR^'KI'VV>I*+9
M[06TMO>6_P!H63EB7/S+\QWG/8]QZ &II$DDVBV,LUU%=RO;QL]Q#C9*VT99
M<<8)Y'UKA/&?B/6]&MO$5Y;:FJRZ>L<MI:6T*RJ$P"QN"5^4L2V &!P 1FNW
MT+1[;P_H5EI%H7:WM(EB1I#EB!W/O7+ZC\.S?IXBMDUVZ@L-<8RS6ZPHVR4J
M%)#'G;\H^7CIUH CU?4O$5WXYLM%TW5HK"VO=)EN0WV59&B=60!OF^]][IP,
M$^U12:MXEU5=:M-*FNS>:4XM(Y8(K81SSK$CLTHD.0I9L87&!W)Z;4'A2XB\
M2:=K3ZLTTEE9M9E7@ \Q6(+$D$8.5&,#@#OUJM?>"+K_ (2:YUK0_$5WH[WP
M47T,<,<J3%1@, X(1L<9P: .DTJ6^FTBTEU.W2WOVA4W$2,&5),?, 1U&<UQ
M,_BNYB\7S:-J.I3Z/=&^C%C'- GV:\M\IN"R%2=Y&X8W#!( KO+6VCL[2*VB
MW%(E"@LVYCCN2>I]37.:CX0EU>WFL-0U)9]-DO1=B)K?][&0X<(DF[@9&/NY
MP2 1Q@ H6^M:K)J7CJQ:_;;I(B:SD\I-R;H/,(/RX//'(Z?G6!->ZGKMW\+K
M[[5'%J-Y;7$KSF(,%9K4%B%X&>3@=/KTKJKSP7--KNL7]IK4UI!K$*1WENL*
MMN94V*RN>5^7 ([]B*CA\!M::?X<CM=8F%YH"LMK/-"KHRLFPJR#&1MZ88'W
M- &/'K_B;3%\8:->ZE#=WNDV(O[+4#;*I=&1SM=%PN04QD=:NP>)]2O(?"^G
M1FX:\U#2!J%S/;+").%C'RB3"#+.2>#@# '.0WQ"NEZ+IVOV]YJ"R^(=<T^;
M:"A0S[(RJ1Q+STW<+DL2Q/-32^!9M0\/>&6CU&?2==T:TCBBNX%5]O[M5=&4
M\,IQT]J *R:]XHTRUL],UA%BO=0U?[%9WCB,N;?:7\QE0E!)A2N.F2#@\@O\
M5V_B.Q\(^+VGUIGLTL6FL)XU1;E2(R71\(%VY P0 V">0>:T-2\"KK'A];/4
M-8O)=32X2[CU155)(YDX5E4#:% XV^Y[G-6$\)SW6@ZEI^MZU<:E<7]LUK)<
MF)(O+1@1A$48'7))R2<=@  "_P"%X9(/#.FK)<RW!-M&P:4*"!L' VJ!@?G[
MUKUG:'IL^DZ1;V-Q?/>O"@3SG14R    !TX'\ZT: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)(
MD4;22.J(HRS,< #W-.KA_BNL_P#PAR-#>7%OB_M580E1O#3(,'(/'.<?GGI0
M!W%%<?\ VE>7OC63PO'J5S%'9:>MU/<A8_.F=W(4?=V@ #/"C)(]#F7P3K=_
MJ+ZUI>J.)KO2+YK7[2$"^>A 9&(' ;!Y XH ZNBN%\6:IJMI=:S]FU5HOLVF
M^?:6UE&KR+( Y:2?>I4)P !D9PW4U3EU_7K^^\ "WU);1-=LY);M%@5AN%N)
M,KGD<DX[<#(/0@'HU%>=6-SXIOM+\7:19ZW*^JZ3=[+&\D@BW2 Q*ZHXV[3R
M2,@#M6EHGB&;Q-!X;?3[Z:,20-=:@"D9;"_(8FRORL9,],<1M0!V=%8/C"^U
M/3= :ZTNVN+B1)HS.EJH:80[AO,:G@MCH*XW4_%T[?#W5M>T#Q)+<F"\A6+S
M8(Q) K/$C12J4'.2Y!QGD<F@#TZ1_*B9RK-M!.%&2?H*S/#FOVGB?0X-7L4F
M2WF:15690K_([(<@$XY4UDW&J:A#\4;#2ENV.GW.F37#6Y1,"1'100V-W1CQ
MFO/M%E\1Z/\ "*+Q'I6M"./3I;F8Z<UNABGC%S)O#,?FW'G!!'88[T >JCQ%
M:'Q8?#GE7 O/LAO-Y3$90,%X.>3D^G8UKUP)O$?XN6EZ594/A=Y2O<#ST.*@
MT[5/%NMZ5HFOZ6)S]JDCFN;:9K<6QMV^\JD?O RC&">I!R.P /1:*\R\4>(]
M:TBUU74(=5,TUGJ<4:06L2M;Q0,\:^7,S+GS#N)(5B1E>@JUXL\3W>CZ]=VF
MH7]YHUE- BZ9J20*]MYI!W"9BK;3NQUP,<\=: /0Z*XF]UC4]8U_6])TN6]A
M_LZ*$))9^0<R2(7#-YO5<;0 !V;)/&.C\.OJ\GA^S;7HX8]5V8N5A;*;@2,C
M'J #[9H TZ*\RUCQ'K6FR1W2:J;F0:[':216T2M:I;O($$;,5!,@!!.TDANN
M!Q5UI?$NL^-O$VB6WB)K"VM(;66W>.TC=XS('./F'(R.<\\#!'- 'H%%>2V?
MB_Q1J.D^%LW\5M?7&K3:7?,+=621HP_S@'I]T' QS[5<DUCQ-H>J^)]!NM9:
M\>#1VU:POGMXQ)& 64HR@!3\PXXZ?H >G45YD-<\0:5X3T/6+K6S=3Z\+"SA
MB>V14M99L;I<CEOER<'C=[<#8N]1U30_'6CZ-)J,]W8:W!.B/*D?FVTT2[MP
M(4 J0>A!P1Z<4 =K17GFCZYK4FFZSH=[JDK^(K74A9Q3^5$#LD^:.4*%VX\O
M<Q!!^XU6;O5-9U;5]=TG3)[^.32EBACEM_L^6E:(/OD\SJ/F PH X;VP =U6
M1H?B*TU^34DM8KB-M/NC:3"=-A+A0QP,YQAAUQ7.66MZY?Z_I/AG49%L-072
MVU#49+7:VXB01JJ$@@ G+'OT IOPWAE@OO&,4]PUQ(NN2 RNH#-^ZCP2  ,X
MQT H Z4>(K0^+/\ A'/*N!>?8S>;RF(R@95X.>3EO3L:UZ\]UJTO+WXPV\%E
MJ#6$C>'I=TZ1*[JOVA/NAL@'..2#QGCN,X:OXQE\+>([:'4S)K7AV\*^?%;Q
MC[="%5\%2I"OL)^[WQUH ]3IKR)&NZ1U49"Y8XY)P!^)(%<WINL-X@U?3Y]+
MOY#IBV"W4X"H1*TO^J!.W(("N2 1_#ZUE_$Y)VM/#HAOKFV#Z]91N(2N&S*,
M$Y!S@@$#IGJ#0!T<?B*TD\5R>'!%<"\CM/MA=DQ&8]^S@YR3G/;M6O7G5W8W
MEQ\7Q:P:I/;R?\(TH>Z6.-I2/M!Y&5V D]]I'7 '40:1XRU:?PWH-M/*\^I7
MVI7%A)<Q)&KLL)D.Y0V$#$(HYXY)QT% 'IE8FL^*;'0M0L+&[BNC-J$GE6WE
M1;A(_IG/'XXJKX:7Q'#J>IPZMODTTE'L)+AHO/&1\Z/Y?RD ]#UQUK&\??\
M(W^ _P#L*O\ ^BS0!WJDLH)4J2,X/44M(S;5SD#TR>]>:6GB/6H-6\+"75#?
M#4;J6VOFBB7[(QV.P$+%0QVE0,C(/.230!Z917ET^I>)[FR\<RIXBE@.ASR-
M:^7:Q?,%A$@1LJ<KSVP??M6Q9^);S7]<T31HYS9&XT5-7NY(54LVXJJQKN!
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MP^)K!]US-I$L3K>B^-N&1\91XO*YY.00>,8H Z^BBB@ HHHH **** "BBB@
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M9G(^\<>@ YS@G&.CHH X-OADC:*^BC7[]-,6[%U;0(D8\@^;YI&[;EN<XW9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]LD#/3/%5].UW2M&UGQ9X<\61-YNH:C)<V\<ENTHOH)%555  =Q 7;CZ>AH
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MWEN NVW8$\]@Q SV/'6H];CGU'6/B?9Z41->36=B8X8VYFV(WF*,=3CY3CU
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M9-+_ +%2X2!AN"RF9E.Q47<QVK[GKVH [W SG'/K1@'J*X/QQXD6\^&<NO\
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MD9#J5W+M/WOI7B7]KPWNF>$+L07%J;;7T,^FV]DZQ6 _>C:0%R7)(R23DDX
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M8+C\!61XACT1?"]G<:/9RPVEYXBM;MGG\PM<X=3),5D^8+QR3C.,]""?6J*
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M!=5 W$]R.W%7M$N4E^+%O>Q-J=W;W6A&)+NXM717<3!B -H" #V ^I/(!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHJKJ&H6NEVAN;R7RX@RH."Q9F.%50.222  .30!:HK%M/%6D
MW4NHQ-.UM-IJB2\CN4,;1(1N#'/&W )R*+;Q5IEQJ-M8EIX)[M#):BX@>,7"
M@9.PL.2!SMX..<4 ;5%<I-\1?#L-M>W'G7;Q6,[0731V4S>0R@%BXVY51NZG
MK@XS@U<A\9:+<:Q;:9'/,9;M6:VE-NXAGVC<P20C:Q YX- &_69KNGZCJ5BD
M.F:Q+I4ZRJYGCA24LHSE<.,<^OM6'=?$SPO:1W,DEU<LEI<&WN62RF;R&&,E
M_E^4<XR>ISC.#5?7;V1_'_@:2SOYC97INB\<4Q\J91;ED8@<'KD&@#K=-T^+
M2]/BLX6=EC!R[G+.Q)+,Q[DDDGW)JU6%J7B_2-)\U[N69;:&40SW2PLT,+G
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MRL^/F*K@$^PR<?G6#IWC31-5MK*XL9YYH[V9X(=MM)DNGWMPVY4#N3@56O\
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M "U7^X3_ '3W]1Q5Q5"J%4  #  [5#>7EOI]I)=74HCACQN8@GJ<  #DDD@
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MT/R Y.,8I=*N,_$?1]42'6;BUET:6%KJYLY$'F>8C$;=H$8 !Z  ]LFO4:*
M/%S!=?\ "D); 6%]]L.IEQ;_ &23S-OVWS,[=N<;.<UT$6K2>&/'7B :IIFH
M7.GZV8;BRN+:T><.1$$:)@H)4\< ]CVKTBB@#S'77DT3Q;INM:CH=X=%N-,6
MS>.P1G-C(LA=0RQ]BK;>,C(X[5+?Z3HEWI>GI'I^I:!'+=2W5G?6J.DUO)M
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MB)H]\FP#(!(8\CD+GN*]DHH X>[<R_%W1[J."X:W&DSQ-,('V*S.C*I;& 2
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M;49LS 1DG^+"\C/&*[*"*'PO'<--?WMS#<SJ+>*>5YY Y&/+0L22#C/M\Q/
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MN(+E DD4BXRK $CH0>">M<I\1LQZ_P"$%%[=VT5UJ?D7 ANY(5DCV$X.UAW
MH ]"HKS;0-8ET[XD^(-,AU2:[\-6>GK=32W,[3"SFR,IYC$G&W+$$G&.V*ZA
M?&%DNK6>G75I?6<E_&\EF\\0VW 4;B%"L2&QSM8 ^V>* .AHKD],\?Z;K,B)
M9:=K$D3/-$\RV3%(WBSE6(Y!..!].E-\.Z]H%EX(TFZTM;L:?=.8;&"4EYI7
M+M\HW,3DD,>3@ <X X .NHK%L?$]C=W][I\Z36-]91B::"[VJ1$>D@*DJ5X/
M(/'?%<;XPUU=4F\&W-K;:E#;7&N6IAN6.R*>,DGE0V>>"-ZC@<4 >F4444 %
M%>;?$S2FTGP)XAUNWU+4TU'(ECDCOYD6(&15"J@?: %]NI)KIK72K'0?^)X^
MH7L5M%9-]H2YO)9H\?*V_#L<$;2..NZ@#HZ*Y]/%UFNLP:5=V=]975S"\]JL
M\:G[0J#+!-K,=P'.T@'VK,@^)>C7%A9:@EIJ8L+JY^S&Z:VQ'"_F&,!SGC+#
MMG&1G% '9T5SFJ^,]/TJ;4XS;W=R-*B2:_>W12+=&!()W,"?E!.%!XI;[QII
MECJ=AI_E7MQ/?P-/;>1;EA(J@' /<\CZ9YP* .BHKA=9^(D</@/5=>TS3[IK
MBRE:TEMYU5'MI@0O[P;N0"RGY2<Y'OC5US2;KQ#%I-Q#)J.FW%K=K-M6X5 %
M##=YBJ2'!4$ ?[7..: .EHK#U'Q1;6$M_&EI=W?]GQK)=FV5#Y0(+#(+ DX&
M> >*V91(87$142;3L+= >V: 'T5PENGC9-$T7S=+MFO(;S%]";\_O(^@EWXY
MYRVSZ<<8JUXN\06\OA[Q%:VL%_<?8[:1;BXLV"BWD\O<!NW*Q(!!(7. >?2@
M#L:*\]TB_P!*30_AY!J27LE]-;0M9O&7""3[/SO((!XSP<_2K&A2&V^)GC7+
MW$D26]C((]SR$$K*2%'./H* .ZHKC_#_ (A\/:?X%TR^TX7:Z;<3>19Q3$O-
M+(TK*%&YB<EL]3P.N .-"U\7Z?<:Q>Z5+#=VMW91B6X$\8V1QD%@Q=25P0#W
M[&@#H**YU?&5@NI:?9W-K>VHU)6-E/-&-D^!NP,,65B.0&"D_7BLU_B;HR6%
MQ?\ V/5#9VMTUK=3_9<+;L&"DOD],GMDCN!Q0!VE%<M+XINE^(D?AQ-,G:W^
MP&Z:92GS9D50PRP(5?FSW)/ XR>@O[^WTRQEO+N39#&!DX))).  !R220 !U
M)% %FBL"#Q7;2ZS-H\MC>VVII;?:HK:81YGCSC*,KE2<\8)!_"N)T6=]?TJ_
M\07NG:FVHZ?J=Q-!/#*B$+'(56'[_*!1AEZ'DC)/(!ZK17F7A.:Q_P"$=T#Q
M9JB:A#JDD2Q^8L@SJ,DPX4JK'?SR-V-N.P''86_BJSEU"\TZ>VN[74+6 7#6
MDL8:1XB<!TV%@PSQP>#UQ0!NT5P5Q\4+27PU<ZQI6C:K=0I8R7D<S6X2$[3@
MJ7)QD=2!DXSC)&*V[+Q,7L=+2>QNFU&]@,J6R^4&=55=[\OM"Y=>^>>E '14
M5RMS92>);[0=;LI]2LOLLSF2)I?+0J#ATDCYW,2N!Z<GL ;?AK0Y]%FU4O>7
MD\%U=F:&.[G\UHP1\V#V!.<+V&.Y(H WZ*R+_P 0P65[/9QVEU>3V]N+F=+8
M(3'&Q8*<,PR3L; &3Q[C/(ZAJ:VOQ5TJ]C2^GCN="ED6UB+.6;S(\83.U3CJ
M>!ZF@#T6BN:@\<Z3<:!#JRK=*);P6"VKQA9OM)?9Y1&<!L^IQWS3+G7+77=&
M\1V*)=VEYI\3)<0NWER1DQ[T(9&(P1@@@_6@#J**\DE:1OAU\-;CSYQ*VH::
MKD2L X;J&&<-T'6O6)9!#"\A5V"C.$4L3] .30 ^HKF(W%K-"LLD+2(4$D9
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M02<=!GB@#KJ*S]#O9M1T:TNKBWE@EDB5F63;DDJ#D;21@UH4 %%%% !1110
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MO 7EZMIYCB?4)+2,VQ$>!YRR]2Q R !G<>PR1Z3?RB&PGD*2/A#\L:%V/'0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG.20,FJ@^(MJUAJ,Z:%K+3Z9(R7UJ(H_,@"J&+$[]I&#D;6)/I5&2TOG\1>
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M# ]O&EQ-(P(Y"$A4'J3SSP,#,]U:7LOB'P#<II]V8=/CF%VWE$>26@\L _\
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M;:ZCJMKIDEE>6DUY9F\MC.$Q+'P#RC'##<.#CK5[Q&VJ)X;U)M%C234Q;O\
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MD+'>3]L?:2VX'[VWG-=[JGBFWTW49]/CLKN]NK>S^VS);A!LBR0#EV4$DJV
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MW\G) P0/7IS7%:9I&L:;\-M4\"S:9<37NRYM;2Y"9AFCE+%92_1=N_D'GY>
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ML#(ZL)5QG:V/NOCG'(]\\5C7'Q?MHHO$#1>']1F.@S"*]*O&%7YBN02W/*]
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M1+/5K(L;:[B66/>,, 1T(]1TJ_0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(?$'2-4U&PTJ^TB
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MM[J^DE*[%\D$D(03NW'&".@)SCH?0** //+73M5C/C\OI5T/[3=FL_N?OOW
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MM-4\*:]XDB;3+F^LM3O&U&TFM]I^=U >)\D;<%1@GC'<=*[JD5U8L%8$J<,
M>AZ\_G0!Y=8>$M4\/0^ ;)+*6[&E3SSWLD!79&95?(&2"0&?L.@K8N[75]!^
M)5SKD&EW&I:9JEG%;R?9BGF6\L9.W*LPRI!/(/!KNJ* ./\ AY8ZEI]AK$>I
M:=+9O-JUU<Q"1T;>DCD@C:3^N*Z/5],M]:T:]TNZ&8+N%X7]@PQD>XZU=HH
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M7!_.G4 <O\.K"]TKP#I&G:C:R6MW:P^5+$Y!P03T()!%=1110 4444 %%%%
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M(-+7$_%NWAF^%^NM+$CM'!O0LH)4[AR/0T =?:6D-C;+;VZE(4^XF20@]!Z
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M/]QUDXW*?ID8/%7-0\<7NE/;?;O"]_%'=ZC%8VS^=$WF;QD-@'(/!&#W')%
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M I*JS;03V&><4 /K(UGP]9ZW<6$]W+<*UA.+B#RGVA9 " QXYX)&#QS7.O\
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M(IFVI,4R"A/;(8\T 8<$TMO\:I;G4;*VLBOAUY))89O,5U$Z_,6*J<C!'(Z
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M;*[7S1!@N482#.?ERIXZ@>M $=U\1&M?"^JZRVC.YTW4FTZ:)+@$%E=4WAB
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M61=^S&3D+R#U]N,<CKZY,:9J0^*;ZU]C/]G-I(L?-\Q<[Q*7SMSG;@X]<]J
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M3BQ@%S&D<P0!U1]P!QV.!G\JGH \9U;5=0\1_!)-9U>VMFF:]AEADC<NPS>
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M:QSAEEA*E@Z.0,C (/&0>,5!_P )Y>QS:"TWAV1;76HQ]FD2Z5G\TQ[PK*0
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MZL<[E<;_ "H]IW8SCDKD@@=B5N_'5XVM_P!E:/X>FU&:33%U*W)N4A$J,P4
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MKJ6J2:7'#J%C=/9MI_VDL3,&"JF[9P6++C@CYA0!V%%,C,AA4RHJR;065&W
M'N 2!GZX%<!+\0=;>PUJ]LO"HGBT:\EM[H&^"DK& 6*?+\QP2<<<8Y).  >A
M45Q$_CVYGO\ 2+;1=&%\-6T][ZTDDN1$#M"G:PVG;]X<\\]N]7[?Q+J6H7-W
M8V&EV[7]A!$U['-=[429TW>2K*IW$#JW Y'7G !U%(S!5+,0% R2>@KAI/B,
M'\/:3KEKI@:RN[Q;*[\^?RVLI"^P[P%.0&XSD=1ZUT-UJMT-0O[2"PBN(K6U
M65F,^TL[;L1XVD=%R3GH1QS0!IVMW;7UK'=6EQ%<6\HW1RQ.'5AZ@C@TU+ZS
MDNIK5+J!KB%0TL2R M&#T+#J <'KZ5R6C^+[9O"GAN33]*AM[G6?DLM.C<)'
M& "S$D+PJJI)POH,<UFZ$]Y%\3O%[RZ?;K<KI]JPCAE^2;_6<Y*C&>AR.W>@
M#T&TN[:_M8[JSN(KBWD&4EA<.C#U!'!J:O/K/QR+3P9X6U+3_#L<=MJ]U':)
M:03*@M][-C:-H!^Z?[HR:UM/\83_ -I:Y8:WI\=C-I5LEX6@G,ZR0L&.02JG
M<-A!&* .KHKB#XZOEA\.7/\ 8T30:^0+;%WAHRR;U#_)CE<].AXYZUVLLB0Q
M/+(P6-%+,QZ #J: '45REMXJU*\ATC4;;0GFTG4YE1)(I"TT,; E)G3;@(<#
M/S< CZ4V?Q?=RV.K:CI.F1WMEI<TD,I:X*23&/\ UGEC:0<<@9(W$'IP2 =;
M45S<P6=M)<W4\<$$2EI)96"J@'4DG@"N/F\?2W&HZ-:Z-I/V]-8LGN[65K@1
M#Y0O##!VXW#)Y/' -4I/'C7?A+Q,^I^'4^WZ)N34-,EG#QNA7<&#%<,K+SR*
M /0$=)(UDC961@"K*<@@]Q3JY>Z\66]H=/L8!90W5Q9"Z"7-QY,44?  S@DD
MDX  Z*>F #G6OQ&AN=+L)IK6.QN;J_DL&%U-M@21%+9$FWYE8 ;3@9W4 =S1
M5+2[F\N[,R7UHMK.LCH8TD\Q2 Q 8-@9!&#T[U1O]>=/$$6@Z?!'/J#6S7<G
MFR%$BB#;020"22W &.Q.?4 VZIVVKZ;>7DMI:ZA:3W,(S)#%,K.@SCE0<CFN
M/U'Q==ZEX(\5&UM5M-7TF*XANX7G/[HB)F$D;!?F!&"N0N>^*T_!NFQR>']"
MU&[TZSCO8-.B@MYHG+L(2BG!)5<9(Z<X]>: .IJ"YO;2S:%;FZA@:9Q'$))
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M>>F.: .YU/3+36--GT^^1Y+6X0QRHLC)O4C!!*D'!'O4>BKIL>E0P:3.DUE
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M '85#/=VUJ%-Q<10ANAD<+G\ZQ=%\2M?Z[J6A7]JMKJ=BJ2%4DWQS1/]UT)
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MX_A('(ZT =]165X:GO+GPYI\U^L8G>WC8E)3)N!4?,25')[CGZFM6@ HHHH
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MHW=M'>6<]K+GRYHVC;'7!&#_ #K'TWP9X>TB=)K'34C>,YC#.[K&?558D+^
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M.P$R"8R;3\IV$]OO>]>GT4 <L-)OM0\3Q>(KRT$#65G);VEIYJL[/(079F'
M^Z  ">Y/I7-1>#]?B^&.A^'?LMN;ZPO(9I3YX\LK'-YG!QG)''2O3J* .3.E
M:I_PLH>(!:+]A&D&RQYHW^9Y@DSCICC'7K67HGAW6=-\'KI-[I-E>J^H32W5
MK)*K)+!(SO@$C&X%EX..G45Z!10!Y]I7A*^T71[VPM].AN='NK_S%T>[F$@A
MMC'AE#-D9W_,%SCWY)JA<^ =2C\!>)=!TJ+R8-2F4V%C/<;ELT^4MEN< L&.
MT9QD<]:]0JK)J5C%J$6GR7D"WLP+1VYD'F. ,DA>N/>@#E[K1-5M/&UMXJL+
M99A-8"QO[(RA7 #;E=&/RD@Y!!(XK(UKP1JMYX:\1+!% =5UR_ANG0RXCA2-
MD*J6QR=J<X'5O09KTFB@#D;S2=7G^(%EKD5JB6L.F2VK%I1O$CLK XZ$#;CK
M6?I/A*ZC\7:;KZ:;%H]TL4@U86TP,5\Q7"X4>C?-N(!X[]1WU% &9XDTV76?
M"^K:7"ZI+>6<UNC/T#.A4$^W-<@?#/B#R_"FL+;VB:KH2&WDLQ<$I/ T:H^'
MVC#_ "[AQCL37</J5C'J$6GO>0+>RJ6CMS(/,8#DD+UQ[U:H YO2=$N&\6ZA
MXFOHA!-<6L=G!;APQ2-26)8CC<6;H,@ #GGB#XC:)J/B3P1J&BZ9%&US=A%#
M2R;$3#JQ)ZGH/2NKI"0 22 !U)H YM[GQ3+:16T6D6EL[[8Y+@WV_P I> S*
MNSYB!G XYQ7)^(O!_BC5['Q=8F"PN6U)]UE?37!#QP_*1 $V_* 5/.0"3GDU
MZ38WUIJ=E%>6-S%<VTHS'-"X96&<<$>XH:_LUU%-/:ZA%Z\9E6 N-Y0'!8+U
MQDXS0!R\>E:TWQ#MM?N+.!;==(:RD6*?<1(TBR<9 RHQC/'/:N<_X0?Q"-"2
M2%;6+5K#7Y=7M$>7,<RNS$QL0,J<,1G'_P!;U.B@#B;+3O$4WQ!3Q'=Z9:VU
ML=(^QM"+S?('\W?QA<'TZ@<CGM6-;>!=;_X0O3[0BV@UC2=7;5+7,NZ*4F5W
MV,0,@%7(SCK7I]5Y+^SAOH+&6ZA2[N%9H86<!Y OWB!U.,B@#G/[)OM3\5V7
MB.]LA;'3K26*VM?.5G>23&XDC@* N!SSDDXQSB67@74;KX-R>#=0:*UO=C!)
M8WWIN$IE0YP#C. >/6O1J* //Y].\7ZQJOA:^OM+T^WETJX=[DB])$NZ,H64
M!.!SD \]CCK71Z-JFK76O:S8:C96\,%JZ&UF@E+^8C;L!_[KX4''HP]B=VFI
M&D8(1%4$ECM&,D]3]: .0^(FG2W&F:5JD*,[:-J<&H2(HR6B0D28'LK$_P#
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MZ)88K>.=C%" <EF?;EF/H!@8'O0!T>BWFL7C7+ZGIT%G#E3:F.X\QG0C)WC
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M!D?4=:F'A[7M$\;76MZ3]EU"WU.VAAOHKJ<PNLD0VK(&"L"",Y&* &_"4N?
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MP1V;&[9E<AO[IZ5NR:'J\_Q L=<FBLS:1Z8]E,%F;=O=U8E1MY VXY()Z\4
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M/.!T!/)QFK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,)WX^>/D#^/I\O-*#QA>VVNM:ZG9$Z<;1[HZA!;3)' 4&623>/0$A@1G'04
M=-?ZMI^E>1]OO8+8SR"*$2N%,CDX"J.YY'2KE>5^+]3U36O"WAO5GM[:*PO=
M6L9HX<GS8D:0%&+="2,94 8SU.*]$BEU4Z[<12VUNNE"%3#.LA,C29.X%<8
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M+*7B656<*LL09064Y[D8/K6K:>(M;?Q/J/AZ]M+"&\6P%_:2Q2/)'M+E-KY
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MYX4D]*Z.B@#D;O3/%6H^'UT99--TM'@$$UW#.]Q($Q@[%*( 2.Y)QGI5'4_
MMUIMIX>E\'36]M>:$KQ0Q7F3%<12 ;U<J,Y) ;('6N\HH XC6_"_B'Q'X?B>
M[O[.UUVUNXKVR\@,UO"\><*2?F8'<V3@=1QQS->>'-;\6>&-2TSQ1-96QNX/
M)2+3R[I&V0PD)?!8[E7 P, 'DYXZF^O[33+*6\OKF*VMHAN>65@JJ/J:?:W,
M-[:0W5M()()XUDC<=&5AD'\C0!R9\/ZUK<>@P>(!9*FE7,=W)+;2LYN98U(0
MX*C8,G<>3TQ[U5A\*ZXFF>,[9AI^_799I("+A\1[XA'\W[OMC/&?3WKNZ* .
M%F\+:W)9^#(E&G[M">-[C-P^)-L1C^7]W[YYQZ>]+!X7UN.U\9QL-/W:Y)(]
MOBX?$>Z(1_/^[]L\9]/>NM_M2Q_MC^R?M*?VAY'VGR/XO*W;=WTSQ3]0O[72
MM/GO[Z=8+6!"\LC=%4=Z .,E\*:X^E>#+51I^_0989)R;A\2>7$8_E_=]\YY
M^GO5J#0/$%IX@\6:I;/IZ/JL<'V,F5V\MXHRHWC9T.<\$X]ZZ^*5)X4EB8/&
MZAE8="#R#3Z .$M/!U_8ZWJ>MZ5;Z?I%W=:>8/L\$K/#+<;MPE<;% QC' R=
MQZ=Y]'\)3Z;XJN_$%M8V.G//9>3+9VL[&*XFW!A(WR +C!&0I)W'/OVE4?[9
MT[^V1HXO83J/E&;[,&RX0$#<1V'(ZT <)8_#_5[/PAX9MEN+)=;\/7!F@<.Y
MAG5B=R,=H*[E;&0#C'>MR7P[J%]K-YKUU%:1WS::VGVMNL[,B!F+,S/L!R3@
M8"\ =\\=;10!YX/!NNIX3\(:2/[.,VAWMO<3.;A]LBQ C"_N\Y.>_3'>M2+P
M_K,/BWQ'JX2P:'4K2&"!#<.&4QAAEODP =_;.,=ZZ^HH;F&X:00R*_EML<KR
M W<9]10!Y^G@O7H_!OA/1@=-,^BWUO<RN;APLBQ$G"_N\Y.>_3WJG=V6JZ_X
MH\0W>CV^A7]IO2PN(Y[R>W<F-?G201@B0;F89<=,C&.OIEQ<PVD7FW$BQQ@@
M%VX STR>U9-[X/\ #>I7YO[W0M/N+H_>EDMU+-_O<<_C0!+X;OYM1T.":>SA
MM)%+Q&*"3?$-C%<HV!E3CC@5K4U$6-%1%"HHPJJ, #T%.H Y";P_K#_$^#Q*
MJV/V&/3FL"AG?S3F3?OQLQ[8S^-:'C71KSQ#X/U+1[ P+/>1&(/.Y55!ZG@$
M_ABM+5M8T[0K![[5+R&TM4X,DK8&?0>I]A5T'(R* .,ET'Q$/%6F:M$VFR0P
MZ?\ 9'@GD=A;2;LF6+"_,2, @[3@8S6+8>!?$=GX6\+:0\FER/HNJ+>,XFD4
M2(I? 'R'D[_H,=Z]-HH XUM \00^*O$.LV;:?&;^SA@M=\KDH\>[!<;.AW<X
M/&*=H'A%M,\7W6O1V=IIB7-H(9[.RE+QS2[PWFD;5 ( ('&3N.<=^DLM4L=1
MENXK.Y2:2SF,%PJ_\LY  =I]\$5<H *YSQMH-YXAT&.VT^2!+N"[@NHOM!(1
MC&X;:Q ) ..N#6NFJ6,FK2Z4ERAOHHEF> ?>5&) ;\P:N4 <<?#VLV7C#_A)
M;+[%-+>6:VVH6CRM&N5.4>-]K$D9VD$#(YXZ5J>&- ;1(M0FG='O=2O9+VX,
M>=JLV %4GD@* ,G&>3@9Q6[10 5R^M:)J<GC#2O$.G"UF^R6\UM+;SRM%N60
MJ=RL%;D;>A'XUU%% '!:EX!N]2T[5+H7T=MX@O+Z'4(IXP6C@DA 6).0"RA0
M03@9+$X[5O>'X_%#L9_$CZ;&R)L2#3B[(Q)&78N >W '3)R3VWZ* "N9\8Z+
MJNL1Z6VER6K&SO5N)K2\=EBN4 (VL5#'@D,.",@>E=-10!Y-XIT'6-)\(_$&
M^OYK%[?4XA<((-^Y6"(I!!X &WKSGKQTKJET34-=G\.W&J1VL-MI;"Z"PRM(
M9IO+*J>5&U1N)[G.!VR=;Q/+H,6B2GQ));+II(#BY;Y'/88_B^G-:*06UI8^
M0H$5M&A'WB JX]>P _*@#S+PK8:MK7@GQ#H]NMI';7VIW]NUT\K;XT>5E?Y-
MN"<$X^8=><8YZ:T\,7UAX[L]4M4M!I5MHXTM$:9O- #A@V-F/X0,9]_:K.EZ
MCX1T?0I-2TRXL[?2Y+C8TT1/EM*7VGZDL<9[UTU ''V'A_6?#NO:Y<:0+*YL
M=6F^U^7<S-&UO<$88\*VY6P#V(QCWI1X"M4^&;>#UF+#[.RBX(P?.+%_,QV_
M>'=BNCL=4L=2DNTL[E)FM)S;SA?^6<@ )4^_(JY0!R=]X/EU3X?2>'[J^*W\
MZ"66\0?\O.\2>8!QQO'3TXJ.QTKQ7J^FW&G>+)],6WDMI+=O[-+EI]ZE"S;@
M HP2< 'G'(Q@]A10!YD_A#QC+X3TOP[-)H[II5W;207GG2!IHH6!4,FSY3@
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MYR66U,'$I.,%N=H R,[L\8I-9\4>)- \-ZAJ-_IMHLMG?1P1L"=EW"\B()%
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M 0.N<\=* .KHK,\/7=]?Z';7FHK$D]POFA(XRFU#RH())W8QGGK6G0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6!XRT";Q+X;ETZVN([>X\V*:*212R[HY%< @<X.W'XUOT4 <K>
M>']6O?%/AW69;BS;^RTG695#+YAE4 [>N N!C.<^U4(_!^JIH7B_3FGLMVOS
MSS(X+8@\V,1D'CYL 9[9]J[FB@#C)_"NJ2MX182V8.A$-)\S?OOW9CXX^7@Y
M[\\>]5[#PEXFT/4;VTT?6[./0+RX>X\N>W9KBU+G+K$00N"22"V<9Z'OW=%
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MM/;2MZ_9)YHG,Z1B42;& .#C!Y[],#J/2XA((4$S(\F/F9%*@GV!)Q^9I]%
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MQ GACPY=:HT7G/'M2*+.-\CL%09[#)&3Z9KD]7BU6+XH>!O[0N[:X5A>D>3
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MQ7X@DT.WTZ*W6,WFI7T5C 9 2J,^27(!&0%!.,C)P* -8Z98&]%Z;&V-V/\
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M/<+N0R1E&QTY5@"*N9&<9YKRB]U[6]<\&> M4-\EO+J6JVRW*1P_*Y)9AWZ
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MA!&1O&SY<CGFNA>&.1XW= S1-O0G^$X(R/P)'XUPGA#_ )*G\0_^NEA_Z(-
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M!@],DG.  >JY&<9YHKA+.757^+FLQ&_\RV@TZWDCMS$,!69_E!SP21RQSGZ
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M@",'U%:= '(_\(?=VNKZ;K5AJ$,>IVUB+"YWP$Q740.1E0V58$9!R?2HM0\
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MM5N[@*^$<B-B"01S[8KH?%'A*?6M1L-7TK5I-)UBQ#)'<K$)5>-L;D="1N'
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M?#*^6- JFZMV( [FX0D_B237H%<YXU\,2^+_  ^^D+?K9122([R>1YC'8P8
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MB[OE4"-1R3QGN<UJ:]X8?6I=)OX[U;76-+E,MO=+#N0[AM=&3=DHPX(W9]Z
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M;54%G#'$7D5>N\D@!2P.,\YQ3H]3UF+QEJ/A&346=Y=-_M#3[]H4WQ_/L9'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]*3ZRTCWMVT09G+KM.U<@ !0 !S@#N>:W-)LY=.TJVLI9UG-O$L0D$>S<%
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M!A'<1+*H8<@, 1GWYH XI?A[J#:?H^GW'BFXEMM(O(KFT/V1!)B,$*KL2=Q
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MM_/C63R;A-DD>1G#+V([B@#-M/"]E9^+]0\1QEOM-[!'"Z?P@KU;ZD!!_P
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M))<B)6(+)"6*J?ESSW! ]*Z"]\!?:;G7_(UJZMK+7(V^TVJ1H1YAC\O<&(W
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M;'6;U!8W3W,4K+&2Q??N1QM *DR,>QZ8/%17WP[TO4=+N[:>>X2[N;X:B;V
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M2'YI,88@X'T&3QSUS%H>OZEK'@OPC=WNJ,LMV\B74,"D7%]L#J A7[O*AF/
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M6UW1MBUV*?D8,H^93@ J/RIEUX6M[KQ%::[]OOH;VWMC:N8G55GCW!L.-O\
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M2;9)+:)=V6!5,;5R.6! X'3BNXA\-6<ES=WE](^H3WEM]DD><+CR.28U"@
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M $V[N8UBO%M639<JO"[@ZMA@. PP<4 9OPB!'PNT8,VYAYV3CK^^DKMJX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445SOC.;5[?1HIM(MI;MDN4:YMH)?+FE@&=RQMQ\W0\$$@$"@#HJ*\
MQ3Q?'+HEL-&O[MSJ.N)8/'J#M'/99CRT+,P8@DH0#@_?X.1FI-:O/$W@G2O$
M.K27=NVGFWC:SMY;N2ZDMY2ZHS;G4$I\X;!)P1Z&@#TJBN<BT*YM]8M[B+7K
MM["6W:&>VGE9S/)U61&W?(<!LA0!CL*X>#7=7D^$/AW5VU*Z.H/J,44D_F8,
MB-=%"&['Y>* /6ZI6EY<W&H7UO+I\MO#;L@AN'92MP"N25 .1@\<UQ,MKJFL
M_$;7M(/B/5+2SAL[6XB6V=%*,S/D [?N_+SQD^M1_P!H:J+KXD0?VO=_\2^*
M-[1\KF'-N9,*-N,9]L^_>@#T>BO+;*ZU:R3X>ZH^MW]R^K"*"[@F<&)U>W+Y
MVX^\",[NIYS2ZUJ^JO%XRCDOKNTUJSF']C6\#D>9'L4QE4Z2EFW!LAL=.,4
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M_BGQ1X;TWQ-IE];VMQ)-]H<S:A)Y/DAR&B:$1E1@#&<[LC.: /3Z*X.S>_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I[E[:\@*B1,C##D%2&'4$8K9HH SM,T:WTN2ZG1Y)KJ[<27%S,07E( 5<X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K)U'0_M^HP7R:KJ=F\2&/R[:<"-P3GYD8%2??
M&?>M:B@"M8:?;:9:"VM8]D89F.6+,S,<LS$\DDDDD\FK-%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>secondamendmenttoleaseag004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 secondamendmenttoleaseag004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD' X&#UI9/$7B+6_%,&FZ)?65I:7NA+J=O)-:EWC+.  PW?-P?;&3P<5>M_
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MMBV4=N5)G>81QL7W=.>1CIWSS71Z;=^*$\4PV]Q:S7&C30,9+B>.*-[>8=
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MH&;3;A1*@7=E"4 ;CG YK1T36;3Q!HMKJU@7-K<KOC+KM)&2.G;I6=X5C1_
M.@,R!BFF0,I(^Z?) R/P)'XUYYX4U/6]"^'_ (&OH;^(V-S=P6,MEY Y25V7
M=OZ[@>>,#M@]2 >R45P5[KGB+63KP\/)<K-IMRUK;*BVYBEE1%8B7S&# $MC
MY<8'.3G BNM5\77OBVPT2*\M=)DN]$:[D0VZS&VG#(IYW8?!)'88/?B@#T*@
MG )KS^76?$VJQ:U#H[7#7>E2?9(GACMQ%<3K&C,9!(VY5+-C"XP.<GH.UTN6
M\GTJTEU&V%M>O"K3P*P81R8^9002" <T 5M$\06/B".]>Q,VVSNGM)?-B,9$
MB@%A@\_Q#J*U*\>AO-;TKP_X]UC2=0BMO[/UR[N/*:W$GG[0A*L3T&/3GWKL
M-8U?4FNX?)U 65M-IIGACMHQ-<R3D]T*M^[48RW')Y(H [&BO-9_%VM'P#X9
M\7&Y6&VD:#^UHXXE($3MM:1<@D8)''H3Z5MZ]XDNM'MM=U>*3S;.Q2*WA@95
MVM<.0"=W!VC?&.O7=Z4 =?65KOB"Q\.6D-S?^<(Y9D@0QQ,_SLP49(X')ZDB
ML?3Y?%<7BFVCFM[F?19H7^T27?V9'MY1RI01-DJ>F""1QS57XK;_ /A#$\O;
MO_M&SV[NF?/3K0!V]%>?S:]KWA7QA;V6MZA#J>FZC:7-Q$T=L(7MW@7>R@ G
M*E>F23GOZK8:MXPU"/0-7LK2>:VOFCDO;>3[,L,<$BYWQ,&\PE<CKG=SP.E
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M,JBJ@8%02Q).0>!QUR.>UCQGX@TWP_XTM%N8/[5\.M$\=VT (FAE&Y"5R '
MR"<8XZ4 >I45Q::IKFG>/]*TV^OX;NSU:TGD$*VX3[.\6P_*W5@0V.?KQTK+
M3Q3K5IJ7AX7%_'<R7^I/97L$$0:UBR'*B.7:"67: 1N;G.0* .SL/$%CJ6MZ
MEI-N9OM6FB,W DB9 -X)7!/7A3R.*U:XGP]_R5;QI_UPT_\ ] DK3\4:]-IM
M_H>DVC+'=:O=F 3,N?*15+NP!X+8  SQDYYQ@@'1T5P=SK^LZ3XFU/P])>)<
M%M*?4K"\FA7<A4[6C=4VANQ! '7G-5M*U+Q=<^!H/$DNMZ:#=:="XBN(!%'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:W4B6JRQ7*+TS&QX89.#DUV=% %73K+^S[&.W,\MPZY+S2XW2,3EF., 9)/
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M130VL<<]P;B8#YY2H7<?H.@]OYU@V'A:2V\1:YJEQ>Q7,6LK&D]L;?:%5$*
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M0WFXQD1^6&"\,>IRW;T-26>M076ESZC-#<V,$#2B3[9%Y154)!?!_AXR#Z4
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M^$] /A?PU9Z+]J^U):*427R]A*YSR,GGFMJBB@ HHHH **** "BBB@ HHHH
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MOE41@[=K9SGYCG/7T% ',_VWXKU_1I-8\.I<>>MY(EO;/]G%K)''*4*N6/F
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M8.#S@^G3 !KZ+*\^AV$LMY%>R/;QE[F'&R9MHRZXXP3S^-9WC'79/#WAYKN
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MP0A'S9)^8YSU]JJZ/X0O- TO2+'3]:(338I8%$UL&69'*GYP&'(*\$$=?KD
MUO#5X+_0+:Z&IQ:FDN]DNXP )$WG;D   @8!&.H-:U97AW0;;PYI(L+4DJ99
M)G; 4%W8LV .%&3P.PQ6K0 4444 %%%% !1110 4444 %%%% !1110 4444
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M)=/E\FZ,L858WZXSGG\,UH:2]])I%HVJ1Q1WYB7[0L+9028^;:?3.:XWX?\
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M,@&,E22&!!..*O\ FZ]JOC;Q3H\?B&XM+2TMK:6W,,$6^,N)"0"5(QD<Y!/
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M)P.!GKQ5Q]1U(?%8:.+]_P"SY=$DNEA\M/DE$R)N!QD\$\'CF@#KJ*\?.O\
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ML>I:=;7T*2I'<1K(JS(4< C."IY!KAHK.?\ X7;>M_:=V NBQ2[0(\%?/?\
M=_<^[_X]SUJJGB'6M5^&=QXXL=2>&=%FNX;,HAA\F-V'EL,;B2J'+9!W'C X
MH ],HKS=]4UWQ#XPM;#3]<FTRRO_  \NHHJV\;M"[2*!C(YX(SGWQC((NV=U
MKGBBV\0#3M::SN]-O&L+7]VFQI(U4L\H*DG<Q/ X QCGF@#NZ*XB?5M6U3Q!
M?:)!)<QO865N\LFGM$I:64,=W[W^$;1@#U.>U=!X7;6SX=M!XB6 :LH*SF @
MJQ!(#<< D8)'KF@#7HKS'Q)XBUG2H+^_AU5KB:UU>*(16L:FVB@:1$\J0LHS
M)AB3M)()'05J3S:WJ'Q(U/0H]>N+2P&F17*>3#$7C9I&4[693_='4'VQUH [
MJLBT\16MYXFOM!2&X2ZLH4FD>1 $97) VG.3T/:N(T7QEJNH^'O"%E-=!=3U
MFZN+>:\6-00EN7W,HQM#,$4=,#<3BK_A^UEM/B]XACENYKH'3+5D:8+N5=\G
MRY &><\]>: ._J*ZN8+*TFNKF18H($:221NBJ!DD_0"N<\1ZU=P^(M(T*S$P
M:]BGGD> H)-L>T;5+\#)?)/7"\=<CFO$$'B0?#/Q=#K=U(JPPSO:2@Q&66 H
M<)+M4KGME<$\<]: .E/CFQA9C>:?J-I ;9+F&>6$&.=69555*L<.691M;!Y%
M:>E:W_:=Y?6DFFWUC/9LH=;J-0KA@2&1U+*PX/0Y'>N"\96%PGPVT3.K7KC[
M78<,(OXI(\=$_AQD?KFMZ\U'49?$\GANWN-0D%K8)<R3PM DTC2.ZC)8!<*$
M_A')(STY .TILDB0Q/+(ZI&@+,S' 4#J2:X&SUCQ+%<>'/#>MSQP:G?&Y:XN
MH-A9XH0"N!@JKMN7/' #8QD$4/'UEKEE\/-:6^UMYE2^@-J\059# \T:[)?E
MP<9;IUP,YY% 'I]%16T+P6Z127$MPR]990NYOKM 'Y"I: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEN0)I Y*RJ5.T*>&W< <GIUV[.YLQXM^)4CRP@/!;@,Q'S 6Y5@#WPW!]^*
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ML7MP4)$BK&X8@XQ@'@GUKF9?#>KSZ;KGA&R22&+1+IM2TNX X8M^]@B7Z,9
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MY$+H074;F4<D+G<0/[O;K7*Z1JMF?BP;UM3FO+>X\/J%O)(2D;$3LQVD* %
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MQI"5$\BP2.D);&/,=5*IU!^8C@@]#4=YXQT"QU![";4%^UK!]H\F.-Y&9,@
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MT-%9-CXFT?4=&;5[6]5[)7,;.5965P=NPJ0&#9P-N,DD<<U"OC#0C'J#/>F
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M-1@N9E%T''F,!=% "<<#;QQBO7Z "BL*Z\8Z#9@M<7X2(3FV,_E.8O-'5/,
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M&PPB9=J3O&!E03N)R,@-S@DBH=8@6[UCQGK]FX;3)?#WV(2IREU<8<C81]_
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MB9I8D>W=3(AN8FRH(YX5B1U&#FNUO[FV?XP:'.LD;1C2KA/-!RH9G0J-W3)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR"/-#8</NZ@CIC&#CGK6IX6?4Y?B-XP2YU(S0VTUM&L9B PK0[PH.> "Y^M
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MP.F6[XP0#T2@$$9!R*X.\U_6++6]:\,SW:F<:2VI6%^L(#!02K*Z_=+ \@@
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MSVH Z^BN?\%>(V\5^%;35I+<6\[[XYX@<A)$8JV/;(R/8UT% !1110 4444
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MMM*M"S10 Y=_O.Q)9F/N6)/XUIU1T;5K77='M=4L69K6ZC$D1==I*GV[5>H
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M=:_J^H6VM26UOJ]HEM=P?9U<_(K*I1R?EX8Y&#G)Z'I#9^!;NT;PJQUM9?\
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M-6T>..<ZQA'D4LJGR9.2 1G'ID9]174Z#IUSI.C6UC=7WVV2%%C\WRA&"%
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MQ.WB&]N()M0-G]CW6]N859-P8ELLQ8Y48YX&?6@#8OK>*[T^YMIV*PRQ-&[
MXPI!!.>W%>4_VGK?P\TM-!\7V U3PHJK;0ZO:+\T$?W4$J=L<<CT'WC7JU_:
M_;M.NK3?L\^)XMV,[=P(SC\:YJ]\)ZKJ>@_V!J&NQSZ:Z+%,_P!CQ<RQC&07
MW[03C!8)^O- $=_KNHZGK^HZ3H[7*+8VT,AGM4@<M)*&*Y\U@-@"CH,G)Y&.
M:^G>(/$%[=Z)H&JP)I6L7%G-=W[1%)-BQN$41_>7+%@W.< $=>19U;P3=2:_
M%K?AW7'T6\^SK:W"BW6>*>-?NY1B,,,\&DU?P-+>G2KW3]<N++6]-W[+]XEE
M\X2',@D3@$$\@# ':@""\UOQ!H=KI^FZE-:2:CJ6K&RM+J->!;\L)'7 'F;0
M1@<9(/3(J1M9U?3/&C>&YKM;F.]L'NK&[FA7?&Z'#(X3:&&""",'MS5G4?!1
MU71H(;S5IY-5@NTOHM2$:@I.O"D(. F.-O<9R<G-6XO#MR^JOK%[>P3:F+0V
MD#QVQ2*%2=S$(7))) S\W0 #'.0#BM.\6>*'\+^$?$ESJ%L\>I7T%I<VBVP
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M=QI<32<N(CG(B7!W2$X &#U/%<:_BO74\->.6BO&%QHCEK6>YME$A0Q"0!E
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MK.C(R#()ZGYCCMZ@USIUOQ8W@[Q1??V^JW/AV[N8DD%G'F[$0#CS!C R#CY
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M&X%. .0,8Z=\UFM\-1_9U[;IKUXLT^KC5X9FC0^5."""1CYAP,@G'H!7=T4
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M>!8+N2&W22.Y5>F8WR 1DX/.*["B@#D-7\""]_LN[T_6+NPU?3=_E:AM65I
MYS()%. P8Y.. ">*FU+P8=3\.?V?/JURVH"YCO1J+(I83H05;8 %VC:!M';W
MYKJ:* .7L/",UOXJ?Q!=ZU<75Q+8K9RQ^4B(X#,V<#H/FX ].2<UFI\-(?\
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MU?3K067VR*!76> =%>-B0?7ZD^V.UHH I:7IYTVR6%[F6ZF)+S7$V-\KGJ2
M !V  &  !3M3LWU#2[FSCN7MI)HRBSQC+1D]&&>XJW10!R.H>!8M:EOKC5KP
M275WIK::9K6#R2(V(8DY9MS9 ]NO'-,M?!-Y%J^CZI<>(KF>ZTVW>WYMXU61
M&V\8 X^Z,\Y/8BNQHH XEOA\S^#M4\-OJQ,&HW$D\DPMQO4N^]@/FQUZ>@]:
MU+KPU/=^)-%UJ74%\S2XY8UC6WPL@D #D_-Q]T8]/>NBHH XG2_A_-H]U);6
M7B*]C\/22M+_ &3Y:%5R<E!(1N"$_P (QWYY-=M110!A>(O#9UVYTJ[BOY;*
M[TVX,\,J(KYRI5@0W'(/7M59/"<UAKM_JFCZF;1M11!>12P"57=1@2KRNU\=
M>H/<5TU% %#1-'M- T:VTNQ5A;VZ[5+'+,2<EB>Y)))]S5^BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;W6](ST0IN&%&#M) '0>AXQ8?P:7'AP'4Y1_8./(_=+^\PGE_/\ \!],<\T
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MG)BRN#I@*+!#OEU,&!B'+8.8USM^7&,$EL<5HZR&E^'?ASQ5IBO+=Z#'#=J
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MA!>*4!)('!9>%)'';L:9XUU1-.UWPVDT(ABFFF!U06_FO:'9@*G!"L^<9(/
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M[NR&MXEFG\N%Y!"ASAG* A <'DXX!/:N$T76K#2)_$/A7Q-I\\]W<ZG<7%O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(D3!I8^1C;&&8MR.O);G-2>(];BU[3O ^H)#-&W]LV]Q<0M$P:W C</O&/E
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MU V+DEL@;1Z9Z]N.:WJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO->P0W4-JS$W$V2D:C)VCJQ
M]%&1R?4#J0*L5Q/@F\;5?$/C'4YSEH=3.G1@_P $4"C@?5G=OJ: .VJM;7UO
M=33PQO\ OK=MLL;##+GH<>A['H:X2V\1^*]8TG3=?T2QFGBN9P[63B!8C;%B
M,AR^\2 8.3QG(VU>\37;Z5\1O"-S"<+J!N+"Y _C7:'3/^ZP/_?1]: .VHHH
MH **** (+V\@T^QN+VZD\NWMXVEE?!.U5&2<#D\#M6$WCO05NX+1GU$7,Z%X
M83I5T'D4=2J^7D@>HKH98DFB:*5 \;C#*1D$>E<)KG_):O"G_8/O/Y+0!V.E
MZK9ZS9_:K&1WB#M&=\3QLK*<$%6 ((/J*NUS&N:O-9Z_8:)IT,JSWT<UU-+
ML9=5CV+\H<A=Q++R<\*>.<CG-5\0^-=&\*75S>0P07$&IQ6\$TT:$W-O)(JA
MB$<A&&X@\$>@H ]*HKC++5==M/'USH-[=V]]'+I9U" K!Y/E.)-A3J<J<@Y.
M36=IWBK5U\1^&+*XOHKLZJMPEZL4(\B&5(R^(9 !N (*GEOJ#0!Z)2$@$ D
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M;*R-C@YXZ>A//&*J-J>O6NL0>&Y[U[R]:WEO9;NRMHHW$7F!8U"R-M[G)YZ
M8YS0!V]%>:WOB+QMINCZ1]N@M+:]GUV/3B98P?M$#$[)/D<A"0,$<GKC'%6(
MM;\3Z3XKO_#VI7UG>--ICZA87@M/+"%&PT;(&Y'((.?Q- 'H5%>9Z;XH\2Q>
M"]/\47][:7"ZA;V\$-DEMMVW$LJH'+[AD8))7CTSW.PE]XQL]3O@-/GOM/\
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M8\#U !ZE17)ZIJVH6&IZ3H$4T]S>7<,T\US%'$'"1[0=BL0H)9QUW8 /!ZC
MU;Q#XUT7PE>W5W!!!<V^I106\T\:$W5O)(J@D(Q",-QSP1Z"@#TNBLW1[;5K
M:&X75M0@O9&F+Q-#;^2$C(&$(W'.#GG-:5 !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4M6U)-(
MTN>_DM[FX2$ F*UB,DC9('RJ.3UH NT4 Y -% !1110 4444 %%%% !1110
M44FY2Y0,-P )&>0#T_D?RJGI.IQZOIZ7D=O=6ZLS+Y=U"8G&UBO*GL<9'M0!
M=HHHH *Y/1-./AWQ9K<3#%EK$ZWMN_83%0LL9/J=JL/4$_W37644 </I'@+4
M-$GDLK+Q+.GAMI6D73#;*70,<F-9LY"$D\8S@]0>:NWVG'7O'>DWB\V6AI,Y
M?M)<2 (%'KM7<3Z$@=<XZNJ1U*-=:32_L]SYC6YN!,(3Y( 8+M+]-W.<>E %
MVBLKQ!XBL/#6BW.K7YE:VM_]9Y$9D8'Z#IU')P*U%8,H8=",T +1144L\<,<
MC-N;RUW,J*7;'LHY/0T 2US.H>%KJ]\;Z;XC74HHQ80R0I;&U+;E?[V6WCG@
M8XK4T#7+/Q)HEMJ^GF0VMP&,9D7:Q 8KT[<@U*NIQMK4FE_9[H2) )S,83Y)
M!8C:'Z;N,X]* ,;Q7X3EU^XT[4-/U232M7TYV-M=I&)!M8 .CH2 RG []JJZ
MIX,U#6/#O]GWNO>;>27,5Q-=M:#!\M@RHB!@%7*^I/)YYKL** .6O_",^H^)
MI=7FU-5672GTQX8K<J=CG<75MYPV>G!_K699?#_4;<^&FE\2&1M +);[+%4#
M1&,QX(W'YMO\7(X^[WKH[KQ-86U]/9JEW<RVP!N/LML\HAR,@-M!YQSM&3C!
MQR*NZ7JEGK6FQ:A82^;:S9\M]I&[!(Z'GJ#0!RP\"W7]A>)M+;5XBNO7$T\D
M@LSF$R*%8 >9SPHQ_6K3^$+HZIH.HQ:N(;G3+5[.4K; B>-MN< L=C?*.?F^
ME=710!0UO3Y-7T*^TV.=8#=P/ 96CW[0P*DXR,G!]:YYO!=VUMX6A_M:$#0"
MA0_9#^^VQF,9_><?*?S_ "KL** .)A\"ZEIVL7TFC^)I['2+^=KBXL!;*[*[
M??,4A.4W?0X[5J6?AF:S\9W6OK?1F*>TCM/LHMR-J(25(??U^8]JZ*LK2_$-
MCJ^I:G86HG$VFR)'<"6(IAF7<,9Y/'?'>@#GHO VI:?K5_-HWB:>PTK4)VN+
MFQ%LKE9&^^8I"?DW?0X[5H2>&+NV\3S:WI.HPV[W%I':S0W%L9EVQD[2I#J0
M?F/7.:Z:J6I:M8Z0ELU]<+"+FX2VAW?Q2.<*M '.W,OAGP3H4>CZI<EEU$SY
M61"\E[(_,G"CEF+=/< 5?\$Z!_PC7A&PTYMYF6,-,9&W-O(Z$]]HPH]E%;Y1
M6*EE!*G()'2EH Y_Q3X=G\11Z8L-^EI]AOXKX%H#)O:,Y4?>7 ]?Z55\2^$;
MK6-2T_6=*UA])UFR1HA<+")4EC;!9'0D9&1D<\5U5% 'F7CNSGTW2?#$-SJX
MFU"7Q':2/=S(J@OR,B,$ *  , _4Y)-=4?#4]QJ-YJMU?0R:C-9&R@=+<B."
M,G<V%WDL2<$G<.@'KG?DMX9B#+%&Y'3<H.*<[+%$S$':@SA5).!Z <GZ"@#D
MHO D,GP[C\'W]\TT442QQ74,?E.FPAD8#)^8$#ZU)I_AG7DT^YAU;Q7+?7#6
MSP6TR6BP^267'F$ G>X]<COZYK8T#7K+Q)I*:GI_F_9WDDC'FIL;*,5/!Y'(
M-:= '*/X+34=6;4M:FM[J=M/DT]_L]L8?-CDQN+_ #,3P.!P!D^V(?#O@_6-
M$$%G<^*9[_2;3'V2U>U5' 'W!)(#EPO'''0=N*[&B@#AI/A_<R^$M>T%]9BV
MZQ=RW3S"S.8_,;<R@>9SR.#_ #K3E\+73^*-.UZ/51%<6]D;*X1;8%9HRX?Y
M<L=AR/\ :XKIJ0,K%@&!*G# 'H<9_J* .4_X0^XN[C1WU;48;S^R;C[1;S+:
M^7.Q ("L^\_+R,X W;1GWW=;TN/6]"U#2I9&CCO;>2W9UZJ&4KD?3-7Z* .-
M?P1=/:Z%.=9!UG121;7GV4!&0H$:-HPW*D 9^;.>01TK9TK0OL6JWVKW<ZW&
MHWJQQR2)'L1(T!VHJDD@9))))R3] +VIZG;:1I\E[>-((4*J?+B:1B68*H"J
M"226 P!WK%'CO16U%].":F;U(A,UN-+N=X0G ;&S.,\4 'C3PO<>+-,M[&+4
M4LDBN8[G>;?S260Y ^\!C-2MI.OW4]L+W7+5K2.59)8;:P,;2[3D*6,K8&0,
MX'.,=ZUM.U"VU73X;ZT9FMYEW(60H<>ZL 0?8BK5 'GTOPVO6TBXTN/Q(R6A
MU(:C; V:LT;^;YA#MN^<9SC[IYYSTK<L_#-[9^*=1UP:I%(]Y:Q6_EO:_=\O
M.UB0XR26.>![8KI:* //X/AI+:>']"M+76_*U/0II)+*_%KQM<G>CIN^8$'!
MP1T'XZ=CX2U*VUO6-7GUN*6YU.UC@=%L]L:% P! WDX^8\9_&NMI-RAPFX;B
M,@9YQ_DB@#B8?AZ8/#F@6,>J[=1T&3?8WRV^!C&"KIN^96'!P1VZ5H2^%)KN
M35;VZOH6U2_LOL G6W(C@A^8X5-^226))+>GI73T4 <A<>!4OO %IX7N]08O
M9)$+:]ABV/&\6-C[23R,<\\Y/2BW\)ZQ)XETG7-3U^*XN-/@E@*06(B657VY
M)R[8/R\XX] ._7T4 9'BG08_%'AF_P!%EG:!;N/9YJKDH<@@X[\@<5FR^%M1
MN=>T#5[K68I9])68$?8]HF,JA6Z/\H  QU]R:ZFB@#@[OX=W%W::U$=;$<NH
MZA'J*2):<0RH5V@J7.]?D'!QS6A9^#KN/Q)>ZQ>:VUP;ZQ6TN84MEC!*[L%3
MDD#YCQR<_P 1Z5UE% &'X2T&X\-:!;:3/J/VY+9!%"_DB+:@Z @$Y/J<]N@J
M;Q-H\OB#P[?:1'=+:B\A:!Y6B\S"L"#@;ASS6M2*RMG:P.#@X/0T 9%AH2P^
M$X_#]_*EY MH+-V6,Q^9'LV<C)Y(]ZQO#O@_6-$$%G<^*9[_ $FTQ]EM7ME1
MP!]P22 Y<+QQQT';BNQHH X9_A_<R>$]?T)]9BVZQ=RW4DPLSF/S&W,H'F<\
MC@_SJQ+X+OGUNZU&+7?)6^L4L[R-;0'<$# -&68[/O'((;K^767-PEK;27$@
M<I&I9A&A=L#T R3^%5-#UFT\0Z+:ZM8[S:W2;XS(NUB,D<C\* .7LO -Y9VW
MA:(ZXDO_  CY)C+6>/-!0QXX?@;3[G/.<<59?P0]Q/XL:YU)6B\10B*1([?:
M8<1>6""6.>.>1UKJYYXK:WDGGD6.&)2[NQP%4#))/IBLC3?%%GJ6J+8);7L,
MDML+N!YH=J319 W*P)QU'RMAN>E %K0M/NM*T:VLKN^%[+"BIYPA$0(  &%!
M..!ZGDGZ#,M_#-Y:^)]:UJ/4H2VIPQ1>4UJ2(O+#!3G?S]XYZ?A7244 <%8_
M#N\TRT\-)9Z^$N-"6:*.1K/<LL<F,@IOX88X8'\*N:5X,U+18;I;+Q$Q>;5)
M-1!FM%(^?=N1PK+NSNZC&,# %;FO^(;'PW8)>7XG\II4B!BB+_,S!1G' Y(Y
M)%:M &'X?\-Q:'=:I=AXS<:E<">80Q>7&I"A1M7)ZXR3GDDFJ>M>%+F[\46G
MB31]373]3A@-K+YMOYT5Q"6W;67<IR#R"#7452M-3CN]0OK-;>ZC:S9%:26$
MK')N7=\C'AL=#CH: .0/PV$^CZS8WFM322:AJ)U.*XBA$;6T_P N&7DYQM'I
MW^M69?!>J:KX=U'3?$'B66_FN[9K9)X;58%B4X).P$[B2HSD]!@8R<]G5+5M
M4MM%TJYU*[\W[/;1M+(8HR[!0,DX% '.6G@[4X_$6F:W=^(?/N;.T>TD5+)8
MTE0E2,#<=O*C/7/;;4'_  KYY?"?B#0;G50ZZO=RWGG1VVPPN[ASP7.X @>G
M'>NOT^]BU+3;6_@W>3<PI-'N&#M8 C/O@U8H K6$-S;V4<=Y="ZN /GF$8C#
M'V4$X'XGZUE:EX6M-2\4Z7KLDCK-8QO&8UZ3 E64-[*R[A[X-;U% &#X>\+6
MOARYU>:UD9CJ-TUQM8<1 \[ /3>SMV^^:Q_^%?--X6\1Z'=:J'36KJ6[,L=M
ML,+R,&(P6.X J/3ZUVQX&:RK?Q!92^'3KMPL]C9K&TL@O(C$\:J3DLIY'3\>
M* ,N7PMJ-SKN@:M=:U%+/I2S C['M$QE4*W1_E  &.ON35GP]X=GT34M:NY;
MZ.X&IW7VID6 Q^6VT+@'<<C"BK.F^(;?4=4N---I>VMU!&LQ2YAVAXVX#*P)
M!Y&,9R.XK7H Y_5_#L^I^*-#UF.^CA&E&8K"T!?S/,38V6W#''3CKZUE3_#V
M/4(/$MOJ5^)H=;F2<^3!Y;V\B!0K*VXYQM4].OY5VM% '.0>'+RXU#3+W7-1
MAOI=,#&W\JV,(:1EVF1\NV6VYP!@#)/IC0\1:+#XC\.W^CSRO%%>0F)I$QN7
M/<9K3H)P,T <Y!X;NY[O3+C6=0@O&TS+6J0VQB3S"NWS'!=LD*3@# &2?3#-
M!\)'2[+6[*^NXKZVU:[GNI4$!CQYWWT^\<K^M:.A^(+'Q"E\]B)@+*[>SE\Z
M(QGS% )X/./F'7%7[RZCL;.:ZF$ACB4NPC0NV!Z  DT <E:^!ITT*T\/7NK"
M[T2TEC:.)K?;,Z1L&CC=]V"H(7HH)  X[QZG\/1J]]XBN+O4(V76(X50"V(:
MU>$$1R(V_P"\"V>V?85U&BZO:Z]HUIJMEO\ LUU&)(]ZX;:?45?H XS5/!6I
MZG9Z1.?$;0Z_I1;[/J<=J!O5@ RR1EB&W8&>1SVIVJ^#-1UGPVVFWFO^;>2S
MQ3S7;6@Q^[8,JI&& 5<KZDG)]:W-5\0V.C7NFVEV)_-U&X%O 4B)7>03RW0<
M ]\U>O+N*PLIKN82&*%"[>6A=L#T !)H EC#B-1(RL^/F*K@$^PR<?G3JHZ-
MJUMKNC6FJV>_[-=1B6/>N&VGID5>H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?B/JVI:#X%U+5
M-*N(X+JV56#/$'X+A3@'C//?-=56)XN\/'Q5X:NM%-W]ECNMHDE$>]@ P;@9
M'<"@#&U;4==;XBV>AV>I16UE=:;+<$_9@[HRNBY!)Y/S'';U!JWX#U?4-5TF
M_CU2=;BZT_4KBQ:X6,)YPC; 8J. <'M4\GANZE\6V?B!]1C\VVLVM/*%L=K!
MB&8YWY!RHQ4GACP[)X=34E:]%T+Z^EOF_<[-CR'+ <GCT[_6@"SXFUI?#OAG
M4M8:+S19V[RB/.-Q X&>V3BLZVC\1P7FF7TFJP76G/;N^HQ21JNQMH*F#:N<
M9R"&8\8YS6YJ>G6VKZ7=:=>1^9;7430RKG&588/TKGO#GA&_T46\%]XDNM4L
M;,;;.WE@1-@Q@;V',A X&<#OC(& #!?Q1KMS\.&\=6=V!M#70TUHT,1@5R"A
M;&_?M&=P;&>V*MC6==UCQR=*L=52ST^XT2/4(F%JK21EY"O\603@=^.O'<6[
M?P +71;GP[%J;#P[/(S?8S#^\C1FW-$LF[A"<]5)P3SW&DOAF6+QB_B"&]C3
M-@+!+;[/\JH&+@Y##G)^F./>@#C5\7^))? WA_4$O+9;Z;6UTVZ<VX(F7SVC
MSC/RY"\X]3C%:;>)M5\-Z]XDM-5O1J=O8Z0-5A/DK$R\N&C^7J"5&"<D>IJ:
M/X>31Z#9:2-9&RTU0:FDAM>6<2&3:?G^[N)]\5J3>$!>>);_ %6]NTFAOM._
MLZ>T\C:#%EC][=G.6/X?G0!G65YXO?4]&NTAGN-.N%SJ"3BV1(@5R'A*,7P#
MV;=D>]-TC4?$?B?P_I_B/2=0@B%S<[_L,R+Y/V8.5(+!2_F;1G.0,\8Q5KPY
MX+U#0S!;7'B>]U#2;0C[)92PHI0#[H>0?,X7L.!P/05#I7@";1KB:UL_$%VG
MAZ29IO[*\E"%+'+()?O!"?X1[\\G(!6\.Q:A)\2O&BG5[EQ!]D6-)41D :)F
M"X"@X4L2 ",]R:I:3XVU6;P7X>DN9XWU76=5DL/M'E +&HED!8+TR$3 ![D$
MYYSU4'AF6S\6:GKMKJ3QC44C\ZU:)64O&A16SUQ@\@8R1U[5DP?#F%/"%KH4
MNI2-+97AOK*]CB"203;V?.,D'EF&/0X]Z 'G5M7TSQRGAN:^^U0:A8R7%G=3
M0KYD,B$!E8(%#+@@@X!SQS7-Z;XI\4/X0\)^)KG58I%O[Z&VN;1;5 KI)(4+
M;NH8<$8P/4'J>Z@\/W!U4ZQ>WL-QJBVIM8)$MRD4*DY8A"Y))(&3NZ  8YSB
MQ_#V2'P?H_AU-7'DZ7=1W,<QMLLY1]Z@C=CJ>?48Z4 =Q7)^(-4U+2/&'A\&
M\9=&U&1[.5/+3Y)RI,7S$9PV",>H%=6N=HW$$XY(&*R/$_AZW\3Z'+IEQ+)"
M&=)$FB.'B=&#!E/8\?K0!Q^C>*M3O(/$FG2:B\FJ07J0Z=*88U#0RG$,@&W#
M#ABQ]%R,5L_VEJL?Q+BT%K\-82:(]R,0J'$HE1-Y.,$X)., <]*T/^$1TY?%
M-AKL2F.6RLS9QQ+PNW^ _507 _WS2R>'97\;Q>)!?*/+LFLA;^3P4+AR=V[K
MD#MC';O0!YA*MV_P+\57%UJ-S=LUQ=*1,$ZBY(W9"@Y./7'H!7<0ZEK>F>/M
M)TN\U%+NRU2RGD$(@5!;O%L/RL.2"&Q\Q/\ 2HYOAT[^&-8\/IK<JV&HSR2J
MK6ZDPAWWL <C)ST)Z#MWK6G\-7-SXFT?6Y=1C\S389(1$MO@2"0*&).[C[HQ
MZ>] '1UP?A^.\?XK^+A)JEU)%!#8[86";=K+*0OW<@ DD8()SR37>5SJ^&)K
M?Q;?Z]9ZF\)OH8HY[9H0ZLT88(V<@XPQR!C/K0!YSX6U'6]"^&GA/5+;44%F
MU^EK+9>0I$D<EPRDES\P8$Y&,#V-=TNLZNOQ(U+1_-CFM(](2\MX!&$_>&1E
MP6Y)^[[#GI52/X>21>#--\-KK \FPNDN4F-K\S%9/, (W8^\?R_.M23PM/+X
MIN]<;4@'N=/_ +/,2P8VJ"6# [LYW,?P_.@#'\&>*I-=U*&VN-5GCU*&W;^T
M=(O+=8I(I?EPT>%!*#YAU;@KDUWM<W;>%I6UK2]5U2_CO+O3(9(H)4MO*=]X
M"DR'<=W Z  9)./3I* /-M5L?%7A'Q!J6O\ AF&+6])OY?/O=++;9HY  K-$
MW<X49'MC'I9MO&MG?:+H \.03H-9O)D*!4$L!4/)* '(7=N&!DXYSSP#OQZ%
MJ]E=7TNGZXBQWD[3&&ZM/-6(D ?)M=2.F>21G)XS69=?#BQE\-6VF6U_=6M[
M:W;7\.I)CS1<L26<CH0=Q!7IC [4 4;GQ#XH\.V.JOJ=N7A>ZMX-*NKOR@Y,
MK!&$JQ'&$)SD8R*U[^ZUOPQ_:>K7E^NH:':Z:]P4E54N!.F3A=B!=A7UR0?:
MFS^"#J_AR^TSQ%K%QJ<]VJJ;H1I 8MAW(8U7A2&YSR3WXP!-IOA6[%G-;^(M
M<FUQ9(&M@LD"0J(V&&R%^\Q'&XGZ8R<@&'J?B'7-#\,:)XIFOA=07+V_V^S\
MI!&J38&8B!NRI88W$Y%))J7BB^USQGI\&MQ6D>DK#);.EFC,-T)DVG=D8SP<
MY/ICOK6?@F2+2]/T:]U4WND:?*DD$+P!9&$9S&DC[L,JD#HJYVC/?,\7A2XA
MU7Q'?KJ:;];2-'4VW$.Q-BX^?GY>N>_Y4 9&F^,+[75\):?%(MK=ZMIQU"[G
MC0$HBJN0@8$99F[@X /<Y"^!X9X/''CJ*YN6N95NK7]ZRA2P\@8R% &<8' '
M3H*D7X=O;V'A_P"Q:R]MJ>A1F"VO1;AA)$0 4D0MA@0.Q'M6MH'A>;1M=UC5
MI]5EO)=4:)Y8S"J*K(@3(QSV]>G7)YH Z.O,?'UO;>*Y-5TUQ>;M.M@MD\%I
M-*HO3B3=N12 5"HO7/[QZ],D#F)Q$RK(0=K,NX ]B1D9_,5F>'])FT73/LD]
MX+N0RR2M/Y6QG9V+DL,GG)/3'&* ,+2/%-SKWPN.O6DB0:@EE(9/,CW".>,$
M."N1_$I_ BL(:_XIATCP1JYU>"7^VVM[:>V>T78&EA+>9D8;((S@$ ].*W--
M\#W.F0^(H(=87[/K<DLSQ?9/E@DD&&9/G[CL<\@?BY_!$[:+X:TT:JH309H9
MH7^S9,IB4HH;Y^F"<X_2@#+?Q9JOAJ\\7V^IW8U2/2;&*^MG:)8FRX<>6VT
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MER!\N<]??IA__"O)?^$';PO_ &Q^X:Z^T^?]E^?/G>=C&['WOT_.M@^&9?\
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M2(W#JJ(I"JN5]^I]:NW'A>2\\5V^N7%[$XCL7LGMA;_+(CD%N=W!R!^'KUH
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M?(\? (XR/0^M6]0\&SZA9:7%)K,CW%GJ$>HR7$L 9IYDZ9 ("KCC '0#GJ2
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M%V@',>[<2V"0,<^O2^%[Y-2\/6]W'JJ:K'*TC)=H /,3>VW(  #!< C Y!H
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M8PH P..>EBSUK6-7\2VWA^YE_LVYMM+2\U VVURTSMM"(6# *,,<XSRHSUR
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWT-O-?&!6/D6@#R.RG!51GDYXQ0!RL?@"[:+18;OQ1?SQZ/<K-:GR(@^%4J
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MAXI\$2>%3JTWV1YS.9O)7S,^;YN/3[WMTXK7E\-R3^++'Q!)?GSK2V>V$2Q
M(ZN06)YSG*C'I[UOT4 %<EJ'@=;W6-9O8M8O+:'6;98+VVC5"'VH44AB"5^4
M\@=:ZVB@#D5\#LEKX;A_MB=SH+!H6>)3YA"; &QCC;QQSW))K1L/#AL?%>J:
MZ+UG;48XHY(#& JB,$+@YSGYCG/7VK;=MD;-M9MH)VKU/L*R_#GB"V\3Z.NI
M6D,\41EDBV3J X*.4.0">X- &M7(7'@61?$=YJVD:_?Z4NH%3?V]ND;+,P&-
MRE@=C$=2*Z^LW2M=T_6I+]+"<2M8736D_P#LR* 2/U_0T 4)_"R2>(]'U:&[
M:%=*@>WAMPF5*.%#9).<X48^G>L-?AF$TJ#3(_$.H+9VFH+?V48CC/D,)#)@
MDKE^2>OKT-=[10!ST7AF2#Q5<Z^FHL9Y[-;/RWB!4*I+*>H);).>Q]*RU^'B
MIX*M/"ZZM-]EM9UG2;R5\PE9/, /;[WMTKM:* .;N_"KWGB4ZV^HLLITY]/,
M:1 +L8ABW7.[< ?T]Z=:^%V_M;3-2U*_^VW.F1216TGDB-SO #-(03N.!V"C
MDG'3'15CZEXBMM+US2=)FM[AI=3=XX9$4>6I5"QW'.>@[ T ;%<[-X7:+Q+<
MZ]I5^;*ZO(EBO$:(21S;.$?&00X!P#G&.H-=%10!R>H^!+6\\'KX;M[R:VMC
M*)I9@JO++()!(6)/&2XR>/88%=3$)%B42NKN!RRKM!_#)I]% &-XH\/1>)]%
M;3I+F:U82QS13Q8+1R(P93@\'D=#67'X*FCUJ[U9M>NY;J\L1:3[XH]K8W8;
M  QC<< ?4YKJY)8XE#2.J L%!8XR2< ?4D@4Z@#CAX#"^'] T==5D$6B7,5S
M _DC<YCSM#<XQR<XQGVJMJ+:/XX\3:=9P13S3:#?O+=3- \:QE5*^7N8 -N8
MJ<#((0^V>ZK-UW6K?P]H]QJEW%,]K;J7F,*ABBCJ<$C/X4 :54=:TFWUW1+W
M2KII%M[R%H9#&<, PP<$]Z=I>HIJNFP7T4,T44Z"2,3 !BI (. 3C(/0\U<H
M YVT\+N)=-?5-1-^-,YM%\D1J'V[1(X!^9PI(&, 9/&>0[0O"ZZ,-826[-Y#
MJEU)=S1R1  /( & Q_#@#@Y^M=!10!R%IX#CM]'BT&74IKC089EEBLY(QOVJ
M^]8VD_B0,!QC.  212ZCX#MM5U#7;F]NO-CUBV2WEA:$8C"9V,ISG<"<Y]?2
MM6?Q';0>*;?P^UO<_:9[9[E) H\LJA (SG.?F':G>'O$-MXCMKN>V@N(1:W<
MEG(DZ@-OC(#=">,T 8NH>!'U+2-+@GUZ]&J:4^ZRU5%43+Q@A^S@C /3.!GO
MEVH^")=6\,SZ3?Z[=W%Q=21R7%\\2!V\M@R*J@!44$= .Y[G-=?10!E7NF7U
MQ<V5U;ZGY$]LCHX,.Z.8-MSN7((P5!&"*/#^@VWAW36L[8EO,GDN)&P%!DD8
MLV .%&3@ = !3-;\16VA76EP7-O<.=2NTLXGC4%5=LD;B2,< ],]*UV.U2V"
M<#.!U- %?4=/MM5TVYT^\C$EM<Q-%*A[JPP:Y[PYX.N="\B*X\17^I6=F-ME
M;W"(!",8&YE 9R <#)P/3IC3\.^(;;Q)97%U:P3PK!=26KI.H#;XSAN 3WK7
MH XF3X=QRZ/J5@VKW"O>:G_:J3I&H:&XW!N!T*Y4<'\ZOV/A&:Q\1W.N?VW=
M37=S:I;RB2*/8Q7=M;  P!N/ Q[DUT]% '$P_#Q8/"VCZ"FK2^1I5XEY#*85
M+LR.74-VQDGH!V_'77PY*OB^7Q&+_P#?O9"R\DPC8$#%P>N<[B>_3CWJ>_\
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M5@I,G #;?F(^@SFM'4_ =EJFC6UI+J%^M]:W NH=4$@^T";&-Y.,<C VXQ@
M#&!4LO@JSO\ P]=Z5K%[>:D]WM\Z[F95E!4Y0IM ";3R !U)SG)H S]0OM3\
M/>-="TX:A<7>GZTLT#B<(7@F1-XD4A1P1D$'@8R/2N4DUSQ-%\/+_P 3-XAN
M'N=-U.2)8?(B$<Z+<B,B3Y<GY3QM*X^O->B6OAQEO[2_U#49K^[LHGBM9)(T
M41[@ SX4<N0 ,],9P!DYR7^'=M)X1OO#;:M>FTO+EKB23;'Y@9I/,(!VXQN]
MJ )8]2N=?\;ZUHD5[/9VNCP0;O(VAY99E9@Q)!X50,#N2<YZ55^$JNG@1$DD
M\R1;Z[#/C&X^>^3@=*T;KP;YGB)=>L=7O+#4)(%M[MX4C9;E%Z%E92 P[$5<
M\+>&HO"NEO807ES<QM-)-F?;E2[%B!@#C)/7- $OB75)-(T&XN;=2]VP$5L@
M4L6E8[4X')Y.3CL#7GNBM;>#_B59V]K#>0Z7KMHEM(UU;O%F\B'RN2P&2ZYS
MZMS7H>H:,VH:OIU^;^>);%VD2W54*.Q4KELC.=K$#!&,U4\6>%(?%ME:6T][
M<V?V6Y2ZCEM@N]9%^Z06!QC)H R=2N=7G^)\.B0:S<6NGSZ1)<%(XHRR.)47
M*L5/.#WSU.!TQS$FK>)E\ ^(M4_X2.Y%UX>OKF"%A!%BY6)^#-\O.1Q\NWUY
MKOO^$8)\4V_B!]3N&NH;,V>PH@1D+!B2,9SD \&L_P#X0" ^'=:T5M5O#;ZQ
M<RW-P^V/>K2'+A?EP ?<'% $%QK5_K7B.YT>T-U"EMI\%PQM)(T<O+OYR^>%
M"CIW)SVK*N;[QE9CP=9ZEJD=OJ%W>R6MZ8(T=)5".ROTX; ' XSVQQ6YJG@-
M+Z]L-2L]:U#3M6M+<6IO+;9F:(<[74@J>>>G7\*LW/@R">31I!J-XKZ5.UPC
M,5=II6!#-(2.<[CTQUXQ@8 .5N/%VJ>$[3QTEU>R:I_8IMFLY;I5#YG485]@
M4%0YST'%6=>TZZL_'/@-Y]5N;PM=3B02A,%_L[_,H &WOQTZ?CNS>!+"\NO$
M,E]<SW,.NQQQW4#!0J^6NU"A R"/<GFJ\/@*7S]&EN_$NJ73:/(7M2ZP@X*[
M<,=GS<'!)Y^E './?^([GP[XYO!XDNXI=#O;G[*8X81N6*%'57^3!7MP!U.2
M>,:(U76K76?!E_+JTLT.NYCN;(Q(L*9@,BF/ W @CNQS[5LIX'B33/$-A_:E
MV8]=DEDN6*QY0R*$;9\O V@#G-22^#$E'A[.IW0_L,@VY")^\(39\_R\_*<<
M8H YY=3\4^)M&N=5T"62*[2^ECMHWDB%OLCE*%)%(+'<JDD]03Q@59637-6\
M>ZUHW]OW-G9QV%O<1BWCB+Q,Y?(5BIR..X)]"*NCX>00:S>75CK6J65A?RF>
M\TZ"11%*Y^\02-R;N^T@GU%:<'AA;;Q-?:[#?SK/=VZ6YBV)L14SMVC&<C)Z
MF@#SV74]3\1>#_AWJ5WJ-Q'=7.LQP3F#:JR$>:-Y&",YC!].3Q7K\:&.)$+M
M(54 NV,M[G&!FN/B^'=I!X7TO1(M5OD&E7@O+2Y C\Q'!8\Y7:1\[=1WK?MM
M*FM]8>^.J7LT+6R0"UD8&,%3GS.F=Q[G_( -.N6^)7_)-/$?_7A+_*NIK*\1
MZ(GB/0;O2);J6W@ND,<KPA=Q4]0-P('Y4 +X9_Y%31_^O&'_ - %<=XQUG5+
M*/Q+<V>KR%[&S2XLX+%%86^$+,TY8;3N(X7).WD#O6XOA&\72(M+_P"$IU3[
M&D2P[5C@5FC QMW"/(R!C((/O4%_\/K6]NM=9-5U"VM-:BV7=I"4V%@FP,"5
M+#C' .#CG(XH S[W4]:O?%WA>S@U>6SM=5TV:>=(HHSM950Y0LIY^<]<CVK.
MM_%^KZ;X=U&SFOC<WT?B7^PK2]G1=RJY0AW  !*JS=L$@9KJ;?P8EOJFBZ@=
M6O99=)MGMHA((R)%8 -NPHY^48QC&*K2?#K3KG2M8T^[O;N:/5+TZ@S@JCP3
M_+AXR!QC:,9S^M &=+8RV7QCT,/?W-TCZ5=;1/M)4AH\D$ =>..V.*Q].U^?
MP_X8\02VI5;F[\77%E%(RY$1DF"ER.^!D_7%=A;>#)DU[3]:O?$.H7E[90/
MI:.)%=6QD, GL/?/?M4:?#[3FT+5M'O+JZNK;4[M[UV;:KQ3,P8LA4#&& (Z
MT 5[^^U/P_XWT/3/[0N+O3]:2>%A,$+V\T:;PZD*.",@@\#&1Z5@Z1KFNV_A
M#4/%VHZ[<72:7+?(;+R(U2X".RIN(4$$$#D8&!TZY[>V\.,+^UU#4-1FO[RS
MA>*UDDC11'O #/A1RY  )Z8Z 9.8-(\&V6F>'[_0Y[B:^L;UY7E6X"@_O22X
M!4#@DGZ4 <EXCM;XQ> ;^[U6>YDGUJU>:,A1&7:-VRH RH'( SR#SD\UZC7$
M)\.B++2;*;Q+JLMKI-W'<V2LL.Z/8&"J6V?-C=CGMQ7;$':0&P<=: /%H[G5
MM'\">)]?T[5IK9]/UV[E2V2-#'+_ *0 PDW D@@G&"N/>NUO=5U'6/$^K:-8
MO=P)I]M =UK)&K^9*&;<=^<@ # '&<YSQA[_  \MI/"VJ^'WU6]-KJ=R]S-)
MMCWAG;>P4[< $CTJ75O JZAJ]OK-GK>H:9JL< MYKFUV?Z1&#D!T8%21V./Z
M8 ,&XO/&,=[X*T[4=62SOK]KF#4/LL<;HQ2)V5U)7AL ''W<]B!@W(;G6;C5
M[WPTNHW]Q)I=I"7NX3#%++)+O(=@PQ@!5  &,YSGBMJX\&P2WVB74>HWD;Z0
M\DD6=KF5Y 0[2%@22<GICK4>O>"8]6UV'7+#5K[2-32+R))[,J1-%G(5U8$'
M!Z'_ .M@ Y2_B\17&M?#V#6;J&VUO??)/<6RJX!$)&Y01C<5QVP">A'%6[23
MQ4;_ ,4>$TUZ::]M+>*[TS47BC\P;PV(Y!MVD;EQG&<$^V.EO/!UO.-(EM[^
M[M[W2I))(+DE9&=I 1(9 PPV[)SC'7C%+,NG^#;+4==OGNKF:X>,W=PL)DD;
M&%0!$'"KG@ =R3DDD@&3H'B&Y\36/AM;6\N(;@H\VI@JFX>6-CQL"O!,I&,
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MH5W*TLFG@+M4,<NBMC*HQSD=>3@C-=:JJB!$4*JC  & !0!P/QD55^&5^%4
M?:+8X [F=":Z#QGK3^'O#-SJ<*(;A&CAC9@,(9)%3)SV&X'\*7Q=X7B\7Z*V
MDW-[<6UL[J[F +N8JP9>6!QR!5S5-$M=<T"XT?5<W-O<Q^7*>%)[@C'0@X(]
MQ0!@6MKXJB\0X^USKI$]LRR&ZDA>6*<<J\>U<8(ZJ>/05R6FZ]XD_P"$*\(>
M)Y]>GFFO+^"VN+8PQB*2.24HV<+NW=,$$ 8Z5VVA^$)](3$_B+5-2>.,QVK7
M91OLX(QD *-S8XW-GC/3)S53X>6T7A;2O#Z:K>BUTVY2YADVQ[RR-O4,=N"
M?:@#&\:Z[J^EVGB:]L]6D>?3UCDM8;-%,=LH52PG+#!9B3\N2=I! '6M"_O-
M9N_B)8:3!K,]I8WFD27+I%%&61PZ#*%E///\6X=>/2>^^'-M?+KL)UC48K/6
MCYES:QE GFE0I<$KN'W0=N<<>G%:$'A$0Z_8ZP=5O);BTLS9J)%C(=&(9BV%
M')('3 &,8H \^UG4-4U'X8ZA'>:K<R3Z;X@&G^>NU&G1;E$!? P3@]L D#.:
M]@MXF@MTB>>2=E',DF-S?7  _2N3;X>VDGA[5M'DU*]:/4;XZ@TN$#Q3%Q)E
M<+C&Y1P0:ZNT@>VM8X9+B6X=1\TTN-SGN3@ #Z  4 </IEO.WQDUXG4;LI'8
M6KB(LI7!:3Y,;>%'7C!R3DFN2T:ZU;1/A=I^NV6K31);ZJ\9LEC3RI8WO61@
MY(+$_,<$$8XXSS7ILOA>,^*I/$%OJ%W;SS6RV\T*;#'($)*$Y4D8+'H1GOWS
ME#X=VP\'+X9_M:]^QK<_:1)MC\S=YOFXSMQC?ST]J ,_QEJVJV0\2S6NK2^9
M86*W%G;V**?LY5&9FN"PV_,0,+G)4' SS4%ZUWJ?C[P/<MJ%U!]KTVXF:.$K
ML5@D9X!4]=Q!)R<=,5M7O@""]N];E.KZA#!K4 CO;>(H%=A'Y8<$J67CL#@]
M\CBIF\$0EM E75]02YT:)X8YU,>Z6-U565OEP.%&" "/KS0!U5<#\._^1A\=
M?]AMO_0%KO6!*D X..#Z5R>G>"9M)OM3N['Q'J,3ZE<&YG7RH&7>>.,QG Q@
M?A0!<\4WD]O'IZP:E'9I)>*EP%4M/,FUCY<2@$[R<=N%#'(QFN(NO$VOQ^ _
M&\\>H7,%WHUZ\=K+*D32K'M1@CX!4XWGGKTYKJ[KP*MU'8RMKFHC4[.\>\34
M/W9D9F7805V;-NS"XV\ #WS7F^'%K-I^O63:QJ7DZW()+D,8R0V%#$';U.T>
MPZ "@"$7NKZ1X]T&VN-8FO+35[.X>:"2)%2)XE1@8]HW ?,1@EOK7+^)KZ]\
M5?!#4_$LFH3Q"Z#21VB!?*2$3;0A&,DX&2V<[O;BO0IO"PN-=T;5I=2N#-I4
M<D<2!$"R!P V[C.2%'3%8DOPPMCHVHZ%;ZWJ-OH=ZYD^P((RL)+;B$8J6"YY
MQGK^.0"74./B]X>/_4(N_P#T*.LF/7]9UCX9W7CBQU*2"YC6>[AM"BF$0Q.P
M\IAC))5#DYSD\8'%=:WA8/XDT[6WU.[>>QMFME1ECVR*V"Q;"CD[1TQTJE'X
M#M8+._TNWO[J+1+^5I)K!0NT;SET1L95&YR/<X(S0!AMJ>N>(_&%G8V.N7.F
M66H^'1J*HD,;-!(TB 8)7GJ,YSWQC((M6U[?^)K?Q2HU6XMX]*D?3X?*5 7D
M2,%Y7!!SEFQMZ8'KS70CPO$GBZ'Q!'>31R16?V%;953RO*W!L=,YR!W[52F\
M#QKK>HZCIVKWNGIJ:_Z=;0A&CE;&-XW*2K$=2.OUYH /AG_R3/PY_P!>,?\
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M$=W;ZY/J&F6L\\0TS4X3NM NU<QRX^ZQ;>,L.AX(Q7I% #))HXC&)'53(VQ
M3C<V"<#WP#^5/K@O&]J]QXY\$J+RZA5[NX4K%)M (@<[L8Z]L^F?6IM,NKSQ
M;J7B:!=2NK%=,N_L-J(&"E&5 3*W'SY9NAXPO3J: .WHKF? &OW?B7P58:G?
MHJWC[XIM@PK.CLA8>QVY_&NFH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&\2^'8/%&EKI]S=7-O
M")4F)MR@8LC!E^\IXR :V:I:M>7&GZ7/=6EA+?SQ@%+:%E5I.0."Q [Y_"@#
M*N_!]I?:\^K75[>222:>VG21$H(WA8Y8'"YR3SD&L^T^'5G;?V(6UK6)FT9C
M]D+S(-L939Y9VH.-O&?O>]=D.0.,>U% '.+X/@;[+'=:A>7=K:7GVV"";9A)
M Q9?F"AMJDY SZ#)'%='6(?$:#QHOALV<ZRM9->K<$KL90ZK@ '.<MW Z=ZV
MZ .=U;PA;ZAX@M]>M=0O=,U.*+[.T]H4_?19SL=75E.#R#CBL_\ X5KH[Z#J
M&D3W5_-#>7K7_FO*!)!.6W;XV &"#ZY_6NRHH Y)O %G=>'[W2=4U75=2-VB
MQM=7,X,L:JP9=F  N& /3D@9S@5-:>"X;;7X-;DUC5;B_BM#:-)+*F)4W;AN
M 4 8(!XP#WSSGIZI7=Y<V^H6-O%I\UQ#<,XEN$90MN N06!.3D\<4 <^OP^T
M[_A$[[P[)?7\EI=SFY,C,@DCD,@DRI" ?? /(-=-9VYM+2.!KB:X91S+,07<
M]R< #\  !V K(U;Q(UG>W-AI^GRZE?6ML+N:")PI$9)"@9ZL=K87VZC(SL6E
MQ]JLX+CRI8?-C5_*F7:Z9&<,.Q'0B@"21$EC:.10R,"K*1D$'M7,Q^ -"C\.
M:7H?DNUIIMREU#N;+%U8GYCW!R01Z'%=110!BZ_X;A\02Z;)/>75O_9]VMY"
M(-F#(H(!;<IR,$\>]1_\(M GB6\UVWO[ZWN+R%(YXXF3RW* A'(*DY 8]\>H
M-;U% ''I\.["/PMI_AY-3U(6=A<+<PMF+?N5]Z@GR^0&YZ5UZ@A0"2Q ZGO6
M+X=\1IXA;552SGM6TZ^:R=9BI+,JJQ/RDC'S>M%QXC2W\7V7AYK.?S+NWDN$
MN"5V83&1C.<_,.H'XT +JWAN'5]9TK4Y+VZAETQWD@2+9M+,I4[MRDG@D=15
M(^!M,FFU]KV:YO(M="B[AF*;/E4*I7:H(( '?MGK73TC$A20"Q Z#J: ,&Q\
M+1V\^GRWFHWFHG3@1:?:MG[LE=NX[5&YMN1D^I[G-;]8OAKQ%'XELKNYCM)K
M7[->2VC1S%2VZ,X/W21U]S23^(T@\86GAUK.?S+FVDN$N"5V$(0" ,YS\PZ@
M?C0 V_\ #,=UXBCUVVO[JROQ;?9':$(RR1;BP!5U(R&).1C\:J7W@73KS1H-
M,2ZO+:.*[%\\L3(9)IPV_>Y93D[N>WITXK7U?53I4=MLT^[OI;B;R4AM0F[.
MUFR2[*H "GDGTK M_'OVJYU2VM_#.MRSZ6P6[C3[,2A*[@!^^^;CTS0!JZSX
M9MM9GTZ[:XN+?4=.<O;7D.T.N1A@005*L.HQ^55[KP;9WFEZO:3WEV9M779>
MW8V"61 NT*/EVJH&0 !W)ZDFMZWG2ZM8KB/.R5 ZYZX(R*EH YB'P3:V^LZ?
MJUOJ5_#>6=H+-F0Q@7$0Z"4;/FQVQC%58?AUI]KJUU=6FIZI;V-W,9[C2XIP
M+:1S][(QD ]P" >G3BNQHH Q+'PU#8>)M1UU+Z[>?4$C2:%]GEX0$)C"@C&3
MW[\UMT5&D\4D\D*2*TD8!=0>5STS^5 &1>>&H;SQ/8Z\U[=QW%E$\,42;/+V
MOC=D%2><#OVK,/P_LFT#6=&;4]1-MJ]S)<W+$Q;]SG+A3LX!P.WTK3U[Q&F@
MWFD6\MG/,-2O$LTE0J%C9@2-V3GH#T';M6W0!#:P&UM(H#*\OEJ%WR8W-CN<
M #\A67XG\,6/BK3$L[UIXFBE6>WN+=]DL$J]'0]CR:VJ* .;3P783:%>Z7JM
MS>:L+Y!'<3WD@,C*.5 V@!=I)(P.O/6IK/PPD-S97%[J5YJ,U@C):-<[,Q[A
MM+?*HW/MXR<]3ZG.]4<\K0V\DJ0O,RJ2(XR-S>PR0/S(H Y5OA]8OX>U?1'U
M/46M=6N9+FY;,6_>YW.%.S !/M]*O1^%(X_$<&N?VG?-=PV1L0#Y6PQE@QR-
MG7(!S[59\,:_%XH\-V6M00/!%=J66.0@LH#$<X^E:] ''O\ #C29O#]YH]Q=
MW\T5Q>M?K,SHLL$Y;<7C95&#DGUZU:M_!-D=&O=-U:^O]9%Y%Y,TU_*&?9V5
M=H 7!YR!G."2<#'344 <YX=\(IH!0R:OJFI^2GEV_P!NF#B%/10 ,G QN.3C
MCC)JB/ASIP\(77A<:GJ?]F3MPGF(3$F\OL4E.F3U.3VS70:QK$&C0V[2J7EN
MKA+6WB4X,DC=!GL, DGT!Z]*;HNJ7.I1W(O-+N-/GMYS"R2D,LF "'C8?>4@
M]>.<CM0!3O?"L-UJECJT5]=6VJVD)MQ=QA-TT1Y*2*5VD9YZ#!Z56O\ P+I^
MH>'[G2'N[R-+NY%W=7$93S9Y0RL&8E2!RJ\  8 '2NHHH PV\,Q/XIMO$#ZA
M>-=06IM0G[ORV0D$Y&S.20#P16Y110!E:KX>T_6=0TJ]O(RTVF3F> @_Q%2,
M'VSAOJHHT[P]I^EZSJNJVT96YU-T>X/;*+M&/3U/N:U:Q#XD0>,QX;-E.)38
M-?+.2NQU#JFT#.<Y;OCI0!7@\&V44FOM+=WEPFN@B[CD* #*;/EVJ"/EXZFJ
MP\!V_P!BT6V?6=5D&CS+/;,[1$EE78H;Y,8"\8&/4Y/-:7AOQ%'XCAU"1+2:
MU-E?2V3I,5+%H\9/RDCJ?4]*VJ ,6P\-PZ?XDU/7$O;J2?45C6:*39Y8$8(3
M;A01@$]^];58GB7Q&GANVLYI;.>X2ZNXK3=&5 C:1@H+9.<<]@:VZ .4?P'9
M-!KULFI:C%;:V\CW$".FU&D $A3*$Y8#OG';%3OX-MWGT"9M2O\ ?H8(MO\
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ME0/,4$ G*G/!/'3FJ%[X%TS4KK6I[R>\E&L6ZV]U&74+L7.S;A<@C)P<_7-
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MM+%='AN$\B10Z/YK+PQ7T49SDGUQQ75ZYX;M]>N=.GN+N[A.GW N8%@9 /,
M(!.5.>"1CIS1#X:@A\4R>(?MEVUY);+:NC%/+,8)8# 7/4DYSW]* .8TRYOO
M%VG>)KM=3O+.ZL;^XLK+R92BP^2  S*.'+'D[@1@X&*R['Q#K'B.Z^'MR=1N
M;)=8MKHW<,&T*S)']X9&>3DC.0,C'3-=G)X.LQJ&HW5I>WUBNI\WL%LZ!)FQ
M@M\RDJQ'!*D$]>O-23>$M/?4M%O899[;^QHVCLX(2HC164(005)/R@#KQVH
MXF"'59K7QMI[>(]6$>BRL]G(LP$H)@$@#OC+ 'H/0G.>,=YX4U"?5?!^BZC=
M,&N+JQ@FE8# +,@)./J:JQ^#[6)M<9;^^W:U_P ?1)CZ[=F5^3CY1C_Z_-:F
MC:5%H>C6FEV\LLD%I$L,1E(+!%& "0!G % 'G'B;6=1L;'5-4LM5N[JXM=8B
MC6:!BEM!&98T-NR$XD8!CDA3R>H(Q703?\ENM/\ L79O_2B.G7/PTT>ZM=2L
MS>ZI':7]U]K:WCN<)%-O#ED&.[#.#D>@%:Z^%[9?$D&NB\O?M<-I]C56=64Q
M$AB#E2220#G.: ,;X<_=\5_]C)>_S6K-[J$FH_$-?#3W$T%K%I?VYE@E:)YF
M:0H!N4A@% )P",EAGI6IH/AVW\/?;_LUS<S"^NGO)1.5/[U_O$848S@<=*J^
M(O!MAXBO;/4'NKZPU&S!6&\L)O+E"'JA)!!4^A'\S0!R_BVSOM.\%Z59ZCJO
M]IW$.NV:FX*!6VF<%0W/+!2.>_6I?&-]>1MXIDM=4O)9['31-;PV3F);!E1W
M+RG< Y8@$*<G Z8.:Z._\&6%_HUIICW5ZD5M<+=>8LH:2256W!W9@23NY_\
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M<2:L8;>[@E<&)U>W+9VX^\"N=W4\_2NJ7P'IZW>IW0U#5#/J=JMM=.UP&W@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6JVKM&Z?O$4L1N!4C(W'D &M'3=.M=(TVVTZQA$-K;1B**,'.U0,#D]:M44
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M \?D7MQ#IUG=0W%TEM(Z*6CC52S $<E#0!V&B:4NBZ8EBEY=W:(S%)+N7S)
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M BO+:ZC@^TK]J@,0EBSM+IGL#CK@\T ;U%<W8^-M+U"YTR.-+I(=4WBPN7C
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MHT*E@_\ ND G/M3H/%=E)K=MI%Q;W=G=7D32V@N8PHN%7EMN"<$ Y*M@X[4
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MB\0>+FGL[N!+G4O/@>:W>-9$\M%R"0,\J:[2F31^;#)'O=-ZE=Z'#+D=1[T
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M(7C]LBJ_BJ";2/'D&N7'AV?6]'N=/6SD2VMA/);2([,K!.NTAR./3Z9]$HH
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MXR PR-P(/Y'D5QNN17EM\3=!U1-/N[FT^PW%JSV\>\([,A7=_=!P>3Q7:44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>&(P01S6M10!D:;H L9EGN=3U#4YX\^7)>NA\O(P<*BJN<<9QG!(SR:UZ**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7US%>,H2WC5?-52^W<1G&!U//2M#5-9ATR>SM?+>>]O79+:W0@%RJEF.20
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M$6J1II91[3R950HWV<2=0.@)Z#&>^>W<^$[^?5?!VB:C=,&N+JP@FE8#&79
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M5NF"0%'4<GK73:<FJ:+\1I/#QUO4+[3M0TQ[Q&NG626UE5PIVL1C:0W0C&:
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MS_V5?@PB?9&Q5I-I( R2-OKT..G% 'J-WJ<B6MC<Z?92:A%=31KNA=0$B?\
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M86&K:C!K'@V2/4KZ]CU&>:&[NY'(@O?W;.&CB).P J,$!<CU!JO97C^&=/\
MB-K5M+<27%EJ$@B$T[NN3%'AF!/."?R&* /6Z*XVRTSQ#;^(],OHM0B&ER1N
ME[#-J$EP;@E<H\89 $;/4+@$=J[*@ HHHH R-5\2:=HVJZ1IMY+LN-5F:&W'
MNJYR?;.U?JPK7KRGQ;8WGBS3M;OK/2[Z6ZAE3^Q[J+R]J&W8G<,N#\TGF#('
M*A>M=]X4U^'Q/X6T[68< 74(9U'\#CAU_!@1^% &P3@9-<]9>*EU<23:-IEU
MJ%E&[)]K1HTCE93AA'N8%L$$9P%]":/'9NQX!U_[#N^T_8)MFW[WW#G'OC-1
M?#HVY^&_APVI4Q_V?"#M_O;1N_'=G/O0!J:+K,.MVTT\4%Q!Y,[P/'<)M=67
MKD?YSUK2KDO%6J2V6IZ-I=AY<;ZM>M'</YQB)V0EMN\ E6;:@SC..!C((YSQ
M'#XI\/\ A#Q;</K)A@2%;C3EBNVGN(,##JTCH"5)Y!ZCIF@#TR>XBMH_,GD6
M--RIN8X&6(4#\20/QJM+>7*:Q;V:Z?*]M)$[O>!UV1L",*1G))R?RKSCQCH4
MT&F:+=7.MZK=O=ZYIY9)+C:D9+@'8JXP.XSG!&1SS703SWEG\4M&TY-0NGL)
M=+G=K>1]R[D9 &)ZD\GDDT :&I^*WM;G4(--TJXU1]-\O[9';L!(N\9 13]]
M@N&(XX(P2>*UM(O;G4-,BNKO3IM/G<MNMIF5F3#$#)4D<@ _C7$^#]+5?&_C
M;9=WJM'=PJK&X9NMNO)#9#$9XR#CBLW0_$VK2>!O"D,MX\]YJVI3VLUS/,8V
M95>8A=X!VD[%48' /&." #U:L34/$::?XHT;0WLYF;5/.\NX#+L7RT+D$9SG
MIVQSUKCM:O\ Q+X(T;7[Z:]@:UF,*Z=%+=/<R6KNZQNQ9U!9 6# $G!&.]3Z
MOI8T[XG^!62\O)PWVU7%S.TF6$'WAG[I/<# Z<"@#T6J.M:M:Z%HMYJMXQ6W
MM(6E?'4@#H/<]![FKU<KXEG-]K-AI T^>_MHO]-O8H0AR 2(E;<P&"X+?]LO
M>@#H=/OK?5--MK^T??;W,2S1-ZJPR/YU9KSOX6W4NG)J_@^[BFAET>X+VL<Y
M&\VDA+1YP2"1R#@G' IV@/J/B_PG8^)8==FL+V2Z:=_F+01PI(RF$QY"XVC!
M8\YYS0!Z%17!VKWOC)O%*0ZM<Z?=6%^]C9&"1E$!15(D901YFYB>&R,  =\D
ME[J6M^)KW0EN1(MCI]O(9(+U[0RR2;\RJ45B0-HP,X&><Y& #O**\VO+GQ7H
MFC:(^M)-K45LLZ:J=&F99B<KY4F!M9L+N# 8Y.>U%UKES_8&@ZMIKZEK^@%9
MS>/9RLEV?F&QR 59MGSJR@CG!QQ0!Z316+X2OK74O#%G=V6HR:C;R!BES+G>
MPW'AL\[AT/N*VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *RO$6@6WB;19])O)[B.UN!ME$#*I89
M!QD@XZ=JU:S=<UJVT'3OMERLDFZ5(8HH@"\LCL%1%R0,DD=2!0!:L;3[#8PV
MHGEF6) BO+C<0!@9P /TK-T3PU:Z')J3PW-S.-1N&NKA)RA4R, &(PHQD #'
M3BF0^(+I=7L]-O\ 1KFUDN]_ES+(DD7RJ6(+ Y#<=,<\X)P:W: .2T;X=Z3H
M5Z)+.\U3[$DIFATV2[+6L+YSE4QV/(!) //6K">"K*.RURT%]?F+6G=[O+1Y
M)==K;?DXRH _^O72T4 <Y)X-LY(]#1KZ^QHI!M,-'U"[1N^3GY>/_K\T'P;9
M&YUNX-[?^9K(3[21(J[2@VJ4(7*D 8_^O6QJES=V>F7%Q8V+7]U&F8[99%C,
MA]-S<"K*%F12R[6(!*YS@^E &)_PB=A//<SZE)-J4MQ9FQ=[K9_J"<LF$51R
M>2>O JGH'@/3_#Y BU'5KN&)2EM!>79DCME(Q^[7 QP2 3D@$@=35SQ-XC_X
M1R/3I#927*WE]#9[E<*(S(P4,<\GKT _*M#[5>?VV+/^SV^P_9_-^V^:N/,W
M8\O9][..<].U &;8^$[6SGTV6:]O;TZ8K+9BZ9#Y65V$Y506.W(RQ/7UYK?H
MJ*WN8;I7:"19%1VC8J>C*<,/P((H YX>";(6>NVOVZ_,6ML[7F6CR2R[&V_)
MQE0!_P#7IJ^!=/2_L+V.^U**XL[,6&^*<(9H%.51\ =/48/O6_J%_;:7837M
MW)Y<$0RQQD^@  Y))(  Y)(%9VI^)+?1;"UFOX)5NKN016UE%AYI7/10.F<<
MDYVCGG'- !X?\+Z?X<T'^Q;4SS67SC9<R>9A6))7TQR>*DTWPUI>E^&(_#L-
MOOTU(# 8I#NWJV=V[USDY^M5+KQ'>:;'!+J.AW$<4\\4 >&5)1&9'" R<C R
MW4;A[UH:[K-MX>T*]U>\)\BTB,C =6QT4>Y. /<T 8_AWP)I_AN>-K?4-5N8
M8,_9;:[NS)%;9&/D7 [$@$YP"<=374U6TZ_M]4TVUU"T??;W,2S1MZJPR/YU
MA)XMDNH;N\TW1KN^T^UEDA>:%T#2,A(?RT)&X @CJ,X. >,@#E\%V:P:[$+Z
M^VZV6-WEH^2R[#M^3CY>/_K\T-X*L/*T@Q75Y!=Z1'Y-I>QLGFK'C:4;*E67
M '53TSUYK:TV]34M+M+^-&1+F%)E5NH#*" ?SIU[/):VKSQ6[W!0;C'&?F8=
M]OJ?;C- &1/X/TN[T+4]*N?.F35"6O)V<"65B  V0  0%4   # XK5T^R&GV
M,=L+BXN-@P9;A][N?4G_  P*=8WMMJ5C!>V<RS6\Z!XY%Z,#5B@#*U[P_:>(
M+>VCN9)X9+2X6ZMYX'"O%*H(##((/!/!!'/2F0>&[%?MKW9DU">^B$%S-=;2
MTD0! CPH"A?F;@ <DD\UL44 <MX>\!Z?X;GC:WU#5;F"#/V6UN[LR0VV1CY%
MP.Q(&<X!/K46G_#K2-+U.2YL[O4XK-YOM!TM;HBT\S.=WEX]><9Q[5UU% '.
MIX/M$FUR5;Z^W:T +KYH^R[!M^3CY>/_ *_-:FC:5#H>CVFEV\LLEO:Q+#$9
M2"P11@#( S@"ETVZO+N*=KW3VLF2=XXU:59/,C!PLGR]-PYP>15V@#(\0^'K
M;Q)9PVMW<7,4<,Z7"^0R@ET.5)R#T(S5>^\*0:@=1674M0%OJ2!+NV5D\N0;
M AZIE<J,$J1_+&_10!S]WX1M;I;Z$7U]#9WT0AN+.-D\ID"!,#*DKE1@E2#^
M0PEYX.L+G6;35(+F]L9[>V%F19S;%E@!R(VX)P#G!4@C/6NAHH X\_#703X7
M&@,UZ;9+@W4,OGD2P2EBVZ-@,*06/;OWJTG@;2WT"]TC49K[5([U0D\]_<&2
M5@O*@-QC:>1@#G)ZDUT-Q<PVD:R3R+&C.D8+=V9@JC\20/QJ6@#E;;P):0ZC
MI-_<:OK%[<:6)%MFN;D'"N "&VJ,\#KU.>2>,=552XU".$720J;BYMHA*T",
M V#G;U( SM/Y53\+ZZOB;PU8:TD!@2\C\P1,VXJ,D=?PH Q;WX;:/?0ZQ;O=
MZFEIJLYN9K:.YVQK,2&+J,=20#@Y'MTKK;>$6]O'"'D<(N-TC%F/N2>IJ2B@
M#!U[PG9:]?6.H-<7=EJ-B6\B\LY DBJWWE.X$,I]"#5)? &FK9ZW;&]U)EUK
M_C\9YPQ;*A3C*X&0/3Z8%/N_&,EOXM?PW#HEY=7JVGVT&*6(*T6_9D%F'.>U
M7_#?B?3_ !38S7%CYT;V\S6]S;SIME@E7JK#)Y^A(H C3PRL#VSVVK:C ]O:
MK:;D:,[XU)*[@R$$C/7 /YG-)/A_H]O<Z9/8RWUB^GVQM%^RSE/-A+;BCG!)
M^;)R,')ZUU5% ')0_#O1[?08M(BGU!8;>\^VVTGVC+V\H9F!3(Q@%FX(.<\Y
MK8L]!BM+FXO6NKFXU">(0M>3;#(J#)"J H4 $DX"\GKFM6JFJ7-U9Z9<7%C8
MM?74:%H[99!&93Z;FX'XT <\/A]I@\'Q^%Q>7_\ 9L<HE4>8F_(?S -VWIOY
M_P#K<5I3>&X)_$5CKDEY=F[LX6@C&4"%6QNR-O? _+C%;$;,T:LZ;&(!*YS@
M^E.H Y9M/L/!$6JZU;0:O>+=7)N)+*U!FQ)(PWLD8QU.">3CG&.:F\*:3':M
MJFL&P-E<ZQ=?:9(7&'50H5 P[,0"Q'8N171T4 %<=>_#;1[Z+6+>2[U)+35I
MC<3VT=SMC64D$R*,=20#@Y'MTKL:* .5U/P%IVHZC:ZE'J&JV.HP0^0UW9W1
M22:/.=LA(.X9Y]?R%2:QX%TG5[33HA)>65QII+6EY:3E9XR?O?.<[MW?.<UT
MU86O^(_[!O=&MVLI)EU.]2S$H<*L;,"<D=3PI[?C0!7OO VCZEX<.C7ANYD,
MHN/M3SDW'G#I+YG7<.@[ <8QQ1;>"[6#29[)]5U>XFF:)FOKBZWW \MPZ ,1
M@ $=,<Y.<YKI:P_%_B/_ (1/PQ>:T;*2\2V +1HX3@D#))[<]@?I0!%+X0M+
M@WDL][>O>W8A5[P,B2JL3[T"[5"C#9/3G//;%W3]"@L=2N=2>>>ZOKB-(7N)
M]@;RT)*J BJ ,LQZ9Y]AC4[5%-<PP201RR*CSOY<0/\ &VTM@?@K'\* 'NI>
M-E5V0D8#+C(]QG(KE$^'NFQ^';30DOM0%E:70NXOG3<) YD&3LY&XDX]_2NM
MHH Y^Z\(6=YK-SJDUY>FXN;!M.D 9 ODG)P %X.23G^G%,ET"WLL:G=WE[?W
M%G:206[SA7:-7 W8"("Q.U1DY/'N<]'10!YU\/?#2W/@#08-4EU$K:[9&TZY
M01HDJMN&04#D X8 DC./05M:EX TV_\ $$NM0WVJZ==7"JMT-/NS"MR%X&\
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M S%0C-M]2HQU^F*Z"N>\3^*E\,2::LFG7%W_ &C=I9P^0Z#]Z^=H.XC XZT
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MH8@@#H/E[GOT% %_1](M-#TU+&S5A$K,Y+'+.[,69C[EB3Z<\5>HHH ****
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MHS=:GJ&H+$0T:W<BD*1T)"JNXCJ"V<'GK4VG:+%IVH7UZES<RRWKAYA,X89
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M54NOL5V\"W0' $@7&>..,5T\44<$*0Q(J1HH5$48"@<  4 >>7@O#\>#]A:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHKG/&<Z1:=8QMJ%Q:&:_AC$5LN9;OG/D*=R[=P'+9& #GB@#
M7U6]?3=)N[V. W#6\32^4&"[L#.,GI7-R>.73P_X6U8:66379[: KYX_T<S<
M@YQ\V.>P_"L?1[F\$OQ"TVX:5;>T1&@MY)S-Y(DMMQ4,><9YQT!)QZUFR_\
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M(LCQ%EZ!D8JP_ @C\*FKR/PIX:GU+X.31Z1?7]GJ1ENFMI(;V5 '2>3:N V
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MW-N9(TB,FQ7E7^ MCCG@GM0!CZ'\/]!\/7WVG3X[I51F>&VDNG>"!CG)2,G
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M7<93M,6=VW;TZ\YZUK5@>*?$4WAU=*>.R2XCO=0@LG8R[#%YC8W8P=W?C(H
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M>0L)'./F']T\#IC&!CI70UG:_J4NC:!?ZG#;+<M:0//Y32;-P52Q&<'' ]*
M(M/\.VEA<Q732W-W<01&&&6[E,C1(<9"_7 R>IP,DUD7'PW\/74%_;2I>&TO
M9_M$EL+MQ$DA<.S(N<*21U'J<8S6_HNH'5M"T[46C$;7=M'.4!SMWJ&QGOC-
M30WMO<75S;12J\ML5691_ 6&X ^^"#^(H \[\0Z2)/%\\M]I7B58%MH;>SOM
M&NI"9$&682[7W9#,<9!XYSS6SIW@];_28X-7N-7D@@O5O+*.\N]\\14+MWNI
M.<,&(!)P",^@[.J6FSZA.+K^T+..U*7#I!LF\SS(A]USP-I//R]J *T/AVR@
M\12:ZKW#7\L MW9I25,8)(7;TX))JUJNF6^L:>UE<F58V='W12%'5D<.I##D
M$,H-7*I:=/J$_P!K^WV<=MLN'2WV3>9YL0QM<\#:3S\O;% %)O"NF3V^I17B
MR7;:E"+>ZEF?YY(P" N1C &YNF.23UJFW@/12VFR!K]9]/5DBN%O91*R, "K
M.&R1P..V.,5TU% ',+\/_#Z:)=Z0EO.MI=7'VEE%P^8Y-^\%#GY,-SQ1J_@+
M1-9DLIYQ>0W=FACAO+>[DCGVGDAI <MDDGGGD^IKIZ* *]A8VVF6,5G:1^7!
M$,*N23ZDDGDDG))/))R:L444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q7Q<_Y)9KO_ %R3_P!&
M)7:UG:YH=AXBTJ73-3B>6SEQYD:RM'NP<C)4@XR!0!S'B-8[_P 3W%G'-/>3
M1:62;'S#%#;;F.)F<<[SC"@ D;<\9S7.?;;X?#3P=XQFO+J633C!)J'[Y_W]
MN3L<N <,5R&R?0UWMSX.T6\U2/4IX)FND@^S,XN9 )HP<A9 &Q(,G^+-2V'A
M71]-\-R>'[:U(TR2-XGA>1GRK#!&6)/3CVH X&#6)=.\6ZY;H\KVNO0;M$:6
M=W4R*WDNJY/"EF63C^'GZ>GV%FFGZ?!9QO(Z0H$#RN7=L=R3R2:K'0=,,FER
M?9(PVE@BSQ_RR!39@>VWC\JT: .+U&].I?%&U\-W3,+"+26O_)#%1<2F4( V
M/O!0"<=,G/85Q4=_-X:T+Q5%93S0QS>+4M)+@R$O!"XB#,&/(POR@]1D=Z]0
MUOPMI6OW%I=7D4JW=FQ-O<V\SPRQYZ@,A!P>XJO;^"/#]O9ZG9BQ:6WU-B]Y
M'/-)()6..3N8X/ Y'/&<YH PM6$_AGQ_X=32?.-IJ<=S%=V?F,R,8X]ZR $G
M#9X)[Y&:R=#M=3\3>%]#\3PZU!:78D6YN+H22,7Y(D@9=VW;GY0O; Q7?Z?X
M>L-.N([A/M$\\47DQRW,[RM''QE5+$XS@9/4X&2<"LVT^'WAJQUM]6MK%HYW
ME\\Q+._D^;_?\K.W=WSC@\CF@#E[Z_N-'\2L?$%K</87.JHUEK=E.66+]X M
MO,@/RJ"-AZJ2<XSDUZ?6)_PB>E>:Y9+AXI+K[8UN]P[1&;=OW;2<?>^;'3/.
M,UMT >7'2UU3Q/\ $&TNK[4FM[6.V>"-;V51&S0%LC#9X;) SM]NE-T77;S6
M)? .E:E/*UO?Z2]W<,7(-U*B* K$<D %F([G&:[E/"FDI>:I=I'<+/JBA;QQ
M=2_O !M'\7RX''&.*A/@O0QI5AIR6TJ0Z<P>R=;A_,MR./D?.X#'&,X(H \^
M\1)-#8?$;P^\DT^E6FG)>VJR2LWV=W1B4!)R5RNX*>!7IGANUBM/#FGQPA@I
MMXV.YV;DJ.Y)H7PYI8T^^LGMS-%J 87;2NSO/E=IW,3G[O ]!TQ5C2=)M-%T
MZ.QLED$$8P/-E:1NF!EF))X '7@ #H* .2^($<KZOX12*\O+=;C51!*(+AT#
MH8W)! .,\=>H[$52%F(O%X\&PS-)8VVF"Z@AO;J5FE+RN'.X'+;<*!D\9KL]
M6\/:=K=Q93WT<SR64HFMS'<21[''&["D9."1SZU5\0^#M%\4/;2ZE;.;BU),
M%Q#,T4L>>H#*0<'TH Y& ZCI>I>%_!^I:V]]%<379GN%=E>18D#) SYR<;^>
M<D* >IJO<Q&SU+XDV=O<726]KI,$UM&+A\0.8IFS'S\OS#/%=IJ'@G0-2T:U
MTJ>R*V]HXDMVBE=)(GZ[@X.[<222<\DY-8/AO0ELO''BF)M.N1I=[;6L,<MP
MKN)]BN)-SMDD_,.6//O0!2DNKGROAC.+JX\RZ,:3D3-^^!M2QWC/S<\\]Z%,
M_P#:WQ-M_MM[LMX('@/VJ3="3;%_D;.5&[G XKHK;X>>';5; +!=/_9\GF6A
MEO9G,/! 526R% /W1Q5W_A$='^T:M/Y5QYFK*$O6%U+^] &T#[WRX''&.* /
M/T#Z%\/?#^N)J-[]JU6+3K2\N+B[<I'&^TLV,_)Q\NX8(!SUR:[#1=!OM(\6
M37)U*%+&[M<?V9&SLOFJPS*I8G;PP! '.0:U!X7T?_A&O^$=DM/.TGRA"+>:
M1I $'0 L2>,#'/&!BH_#WA+2/#".NFPS!G 4O/.\S!1T4%B<*/0<4 7=<N([
M30-1N)KTV,<=M(S707<8?E/S@=R.N.^*\_T=[FQ\<>%(H1<PVM]I=QYIGG+2
M7901E994R0KY).<D_,0<=*](OK*VU*PN+&\B6:VN(VBEC;HRD8(_*L&T\!>'
MK*YTVYCMKAI].#+;22W<KLJD ;268Y48&%/ ["@#I:\X^#.Z'PYJUC<G&I6V
MKW O%;[V\D'<?J._?%>CUAWOA/2KW5CJJK<6FH,H22YL[AX6E4= ^T@/CW!Q
M0!K//;Q2.7DC5TCWN21E4YY/H.#^1KRCQ+8:SJWA6Y\0VND2KJ<=XNL6=P94
MRL<8_=IMSNYB'*_WF->CS^&]-N=)N=-F2=[>Z&VX8W,GF2C&,-)NW$8XQG&.
M.E7A91+8?8@TOD[/+SYK;\?[V=V??- '.7QT'Q[X'LQ?$_8-76,Q,K8>.0C<
MN#V8$8^HQ7.Z=<^*/!7B;2=!UR\37-%U"5H+*_==MS;R!20K_P![C(SUZG/:
MNHM? 7AVRT-=%@M)ETY)A.D!NI2$<$D%26RO)SP1SS5VW\-Z?;:A%J$C75U<
MVZL('NKAYO)!&#M!)Y(XSUQQF@#SBUT)]:T#QK/-K.KQW&FZM>"QD%_(/(,:
M*5/7YNP^;.!TQDFO1?!]_=ZKX,T74+X?Z7<V44LIQC+%02<=L]?QKE?"?AE;
MN3Q2NJVNH017^KSSB%VDCCN(&V[21G'.""."1P>*]#1%C1410JJ,!0, "@#B
M_%+RQ?$'P3Y=Q<(DUQ<I+$LS"-P(&(RF=I(/?&:YB;33?6WQ',^H:FW]G3/)
M9@7TH\EA;JX((;)P>@.0.PKTC4/#^G:IJ=AJ-W'*UU8,S6SI.Z",D8)PI .1
MQR#Q59?!^C*FK((KC;JV?MH^UR_O<C:?XN...,<4 <;?7VM/I>@:W)I\FNZ>
MVCQ/?6EM/LN(I'4-YZ+D;B<$#H1@XQS47^C:WXC\$P66KZF^E7VD3[]MU)&9
M@BQ@%L'Y6Y.2,'KS7;Q>$=+MA;_96O;<V]LMI&8KR4'R5SA#\W.,G!/([$5S
M6K>'D7QYX5BL;"\@TO3;2XA\ZU5U6!F"!!N'7[ISU'K0!SC:IJ/A/_A)="CU
M&X;2[75K""&ZN9F9K:&XPTB^9G< !@9SD;L]:W-:MM7\'6^NZ]9:A D1TJ1H
M]-0O(OG)_P MQN)Q@$9 &#QFNR/AC1WT>\TJ:S6>TO69[I9F+M,QQEF8G)/
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MV#3+6*STZ"&$,$" _,[.>1ZDDUF#P;H?DZM"UK))'J^3>K)<2.)21C/+<'
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M.NJ65W]L6:X>193&(V5MI.%(+'[H QQTK$N8-;U3P_J,"?VA_P )2NM,D5S
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M==PX/M7F]Q;0S_LQQ/*@9HM+#H<_=.<9KU72;.WL=,@AMHQ''L#;02>2!ZT
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MF1_99@FEX^Q 7<P\G P,?-Z<<]N.E+X@\':#XHDMY=7L!--;$^3,DCQ2)GJ
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M27.21D]2>M=;!H.F06EW;?95ECO<FZ\]C*T^1M^<L26XXP>@X%:5% &!X?\
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MX..Q(R.U '!>4=6OOA9)=W%S(]Y82?:")W'F?Z(&.<'J23D]3DUGWNH3>%-
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M7&TCM^/7->UUA?\ "':#_9]E8?8F%K8RB:UB$\@$+CHR_-P1V].U;H& !Z4
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MWK74C4=!\<?#ZRGU2-'T[6$CB>,G&V5F VY[$., ^H%=-%90PV*V4?F"!4V
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M\F!.[MM+'CT !)H0ZG_;4H<6G]E^0OED%O/\W)W9_AVXQCOFO-]5T'1;>_\
MA_8PXU&UAOY[59[P+*[HL<GR%B.5## '3@5=F+Z=\2O$D^EQ!YU\-I-#&O(:
M0/)M 'OM48% 'H^1G&1GTH+ 9R0,5X[?1Q-\%])\4:5@^(8UMIX[U>9IKAY%
M21&;JP8LRE3QT]*V;?P]I>L?$WQA:ZC:+<6[65F[0R,60L1)DXSC([>G:@#T
MJBN-^&%\9?AEX=DN[@&62#RU:1^6(+  9ZG _2NRH *Y76_$NHZ;XUT'08+:
MUDBU<3E9G9@T7E(&;('WLYXY%=57 ^*O^2N_#_\ W=1_]$B@#:U36[]_$3>'
MM'^RI?KIYOC)=HSQXW[$3"L#R0V3GC'0YXVM.DO)=-MI-0@C@O&C4S11OO5'
MQR >XS7$)I.FM\<;AFT^T+#0X[@$PKGS?M#_ #]/O<#GK7H- '*:7XEU*_\
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M]9O&LYBY+6Y29=I0Y^4\=1R>]=?=2#7/B'?:)J4FGE/[,@DL[>_MC,LBMO\
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MK*_X1K1OME[>#3H%N;Y=ES*@VM*, 8)'J ,^N.:TI)HHE#22HBDX!9@ 33Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6]KBVTFW\4QQ3*B92"V8Q&0!1T3D@@8X8CO7JD?AG0X9;.6+2K1)+)=MLRQ
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M:W%W;#$,TD89D&<XS]>?K47_  BV@?V/)I']CV7]GR'<]OY*[&;KN([GWZT
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MY6&ZTZ^F^'=]9Z<=.0:G=0&"4#= P24-&&'50X('T%>FWVCZ?J4T$UW:I)-
M&$,O(>/=C=M8<C.!G'7%0WGAS1=0TJ+2[K3+66QB8-' T8VH1T('8\GD>IH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%BN&^SJ-L7OAAE^?^>E9/Q'M1:6>F^*X80]SH-TMRY"Y9K<_),H_X"Q;_@-
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MWAZ[\(:/#J,EWX:EU>Y\V68KY(E";HH@0 I02$X'3<OM6]H@L;+XN^+6C,$
M:PM)9<$*,CS-S'\,9H [^BHK>Y@O+:.YMIHYX)5#1RQ,&5P>A!'!%2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%32Z/IDVH+J$NG6CWJ+M6X:%3(!Z!L9Q51/$^E2>)9-!2\A-]%$)9$WCY<G
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M['Q!J.F_VS(""D$FP2\G!56.>1C(]<U>O-2L=."&]O;:V$APGGRJFX^@R>:
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M2TM["TBM+2"."WA4)'%&H544=  .E34BLKHKHP96&00<@BEH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KDOB@0/ACXBR<?Z&]=;5>\L+/48?)O;2"YBSG9/&'7/T- 'G'B"RL[M_
MAL9X(9?,G2,EE!W(;9CM/JI...AK5\(006?Q&\<6MK%'# K6+B*-0JJS0G)
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M=&E;_MGV5MOE_>VY&_'OMW5@^(6M=3B\ 7WAXQ^=_:,)MC#C(M/+;SEXZ*%
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MI?L^S[V_8<8]\]/>O/\ 4S;:I\+O!TVAE!J$=S9+8^7]])1@2J?HOF;OH<T
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MW\)_">XGECC@2:W#R.P"K_HSCDGIS6UXHG?PIXJL_%FG6QNK;581I]U%$/\
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MQ1::_K-I;Z;9+:?93/LA5#(KDC<>6/ ZGM73RZ[I$#VJ3:K91M=@&W#W" S
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M#6S0!4NM*TZ^ACAN["UN(HO]6DL*NJ?0$<4Z?3K&ZCCCN+.WF2/[BR1*P7Z
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M[ WKC&,UC_V=KM_XA+ZG-IW]BVTXGM(K=7\Z1@N%\TD[<*26&.I"GC'/144
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M6!,L6XC)_=JO.!S@=>]=GH.I7.IK-,UQ87ED51K:\LB=DH.=P(W-@@@=SU_
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M$9X'0]S6)XQUV_\ $?PO\2:EIZ6HTH1SP1B0,9)D1BC2!@<+\P;"X.0.HSP
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M\A4F*0.K'!7<>5*$<,<^U:?P_N=0O? NC7>HS1S2SV<4@=0=QR@.6R>3GTH
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MY/? ]* .UJI:ZG8WUU=VUK=1RSV;B.X13DQL1D _@:MUPR^-+BUMO&5U<:7
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M2.5QDRA1\N4YV[1R<9ST%8]SX(\0S:9X@@BN-/CDU#6$U)(VE=HY$&P&&7Y
M=I"<XSG.,5Z/10!Q-GX5UL^)=9U&\GTY+;5=/CM7CMPY:)D#@ 9P"/GSNXSC
M&T=:U_!FE:GH?A>QTK5'M'DLX4MT:V+$,JC 8E@.3Z8X]ZWZQ[[Q5H>F7B6M
M[J,4$CRB ,X(02$9"%\;5;&#@D'F@#8KD='\/:M8_$#7->N!9?9-3B@C5(YG
M,D?E*1DY0 YSZ\>]==10!Q>K^'O$EGXOE\0>%[K3C]M@2"^L]0WA&*9V2*R
MD$ D8Z5)?^'=;NM:\,:@UQ9SMI<LTURSLT?F-(C+M10K85=W&3G  ]Z["B@#
MSO4_!6OWR^,?(N[*V?6Y+>2 B5VP(E52DGRCY7"D''J1S5ZS\.^(H?&/]O2?
MV0B-I2V+6L)D 0JY90K;>5YZX&.FWO7;44 ><0^!M<A\ ^'O#X?3FN-+OH;E
MY/.<(ZQR;P!\F<G./;WK?LM!U2Q\>:IK,<MF;#4X+=9D8L98WB5AA>,$'=U)
M[=*Z"_OK;3+"XOKV98;6WC,DLC9PJ@9)XJ2">*YMXKB%P\4J!T8=&4C(/Y4
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M)]Z,D$!A[CK7!:?X)\1V_P#PB9EOM)4Z"SIB*&3$J-&4+DDC+G.2.!G)R>E
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M(ZBLZ'P]807UC=1PHOV"W^SVRA1E%QMY;J<+P!TY/7/&!X5O7MO''BWP\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5%<W,-G:RW-Q(L4$2%Y';HJ@9)J6N-\3:VT'B
M"WLKG1M9NM/@5;EFLK%YDFER=JDCC"XW8[G;Z'(!L^%_$4'BK08M6MH)H(9)
M)45)AAQL=DY';.W.*V:\]^#NI+>>#&MQ:WD)@NKAB\\!1'WSR'"D_>(Z'T/%
M>A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G:)HMGX?T
MQ=/L X@6220!VW'+N7;GZL:T:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>secondamendmenttoleaseag005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 secondamendmenttoleaseag005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K-U;3[O4#:I;:E/8Q)(7F:WV[Y!M("Y92
M,D$]^*TJ0D*"20 .230!YMX>CUO7=1\76)\3:G$VG7IMK.1?*^4; 06&SGDU
MTMUX[\.Z;<SV5[J8%W:F)+A$AD?:SG"]%Z9'7H,C.,BL/X?2H?%/C7J!/JGF
MPEE($J; -RY^\,CJ*L:')'_PMOQ2Q'^MM+-(W*G#E ^\ ]"1D9 H W[[Q9HN
MG3;+N[:-!,(&G\ES"DAX"M(%V*<G')X/!I-2\6Z+I,MU'=W;*;0(UTR022+
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MWB8@W<N?]6P (",3RO XZ\5E_$^&0Z=X>O0#Y%AK]E<W!["/<5)/XN*=\1W
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MEQPN?;I0!QWB#Q)%;?$.#0]9U2?2=-FLEDM)8W\I;B<L0P:3MM 7"Y .><Y
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MH"J/)(3^[C7 #$X)..!N'OC!\'0OX(\42Z!=Q1FTU.,75E-"&9+8Y)-L6/1
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MUY9W4GF+/$6"L5)&489R,$#@Y!J/QAI5U9^-O#OC"VMY;F"P$MM?10H7=89
M0)%4<G:3D@9..U-\<WT7BOPM<>'?#TJ7U[J6R$O#\T=LFX%WE8<+@ \'DG
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M=.U^WFGTV=IHX9F@D+1LA#KC(PP![CGI6C34=9$5T8,C %6!R"/6G4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 445R7Q,NKK3_A]J^H6-U/:W=K#YD4L+E2#N';H>/6@#K:*\Q\5
M:O=^&_"FGZOI&NW%QJKM $T^:43B^+E0R!3E@<$G*XQBMO7;BZA^)G@^*.[N
M(X+J*]\ZV$I\MBD:E25Z$@L: .SHK#OO%VCZ=]I:>:7R+6017-Q' [Q0-QP[
M@8&,C/IGG%6[S6[*S>&(N\\\Z&2*&WC,KN@QE@%_AY')XY ZF@#1HKS[Q'X@
MBU1?!FJZ)JDYL[S6XK=Q$[(LB;9"RNO!R&0<'TKJCK^G3KJ,:R7.VRW)<2I;
MR;4('(5@N&(S_#G% &O6+KVC:CJ[VJV>NW&FVR[UNHH(49KA& & S#*$<\CU
MK,T_Q5X=T;PSH;MJUW/9WNV&TN[M7=YB<X+OMX/!/..!6II/BG2M9DOX[::6
M.6P(^TQW4#P/&""58JX!VD D'VH U8((K:WC@A0)%$H1$7HJ@8 %25SO_";Z
M&'L0\]PJZ@I:R<VLA6X Y)3"\\<\XXYZ<UT5 !16)XP>6'P;K-S;SRP7%O93
M3121.5975&(/'7D=#Q7GESKFM:#X3\$Z];:Q=WEWJDEK%<V-RRR+<B5,L4XR
MI!Z8..>: /7J*YIO'GA\:F^G"YG:ZCNDM)$6TE.R1_N[OEX!R/F/'/6I[GQC
MHMIN>:XD6U6?[.]WY+F!),[=IDQM'S<$] >"<T ;U%<]J7C;0M*U&;3KFXF-
M[%")C;Q6TDCLI.!M"J=W?IG&#G&*GL?%FBZEH4.LV=Z)K.=_+C*(Q=GSC8$Q
MNW9[8S^% &AJ5O<W>FW-O9WK65S)&5CN5C#F)NS;3P?I570](DTFT<7-])?W
MT[B2YNY$5#*P 485>%    'ZDDU1;QQH,5CJ5U/<30#3"!>Q26\@DAR,@E,9
MP1R"./>LG5_B9I5G8M+817=U*+BW@R+20(!,P ;=C##&<8SDX ZT =Q16-!X
MITNXUV/15:Y34)(/M*PRVDL?[O.-V64#KQUZU=LM4M=0GO(;<R%[.7R9MT3*
M ^ < D8;@CIGK0!<HHK!U'QCHNE2WBW,\FVQ*"\ECA=TM]^-N\@<<$'V!!.*
M -ZBL/4/%^C:;JRZ7<3S&^: W"0Q6\DC2("!\FU3N//09/7TIUIXLT6]\/MK
M<5WML48QNTD;*Z.&VE"A&[=NXVXR21CK0!M4V12\;*KM&2,!UQE?<9!%<':Z
MS)=_&2.TCGU".W_L225[.X5XT#^=& X4\'C(S]1ZUWU $-I:0V-JEO;KMC3.
M,DDDDY))/)))))/4FIJX;XHW=[IV@6-UI]]<VD[:C;P,\$A7*.^&&.GX]:JM
MJ^H^'_BE8: FHW.H:9>V,MQ-%.!)):%,X<,HW%6P!@YYZ4 >AT5S6F^/O#NK
MR0K9WDCI+'+()6MY$C B)#[G( 4C&<$@XP>XS:M_%FDW%[:6HEFB>]4M:-/
M\:W  R=C, "<<XZD<CB@#;HKS71O%MMX?U;Q@-8O[^X@M=2 3]W)<>1%Y2$D
M[0=B D\G KJ-3U+27U[P]%)J=Y%<7#O)9Q6Y<170\LD[R!M8!>0"1SB@#HJ*
M\RT?QE9>'-5\6IK>HW\T5OJFV,F.2X\B+RD.3M!V)DGK@=:ZC4M6T:XU3PX6
MU6[1[J4RV*VK/Y5UF,G#D#:5QS@D=J .EHKEM+\9P:EXAUS33:7D4>F,D>\V
MLA+$H68\#@8(P#R>W45!I7BKPWH_A'2;K^V+RYTZ[F,%M>7@DD>1FD(^=BO
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M.79"X;:?,.WY!DX^;%7[7Q=H]WK7]DQS3"Z:)I8M]O(B3HOWC&Y&' R/NDT
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MW$LT4-U$8G>%MK@'T- 'E?A[6M'N4\(PZSJ-S ='51;I)I<\(:0IY:!Y2-N
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M'9D#8QNVL#UKD=!UC1)-(\+6.LZA>6MKH\R7,"S:7/&<@,(A)+C9A0W+#AL
M\#K[!JFGQ:MI5WIT[RI%=0M"[1-M<!A@D'L>:P[/PQJ:VXLM2\27%]IX3RS
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MUS;+<('$-U'Y<B>S+V-7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME6+G(SD,3QCDDT <]+XSU7PS8>-4U"Z_M2719K=;2::-8RYG5=JN$ &%9NH
MXJ;6[&^M/B'X#:ZU6:]W370=9(HU ?[.W*[5& >>#GMSUSKW/@&UU&7Q*-1N
MVN+?7UC$\2Q[/*,:A4*')Y& ><\@?2HXO!%_)?:'=ZAXGN[J71W=H6%O&A<,
MFSYC@Y..">_L>: .SKS;QU;6GBV?5-(G2],=C:[+9X+.:95O& <,612 44)W
MSB5J]'<.8V$;!7(.UB,@'Z<9K-T#29=%T][::\-V[S23-,T81F9V+'.#@\G
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M7:1Q6<%Q975S:QK+$S[P<KM *Y4'#*#U]JENOAV+NUU>)]8E234+^/4EECA
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M*ED?<QPRYPP^=AV[>E7M/\(36&MZIJ_]M7$UWJ-O'#+YD2;,H" V !TW' !
M]<]: //;-+EOA=\-A!J%S;++JEK$ZP[,-EG8$[E.2"H('3U!XQW9U'5H?B9;
MZ&=0\RQ?19+@*\*[O-61$WL0!GJ>!@<]*8GP_2/PAI&@IJLR-I%U'<V=TL2[
M@R$D;E.0WWB.W;\=%O#C1>*[?Q'+JA)MK$V;)+&,-&6#,S-D8;*@Y   [4 <
M(NN>-IOA]=^*H=>@\W3)[AFM#9ILN8XI6!#'JORCC;CIR23D;L5\EY\5M)U#
M:42;PS)-M/4 RQMC]:RO .DGQ'X&O-.DU5#IMQJ%S]HMXXQYFPS,=@?/"L/]
MDG#'!'&.V;PSGQC;^(([L((+(V*VHA&WRRP8\YZY ]L=J .8L=:\6ZYI.CZ_
MI$5PPNI4EFM)?LPMC;L3D*V?,#@8Y)Y(/&.!Z-7%:1\/GT6X>VL_$-^OA\RF
M5=(*(47)R4$F-PCS_",9[DY.>UH X73]0\1>*M ?7-%U.*UF-[(EO:31J8##
M'*4(D.TON8*3D$8) ]2;5KJ=_P")?$'B&PL]2ETZ'2GCMHVACC=GE9-S.V]3
M\HR  ,=#SR,1VW@!K#4[TV&OWMMHU].UQ<:6B(5+M]X*Y&Y%;N!^!%:+^%GM
MO$=YK>CZA]BFOXT2\B>$2QR%!A7 R-K@<9R0>XH Y.P\;:SJ-CX2NGE6WGNM
M6?3-1@2-3'(4$F64D;ADH#P>Y%:%SKNM1ZIX]M8M0^72K*&YLB\*'RF:*1V'
M &X94=<UI7G@.U?0=*T[3KV:RFTNZ%Y;W6U9&,OS;F<' ;=O8GIU_"F+X%D%
MSK]RVN74DVM6J6UP7B3 "H5W  #G#-@# '<&@#%LM;\16Y\#:A=ZN+F'6UCA
MN;7[.B*"T!<.K ;MV1SS@YX JII>K7?ARR^(.MS:A=7IL=2D5(9_+VNWE1!"
MQ"@C&0, @8'3O74-X*D:S\-6W]J870&1H#]GYE*H4&_YO[I[8YIZ^!K1KCQ
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MLSE<B0[B2 V1E>,5>\(Z)_;/@[PI)?:BEW9V-O;W$4$<04^:L8VB1LG=L)X
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M&X:;4W>.&1$!C4JI8[B3QP.V:RWU&[UOQCJVA07\MA%IMI"Y:$+ODDEW$'+
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MVG@')8\8 '(&:XF7Q3XB;X;3:@FHO%?VFM&P,CPQEI(_M CPX QG!Y*XZ=:
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M#$$*,_='7(KBVU'5=?\ !OP_U&\U:Z%U=:ZL,SQ"-0^&FPQ7;C(\M<<8]LT
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MISM]\9QCJ,.#Q"=0\+K?Z5XICEM9=3CC:XFBQ<1Q';N@5 G,V<@ J20<]>:
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M +@#_:SGC$.GZQX@N=4T/PUK,T=GJ;Z?->7\UH5/F%)!&JH2"!G.XX'&,#%
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MO;%HX@<%2N&.WYC@X)/Z'FA/A[';:O>7%AKFI6>FW\QGN],B9?*D=OO8)&Y
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MZE2I52" !L P<YYR23FNMHH YV/PJR>*;77VU6YEN(+0V91T3$B%@S$X Y+
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M\U*673-0E66:U:-25QM^5&ZJ"5!/4\G!%=-10!6U"S34--NK)V*)<0O"67J
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M:57IO4J1D=B!Q0!BS77BG_A)/"&EWVL_9I[ZSNA?K:+&R>9$J_,A*\$[CUR
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ML+IG3S;4I]S9A0N ,CD'(/.>,;.GZ%'::G+JEQ<RWFHRPK 9Y%5=L8).U0H
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M0 4444 %%%% !117/^+KF2WTVU\O4OL(DO88WV(6EG0MS%'CD.P& 1T&3QU
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MQ*M,^]@#$QP6/)QTR>?K0!WM9,'B/3KCQ1=>'8YLZA:VR7,B=MK$C\Q\I/\
MO+5Z_O8--T^XOKEML%O&TLA]%49->1:P]WX=N-"\:SZ5?6]W!=,=9D=%VF"X
M(!!(8DB,[ O'110![+17%^-[S4(-3\*C3]4GM8KW4UMY5B"E70QNV>0>?E&.
M<>H-9NG6>IW?B[Q-X<?Q'JPL;:*VN(7$B^<C2*^0)-N=N5SC^F00#T:BO+=#
M\5ZOJ^@>";.:8/=:O#</<2^<8&E\CC:&525)SN)&#\IP12>)3XM\.^!]?FFU
MKRS#=0/8-%-YTR0R2JC1R,R D#)P1SZGB@#U.L7Q3XCC\+:/_:4UG/<Q"6.)
MO)*C:78*"<D<98=,US<E[?>'?B']GFU2]OK&XT>>\EAG*D+)$Z\H !M!#$8K
MF_$3W.N_!ZU\1W5_<-=7D]K<21)*?)"M<)B,)T 7CG&XE>3R: /8J*X.5=2U
M'XFZKHS:YJ$.G_V7#<+' R(T;-(ZG:VWC[HYZ^^.*Y<:KKZ_"RW\4R:_?/?V
M-X(0@VK',BW7DGS%Q\Q*]3GTQWR >R45PEY=:KXB\1^(M(LIF@_LQ88H3'>M
M;LCR1[_,.U3N'.,'CY3QS5&>3Q,GB+P7I>HZZT=Q>6]XE_\ 8=IC=XD&&4E
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M$")FSR.HQQG(SC(- ':T5Y>M_K7A[5_%6@2^)'-O%IB:A9:EJ($C6A8E"&(
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M$9N<XWD9SGIS6WJ*:M9>._#]E%X@U#R-9MKD72L4(0QJK Q#;A#R1GGCWYH
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M.12\;*KLA((#KC*^XR"/SKR2>XO=8^ >M7.HW]S/<QB]!E+X,@2610&Q@$8
MXZ<4 >A:7KUSJ&I"UFT:\M89+874-TVUHG4D#8Q!^5^0=O/&>:VZS= M1::'
M9H)II<Q(VZ9RY&5'&3VK2H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0>OL*W=#T*/1+=T^VWM]<2$>9=7LOF2OCH,X  &3@  <D]236K10!G:EI/\
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M6VT^2[6><1S.DBKY"8)+G/4 @# YYH Q[GP58W#:'(EY>V\^C BVF@,8=@0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YSQI)J\6C0RZ/;R73I<HUQ;0S>5+-",EEC;C#=#P02 1WKHZ
MH:KI2:JEMFYN;:2VG$\4MNP#!@K+SD$$88\$8H \VU#Q%'<>")]2T74]6BFB
MUFWB>"[DD6>UW/$CPN&)R.IYS]ZMW5-8N]*^)%Z$FGDM(O#<M\;0R$HTJ2@
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M9"2_0#@Y/'2J^G^#-/T^*RMA<WMQ8V$@EL[2XD5HX&&=N#M#-MR<!B<<8Z#
M!R,L6I:AJ?Q MY/$&K1QZ;Y;V@AG\LQL;?S.J@< GH, ]\\8G_MK5+JW^&E\
MVH3HVI&/[9$A"I,3;ER6 'J.G3VKJ4\(6D=QK<ZWMZ'UD 79W)SA=@V_+Q\O
M'_U^:B7P18);Z' MY?"/1"#9#>GRX7:,_+\WR\<T 8]C]M\:0>)6AUBZTZ]L
M]3EL;1H)&"VXBVX9HP0'W').[/!P.E=S;,6M86,RS$H"94& _'WA['K7-7?P
M_P!)NM>N-6CN=1LY+O'VR"TNFBBNL<?O%'7CC@C/XFNI551%1%"JHP !@ 4
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MH(!)W8)SUSS717L&N>&9[[7XKJ-;"/39F;3Y+^:Z\Z9$9T=#(!M.%P0.HYH
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M'Q3\80Q23/&;:Q91-*TA7(DX!8DX_'C/I2>-;"&Z^(7@<R-< O/=(?*N)(\
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M\"@,%V8]<#C-7A976J>*_'=C/K6K);6D5J]ND-X\?ELT+-D%<$#/..A[@X&
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M>&WU>5Y;U3+S(S@!B#CY<@ <8Z4'P/I)U"UOM]ZL\%J+,LERR>="#E4DVXW
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MA$F2>-X9"CQR(<JRL.A!K3HH PKCPI82ZA;:C!+=6E_!!]G%U!+\\D6<[7W
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MP ,#<,'# <;EPV.]$_A+2Y;C1Y8UEMQHX(LHX&VI%E=IXQS\O'-;M% '/_\
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MQO+NRA0 ,\YYXQQS7*^,_!%]HGP/T_PII]I=:CJ*SI+*+6W>0%B69SD#@ G
MSC@"@#U;PF&/A+2)))III9;.&222:5I&9F0$DEB3UKS;QOJ&HVOQN\+:7;:I
MJ,%A?(C7%O%=R*CG>_8-QP!TQ721>)[C2O %E;V.C:S/K$5A% EO_9<ZA)0@
M7YF9 N >O/;C-<OXYLM1E^-/A;5H-+U.YL-/C1;FYALI753O?/W5YX(/&: /
M8998[6V>61B(XD+,2<X '->5_#;6=0^)5WK.O:I=W<.GPS_9K&PMKAX4C&,E
MF*$%VP5ZG'7CICL)M>DU;6['2;33-2^Q3+*;VYN+&6&,)Y; )F10=Q8J>/3W
MKC?AOI-]\,[K6M!U:TNY-/FN!<6-_;V[S)(,;2&V E&P%X(]<=L@$FB^)K_2
M/BYJ'@'4+RXO-.NHO-L)II"9H<Q[RADSN(QN ).1@<UG^ M0U*R^)/B;P5XA
MU;4KMBF^PEFO)-WECGY3GABK*<CGY36CX?\ "^H:[\7[[QW?6<]EI\">1I\5
MPA267Y-A<H>5&"QP0#R/2G_$;P-?ZQXZ\,:YH[R03>:;.]GBZI"58[L]OE\Q
M<^K** ,;X2^*;J+Q/XET/7M8O+PVZ&XM+F[G<AK=3RP!. "I1P0,X)K3\>MJ
M6B?!VYU:#4=4MM1:9+E7-[+OA6648C^]T5&"X]L]:?XM^'DM[\4?#6K:;&8;
M%XFMM1\L841(IPI]G4E/H!6K\9;2[U/X<7VG:?975Y=SR1>7%;P/(3MD5CG:
M#C@'K0!G7%CJNK_!W0I;#6M0MM9NH;1EO/MDN6DEVAMWS<@Y_#M63X.\=7VJ
M>'M:\(^)IKFT\3:7;3;)1,T<DP120=RD$LO!_P!H8//-=-I<TME\.?"MI-I^
MI"Y@-E'-$+&4M&8RF\L O &#SW[9K,^+GP[D\262^(] 5XM>LX\XC!5KB/'W
M?7<!G'KR/3  SXA>+]1T"/PWX3T&YDCU/6&CC-Y,QE>)&8+G+9RQ)/)Z 'VQ
MV,O@Y$TIH;#6=7M]0"82^>^EE;?C[S([%&&>HQCTQ7(_$KP5JFJ77ASQ1HD'
MVC4=%>-WM"0K3(K*X"Y[@@\=\^V"[XCZOJ>N>$85\*1>(;?6C.F(HK:YMW1>
M=P<X"_B3CT- 'HNCPW-OHEA!>N7NX[:-)G+;MSA0&.>_.>:\C>\N)?CQK&A7
M>NZG;Z-%8>>(QJ4L:Q-Y<9W [N.23@\>U>K^'K:XL_#NG07C3-=K;1^>9I3(
MYDVC=EB3GG/>O+(M&FO/VA-0U6]T*[FT>6U6*.XGT]VB,@C0=UP.01GI0!L?
M!7Q'KOB'0-1;6)Y+N"VNO*L[V5<-,G?)[XXY]\=J@E^(5W:_&NVTFY#1Z%?6
MYM+5S]V2=78%Q_P,-'^1[UW/B._ET;P_)_9UG<27# 0VZ6MLTOED\!BJ@X5<
M[C],=37FGQ0\!7,W@O3;C1[O5[Z_TMT-C#]F4N%.T'_5Q*P/"MEC_">] '1_
M%[QW=^"?#< TP+_:FH2F&W=AD1@#YGP>I&0 #QS[8K:L/!JPZ1%'=:QK$NIF
M,&6^&H2[O,QR0N[8!GHNW&.QKB_&_AG5_B;\.M)OX;.:R\06!\QK2ZB,)9R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$T+PO8^';O4[BQEN/
M^)E=/=SQR,&7S7.21QD?3-;=% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8EUX6L;WQ58>(IY
M;AKRP1TMTW 1H'4JW &3G/<UMT44 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9FNZRFB:>+
MC[)<WDSN(X;6U4-+,QR<*"0. &8\]%-:=8'B?PC8>*H[<7=S?6TUJ6:WGL[E
MHGC8C&X8X)X[@]_6@"WH.K3ZS8M<W&D7VEL)"@AO0H=@ /FPI/'./PK4KE?
MESJS:;J&G:S<_:[G2[Y[-;S;@W$85&5C_M8?!]Q754 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !61JGA]-3U&WOAJ6I6<L"%-MI<E$D4G.&4@@
M_7&?>M>B@"O965OI]JMO;1[(U)/)+%B3DDD\DDDDD\DFK%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>secondamendmenttoleaseag006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 secondamendmenttoleaseag006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H^-GB'6O#-I
MHUSHNJ3V;W-R890@5@RXST8'!KU>O&?V@(I;VQT&WM(9;B:*[,DB0QERBX')
M ' H W?B:OBRQLK*3PCJ=TMW''))+ =LGGH@!. RGYN>@Z].N*;H?CI/'?@J
MUO[.]ET_4X+VUM[V&!AE=\R(W# _*RDX/;\#73WVJV)\4:&%N$821SX9>5&0
MN,D<#.#C/6O/_$WP^NM#^(^D^)?#H>/3K_4;=-4M8API\Y&WX_NE@"?0\]#P
M >QJNU0N2<#&2<DUR_Q$36AX*U"Z\/WTUIJ5I&9XS&%;>%Y92"#G*YQ[XKJ:
M0@$$$9!Z@T >+R^+M8U?X#Q^)=+UNXM]9LB$N6PK>:X8*RD%2.00PP.*Z7P[
MXBG\4?#+1+BVU&XCU2]ECMGG5AO653^].",?<5V QTQ6'\/_  +>Z'X[\3:=
M.A/AV"=;BUB9?ED>1& QZA49E/OM]*F^$W@S4/#.O^([>Z:3^SK&\:/3T;HQ
M=5)D^NP1C\6% ">,M<UK3/B_X7T*RU>[BTW4$0W$(*G=\[ X)&1D =#6IX^&
MO>'_  CXCU^#Q!>QS1,C6<*"/RXDW(N#E223ECR>XKG?'P:3XZ>$;N..1[:T
M5%N)D0LD1WOPS#@=1UZ5U_Q>/G?"_6+>$&6>X2,0QQ@LTA\Q#\H')XYH @\$
MQ:[K7AOPSKLWB"]E,\;-?P/L"2*R. 5PH*D-L/!]:X]/'GB7P-XYV^)[R6^\
M*W]S/;V]RZ+N@\N9DR2JCD;>1W!R.F*[_P"%\BP_#/18YCY4EO;;9DD&TQD$
MYW ]/QJ&+1='\=>"M0TB\!>*2]NV#;2KQ,;B1DD4'D<$$'H0?0F@#5L(Y;K7
M-8 U2ZEM3'"UNJR#;&&4DE2!SG ZDUYK\,?$FK>)O#U]<Z]XGU%)_P"T$LK8
MP&)22X&, I@D9)^@-;WPITO5O"=AKVF>(9B183I'!.Y^5H I*E2>HY/';IVQ
M7#?"+2](M=(NY]?M'L]0M-3CN[6:6T?S J@$A3MR0<$8]\XH [KQMXBUOP1X
M+T7[?>3RO)J"VVH:C%&ID$&YB648VAF4#MQSWK>\/7::K?6>HZ!XC?4]":-U
MGADD$C1R8!4[B-X[Y5O4=*IW?BJVU;3K%K_1+BXT/4[B>WDCDLW=DB3A99$P
M2%+*>2. RGM7)^'O!MEH?Q<L+SP1=R2:+);RMJ:)(9(8N"$0/W)8@A221MST
MH L>#_'$7BN;4+/4?$=SH_B874D<%JY58HP#A%5&&U_0@_-G.,<5ZII*WB:-
M8IJ#;KU;>,7!R#F3:-W3WS7COB;1?"GCOPB=9O[272?%9M=XC6%HYYY@O $9
M&958XP0"<$<C&*]/\$V^JVG@G1X-;9FU*.V43ESE@>P8]R!@'W% &EJ]K<WN
MDW5O97;VET\;"&=,9C?'RGD$$9[5Y-X"\4:WXC\#>)[/4]:N+7Q'I3R%KA]H
M\H!3MR,8P&5P>/Z5[-7D%UX(O[?XZ/=60:/1=8M#/J&!\K;&7<G_  )@A/L[
MT 2_#'QO>:W\/M8GU>[N9]8L)&CE!(5R6'[L*   2V5Z=15?XM:QXB\%>$M
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M0Q2N8WW1N#@HR8W*V>Q&>:Y8W+:5X^T37KHG^Q+K0_L N<'9;S!P_P Y_A#
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M*]_:V?VMEDNV*VTCPNL4[#J$D*[&/I@\]LUB>/O$UM9^$M?6RU"Z@O;2W?\
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M5Q*6C:.2**XC\EB&P0 V#C@^H..E 'HE%%>?:IXMU"P^(VF D#PW+*VDR/\
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M'(QB@#HZ*YA_'>D'0]8U*W2\E.DJ3<VK6LD<R';N&48 @$<Y/&/I6GX<U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8GBO59=+T20VPE-Y<$00-'"TGELY"^80H/RKG<?85MT4 >9>-_"4EGX'@GT
MO4M0GNM%:*ZTV%D1_GCQA0$0,<KD=>_-3^(-5&M3>!M0BM+Q -26>XC>V<-;
MCRG!WC'RX9@,GBO1J* .%T>9;?XF^,+F:.9+>2VLPDIA?;(463>%.,,1D=*X
MG2([W2/!_@35;K2]1FLM-CNK74;>&.19X/,(VOL&&(&WGV->X44 >3^*8M/O
M?A[K%SH>B7D0O[FU8,UO+YUV4F1F<H06P%'4]<'M@G7UE9KWXFVS6?G*)- N
M;=+D1-L25W4H"V, \$XKT&B@#Q.?4)'^#UGX<DTK4H]9TZ:TAN+464C$>7.F
M6!"D,"!D$'G-=EI\ZCXLZO>-%.EL^D6Z+*\#JI97=F7)'4 CCK7=44 >+>5.
M/@,MA]CN_MHU#=]G^S/YF/MWF9VXSC9SFMB]NX-$\=:VVN:;JESIFL"&:RN;
M..:1#B)8VB98^A^7(R.]>HT4 ></;1V?C?P,EMI4MC:6UM>@PI$Q6V$@38K,
M 0I.#QGKD5A:G9W=]X*^)=M;6=T\USJ33P)Y# S)B+YDR/F'R-T]*]DHH K6
M%]%J5E'=P),L4@RGG1-&Q'KM8 C\17CVI7ESJ.DVLL^EZE;W=GXCBFGL+:PD
M6&WC6XSO&U<2LPPQ;YB2QP *]JHH \J\0Q7,&KZGK'AF>^M=9,T:SZ1<0E[?
M4QM0 A2, [3@LIXVG..M=YXLTZZUCP?K&G63[+JZLY8HCG'S,I &>V>E;-%
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MUU-87L>H?VE9/=VYM9 \;)(#(VW;G;P3GI@BMKS!_P +F^U^7+]F_L#R?/\
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M0.Y&0/6N:^.>H7%K\,]0BLY2KR20I<;#\RQ,Q'/H"5V^_(KHOA_:VR_#/P_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %8GBW0'\4>&[O11=BUCNUV22>5O
M8+D'CD8/'O6W10!Q>C^#=:T+PG%X>T_Q+'%!#&T<=Q]@S,H8DY!\S;GD]JT=
M/\,W.GWVDR+J:R6FFV(LX[=[?D\(#)NW?>.P#IP"?7-='10!PWB;X=-X@\9Z
M9XGM]7.GWNGA1%Y=ONW@$G#DL,CEAVX)KHK;2[Z+Q#<:G+?PR13P1P&W6V*X
M"%R"&WGG,C9X].E:]% &!/X1TZ7QI:>*8U\K4(87@E*CB9",#=[CL?3CTQ@Q
M_#N[M_B!>^,K?742_NH_*:)K+=&J[57@;\YP@[UWM% '+^'? ]CX>U#4=76>
M6\UK4"3<7UR 2>^U57 5>!P/0<\"LC0/AU>^&_$FLZY8Z_&UQJTK2W"36.Y
M2Y;Y<2 CECW-=_10!S-MX0$]MK4.OWO]KKJVU95:$1*D:C"HH!. #D@YSDYZ
M\U1T_P &:OH_AM_#VF^)/+TX*T<,DUGON88VS\JR!PO&3@E>/RKM** .1A\
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M_P#[5FKTFQ_Y"_B<_P#36,?^0$_QH 9X3\;:3XUMIKG1A<R6T+^6\LD>P!\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *R/$^@KXFT"ZT>6ZDMH+I-DKQ*"VWT&>!6O10!B^%/#J>%/#]MHT%W+
M<V]L"L32J P!)."1@'D^E9&K_#^'6/&UAXJDU2YBO;!0EO&B)Y87+'!!&3]X
M]Z[&L'Q#XKM?#=Q80W5G>S-?S"WMS;HC!I#T7EA@\?3WH U[R"2YLI8$F,+R
M(5\P*"1GN >*YKP)X$MO .GW%A87]Q<VL\IF*W"KD.0!D$ <84<5;/C'3K?4
M[;3M2AN],N;MMEO]LBVI*W]U9%)3=[9S70T %<J?!%O9^)KKQ#HEY)IM]>+M
MNT5!)#<=]S(<8;W!'?U-:.L>(X-&U32;&:VN';4[C[/%*@78C;2WS9.>@/0&
MMF@#FM%\%V6E:[>Z_//+?ZU>#;)=S@#8@P B*  J\#U/'6J.D_#V#2?'-]XL
MCU6YDOKY2D\;HGEE25.  ,C[@[UV=% &+XJ\.IXK\/W.C3W<MM;W("RM$H+$
M @X!.0.GI2^%O#Z>%O#]MHT-U+<V]LI6)I5 8#).#C /7TK9HH *R=,T*/3M
M9U?5#.\UQJ<D;.6  C1$"J@]A\Q^K&M:D)P"<$^PH X[5OAUI^I7FL2Q7<]I
M#K:Q+J4,04B;RSP5)'R$@D$\YSV/-7]4\&:=?'19;;-E=:*P^P2QJ"(UV[2A
M!ZJ0 ,=>.M.TWQ9'JNCZO?VFFWS/IMQ-:O:E5\V22,#(4!B.2<#FMVWE,]M%
M,T3Q,Z!C')C<F1G!QW% '-6?@#1;;PSJ6AS(]S%JDDDU]+(0'ED<Y+<<#!QC
M'3 HT;P1:Z9K-MJ]S=RWU[9V*Z?:O*JJ(H5SV'5SGEOR KJ:I7U_)9W%E$EA
M<W(N9O*:2$ K ,$[WR1A>,<>M $6N:6^LZ8]BEY):!RI:2)%9N"#QN!'4>E0
MS^'+&\UW3-;NT\W4-.CDCAEP!]\ $D?0''IN-:HEC:9H0ZF1%#,@/(!S@D>^
M#^1I] '&1?#V&+X@2>,AJMR=0D3RVC,:>5LVA<8QGH!WZUNZ-HTNE37\LFHR
MWCWLYN',J*"K;54 ;0/E 4  ^G6D\3>((?"_A^ZUFYMKBX@MEW.D 4MCU^8C
MBM19-\*R!2<KN [T <9H?PY@\/\ BS4O$-CJUTMQJ)<W%N43R6+'=G;C(P>>
MO<^M/\-?#RU\-:[K&JQ:C<73ZN[/>13QH48DLW& ,<L>.>*T=.\6QZKH6IZG
M9Z9?2/87$ULUIM7SI)(^&"@,1UZ<UOPR&6".0QO&74,4?[RY'0X[T <;X9^'
M-OX.NM2?0]5O(+6^8N;20*\<1[%,C(('').1C.<4O@[X>0^!]+O=/TK5KIH[
MIO,+31HS(^ ,C '8=\UMZYXC@T&ZTJ">UN)/[2O$LXY(PNU';)&[)!Q@'H#T
MK88[5)P3@9P.IH S])TH:;H=OI4LYO(H(1 &F1<L@7: P'!X]JQ8_ EI9^$Y
M_#FF7EQ8V,TSR'RPK,$=MQC&X'Y>WKCBIK[QBFF>'K#5K[2-1@%W-' ;=U02
M0L[[5WC=P,GMFMA[^1=:BT\6%RT3P-*;L >4I! V$YSN.<].U &;XI\+P^+?
M#$NAW]RZ13;?,EC1=V5((*YR <BIO"^@?\(QH%MHZ7T]Y#;#9"]P%WJG9<@#
M('0>U:T<L<I<1NK%&VMM.<'T/OS3Z .+UCX>1:QXVL_%;:Q=P7]E'Y=NL4<9
M15^;@A@<_?:K.B> -,TCQ-=^))KFZU'6KH;6NKIE^1< 815 "C  Z=!75T4
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M;1Q33$Y\QU4!FR?4@FKU% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%191;D><KE0,+F'*]/O5V6K^%K#7=*M-/U)IKA+:>*X61V&]W0_Q<8PP+ @
M##$#%2Q>';"'Q3<>(DC(OY[5+5SVVJQ.?J<@?110!POC37-5TO3_ !+?V>K3
MS7.G/$UNEH!Y-J@"96;=P[,2<@;B 5.!6CK#ZUJ'Q&BT2UU^[L+.YT62Y(AC
MC)CD$B*"I*^_?/&<8SD7+_X;V%_'KMN=4U.*RUF0S7%I%(@02D %U.W=_".,
MX]NF-*'PE'#XDM-<.J7\EU;6ALPLAC*R1E@QW?)G)8 \$8Z# XH YLW7B+Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR '(&2!D BNKZUY+\0++6A\-K:ZO[VUO=%MDMYKZPA@-O)<1@KA?,+/CG!P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !69K^A6GB32)M+OVF^R3C$J1/L+
MC.<$]>H[5IT4 <U<>!])OK2&SU&6^OK.$J5MKBZ<Q';]W<HQN P.&R*K>*&D
MUHS>$!H5[);7D*"2^**+:.,M\WS9SO 'R@#KCMS7744 9VJ:+:ZMH<ND2F:"
MUD14_P!&D,;* 00%(Z=!^%5KO4M5L[EK>U\/7-Y @ 6<742[N!V9L^W-;5%
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MA RR-@#(^8;2 !C&,8'I5BQM=3LI[>=_#>JW<]K$T-M)=:C;NT"G .WYADG
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M *%.Z_\  R#_ .*H_MO7?^A3NO\ P,@_^*KH:* .>_MO7?\ H4[K_P #(/\
MXJC^V]=_Z%.Z_P# R#_XJNAHH Y[^V]=_P"A3NO_  ,@_P#BJ/[;UW_H4[K_
M ,#(/_BJZ&B@#GO[;UW_ *%.Z_\  R#_ .*H_MO7?^A3NO\ P,@_^*KH:* .
M>_MO7?\ H4[K_P #(/\ XJC^V]=_Z%.Z_P# R#_XJNAHH Y[^V]=_P"A3NO_
M  ,@_P#BJ/[;UW_H4[K_ ,#(/_BJZ&B@#GO[;UW_ *%.Z_\  R#_ .*H_MO7
M?^A3NO\ P,@_^*KH:* .>_MO7?\ H4[K_P #(/\ XJC^V]=_Z%.Z_P# R#_X
MJNAHH ;&S-&K,A1B 2I.<'TIU%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*=3E2#NSP>F>E7(O#FE0Z_+KD=LRZA,BI))YKX?:-JDKG:6 )&[&<'K6K10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YCQ[XM7P9X:.I&-'DDG2W
MB\S.Q68_>;'.T $\=<8[T =/17-V]_KJW^DGS].U/2[UF$EW:Q-&8QY;,I W
ML&4E0,Y&/?.1'X_\81>"/"=QJ[1K+,&6*"%CC>['I^ R?PH ZBBJ=C?Q:OH]
MOJ&GRJ8KJ%989&7<,,,@D CUZ9KS3PY\5[\^.I?#'BNRM;(RNR6-W K*DQ#L
MHSN8\,00.>",&@#U>BN>AUFZL[G7I]7N;)--TS!#QPLK!?+60EB6(. <8 Y_
M2L3PEXH\0>.[.?6-/%EI>D>:T5J+FW:>:;;P7;#J%&>,#/0\^H!WE%8.A:AK
MD^JZG8ZS:6T0M1$8)[<MMN%;=EL'[OW0-O."#R<BLOQ'\0++P]XW\/\ AR8*
M6U,L)9"?]5GB/_OI^* .RHK)\37M_IWAZ\O=--M]I@C+JMPC,C>QP01]?TKE
M_ACX^NO&EMJEOJMK#9ZOIMQY4\$60 O0'!).<A@?H/6@#OJ*\MT[XDZSJOQ5
M'A>&VL(M-DC::&=D=Y'B"DJWW@/FQD<="*UY/'5UJWQ!E\(>'8K<O91F6_OK
ME6=(L8&Q44KN;+ 9W#'/7% '=T5PD_CFZ\/^/+'PSXACMFBU- ;&_MD:-2^<
M>6Z,S8.<#(/<<<\=5KLVIP:1(^C0P2WY>-(EG!,8W.JLS;2#@*2>/2@#1HKS
M"X\;>)[?XJ6?@DR:0QN;<S&\^QR_+A';&SSN?N8Z]ZG\8^,?%/@_P3/K%S;Z
M6]Y;WOD%!#)Y<L9/RNOSY'&,CGG(H ](HKSKQ1XVUSP_\+[+Q7&NG2W,T<$D
MD+0.$Q*!P/GSQGKW]JC\2^.M=T+X6:?XMC33I;FXC@ED@:!P@$J@X!\S/&>O
M?VH ])HKB+76O%=UI.CZE!+H]S]K2UN+FT6TE22.&4KN*MYK E03U ^Z?I5#
MQ3XWUW1OB3HGA>T73C;ZJH8330.S1?,PZ"0!NGM0!Z-17 6/CS4+;XG?\(3K
M5M:O+-#YUK>6@9%8;2V&1BV.%;^(]/>MSQUXIC\&^$+[6659)8EVP1-T>0\*
M/IW/L#0!T=%9^C:M!KVA6>JV+#R;N!98R>=N1T/N#P?I7G%A\0/%6I:_XMTR
M"+1PV@*[J7@E'V@*3QGS/D.!UP: /5Z*\GG^+-[=_"63QIIEE;13VTXM[BUN
M59U+%E'RL&7C# ]/;WK<LM>\67WAO2-8MI-'GDO+>&[ELA:2JZQ-MW[6\TY*
MANX&<4 =Y17G/C+QSK?A[Q_X?\/V<>GO;:NZ)YDT+EXLN%/1P#USVKJ]8O-5
MM-1T6"TELQ'>7)MYC+ S$8BDDW+AQ_SSQ@YZYS0!MT5YGXU\9>+?"'A>YUZ6
M'22@OFMX+1K>3=Y6]@CL_F 9(4' 7O70Z/?^*;TZ;/.VF/8WUCY_F16LBM!*
M0I52#(0RD,W.1TH ZNBO./AEX^U7QE%K-QJJ:?:P:=+Y9\F-QG@DL69S@<>E
M2^&O&6M>/KN^N?#ZV5AH5I,8$N[R!YI;EP 3M0.@5<$=23R/? !Z%17$:KXN
MUCPQIOB*]UNPMY8=,MH);:2U+*MT9&=>0<[,$*",MC.<G(J:QUO7KO2=*U6T
MN=)U2TO)8%G^RQ.AA5V4,5.]MVW."" 1U[8H [&BBN&^*?C'5/ WAN+6-.BL
MY\W"P-%<1L?O!CD%6']WIB@#N:*\]\6^*_%.A>#=,UK3+;3[ZZN%5IK;[/(.
M#$TC%<2=@AXYS^E3:3\0/^$H^'DWB#0VM8[ZV3-S;7*,XC<#E3A@<'J#Z?C@
M [RBN(\9>.Y/"\^E:+:6T>H^(M3<1V\(S'&,G&]^20N>V>QYXJUJ-QXSTC19
M+W?I.ISHNZ2WAMI(=H[E27;=MZX(!..HZ4 =;1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM=(DV,T,;KD?,2Q+.< !>F/QKFOB-X9UGQ%X$N->^P6B7,4QU6.=+MC.L.T
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MDZE+%+?:7974D(Q$\]NCE!_LDCC\*?9:1INFO(]AI]I:M*<R-!"J%SZG YH
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M/+EP<@ %>1M./NXK%\:ZEI]QX5\<BREM[3R]25)XYY"]Q<3H8AN4$_(@"C&
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MC\5H--STCC,\8<1GLN[>./0UVUM:6FG_ !K$%G!#;1R>'"S1PH$#%;@ ' ]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYC[WX5;&H6AU$Z?]H3[8(_-,.?FV9QNQZ9XS0!9HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*XGXMSPP_"_75EE1&DM]J!F +'<.!ZFNVI" >H!H \9\7Q>&&\%6%WH%W#)X
MFMUA;34L9_.E,WRY'E@D$8SG(XKJ?&$5_I^E:)XR:#.J:*JO?Q0\^9 Z@3H/
M7'WAZ;:[T*!T %8&IZ-JVJ:THEU.!=!VHTEFMO\ O9'5MV"^?NG R,<@$=\T
M 5XI+#0_!UQJ?B81Q17#&[OQ-'Y@5I&&$( .=HV(./X173HRLBLI!4C((]*&
M574JRAE/4$9!K'OM*U:YO'EMO$5S:0MC;"EM"X7CU92??\: -FBN>_L/7?\
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M.VZA.ZRO<8D'.X1[?SP<>N*V_P"P=;QC_A*[K_P"M_\ XBC^P=;_ .ALN_\
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M_B*/[#UW_H;;S_P#M_\ XB@#H:*Y[^P]=_Z&V\_\ [?_ .(H_L/7?^AMO/\
MP#M__B* .AHKGO[#UW_H;;S_ , [?_XBC^P]=_Z&V\_\ [?_ .(H Z&BN>_L
M/7?^AMO/_ .W_P#B*/[#UW_H;;S_ , [?_XB@#H:*;&K+&JLY=@ "Q&,GUXI
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***YSQOXG/A7P_P#:X85GOKF=+2RA8X629SA0?8<D_2@#
MH@H&< #/)Q2X&<XY]:P(M!U(60,WB.^.HE>9U6,1AO:+;MVY['G'?/-6+6^?
M2M"TX:W/NOS$D<OE(7::8+\VQ5!)Z,< =,^E &L0#C(!Q2U@-XU\.)I9U)]4
MB2V6?[,Q=65TESC8R$;E;)'!'>K&F^)]&UC4KC3["^66Z@02/'L9<H3@,I(
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M0R[F:1@!D#@ ?6NEKC[6\OA\7+_3GOIY++^QXKE(&(V1N964D  =E'7)KL*
M$(!&",CWK-UVTU:\L4CT;5(].N1*K--);"<%.Z[21UXY]JTZ* *>EZ>FEZ=%
M:)(\I7+/*^-TCL2S.<<9+$G\:N444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<3\3_  ]J&O>'+6;24$NHZ5?1:A!"3CS3'G*_4@G'
MN*[:B@#A]>\3Z!KG@;4XY)X4NIK*51870VW"2E#A?+;YMP/3 ^E<FL,GA;0O
M .IZE87T.F6UC)!J7V821R6TLBQD2.$PW5"#]?7BO9** /(O%2Z%-\/]5O-#
MM)Q!J%_:2&>;S2UXRS(6<+)\Q 4=>^#V&3L:PPO/BFJ65P@DG\-SP13*WRB1
MI%*#([X^8#TYKT6B@#R7PG>>'M5TW0]$U#3-4;Q#I3PAK"=[C;;RQ87SLD^6
M% R1]<#KBMCP5<PK<^.9(H5N)3JTT\<2CF=/*0#;Z@D,,]*]"HH \5L=5@NK
MKP!?JMPJ0W4B36EO9.D-DS0N!"H"Y)!XY)/?@&NQ\)31O\1?')5P1)/:F,_W
MPL"JQ'KAA@XZ&NYHH \_\<:?=Z?XP\-^,K>VFNK;33+;WT4*%Y%AD7'F*HY(
M4DD@<XKI;?Q7I&HHHTF\BU"=\ 16[;BON_\ < [EL?B<"MNB@#SS0;^+P]XG
M\767B&18#>WOVVUEF'RW,+1JH1#_ !%=NW:.>>E<Y86-SX3T+X<W.LI+!;V-
MY<FX9U)^S+,DGEJ^.F-RCV/%>S44 >.WU['<P_%9ECG475M'Y'F0.OF$VH4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %4-7UBRT.Q-W?2E$+"-%52SRNQPJ(HY9B>@%7
MZ\[\26]QJWQ?\/Z>UW+:VUKIT]["\:J29MP0X# KD*>X.,F@#NK&XN;F'S;B
MS:TW<K&\@9P/]K;D _0GZU:KD/!VJZK+K?B30=5N3>-I-Q$(;QD5&ECE3>H8
M* NY1P2 ,YZ5U] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZ
MIHEKJL]G<R-)#>6;E[:YA(#QY&&'((((X(((/'H*TJ* *6FZ5;:6D_D!FEN)
M3-/-(<O*Y &YC]   ,     5=HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581217888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">501 Canal Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,510,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938671048096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 54,417<span></span>
</td>
<td class="nump">$ 45,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,612<span></span>
</td>
<td class="nump">12,403<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">68,636<span></span>
</td>
<td class="nump">94,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,017<span></span>
</td>
<td class="nump">26,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">20,935<span></span>
</td>
<td class="nump">25,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets', window );">Refundable research income tax credits and other non-current assets</a></td>
<td class="nump">17,373<span></span>
</td>
<td class="nump">16,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">128,961<span></span>
</td>
<td class="nump">165,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,468<span></span>
</td>
<td class="nump">15,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">8,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">18,474<span></span>
</td>
<td class="nump">23,554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">40,242<span></span>
</td>
<td class="nump">47,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">30,817<span></span>
</td>
<td class="nump">33,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,264<span></span>
</td>
<td class="nump">82,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,515,926<span></span>
</td>
<td class="nump">1,492,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,455,465)<span></span>
</td>
<td class="num">(1,406,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5,801)<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">56,697<span></span>
</td>
<td class="nump">82,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 128,961<span></span>
</td>
<td class="nump">$ 165,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax, Refundable Research Credits And Other Non-current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938582129472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 157,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">35,891<span></span>
</td>
<td class="nump">63,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,767<span></span>
</td>
<td class="nump">18,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">4,349<span></span>
</td>
<td class="nump">20,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">52,007<span></span>
</td>
<td class="nump">139,923<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(51,526)<span></span>
</td>
<td class="nump">18,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">2,535<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(48,991)<span></span>
</td>
<td class="nump">21,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (49,089)<span></span>
</td>
<td class="nump">$ 21,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net (loss) income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract', window );"><strong>Shares used in computing net (loss) income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">180,342<span></span>
</td>
<td class="nump">168,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">180,342<span></span>
</td>
<td class="nump">169,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic And Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of Shares Outstanding, Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584536320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (49,089)<span></span>
</td>
<td class="nump">$ 21,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(980)<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Net pension gain (loss)</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (50,295)<span></span>
</td>
<td class="nump">$ 23,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938582234464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,793,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 294,958<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">$ 1,450,239<span></span>
</td>
<td class="num">$ (1,148,545)<span></span>
</td>
<td class="num">$ (8,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,962,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">9,705<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">9,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension gain (losses)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">21,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,771,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">335,610<span></span>
</td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">1,467,062<span></span>
</td>
<td class="num">(1,127,412)<span></span>
</td>
<td class="num">(5,758)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,133,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">82,887<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">1,492,077<span></span>
</td>
<td class="num">(1,406,376)<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,761,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">21,788<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">21,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</a></td>
<td class="num">(402)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension gain (losses)</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(49,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,686,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 56,697<span></span>
</td>
<td class="nump">$ 2,037<span></span>
</td>
<td class="nump">$ 1,515,926<span></span>
</td>
<td class="num">$ (1,455,465)<span></span>
</td>
<td class="num">$ (5,801)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581791440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (49,089)<span></span>
</td>
<td class="nump">$ 21,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">4,349<span></span>
</td>
<td class="nump">20,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on marketable securities</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization in operating lease right-of-use assets</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">8,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="nump">354<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">232<span></span>
</td>
<td class="num">(3,348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(783)<span></span>
</td>
<td class="nump">6,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="num">(4,939)<span></span>
</td>
<td class="num">(1,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(2,559)<span></span>
</td>
<td class="num">(8,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="num">(1,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(149,766)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(48,663)<span></span>
</td>
<td class="num">(66,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">82,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Sales of marketable securities</a></td>
<td class="nump">34,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">35,840<span></span>
</td>
<td class="nump">35,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">22,122<span></span>
</td>
<td class="nump">8,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(670)<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">8,629<span></span>
</td>
<td class="num">(22,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">46,704<span></span>
</td>
<td class="nump">101,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">55,333<span></span>
</td>
<td class="nump">79,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_StockIssuanceCostsNotYetPaid', window );">Offering expenses in relation to issuance of common stock included in unpaid liabilities</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in unpaid liabilities</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">5,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering expenses</a></td>
<td class="nump">22,524<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockIssuanceCostsNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockIssuanceCostsNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584518048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. The Company believes its zinc finger (&#8220;ZF&#8221;) epigenetic regulators are ideally suited to potentially address devastating neurology disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system (&#8220;CNS&#8221;) in preclinical studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company announced its strategic transformation into a neurology-focused genomic medicine company focused on developing epigenetic regulation therapies designed to address serious neurological diseases and novel adeno-associated virus (&#8220;AAV&#8221;) capsid delivery technology. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#8220;2023 Annual Report&#8221;) as filed with the SEC on March 13,&#160;2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2023, included in the 2023 Annual Report.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity, Going Concern, and Capital Resources</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects will require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#8217;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of March&#160;31, 2024, the Company had capital resources of $54.4&#160;million consisting of cash and cash equivalents. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements&#8212;Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effects of management&#8217;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probable of being effectively implemented, the plans must have been approved by the Company&#8217;s board of directors before the date that the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on additional financing to fund its operations after the current resources are exhausted raise substantial doubt about its ability to continue to operate as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. The Company&#8217;s current operating plan, its cash and cash equivalents as of March&#160;31, 2024 are expected to allow the Company to meet its liquidity requirements only into the third quarter of 2024, which is less than one year following the date these Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through the sale of the Company&#8217;s common stock;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through debt or royalty financing; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish collaborations with potential partners to advance the Company&#8217;s product pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to raise capital on acceptable terms, or at all, or if it is unable to procure collaboration arrangements or external direct investments to advance its programs, the Company would be required to discontinue some or all of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful. Additional capital may not be available to the Company on a timely basis, on terms that are acceptable or at all. In particular, the perception of the Company&#8217;s ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of its operations, particularly in light of currently challenging macroeconomic and market conditions. Further, the Company may be unable to attract new investments as a result of the speculative nature of its newly reprioritized core neurology preclinical programs. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which would have a material adverse effect on its business and prospects, or the Company may be required to cease operations entirely, liquidate all or a portion of its assets, and/or seek protection under the U.S. Bankruptcy Code.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary (&#8220;Kite&#8221;). This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $8.9&#160;million, a decrease in net loss of $8.9&#160;million, and a decrease in the Company&#8217;s basic and diluted net loss per share of $0.06 and $0.05, respectively for the three months ended March 31, 2023.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company&#8217;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaboration and license agreements for the three months ended March&#160;31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license agreements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to acquired in-process research and development (&#8220;IPR&amp;D&#8221;) projects and are initially measured at their respective fair values as of the acquisition date. Goodwill and indefinite-lived intangible assets are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#8217;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value (but not in excess of the carrying value of goodwill).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing each annual impairment assessment and any interim impairment assessment for its indefinite-lived intangible assets, the Company determines if it should qualitatively assess whether it is more likely than not the fair value of its IPR&amp;D asset is less than its carrying amount (the qualitative impairment test). If the Company concludes that is the case, or elects not to use the qualitative impairment test, the Company will proceed with quantitatively determining the fair value of the IPR&amp;D asset and comparing its fair value to its carrying value to determine the amount of impairment, if any (the quantitative impairment test).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the qualitative impairment test, the Company considers the results of the most recent quantitative impairment test and identifies the most relevant drivers of the fair value for the IPR&amp;D asset. The most relevant drivers of fair value identified are consistent with the assumptions used in the quantitative estimate of the IPR&amp;D asset. Using these drivers of fair value, the Company identifies events and circumstances which may have an effect on the fair value of the IPR&amp;D asset since the last time the IPR&amp;D&#8217;s fair value was quantitatively determined. The Company then weighs these factors to determine and conclude if it is not more likely than not the IPR&amp;D asset is impaired. If it is more likely than not the IPR&amp;D asset is impaired, the Company proceeds with quantitatively determining the fair value of the IPR&amp;D asset.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing the quantitative impairment test, the Company uses the income approach to determine the fair value of its IPR&amp;D asset. This approach calculates fair value by estimating the after-tax cash flows attributable to an in-process project over its useful life and then discounting these after-tax cash flows back to a present value. This estimate includes judgmental assumptions regarding the estimates that market participants would make in evaluating the IPR&amp;D asset, including the probability of successfully completing clinical trials and obtaining regulatory approval, the timing of and the expected costs to complete IPR&amp;D projects, future net cash flows from potential drug sales, which are based on estimates of the sales price of the drug, the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">size of the patient population and cure rate, its competitive position in the marketplace, and appropriate discount and tax rates. Any impairment to be recorded is calculated as the difference between the estimated fair value and the carrying value of the IPR&amp;D asset on the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If this review indicates that the carrying amount of the asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, impairment of indefinite-lived intangible assets, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash in current assets consists of a letter of credit for $0.9&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,417&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,204&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,241&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants to Purchase Shares of Company Stock </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#8217;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#8217;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If financial instruments, such as the warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants are also required to meet equity classification criteria to be classified in stockholders&#8217; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#8217;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. The warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 712&#8221;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 420&#8221;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584490272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581432656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were not material during the three months ended March&#160;31, 2024. There were no realized gains and losses on the sales of investments during the three months ended March&#160;31, 2023. Total unrealized gains for securities with net gains in accumulated other comprehensive income (loss) were not material during the three months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses related to its marketable securities for the three months ended March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2023. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that were in a continuous unrealized loss position for greater than 12 months as of December&#160;31, 2023. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. No significant facts or circumstances had arisen to indicate that there had been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, the Company determined that no allowance for credit losses related to its marketable securities was required at December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods the Company had investment in debt securities, the Company also considered whether it was more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. No impairment charges were recorded during the three months ended March&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584543088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET (LOSS) INCOME PER SHARE</a></td>
<td class="text">BASIC AND DILUTED NET (LOSS) INCOME PER SHARE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share has been computed by dividing net (loss) income by the weighted-average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding. During the three months ended March 31, 2024, both basic and diluted weighted-average number of shares outstanding included 251,177 shares from pre-funded warrants to purchase 3,809,523 shares of common stock with an exercise price of $0.01 per share.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net (loss) income per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>Warrants to purchase shares of common stock with the exercise price of $1.00 per share entitle holders to participate in dividends but are not required to absorb losses incurred and as a result were excluded from basic net loss per share calculations during the three months ended March 31, 2024. The computation of diluted net loss per share for the three months ended March 31, 2024 excluded 55.6 million shares subject to stock options, restricted stock units outstanding, warrants to purchase common stock, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net income per share for the three months ended March 31, 2023 excluded 14.7&#160;million shares subject to stock options because their inclusion would have had an anti-dilutive effect on diluted net income per share.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938676653120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company was responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) 15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and was eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid. The Company is eligible to earn from Pfizer up to $220.0&#160;million in remaining milestone payments for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are 14% - 20% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $134.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three months ended March&#160;31, 2024 and 2023. The remaining development, intellectual property and regulatory milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Pfizer&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales milestones and royalties are not recognized until triggered based on the contractual terms.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, subsequently assigned to Alexion, AstraZeneca Rare Disease (&#8220;Alexion&#8221;) in September 2023, for the development and commercialization of potential gene therapy products that use zinc finger transcriptional regulators (&#8220;ZF-transcriptional regulators&#8221;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-transcriptional regulators that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer (now Alexion) an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-transcriptional regulators that satisfy pre-agreed criteria. During a specified period, neither the Company nor Alexion will be permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins (&#8220;ZFPs&#8221;) that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Alexion also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Alexion to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Alexion without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Alexion to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Alexion to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Alexion&#8217;s material breach, Alexion will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Alexion for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Alexion contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">worldwide net sales of the licensed products reach specified levels. In addition, Alexion will pay the Company royalties of 14% - 20% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party is responsible for the cost of its performance of the research program. Alexion is operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Alexion in accordance with ASC Topic 606 and concluded that Alexion was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $17.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three months ended March&#160;31, 2024 and 2023. The remaining development milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Alexion&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales related milestones and royalties are not recognized until triggered based on the contractual terms. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, Pfizer notified the Company of Pfizer&#8217;s assignment of the collaboration and license agreement to Alexion, AstraZeneca Rare Disease, pursuant to a definitive purchase and license agreement for preclinical gene therapy assets and enabling technologies that closed on September 20, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company also had a collaboration and license agreement with Kite. During the three months ended March&#160;31, 2023, in addition to the agreement with Kite, the Company had collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;), and Biogen MA, Inc. (&#8220;Biogen&#8221;). These collaboration agreements were designed for the research, development, and commercialization of various potential therapy products, including potential engineered cell therapies for cancer and gene regulation therapies to treat neurodevelopmental disorders and diseases. The collaboration agreements with Novartis and Biogen were both terminated effective June 2023. The Company&#8217;s services under the Kite collaboration agreement were completed during the year ended December 31, 2023, and the agreement expired pursuant to its terms in April 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed each of these collaboration agreements in accordance with ASC Topic 606, concluding Kite, Novartis and Biogen were customers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under these agreements were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other license agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and December&#160;31, 2023, the Company had no receivables, no deferred revenue, and no amounts included in transaction price remaining to be recognized related to any license and collaboration agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581208496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesTextBlock', window );">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</a></td>
<td class="text">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company experienced a sustained decline in stock price and related market capitalization, the collaboration agreements with Biogen and Novartis were terminated, and actions were initiated including deferral and reprioritization of certain research and development programs, announcement and execution of restructuring of operations and reductions in force. As a result, throughout the year the Company tested various long-lived and indefinite-life intangible assets for impairment and recognized a pre-tax goodwill impairment charge of $38.1&#160;million, a pre-tax indefinite-lived intangible asset impairment charge of $51.4&#160;million along with the income tax benefit from the reduction of the associated deferred tax liability of $6.3&#160;million, and a pre-tax long-lived assets impairment charge of $65.5&#160;million during the year ended December 31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three months ended March 31, 2024</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company&#8217;s Board of Directors approved the wind-down of operations in France and corresponding reduction in workforce, including closure of the Company&#8217;s cell therapy manufacturing facility and research labs in Valbonne, France (the &#8220;France Restructuring&#8221;), and also initiated several actions aimed at reducing costs, including actions to commence the closure of its facility in Brisbane, California. As such, the Company reassessed its long-lived assets for impairment as of March 31, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the France Restructuring, the Company concluded its equipment, furniture and fixtures located in France met the held for sale criteria as of March 31, 2024. The Company wrote down the carrying value of these assets to their estimated fair value of $1.0&#160;million, net of the estimated costs to sell, recognizing a loss of $1.8&#160;million. Assets held for sale are included within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations. The sale of these assets is expected to occur within one year, either collectively or separately through vendor(s) or at auction.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reassessed whether its remaining long-lived assets continued to represent a single asset group for purposes of impairment assessment. After considering changes in the manner in which the right-of-use assets and leasehold improvements related to the Company&#8217;s Brisbane and Valbonne, France, facilities are used, costs incurred to cease use of these assets, the France Restructuring, and the Company&#8217;s activities to market these facilities for sublease, the Company concluded the identifiable operations and cash flows of these assets are now largely independent of the operations and the cash flows of each other, as well as of the remainder of the Company. Accordingly, the Company assessed impairment of the resulting asset groups separately.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the changes in the use of assets related to the Brisbane and Valbonne facility leases, the Company concluded there were indicators of impairment for these asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $2.0&#160;million on the right-of-use assets and $0.5&#160;million on the related leasehold improvements during the three months ended March 31, 2024. No impairment was recognized on the remaining long-lived assets, as their carrying values were not in excess of their fair values.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess whether its long-lived assets are impaired in future periods. As the Company finalizes the wind-down of its France operations and corresponding reduction in force of all France employees, as well as the closure of its Brisbane facility, it is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three months ended March 31, 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and other long-lived assets. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operated as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a pre-tax goodwill impairment charge of $38.1&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before completing the goodwill impairment assessment, the Company also tested its indefinite-lived intangible assets and then its long-lived assets for impairment. Based on the qualitative assessment, the Company determined it was more likely than not that its indefinite-lived intangible assets were not impaired. The Company determined all of its long-lived assets represented one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable as it exceeded the future undiscounted cash flows the assets were expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction and a cost replacement method to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level&#160;3 nonrecurring fair value measurements. Based on this analysis, the Company recognized pre-tax long-lived asset impairment charges of $11.2&#160;million on the right-of-use assets, $5.0&#160;million on the related leasehold improvements, and $4.2&#160;million on construction-in-progress, during the three months ended March 31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938579927968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company entered into an amendment to the operating lease of office and research and development laboratory facilities in Brisbane, California. The amendment established early termination rights for the landlord upon thirty days notice to the Company, with the earliest date the landlord may terminate the lease being September 30, 2024. Additionally, the amendment authorizes the landlord to draw on the existing letter of credit to satisfy the majority of the Company&#8217;s February 2024 through April 2024 rent payments and obligates the Company to provide a cash security deposit or replenish the letter of credit back to $1.5&#160;million by June 1, 2024.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the amendment represented a lease modification to be accounted for as a single contract with the existing lease under ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span>, and remeasured its lease liability using the current incremental borrowing rate of 9.6%, and recorded an adjustment to reduce both the lease liability and the corresponding right-of-use asset by $1.9&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938579949168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938582260096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. In December 2022, the Company entered into Amendment No. 2 to the Open Market Sale Agreement&#8480; which increased the aggregate offering price under the at-the-market offering program by an additional $175.0 million. Approximately $194.5&#160;million remained available under the sales agreement as of March 31, 2024. The Company is not obligated to sell any shares under the sales agreement. No shares were sold under the sales agreement during the three months ended March&#160;31, 2024. During the three months ended March&#160;31, 2023, the Company sold 3,962,430 shares of its common stock for net proceeds of approximately $9.7 million. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance and Sale of Common Stock and Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Investors&#8221;). On March 26, 2024 the Company issued and sold in a registered direct offering (the &#8220;Registered Direct Offering&#8221;) an aggregate of 24,761,905 shares of common stock of the Company, par value $0.01 per share, and pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of common stock, together with </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accompanying warrants (&#8220;Common Warrants&#8221;) to purchase up to an aggregate of 28,571,428 shares of common stock. The combined offering price of a unit consisting of one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.84. The combined offering price of a unit consisting of a pre-funded warrant to purchase one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.83. The pre-funded warrants are immediately exercisable at any time, until exercised in full, at a price of $0.01 per share of common stock. The Common Warrants are exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $1.00 per share. Both pre-funded warrants and Common Warrants can be exercised net in limited circumstances and entitle holders to dividends if and when paid by the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barclays Capital Inc. and Cantor Fitzgerald &amp; Co. (the &#8220;Placement Agents&#8221;) acted as the placement agents for the offering, pursuant to a Placement Agency Agreement, dated March 21, 2024 (the &#8220;Placement Agreement&#8221;). Pursuant to the Placement Agreement, the Company paid the Placement Agents a cash placement fee equal to 6.0% of the aggregate gross proceeds raised in the Registered Direct Offering from sales arranged by the Placement Agents. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received aggregate net proceeds from the Registered Direct Offering of $21.8&#160;million, net of the Placement Agents&#8217; fees of $1.4&#160;million and other offering costs of $0.7&#160;million. </span></div>Common Warrants and pre-funded warrants were determined to be equity-classified and proceeds received from their issuance were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The Company determined that the warrants should be equity classified because they are freestanding financial instruments, do not embody an obligation for the Company to repurchase its shares, do not contain exercise contingencies tied to observable markets or indices, permit the holders to receive a fixed number of shares of common stock upon exercise in exchange for a fixed amount of consideration, subject only to adjustments that are inputs to the fair value of a fixed price/fixed consideration-option, and meet the equity classification criteria. The Common Warrants and pre-funded warrants had not been exercised and remained outstanding as of March 31, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938579949168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING CHARGES</a></td>
<td class="text">RESTRUCTURING CHARGES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;April 2023 Restructuring&#8221;), designed to reduce costs and increase focus on certain strategic priorities. The April 2023 Restructuring resulted in the elimination of approximately 110 roles, including 55 full-time employees and 55 contracted employees and eliminated open positions, in the United States, or approximately 23% of the total United States workforce as of April 26, 2023, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The Company had estimated that it will incur $5.0 million in expenses related to employee severance and notice period payments, benefits and related restructuring charges for the April 2023 Restructuring. No expenses related to the April 2023 Restructuring were incurred during the three months ended March&#160;31, 2024. The Company expects the April 2023 Restructuring and the cash payments related to the April 2023 Restructuring to be substantially complete by the third quarter of 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">November 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;November 2023 Restructuring&#8221;), designed to reduce costs and advance its strategic transformation into a neurology-focused genomic medicine company. The November 2023 Restructuring resulted in the elimination of approximately 162 roles, including 108 full-time employees and 54 contracted employees and eliminated open positions, in the United States, or approximately 40% of the total United States workforce, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. As of March&#160;31, 2024, the Company estimates it will incur approximately $8.7 million to $9.7 million in expenses related to employee severance and notice period payments, benefits, Brisbane facility close-out costs, and other related restructuring charges for the November 2023 Restructuring. The Company had recorded $6.7 million of expenses relating to the November 2023 Restructuring in the fourth quarter of 2023. The Company incurred $0.7 million of expenses during three months ended March&#160;31, 2024, of which $0.5 million is included in research and development expense and $0.2 million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur additional estimated costs of $1.3 million to $2.3 million through the second quarter of 2024. The Company expects the November 2023 Restructuring and the cash payments related to the November 2023 Restructuring to be substantially complete by the second quarter of 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">France Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company&#8217;s Board of Directors approved the France Restructuring which will result in the elimination of all 93 roles in France, or approximately 24% of the total global workforce. The Company is expected to make severance payments as required by French law and the terms of the applicable collective bargaining agreements, and other employee-related costs. As of March&#160;31, 2024, the Company estimates it will incur approximately $7.8 million to $9.6 million in expenses related to employee severance and notice period payments, benefits, contract termination costs, and other related restructuring charges for the France Restructuring. The Company had recorded $4.7 million of expenses relating to the France restructuring in the fourth quarter of 2023. The Company incurred $0.2 million of expenses during three months ended March&#160;31, 2024, of which $0.1 million is included in research and development expense and $0.1 million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur additional estimated costs of $2.9 million to $4.7 million through the fourth quarter of 2024. The Company expects the France Restructuring and its related cash payments to be completed no later than the fourth quarter of 2024. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Sangamo may also incur other cash expenses or charges not currently contemplated or estimable due to events that may occur as a result of, or associated with, the April 2023 Restructuring, November 2023 Restructuring and France Restructuring. There were no restructuring charges incurred during the three months ended March&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584740736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exercise of Pre-funded Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 8, 2024, the Company issued an aggregate of 3,809,523 shares of common stock at an exercise price of $0.01 to an investor upon exercise of pre-funded warrants issued as part of the Registered Direct Offering. Following this issuance, none of the pre-funded warrants sold in the Registered Direct Offering remain outstanding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Deficiency Notice</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2024, the Company received a deficiency notice (the &#8220;Notice&#8221;) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying the Company that, for the last 30 consecutive business days, the bid price of the Company&#8217;s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company&#8217;s common stock on the Nasdaq Global Select Market.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938673286176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#8220;2023 Annual Report&#8221;) as filed with the SEC on March 13,&#160;2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company&#8217;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaboration and license agreements for the three months ended March&#160;31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license agreements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to acquired in-process research and development (&#8220;IPR&amp;D&#8221;) projects and are initially measured at their respective fair values as of the acquisition date. Goodwill and indefinite-lived intangible assets are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#8217;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value (but not in excess of the carrying value of goodwill).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing each annual impairment assessment and any interim impairment assessment for its indefinite-lived intangible assets, the Company determines if it should qualitatively assess whether it is more likely than not the fair value of its IPR&amp;D asset is less than its carrying amount (the qualitative impairment test). If the Company concludes that is the case, or elects not to use the qualitative impairment test, the Company will proceed with quantitatively determining the fair value of the IPR&amp;D asset and comparing its fair value to its carrying value to determine the amount of impairment, if any (the quantitative impairment test).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the qualitative impairment test, the Company considers the results of the most recent quantitative impairment test and identifies the most relevant drivers of the fair value for the IPR&amp;D asset. The most relevant drivers of fair value identified are consistent with the assumptions used in the quantitative estimate of the IPR&amp;D asset. Using these drivers of fair value, the Company identifies events and circumstances which may have an effect on the fair value of the IPR&amp;D asset since the last time the IPR&amp;D&#8217;s fair value was quantitatively determined. The Company then weighs these factors to determine and conclude if it is not more likely than not the IPR&amp;D asset is impaired. If it is more likely than not the IPR&amp;D asset is impaired, the Company proceeds with quantitatively determining the fair value of the IPR&amp;D asset.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing the quantitative impairment test, the Company uses the income approach to determine the fair value of its IPR&amp;D asset. This approach calculates fair value by estimating the after-tax cash flows attributable to an in-process project over its useful life and then discounting these after-tax cash flows back to a present value. This estimate includes judgmental assumptions regarding the estimates that market participants would make in evaluating the IPR&amp;D asset, including the probability of successfully completing clinical trials and obtaining regulatory approval, the timing of and the expected costs to complete IPR&amp;D projects, future net cash flows from potential drug sales, which are based on estimates of the sales price of the drug, the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">size of the patient population and cure rate, its competitive position in the marketplace, and appropriate discount and tax rates. Any impairment to be recorded is calculated as the difference between the estimated fair value and the carrying value of the IPR&amp;D asset on the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If this review indicates that the carrying amount of the asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, impairment of indefinite-lived intangible assets, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash in current assets consists of a letter of credit for $0.9&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_WarrantOrRightPolicyPolicyTextBlock', window );">Warrants to Purchase Shares of Company Stock</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants to Purchase Shares of Company Stock </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#8217;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#8217;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If financial instruments, such as the warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants are also required to meet equity classification criteria to be classified in stockholders&#8217; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#8217;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. The warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 712&#8221;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 420&#8221;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_WarrantOrRightPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_WarrantOrRightPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 420<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584575808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaboration and license agreements for the three months ended March&#160;31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license agreements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,417&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,204&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,241&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,417&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,204&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,241&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581608032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584556192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Marketable Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584644368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Components of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net (loss) income per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581668368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under these agreements were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other license agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584611184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584706192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Accrued Restructuring Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938583610128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 78,241<span></span>
</td>
<td class="nump">$ 54,417<span></span>
</td>
<td class="nump">$ 45,204<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Change In Agreement Estimate, March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenue</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent', window );">Decrease in net loss</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic', window );">Decreased net loss per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted', window );">Decreased net loss per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Basic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Net Income (Loss) Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938674141040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details) - Revenue from contract with customer - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember', window );">Other license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581451792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 54,417<span></span>
</td>
<td class="nump">$ 45,204<span></span>
</td>
<td class="nump">$ 78,241<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Current restricted cash</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 55,333<span></span>
</td>
<td class="nump">$ 46,704<span></span>
</td>
<td class="nump">$ 79,741<span></span>
</td>
<td class="nump">$ 101,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938578767792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938583554832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value, total</a></td>
<td class="nump">$ 54,417<span></span>
</td>
<td class="nump">$ 45,204<span></span>
</td>
<td class="nump">$ 78,241<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value, total</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value, total</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">$ 8,956<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938584606912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 10,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">24,943<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 35,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938582179776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Realized gain and losses on the sales of investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded', window );">Allowance for credit loss related to marketable securities, not previously recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for credit loss related to marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938583269648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">180,342,000<span></span>
</td>
<td class="nump">168,533,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">180,342,000<span></span>
</td>
<td class="nump">169,181,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">55,600,000<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">251,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">251,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD) (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Offering price of each common stock (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938582542544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (49,089)<span></span>
</td>
<td class="nump">$ 21,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">180,342<span></span>
</td>
<td class="nump">168,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">180,342<span></span>
</td>
<td class="nump">168,533<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding - diluted (in shares)</a></td>
<td class="nump">180,342<span></span>
</td>
<td class="nump">169,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net (loss) income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share-based payment arrangements (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share-based payment arrangements (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic And Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss) Available To Common Stockholders, Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581954576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">76 Months Ended</th>
<th class="th" colspan="1">83 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>product </div>
<div>milestone</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products | Achievement of specified clinical development intellectual property and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved', window );">Collaborative arrangement, number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72 | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72 | Achievement Of Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938581439520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 157,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">132,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">130,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember', window );">Other license agreements | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 3,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938671063904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100<span></span>
</td>
<td class="nump">$ 38,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets, indefinite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment on right-of-use assets</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">65,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair value of equipment, furniture and fixtures</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">4,349<span></span>
</td>
<td class="nump">20,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount', window );">Reduction in deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_EquipmentFurnitureAndFixturesMember', window );">Equipment, Furniture, And Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938583502160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment on right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="nump">$ 65,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">$ 1,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination', window );">Lessee, Operating Lease, Required Notice Of Termination</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount', window );">Lessee, Required Letter Of Credit Outstanding, Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember', window );">Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment on right-of-use assets</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Required Notice Of Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Required Letter Of Credit Outstanding, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeRequiredLetterOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938583645088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,719<span></span>
</td>
<td class="nump">$ 8,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Direct offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">4,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,334<span></span>
</td>
<td class="nump">$ 3,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938576558048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2024</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD) (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Offering price of each common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">24,761,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds', window );">Cash placement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockAgentPlacementFees', window );">Net of placement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockOtherOfferingCosts', window );">Proceeds from other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember', window );">Direct offering | Pre-funded warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember', window );">Direct offering | Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares of common stock for each Common warrant (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit', window );">Sale of stock, number of shares issued in transaction, per unit (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance', window );">Warrants exercisable, period after issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember', window );">Direct offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">28,571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares of common stock for each Common warrant (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit', window );">Sale of stock, number of shares issued in transaction, per unit (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD) (in dollars per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Offering price of each common stock (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember', window );">Jefferies LLC | At-The-Market Offering Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_StockOfferingProgramMaximumValue', window );">Stock offering program, maximum value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice', window );">Stock offering program, increase to aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockOutstandingAmountAvailable', window );">Sale of stock agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,962,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockAgentPlacementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Placement Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockAgentPlacementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Increase To Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockIncreaseToAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Shares Issued in Transaction, Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Other Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockOutstandingAmountAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Outstanding Amount Available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockOutstandingAmountAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockOfferingProgramMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Offering Program, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockOfferingProgramMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding, Exercisable, Period After Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sgmo_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938575636144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2024 </div>
<div>employee</div>
</th>
<th class="th">
<div>Nov. 01, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Apr. 26, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember', window );">April 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of positions eliminated in restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember', window );">April 2023 Restructuring Plan | Full-Time Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember', window );">April 2023 Restructuring Plan | Contracted Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of positions eliminated in restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Full-Time Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Contracted Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of positions eliminated in restructuring</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sgmo_FullTimeEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sgmo_FullTimeEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sgmo_ContractedEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sgmo_ContractedEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938579858384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2023</a></td>
<td class="nump">$ 11,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(5,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at March 31, 2024</a></td>
<td class="nump">$ 7,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139938583422656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Apr. 09, 2024</div></th>
<th class="th"><div>Apr. 08, 2024</div></th>
<th class="th"><div>Mar. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Direct offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_DirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M.\2.LD.C!);9V\TYLQ3E>W K)ZY8Q7D*!\1*!\2.<D!FJ08^'CS!7"KK6'1
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MJF<?M.+F)86V]6"K9083Z#L3M1;VL()V6C7[SK)VKF&W1W$P+F4FN\!WT93
MGE+0>]'1(<_P;9;7,#">'Z"5=J\]0/PN;X=!]PB$=@9VC-GCYRG 0)UNT/>"
M:/Q@3&9RMTX\EYZ"\"@&6:52FA:*-+CI%E1E+/8Y?28$W)*2;+.)M#+@T76T
MG->MHAA.E''8(Q+:&7E5UP[<!C!(+*-2 ^XB;U"A6ZFZ&7)]?ZJ0]UB$K^'B
M,:TZ]SQY_A\#W&06ANY4^>[Y".V O*3EW5P05H ]974^T&W+GV/"=0RZ3J3!
MTF3F^M W"T<]+=$16FHP.:(7Z0"$R!ECTF0%HPF>H)Z2R$[))B6.*=1A%B(4
MC-/68!8ASYTXS*%!OV=GWIH612;4^:C!=4)+=1HA93*E]S^T;,#8^OU_1X<Q
M]RA%KI54&T&3^QW-4\+XNS<1@N''^I@HGLT-KQ7,K^YX?Y.WP]A[2B-[,RG;
MCBV16R<%7*V",5Y;I]@&\>)F$O4H17:4JDR4E6A:ELY'Y+CCRF.P@F$T43%1
M#U%T!**I/-#*0BGWL^K:YEDICXC[3.YOHU0=AU!6OQB-VQ^3H1<C)YRJ/3TZ
MD1V=DOI54>58'6932?<D,_8^2*?A''H2AX%6(XV63N"&P836'IW(CLZAUK8#
MEF<51G;J[>B#9!+EYE*DXW'N1\[XQ&LR\_QX"D8]19&=HDUYYY/%Q"A9!Z,?
M!+&6Q;I9A*(I(KD]/UT[/S4BU37_=2&T4P0'2#4T&B8[4Z.Q&+RL56_*OV)V
MEY5<GD>V<J#S(92KP)J7S\V-H/OZ_>TM%8(6]>6.8"E>&<C?MY2*7S?JE7#W
M+X#5OU!+ P04    " ![@*E8$(H?L:0$  #\$0  &    'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;*V8;6^C.!#'OXK%K4ZMU!9L'@*])%*;=/<B;1_49.]>
MN\%)T +.V4[2^_8W0 ($#+>5^B9@,C/\QF/FCQD>N/@I-XPI])[$J1P9&Z6V
MMZ8IEQN64'G#MRR%?U9<)%3!4*Q-N16,AKE3$IO$LCPSH5%JC(?YM1<Q'O*=
MBJ.4O0@D=TE"Q;_W+.:'D8&-TX77:+U1V05S/-S2-9LS]6/[(F!DEE'"*&&I
MC'B*!%N-C#M\.R&Y0V[Q5\0.LG:.LE3>./^9#6;AR+ R(A:SI<I"4#CLV83%
M<18)./XY!C7*>V:.]?-3]*]Y\I#,&Y5LPN._HU!M1H9OH)"MZ"Y6K_SP)SLF
MY&;QECR6^2\Z'&TM RUW4O'DZ P$29061_I^G(B: \31.Y"C VDZ.!T.]M'!
MSA,MR/*TIE31\5#P Q*9-43+3O*YR;TAFRC-RCA7 OZ-P$^-)\]/TX>G^<,4
MP=G\^?ML>K> P7P!A\>'I\4</7]%SR\/KW>+&1B@:_1C/D477RZ1W%#!)(I2
MM-CPG:1I**_0E[/QT%2 F-W(7!YQ[@L<TH%CHT>>JHU$#VG(PG-_$U(K\R.G
M_.Y);\!'*FZ0C:\0L8BCX9G\NKO=@V.7TVWG\>R.>*]LS](=D[>ZJ2E<';UK
M]CS?RBU=LI$!#ZQD8L^,\>^_8<_Z0Y?7)P4[R](ILW3ZHI=9ZI(L/+W<,^LQ
M^['CXZ&YK[.W;; ["-Q!:79&Y994;N_</V^9H"I*UXB]0Q>4'55P/[,*GQ3L
M+%^OS-?[GRI(1L5R@^!1A,ZVAY:]A0:L=$D7D=S:C-NN'S3KTK;R;((]?5D&
M)>:@%_,;2Z$N<4Y)0VAQD519G?9,!SIH(6 \\ 8-4(V5C^T.4+\$]7M!9\F6
M1B*;0<17*.;I^CH&2J"6DBGM8O=;'([M! W8MA&Q'-O6PP8E;/ !V#7GX2&*
M8QUCT+J]U0!L6]@PF[X>$%N5\EB]B NNH.R\]51J5<-J,;CPIM*LN\8,VT%
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MV'! G&H'MW!PMQWJ>QR\PL$S0G-F1M: *NIW!5\1H:T130],;(PWJDF8OL5
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M_:=X^H/M QH:?[%(5?$7/>UM@QZ*MTJ+;#\8$&0\+S^CY_U$' P /^X!9#^
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MJD_&M 7=882#<.+&/JVP3_W8#R:U610I Q5%TLAE7RS[4#6>-)G:<X])T K
M-B+!E+CQXZ 6NL ;P4*+^&??2'Z"@)R@#U*=*;)WU8 PQNUT=EA-R'C< ?1
MD?$'JF\E1/+$T]0)$UL VG/I,*$33#NR 9,:)/%2J>'Z>!WE*Z9:'%FL?5&(
M*8\>>=K-E_NO.!)A'LM;<T)JM<=>:9U=YYJ!7VU4A?&=*69GS-1>CV'87C3;
MJ$](!_O@6IZQ7Y^!?PSCJ+<@AG;R4]*&:!OU*>UB&5PK-/8*V^Q>,LC^!+%G
M4Z"L3"2AUTQZ6&7OLP%F/&GSHL-J1$B'^N!:*[%?+*M9W40O!84?( ;"W[)&
M(3CAV[H(/1&UZ,9AAJ?!L". 6C^Q7T#G>Y2'I%@$P;)-*EX80X\L9TO>,?>V
M4O;)<&B!=YA-AM.NG*XE%?LU]5NA/F]-L$L2"9ZT,;K-NI2GED[LU\Z[(AER
MD?=!VZ7A];?P.F32 NM0R0ZDI-9(XM?(2[9D@# !AMBQ?.M&1VS9:ZN.PZ2/
MP^EX-.I 6(LC\8OC[7NZ<R=J6PC[X60T:K.$RPZL@J #>:V8Q*^8U_D.Y.$=
M^T%R5%D\EK=FU+4L$K\LWF\EM F&R*&7>7>?2VP!M%+,H9$4^+R##DFMDL2O
MDC>1WB/[&&1;$#'&%FK;:D+PL$.$2"V;Q"^;BRC]*%Y;#6DXIA9@VZRK$FK%
M)'[%;.3$1IH*UB^EXOR]Y1O3^3H1V_IGH75)9$ ZB[?62.+7R(IV .Z.)T ]
MCR_ /J\5_0;U.#:3PTEH@7>9C4E'2T5JB203+_%\Y7F4Q^\A'J_4?IAXCN2M
M&74MNL0ON@_1,S,]&3=BED8:EFQ_N*/6D335H77*7G=9)O%,#CY%TGV626RY
M[8=!NRMV60$)='0YM-9EZM=E9_HMJW7UIQ]U;&:AJVEC=YA-@J"CI:"U8%._
M8%\MERPNY_BYW# BT&M6;1ZAUS21G93QF778 9=!/WU2,(+94DD>F^4S!L[X
M7(H];E>7PXJ..O;JM!9UZI7/8F%X'LNB"_V4L/+*G'_^SU$1>SE&I-U6.ZQ@
MITB"#D&A!X?7?MV^>#_Z$]@?K'B>FTPTA,XD%XDS)%NR0UBH]N[7888#/ W#
MCIAJ9:=^9?]03,SLXKS1V%(^'%+:[B<=9N/I.,0=P=2*3_UGV8OM9E/R5Y26
M,2U3\&&.%5.AMK+KQX:C'E(?RUMS#NI&@OH;B3O@%FG2KCHMX'G)]F8+"W3/
ME=H"1S*SDK"]S>"I,L> IF;3;5+N(+9YH1)O[,FHW5J,:?O4V&'4T7K0NO6@
M_M;CWMD@_9,([/XB'%DT:1L-\:2K].H>A/JWZ9=<EBI0+I@3WE&[CV-Y:\9;
M=Q]T>IR>BWJ[F ]'?21OS9__ZC8E]+<ID*HQ8XE"2RFRSN([*;HP>"C:Y>O\
MO=#5O0Q)6S0<9AV5%]:M2^AO7>8:Z35#-\66"MUY<M?OZ*.K>"QOS;#KGB;T
M'U2\.W?#HQY4',M;,^JZX0G?.*CX?^0NM7[%;O.MPV2*<;L[&!R\X)$QN2K>
M>U&H.'@N7Y"HGE;OULR+-TI:S[_@TXOR#9G:3?G"#F0Y-'$*I6P)+H//8R@E
M6;X#4]YHL2E>(WD46HNLN%RS*&'2&,#_ET+HUQOS!=6;2+/_ E!+ P04
M" ![@*E8W)]"3<8H  ",AP  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;+T]:7/;1I9_!:7-3ME5$"W)\A';<94L.UGM)+;+LF=J9VL_-,$FB3$(,&A
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MD@ IFAI1C41$'(0H:IEXB\)N<37<NZ^)>+= DT6YK9!MF#B^U 0([4.@GVT
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MY1CB0,K#'X1/666H8@6!C#3-RJ$E0D90,3YJ=GA$\@,!I; VV&!KC"# 6JY
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M@#9<)O3/?K$2>O+!L@),=Z(FN@ZW_SZ"^8>B"G-KF&<Q6Q32M<@&/JZ$4[
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M3BS(?5AC.%R,A#W W#!W@6-*UU$)O& .ORQ.ZKV-#H["!ROY2K4;H9$Q<?<
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M2?96#L2@#SVJRE@RW7P%H-ZK8!YM&@-&DP'[NT%(L>?X-SHW&?CFU?YX>^_
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M?JI?K"JJF84*GR:@:IG1R(G:7:#SE:*.MWUQ"IHA=O0/4$L#!!0    ( 'N
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MBH@'$[N&.8^VPZV88C1D=I??OJMNL+X%%4QB".S1FA;1L1XEY.P6D*<O'VD
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M+=?2W MUMU9.*Y-AJ00Z^  LP7.N,E)&:"-0!MDWL78Z4QPIIPH9L 0X\@W
ME<FU#K+0_TBJ]"@=A5'(N74R%O_2*04L04PW.JS$I;9+95C6!WLK7=!XH1#F
MH!RJC(2/^:UD\$@OM=%!\\':9$65DZU  .6<+))>T-$ZK(JJ"+L0F7)DD*#
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MC%U:5V6MUN 5RE!+>^RU2KH;Z4S$C[YEZ2,'\HKNE?F"89B-T$'U=<'X^S<
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M\!]:@/<+:T/]@0YH_F+B_+]02P,$%     @ >X"I6+C]A!?. P  , @  !D
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M%2N?#)CVMWS_8E7E;M9S97%/=X]+P;''R #C"Z5L^T(+=#^U7/\%4$L#!!0
M   ( 'N J5C&):1_N 8  !X7   9    >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;-6867/;-A" _PI&43/)C"R)E'P?,[9S/N08.VX?.GV R)6(,4@P &C9
M_[Z[ $E3"BFKK=-I7R22 /;>#R1.EDK?F@3 LOM49N:TEUB;'XU&)DH@Y6:H
M<LAP9*YTRBW>ZL7(Y!IX[!:E<A2.QWNCE(NL=W;BGGW59R>JL%)D\%4S4Z0I
MUP\7(-7RM!?TJ@=78I%8>C Z.\GY J[!WN1?-=Z-:BFQ2"$S0F5,P_RT=QX<
M74QIOIOPJX"E:5PS\F2FU"W=?(Q/>V,R""1$EB1P_+N#2Y"2!*$9WTN9O5HE
M+6Q>5]+?.=_1EQDW<*GD;R*VR6GOH,=BF/-"VBNU_ "E/[LD+U+2N%^V]'.G
M.#DJC%5IN1@M2$7F__E]&8?&@H-QQX*P7! ZN[TB9^4;;OG9B59+IFDV2J,+
MYZI;C<:)C))R;36."EQGSZ[>7G^[NKG\=G/U\?-[=OGA_.K]V^N3D471-&$4
ME6(NO)BP0\R$?5*930Q[F\40KZX?H4FU76%EUT6X4> GKH=L$@Q8. ZG&^1-
M:C\G3MZDRT\P5A>1+;3(%HQG,;L"R2W$[)SJ0E@!AOU^/L-96"A_M$7 *YBV
M*Z#F.3(YC^"TA]UA0-]![^SEBV!O?+S!_&EM_G23].W3M%%,NY&MLMEYKH6D
MZ$_8:NR^9-78GLO.9,!L NQ2I3G/'AC<0U107#GV;'.=FC-$B>;4C,9E@+-(
M:9R4JRRF&1KBPO>JR%PS(W,B8*](_,L7!V$X/NZRR@T'QZ\'V)%&+#+4;Y47
M"*C%6*]19!&2RP";*^PMAIHBT!;1Q2CO%A8B8JA!:5</0_8--7<& BW'U@>2
MZB( 4F"#.O_(69[G6MT+! ?(!Q8$8Z:5!#,@(V3A'-[=9?-"RAV+F&.0YE(]
M 'A+<2C"CJ)B1 VK8Y4B'" XLUP9X:(ZJ$RYR02-7EN<A$^57K,FG/Q")M)4
MJRR7JPL:L>>&YJWGNPPE>D$F9. =,'"'Z<UP5<X?D-MES!5JT;4'.[IL.Y>4
M9C!X'#LOT)H[C'-9,E2C(H(=(F^,65+1+2Y-T6WC(\V77,=EJJH:3#@&"46D
M3I--N&7"(EBE)'V%9OW=X1AI*F59;'!/ M'SRCHLGLKBAE_D3J:L(!<!RR2N
M/1VP&60P%Z7/E9C5#H@2KA>H!$/K0M]564/V6;6:M&D16X(&[QZ6/8O]0Y?A
M1*,7J><S$)\9TC5*:KRN!H\41^C'1F7D)$V(N$D>T[VMJ3@^P[@62%N>6<$E
MEB0E58(%-GLHK18Z9M\+KBV6#U:"M_2SNH-TAD_:R50/!_\^FS:8MB6>>'SG
MZHS*Z!%(>)$9__KE]>-2SC(HD"=J\;#C6(82%Y"I%.>G$(L(P>]"BF[[]&X*
MW%\CV5[X(\F"\4$WRJ8_$V73\78H^V]2Z]SQ=;4=UVJVY)A90]AJ%/H'P_T:
M:%@?_</&_?,";L NM# SC@4VYY&0PF+S2F5@!]_YJP ]AG [%&ZHSA_1K@%[
MDY+8WVMXB7%<];(DS1/BJSJ;JT+;9 TXDU7E-5W[XP[%-7:?0.Z 5BT3@8]0
MUNYCJLQCB0KZZC'@UE$\8TR35#FEHU+HGJ. L$L ,@%3*TNZ8*L)QQ7\$*I%
ME/[SJ,0%V7^)U*/!F*Z,DB+F=4_Y'D'SO]3$[-A 5%6JCSWRN"M[ZJ&8?C"<
MK)1NV+Q/M"H6B;/08-JSEBVA:_/:E/2M]J]- K;9PKH,?N>;[8?-RY=(&P5H
M_PCVCPV[4,@-DO1&8!=8I8T'P1UX?UI%^SIS[/"D[^(\3CB<>+C3%"^L[?5Q
MNL;<A50S_*MAN]8VILR+#VW*;]NQ2PGX7@AJ,(S@.PT9FBWYLLX61C$UE68T
M28J(SR1M=-)]Y6-5SY K^#[O<KS )BSA]132GY'$^\.#-1+O_3025_NJBTR5
MR;^)X+;2V<3>Z9;L+>7JYX!N^(S0#?XI=#L%_!^@&PX/5ZJTF<TF=%LSM &Z
MK0!R;UX-OJY2UZ.T@B>5/:-I5)5\0YF41LRQ]]72Y=^Q '/!JR-&![4HT@4=
M\W1\C R>W"=:7:JZI\[[4N 72U9V7*54"CZC-R0Z7%)9*]$[LG[!I=-Z[4YF
M>0N<V"M71*HP:*1Y?831H/IOGL.MKZB$XO?P&XB\T^7@A/59$ SV)^L1J!P]
M# )VN9*W5[N#8#]\W92ZIJ_/]@?3_9"U'8"-&F>6*: *.IDU6 9%9OWQ9?VT
M/OP]]V>>C]/]R3%J70C\;I,PQZ7X:K;;8]J?QOH;JW)W CI3UJK472; 8] T
M <?G2MGJAA341^)G?P)02P,$%     @ >X"I6,X'\GW* P  7 @  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&ULE5;;;MLX$/V5@5H4">"U9-ENW<0V
MD(N[NT":IG'3/BSV@99&%A&*5$@JCO]^AZ1DN]@DVWV1>9DY<V8X%T\W2M^;
M$M'"4R6DF46EM?5)')NLQ(J9OJI1TDVA=,4L;?4Z-K5&EGNE2L1IDKR/*\9E
M-)_ZLQL]GZK&"B[Q1H-IJHKI[3D*M9E%@Z@[N.7KTKJ#>#ZMV1J7:._J&TV[
M>(>2\PJEX4J"QF(6G0U.SD=.W@M\Y[@Q!VMPGJR4NG>;/_-9E#A"*#"S#H'1
MSR->H! .B&@\M)C1SJ13/%QWZ)^\[^3+BAF\4.('SVTYBR81Y%BP1MA;M?D#
M6W_&#B]3PO@O;()L^C&"K#%65:TR,:BX#+_LJ8W#@<(D>4$A;152SSL8\BPO
MF67SJ58;T$Z:T-S"N^JUB1R7[E&65M,M)ST[7]Z=+Q=?[Q;7WV#QG;[+:6P)
MUEW&60MQ'B#2%R"&\%E)6QI8R!SSG_5CHK/CE':<SM-7 3\SW8?AH =IDHY>
MP1ON?!QZO.%+/C8K@P\-2@N+1_H:^.ML9:RFC/C[.7<#VNAY-%<E)Z9F&<XB
M*@.#^A&C^;LW@_?)Z2M<1SNNH]?0?^T]_B<$+)Y09]P@J )N-/Y6-.ZEX ?3
MFKEP?)%P5FLN8!)BW@-;(ERHJF9R"]R8AJ09E=!ZK7'-K <:]B;)Q]XX'8(I
M&07"G66JJJC4*&NS>V#6Z6!GFPQD7O%MTD\&8)6[Y?(125I#4ZL#69*J]SPW
M'<^.B8&::>ND',];7'-C4=/-)==4[?"E*%!SN>[#)R6H[="2)'D 8#+#'D@E
ML0-XSI11(B=V_V& VI)K?$#=SE@F<V_SFIF</< E%CSC*+,M7"OK?-^%V47X
MWW$F9*0.1?ZYMM+IRJ![Y"3?O9FD:7(:X/QF<'H,A5:5![HBEH[4UX8)3@#,
M]3T#2\N*POGZC61:<DO_0E1H]]3WKZXNX*C#]O<[;&>]V(;X[9G:DMD>T$3P
MIX(9"\.$'E\:S!K796'5&,I*8R!G6Q/<7/%\GP,':,[6X,.I^3EY2I9#)I2A
M<*S<Y("W@WZ20(TZI%O I(;(JZ;RDH[DWH:F@N?NQ59;+TGD*#8N>T0;I5:B
M\@V!*+61Z8)XVPB$\6B<'+'CH\%Q/T0O/$9)&2@5\*K"G+MR0,H'2@L5\J6S
M\"M^MBJM\=^%6C$!2S^TVN?I/]=5XH..7Z%>^[GFH!MI0_/?G>Y&YUF8&'OQ
M,'?)RII3F@@L2#7I?QA'H,,L"QNK:C\_5LK2-/++DL8_:B= ]X52MMLX [L_
M%/-_ %!+ P04    " ![@*E8XH$UN/(B  #]=   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6R]/6USTTB:?T7%WFZ%*L<D@6$8F*$J9& NM1!R">S6
MWM5]:$MMNP=9$FHIB>?7W_/6;Y+LA#EJOT#B2-U//^^O[9]OZ_:+76O=97>;
MLK*_/%IW7?/RR1.;K_5&V7G=Z K^LJS;C>K@UW;UQ#:M5@6]M"F?G!P=/7^R
M4:9Z]/IG^NRR??USW7>EJ?1EF]E^LU'M]HTNZ]M?'AT_<A]<F=6ZPP^>O/ZY
M42M]K;O/S64+OSWQJQ1FHRMKZBIK]?*71Z?'+]\</\,7Z(E_&'UKHY\S/,JB
MKK_@+^?%+X^.$")=ZKS#)13\=Z//=%GB2@#'5UGTD=\37XQ_=JN_H\/#81;*
MZK.Z_*<INO4OCUX\R@J]5'W97=6W_ZGE0#_@>GE=6OHWNY5GCQYE>6^[>B,O
M P0;4_'_ZDX0\9 73N2%$X*;-R(H?U6=>OUS6]]F+3X-J^$/=%1Z&X S%5+E
MNFOAKP;>ZUY_O/KM].+\OT\_G7^\F&5O3J_/K[./[[++J[?7;R\^T<?9Z<6O
MV?7G#Q].K_Z%?[L^_^WB_-WYV>G%I^ST[.SCYXM/YQ>_99<?WY^?G;^]S@XN
MZ]+D1MO'/S_I $3<Z$DNX+QA<$YV@/,T^U!7W=IF;ZM"%^G[3^!H_GPG[GQO
M3O8N^$&U\^SI\2P[.3IYMF>]IQY?3VF]I[OPU:Y49?Y0R%*S[*RN+!RV4,QA
M59%=MMKJJN,/ZF7VSE2JRHTJLVOX4 ,_=S;[G].%[5I@R/^=PA #\&P: )32
ME[91N?[E48-[M3?ZT>N__>7X^=&K/<=[YH_W;-_JK]\H:RS"'9]C"L@_L4SV
M::U!"O-ZTZAJ:ZI5UE>J+TRG"T1D :+./PE*X9=)[*W5C<X66E<9(*!1+3QG
MJBRO*]11IMN"!'7K;*4KW:JRW.*6NL'5<.^^ZG#GIC6P;E-JB^]V -CGB@"A
M?0CTTXUN3:ZR@[_]Y<7)R=&KS_/K>?;;Z>DE_7[\ZG$&^\';'3RVR98>4E.Q
MKG0<T?2M[57595U-&[4][HI_:?6J+^E!VG ,Q;7.^]9T1IY_>Y>O5;72@*/-
MQEA2C ZZZ[=G#JYY=@H';0LX9[F=X;+;K*BSJNX MKSL"Z!"6;H=A^ NZ[J#
M1V'+5G_M#6)WL<W\X>G02,)2=SHZM?7TF6?GC-&Z,95(P495H.+QSS/:6Q6_
M@VIC<AX Y8!;B"QU!?2"YRL$J00(X/PM_B%ZX7%&+Q0:0:MTKJT%<T)PJ6RI
M3)LU QD$8.PTK/06PMH $>O"NE=AY<!E@K1BGGV$QQ0!"H^!V@_O=^M6ZVS#
MNDNC[LI \^1KKWHRX%,B@8/8P$E-50"'H5ERU'#K=FO5 =:V $&F[QHP8;KP
MFVVU:G$3!.176&ZST*W?:$YBMD.>WJ@2<*"S:S+X\)G*8)_A&D^S6V7!M+4
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M<\8Q<D7A3S.TV[YZ-),"4YKA=$H?Q02K5A-ATFF,)- *^?JP;Q#'PC18APM
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MM> []K[VVA?*N<0A\/K3+,"N)T9_G($;,41?A4-F!SPL9/M&OFQH@6W65"P
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MAD_WB%BS6&U9' \+L0@/6&0U"UBC0& 28IY2B_G8&=[46<4]7P )45'!!ID
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MQ]OP?GVS@]=[<LBI>C-W-'(P2$[4Q%O5\?R?Q O@3G"=*;CA,8V?^SO(O4O
M;Q-8^1<![XB\@L"SP7?]P06\H!,DJ/""G^ ]R)1P]HV8FK%A+;@2.8M)74(\
MAHVDBG)=+X@$WC%.>,1(#CM<I%BO6L&_X4%IB17W7Y]"-8%!/P%S"V>J)!%=
M6*6))1^IM7SUPANY;R^D-^C2&UQ"7UXS1=)4TK1+8$L?*3_2/J(7H?J)-F@*
M+VPD4A22QG#$HY:@,[0!@K$;D4Y4XEQ!(G)\&A2\9AR-Q%&AS.K-#/89FCXK
ME^J,S2=H66.8'%6/00OXP/09_@Q-*@9MGCF+\"VAD"!HPI[0)\+#94BMEN(E
MO'HQ\3W_+8X\SQX,7$10E,@H Y,<NBMX))*9TO_!M_6<C":P%QJ+X1F:;P?N
MI(_RO4! S=0%VL<RD2C!,_KGX&-[-!WU,&TM?-L=3GM(3>WQ<-C':<5$2OEO
M"&EN@\!3E;^6,W#M4>#B;5+Z#Y6AACR%DGRMZP ["\@?^=O L2/]0F[/'HW]
M/L$#H[C?98<*%@W5COSW.GP)@XF'W\ >3ELTV7BV>]YP;$^'8^B[@<[9ZUM0
MF58]1B'E(]?U0]RM=FTLK%_O[^9U#\3'+&5<04X3='6OQD,+9-U7ZHD69?66
M'X3&SE -,VS%5!H#W$^$T.W$!.B:^_)_4$L#!!0    ( 'N J5C<3/&TW0(
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M'T,?)M23V9HCR"4D1J:/6Q4365*7:N8*_>;9VGB(^U'TP]SG.<)2<FK>0JS
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MR>P1)HYS_S1[]&8W,+^_]1S/7< O,".<D_0%@),I2D(C<:IZGQ93./ET"I]
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M:&Q/BF&*331(<P#WUT+HP\0DJ-OR\5=02P,$%     @ >X"I6(4!UE-L P
MC H  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULK59=CYLX%/TK%EM5
MK90.WZ0S39 80F:1=D@4,ENUU3YXB!.L J:VDW3WUZ\-#),$)I.'>4EL<\ZU
MCX^O?4=[0G^R%"$.?N=9P<9*RGEYHZHL25$.V14I42&^K G-(1==NE%921%<
M5:0\4PU-<]0<XD)Q1]78G+HCLN49+M"< K;-<TC_O449V8\577D:6.!-RN6
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M5VW%]%:NX_B^A"DJ^'L5?*,*XHSX*LYR,020?'_F"RF6:5;$__$YF:5YT22
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M8U;(8#SO-+TFI0W<7[^J?W&UFUKF1.% L.]TH8N>=^G! G-2,3T1FQO<U>,
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MYE7>Z?.)D0O7^R;24"=UPSE=CE#9#?1]*J6YFU@#Y74K^ -02P,$%     @
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MG-\(MLF&ME^8$"S*+M>4+&F2&LC/7Q@3AYOT!>7<?_0_4$L#!!0    ( 'N
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M(B/1[!8Y:W"R3N]57PGG)$H?5P@&B,H!XOV"$+YKR F*N_S!_U!+ P04
M" ![@*E8Y5CIS.4#   K$@  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6RM6%N/VC@8_2M6MEJU$D,N$(:9!:29)-U%&F $=/M0[8-)/HC5)*:V&=I_
MOW:22;F$=*C\ K'SG6-_YSB^#?:4?>4Q@$#?TR3C0R,68GMOFCR,(<6\3;>0
MR3=KRE(L9)%M3+YE@*,<E":F8UD],\4D,T:#O.Z9C09T)Q*2P3-#?)>FF/UX
MA(3NAX9MO%;,R286JL(<#;9X PL0G[;/3);,BB4B*62<T PQ6 ^-!_L^L'-
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MIJD(.;I, Q(T]4WPK7+0>79P[G0"7F-VCES[,W(LQVNQ9_'MZFZ+NM^M/LM
MW1JVS=[PQJW"Y2H\]ZUPA9B1L_7KF,P8P^F.0$4*M'Y"=;DE?E+#LP-FP>>F
MVH)R@?[Z'69!5X(D_.^VB!4F>>TFR87I@F=X0R8&K#R<L#TQIC_^8/>MG]KH
MU@GF:P)KA,*K0N%UH4_OJ< QXJI("J(W=69)421M?!:X?84KU^7]U!G8H[&Y
MK_/T6FCH# 9-(;_3PN_TOU?YW^OT?Y6O.?F:R\RZW,O??Y ?,5C.$=UN"8O2
M'8PL(0NWN2QE!-D'*2I:UX3.F=Z;83K!?$U@#8;[%</]CU?L?9VAT GF:P)K
MA&)0A6+0F>PW>;(F##(;I7"4446/(LYS8#S(5:Z+D* ,TIX&Z 2V0"YCPD_;
M&.Z<Z;T,ZP3S"[!>;<UQA]:H)S>^?0MYPXJ\82=Y=S S9IL0P9$ SF1[.&QF
M,DG;R.E$>B\Y.L%\36 -!D<5@Z./MQ*,=(9")YBO":P1"MMZ.3%;_]/&7P+7
M"\QVA[VCG;]%RAL.W*.MO]O([R6A=FVP.TGXA:2$ 0VRI'$ %Y.("X;E':[5
M\4ZP]^:25C1?%UJ32.>%2.?CE79IDZYXZ$3S=:$UX_%RP;([+PW_I;K=5T=V
MVW6]X^I^+>5ZEG=<W5IO-F;M?2 A;*?>63@XEJ>BN$E7H]5;SDR]8!R-S^V+
M1?$B\P)3/!#!/7D7I1S%9 N0UOD EB]6O+D4'4$S]0JQID+01#5#@@/"I !\
MWU(JGCMR@NKE:_HO4$L#!!0    ( 'N J5AAT<>8J0D  %)J   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;,6=:V_;R!F%_\I 7;0)X%CB13?7%N"8
M,YRT<>+&21=%T0^T-)*(\*(E*3L!]L=W>+&HH:FQN'L,YX--T7R?=R2=S.T,
MA^</<?(]70N1D1]A$*47O766;<[Z_72^%J&7GL8;$<F_+.,D]#+Y,EGUTTTB
MO$41% 9]<S 8]4//CWJS\^+<33([C[=9X$?B)B'I-@R]Y.=[$<0/%SVC]WCB
MB[]:9_F)_NQ\XZW$K<B^;6X2^:J_HRS\4$2I'T<D$<N+WJ5QQFTS#RBN^+<O
M'M*]8Y*_E;LX_IZ_^+"XZ WR$HE S+,<X<E?]^)*!$%.DN7XK8+V=CGSP/WC
M1SHKWKQ\,W=>*J[BX%=_D:TO>I,>68BEMPVR+_$#%]4;&N:\>1RDQ4_R4%X[
MGO;(?)MF<5@%RQ*$?E3^]GY4'\1>@#$^$&!6 68SP#X08%4!5C-@>"# K@+L
M8S,,JX#AL1E&5<#HV SC*F!\;,"D"I@4WV[Y=13?I>-EWNP\B1](DE\M:?E!
M(8@B6GZ%?I1K]S9+Y%]]&9?-;K]^OOHG__S1H5]N_T;HO[Y]^/H?\L81F><'
MZ5ORCGR[=<B;7]Z27TB?I&LO$2GQ(_(M\K/T1)Z4Q]=^$$@9IN?]3!8HQ_;G
M57*G3&X>2&Z0ZSC*UBFAT4(L6N*9/M[2Q/?E!['[-,S'3^.]J05>>\DI,4<G
MQ!R8=DMYKHX)-PZ&._IP1\Q/B56&FRWA5!]^N5WMP@=M'^81A;<.%]X]/MQJ
M">?/%'XCPP>3MNS*-VGM=&T5/.N0KG.IOLMKM06YBD-9U:=>45E>)HD7K82L
M?C-R]Y/L7W?C_2Q.7SYXR8+\]Z-$D@^9"-/_M;R?]V5^NSU_WN2<I1MO+BYZ
MLDU)17(O>K.__L48#?[>IBLDS$'"*!+&D# 7">,@F*)5>Z=56T>?27V&4IFR
MKI]_)QLO(?=>L!7DC:Q;%W$0>$E*-B(I:]^W;5(L\>,"GW=6[F>#TX%QWK_?
MEYBV#%TEAH11)(PA82X2QD$P16+#G<2&6HG=R$INN<U;22(K-UD#9FW-]7LM
MI&N=AH0Y2!A%PA@2YB)A' 13!#?:"6[TRNWO"*E5),Q!PB@2QI P%PGC()BB
MU?%.JV-MY?AI&][)]C5>DDB.M<MFV$_3K93D8IOXT8ID:Y$WP7Z\*%KE<AS4
MVA1K,W55)1+F(&$4"6,E;+C7?;$F@^DP'T;L]V!<9%(.@BF"F^P$-]$*[K;L
MZ27^7/;RY #[;8>^GI;<56!(F(.$422,38[H'[O(C!P$4]0UW:EKJE77Y^52
M%+56*3!9K0EOOB;S_5'&\7K3YNJJ-R3,0<(H$L9*V&A/;TVQ(=-Q$$P1FS&H
M)Q '6KDY?B+FF919J;HV#>D)744$I3E0&H72&)3F0FD<15-5MS=M;;SR^*(J
M $JT2)H#I5$HC4%I+I3&4315M&8M6O.9B;XH]1<B*94JJTWAWTM=RN-,BC;U
M"CNO58M:;F<M(FD.E$:A-%;1#&.O*3:-TTFC-88FY2B:*K+:^#"T<]6S6R\H
M.GU%1^^$1+O![:-[5XYL?45TSPUKJYS[8S33'H^,Z6#8F&;6EZZSN*!>!I3&
MH#072N,HFJK!VM PGG$TO'1--H%,4#2X2R%:IYOUE,[56DF;J,.\D:I/!YJ3
M0FD,2G.A-(ZBJ8JJ_0M#;V!\$OD0XQA-03T,*,V!TBB4QBK:='_0>FHW&TJH
M/X&BJ9*J'0I#.ZD\NTGBN1"+E"R3."1QMBZ:R6KN1/S(AQ0') :U'J T!TJC
M4!JK:%.E@AXW)0:U%5 T56*UL6#HG87&W CYG;08L?+L[?8N%;]M\WJ-WLN?
MK:J#6@M0F@.E42B-06DNE,91-%6>M0UA3%Y[$@5J5T!I#I1&H30&I;E0&D?1
M5-'6[H:AMS?^]&HI/;^S)J&>!I1&H30&I;E0&J]H!RT^=35P[6V8>F\#N3)
MGZJK[* T!TJC4!J#TEPHC5<TW=(%57FUOV%JIZ);>HY5O:=;OJ=G=I88U+*
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MX4FUYQ?(OR_C.'M\D2?8/49J]G]02P,$%     @ >X"I6(D+4B<M#   7K\
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M*4F2+ LC@(4=) F&P-.((Y@#\( A2>+>@WOOHWC]GHHW_[L;_0902P,$%
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M\8&J'Q]+!\EO62VI"$I)%X(?]JS]TC>CWF*BO<80A]/U&,1K\3MAY-LMJVC
MJT-#6WF,HZ!U#]AV.[;O+-26#9U;/G^@HG\?]0?1YOAN4D%ID1+73#T0T6;
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MU+6OZK(VYN7F]/GO].GRW0]02P,$%     @ >X"I6.Y)W?^> 0  "!H  !H
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MCWK[=^H=T_44XJ/GOL;[OY/JU%T;'K>_+>^;+X_*#6<'/WX6OU!+ P04
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MUJN__JG1KG&MRN;HS[H_1_-/4$L! A0#%     @ >X"I6 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" ![@*E8?/ ^Y.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " ![@*E8F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'N J5@L
M'A4]S 4  ,,>   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " ![@*E8N.%;K\@%   .&   &
M    @($0#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M>X"I6!"*'[&D!   _!$  !@              ("!#A0  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( 'N J5ARA51\- ,  )D(   8
M          " @>@8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " ![@*E8"YQ@@H('  !=,P  &               @(%2'   >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ >X"I6%G;A&77!P  E20
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M965T,3 N>&UL4$L! A0#%     @ >X"I6,1Y0*=1#@  )C0  !D
M     ("!]F8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'N J5C&):1_N 8  !X7   9              "
M@5R.  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ >X"I
M6,X'\GW* P  7 @  !D              ("!2Y4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " ![@*E8XH$UN/(B  #]=   &0
M        @(%,F0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( 'N J5@9+$1>4@0  %P-   9              " @76\  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ >X"I6".<X$Z9 P  &@D
M !D              ("!_L   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " ![@*E8H/\]G3 $  #X"0  &0              @('.Q
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( 'N J5C1'F\R
M60,  * '   9              " @37)  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ >X"I6-%9W!9I P  Z <  !D
M ("!Q<P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " ![
M@*E8W$SQM-T"   >!@  &0              @(%ET   >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( 'N J5@JN&.X\0(  '\&   9
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M970R.2YX;6Q02P$"% ,4    " ![@*E8?$&#+M$(  "86@  &0
M    @('2[0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M 'N J5C!4FVBEP(  ),%   9              " @=KV  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ >X"I6-06MB\* P  >@D  !D
M             ("!J/D  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " ![@*E8USM?T<H#  #;#0  &0              @('I_   >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( 'N J5@0=G5D2P0
M "H2   9              " @>H  0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ >X"I6-4B:Y;X"0  F6D  !D              ("!
M; 4! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ![@*E8
M+_2TG_T$   #(   &0              @(&;#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'N J5AK1KMOC 0  -<7   9
M      " @<\4 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ >X"I6.58Z<SE P  *Q(  !D              ("!DAD! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " ![@*E8K=D&= 0$   %$P
M&0              @(&N'0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( 'N J5AAT<>8J0D  %)J   9              " @>DA 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ >X"I6(D+4B<M
M#   7K\  !D              ("!R2L! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " ![@*E8&Y:Z;IH"  !)!@  &0
M@($M. $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( 'N
MJ5C=H/OS#@,  &\,   9              " @?XZ 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ >X"I6!HQ->8Y P  R!,   T
M         ( !0SX! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ![@*E8EXJ[
M',     3 @  "P              @ &G00$ 7W)E;',O+G)E;'-02P$"% ,4
M    " ![@*E8AR&+A.X#   ^'0  #P              @ &00@$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ >X"I6.Y)W?^> 0  "!H  !H
M     ( !JT8! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ >X"I6*C*A]FK 0  01H  !,              ( !@4@! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #, ,P#<#0  74H!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>183</ContextCount>
  <ElementCount>211</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARE</Role>
      <ShortName>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS</Role>
      <ShortName>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - RESTRUCTURING CHARGES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGES</Role>
      <ShortName>RESTRUCTURING CHARGES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables</Role>
      <ShortName>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARE</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - RESTRUCTURING CHARGES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables</Role>
      <ShortName>RESTRUCTURING CHARGES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/RESTRUCTURINGCHARGES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails</Role>
      <ShortName>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails</Role>
      <ShortName>BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails</Role>
      <ShortName>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING CHARGES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails</Role>
      <ShortName>RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:WarrantsAndRightsOutstandingTerm -  sgmo-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sgmo-20240331.htm">sgmo-20240331.htm</File>
    <File>sgmo-20240331.xsd</File>
    <File>sgmo-20240331_cal.xml</File>
    <File>sgmo-20240331_def.xml</File>
    <File>sgmo-20240331_lab.xml</File>
    <File>sgmo-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="469">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sgmo-20240331.htm": {
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "sgmo-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sgmo-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 176,
   "keyCustom": 35,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 28,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 1
   },
   "contextCount": 183,
   "entityCount": 1,
   "segmentCount": 59,
   "elementCount": 376,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 469,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://www.sangamo.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000007 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "0000008 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES",
     "longName": "0000009 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARE",
     "longName": "0000010 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE",
     "shortName": "BASIC AND DILUTED NET (LOSS) INCOME PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES",
     "longName": "0000011 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS",
     "longName": "0000012 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS",
     "shortName": "IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000013 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION",
     "longName": "0000014 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITY",
     "longName": "0000015 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGES",
     "longName": "0000016 - Disclosure - RESTRUCTURING CHARGES",
     "shortName": "RESTRUCTURING CHARGES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.sangamo.com/role/SUBSEQUENTEVENTS",
     "longName": "0000017 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "longName": "9954474 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables",
     "longName": "9954475 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE (Tables)",
     "shortName": "BASIC AND DILUTED NET (LOSS) INCOME PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
     "longName": "9954476 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables",
     "longName": "9954478 - Disclosure - RESTRUCTURING CHARGES (Tables)",
     "shortName": "RESTRUCTURING CHARGES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954479 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails",
     "longName": "9954480 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails",
     "longName": "9954481 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-45",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
     "longName": "9954483 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "longName": "9954484 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails",
     "longName": "9954485 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnSaleOfInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnSaleOfInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
     "longName": "9954486 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Narrative (Details)",
     "shortName": "BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
     "longName": "9954487 - Disclosure - BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)",
     "shortName": "BASIC AND DILUTED NET (LOSS) INCOME PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
     "longName": "9954488 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-97",
      "name": "sgmo:AgreementTerminationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "sgmo:AgreementTerminationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
     "longName": "9954489 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails",
     "longName": "9954490 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)",
     "shortName": "IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9954491 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:OperatingLeaseImpairmentLoss",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
     "longName": "9954492 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
     "longName": "9954493 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
     "longName": "9954494 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)",
     "shortName": "RESTRUCTURING CHARGES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-158",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-1",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails",
     "longName": "9954495 - Disclosure - RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)",
     "shortName": "RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9954496 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r601"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r69",
      "r123",
      "r447",
      "r468",
      "r469"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r26",
      "r366",
      "r369",
      "r399",
      "r464",
      "r465",
      "r638",
      "r639",
      "r640",
      "r647",
      "r648",
      "r649"
     ]
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AchievementOfCommercialMilestonesMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement Of Commercial Milestones",
        "label": "Achievement Of Commercial Milestones [Member]",
        "documentation": "Achievement of Commercial Milestones."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r477",
      "r647",
      "r648",
      "r649",
      "r678",
      "r698"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r316"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AgreementTerminationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AgreementTerminationTerm",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination, term",
        "label": "Agreement Termination, Term",
        "documentation": "Agreement Termination, Term"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease",
        "label": "Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease [Member]",
        "documentation": "Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r353"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "sgmo_April2023RestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "April2023RestructuringPlanMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2023 Restructuring Plan",
        "label": "April 2023 Restructuring Plan [Member]",
        "documentation": "April 2023 Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r656",
      "r657",
      "r658"
     ]
    },
    "us-gaap_AssetImpairmentChargesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentChargesTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS",
        "label": "Asset Impairment Charges [Text Block]",
        "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r119",
      "r140",
      "r176",
      "r183",
      "r187",
      "r229",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r361",
      "r363",
      "r385",
      "r443",
      "r514",
      "r601",
      "r614",
      "r671",
      "r672",
      "r684"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r124",
      "r140",
      "r229",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r361",
      "r363",
      "r385",
      "r601",
      "r671",
      "r672",
      "r684"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash equivalents and marketable securities",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "sgmo_AtTheMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AtTheMarketOfferingAgreementMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "documentation": "At the market offering agreement."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At the Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Marketable securities, gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r441"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r440"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_BiogenMAIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "BiogenMAIncMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biogen MA, Inc.",
        "label": "Biogen MA, Inc. [Member]",
        "documentation": "Biogen MA, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CNineORFSevenTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CNineORFSevenTwoMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "C9ORF72",
        "label": "C Nine O R F Seven Two [Member]",
        "documentation": "C nine ORF seven two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment included in unpaid liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, gross unrealized gains",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax",
        "documentation": "Cash and cash equivalents accumulated gross unrealized gain before tax."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash equivalents, gross unrealized losses",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax",
        "documentation": "Cash and cash equivalents accumulated gross unrealized loss before tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash equivalents, at carrying value, total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r118",
      "r578"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, estimated fair value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r75",
      "r138"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r75"
     ]
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents and marketable securities, estimated fair value",
        "label": "Cash Equivalents And Available For Sale Securities",
        "documentation": "Cash equivalents and available for sale securities."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash equivalents and marketable securities, amortized cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents and marketable securities, gross unrealized gains",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total cash equivalents and marketable securities, gross unrealized losses",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r608",
      "r609",
      "r610",
      "r611"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate by Type [Axis]",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "documentation": "Information by type of change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r151"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate [Line Items]",
        "label": "Change in Accounting Estimate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate, Type [Domain]",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r151"
     ]
    },
    "sgmo_ChangeInAgreementEstimateMarch2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "ChangeInAgreementEstimateMarch2023Member",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change In Agreement Estimate, March 2023",
        "label": "Change In Agreement Estimate, March 2023 [Member]",
        "documentation": "Change In Agreement Estimate, March 2023"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r120",
      "r121",
      "r122",
      "r140",
      "r160",
      "r164",
      "r166",
      "r168",
      "r174",
      "r175",
      "r229",
      "r265",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r278",
      "r279",
      "r282",
      "r285",
      "r292",
      "r385",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r502",
      "r523",
      "r541",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r621",
      "r645",
      "r651"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price of each common stock (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock for each Common warrant (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of new stock issued during the period (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of products approved",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "documentation": "Collaboration and license agreements number of products approved under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r111"
     ]
    },
    "sgmo_CollaborativeArrangementNumberOfMilestonesAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CollaborativeArrangementNumberOfMilestonesAchieved",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, number of milestones achieved",
        "label": "Collaborative Arrangement, Number Of Milestones Achieved",
        "documentation": "Collaborative Arrangement, Number Of Milestones Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CollaborativeArrangementTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement transaction price",
        "label": "Collaborative Arrangement Transaction Price",
        "documentation": "Collaborative arrangement transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper securities",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r608",
      "r609",
      "r610",
      "r611"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r59",
      "r444",
      "r501"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r259",
      "r260",
      "r563",
      "r668"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605",
      "r606",
      "r608",
      "r609",
      "r610",
      "r611",
      "r647",
      "r648",
      "r678",
      "r697",
      "r698"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r63",
      "r502",
      "r520",
      "r698",
      "r699"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r446",
      "r601"
     ]
    },
    "sgmo_CommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CommonWarrantMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common warrants",
        "label": "Common Warrant [Member]",
        "documentation": "Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r128",
      "r130",
      "r134",
      "r437",
      "r454"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r57",
      "r58",
      "r192",
      "r562"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r57",
      "r58",
      "r192",
      "r470",
      "r562"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r57",
      "r58",
      "r192",
      "r562",
      "r625"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r57",
      "r58",
      "r192"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r40",
      "r57",
      "r92",
      "r562"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r57",
      "r58",
      "r192",
      "r562"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r582"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in Progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales per developed licensed product which will trigger royalties by counterparty",
        "label": "Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty",
        "documentation": "Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_ContractedEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "ContractedEmployeesMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracted Employees",
        "label": "Contracted Employees [Member]",
        "documentation": "Contracted Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r597",
      "r696"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r83",
      "r84"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r274",
      "r280",
      "r400",
      "r579",
      "r581"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and sales-based milestone payments to be received",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "documentation": "Customer contract liability milestone payment eligible to receive."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss related to marketable securities",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable securities, amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total marketable securities",
        "verboseLabel": "Marketable securities, estimated fair value",
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss related to marketable securities, not previously recorded",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded",
        "documentation": "Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table Text Block]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r179"
     ]
    },
    "sgmo_DirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "DirectOfferingMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct offering",
        "label": "Direct Offering [Member]",
        "documentation": "Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r319",
      "r347",
      "r348",
      "r349",
      "r599"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in dollars per share)",
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r158",
      "r160",
      "r166",
      "r167",
      "r168",
      "r172",
      "r374",
      "r375",
      "r438",
      "r455",
      "r584"
     ]
    },
    "sgmo_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share",
        "verboseLabel": "Net (loss) income per share:",
        "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic And Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in dollars per share)",
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r160",
      "r166",
      "r167",
      "r168",
      "r172",
      "r374",
      "r375",
      "r438",
      "r455",
      "r584"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r164",
      "r166"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIC AND DILUTED NET (LOSS) INCOME PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r169",
      "r170",
      "r171"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in deferred tax liabilities",
        "label": "Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "sgmo_EquipmentFurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "EquipmentFurnitureAndFixturesMember",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, Furniture, And Fixtures",
        "label": "Equipment, Furniture, And Fixtures [Member]",
        "documentation": "Equipment, Furniture, And Fixtures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r114",
      "r131",
      "r132",
      "r133",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r173",
      "r230",
      "r231",
      "r294",
      "r350",
      "r351",
      "r352",
      "r358",
      "r359",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r399",
      "r464",
      "r465",
      "r466",
      "r477",
      "r541"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r381"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r381"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r55",
      "r56",
      "r91"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r378",
      "r407",
      "r408",
      "r409",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r382"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r306",
      "r311",
      "r378",
      "r407",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r306",
      "r311",
      "r378",
      "r408",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r378",
      "r409",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r407",
      "r408",
      "r409",
      "r590",
      "r591",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value on recurring basis",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r382"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r276",
      "r290",
      "r371",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r453",
      "r588",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r659",
      "r660",
      "r661",
      "r662"
     ]
    },
    "sgmo_FranceRestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "FranceRestructuringPlanMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France Restructuring Plan",
        "label": "France Restructuring Plan [Member]",
        "documentation": "France Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_FullTimeEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "FullTimeEmployeesMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Full-Time Employees",
        "label": "Full-Time Employees [Member]",
        "documentation": "Full-Time Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain and losses on the sales of investments",
        "label": "Gain (Loss) on Sale of Investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r525"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r242",
      "r243",
      "r244",
      "r589"
     ]
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "label": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets, indefinite-lived",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r665"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r44",
      "r82"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r70",
      "r97",
      "r176",
      "r182",
      "r186",
      "r188",
      "r439",
      "r451",
      "r586"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r250",
      "r526"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r526"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r109",
      "r154",
      "r155",
      "r180",
      "r357",
      "r360",
      "r456"
     ]
    },
    "sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable research income tax credits and other non-current assets",
        "label": "Income Tax, Refundable Research Credits And Other Non-current Assets",
        "documentation": "Income Tax, Refundable Research Credits And Other Non-current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest receivable",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenues",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r642"
     ]
    },
    "sgmo_IncreaseDecreaseInEarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "IncreaseDecreaseInEarningsPerShareBasic",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decreased net loss per share, basic (in dollars per share)",
        "label": "Increase (Decrease) In Earnings Per Share, Basic",
        "documentation": "Increase (Decrease) In Earnings Per Share, Basic"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_IncreaseDecreaseInEarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "IncreaseDecreaseInEarningsPerShareDiluted",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreased net loss per share, diluted (in dollars per share)",
        "label": "Increase (Decrease) In Earnings Per Share, Diluted",
        "documentation": "Increase (Decrease) In Earnings Per Share, Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "IncreaseDecreaseInNetIncomeLossAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in net loss",
        "label": "Increase (Decrease) In Net Income (Loss) Attributable To Parent",
        "documentation": "Increase (Decrease) In Net Income (Loss) Attributable To Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "negatedTerseLabel": "Lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r642"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in revenue",
        "label": "Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax",
        "documentation": "Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of share-based payment arrangements (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r168",
      "r318"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income, net",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Marketable Securities by Contractual Maturity",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r99",
      "r100",
      "r113",
      "r195",
      "r197",
      "r383",
      "r384"
     ]
    },
    "sgmo_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_KitePharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "KitePharmaIncMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kite Pharma, Inc.",
        "label": "Kite Pharma Inc [Member]",
        "documentation": "Kite Pharma Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Discount Rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "LesseeOperatingLeaseRequiredNoticeOfTermination",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Required Notice Of Termination",
        "label": "Lessee, Operating Lease, Required Notice Of Termination",
        "documentation": "Lessee, Operating Lease, Required Notice Of Termination"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_LesseeRequiredLetterOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "LesseeRequiredLetterOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Required Letter Of Credit Outstanding, Amount",
        "label": "Lessee, Required Letter Of Credit Outstanding, Amount",
        "documentation": "Lessee, Required Letter Of Credit Outstanding, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit established as a deposit",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r140",
      "r229",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r362",
      "r363",
      "r364",
      "r385",
      "r500",
      "r585",
      "r614",
      "r671",
      "r684",
      "r685"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r96",
      "r449",
      "r601",
      "r646",
      "r663",
      "r681"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r117",
      "r140",
      "r229",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r362",
      "r363",
      "r364",
      "r385",
      "r601",
      "r671",
      "r684",
      "r685"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManufacturedProductOtherMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other products",
        "label": "Manufactured Product, Other [Member]",
        "documentation": "Article or substance produced by labor or machinery, classified as other."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r312",
      "r434",
      "r463",
      "r492",
      "r493",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r573",
      "r574",
      "r587",
      "r592",
      "r598",
      "r603",
      "r673",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "sgmo_MilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "MilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments received",
        "label": "Milestone Payments Received",
        "documentation": "Milestone payments received."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_MilestoneRevenueReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "MilestoneRevenueReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue receivable",
        "label": "Milestone Revenue Receivable",
        "documentation": "Milestone\u200b revenue receivable."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r312",
      "r434",
      "r463",
      "r492",
      "r493",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r573",
      "r574",
      "r587",
      "r592",
      "r598",
      "r603",
      "r673",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "terseLabel": "Net (loss) income",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77",
      "r98",
      "r115",
      "r127",
      "r129",
      "r133",
      "r140",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r165",
      "r176",
      "r182",
      "r186",
      "r188",
      "r229",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r375",
      "r385",
      "r452",
      "r522",
      "r539",
      "r540",
      "r586",
      "r612",
      "r671"
     ]
    },
    "sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available To Common Stockholders, Basic And Diluted [Abstract]",
        "documentation": "Net Income (Loss) Available To Common Stockholders, Basic And Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Institutes for BioMedical Research, Inc.",
        "label": "Novartis Institutes For BioMedical Research Inc. [Member]",
        "documentation": "Novartis Institutes For BioMedical Research Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_November2023RestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "November2023RestructuringPlanMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2023 Restructuring Plan",
        "label": "November 2023 Restructuring Plan [Member]",
        "documentation": "November 2023 Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of milestones included in transaction price",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "documentation": "Number of clinical or regulatory milestones included in transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r182",
      "r186",
      "r188",
      "r586"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment on right-of-use assets",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term portion of lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization in operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r78",
      "r79",
      "r89"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net pension gain (loss)",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12",
      "r69",
      "r90"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r12",
      "r90"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r5",
      "r386",
      "r393"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net pension gain (losses)",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r69"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on marketable securities, net of tax",
        "verboseLabel": "Net unrealized (loss) gain on marketable securities, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r228"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "sgmo_OtherLicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "OtherLicensingAgreementsMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other license agreements",
        "label": "Other Licensing Agreements [Member]",
        "documentation": "Other Licensing Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r641"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "sgmo_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer Inc.",
        "label": "Pfizer [Member]",
        "documentation": "Pfizer."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_PfizerSB525Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "PfizerSB525Member",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer SB-525",
        "label": "Pfizer SB-525 [Member]",
        "documentation": "Pfizer SB-525 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_PreFundedCommonStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "PreFundedCommonStockWarrantMember",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants",
        "label": "Pre Funded Common Stock Warrant [Member]",
        "documentation": "Pre Funded Common Stock Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r445",
      "r601"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of offering expenses",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities",
        "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r655"
     ]
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of marketable securities",
        "label": "Proceeds from Sale of Held-to-Maturity Securities",
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r196"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r436",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r576",
      "r593",
      "r602",
      "r627",
      "r669",
      "r670",
      "r674",
      "r695"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r436",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r576",
      "r593",
      "r602",
      "r627",
      "r669",
      "r670",
      "r674",
      "r695"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of equipment, furniture and fixtures",
        "label": "Property, Plant, and Equipment, Fair Value Disclosure",
        "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r442",
      "r450",
      "r601"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r305",
      "r312",
      "r342",
      "r343",
      "r344",
      "r410",
      "r434",
      "r463",
      "r492",
      "r493",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r573",
      "r574",
      "r587",
      "r592",
      "r598",
      "r603",
      "r606",
      "r666",
      "r673",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r305",
      "r312",
      "r342",
      "r343",
      "r344",
      "r410",
      "r434",
      "r463",
      "r492",
      "r493",
      "r546",
      "r548",
      "r550",
      "r551",
      "r553",
      "r573",
      "r574",
      "r587",
      "r592",
      "r598",
      "r603",
      "r606",
      "r666",
      "r673",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r274",
      "r280",
      "r400",
      "r580",
      "r581"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r677"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues under agreement",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r677"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r677"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r354",
      "r692"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r102",
      "r138"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "verboseLabel": "Current restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r644"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r636",
      "r644"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING CHARGES",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r249",
      "r252",
      "r258"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r251",
      "r255",
      "r257"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected cost remaining",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees eliminated in restructuring",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of positions eliminated in restructuring",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges",
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r253",
      "r255",
      "r667"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at December 31, 2023",
        "periodEndLabel": "Balance at March 31, 2024",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r254"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r88",
      "r448",
      "r467",
      "r469",
      "r476",
      "r503",
      "r601"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r230",
      "r231",
      "r350",
      "r351",
      "r352",
      "r358",
      "r359",
      "r365",
      "r367",
      "r368",
      "r370",
      "r373",
      "r464",
      "r466",
      "r477",
      "r698"
     ]
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer concentration risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r181",
      "r184",
      "r185",
      "r189",
      "r190",
      "r192",
      "r303",
      "r304",
      "r436"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contract with customer",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r624"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r575"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "verboseLabel": "Revenue related to Sanofi agreement:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_RichmondCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "RichmondCaliforniaMember",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Richmond, California",
        "label": "Richmond, California [Member]",
        "documentation": "Richmond, California"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SBFiveTwoFiveAndOtherProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SBFiveTwoFiveAndOtherProductsMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "S B Five Two Five And Other Products",
        "label": "S B Five Two Five And Other Products [Member]",
        "documentation": "S B Five Two Five And Other Products"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SBFiveTwoFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SBFiveTwoFiveMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "S B Five Two Five",
        "label": "S B Five Two Five [Member]",
        "documentation": "S B Five Two Five"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockAgentPlacementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SaleOfStockAgentPlacementFees",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of placement fees",
        "label": "Sale Of Stock, Agent Placement Fees",
        "documentation": "Sale Of Stock, Agent Placement Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockIncreaseToAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SaleOfStockIncreaseToAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock offering program, increase to aggregate offering price",
        "label": "Sale Of Stock, Increase To Aggregate Offering Price",
        "documentation": "Sale Of Stock, Increase To Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionPerUnit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction, per unit (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction, Per Unit",
        "documentation": "Sale of Stock, Number of Shares Issued in Transaction, Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockOtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SaleOfStockOtherOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from other offering expenses",
        "label": "Sale Of Stock, Other Offering Costs",
        "documentation": "Sale Of Stock, Other Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockOutstandingAmountAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SaleOfStockOutstandingAmountAvailable",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock agreement",
        "label": "Sale Of Stock, Outstanding Amount Available",
        "documentation": "Sale Of Stock, Outstanding Amount Available"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "SaleOfStockPlacementFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash placement fees",
        "label": "Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r650"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r313",
      "r622",
      "r650"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r151"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Basic and Diluted Net Income (Loss) per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r160",
      "r164",
      "r166"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "label": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "documentation": "For a long-lived asset to be held and used by an entity, the table may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r677"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restrictions on Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r94",
      "r694"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Restructuring Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ]
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r489",
      "r490",
      "r491",
      "r547",
      "r549",
      "r552",
      "r554",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r577",
      "r594",
      "r606",
      "r674",
      "r695"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock price (USD) (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r120",
      "r121",
      "r122",
      "r140",
      "r160",
      "r164",
      "r166",
      "r168",
      "r174",
      "r175",
      "r229",
      "r265",
      "r267",
      "r268",
      "r269",
      "r272",
      "r273",
      "r278",
      "r279",
      "r282",
      "r285",
      "r292",
      "r385",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r502",
      "r523",
      "r541",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r621",
      "r645",
      "r651"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r24",
      "r114",
      "r131",
      "r132",
      "r133",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r173",
      "r230",
      "r231",
      "r294",
      "r350",
      "r351",
      "r352",
      "r358",
      "r359",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r399",
      "r464",
      "r465",
      "r466",
      "r477",
      "r541"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r489",
      "r490",
      "r491",
      "r547",
      "r549",
      "r552",
      "r554",
      "r561",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r577",
      "r594",
      "r606",
      "r674",
      "r695"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r173",
      "r436",
      "r471",
      "r488",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r607"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r313",
      "r622",
      "r623",
      "r650"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r173",
      "r436",
      "r471",
      "r488",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r607"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "sgmo_StockIssuanceCostsNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "StockIssuanceCostsNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses in relation to issuance of common stock included in unpaid liabilities",
        "label": "Stock Issuance Costs, Not Yet Paid",
        "documentation": "Stock Issuance Costs, Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering expenses (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r62",
      "r63",
      "r88",
      "r472",
      "r541",
      "r556"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r62",
      "r63",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering expenses",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r62",
      "r63",
      "r88",
      "r477",
      "r541",
      "r556",
      "r613"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r62",
      "r63",
      "r88"
     ]
    },
    "sgmo_StockOfferingProgramMaximumValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "StockOfferingProgramMaximumValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock offering program, maximum value",
        "label": "Stock Offering Program, Maximum Value",
        "documentation": "Stock Offering Program, Maximum Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r80",
      "r504",
      "r520",
      "r542",
      "r543",
      "r601",
      "r614",
      "r646",
      "r663",
      "r681",
      "r698"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r139",
      "r277",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r294",
      "r372",
      "r544",
      "r545",
      "r560"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r402"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r403"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r683"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r276",
      "r290",
      "r371",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r453",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r659",
      "r660",
      "r661",
      "r662"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government-sponsored entity debt securities",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r693"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury bills",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r595",
      "r597",
      "r693"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r104",
      "r106",
      "r107",
      "r108"
     ]
    },
    "sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "WarrantOrRightOutstandingExercisablePeriodAfterIssuance",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable, period after issuance",
        "label": "Warrant Or Right Outstanding, Exercisable, Period After Issuance",
        "documentation": "Warrant Or Right Outstanding, Exercisable, Period After Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_WarrantOrRightPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "WarrantOrRightPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to Purchase Shares of Company Stock",
        "label": "Warrant Or Right, Policy [Policy Text Block]",
        "documentation": "Warrant Or Right, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of warrants",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average number of common shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r168"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHARENarrativeDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r168"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sangamo.com/20240331",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in computing net (loss) income per share",
        "label": "Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract]",
        "documentation": "Weighted Average Number Of Shares Outstanding, Basic And Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSINCOMEPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i-k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "420",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-14"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001628280-24-022194-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-022194-xbrl.zip
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MVTNEJ9:2N&4K>0!I#T:;-B53BD"-/+GF.$<+;JKMX2UL<: MH!&$#W':)@$
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M%@5MU>Q 9 -JYXCD9M*_L_YR-]\C&[42F[@[$[B>+"EZ#5@Z<'T&\ARYWW^
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MJ6FIG,R&S,Y #.R+YIF-AYTD9Z\0]MN[PEI*/D]F8V%'\'D.3QUAXU?L5.0
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M%1$SRP"#.?=CRE\SJV-X@K=0Y98GG7?8AMP*(2+EQBEAI2[EAL0"8J&QI=S
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M#EI)"*90LNF.YP/\C$ /-<>K:5E,PO1CD&;GEP^"$&ECB]CVG,)A4'5LJDQ
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M!.'NO0-@HGH0>NRS]&84%SR$L_T[NX-9#!E?X$VUS*PV #,36$B'8%2/ B\
MUYH\U0'5DF7E,56!)??WZ9RW[I-?-#X'$L:'X"?XUF65_3 'RX1;#%PNF_<%
MGWF0L9O7).1&$A_&[S()P"YA48?ITD3[$^$6AD4F;'=I>B7;HL:\1!;S8DD7
M;/W84V"6%HJ!,(ZQ?CLD5MS&TWM>42HK0X)'RDYE"28V4Q>8FN>DK8R5@>OK
M<>6!KW^E3) MK*W.]L1C>W HO,&3G>3#]60T!YK@!!2L00A=;09/$$4^SRNZ
MP+1'4"I1M BO8J8]6Y6?V"G@&[%_N<'8UR?*E8/B!L>(>AN'96$^9?@>C"3C
M*R8\X@2ZU<>E*2HW7%1ZK#D\D^]A^08+&%'>[MV;E3ORE2.6YX3B%9/#YOC-
M!.\;AQI6,H))I/_:6( O1=]NH@]$%,H'HO1-)Y:'I//6%USA$Y;!%N;WLPSK
MV=;4P-&#L C-6<[!5F);"E'&05&Y9UTN=!UYPZ"8PS0G>4$<.?8T-Y@E%&^7
M#&S0$7"-'TH(C[=MQ0LI%B:16:7=BCA4&*7TX%YOP(4:"V+%=C("4,@<S#"%
MZ5X'CQ^!/)@?S5QN\\KM%M,+A1C<# Q.[6=_")RN#V$%*(_/<O, IF^8.L_C
MX@%6E*J80N;H.I;\HCBP)RMF)=EFSVP#:L.:1%FN:]4(P ]D]2P'2G?<^?U=
MFP9NF+PZEW<5]2B)C'#.;"&((_7"S S$!+7!F\&X)+-L31T+(WB;G%GAS;K-
MXNG89P-PUF]!QR8G(;8OB/5""<FV:V/(6B4- 5@<BFN$$!,9O$HS[+:$$HO)
MMU#*]F=]%;"=@!O*U*+RP_Q%>>LE>#$Z(S9Q)_FP_H.9".APNN8(/7<2IAXL
M".;0UEGO>V$-G\4>(/&T+SS=LCC46@4XY[O;H,4MY7]OYG?MF$QBMN^$,O=_
M8E*+Q[>FFG^V@P=4?C&YNQ&K(H@L@Z+RL5QD2>FME!.C$OA<J#@P3/1LL\QP
M3 N<NE!@YJ,#!5I$9]?2,<_?92'+*,0V]3N-Z/I!V)8$_@MBB3(*\[C)5!-Q
MZZ1/=8<GL@]X%GI1DGQ?)/\V9[TC"9\I3PD=H?&(%;K(X$-XC#69V[*-S(C(
M,(]^PX@;TC+:GN?;N7/R(+:E&S-8O  0AB?1H!_GLJ_FMO7!@$7[!QQ$_1?+
M)2?V?!7$PJ.E/7L8Y1#+[EO$#G-66%X1?<O'O9803Z%_0PWN[9C>KPF3!8SV
MW':%J^9=/#0F"$]39CW^<&%*S2^\T]]<3F)1F1]=Y"%1#M!9-"&P9U7CF*&6
MYYF.$VZA8+AC&HP>$G<T"QU%(8<(<2N,=PF]?4&O\T)MQ1Q@3"S,(EJ;G;BN
MEI#%OY9B#Y'1^XS/Q+Z0%"-ZJ.98/)^,''2(AA,/,$Y"7(#*,Z<]0:9Q5%:P
MA2GJW)DW1_W ]5@\/^I>,FM2.2839YI9RP<PBTO$12&SCEA(66)KCY90S/6)
M8M\<9OE9IAJ+$>%1%#H&[-'KPB8P7#QXILON6YTB-XNPSA"ZA2)C3KEE\<<#
M9O\-DLTSS&E7'19KUGG$E,>608H1'EU&VPLX(IB6O"^];X,H"S/M\.%@];DL
MZ(P/Y5M2K)[+\UG0F<>D^$*8"&"=&XY@.3S'V@3-AZA"EU*">G^[52!M6& ^
MW)AP&,@!?3&LQ\RX//L>=>8SC>KYF&J>98+"):;').C8-9EWP+8I9CV:QXSV
M+(3$^ 5H'L9#F4&''9[<L'TN>@TV#_WR_5O^5,H:*_&<T*+28SL\.*1PJV->
MDX<CH]-=&,86_''S(PU;$+(491P!P#E>&QG=RG8S!G.,);&?0>S?LS@KIE\N
M]OJ)L#\#4;S<,6H:Y,RG3]&H"1^O7F.XF#W =_QPDY++S.F>X]37>4:X,>3#
M\DR-SYE\!>2@V3D?KY7@V",X%O>5@$]!7#*!AAK\.=8XS*71'DYL2SKT:,#N
ML\P!9G1XOTP04T!\\'Z<":7>PKU1;/X7G82[^)@5QO$2W1)I]# .&M_B>3;1
M_$41-,L#F<0J/E?GV<MDZ B*%9D,+9.A19I$2LG01\SFC/7Q7)&LE"@=*=X!
M@I_L,2WH"/UO.P!WV D\S#\88U2&Z&RC@#=]@]E'3@W1\;P'4P<Q[L$3@IG/
MA3M:+Z818)2 V60^3VA$P>W)F//>U.U/>T!>'.X=/UM.'^VIJ!'!M+.W%UI"
M8<J4S0S^E\4:HG@S\KB-'MLQY &9!5_X0WEYL]12YMHD2^;*KVI?GH]GJ\3G
M,LWZ"N-!+ 8%CHL>ZU<W C[@R4[2,MQC'&@6AS8<YBA@F5E^+DZ'5A=O@SS&
MV+1.PR):E%Q6V" %(]@&V&9>U(#CCG@&^4/I(0&QJ3)2^,>/*_YD!K[0H5BD
M=F0-8C\I#]R&HG)-H[>\$_J995:N0-"TWG<3U"+_A'(?^+V^X*O50=2+/-[I
M>;&[R-8,R7,#60OI^!8!R@@,CTF^V&/B\V:H#(%B?4JYW&0YP9;YB[)MQ!EU
M@7@O#KH95BR9E(-L53HIY@S,LDFC#"HI# ^9'C (XDS&VS ZCL$HS LV##K
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M6?2G@:)S.\^K.QH3TT7%S<Y=P<-8+" EZ '/H^\<FYM%^7\&)ML&^3^C]OT
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M-)PV"A:A(P[5HP&*;F)7/@3A3U8-T.Y9X,TCE_ "__886,!,6364M30/@W^
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MIZU\0[;3UL8CABK=Y8%/?F -',Q6O^F6Y]B[)0RQ+8F:W8+S*F!!V_4CZE>
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MFF9\+6Y)S?^AW4IO6 7MG+;>OK<N9RCOA?9(\V/$7]0O0:=VO(!SD/:I1AM
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M<.Y\]Y\+H:O&..%9PEC?P!BLZ92IG<]MRS&+A9]<C/7&;8HFQO#GLE<TZ%<
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MQ[:Q>WGY(0#/#N$VYZ"\8/(V@!" ^AF@XH#^8<,AY?H PN4<WX':"SX&6,)
M@;66L!_"L@;",PIF B&! (]BV(8=3LQG$9O@>8 >OA(PJFE=\ 4&(3\A80BT
MJWXW<:=TDA@H$FZ92!30W(=S+0EW\1.]U;$->\'GY#&!Y_*F<?\ %L)G3Q_
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M+# ZD)761#@C?R)1M"1S>'BZ8>9PA:0E>H=0# 8^!2;@5O,\;I5\LE?D#3<
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MEE;Q9^J$$7WS&,B6()O4\>5\\]&$!W[;W@_8(T@Q &!PZ]-G&LI?!>C3$_G
MTV'= 5B?G&P/ZV*[P8#4&M<3VW+&N$(IR+1SX 88)LU\+X6S?EDN"MEJE0QM
M8TPN<?RKPAX-ZFC$R#3)6UL V8<@G$3"+XA%=T#EB!\*)FX;X-F6767.E$&A
M+ U&$AVV9SP]"I:N8SPH:A76<JR*![]+>/'EVNXD/;G>37,J8*\^A\:EC'P$
M8;5;)2'G-%@2>@*HH)*\-5QP'F%G/4<&P(1B!@H!:@KZNA/:V80J'@6&SLN
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M."(;Z$8+R1(<NT'D O'9)L%Q3((#,I(C+Z7S[,DT<V 6ABF%;,S<BF2\H3C
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MX'4,_V%+%9:ZTA*,7T[PSA(B; ;![$A?;^# ,=0]!#[K2 U+N Q]L(M9J?5
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M /4,+"5O23;\7! B*\Z?68S%I+F@L.'*B-$UD#T]H&IHJU=)7(-[SZB2@!;
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M "[1="F]L?_ DJ5E67:SQD.J=E9)8J-YZ'K\$67SZ;$*Y.H')+BE2%FJO"A
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MEJX*W/V?X655/@M8H!*?Q4&G^\M?XLAO6(J*B:-JC4MU=+;P%&3FR1;AD<;
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M2Z$DFIT4U"ZY@!UQ[QGU^*\\ "-(!9H:ZG2YU;.1$Q?C&W!?$Z</EOCB@\,
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M!9*J&6*('%_!@33;M<,"OTD2C/(PRS'2/0P0>8DEO!G.845PR>X,/,5UKD-
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M7C1(^1V20B21 HV]FP[_T*H1E=F8;1[=#QN4.'^19_HQOL<@00J/X2[A CJ
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MNIRC-U:@L/ Q-N(%7E'L6,Z,8B$!%ZEYA\QI',<9R(+XXJ>@]^ ]$66U5.\
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M_$0E9NFGL]@$QZ@2@'6,0*!PH%QW<0^7(Y+J8))./A-3'5X>27.]$L/PJF;
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M]5]I>%2O?=RI_T;3DYI_?]#K/<F8CGOM;O]DX:->TW+QDL&FH 3\UR_]7TK
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MP0F^V9 56TK"VD46XT'H?W513?__ P=68G)18BH- FNH! DX#8&&<D$W_I2
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MMM?*:VKX"FQ4<N0,* ?BK?W<B5>9(0CNC:F%+U)^J($4P_1*C<S<L<&F^;+
MR$!<!ZT_XRID>UTV'^.[-N.>!]H&'<]L>G!L5^\POS><.36+H*M:[!58#F:4
MSZG.@#],,A=+3RKVXS_,9CH=8OG4=!&Q_&[NRJT*(]%S7H0V^,;EM95G ,:4
MW^U"I%7H8U@;:G%GOGX>;G56[ D-U$V>CZL[,)5PZQ,;#DWW2_Y8'%3$\<;L
MHOB@U6>PI(*K6O6@"7+FU&-=RO498BZ9^X7IJV BJCXS 4*\V)]H"Z:+'RJH
MP^J(<[D!MRQG@7?;ML<LBXD-\4'P0N0E@#ID4URB';[LFA;,!7"GKL1I'%%B
M)0SHGVPR 8G,[73J^4.1U;(274@OW$W*;9BZ[B#:7@LVMTHL_5LY'+/'T6Y@
M@3ZOK"ET:4.F,_,%%=O:R3P2>:^"'X#P4E&,P<;'"V(V41#;E>IJ*[4YT-2P
MK]N,M@R'(X6SP!XT*&;'$&N.Z.N037S;0%5@P6;HB.LB5L1UJ>_-&.\Y=MWG
M&(&JKLL\-\^P=V9949O8."RH)@X+MC:/;VT=EW),_@(C 5)=]]D&[V;AIML3
M>-9'/.Z&MG&04<H7L/L('C=+"I.>/A_B[UF)%U(L@_]'[-5[M!S]R];1*41[
MQ*C)BZ04B:U-?0;#8M3QMYT<<(E4$BAO;5^)%7]]Z/N^A[:#OW#6?&5<-UU4
M<"!44B<>XVW7]8,?/2H$90E^W[\"TF'@KL&IPS2%F=)A'NC7GP3./=$1=>[X
M.;6/DERJ.IV#PRGYIKW>IA+FK"ZX:>V0VLOIJI"T]7S4!:PI3)I@EF4D11"I
M6+[!C+8]@JGH0E^Q5L/-G%F[/^,C35\3<L$IN GYV/P*Q$%!"M3,!SNS:37,
MUQO-L%[PA4&./!$/_TGL=CM!)3HD]L<CS2"9GW(Z[])7<^[/?Z.6O]TBY81[
MU(N/&DLVP._K!>'+;EL%5[-6K<&R-J[>U-JIV)-'7@DK;0( .NXPQTD>]=CZ
M$XQ#9OC"X;7M!@.\8/6%=AV3CJ$%ANV2N."@,BJ[5Z).IYQ-H6.J88B=.&K%
M-1(\IHC75E;09=[,,<(&3<N<FF)'*"BG;/<-AQ52V;'$G]\U?(OU)XEBN_21
M]U7]791,@P*%BH9G>LNP).^J$(%C)9Y.@?G(\5;CYXJ7=<@3MBJH=DS/428A
M;/F6-3+GK#E?6,Z2R3SCUN95\/IERA3@B[B'!0H\L7&0PL<&QPK7BM34T_>J
MKOMSC)B9L7.!: ^N54TC$>#^1 1ST<[ R%GY[SB^RTM.2O&H:E38<U[ *YJ0
M0P7,F0OF_V@Z71A]'9U<X ZEN4MY/I6(L.H^K,40!$9/UT8Q39Q=#NA2;)H6
MC@+V85E5*TF8NCJ%.P.+ZL'ORK.<$KR$ZD_06;%O$LUD<0*P2&>SJ*K:V<A*
MF5$P3L@AJ$*D$-3^M,>;RYLB1<*UAI7P2!F5DU6 6KKFDJ*L1!<W':$;^K_M
MN_<Y%-5-DV*'D'1\R3Q"Q$X#[NB,&84\2T%&1YR(BT!JD1T<ACLM#.)JQD')
MJ)0K]NC=Q([#QGZ];+M_;[;?^PS 'ENN>$CUJ'NZ&P(JFNE 6 GA1%>5!J49
M#2OA +7'%CBOT5<'_^1W(;-I)19:SEKX7*\1G"T6[JG06>0"A%7H7Y#7A=O
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MXZF/<],Q3O.?EH8D_>_%=+9LGCE'=#AIYK^8S9IAN)B5$M*3R:%?G(0TC.?
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M><ED"(HX7SK)1R<CBSFQZE<!/@BF':_HOE%':ZPII^&-*U,A>4U<$(7'MK!
M2A^JWQ6^*K@N>4=U>+.:Y[.NGBJ>T0NS&ZUL/^"L+%O(I5 -D5Y?4'C[A.G
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MQ"K!(1AK*=0^J?,H@%UR&S;)OO:TN*)/L'R]_!.0W[_]]']02P,$%     @
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M=(Y 1O$R ,'?PK!0O"+&QYZ^/N;K9Y$$V5\.)A41/WQV5;S-A>_7%/"#1U=
M.WT0N8"+ *.:4.\\]Q;..<C[",LCQWYXYB^:/\?FXM<INMVCP_=[AR=[[_&;
MDZ.#_?<[IWOO3T[QZ\>]P].3HP\GIT>[?_OKT<'[O>.3O?_ZO'_ZW\^/87QV
MT9"R\E)Q-=?_YRJON34DY$Y_V"_+T0'^.'M7P=_QX.#;!(8)KM:J.9A!$^]\
M:%!6RN9:M0,?8##];>]R3,Z\_]([F>"V578P1 _[^.VXEYPS/$4@PCE:MA:#
M.U!@Q'H#.5!N -Q#8HSG1,M^'*;4F+T"*<+%KS"8C.>_*?(74]DO1G$EX@KC
M.O5A #VI3&1:1Z*,=$0RG4C(!C=9IADPW#!UEEV-:8K@[GAN2+,SFH]L-BF7
MVEORJ+FHJL])4TV,5YI"T'_ZI1DE&*$YA7^:KA1_B8-F#.D__C097<+-+YOA
M!%F]-YB^$*<JG)5OJC%A[Y^7_<GWW>;B2S/$'\<[W_KCGO:9"C2EB$@V$QFL
M)2%)(,%G&9EAWKM'5L$ZQ'@,4$6>/+'?/\&;%12]B#-K"_PQ"JW)AGN8WD]W
MJE:@>O<LD$IL>!10118LM*">X,#ZBFNZDOK&*.&UMC0Q2Y1%3TJ* BY31CP/
M(2M'<=VLO0MND IWC-/M,V$987?  (1ST0Q/)DW\_>/49NUIKBQPJX@)/N">
MF0P.,2=BN$8WW"8I7*BL_0<@:FK^,4/_H=HK**>I*=F'JJ;KJGHGI:D0_>"3
M[Z?]X:[_TI_XP0P<E];$Z#@!Q2,R&P?M)-4$DO):2B>YRI75_B2@UT"!>A+O
M8.8?PP3'!VG/CX;]X=EXAHIFT$HJ-)D9\E/FJ(E73A":(Z6" :YSHC(/'D?R
M&@A00<8/-<_77@ABO+RX')2@[='D'$9EQ",X+QOD5]@?HJ,.UQ0-7'BG20 T
M@Z7-$L?.#*%&:)J9IUFPVHM"6W"O@1_=:.(A9<3:GN1E&/=3WX^^G_@!'.7I
MMC:UB%)6@3DF2;017>Q,$W$<##%)4HX_YFBJAQ<6@7D-'F0507>P:-R"<^@O
M\-O3D1^.?2SRG<V$-@@[<B6?1[<EO[*..N^3I!M==&!DM$!*4_)<A42TQ_5,
M F1B@\(=D5&@+EDMK7HE;'G.]=P669910462E .)WL[D]!P^^M'O,#G*&49H
M)LW=); B:,Z)XH!;'K>1!)D5R2)QD,E*P>\9'P]/.)Y^Q>9-B-K*:*I+L@/'
M$PV9$?@QO(>K?^]?><7GS0"?/[ZRJHZ;P>!#,_K#CQ):5$IQ[101(B%<PQBQ
M20@"/#'C?$A4^,HKPI(0MT"<NH<;7:JD P;=BJ6<G/L1C(\N)R6/HB2G]+P/
MT:/'3+3PF<AH$K'.>*(93S1+;D+FW06L'N#9/#<Z5>;BJ-9ZFNC"V'@PZI["
M%T>G!-%@@$@TO(DW5!$JJ1=2Y2Q";6X\1/&Z&;&FU+MP50JB_?'X$M+[R[(-
M?L+-L$E7?#V$/Z9_PO53Y(*&DL38U*4.)%B+*VE4V7(3<?"F"VX\B^P-\*6N
M=KH(>#R.\N]^< DW("&G0,$')'JR1*JDB<MHNE$ +QCW5FB[&0K=!?8F&;2&
M;AX22':Z"$V_OD,QI1+Q0_=PFM39 P@:[7%-C. (V6I&@HL*)1.L\"[%X/0F
M5Z3'8;Y)<E73VT.JJ2[7JD6(D?XB)IP<&8TTJ200IZ0EBHD<'!6:F]HNUO(H
MWR31:FGM(<_T^@?(_^]R/"E.Z/BT67"V.44>[B,_!A3=N#^!$QA][4>X&NHQ
MQ.;L2J734?=XL+CG6T:4XX%(4)Q8&33.*,I!^Z0@UMY.NQ[3Z^;PBV+$0\:;
M=1F_Z%#NH!F/47[0/QON7HY&,(S?IX&\P71L-U(Y]=]Z(+D3'+T?E3PZ0RS&
M<EU%$8/[!*4:F*E^0%8!]NOF[:;U^I":MDMJ?KHZ<-@97ITJ?VK&DQ%,^J-I
M /$=#%&;DT\#'-?-B Y+T+@,BWIN34J9^"Q0K,QSXC3E1#KM(4<>M:]M@W8T
ME+=+X4WI_R&M75>T_CQ$B0[Z_X+T5Y0F6DN_H4+*6(^&)Q#1?IKT8;PSPBUE
M>';;G+H>%_>,)8&35*G@B)1<$&=+&AXD%VUP0D/M:$]78WF;Q-XH QZ)3J]]
MB(% ;J9HST0O-(N21!W09]2,XCR+E#"JT&>,T4I=^]C[#H#73:+59?V(YFLF
M63\\-%$N<BXY(U3KC+2DDCAA-=&:J> ]0QNWMGW8_OBJRB%,TH*YB*8[\PQ-
M=Z !%5E&**-3*8KD[A_D=W8(\^^_WJ/[ ?[8U27-W9V3OWXX./K'R5UN5;J;
M>?/T#5S)7#"4[FYB,BNX!E^RH;TG$KT]8FDL<37'K=6,0Z9=74X[Z.@FIDU4
M%>NJY 6B0<6<(#X%3W)(X+T!EVWM%/L7<Q-S&7T^<Q-S&3&^F)N8"U.[/ Y>
M"9L)<R"+E<U1,$KA!F4A2!,S];7S[5]Z_NQ2"FZ=/[N,H+>3"=D&X<_\V574
MN7Q*Y"JZV YK$"151CD2E$<S&;\2SP"!VPQ6I)@$JY[&\*/ESW9,EF544#M_
M]GU_!/%^PJ?T/E&M$@DVH<5MT&L*V1G"@$=K#<._B><,T(5/?Y%9LTNIH*DI
MOXKICL^D\4H3O)3.$@T"/46?@3@J,XE&&Z:U\([[5EK]L1*B5U9M'4EVL*H?
MPF37C\\_C9JO??2>WGW_C(;H_O (328_090[./RO5_&L,)Z,4!H]YM%^ELP2
M1DVIC1:!^(*=,IZ9CLID6MMW6![EBTB+7L?3Z%@Q'61&WPUTQ<@D0/3$JI+S
M)-%HMAXHH=RG[*W"?^+K"BIVK;$GXXK+B+N#9>3.Z7LY.A_&_@#N0#QMEI4.
M!!!">$I .$5DXH&@SU7N%UAF6*:2Z]J!ER[&\>J9N'7E=Y"XO7_QQ?='94Q'
M^: 9GAWTOT+:&8]A,OXK#-*'9H1#Z!DGC0XQ$"X8X.9-);%"&$)S8-E9W-)9
M;8:V K9YRFV? _>O%5578 ?+YGOX@B9_?YK2@=\/8')U5KYST8PF_7]=I=H)
M:W$.6DYP'N+4I%F1$*@F(C P@C)*?>T:2&UP_>18??5U4V%C=(7K%JBC_+X_
MCLUEJ24U3)]&<-&_O!CO#[_"3+X]P;EBFCG"\[0NB$LX,1).$319,UJOD=,.
MRFVL@/0G#3>AX@ZNM5Q+XZ"<P!^78MQ'&04U7:-OCV3O6TG5A)X3AG%/#?':
M1311;")>@2;:<^I<<%Q53\E=%N-/,G:KUBXNQSR>WQZ2] )- ^+2])ZZHL2"
ML,192,RR&$RN77KNI=P\>'&4JJ"B#JZZ_-8TZ8_^8("KZ_YPXH=G_3"X8OF-
MZ=E3(8CL?2;>E&'GR$G(RA.1'9.<@S&A=JRL#:Z?I*JOO@YNN3Q,4[N6QNQ&
MP[4HHA/*\."(X2R@(R,B\0(LR5RA7R^CBS'5]D1;HWOU$9".%-6!U?40:;$>
M+XMP)C!"VQ#G)O2_EN0'E&&/XN8;RFZ<(V0BE67$:EQC<6M&_\7&E'SMPMS+
M(7P)N:-U=/TLI:HIJH- QJ-HI\['#<R>LN""IYDPI=#-H)H3+QE:>HI)X9.2
MEF^$3/=PO2T*K:.4+N*L#S"BJXK[;WH/&48C2#,W87Z!Y"J"UZ, S'O%":52
MHNT'Q7TH!6L#.&&M4=;43E5;#>D;(E=UQ6UJ^YM.B4_^>YD/)7IWM<X>]'WH
M#Z8V0H]F*8SBF0A1)DG2F5A6)DF0B4:06HC:M7M60_J&Z%9=<1T$%QZBWKOX
M,FB^ QS#M-3N;:S.9>U*]=Y@\8N,&;%"#,389"RG7B5?.^2Z#+XW1*U*2NH@
MZ/"$2*;QMCG4[[V<C(JR7"\"A1+)T\J_U!.'/C$'])"#[+YRX0)P;XA*-=2S
MF<A"V:0/FV&<7C:?W.:\E!J"U)YP7:Z7:X%8-4LD@=74)\>]J9W6NPR^M\2F
M.DKJH#S%0ZR[S7 J@G_T)^>[E^-)<P&C&_X+RUER+I#D*2,X$4K:HRMM)VP(
M"= 7D;6O&BX)\0W1JIZJ.J@NT3Z4UW,1'+>X)6LARV5JG @.=*E-'1QE.G.@
MM0]MVJ-[]4'0CA35@5F^ .G5X?CC@J':"XN[,E$Z"2(EKJP6!",I 4/, +FZ
M.;4\RM>:]%Q+,1T$/M'[G-><BO^\[(]F2?[%([TI!=&3R@D>5"1,*I2)<X98
M!['4T,_96*H@UV9/*V O9DVJIN&F:_5TP:%1$P'2^ -*ZZ.?S%!-PVE7Z'>&
M:=</!N.C7%(73YO9A[[?&H(/02:%$RX))4O^MR!.&T9HD"&Y!)'1VO94!=BO
MGW\;5FT'$?K;0[BZ(K40*8O12V"(+SE1RB.C>YO0$8F4NZ#0B)2A]@%/>W1O
MBFL5%=5!%/[!JHS0T4J<?"^5P"8X)4J=E"_3# QP3)E2>UOC HU(T:X(T:);
MFQ5U+AHCH'9MHO;H7C^ENE'45DWZ7@P!J!."I%!\G)*:'3)N_D;QY+3B'5"J
M/;I73ZF.%-5!K'T!T@_]H1_&QP7CM?#!HM,<N6/HUUI# GA!O-*JM&OFH?H1
MSO(H7ZN76$LQ'=M0I<XVXL3M^5;MLUZ@ C+*A 1J-9%*E1,FB9)1T5-K+$>S
MKT/3Z5%0+V8MJJ;9)RRF]=72871A=A!YVISZ;R5(>WY5=O)#,UJ0&YVTM]DG
MB@+AZ#-XKPAZM27-P@H/#HQBM>^,K8KU];-L$TKL8-%J+Z:>=R9RK8 P8P).
M#E$*4)>JEL(+I5G@-FXH.OH(NE=/L(X4U8'CMY?SM,+-WK=X[H=G<(P3XFA8
MP)=_BC/Q%1W7Z5Q!N?0C3I?R!W0T[O[BUB=[-&G+(QJ(5@(Z'CJ4!$9MT%X4
M:#Y&'^JGS70PC!_>*-NV:CM@ZUK@KRH^/SQKC8/+LNK?%M.5Z'I1R)2AS$A=
M[C-%[8C/P(CQ+,>B&&YJ$WFS(_SA.?Z""=%!2&6]N2NMT,Y%2702LCCOAI1L
M<F*D5\;S9"#4+HWQMA?@S:FK@UC+>N"5,=3SH-$WRVC5Z.1+LU=)8G \T)QX
M=B]JY5S;,F^&$9]X$S,;IFMC;TJDFSRA"+IT&B!!AW(OTAOB6)"H6Y<M#2QG
M4?M:8&MP/_R,ZT8-%9/SIJ4'KYN[E>C&;C.>C ^;R7_#I'3&ZG&@.AH7T,^0
MI?Z-H<0JD8G(UH7(3 GEWN7'@CJ.3[UE"PY8-YIINA!K!V&C6;;@] 9.ZD\N
M1S#>O\H93>\N)[=P2L<]TQZ7>85+OP2-M@;Z@4384AI$2QML[>6A+;;71II.
M=;,P^E.SR<31\6\[A_O_=^=T_^CPW<[)_LG1AT_'>R=[AZ?37^T<OC_Y_/'C
MSO%_'WTXV?_M</_#_NX._FUW]^CSX>G^X6^?C@[V=_?W3@[]J"0$?D4;>.+[
M@_'=0;1K2=$9EO4;6&Q&3)7:7>Q.?8[KRU3%#T'N7^ V>;-%JJ2-E^B!&&/1
MN@H>%[/2"\?&R(V)+#JH;ET]#VOMNB_Q'-)ER9)8_+*K'@ .)SO:E(HH"B59
M0E,2N'>$<QX-"Z5";^U%LC6X3;71J,V3!R5>.M'&MEMNC$>3WFX9!8R^^-'D
M>RDK/2T"K[(/T<=,-"^'29HK$B(51 CIO6;"\]@J6P]?<(M.^-,-E1:]>VN-
M-;K1<%-1TC7KX2.>8_AR.8KG?@P[9R.8,NH^Q%E9\38@E^FV\0PM6@/;;*.-
M.CIL-J6 [;&%*>T,Y\1(QA&L3KC.FDBT@6R4MSS)5OO1RV;)@@8;VR3)$G*O
MW5KC;_T)?#KWHPN/SL*L<P#STLF4!<G6IEGU*XDK9J2.:4=3DL$\9T<O>OCF
MO*\.==!4%& ']?(7[X/OOI_B,Z:T9LQ(%X,C4=%<ZF5DX@)SQ!I/%4/*VUP[
M6;$-KM=I172FF0ZR,YX8/SYA-EW:8.RHC5<;?-MIY%5?NZWILZ9JN@@5ML'J
M<X*DM49PPA')#"-!&D]HR,F#+:4P:C=BWQY]GNGL]3+8LXQ&:MLBUP#G>_4<
MWT=\QWG1Y&Q_C32J2,$0C;LID0I!>A<%H4JDE)-BYGZ?\P4&2MLW;CYF7%]9
M3=>2KMTD[&%&PS%\A>$EE*S:QRH+['V;I3R4DF#X_U0ZHJ,L6%!&$I9M&8$0
MQ$EGT'S/.&,<U3JZ5ERI N<E$6F] -N65-0]R>Z4#MZ93$;]<#F]UWO:?/*E
M.$I/:JD"XVC9>XF+L*"<!) H/4]E9E$[G#4K4NK9E[]Z M45?^TMZI&27GXT
M1)F4+*QYMG4_]KS2W"4 Y#!^D<)8XK-U!)ACS'$)"'1%BCSZPE=/B_7%7-%5
M:HGQ?7]P.8'4*WMRH.!(8"7G7FE%O/ "]U3*P:,]%^.SYY++O?+-T6$547>0
MV'L DPF,QD=Y=P2I/SFZG(PG?CC=[RZ*6'K)4YVI3P1"CDC8A*.G)N/.)[.F
MR4=6O>+9<YA>#U<ZT4)'^:_3\@QW<O=V)KM^-/J.*/_N!Y?0XSI[%:,CPF6#
M5,;!.\,EH=Y[+G)@--:F2BM@KX\O]?6Q,)'U):;-S$SV<1'\"5KL$SCK1[2U
M)L-I.^'=9H <;D9^UH/LH!]+1 ,GT]QY'+^ ?)MZ@W@YB3H=*:96AD\SQ/=-
MKEY_W!__?FLR.N]!4MQ[P:*%GJ@E-D D-#*6A N9J]J71!>C67NUOO_DJV.
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M:%A&>?*E&8X;-$CVIM=&1_TQC-]#F)P4<V1FL4PQ<VT$ \.(IH*7NGQ  J!
M:'11<%"*06VO<!6<;YALG:NUDVSVBPNTK%$6G_R7ZULY7#(OK1?$1.F*RR2(
M$S&4"^<F:,J-<K5/AA\%\H;)M+YB.KF]._I2$J?A42JSK&W0K@S2X:IJ;2:>
M6D6R"H'F8"@NK-59\P2@-\V>6HKJP 6=NN7O?/P=T@-HBDGNG(V$296)1)3$
M&9=(,-HJSW#(K';;SR?@O&$&U5)2!R6"/Y^<CJ91G.\/D%FNDXREIG4N+<"=
M F)32(1F7!PS9\RPVEUS%Z-YP^RII**%I8+7V,)@-.GG/GZL#/\]?&G&_<D\
MHLMQ!33&$JJI)5(K15S@!LF=968A9$%KWPQ_ LX;ID\M)3WDC^ZF/OEUR/E]
M?UR2T"]'T$-DP*W2))<[1U+%3)P5CB23C#:2BZRJ-Q%L"VZ+9S9;O[;0C08[
M"!/<M=UVOOK^H)Q*?&A&)XCYIEM0C*-+2/O%T83QI(=@+0?CB0_>$TDC+2VP
M4$ ^0O3):V%JF^&K(7W+)-R ;CN(%ER)[;&I8IR)P?&2YIIQ538H"Z?*21GW
M%*(.DF??A=W^<W'K0D,+0P<U+ZGN[IS\=>^_/N__?>>@W/?<.7S_<>?X;WNG
M.^\.]D[V=O&_/]W?.SFYO+CPH^]-OK=>^V&ZGC7Y:M;<S*<UKKIN -7Z%V8W
M+;I*UVYO^@C?7_!NWG\S#4J_F2AP]^6R]#-C(I-@>23@N+16*VM<[6NU2P'L
M=GN_2D!@-$#*S),@2XZ)B Z-Z#A--(D>@G4.:B>;MH"UJ:NNW?%EN>UX>5V\
MF$NJ"XYN@P7/,O5$BX2R"DZ@K'(BC$M)$U.1TMK;]0M+$JJN\9;I/\M(_J4G
M4[09R\_TGT4V8PV"=)E5L8IV7SICT=C53CATX8&7R'5(.)D#)9Z+F)UQ0:>?
MZ3\_&E&74>KFTG^XLQ)"\H2:4H"?:H5>>DD@M2*DI*52M/91Q*M,_UE*N^W2
M?Y9131<%O.ZZ8S-0!IU^26-Q\YU&8R.CG9&<(BHQ9C+#@=HN6EH^ /*&Z;*^
M8CI87E;**J(>05$;"<^Y%.ZU* "7*%&(V$<)SMWOJOPS66RS7.M<K9VD_SR6
MDR2X]TDS2[P 1Z2W&K]C0(QQ5"5A5."U$Q-?8[+86@O7VHKII);R4SE(-D=I
M_/08-QDBI:8DH+=-@@H0C0+A6.T(Q&M.%EN//;44U4&RSU-Y2";Q"#92DK)&
M@DO G5E$1:+7/"45K+:M6HC^3!9;DT&UE-1!OL\3F4@N1R%C"L3+4@_6EB02
MJP6Q4CD>9(ZA>B>B5YLLMIXI5$5%723[/)&')*SPNI0-D,$KM,5HN2EN!=&!
M!4&#I916]]=>;;+86MM7)24]Y(^IDR^Q$\;3]B<]BMMEN5%,G ZAM%/AI#1K
M)2QKP6PR5,;:URKN(M@\2S9WA+>&K#N*\3Q,,MN9[/K1Z#M.E&EV1L]H'Q)G
MF=C">*E=)-9$0:*.,MK(A&2UR^FU K9YGJRCO5;Y?>N(OG;/B 4(8[R\N!S@
M,I9^&S7C\><A[HJ#_K_P1Y3@NY*J :?^&ZYI2L=2:-Z6FB0R&$=P2V0HH$ =
MVE=*W_><%G2)6 O&#TF1#4N_8@AF)>0'^-,-<EQ<(]K@G/"@&"ZN ,0I+XFR
MX /5D7)M.N'-'1AOAS>K2[^+8$SKI&<EC68@0LG61[LI4X'^FM:DI/,'P!$P
M63TP\W+3UCO?E]9500<AEZ=38W8N&K2WD=^[S7BR*%%Y)^._=P:#Y@^T^,M_
MN3N"U)^4*=$+GC(JBR='2Q!; "56246XPO$QX,GSVE&;;D?T0[/R!2F[@^C/
M_?'<&VW+/3\%'Y@#69H=4H+F(2?.)$U*SS+)@W=,U;Y1407X#TW,S:NN@P#2
MJH.X:SN(K)/AJ<1,@RTVIR;>9D%HMMPY*JWDU2]7U #^)OFWNNHZ"$"M>,U(
M&5R<RS3)Z,^4<V9TDTUIG":BB$E9Q5GM]($?Y0K9QK;>*LIY2"F[M@=ZV_FY
M=9/D05COCNW0\S$)G\ME;Z]P(HA0&CWS3(+BUDB30-QW*Y[P/E>"\!J#GQM4
M2A=!L+:HG]SB\;DR!8Y;/.A2A]5:XG'VD<P<B]I[KGR[KJFU$/TD6DV5=1%$
M6W$0=[=V'APX:1W),J*7KKTA(41+0#+&#4214N>\V[*Y]?)YM[K**@;AEAY$
M#V>'T. 8H;@^$^DCFHTR,R(5NM&,FL! 5>?63_XL*_J%P;>:]Z3?[9SL[^X<
MOG^_?_#Y=._]X=[IP=')R?[A[M''O4][QR=_W3G>._2CTIKX*ZQQ\WFE]ZQ_
MEWG]X56ZG;SG1T,TM\>?8'1R[D?POC^X1/?NAG].*I63<@1BX4/0BH3D'8F!
M6JYHXIF+RE[1<YC6]0]O)N""-[W[7G)+F^'NP(]G1=&3<%Q$2@GZ&Z4&(67$
M1>X(9T'3)%FTOG;BRPHP-W5'N2IK[GN(7:OGI5Q3GL(_RO\HTWPX.1H=]\_.
MKRZ9J9"B2SJA7V)QQP:#WSD7B<N&<4TU**C=+&<AF&U=5>Z<!?</JJIHHXMB
MM8\!F_<2:P&MH[O(3\#:SM7B2@IL0XLUI+]A@F1NE=2@B<U>XCJ<&-IU.",R
M>*.5L515CVENG!C/W.3=/"^6$7KM -.G$91+GR7451;'DTD3?Y^!G&>'BJB\
MM9SH5#KZ"AU(*.U=6#2.)Q."B[25E_7LJS;O6E732M.92#M(N_P'E&$"^G<P
M\F=P>%E '>7I9CD^NIR,)WZ89A6W8B\[:55RDI1V7NA0AM(4RGO"50(?G-3<
MU,['70K@YEG3J37;G7(VQZ290!Y@[O$D*3 EB/2.XPJ:5,D0-(3C'.","FY=
M[6X?2T)\&VRJHJ!-F2;74^ Z_+2+SF8QZ&>?&\\^..X!"B3;#(0[GW , A=6
M;P/QV3F:DHDV5R^NOQ[D5\:W32JP@[O;4X%\&O4C]#)8W/]+VUTN %?62$LJ
M*B>.HG<()NA,:]\ZN'G[*V/%BF+M(L/W,7[N?2O7PL=7"*__>$U*UJ.!*D@R
MD:Q-)-*X3$*D2%*T^9G03-CZ1:I7 ?K*:-.]LKJXBCV<]%.10O_KK0.3JSP5
M2!]0@N@6?+F<^**8A\&JG8OF<CCI>2%T5BX1,!HW8YHM\4%9=!.8THD;AOY'
M[62V&L!?&0,WK\R%Z;V;/BPK VN&Y22PR5-? RW$F6P/8;(_Q(=!.3?^,I=[
MMV=JJ\+9S-%;%6%MZH0NI2C ,843 F>%3(!T1"(2+WAPP6L5JS?&?HDG="K(
MDM=L258H 0F ZT)PC@2;T-5!3T?$VH4-?N03NF584^.$;AGUO)03NIT__"B5
M>_Q7X>)H5?0)B.-H?L@4$WZG,TD2N+.ZY+Y6W\-O _B13N*6TO;]37IEJ7<0
MP9B.$[> :?3W"XK*7XD<C=2S*=G&[[[??.:3_SZM%%I&<#.,8?HT\,-#?P'S
M@Z,68^KHV*Z+\6SGO&\-FCSFSKX$'?\H_*5*)+2S(Q%6&((S'<K5HD!HL%QX
MJZG6G<12?@C>/G,<^<)INXQJ.Z#K,8PGHWXLL>QRS/89%3(^/OD\[X)&J3 ^
M!**CQUW%44%\8IXHFY(%&UA0M?MD/@EH"[FC6]=YTY7".CC.FD*Z+:@R\'F%
MMBR<XE:1I&EI*N6 >"4I$=YPKT)BU-7.:WP"SD\F55-6[8R*.P[_=0KU:7,K
M&^"\&>"+QM-(P<YUI.#ZNIQ0DB6M*,D\JE),DI' @!.:@G?*>LKB/:HMR+A8
M&\H+#.>MXH=N02\=K$YW!M S-C-M>" FEIH!$7GN/7B27 X"<J!&U][;[@#8
M'#6VH;VFEN@[L'G:9HC,!'!3,F4Z@:[E8:A7+'I-8F(,)Y*0Q$M<*#5+SB?A
M<(VL'9ZH@_R5+$I;5.<627DU.^>@E498RB2B1+FLI (K9S.!).6=!B&MJ%X5
M?26@FZ?<-EBQ3B;:2BK=-@][/"7/6"A-MSTGDIE ;'1H?VIIC=$B ZMMU+_P
MW,8-*'VMA,=E-+9%>EU+)M'H,J H N>Q9-5E$@)+)!8/)2'8*+?%L)^+6U>*
M[" S;;E90JF7%$"3 *P4%*,(FX)!OUH;;:F.O'KGRC76M>6E@<;X:!IT\(.9
M S!]S<YD,NJ'R\F5:_ P&G$K6-&3%+7' R5.YA)Z0+L-.6,) !AG\7^1V\HB
M6A_URYVJJ\V39JMJW=PT79AO'2WCWJM(6(B4E): Q%HKB M,N9R98J9V_[L7
MGQ"_4<IUJ;#:Q3'NNZ'W(AU[GTZN11)RB-Y%]$4U541F+8GUN M$YGST3'IA
MVH40V[_SY1*E S.B2WUTD/;\*-*>CT9KG")$NPB%R[A6:@/$.I8@!G!6U;[9
M]2B0#8<2NU);4UOF'?@O"R)9/1V$,+1T%7$:';@4< YH)8G"[=0KIR33M8.!
M"Z"\#3*L(O>%YDK-U."/.__[Z'CW\\GIT<>]XY-/.\>GAR7'=1_E</C^Y/1X
MYW3OM_W=G8.#_9W#W;V33[G_+QBAW;9&^N^ZKUP_Q;?JH"NE\1[#&%#7I1CZ
M>_@*@^;+/5MWMQE.>7G:(*ER,[KXT(R.)N<PNE4,*D9 ?\]R$E6QACEN<BX'
M1BS-1HJ,CF"H?=^R!NYZZ<!KH+E*3+0N!9LX*P[$M*^M0N/ :)R@/%(I/<WW
M;[]7S!)>%_VFDH<WSM7%"<8;5?BV\X['HTEOMUPQ@=$7/YI\+YD5TS0QPVD4
MN"D19M'4D!K=HF! $F= )V.RM+K5/5A\P2W&XD\W;%WT[NUG'6^6 DU%5=1,
M14$\Q_#E$N7@Q[!S-H+9T.]"G.7AM &Y3(+Q,[QI#6RSF<)U=-AL2@%;8TM0
M*DCA%3&QM$QFJG3IR99H::F&8&2^7W?S1V3)@KS<+9)D&;E7KQ,TM7EGZ76:
M:6&C X(+(2?22DJ\0G?(FR"L=& SS\]9_0^>ND''KSNI-S5$5C%W[!:0DW>*
MJWF[ZB1BC,:1G+TOMA8GP>+H<C&R9&(ZQ':5<Q\\^I5J<57AU9Z&.P/X5E)=
MS_WHPD>XG/2C'XS1%?WS3HE2_%\80O3'TP #&D%CF$%6/@6M1"A5Q$L^;"J]
MLKPAT6CJ1%3!I6?=]#7>_^I(L0$UU*SHCD+Y-&K299P<C:ZZ$%]M6;:TIE<&
M",12APPH19>+*1)99$%&:W2[SJK/;.2/O?L-NPEKJZ(;:MRTJ(;KAM,M0%5T
M"Q8"V;P;L+Z.'BJ\DH KF_V+P9D8;:+<D9!XZ<H4(G&@*#% G4Y<XV97(XBP
M8:T_8=9O2.G+R+6V_7#R[D/_*YS^T91_(;3I>C:'.J].F3,M*7O$*(:F*MJG
MI8. (SS))$T.*:9V9\<M7K99RZ"23IH.!5K;]K^#;X;'9<>  8[.4QQLDFC
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MN=5DWNK11&>,4"0R!:50HR#>JDR88,I1$4! [632+1#DF9CR=OBQC.B[.5\
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M&A2"Y$HKG0R(VE7BG\/T6MA14_0+HYD+DF-FORY?@A_#?_[;_P]02P,$%
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MLN]LA X>OZQ4:*8*79/MYDVL(+3S(Z&!<?,@Z])-<\M.?@//J0T\SI[#Q=Y
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MG1O](3@LZT9_&'X+OA$?BMMZ,"A^O2O%,)+&6T,&169C=1EV9+_X\DK.5Q2
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M=M^P& N12"(A*0JS0(^T"\@8@H(*0KD4F-C1$#M)'=@3M&J BRE8*@(6FIR
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M1) 1@6-3[ER( '0X&S*'CX=6!"MBI4,(QII-[*RW'4,BXAS>[&:;Z>0/TI?
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MB2[7KU_I8TOBQS(BBIQB6+#*7(D6!21EJ7<=*4><*YRDW(E=R4OJX$D86Z'
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M6SJF4O\/!)87T(Y%F;;!X\J@R1@_K!R(Q"PF<&\?57Y^&]JSF"!&C"D/QXY
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M&:KIPW?6A":)R"J50B[U/A'E"8%,\0325#*4Y#QGRNFTQEORT$<YMJC?4'(
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M.5U'O:<.!V>$2.6$ K],V-(/D$\,<V:D0=K;;C.@5BNI_R?NZ<\)R5)4EEQ
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M"!$&<<85Q+Q"%:T243*O,ZP(.@WL,;=:#<!4&#H-;ONMD<'U\[V[W(9;]:Y
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M+; .ZZ2$I,BYCNV$9'H-%@+)MIG7O6-TYRS=Z1N[V\WKWO]MV:HA+.G:S.Q
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MV'+J<V%KO]/J:Y))S'!5V.SP"J)*"HAY06%)$L2J%"4E$3XG+9VQ!SYAJ;<
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M%^TIGK#F$(;CJBI+IB 1M# <D (R0G*8TB)A1.942J]J(V?) ^^\.GJ 8[2
M)LW)SUNY8^KFH 9!RL\G7=^^_W2"Q'" @S!O@R/Y''>YH[H9;SCV/8O_ &'.
MY".=+BT9]1?MOYZ7=JO^<2G_\]GP"S8)X"E2E%5I#GEI6()RB2%5>@N4D%*F
MN415GCFEW'G('-B!& UJPO0KT%$";+3P\QXN(+KYC<C0^'F,HT@,D$OO860D
M+^$B<53_X '!OF?P^:@_6\#]=&WR53[-Q?1E*I[IS"8K9&4I*L$(1 7-(**R
MA$PH#GDN2U6BI)*56]+M*0D#KW<KTR2F;J5Z$P<<1Z9_64>QUV\1!YCJQ2'0
M:\X%' +'QQV-0Z#7K"Z'0/^# 3GU36^LO8Y8G??_'TN]G?USK@,,>^K_AU[@
M[Z1:+.4]_3DQ+!Y9@12L<,4@4JEY-Q<(8H197I9Y4G(G!K_+51DZ->N@^>&#
M408\;[0!#UH=GV3SRY _L_)'Q=//15@HK^>'C09!-["RNH&M<L!H!VKU#%/Z
M:$![Y%*/!GA8&K3%VQP"[7?R!+0#_-'O-6 U\&OZ,Q9Y4A2P>G.0+Y,P7OIP
M%"1V,G_CC!B8A]2RW'S>ID.D@G.]68/4-/]&2%##]J1@DN99P7G"E/"*X Y%
M#)W1T J\( WA""YN0=EEUOKY9D]#_1.63MH2*VOI4,"XJ4LG#3S(7SK]9"R^
M 7/L-L&LHB3)4KTG,\FS6"%SOVMZ\@A,LJ1,.7*B!ND7,_3VZS =O*[1\N5:
M/HZ1VT*\W'+/C9*_T1&(!;HV#<8I8(6\,9U U]#S3 ([3P?0(#:4;W_.5T^2
M3]54BN9D3C"ED@0+*!/3JB3%A@I$OQR54I7*5,I+PIRI$$])&?K]N*$+]&)
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MYE]@^DAF YI @ 9)4#(6=W%A45:A=-9+6241%,^U3?@5R.JG0TAWJ*JMB0;
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M<5DI(M%](!Y0'#2 HR(YH^VN%L>VO/3=_J3_Q;%3-#1P9+P@@CM6%*?6)W3
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MI !M$1%M[82VU2C[&5(YUL'>TXVY _VU4$/^4)9/><G26N/1Q?:^^/6I^/5
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MDH*6KOM?$DI3E_U>"P[&. *!4B*#XB0DW&6C!ID2\S2KVBVJ>KWLO^DQ'K]
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M_5P1[ A&G:JAA1#N4W?@W?4[&,<OEW[ZSX5=AYZ =@"2@)2RC&!GQ+G$2
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MTDNC4)O=K=B[5G_9HMTLB&6LW%UXAE_%1#QPY7VTY9IM!UA[2E<C8*L%AA7
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M>V*/+YDPZ"E*&HMOZ#2>+QF/EN1*ARS&3&8H&-O%6/AGA/Q$"6_;0&U[)36
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MJN96'4>5%"081"L9J* T>)4MN%1Y%Q1'K3LQ!KQ42;8>L-\N-P.XB-U.]4/
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M92_T-A\I=(K:<0=,\PR*453D:@, QL@-U=YD%5KWQMI O*&49AS"K]^7U08
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M0MRCG@-'/\)HO#P3R*D)EJ4 I2XDQ;T 5[RJ51*DO6(EEW93K#T_7,\WQL-
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M!";OIC-,87[3B::HF PI(0I;K_%IBPS&1BB\I&23D$F7AABY/WJ/ &ECTB=
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MS^MGL/:EU7(M<W[M+U7D%!=T'=95/O)Q5O,W?BIVP)^H_1]02P,$%     @
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M=_FT#[_JO_'KM(/P5=S_ 5!+ P04    " ![@*E86Q?85 <&  !>&P  %P
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M50)C*C&=N1$6$6KB,%6*@!AX0!7@9W, QS:]5"PSFC%\#@JY]*IQC<.L0I4
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MIXK&OH A,_>^!ZIHF^!6A$9PXBG<_2)_[]51]5F^WSKP[]7^ E!+ 0(4 Q0
M   ( 'N J5B@A"<Q2Q<  $U%   <              "  0    !S96-O;F1A
M;65N9&UE;G1T;VQE87-E86<N:'1M4$L! A0#%     @ >X"I6%NJ>4F%4 $
M_/<- !$              ( !A1<  '-G;6\M,C R-# S,S$N:'1M4$L! A0#
M%     @ >X"I6$KH;=X]$   #)X  !$              ( !.6@! '-G;6\M
M,C R-# S,S$N>'-D4$L! A0#%     @ >X"I6(_944>:&   _^,  !4
M         ( !I7@! '-G;6\M,C R-# S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M 'N J5BR%[M)*$T  ,)' P 5              "  7*1 0!S9VUO+3(P,C0P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " ![@*E8HAV;6#ZQ  !AK@8 %0
M        @ '-W@$ <V=M;RTR,#(T,#,S,5]L86(N>&UL4$L! A0#%     @
M>X"I6)K_KF9D<0  1>,$ !4              ( !/I " '-G;6\M,C R-# S
M,S%?<')E+GAM;%!+ 0(4 Q0    ( 'N J5C".^RNP0<  *DF   7
M      "  =4! P!S9VUO+3(P,C0P,S,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    (
M 'N J5@!J 9DS@<  !PG   7              "  <L) P!S9VUO+3(P,C0P
M,S,Q>&5X,S$R+FAT;5!+ 0(4 Q0    ( 'N J5A;%]A4!P8  %X;   7
M          "  <X1 P!S9VUO+3(P,C0P,S,Q>&5X,S(Q+FAT;5!+!08
.."@ * *,"   *& ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>sgmo-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-05-06</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:FullTimeEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:ContractedEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:FullTimeEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:ContractedEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:DirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-09</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="employee">
        <measure>sgmo:employee</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-28">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-154" id="f-514">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">501 Canal Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">207510076</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">54417000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">45204000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">916000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">691000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">923000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">12612000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">12403000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">68636000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">94328000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">22017000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">26874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">20935000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">25991000</us-gaap:OperatingLeaseRightOfUseAsset>
    <sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">17373000</sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets>
    <sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">16627000</sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">128961000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">165320000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">15468000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">15259000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">6300000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">8918000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">18474000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">23554000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">40242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">47731000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">30817000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">33515000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">1205000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">1187000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">72264000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">82433000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">2037000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">1781000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">1515926000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">1492077000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">-1455465000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">-1406376000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">-5801000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">-4595000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">56697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">82887000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">128961000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">165320000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-82" unitRef="usd">481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">157957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">35891000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">63216000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">11767000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">18136000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">4349000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">20433000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">38138000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-92" unitRef="usd">52007000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">139923000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">-51526000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">18034000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c-1" decimals="-3" id="f-96" unitRef="usd">2535000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">3293000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">-48991000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">21327000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">98000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">194000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">-49089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-104"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-105"
      unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-106"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-108" unitRef="shares">180342000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-109" unitRef="shares">168533000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-110" unitRef="shares">180342000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-111" unitRef="shares">169181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">-49089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">-980000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">2045000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-50295000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">23779000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-122" unitRef="shares">178133548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">1781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">1492077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-125" unitRef="usd">-1406376000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-126" unitRef="usd">-4595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-127" unitRef="usd">82887000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-10"
      decimals="INF"
      id="f-128"
      unitRef="shares">24761905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-10" decimals="-3" id="f-129" unitRef="usd">248000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-11" decimals="-3" id="f-130" unitRef="usd">21540000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">21788000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-10"
      decimals="INF"
      id="f-132"
      unitRef="shares">790633</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-10" decimals="-3" id="f-133" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-11" decimals="-3" id="f-134" unitRef="usd">-410000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">-402000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-136" unitRef="usd">2719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">2719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-12" decimals="-3" id="f-138" unitRef="usd">980000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">980000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-12" decimals="-3" id="f-140" unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="-3" id="f-142" unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-144" unitRef="usd">-49089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">-49089000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-146"
      unitRef="shares">203686086</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">2037000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-148" unitRef="usd">1515926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-149" unitRef="usd">-1455465000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-150" unitRef="usd">-5801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-151" unitRef="usd">56697000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-152"
      unitRef="shares">166793320</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-153" unitRef="usd">1668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-154" unitRef="usd">1450239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-155" unitRef="usd">-1148545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-156" unitRef="usd">-8404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-157" unitRef="usd">294958000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-23"
      decimals="INF"
      id="f-158"
      unitRef="shares">3962430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-23" decimals="-3" id="f-159" unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-24" decimals="-3" id="f-160" unitRef="usd">9665000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-161" unitRef="usd">9705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-23"
      decimals="INF"
      id="f-162"
      unitRef="shares">1015818</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-163" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="-3" id="f-164" unitRef="usd">-1119000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-5" decimals="-3" id="f-165" unitRef="usd">-1109000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-166" unitRef="usd">8277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-167" unitRef="usd">8277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-25" decimals="-3" id="f-168" unitRef="usd">-2045000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-5" decimals="-3" id="f-169" unitRef="usd">-2045000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-25" decimals="-3" id="f-170" unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-171" unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-25" decimals="-3" id="f-172" unitRef="usd">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-173" unitRef="usd">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-174" unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-175" unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-176"
      unitRef="shares">171771568</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-177" unitRef="usd">1718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-178" unitRef="usd">1467062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-179" unitRef="usd">-1127412000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-180" unitRef="usd">-5758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-181" unitRef="usd">335610000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-49089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">4349000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-5" decimals="-3" id="f-185" unitRef="usd">20433000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">1406000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">3489000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">273000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-5" decimals="-3" id="f-189" unitRef="usd">1048000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">1120000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-5" decimals="-3" id="f-191" unitRef="usd">2092000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">2719000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-193" unitRef="usd">8277000</us-gaap:ShareBasedCompensation>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-5" decimals="-3" id="f-195" unitRef="usd">38138000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">-354000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c-5" decimals="-3" id="f-197" unitRef="usd">229000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-232000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-199" unitRef="usd">3348000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">783000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-201" unitRef="usd">-6223000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-4939000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-5" decimals="-3" id="f-203" unitRef="usd">-1905000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">-2559000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-5" decimals="-3" id="f-205" unitRef="usd">-8599000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-1218000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-207" unitRef="usd">-1212000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">18000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-5" decimals="-3" id="f-209" unitRef="usd">22000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-5" decimals="-3" id="f-211" unitRef="usd">-149766000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">-48663000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-213" unitRef="usd">-66300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-5" decimals="-3" id="f-215" unitRef="usd">36225000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">1110000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-217" unitRef="usd">82153000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">34730000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-219" unitRef="usd">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-221" unitRef="usd">10200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">35840000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-223" unitRef="usd">35728000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-32" decimals="-3" id="f-224" unitRef="usd">22524000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-33" decimals="-3" id="f-225" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-34" decimals="-3" id="f-226" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-35" decimals="-3" id="f-227" unitRef="usd">9111000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">402000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-5" decimals="-3" id="f-229" unitRef="usd">1109000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">22122000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-231" unitRef="usd">8002000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">-670000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-233" unitRef="usd">367000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">8629000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-235" unitRef="usd">-22203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-236" unitRef="usd">46704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-237" unitRef="usd">101944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-238" unitRef="usd">55333000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-239" unitRef="usd">79741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sgmo:StockIssuanceCostsNotYetPaid contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">736000</sgmo:StockIssuanceCostsNotYetPaid>
    <sgmo:StockIssuanceCostsNotYetPaid contextRef="c-5" decimals="-3" id="f-241" unitRef="usd">0</sgmo:StockIssuanceCostsNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">460000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-5" decimals="-3" id="f-243" unitRef="usd">5184000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-244">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. The Company believes its zinc finger (&#x201c;ZF&#x201d;) epigenetic regulators are ideally suited to potentially address devastating neurology disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system (&#x201c;CNS&#x201d;) in preclinical studies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, the Company announced its strategic transformation into a neurology-focused genomic medicine company focused on developing epigenetic regulation therapies designed to address serious neurological diseases and novel adeno-associated virus (&#x201c;AAV&#x201d;) capsid delivery technology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#x201c;2023 Annual Report&#x201d;) as filed with the SEC on March 13,&#160;2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2023, included in the 2023 Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity, Going Concern, and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects will require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#x2019;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of March&#160;31, 2024, the Company had capital resources of $54.4&#160;million consisting of cash and cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&#x2014;Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 205-40&#x201d;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#x2019;s evaluation should initially not take into consideration the potential mitigating effects of management&#x2019;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviates the substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effects of management&#x2019;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;probable of being effectively implemented, the plans must have been approved by the Company&#x2019;s board of directors before the date that the financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on additional financing to fund its operations after the current resources are exhausted raise substantial doubt about its ability to continue to operate as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. The Company&#x2019;s current operating plan, its cash and cash equivalents as of March&#160;31, 2024 are expected to allow the Company to meet its liquidity requirements only into the third quarter of 2024, which is less than one year following the date these Condensed Consolidated Financial Statements are issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#x2019;s cost structure and operating plan. Management&#x2019;s plans include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#x2019;s control:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;raise funding through the sale of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;raise funding through debt or royalty financing; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;establish collaborations with potential partners to advance the Company&#x2019;s product pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is unable to raise capital on acceptable terms, or at all, or if it is unable to procure collaboration arrangements or external direct investments to advance its programs, the Company would be required to discontinue some or all of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful. Additional capital may not be available to the Company on a timely basis, on terms that are acceptable or at all. In particular, the perception of the Company&#x2019;s ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of its operations, particularly in light of currently challenging macroeconomic and market conditions. Further, the Company may be unable to attract new investments as a result of the speculative nature of its newly reprioritized core neurology preclinical programs. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which would have a material adverse effect on its business and prospects, or the Company may be required to cease operations entirely, liquidate all or a portion of its assets, and/or seek protection under the U.S. Bankruptcy Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary (&#x201c;Kite&#x201d;). This adjustment was driven by a reduction in the estimated future level of the Company&#x2019;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $8.9&#160;million, a decrease in net loss of $8.9&#160;million, and a decrease in the Company&#x2019;s basic and diluted net loss per share of $0.06 and $0.05, respectively for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#x2019; product sales. All funds received from the Company&#x2019;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of the Company&#x2019;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#x2019;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#x2019;s services under the existing contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#x2019;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#x2019;s performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#x2019; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from collaboration and license agreements for the three months ended March&#160;31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and are initially measured at their respective fair values as of the acquisition date. Goodwill and indefinite-lived intangible assets are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#x2019;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value (but not in excess of the carrying value of goodwill).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing each annual impairment assessment and any interim impairment assessment for its indefinite-lived intangible assets, the Company determines if it should qualitatively assess whether it is more likely than not the fair value of its IPR&amp;amp;D asset is less than its carrying amount (the qualitative impairment test). If the Company concludes that is the case, or elects not to use the qualitative impairment test, the Company will proceed with quantitatively determining the fair value of the IPR&amp;amp;D asset and comparing its fair value to its carrying value to determine the amount of impairment, if any (the quantitative impairment test).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the qualitative impairment test, the Company considers the results of the most recent quantitative impairment test and identifies the most relevant drivers of the fair value for the IPR&amp;amp;D asset. The most relevant drivers of fair value identified are consistent with the assumptions used in the quantitative estimate of the IPR&amp;amp;D asset. Using these drivers of fair value, the Company identifies events and circumstances which may have an effect on the fair value of the IPR&amp;amp;D asset since the last time the IPR&amp;amp;D&#x2019;s fair value was quantitatively determined. The Company then weighs these factors to determine and conclude if it is not more likely than not the IPR&amp;amp;D asset is impaired. If it is more likely than not the IPR&amp;amp;D asset is impaired, the Company proceeds with quantitatively determining the fair value of the IPR&amp;amp;D asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performing the quantitative impairment test, the Company uses the income approach to determine the fair value of its IPR&amp;amp;D asset. This approach calculates fair value by estimating the after-tax cash flows attributable to an in-process project over its useful life and then discounting these after-tax cash flows back to a present value. This estimate includes judgmental assumptions regarding the estimates that market participants would make in evaluating the IPR&amp;amp;D asset, including the probability of successfully completing clinical trials and obtaining regulatory approval, the timing of and the expected costs to complete IPR&amp;amp;D projects, future net cash flows from potential drug sales, which are based on estimates of the sales price of the drug, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;size of the patient population and cure rate, its competitive position in the marketplace, and appropriate discount and tax rates. Any impairment to be recorded is calculated as the difference between the estimated fair value and the carrying value of the IPR&amp;amp;D asset on the Company&#x2019;s Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If this review indicates that the carrying amount of the asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, impairment of indefinite-lived intangible assets, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash in current assets consists of a letter of credit for $0.9&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#x2019;s useful life or the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants to Purchase Shares of Company Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#x2019;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#x2019;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If financial instruments, such as the warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#x2019;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#x2019;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#x2019;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants are also required to meet equity classification criteria to be classified in stockholders&#x2019; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#x2019;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. The warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Nonretirement Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 712&#x201d;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 420&#x201d;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-07&#x201d;), which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-09&#x201d;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-245">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#x201c;2023 Annual Report&#x201d;) as filed with the SEC on March 13,&#160;2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-246">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-247" unitRef="usd">54400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-248">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-36" decimals="-5" id="f-249" unitRef="usd">8900000</sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent contextRef="c-36" decimals="-5" id="f-250" unitRef="usd">-8900000</sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent>
    <sgmo:IncreaseDecreaseInEarningsPerShareBasic
      contextRef="c-36"
      decimals="2"
      id="f-251"
      unitRef="usdPerShare">-0.06</sgmo:IncreaseDecreaseInEarningsPerShareBasic>
    <sgmo:IncreaseDecreaseInEarningsPerShareDiluted
      contextRef="c-36"
      decimals="2"
      id="f-252"
      unitRef="usdPerShare">-0.05</sgmo:IncreaseDecreaseInEarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-253">&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#x2019; product sales. All funds received from the Company&#x2019;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of the Company&#x2019;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#x2019;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#x2019;s services under the existing contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#x2019;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#x2019;s performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#x2019; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from collaboration and license agreements for the three months ended March&#160;31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock contextRef="c-1" id="f-254">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from collaboration and license agreements for the three months ended March&#160;31, 2024 were not material. Revenues from collaboration and license agreements as a percentage of total revenues for the three months ended March&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-37" decimals="2" id="f-255" unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-38" decimals="2" id="f-256" unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-39" decimals="2" id="f-257" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-40" decimals="2" id="f-258" unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-259">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Goodwill, Indefinite-lived Intangible Assets and Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and are initially measured at their respective fair values as of the acquisition date. Goodwill and indefinite-lived intangible assets are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#x2019;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value (but not in excess of the carrying value of goodwill).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing each annual impairment assessment and any interim impairment assessment for its indefinite-lived intangible assets, the Company determines if it should qualitatively assess whether it is more likely than not the fair value of its IPR&amp;amp;D asset is less than its carrying amount (the qualitative impairment test). If the Company concludes that is the case, or elects not to use the qualitative impairment test, the Company will proceed with quantitatively determining the fair value of the IPR&amp;amp;D asset and comparing its fair value to its carrying value to determine the amount of impairment, if any (the quantitative impairment test).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the qualitative impairment test, the Company considers the results of the most recent quantitative impairment test and identifies the most relevant drivers of the fair value for the IPR&amp;amp;D asset. The most relevant drivers of fair value identified are consistent with the assumptions used in the quantitative estimate of the IPR&amp;amp;D asset. Using these drivers of fair value, the Company identifies events and circumstances which may have an effect on the fair value of the IPR&amp;amp;D asset since the last time the IPR&amp;amp;D&#x2019;s fair value was quantitatively determined. The Company then weighs these factors to determine and conclude if it is not more likely than not the IPR&amp;amp;D asset is impaired. If it is more likely than not the IPR&amp;amp;D asset is impaired, the Company proceeds with quantitatively determining the fair value of the IPR&amp;amp;D asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performing the quantitative impairment test, the Company uses the income approach to determine the fair value of its IPR&amp;amp;D asset. This approach calculates fair value by estimating the after-tax cash flows attributable to an in-process project over its useful life and then discounting these after-tax cash flows back to a present value. This estimate includes judgmental assumptions regarding the estimates that market participants would make in evaluating the IPR&amp;amp;D asset, including the probability of successfully completing clinical trials and obtaining regulatory approval, the timing of and the expected costs to complete IPR&amp;amp;D projects, future net cash flows from potential drug sales, which are based on estimates of the sales price of the drug, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;size of the patient population and cure rate, its competitive position in the marketplace, and appropriate discount and tax rates. Any impairment to be recorded is calculated as the difference between the estimated fair value and the carrying value of the IPR&amp;amp;D asset on the Company&#x2019;s Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. If this review indicates that the carrying amount of the asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, impairment of indefinite-lived intangible assets, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-260">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash in current assets consists of a letter of credit for $0.9&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-3" decimals="-5" id="f-261" unitRef="usd">900000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-263">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-262">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-264" unitRef="usd">54417000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-265" unitRef="usd">45204000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-31" decimals="-3" id="f-266" unitRef="usd">78241000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-22" decimals="-3" id="f-267" unitRef="usd">100444000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-268" unitRef="usd">916000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-269" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-31" decimals="-3" id="f-270" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-22" decimals="-3" id="f-271" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-272" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-273" unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-31" decimals="-3" id="f-274" unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-22" decimals="-3" id="f-275" unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-276" unitRef="usd">55333000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-277" unitRef="usd">46704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-278" unitRef="usd">79741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-279" unitRef="usd">101944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-280">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#x2019;s useful life or the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <sgmo:WarrantOrRightPolicyPolicyTextBlock contextRef="c-1" id="f-281">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants to Purchase Shares of Company Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#x2019;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#x2019;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If financial instruments, such as the warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#x2019;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#x2019;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#x2019;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants are also required to meet equity classification criteria to be classified in stockholders&#x2019; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#x2019;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. The warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.&lt;/span&gt;&lt;/div&gt;</sgmo:WarrantOrRightPolicyPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock contextRef="c-1" id="f-282">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Nonretirement Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 712&#x201d;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 420&#x201d;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-283">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-07&#x201d;), which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-09&#x201d;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-285">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-284">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-286">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-41" decimals="-3" id="f-287" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-42" decimals="-3" id="f-288" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-43" decimals="-3" id="f-289" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-44" decimals="-3" id="f-290" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-45" decimals="-3" id="f-291" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-46" decimals="-3" id="f-292" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-47" decimals="-3" id="f-293" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-48" decimals="-3" id="f-294" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-49" decimals="-3" id="f-295" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-50" decimals="-3" id="f-296" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-51" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-52" decimals="-3" id="f-298" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-53" decimals="-3" id="f-299" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-54" decimals="-3" id="f-300" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-302" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-57" decimals="-3" id="f-303" unitRef="usd">22566000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-58" decimals="-3" id="f-304" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-59" decimals="-3" id="f-305" unitRef="usd">22566000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-60" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-61" decimals="-3" id="f-307" unitRef="usd">2826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-62" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-63" decimals="-3" id="f-309" unitRef="usd">2826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-64" decimals="-3" id="f-310" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-65" decimals="-3" id="f-311" unitRef="usd">1405000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-66" decimals="-3" id="f-312" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-67" decimals="-3" id="f-313" unitRef="usd">1405000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-68" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-69" decimals="-3" id="f-315" unitRef="usd">2377000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-70" decimals="-3" id="f-316" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-71" decimals="-3" id="f-317" unitRef="usd">2377000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-72" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-73" decimals="-3" id="f-319" unitRef="usd">5593000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-74" decimals="-3" id="f-320" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-75" decimals="-3" id="f-321" unitRef="usd">5593000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-76" decimals="-3" id="f-322" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-77" decimals="-3" id="f-323" unitRef="usd">1031000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-78" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-79" decimals="-3" id="f-325" unitRef="usd">1031000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-80" decimals="-3" id="f-326" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-53" decimals="-3" id="f-327" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-54" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-55" decimals="-3" id="f-329" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-56" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-53" decimals="-3" id="f-331" unitRef="usd">38306000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-54" decimals="-3" id="f-332" unitRef="usd">2508000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-333" unitRef="usd">35798000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-334" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-335">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were not material during the three months ended March&#160;31, 2024. There were no realized gains and losses on the sales of investments during the three months ended March&#160;31, 2023. Total unrealized gains for securities with net gains in accumulated other comprehensive income (loss) were not material during the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses related to its marketable securities for the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2023. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that were in a continuous unrealized loss position for greater than 12 months as of December&#160;31, 2023. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. No significant facts or circumstances had arisen to indicate that there had been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#x2019;s review of these securities, the Company determined that no allowance for credit losses related to its marketable securities was required at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods the Company had investment in debt securities, the Company also considered whether it was more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. No impairment charges were recorded during the three months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-81" decimals="-3" id="f-337" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-81" decimals="-3" id="f-338" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-81" decimals="-3" id="f-339" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-340" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-82" decimals="-3" id="f-341" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-82" decimals="-3" id="f-342" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-82" decimals="-3" id="f-343" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-344" unitRef="usd">8956000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-83" decimals="-3" id="f-345" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-83" decimals="-3" id="f-346" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-83" decimals="-3" id="f-347" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-348" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-84" decimals="-3" id="f-349" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-84" decimals="-3" id="f-350" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-84" decimals="-3" id="f-351" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-352" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-85" decimals="-3" id="f-353" unitRef="usd">22347000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-85" decimals="-3" id="f-354" unitRef="usd">219000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-85" decimals="-3" id="f-355" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-85" decimals="-3" id="f-356" unitRef="usd">22566000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-86" decimals="-3" id="f-357" unitRef="usd">2825000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-86" decimals="-3" id="f-358" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-86" decimals="-3" id="f-359" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-86" decimals="-3" id="f-360" unitRef="usd">2826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-87" decimals="-3" id="f-361" unitRef="usd">1399000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-87" decimals="-3" id="f-362" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-87" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-87" decimals="-3" id="f-364" unitRef="usd">1405000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-88" decimals="-3" id="f-365" unitRef="usd">2368000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-88" decimals="-3" id="f-366" unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-88" decimals="-3" id="f-367" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-88" decimals="-3" id="f-368" unitRef="usd">2377000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-89" decimals="-3" id="f-369" unitRef="usd">5599000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-89" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-89" decimals="-3" id="f-371" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-89" decimals="-3" id="f-372" unitRef="usd">5593000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-90" decimals="-3" id="f-373" unitRef="usd">1026000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-90" decimals="-3" id="f-374" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-90" decimals="-3" id="f-375" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-90" decimals="-3" id="f-376" unitRef="usd">1031000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-377" unitRef="usd">35564000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-378" unitRef="usd">241000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-380" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost contextRef="c-4" decimals="-3" id="f-381" unitRef="usd">38072000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">241000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">7000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities contextRef="c-4" decimals="-3" id="f-384" unitRef="usd">38306000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-385">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-3" id="f-386" unitRef="usd">10855000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-4" decimals="-3" id="f-387" unitRef="usd">24943000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-388" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-1" decimals="INF" id="f-389" unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-5" decimals="INF" id="f-390" unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-5" decimals="INF" id="f-391" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-4" decimals="0" id="f-392" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-393">BASIC AND DILUTED NET (LOSS) INCOME PER SHARE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share has been computed by dividing net (loss) income by the weighted-average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding. During the three months ended March 31, 2024, both basic and diluted weighted-average number of shares outstanding included 251,177 shares from pre-funded warrants to purchase 3,809,523 shares of common stock with an exercise price of $0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted net (loss) income per share are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.193%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of common stock pursuant to employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Warrants to purchase shares of common stock with the exercise price of $1.00 per share entitle holders to participate in dividends but are not required to absorb losses incurred and as a result were excluded from basic net loss per share calculations during the three months ended March 31, 2024. The computation of diluted net loss per share for the three months ended March 31, 2024 excluded 55.6 million shares subject to stock options, restricted stock units outstanding, warrants to purchase common stock, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net income per share for the three months ended March 31, 2023 excluded 14.7&#160;million shares subject to stock options because their inclusion would have had an anti-dilutive effect on diluted net income per share.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-91" decimals="0" id="f-394" unitRef="shares">251177</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-91" decimals="0" id="f-395" unitRef="shares">251177</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-92"
      decimals="INF"
      id="f-396"
      unitRef="shares">3809523</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="c-92"
      decimals="2"
      id="f-397"
      unitRef="usdPerShare">0.01</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted net (loss) income per share are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.193%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of common stock pursuant to employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-399" unitRef="usd">-49089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-400" unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-401" unitRef="shares">180342000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-402" unitRef="shares">168533000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-403" unitRef="shares">180342000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-404" unitRef="shares">168533000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-93" decimals="-3" id="f-405" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-94" decimals="-3" id="f-406" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-95" decimals="-3" id="f-407" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-96" decimals="-3" id="f-408" unitRef="shares">348000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-409" unitRef="shares">180342000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-410" unitRef="shares">169181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-411"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-412"
      unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-413"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-414"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-92"
      decimals="2"
      id="f-415"
      unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-416" unitRef="shares">55600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-5" id="f-417" unitRef="shares">14700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-418">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, the Company was responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) 15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and was eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid. The Company is eligible to earn from Pfizer up to $220.0&#160;million in remaining milestone payments for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are 14% - 20% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $134.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three months ended March&#160;31, 2024 and 2023. The remaining development, intellectual property and regulatory milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Pfizer&#x2019;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales milestones and royalties are not recognized until triggered based on the contractual terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, subsequently assigned to Alexion, AstraZeneca Rare Disease (&#x201c;Alexion&#x201d;) in September 2023, for the development and commercialization of potential gene therapy products that use zinc finger transcriptional regulators (&#x201c;ZF-transcriptional regulators&#x201d;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-transcriptional regulators that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Pfizer (now Alexion) an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-transcriptional regulators that satisfy pre-agreed criteria. During a specified period, neither the Company nor Alexion will be permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins (&#x201c;ZFPs&#x201d;) that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Alexion also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Alexion to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Alexion without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Alexion to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Alexion to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following termination by the Company for Alexion&#x2019;s material breach, Alexion will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time. Following termination by Alexion for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Alexion contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;worldwide net sales of the licensed products reach specified levels. In addition, Alexion will pay the Company royalties of 14% - 20% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party is responsible for the cost of its performance of the research program. Alexion is operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Alexion in accordance with ASC Topic 606 and concluded that Alexion was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $17.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three months ended March&#160;31, 2024 and 2023. The remaining development milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Alexion&#x2019;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales related milestones and royalties are not recognized until triggered based on the contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, Pfizer notified the Company of Pfizer&#x2019;s assignment of the collaboration and license agreement to Alexion, AstraZeneca Rare Disease, pursuant to a definitive purchase and license agreement for preclinical gene therapy assets and enabling technologies that closed on September 20, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, the Company also had a collaboration and license agreement with Kite. During the three months ended March&#160;31, 2023, in addition to the agreement with Kite, the Company had collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;), and Biogen MA, Inc. (&#x201c;Biogen&#x201d;). These collaboration agreements were designed for the research, development, and commercialization of various potential therapy products, including potential engineered cell therapies for cancer and gene regulation therapies to treat neurodevelopmental disorders and diseases. The collaboration agreements with Novartis and Biogen were both terminated effective June 2023. The Company&#x2019;s services under the Kite collaboration agreement were completed during the year ended December 31, 2023, and the agreement expired pursuant to its terms in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed each of these collaboration agreements in accordance with ASC Topic 606, concluding Kite, Novartis and Biogen were customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under these agreements were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license fee fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and other fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost-sharing payments for research services, net variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, the Company had no receivables, no deferred revenue, and no amounts included in transaction price remaining to be recognized related to any license and collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <sgmo:AgreementTerminationTerm contextRef="c-97" id="f-419">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c-98" decimals="-5" id="f-420" unitRef="usd">70000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive contextRef="c-99" decimals="-5" id="f-421" unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive contextRef="c-98" decimals="-5" id="f-422" unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="c-100"
      decimals="INF"
      id="f-423"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <sgmo:MilestonePaymentsReceived contextRef="c-100" decimals="-5" id="f-424" unitRef="usd">55000000</sgmo:MilestonePaymentsReceived>
    <sgmo:MilestoneRevenueReceivable contextRef="c-101" decimals="-5" id="f-425" unitRef="usd">220000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable contextRef="c-102" decimals="-5" id="f-426" unitRef="usd">175000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-103" decimals="2" id="f-427" unitRef="number">0.14</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-104" decimals="2" id="f-428" unitRef="number">0.20</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:CollaborativeArrangementTransactionPrice contextRef="c-105" decimals="-5" id="f-429" unitRef="usd">134000000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:AgreementTerminationTerm contextRef="c-106" id="f-430">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived contextRef="c-107" decimals="-5" id="f-431" unitRef="usd">12000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive contextRef="c-108" decimals="-5" id="f-432" unitRef="usd">60000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive contextRef="c-109" decimals="-5" id="f-433" unitRef="usd">90000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-110" decimals="2" id="f-434" unitRef="number">0.14</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-111" decimals="2" id="f-435" unitRef="number">0.20</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:MilestonePaymentsReceived contextRef="c-112" decimals="-5" id="f-436" unitRef="usd">5000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="c-112"
      decimals="INF"
      id="f-437"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="c-112"
      decimals="INF"
      id="f-438"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice contextRef="c-107" decimals="-5" id="f-439" unitRef="usd">17000000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-440">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under these agreements were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license fee fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and other fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost-sharing payments for research services, net variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-3" id="f-442" unitRef="usd">11440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-116" decimals="-3" id="f-444" unitRef="usd">868000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="-3" id="f-446" unitRef="usd">12308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-119" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-3" id="f-448" unitRef="usd">7696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-121" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-122" decimals="-3" id="f-450" unitRef="usd">2059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-123" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-124" decimals="-3" id="f-452" unitRef="usd">9755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-125" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-126" decimals="-3" id="f-454" unitRef="usd">130630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-127" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-128" decimals="-3" id="f-456" unitRef="usd">1672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-129" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-130" decimals="-3" id="f-458" unitRef="usd">132302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-131" decimals="-3" id="f-459" unitRef="usd">481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-132" decimals="-3" id="f-460" unitRef="usd">3592000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-461" unitRef="usd">481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-462" unitRef="usd">157957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AssetImpairmentChargesTextBlock contextRef="c-1" id="f-463">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company experienced a sustained decline in stock price and related market capitalization, the collaboration agreements with Biogen and Novartis were terminated, and actions were initiated including deferral and reprioritization of certain research and development programs, announcement and execution of restructuring of operations and reductions in force. As a result, throughout the year the Company tested various long-lived and indefinite-life intangible assets for impairment and recognized a pre-tax goodwill impairment charge of $38.1&#160;million, a pre-tax indefinite-lived intangible asset impairment charge of $51.4&#160;million along with the income tax benefit from the reduction of the associated deferred tax liability of $6.3&#160;million, and a pre-tax long-lived assets impairment charge of $65.5&#160;million during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Three months ended March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2024, the Company&#x2019;s Board of Directors approved the wind-down of operations in France and corresponding reduction in workforce, including closure of the Company&#x2019;s cell therapy manufacturing facility and research labs in Valbonne, France (the &#x201c;France Restructuring&#x201d;), and also initiated several actions aimed at reducing costs, including actions to commence the closure of its facility in Brisbane, California. As such, the Company reassessed its long-lived assets for impairment as of March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the France Restructuring, the Company concluded its equipment, furniture and fixtures located in France met the held for sale criteria as of March 31, 2024. The Company wrote down the carrying value of these assets to their estimated fair value of $1.0&#160;million, net of the estimated costs to sell, recognizing a loss of $1.8&#160;million. Assets held for sale are included within prepaid expenses and other current assets on the Company&#x2019;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations. The sale of these assets is expected to occur within one year, either collectively or separately through vendor(s) or at auction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also reassessed whether its remaining long-lived assets continued to represent a single asset group for purposes of impairment assessment. After considering changes in the manner in which the right-of-use assets and leasehold improvements related to the Company&#x2019;s Brisbane and Valbonne, France, facilities are used, costs incurred to cease use of these assets, the France Restructuring, and the Company&#x2019;s activities to market these facilities for sublease, the Company concluded the identifiable operations and cash flows of these assets are now largely independent of the operations and the cash flows of each other, as well as of the remainder of the Company. Accordingly, the Company assessed impairment of the resulting asset groups separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the changes in the use of assets related to the Brisbane and Valbonne facility leases, the Company concluded there were indicators of impairment for these asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $2.0&#160;million on the right-of-use assets and $0.5&#160;million on the related leasehold improvements during the three months ended March 31, 2024. No impairment was recognized on the remaining long-lived assets, as their carrying values were not in excess of their fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will continue to assess whether its long-lived assets are impaired in future periods. As the Company finalizes the wind-down of its France operations and corresponding reduction in force of all France employees, as well as the closure of its Brisbane facility, it is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#x2019;s stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and other long-lived assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operated as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#x2019;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#x2019;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a pre-tax goodwill impairment charge of $38.1&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Before completing the goodwill impairment assessment, the Company also tested its indefinite-lived intangible assets and then its long-lived assets for impairment. Based on the qualitative assessment, the Company determined it was more likely than not that its indefinite-lived intangible assets were not impaired. The Company determined all of its long-lived assets represented one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable as it exceeded the future undiscounted cash flows the assets were expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction and a cost replacement method to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level&#160;3 nonrecurring fair value measurements. Based on this analysis, the Company recognized pre-tax long-lived asset impairment charges of $11.2&#160;million on the right-of-use assets, $5.0&#160;million on the related leasehold improvements, and $4.2&#160;million on construction-in-progress, during the three months ended March 31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetImpairmentChargesTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-133" decimals="-5" id="f-464" unitRef="usd">38100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-133" decimals="-5" id="f-465" unitRef="usd">51400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount contextRef="c-133" decimals="-5" id="f-466" unitRef="usd">6300000</sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-133" decimals="-5" id="f-467" unitRef="usd">65500000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="c-3" decimals="-5" id="f-468" unitRef="usd">1000000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-134" decimals="-5" id="f-469" unitRef="usd">1800000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-1" decimals="-5" id="f-470" unitRef="usd">2000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-135" decimals="-5" id="f-471" unitRef="usd">500000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-5" decimals="-5" id="f-472" unitRef="usd">38100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-5" decimals="-5" id="f-473" unitRef="usd">11200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-136" decimals="-5" id="f-474" unitRef="usd">5000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-137" decimals="-5" id="f-475" unitRef="usd">4200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-476">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 5, 2024, the Company entered into an amendment to the operating lease of office and research and development laboratory facilities in Brisbane, California. The amendment established early termination rights for the landlord upon thirty days notice to the Company, with the earliest date the landlord may terminate the lease being September 30, 2024. Additionally, the amendment authorizes the landlord to draw on the existing letter of credit to satisfy the majority of the Company&#x2019;s February 2024 through April 2024 rent payments and obligates the Company to provide a cash security deposit or replenish the letter of credit back to $1.5&#160;million by June 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the amendment represented a lease modification to be accounted for as a single contract with the existing lease under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;, and remeasured its lease liability using the current incremental borrowing rate of 9.6%, and recorded an adjustment to reduce both the lease liability and the corresponding right-of-use asset by $1.9&#160;million.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sgmo:LesseeOperatingLeaseRequiredNoticeOfTermination contextRef="c-138" id="f-477">P30D</sgmo:LesseeOperatingLeaseRequiredNoticeOfTermination>
    <sgmo:LesseeRequiredLetterOfCreditOutstandingAmount contextRef="c-139" decimals="-5" id="f-478" unitRef="usd">1500000</sgmo:LesseeRequiredLetterOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-139" decimals="3" id="f-479" unitRef="number">0.096</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-140" decimals="-5" id="f-480" unitRef="usd">1900000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-138" decimals="-5" id="f-481" unitRef="usd">-1900000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-482">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-141" decimals="-3" id="f-484" unitRef="usd">1385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-142" decimals="-3" id="f-485" unitRef="usd">4873000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-143" decimals="-3" id="f-486" unitRef="usd">1334000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-144" decimals="-3" id="f-487" unitRef="usd">3404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-488" unitRef="usd">2719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-489" unitRef="usd">8277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-490">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#x2019;s sales agent or principal. In December 2022, the Company entered into Amendment No. 2 to the Open Market Sale Agreement&#x2120; which increased the aggregate offering price under the at-the-market offering program by an additional $175.0 million. Approximately $194.5&#160;million remained available under the sales agreement as of March 31, 2024. The Company is not obligated to sell any shares under the sales agreement. No shares were sold under the sales agreement during the three months ended March&#160;31, 2024. During the three months ended March&#160;31, 2023, the Company sold 3,962,430 shares of its common stock for net proceeds of approximately $9.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuance and Sale of Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 21, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional investors (collectively, the &#x201c;Investors&#x201d;). On March 26, 2024 the Company issued and sold in a registered direct offering (the &#x201c;Registered Direct Offering&#x201d;) an aggregate of 24,761,905 shares of common stock of the Company, par value $0.01 per share, and pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of common stock, together with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accompanying warrants (&#x201c;Common Warrants&#x201d;) to purchase up to an aggregate of 28,571,428 shares of common stock. The combined offering price of a unit consisting of one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.84. The combined offering price of a unit consisting of a pre-funded warrant to purchase one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.83. The pre-funded warrants are immediately exercisable at any time, until exercised in full, at a price of $0.01 per share of common stock. The Common Warrants are exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $1.00 per share. Both pre-funded warrants and Common Warrants can be exercised net in limited circumstances and entitle holders to dividends if and when paid by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Barclays Capital Inc. and Cantor Fitzgerald &amp;amp; Co. (the &#x201c;Placement Agents&#x201d;) acted as the placement agents for the offering, pursuant to a Placement Agency Agreement, dated March 21, 2024 (the &#x201c;Placement Agreement&#x201d;). Pursuant to the Placement Agreement, the Company paid the Placement Agents a cash placement fee equal to 6.0% of the aggregate gross proceeds raised in the Registered Direct Offering from sales arranged by the Placement Agents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received aggregate net proceeds from the Registered Direct Offering of $21.8&#160;million, net of the Placement Agents&#x2019; fees of $1.4&#160;million and other offering costs of $0.7&#160;million. &lt;/span&gt;&lt;/div&gt;Common Warrants and pre-funded warrants were determined to be equity-classified and proceeds received from their issuance were recorded as a component of stockholders&#x2019; equity within additional paid-in capital. The Company determined that the warrants should be equity classified because they are freestanding financial instruments, do not embody an obligation for the Company to repurchase its shares, do not contain exercise contingencies tied to observable markets or indices, permit the holders to receive a fixed number of shares of common stock upon exercise in exchange for a fixed amount of consideration, subject only to adjustments that are inputs to the fair value of a fixed price/fixed consideration-option, and meet the equity classification criteria. The Common Warrants and pre-funded warrants had not been exercised and remained outstanding as of March 31, 2024.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <sgmo:StockOfferingProgramMaximumValue contextRef="c-145" decimals="-5" id="f-491" unitRef="usd">150000000</sgmo:StockOfferingProgramMaximumValue>
    <sgmo:SaleOfStockIncreaseToAggregateOfferingPrice contextRef="c-146" decimals="-5" id="f-492" unitRef="usd">175000000</sgmo:SaleOfStockIncreaseToAggregateOfferingPrice>
    <sgmo:SaleOfStockOutstandingAmountAvailable contextRef="c-147" decimals="-5" id="f-493" unitRef="usd">194500000</sgmo:SaleOfStockOutstandingAmountAvailable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-148"
      decimals="INF"
      id="f-494"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-149" decimals="0" id="f-495" unitRef="shares">3962430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-149" decimals="-5" id="f-496" unitRef="usd">9700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-150" decimals="0" id="f-497" unitRef="shares">24761905</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-151"
      decimals="INF"
      id="f-498"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-152"
      decimals="INF"
      id="f-499"
      unitRef="shares">3809523</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-153"
      decimals="INF"
      id="f-500"
      unitRef="shares">28571428</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit
      contextRef="c-154"
      decimals="INF"
      id="f-501"
      unitRef="shares">1</sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-154"
      decimals="INF"
      id="f-502"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-154"
      decimals="INF"
      id="f-503"
      unitRef="usdPerShare">0.84</us-gaap:SaleOfStockPricePerShare>
    <sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit
      contextRef="c-155"
      decimals="INF"
      id="f-504"
      unitRef="shares">1</sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-155"
      decimals="INF"
      id="f-505"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-155"
      decimals="INF"
      id="f-506"
      unitRef="usdPerShare">0.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="c-155"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">0.01</us-gaap:SharePrice>
    <sgmo:WarrantOrRightOutstandingExercisablePeriodAfterIssuance contextRef="c-156" id="f-508">P6M</sgmo:WarrantOrRightOutstandingExercisablePeriodAfterIssuance>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-155"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sgmo:SaleOfStockPlacementFeePercentageOfGrossProceeds contextRef="c-157" decimals="2" id="f-510" unitRef="number">0.060</sgmo:SaleOfStockPlacementFeePercentageOfGrossProceeds>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-32" decimals="-5" id="f-511" unitRef="usd">21800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:SaleOfStockAgentPlacementFees contextRef="c-32" decimals="-5" id="f-512" unitRef="usd">1400000</sgmo:SaleOfStockAgentPlacementFees>
    <sgmo:SaleOfStockOtherOfferingCosts contextRef="c-32" decimals="-5" id="f-513" unitRef="usd">700000</sgmo:SaleOfStockOtherOfferingCosts>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-515">RESTRUCTURING CHARGES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2023 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 26, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#x201c;April 2023 Restructuring&#x201d;), designed to reduce costs and increase focus on certain strategic priorities. The April 2023 Restructuring resulted in the elimination of approximately 110 roles, including 55 full-time employees and 55 contracted employees and eliminated open positions, in the United States, or approximately 23% of the total United States workforce as of April 26, 2023, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The Company had estimated that it will incur $5.0 million in expenses related to employee severance and notice period payments, benefits and related restructuring charges for the April 2023 Restructuring. No expenses related to the April 2023 Restructuring were incurred during the three months ended March&#160;31, 2024. The Company expects the April 2023 Restructuring and the cash payments related to the April 2023 Restructuring to be substantially complete by the third quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;November 2023 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#x201c;November 2023 Restructuring&#x201d;), designed to reduce costs and advance its strategic transformation into a neurology-focused genomic medicine company. The November 2023 Restructuring resulted in the elimination of approximately 162 roles, including 108 full-time employees and 54 contracted employees and eliminated open positions, in the United States, or approximately 40% of the total United States workforce, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. As of March&#160;31, 2024, the Company estimates it will incur approximately $8.7 million to $9.7 million in expenses related to employee severance and notice period payments, benefits, Brisbane facility close-out costs, and other related restructuring charges for the November 2023 Restructuring. The Company had recorded $6.7 million of expenses relating to the November 2023 Restructuring in the fourth quarter of 2023. The Company incurred $0.7 million of expenses during three months ended March&#160;31, 2024, of which $0.5 million is included in research and development expense and $0.2 million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur additional estimated costs of $1.3 million to $2.3 million through the second quarter of 2024. The Company expects the November 2023 Restructuring and the cash payments related to the November 2023 Restructuring to be substantially complete by the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;France Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2024, the Company&#x2019;s Board of Directors approved the France Restructuring which will result in the elimination of all 93 roles in France, or approximately 24% of the total global workforce. The Company is expected to make severance payments as required by French law and the terms of the applicable collective bargaining agreements, and other employee-related costs. As of March&#160;31, 2024, the Company estimates it will incur approximately $7.8 million to $9.6 million in expenses related to employee severance and notice period payments, benefits, contract termination costs, and other related restructuring charges for the France Restructuring. The Company had recorded $4.7 million of expenses relating to the France restructuring in the fourth quarter of 2023. The Company incurred $0.2 million of expenses during three months ended March&#160;31, 2024, of which $0.1 million is included in research and development expense and $0.1 million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur additional estimated costs of $2.9 million to $4.7 million through the fourth quarter of 2024. The Company expects the France Restructuring and its related cash payments to be completed no later than the fourth quarter of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#x2019;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Sangamo may also incur other cash expenses or charges not currently contemplated or estimable due to events that may occur as a result of, or associated with, the April 2023 Restructuring, November 2023 Restructuring and France Restructuring. There were no restructuring charges incurred during the three months ended March&#160;31, 2023.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-158"
      decimals="-1"
      id="f-516"
      unitRef="employee">110</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-159"
      decimals="0"
      id="f-517"
      unitRef="employee">55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-160"
      decimals="0"
      id="f-518"
      unitRef="employee">55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-158" decimals="2" id="f-519" unitRef="number">0.23</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-161" decimals="-5" id="f-520" unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-162" decimals="INF" id="f-521" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-163"
      decimals="0"
      id="f-522"
      unitRef="employee">162</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-164"
      decimals="0"
      id="f-523"
      unitRef="employee">108</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-165"
      decimals="0"
      id="f-524"
      unitRef="employee">54</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-163" decimals="2" id="f-525" unitRef="number">0.40</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-166" decimals="-5" id="f-526" unitRef="usd">8700000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-167" decimals="-5" id="f-527" unitRef="usd">9700000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-168" decimals="-5" id="f-528" unitRef="usd">6700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-169" decimals="-5" id="f-529" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-170" decimals="-5" id="f-530" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-171" decimals="-5" id="f-531" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-172" decimals="-5" id="f-532" unitRef="usd">1300000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-173" decimals="-5" id="f-533" unitRef="usd">2300000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-174"
      decimals="0"
      id="f-534"
      unitRef="employee">93</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-174" decimals="2" id="f-535" unitRef="number">0.24</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-175" decimals="-5" id="f-536" unitRef="usd">7800000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-176" decimals="-5" id="f-537" unitRef="usd">9600000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-177" decimals="-5" id="f-538" unitRef="usd">4700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-178" decimals="-5" id="f-539" unitRef="usd">200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-179" decimals="-5" id="f-540" unitRef="usd">100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-180" decimals="-5" id="f-541" unitRef="usd">100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-181" decimals="-5" id="f-542" unitRef="usd">2900000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-182" decimals="-5" id="f-543" unitRef="usd">4700000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-544">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#x2019;s Condensed Consolidated Balance Sheet as of March&#160;31, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-4" decimals="-3" id="f-545" unitRef="usd">11733000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-546" unitRef="usd">911000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-3" id="f-547" unitRef="usd">5172000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-3" decimals="-3" id="f-548" unitRef="usd">7472000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-549">SUBSEQUENT EVENTS&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exercise of Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 8, 2024, the Company issued an aggregate of 3,809,523 shares of common stock at an exercise price of $0.01 to an investor upon exercise of pre-funded warrants issued as part of the Registered Direct Offering. Following this issuance, none of the pre-funded warrants sold in the Registered Direct Offering remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nasdaq Deficiency Notice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2024, the Company received a deficiency notice (the &#x201c;Notice&#x201d;) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) notifying the Company that, for the last 30 consecutive business days, the bid price of the Company&#x2019;s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company&#x2019;s common stock on the Nasdaq Global Select Market.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-152" decimals="0" id="f-550" unitRef="shares">3809523</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-152"
      decimals="INF"
      id="f-551"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-183" decimals="0" id="f-552" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
